

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number  
WO 01/51633 A2

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/47, C12N 5/10, 5/08, 1/21, C07K 16/18, G01N  
33/68, C07K 19/00, C12N 15/11, A61K 38/17, C12Q 1/68

(21) International Application Number: PCT/US01/01574

(22) International Filing Date: 16 January 2001 (16.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/483,672 14 January 2000 (14.01.2000) US

(71) Applicant (for all designated States except US): CORIXA  
CORPORATION [US/US]; 1124 Columbia Street, Suite  
200, Seattle, WA 98104 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): XU, Jiangchun  
[US/US]; 15805 S.E. 43rd Place, Bellevue, WA 98006  
(US). DILLON, Davin, C. [US/US]; 18112 N.W. Mon-  
treux Drive, Issaquah, WA 98027 (US). MITCHAM,

Jennifer, L. [US/US]; 16677 N.E. 88th Street, Redmond,  
WA 98052 (US). HARLOCKER, Susan, L. [US/US];  
7522 13th Avenue W., Seattle, WA 98117 (US). JIANG,  
Yuqiu [CN/US]; 5001 South 232nd Street, Kent, WA  
98032 (US). REED, Steven, G. [US/US]; 2843 122nd  
Place N.E., Bellevue, WA 98005 (US). KALOS, Michael,  
D. [US/US]; 8116 Dayton Ave. N., Seattle, WA 98103  
(US). FANGER, Gary, Richard [US/US]; 15906 29th  
Drive S.E., Mill Creek, WA 98012 (US). DAY, Craig,  
H. [US/US]; 11501 Stone Ave. N., C122, Seattle, WA  
98133 (US). RETTER, Marc, W. [US/US]; 33402 N.E.  
43rd Place, Carnation, WA 98104 (US). STOLK, John,  
A. [US/US]; 7436 Northeast 144th Place, Bothell, WA  
98011 (US). SKEIKY, Yasir, A.W. [LB/US]; 15106 S.E.  
47th Place, Bellevue, WA 98006 (US). WANG, Aijun  
[CN/US]; 3106 213th Place S.E., Issaquah, WA 98029  
(US). MEAGHER, Madeleine, Joy [US/US]; 507 N.E.  
71st, #1, Seattle, WA 98115 (US).

(74) Agents: POTTER, Jane, E.R.; Seed Intellectual Property  
Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle,  
WA 98104-7092 et al. (US).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER



(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Il-  
lustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that  
encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing  
such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases,  
particularly prostate cancer.

WO 01/51633 A2



(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Handwritten marks and signatures on the right margin, including a large '3' and several circular stamps.



## COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER

### 5 TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to therapy and diagnosis of cancer, such as prostate cancer. The invention is more specifically related to polypeptides, comprising at least a portion of a prostate-specific protein, and to polynucleotides encoding such polypeptides. Such polypeptides and polynucleotides  
10 are useful in pharmaceutical compositions, *e.g.*, vaccines, and other compositions for the diagnosis and treatment of prostate cancer.

### BACKGROUND OF THE INVENTION

Cancer is a significant health problem throughout the world. Although Cancer is a significant health problem throughout the world. Although advances have  
15 been made in detection and therapy of cancer, no vaccine or other universally successful method for prevention or treatment is currently available. Current therapies, which are generally based on a combination of chemotherapy or surgery and radiation, continue to prove inadequate in many patients.

Prostate cancer is the most common form of cancer among males, with  
20 an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality. This prevalent disease is currently the second leading cause of cancer death among men in the U.S.

25 In spite of considerable research into therapies for the disease, prostate cancer remains difficult to treat. Commonly, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases. Two previously identified prostate specific proteins - prostate specific antigen (PSA)

and prostatic acid phosphatase (PAP) - have limited therapeutic and diagnostic potential. For example, PSA levels do not always correlate well with the presence of prostate cancer, being positive in a percentage of non-prostate cancer cases, including benign prostatic hyperplasia (BPH). Furthermore, PSA measurements correlate with prostate volume, and do not indicate the level of metastasis.

In spite of considerable research into therapies for these and other cancers, prostate cancer remains difficult to diagnose and treat effectively. Accordingly, there is a need in the art for improved methods for detecting and treating such cancers. The present invention fulfills these needs and further provides other related advantages.

## 10 SUMMARY OF THE INVENTION

In one aspect, the present invention provides polynucleotide compositions comprising a sequence selected from the group consisting of:

- (a) sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;
- (b) complements of the sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;
- (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;
- (d) sequences that hybridize to a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375,

381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, under moderately stringent conditions;

5 (e) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

10 (f) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788; and

15 (g) degenerate variants of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

20 In one preferred embodiment, the polynucleotide compositions of the invention are expressed in at least about 20%, more preferably in at least about 30%, and most preferably in at least about 50% of prostate tissue samples tested, at a level that is at least about 2-fold, preferably at least about 5-fold, and most preferably at least about 10-fold higher than that for other normal tissues.

25 The present invention, in another aspect, provides polypeptide compositions comprising an amino acid sequence that is encoded by a polynucleotide sequence described above.

The present invention further provides polypeptide compositions comprising an amino acid sequence selected from the group consisting of sequences  
30 recited in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383,

477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791.

In certain preferred embodiments, the polypeptides and/or  
5 polynucleotides of the present invention are immunogenic, *i.e.*, they are capable of eliciting an immune response, particularly a humoral and/or cellular immune response, as further described herein.

The present invention further provides fragments, variants and/or derivatives of the disclosed polypeptide and/or polynucleotide sequences, wherein the  
10 fragments, variants and/or derivatives preferably have a level of immunogenic activity of at least about 50%, preferably at least about 70% and more preferably at least about 90% of the level of immunogenic activity of a polypeptide sequence set forth in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-  
15 629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 or 789-791, or a polypeptide sequence encoded by a polynucleotide sequence set forth in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626,  
20 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

The present invention further provides polynucleotides that encode a polypeptide described above, expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

25 Within other aspects, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide as described above and a physiologically acceptable carrier.

Within a related aspect of the present invention, pharmaceutical compositions, *e.g.*, vaccine compositions, are provided for prophylactic or therapeutic  
30 applications. Such compositions generally comprise an immunogenic polypeptide or

polynucleotide of the invention and an immunostimulant, such as an adjuvant, together with a physiologically acceptable carrier.

The present invention further provides pharmaceutical compositions that comprise: (a) an antibody or antigen-binding fragment thereof that specifically binds to  
5 a polypeptide of the present invention, or a fragment thereof; and (b) a physiologically acceptable carrier.

Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) a pharmaceutically acceptable carrier or excipient. Illustrative  
10 antigen presenting cells include dendritic cells, macrophages, monocytes, fibroblasts and B cells.

Within related aspects, pharmaceutical compositions are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

15 The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins, typically in the form of pharmaceutical compositions, e.g., vaccine compositions, comprising a physiologically acceptable carrier and/or an immunostimulant. The fusions proteins may comprise multiple immunogenic  
20 polypeptides or portions/variants thereof, as described herein, and may further comprise one or more polypeptide segments for facilitating and/or enhancing the expression, purification and/or immunogenicity of the polypeptide(s).

Within further aspects, the present invention provides methods for stimulating an immune response in a patient, preferably a T cell response in a human  
25 patient, comprising administering a pharmaceutical composition described herein. The patient may be afflicted with prostate cancer, in which case the methods provide treatment for the disease, or a patient considered to be at risk for such a disease may be treated prophylactically.

Within further aspects, the present invention provides methods for  
30 inhibiting the development of a cancer in a patient, comprising administering to a

patient a pharmaceutical composition as recited above. The patient may be afflicted with prostate cancer, in which case the methods provide treatment for the disease, or a patient considered to be at risk for such a disease may be treated prophylactically.

The present invention further provides, within other aspects, methods for  
5 removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a polypeptide of the present invention, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the polypeptide from the sample.

Within related aspects, methods are provided for inhibiting the  
10 development of a cancer in a patient, comprising administering to a patient a biological sample treated as described above.

Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a polypeptide of the present invention, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a  
15 polynucleotide encoding such a polypeptide; and (iii) an antigen presenting cell that expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

Within further aspects, the present invention provides methods for  
20 inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population as described above.

The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient with one or more of: (i) a polypeptide  
25 comprising at least an immunogenic portion of polypeptide disclosed herein; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expressed such a polypeptide; and (b) administering to the patient an effective amount of the proliferated T cells, thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

Within further aspects, the present invention provides methods for determining the presence or absence of a cancer, preferably a prostate cancer, in a patient comprising: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within preferred embodiments, the binding agent is an antibody, more preferably a monoclonal antibody.

The present invention also provides, within other aspects, methods for monitoring the progression of a cancer in a patient. Such methods comprise the steps of: (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) with the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

The present invention further provides, within other aspects, methods for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide of the present invention; (b) detecting in the sample a level of a polynucleotide, preferably mRNA, that hybridizes to the oligonucleotide; and (c) comparing the level of polynucleotide that hybridizes to the oligonucleotide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within certain embodiments, the amount of mRNA is detected via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide of the present invention, or a complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to an inventive polynucleotide, or a complement of such a polynucleotide.

In related aspects, methods are provided for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide of the present invention; (b) detecting in the sample an amount of a polynucleotide that  
5 hybridizes to the oligonucleotide; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

Within further aspects, the present invention provides antibodies, such as  
10 monoclonal antibodies, that bind to a polypeptide as described above, as well as diagnostic kits comprising such antibodies. Diagnostic kits comprising one or more oligonucleotide probes or primers as described above are also provided.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All  
15 references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

#### BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE IDENTIFIERS

Figure 1 illustrates the ability of T cells to kill fibroblasts expressing the representative prostate-specific polypeptide P502S, as compared to control fibroblasts.  
20 The percentage lysis is shown as a series of effector:target ratios, as indicated.

Figures 2A and 2B illustrate the ability of T cells to recognize cells expressing the representative prostate-specific polypeptide P502S. In each case, the number of  $\gamma$ -interferon spots is shown for different numbers of responders. In Figure 2A, data is presented for fibroblasts pulsed with the P2S-12 peptide, as compared to  
25 fibroblasts pulsed with a control E75 peptide. In Figure 2B, data is presented for fibroblasts expressing P502S, as compared to fibroblasts expressing HER-2/neu.

Figure 3 represents a peptide competition binding assay showing that the P1S#10 peptide, derived from P501S, binds HLA-A2. Peptide P1S#10 inhibits HLA-A2 restricted presentation of fluM58 peptide to CTL clone D150M58 in TNF release



bioassay. D150M58 CTL is specific for the HLA-A2 binding influenza matrix peptide fluM58.

Figure 4 illustrates the ability of T cell lines generated from P1S#10 immunized mice to specifically lyse P1S#10-pulsed Jurkat A2Kb targets and P501S-transduced Jurkat A2Kb targets, as compared to EGFP-transduced Jurkat A2Kb. The percent lysis is shown as a series of effector to target ratios, as indicated.

Figure 5 illustrates the ability of a T cell clone to recognize and specifically lyse Jurkat A2Kb cells expressing the representative prostate-specific polypeptide P501S, thereby demonstrating that the P1S#10 peptide may be a naturally processed epitope of the P501S polypeptide.

Figures 6A and 6B are graphs illustrating the specificity of a CD8<sup>+</sup> cell line (3A-1) for a representative prostate-specific antigen (P501S). Figure 6A shows the results of a <sup>51</sup>Cr release assay. The percent specific lysis is shown as a series of effector:target ratios, as indicated. Figure 6B shows the production of interferon-gamma by 3A-1 cells stimulated with autologous B-LCL transduced with P501S, at varying effector:target ratios as indicated.

Figure 7 is a Western blot showing the expression of P501S in baculovirus.

Figure 8 illustrates the results of epitope mapping studies on P501S.

Figure 9 is a schematic representation of the P501S protein showing the location of transmembrane domains and predicted intracellular and extracellular domains.

Figure 10 is a genomic map showing the location of the prostate genes P775P, P704P, B305D, P712P and P774P within the Cat Eye Syndrome region of chromosome 22q11.2

Figure 11 shows the results of an ELISA assay to determine the specificity of rabbit polyclonal antisera raised against P501S.

SEQ ID NO: 1 is the determined cDNA sequence for F1-13

SEQ ID NO: 2 is the determined 3' cDNA sequence for F1-12

SEQ ID NO: 3 is the determined 5' cDNA sequence for F1-12

- 5  
10  
15  
20  
25  
30
- SEQ ID NO: 4 is the determined 3' cDNA sequence for F1-16  
SEQ ID NO: 5 is the determined 3' cDNA sequence for H1-1  
SEQ ID NO: 6 is the determined 3' cDNA sequence for H1-9  
SEQ ID NO: 7 is the determined 3' cDNA sequence for H1-4  
SEQ ID NO: 8 is the determined 3' cDNA sequence for J1-17  
SEQ ID NO: 9 is the determined 5' cDNA sequence for J1-17  
SEQ ID NO: 10 is the determined 3' cDNA sequence for L1-12  
SEQ ID NO: 11 is the determined 5' cDNA sequence for L1-12  
SEQ ID NO: 12 is the determined 3' cDNA sequence for N1-1862  
SEQ ID NO: 13 is the determined 5' cDNA sequence for N1-1862  
SEQ ID NO: 14 is the determined 3' cDNA sequence for J1-13  
SEQ ID NO: 15 is the determined 5' cDNA sequence for J1-13  
SEQ ID NO: 16 is the determined 3' cDNA sequence for J1-19  
SEQ ID NO: 17 is the determined 5' cDNA sequence for J1-19  
SEQ ID NO: 18 is the determined 3' cDNA sequence for J1-25  
SEQ ID NO: 19 is the determined 5' cDNA sequence for J1-25  
SEQ ID NO: 20 is the determined 5' cDNA sequence for J1-24  
SEQ ID NO: 21 is the determined 3' cDNA sequence for J1-24  
SEQ ID NO: 22 is the determined 5' cDNA sequence for K1-58  
SEQ ID NO: 23 is the determined 3' cDNA sequence for K1-58  
SEQ ID NO: 24 is the determined 5' cDNA sequence for K1-63  
SEQ ID NO: 25 is the determined 3' cDNA sequence for K1-63  
SEQ ID NO: 26 is the determined 5' cDNA sequence for L1-4  
SEQ ID NO: 27 is the determined 3' cDNA sequence for L1-4  
SEQ ID NO: 28 is the determined 5' cDNA sequence for L1-14  
SEQ ID NO: 29 is the determined 3' cDNA sequence for L1-14  
SEQ ID NO: 30 is the determined 3' cDNA sequence for J1-12  
SEQ ID NO: 31 is the determined 3' cDNA sequence for J1-16  
SEQ ID NO: 32 is the determined 3' cDNA sequence for J1-21  
SEQ ID NO: 33 is the determined 3' cDNA sequence for K1-48

SEQ ID NO: 34 is the determined 3' cDNA sequence for K1-55  
SEQ ID NO: 35 is the determined 3' cDNA sequence for L1-2  
SEQ ID NO: 36 is the determined 3' cDNA sequence for L1-6  
SEQ ID NO: 37 is the determined 3' cDNA sequence for N1-1858  
5 SEQ ID NO: 38 is the determined 3' cDNA sequence for N1-1860  
SEQ ID NO: 39 is the determined 3' cDNA sequence for N1-1861  
SEQ ID NO: 40 is the determined 3' cDNA sequence for N1-1864  
SEQ ID NO: 41 is the determined cDNA sequence for P5  
SEQ ID NO: 42 is the determined cDNA sequence for P8  
10 SEQ ID NO: 43 is the determined cDNA sequence for P9  
SEQ ID NO: 44 is the determined cDNA sequence for P18  
SEQ ID NO: 45 is the determined cDNA sequence for P20  
SEQ ID NO: 46 is the determined cDNA sequence for P29  
SEQ ID NO: 47 is the determined cDNA sequence for P30  
15 SEQ ID NO: 48 is the determined cDNA sequence for P34  
SEQ ID NO: 49 is the determined cDNA sequence for P36  
SEQ ID NO: 50 is the determined cDNA sequence for P38  
SEQ ID NO: 51 is the determined cDNA sequence for P39  
SEQ ID NO: 52 is the determined cDNA sequence for P42  
20 SEQ ID NO: 53 is the determined cDNA sequence for P47  
SEQ ID NO: 54 is the determined cDNA sequence for P49  
SEQ ID NO: 55 is the determined cDNA sequence for P50  
SEQ ID NO: 56 is the determined cDNA sequence for P53  
SEQ ID NO: 57 is the determined cDNA sequence for P55  
25 SEQ ID NO: 58 is the determined cDNA sequence for P60  
SEQ ID NO: 59 is the determined cDNA sequence for P64  
SEQ ID NO: 60 is the determined cDNA sequence for P65  
SEQ ID NO: 61 is the determined cDNA sequence for P73  
SEQ ID NO: 62 is the determined cDNA sequence for P75  
30 SEQ ID NO: 63 is the determined cDNA sequence for P76

SEQ ID NO: 64 is the determined cDNA sequence for P79

SEQ ID NO: 65 is the determined cDNA sequence for P84

SEQ ID NO: 66 is the determined cDNA sequence for P68

SEQ ID NO: 67 is the determined cDNA sequence for P80 (also referred

5 to as P704P)

SEQ ID NO: 68 is the determined cDNA sequence for P82

SEQ ID NO: 69 is the determined cDNA sequence for U1-3064

SEQ ID NO: 70 is the determined cDNA sequence for U1-3065

SEQ ID NO: 71 is the determined cDNA sequence for V1-3692

10 SEQ ID NO: 72 is the determined cDNA sequence for 1A-3905

SEQ ID NO: 73 is the determined cDNA sequence for V1-3686

SEQ ID NO: 74 is the determined cDNA sequence for R1-2330

SEQ ID NO: 75 is the determined cDNA sequence for 1B-3976

SEQ ID NO: 76 is the determined cDNA sequence for V1-3679

15 SEQ ID NO: 77 is the determined cDNA sequence for 1G-4736

SEQ ID NO: 78 is the determined cDNA sequence for 1G-4738

SEQ ID NO: 79 is the determined cDNA sequence for 1G-4741

SEQ ID NO: 80 is the determined cDNA sequence for 1G-4744

SEQ ID NO: 81 is the determined cDNA sequence for 1G-4734

20 SEQ ID NO: 82 is the determined cDNA sequence for 1H-4774

SEQ ID NO: 83 is the determined cDNA sequence for 1H-4781

SEQ ID NO: 84 is the determined cDNA sequence for 1H-4785

SEQ ID NO: 85 is the determined cDNA sequence for 1H-4787

SEQ ID NO: 86 is the determined cDNA sequence for 1H-4796

25 SEQ ID NO: 87 is the determined cDNA sequence for 1I-4807

SEQ ID NO: 88 is the determined cDNA sequence for 1I-4810

SEQ ID NO: 89 is the determined cDNA sequence for 1I-4811

SEQ ID NO: 90 is the determined cDNA sequence for 1J-4876

SEQ ID NO: 91 is the determined cDNA sequence for 1K-4884

30 SEQ ID NO: 92 is the determined cDNA sequence for 1K-4896

- SEQ ID NO: 93 is the determined cDNA sequence for 1G-4761
- SEQ ID NO: 94 is the determined cDNA sequence for 1G-4762
- SEQ ID NO: 95 is the determined cDNA sequence for 1H-4766
- SEQ ID NO: 96 is the determined cDNA sequence for 1H-4770
- 5 SEQ ID NO: 97 is the determined cDNA sequence for 1H-4771
- SEQ ID NO: 98 is the determined cDNA sequence for 1H-4772
- SEQ ID NO: 99 is the determined cDNA sequence for 1D-4297
- SEQ ID NO: 100 is the determined cDNA sequence for 1D-4309
- SEQ ID NO: 101 is the determined cDNA sequence for 1D.1-4278
- 10 SEQ ID NO: 102 is the determined cDNA sequence for 1D-4288
- SEQ ID NO: 103 is the determined cDNA sequence for 1D-4283
- SEQ ID NO: 104 is the determined cDNA sequence for 1D-4304
- SEQ ID NO: 105 is the determined cDNA sequence for 1D-4296
- SEQ ID NO: 106 is the determined cDNA sequence for 1D-4280
- 15 SEQ ID NO: 107 is the determined full length cDNA sequence for F1-12  
(also referred to as P504S)
- SEQ ID NO: 108 is the predicted amino acid sequence for F1-12
- SEQ ID NO: 109 is the determined full length cDNA sequence for J1-17
- SEQ ID NO: 110 is the determined full length cDNA sequence for L1-12
- 20 (also referred to as P501S)
- SEQ ID NO: 111 is the determined full length cDNA sequence for N1-1862 (also referred to as P503S)
- SEQ ID NO: 112 is the predicted amino acid sequence for J1-17
- SEQ ID NO: 113 is the predicted amino acid sequence for L1-12 (also
- 25 referred to as P501S)
- SEQ ID NO: 114 is the predicted amino acid sequence for N1-1862 (also referred to as P503S)
- SEQ ID NO: 115 is the determined cDNA sequence for P89
- SEQ ID NO: 116 is the determined cDNA sequence for P90
- 30 SEQ ID NO: 117 is the determined cDNA sequence for P92

SEQ ID NO: 118 is the determined cDNA sequence for P95  
SEQ ID NO: 119 is the determined cDNA sequence for P98  
SEQ ID NO: 120 is the determined cDNA sequence for P102  
SEQ ID NO: 121 is the determined cDNA sequence for P110  
5 SEQ ID NO: 122 is the determined cDNA sequence for P111  
SEQ ID NO: 123 is the determined cDNA sequence for P114  
SEQ ID NO: 124 is the determined cDNA sequence for P115  
SEQ ID NO: 125 is the determined cDNA sequence for P116  
SEQ ID NO: 126 is the determined cDNA sequence for P124  
10 SEQ ID NO: 127 is the determined cDNA sequence for P126  
SEQ ID NO: 128 is the determined cDNA sequence for P130  
SEQ ID NO: 129 is the determined cDNA sequence for P133  
SEQ ID NO: 130 is the determined cDNA sequence for P138  
SEQ ID NO: 131 is the determined cDNA sequence for P143  
15 SEQ ID NO: 132 is the determined cDNA sequence for P151  
SEQ ID NO: 133 is the determined cDNA sequence for P156  
SEQ ID NO: 134 is the determined cDNA sequence for P157  
SEQ ID NO: 135 is the determined cDNA sequence for P166  
SEQ ID NO: 136 is the determined cDNA sequence for P176  
20 SEQ ID NO: 137 is the determined cDNA sequence for P178  
SEQ ID NO: 138 is the determined cDNA sequence for P179  
SEQ ID NO: 139 is the determined cDNA sequence for P185  
SEQ ID NO: 140 is the determined cDNA sequence for P192  
SEQ ID NO: 141 is the determined cDNA sequence for P201  
25 SEQ ID NO: 142 is the determined cDNA sequence for P204  
SEQ ID NO: 143 is the determined cDNA sequence for P208  
SEQ ID NO: 144 is the determined cDNA sequence for P211  
SEQ ID NO: 145 is the determined cDNA sequence for P213  
SEQ ID NO: 146 is the determined cDNA sequence for P219  
30 SEQ ID NO: 147 is the determined cDNA sequence for P237

SEQ ID NO: 148 is the determined cDNA sequence for P239  
SEQ ID NO: 149 is the determined cDNA sequence for P248  
SEQ ID NO: 150 is the determined cDNA sequence for P251  
SEQ ID NO: 151 is the determined cDNA sequence for P255  
5 SEQ ID NO: 152 is the determined cDNA sequence for P256  
SEQ ID NO: 153 is the determined cDNA sequence for P259  
SEQ ID NO: 154 is the determined cDNA sequence for P260  
SEQ ID NO: 155 is the determined cDNA sequence for P263  
SEQ ID NO: 156 is the determined cDNA sequence for P264  
10 SEQ ID NO: 157 is the determined cDNA sequence for P266  
SEQ ID NO: 158 is the determined cDNA sequence for P270  
SEQ ID NO: 159 is the determined cDNA sequence for P272  
SEQ ID NO: 160 is the determined cDNA sequence for P278  
SEQ ID NO: 161 is the determined cDNA sequence for P105  
15 SEQ ID NO: 162 is the determined cDNA sequence for P107  
SEQ ID NO: 163 is the determined cDNA sequence for P137  
SEQ ID NO: 164 is the determined cDNA sequence for P194  
SEQ ID NO: 165 is the determined cDNA sequence for P195  
SEQ ID NO: 166 is the determined cDNA sequence for P196  
20 SEQ ID NO: 167 is the determined cDNA sequence for P220  
SEQ ID NO: 168 is the determined cDNA sequence for P234  
SEQ ID NO: 169 is the determined cDNA sequence for P235  
SEQ ID NO: 170 is the determined cDNA sequence for P243  
SEQ ID NO: 171 is the determined cDNA sequence for P703P-DE1  
25 SEQ ID NO: 172 is the predicted amino acid sequence for P703P-DE1  
SEQ ID NO: 173 is the determined cDNA sequence for P703P-DE2  
SEQ ID NO: 174 is the determined cDNA sequence for P703P-DE6  
SEQ ID NO: 175 is the determined cDNA sequence for P703P-DE13  
SEQ ID NO: 176 is the predicted amino acid sequence for P703P-DE13  
30 SEQ ID NO: 177 is the determined cDNA sequence for P703P-DE14

SEQ ID NO: 178 is the predicted amino acid sequence for P703P-DE14

SEQ ID NO: 179 is the determined extended cDNA sequence for 1G-

4736

SEQ ID NO: 180 is the determined extended cDNA sequence for 1G-

5 4738

SEQ ID NO: 181 is the determined extended cDNA sequence for 1G-

4741

SEQ ID NO: 182 is the determined extended cDNA sequence for 1G-

4744

10

SEQ ID NO: 183 is the determined extended cDNA sequence for 1H-

4774

SEQ ID NO: 184 is the determined extended cDNA sequence for 1H-

4781

SEQ ID NO: 185 is the determined extended cDNA sequence for 1H-

15 4785

SEQ ID NO: 186 is the determined extended cDNA sequence for 1H-

4787

SEQ ID NO: 187 is the determined extended cDNA sequence for 1H-

4796

20

SEQ ID NO: 188 is the determined extended cDNA sequence for 1I-

4807

SEQ ID NO: 189 is the determined 3' cDNA sequence for 1I-4810

SEQ ID NO: 190 is the determined 3' cDNA sequence for 1I-4811

SEQ ID NO: 191 is the determined extended cDNA sequence for 1J-

25 4876

SEQ ID NO: 192 is the determined extended cDNA sequence for 1K-

4884

SEQ ID NO: 193 is the determined extended cDNA sequence for 1K-

4896



- 4761 SEQ ID NO: 194 is the determined extended cDNA sequence for 1G-
- 4762 SEQ ID NO: 195 is the determined extended cDNA sequence for 1G-
- 5 4766 SEQ ID NO: 196 is the determined extended cDNA sequence for 1H-
- SEQ ID NO: 197 is the determined 3' cDNA sequence for 1H-4770
- SEQ ID NO: 198 is the determined 3' cDNA sequence for 1H-4771
- 10 4772 SEQ ID NO: 199 is the determined extended cDNA sequence for 1H-
- SEQ ID NO: 200 is the determined extended cDNA sequence for 1D-
- 4309 SEQ ID NO: 201 is the determined extended cDNA sequence for 1D.1-
- 4278 SEQ ID NO: 202 is the determined extended cDNA sequence for 1D-
- 15 4288 SEQ ID NO: 203 is the determined extended cDNA sequence for 1D-
- 4283 SEQ ID NO: 204 is the determined extended cDNA sequence for 1D-
- 20 4304 SEQ ID NO: 205 is the determined extended cDNA sequence for 1D-
- 4296 SEQ ID NO: 206 is the determined extended cDNA sequence for 1D-
- 4280 SEQ ID NO: 207 is the determined cDNA sequence for 10-d8fwd
- 25 SEQ ID NO: 208 is the determined cDNA sequence for 10-H10con
- SEQ ID NO: 209 is the determined cDNA sequence for 11-C8rev
- SEQ ID NO: 210 is the determined cDNA sequence for 7.g6fwd
- SEQ ID NO: 211 is the determined cDNA sequence for 7.g6rev
- 30 SEQ ID NO: 212 is the determined cDNA sequence for 8-b5fwd

SEQ ID NO: 213 is the determined cDNA sequence for 8-b5rev  
SEQ ID NO: 214 is the determined cDNA sequence for 8-b6fwd  
SEQ ID NO: 215 is the determined cDNA sequence for 8-b6 rev  
SEQ ID NO: 216 is the determined cDNA sequence for 8-d4fwd  
5 SEQ ID NO: 217 is the determined cDNA sequence for 8-d9rev  
SEQ ID NO: 218 is the determined cDNA sequence for 8-g3fwd  
SEQ ID NO: 219 is the determined cDNA sequence for 8-g3rev  
SEQ ID NO: 220 is the determined cDNA sequence for 8-h11rev  
SEQ ID NO: 221 is the determined cDNA sequence for g-f12fwd  
10 SEQ ID NO: 222 is the determined cDNA sequence for g-f3rev  
SEQ ID NO: 223 is the determined cDNA sequence for P509S  
SEQ ID NO: 224 is the determined cDNA sequence for P510S  
SEQ ID NO: 225 is the determined cDNA sequence for P703DE5  
SEQ ID NO: 226 is the determined cDNA sequence for 9-A11  
15 SEQ ID NO: 227 is the determined cDNA sequence for 8-C6  
SEQ ID NO: 228 is the determined cDNA sequence for 8-H7  
SEQ ID NO: 229 is the determined cDNA sequence for JPTPN13  
SEQ ID NO: 230 is the determined cDNA sequence for JPTPN14  
SEQ ID NO: 231 is the determined cDNA sequence for JPTPN23  
20 SEQ ID NO: 232 is the determined cDNA sequence for JPTPN24  
SEQ ID NO: 233 is the determined cDNA sequence for JPTPN25  
SEQ ID NO: 234 is the determined cDNA sequence for JPTPN30  
SEQ ID NO: 235 is the determined cDNA sequence for JPTPN34  
SEQ ID NO: 236 is the determined cDNA sequence for PTPN35  
25 SEQ ID NO: 237 is the determined cDNA sequence for JPTPN36  
SEQ ID NO: 238 is the determined cDNA sequence for JPTPN38  
SEQ ID NO: 239 is the determined cDNA sequence for JPTPN39  
SEQ ID NO: 240 is the determined cDNA sequence for JPTPN40  
SEQ ID NO: 241 is the determined cDNA sequence for JPTPN41  
30 SEQ ID NO: 242 is the determined cDNA sequence for JPTPN42

SEQ ID NO: 243 is the determined cDNA sequence for JPTPN45  
SEQ ID NO: 244 is the determined cDNA sequence for JPTPN46  
SEQ ID NO: 245 is the determined cDNA sequence for JPTPN51  
SEQ ID NO: 246 is the determined cDNA sequence for JPTPN56  
5 SEQ ID NO: 247 is the determined cDNA sequence for PTPN64  
SEQ ID NO: 248 is the determined cDNA sequence for JPTPN65  
SEQ ID NO: 249 is the determined cDNA sequence for JPTPN67  
SEQ ID NO: 250 is the determined cDNA sequence for JPTPN76  
SEQ ID NO: 251 is the determined cDNA sequence for JPTPN84  
10 SEQ ID NO: 252 is the determined cDNA sequence for JPTPN85  
SEQ ID NO: 253 is the determined cDNA sequence for JPTPN86  
SEQ ID NO: 254 is the determined cDNA sequence for JPTPN87  
SEQ ID NO: 255 is the determined cDNA sequence for JPTPN88  
SEQ ID NO: 256 is the determined cDNA sequence for JP1F1  
15 SEQ ID NO: 257 is the determined cDNA sequence for JP1F2  
SEQ ID NO: 258 is the determined cDNA sequence for JP1C2  
SEQ ID NO: 259 is the determined cDNA sequence for JP1B1  
SEQ ID NO: 260 is the determined cDNA sequence for JP1B2  
SEQ ID NO: 261 is the determined cDNA sequence for JP1D3  
20 SEQ ID NO: 262 is the determined cDNA sequence for JP1A4  
SEQ ID NO: 263 is the determined cDNA sequence for JP1F5  
SEQ ID NO: 264 is the determined cDNA sequence for JP1E6  
SEQ ID NO: 265 is the determined cDNA sequence for JP1D6  
SEQ ID NO: 266 is the determined cDNA sequence for JP1B5  
25 SEQ ID NO: 267 is the determined cDNA sequence for JP1A6  
SEQ ID NO: 268 is the determined cDNA sequence for JP1E8  
SEQ ID NO: 269 is the determined cDNA sequence for JP1D7  
SEQ ID NO: 270 is the determined cDNA sequence for JP1D9  
SEQ ID NO: 271 is the determined cDNA sequence for JP1C10  
30 SEQ ID NO: 272 is the determined cDNA sequence for JP1A9

SEQ ID NO: 273 is the determined cDNA sequence for JP1F12  
SEQ ID NO: 274 is the determined cDNA sequence for JP1E12  
SEQ ID NO: 275 is the determined cDNA sequence for JP1D11  
SEQ ID NO: 276 is the determined cDNA sequence for JP1C11  
5 SEQ ID NO: 277 is the determined cDNA sequence for JP1C12  
SEQ ID NO: 278 is the determined cDNA sequence for JP1B12  
SEQ ID NO: 279 is the determined cDNA sequence for JP1A12  
SEQ ID NO: 280 is the determined cDNA sequence for JP8G2  
SEQ ID NO: 281 is the determined cDNA sequence for JP8H1  
10 SEQ ID NO: 282 is the determined cDNA sequence for JP8H2  
SEQ ID NO: 283 is the determined cDNA sequence for JP8A3  
SEQ ID NO: 284 is the determined cDNA sequence for JP8A4  
SEQ ID NO: 285 is the determined cDNA sequence for JP8C3  
SEQ ID NO: 286 is the determined cDNA sequence for JP8G4  
15 SEQ ID NO: 287 is the determined cDNA sequence for JP8B6  
SEQ ID NO: 288 is the determined cDNA sequence for JP8D6  
SEQ ID NO: 289 is the determined cDNA sequence for JP8F5  
SEQ ID NO: 290 is the determined cDNA sequence for JP8A8  
SEQ ID NO: 291 is the determined cDNA sequence for JP8C7  
20 SEQ ID NO: 292 is the determined cDNA sequence for JP8D7  
SEQ ID NO: 293 is the determined cDNA sequence for P8D8  
SEQ ID NO: 294 is the determined cDNA sequence for JP8E7  
SEQ ID NO: 295 is the determined cDNA sequence for JP8F8  
SEQ ID NO: 296 is the determined cDNA sequence for JP8G8  
25 SEQ ID NO: 297 is the determined cDNA sequence for JP8B10  
SEQ ID NO: 298 is the determined cDNA sequence for JP8C10  
SEQ ID NO: 299 is the determined cDNA sequence for JP8E9  
SEQ ID NO: 300 is the determined cDNA sequence for JP8E10  
SEQ ID NO: 301 is the determined cDNA sequence for JP8F9  
30 SEQ ID NO: 302 is the determined cDNA sequence for JP8H9

- SEQ ID NO: 303 is the determined cDNA sequence for JP8C12  
SEQ ID NO: 304 is the determined cDNA sequence for JP8E11  
SEQ ID NO: 305 is the determined cDNA sequence for JP8E12  
SEQ ID NO: 306 is the amino acid sequence for the peptide PS2#12  
5 SEQ ID NO: 307 is the determined cDNA sequence for P711P  
SEQ ID NO: 308 is the determined cDNA sequence for P712P  
SEQ ID NO: 309 is the determined cDNA sequence for CLONE23  
SEQ ID NO: 310 is the determined cDNA sequence for P774P  
SEQ ID NO: 311 is the determined cDNA sequence for P775P  
10 SEQ ID NO: 312 is the determined cDNA sequence for P715P  
SEQ ID NO: 313 is the determined cDNA sequence for P710P  
SEQ ID NO: 314 is the determined cDNA sequence for P767P  
SEQ ID NO: 315 is the determined cDNA sequence for P768P  
SEQ ID NO: 316-325 are the determined cDNA sequences of previously  
15 isolated genes  
SEQ ID NO: 326 is the determined cDNA sequence for P703PDE5  
SEQ ID NO: 327 is the predicted amino acid sequence for P703PDE5  
SEQ ID NO: 328 is the determined cDNA sequence for P703P6.26  
SEQ ID NO: 329 is the predicted amino acid sequence for P703P6.26  
20 SEQ ID NO: 330 is the determined cDNA sequence for P703PX-23  
SEQ ID NO: 331 is the predicted amino acid sequence for P703PX-23  
SEQ ID NO: 332 is the determined full length cDNA sequence for  
P509S  
SEQ ID NO: 333 is the determined extended cDNA sequence for P707P  
25 (also referred to as 11-C9)  
SEQ ID NO: 334 is the determined cDNA sequence for P714P  
SEQ ID NO: 335 is the determined cDNA sequence for P705P (also  
referred to as 9-F3)  
SEQ ID NO: 336 is the predicted amino acid sequence for P705P  
30 SEQ ID NO: 337 is the amino acid sequence of the peptide P1S#10

- SEQ ID NO: 338 is the amino acid sequence of the peptide p5  
SEQ ID NO: 339 is the predicted amino acid sequence of P509S  
SEQ ID NO: 340 is the determined cDNA sequence for P778P  
SEQ ID NO: 341 is the determined cDNA sequence for P786P  
5 SEQ ID NO: 342 is the determined cDNA sequence for P789P  
SEQ ID NO: 343 is the determined cDNA sequence for a clone showing  
homology to Homo sapiens MM46 mRNA  
SEQ ID NO: 344 is the determined cDNA sequence for a clone showing  
homology to Homo sapiens TNF-alpha stimulated ABC protein (ABC50) mRNA  
10 SEQ ID NO: 345 is the determined cDNA sequence for a clone showing  
homology to Homo sapiens mRNA for E-cadherin  
SEQ ID NO: 346 is the determined cDNA sequence for a clone showing  
homology to Human nuclear-encoded mitochondrial serine hydroxymethyltransferase  
(SHMT)  
15 SEQ ID NO: 347 is the determined cDNA sequence for a clone showing  
homology to Homo sapiens natural resistance-associated macrophage protein2  
(NRAMP2)  
SEQ ID NO: 348 is the determined cDNA sequence for a clone showing  
homology to Homo sapiens phosphoglucomutase-related protein (PGMRP)  
20 SEQ ID NO: 349 is the determined cDNA sequence for a clone showing  
homology to Human mRNA for proteosome subunit p40  
SEQ ID NO: 350 is the determined cDNA sequence for P777P  
SEQ ID NO: 351 is the determined cDNA sequence for P779P  
SEQ ID NO: 352 is the determined cDNA sequence for P790P  
25 SEQ ID NO: 353 is the determined cDNA sequence for P784P  
SEQ ID NO: 354 is the determined cDNA sequence for P776P  
SEQ ID NO: 355 is the determined cDNA sequence for P780P  
SEQ ID NO: 356 is the determined cDNA sequence for P544S  
SEQ ID NO: 357 is the determined cDNA sequence for P745S  
30 SEQ ID NO: 358 is the determined cDNA sequence for P782P

SEQ ID NO: 359 is the determined cDNA sequence for P783P

SEQ ID NO: 360 is the determined cDNA sequence for unknown 17984

SEQ ID NO: 361 is the determined cDNA sequence for P787P.

SEQ ID NO: 362 is the determined cDNA sequence for P788P

5 SEQ ID NO: 363 is the determined cDNA sequence for unknown 17994

SEQ ID NO: 364 is the determined cDNA sequence for P781P

SEQ ID NO: 365 is the determined cDNA sequence for P785P

SEQ ID NO: 366-375 are the determined cDNA sequences for splice variants of B305D.

10 SEQ ID NO: 376 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 366.

SEQ ID NO: 377 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 372.

15 SEQ ID NO: 378 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 373.

SEQ ID NO: 379 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 374.

SEQ ID NO: 380 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 375.

20 SEQ ID NO: 381 is the determined cDNA sequence for B716P.

SEQ ID NO: 382 is the determined full-length cDNA sequence for P711P.

SEQ ID NO: 383 is the predicted amino acid sequence for P711P.

SEQ ID NO: 384 is the cDNA sequence for P1000C.

25 SEQ ID NO: 385 is the cDNA sequence for CGI-82.

SEQ ID NO: 386 is the cDNA sequence for 23320.

SEQ ID NO: 387 is the cDNA sequence for CGI-69.

SEQ ID NO: 388 is the cDNA sequence for L-iditol-2-dehydrogenase.

SEQ ID NO: 389 is the cDNA sequence for 23379.

30 SEQ ID NO: 390 is the cDNA sequence for 23381.

- SEQ ID NO:391 is the cDNA sequence for KIAA0122.
- SEQ ID NO:392 is the cDNA sequence for 23399.
- SEQ ID NO:393 is the cDNA sequence for a previously identified gene.
- SEQ ID NO:394 is the cDNA sequence for HCLBP.
- 5 SEQ ID NO:395 is the cDNA sequence for transglutaminase.
- SEQ ID NO:396 is the cDNA sequence for a previously identified gene.
- SEQ ID NO:397 is the cDNA sequence for PAP.
- SEQ ID NO:398 is the cDNA sequence for Ets transcription factor
- PDEF.
- 10 SEQ ID NO:399 is the cDNA sequence for hTGR.
- SEQ ID NO:400 is the cDNA sequence for KIAA0295.
- SEQ ID NO:401 is the cDNA sequence for 22545.
- SEQ ID NO:402 is the cDNA sequence for 22547.
- SEQ ID NO:403 is the cDNA sequence for 22548.
- 15 SEQ ID NO:404 is the cDNA sequence for 22550.
- SEQ ID NO:405 is the cDNA sequence for 22551.
- SEQ ID NO:406 is the cDNA sequence for 22552.
- SEQ ID NO:407 is the cDNA sequence for 22553 (also known as
- P1020C).
- 20 SEQ ID NO:408 is the cDNA sequence for 22558.
- SEQ ID NO:409 is the cDNA sequence for 22562.
- SEQ ID NO:410 is the cDNA sequence for 22565.
- SEQ ID NO:411 is the cDNA sequence for 22567.
- SEQ ID NO:412 is the cDNA sequence for 22568.
- 25 SEQ ID NO:413 is the cDNA sequence for 22570.
- SEQ ID NO:414 is the cDNA sequence for 22571.
- SEQ ID NO:415 is the cDNA sequence for 22572.
- SEQ ID NO:416 is the cDNA sequence for 22573.
- SEQ ID NO:417 is the cDNA sequence for 22573.
- 30 SEQ ID NO:418 is the cDNA sequence for 22575.



SEQ ID NO:419 is the cDNA sequence for 22580.  
SEQ ID NO:420 is the cDNA sequence for 22581.  
SEQ ID NO:421 is the cDNA sequence for 22582.  
SEQ ID NO:422 is the cDNA sequence for 22583.  
5 SEQ ID NO:423 is the cDNA sequence for 22584.  
SEQ ID NO:424 is the cDNA sequence for 22585.  
SEQ ID NO:425 is the cDNA sequence for 22586.  
SEQ ID NO:426 is the cDNA sequence for 22587.  
SEQ ID NO:427 is the cDNA sequence for 22588.  
10 SEQ ID NO:428 is the cDNA sequence for 22589.  
SEQ ID NO:429 is the cDNA sequence for 22590.  
SEQ ID NO:430 is the cDNA sequence for 22591.  
SEQ ID NO:431 is the cDNA sequence for 22592.  
SEQ ID NO:432 is the cDNA sequence for 22593.  
15 SEQ ID NO:433 is the cDNA sequence for 22594.  
SEQ ID NO:434 is the cDNA sequence for 22595.  
SEQ ID NO:435 is the cDNA sequence for 22596.  
SEQ ID NO:436 is the cDNA sequence for 22847.  
SEQ ID NO:437 is the cDNA sequence for 22848.  
20 SEQ ID NO:438 is the cDNA sequence for 22849.  
SEQ ID NO:439 is the cDNA sequence for 22851.  
SEQ ID NO:440 is the cDNA sequence for 22852.  
SEQ ID NO:441 is the cDNA sequence for 22853.  
SEQ ID NO:442 is the cDNA sequence for 22854.  
25 SEQ ID NO:443 is the cDNA sequence for 22855.  
SEQ ID NO:444 is the cDNA sequence for 22856.  
SEQ ID NO:445 is the cDNA sequence for 22857.  
SEQ ID NO:446 is the cDNA sequence for 23601.  
SEQ ID NO:447 is the cDNA sequence for 23602.  
30 SEQ ID NO:448 is the cDNA sequence for 23605.

- SEQ ID NO:449 is the cDNA sequence for 23606.
- SEQ ID NO:450 is the cDNA sequence for 23612.
- SEQ ID NO:451 is the cDNA sequence for 23614.
- SEQ ID NO:452 is the cDNA sequence for 23618.
- 5 SEQ ID NO:453 is the cDNA sequence for 23622.
- SEQ ID NO:454 is the cDNA sequence for folate hydrolase.
- SEQ ID NO:455 is the cDNA sequence for LIM protein.
- SEQ ID NO:456 is the cDNA sequence for a known gene.
- SEQ ID NO:457 is the cDNA sequence for a known gene.
- 10 SEQ ID NO:458 is the cDNA sequence for a previously identified gene.
- SEQ ID NO:459 is the cDNA sequence for 23045.
- SEQ ID NO:460 is the cDNA sequence for 23032.
- SEQ ID NO:461 is the cDNA sequence for clone 23054.
- SEQ ID NO:462-467 are cDNA sequences for known genes.
- 15 SEQ ID NO:468-471 are cDNA sequences for P710P.
- SEQ ID NO:472 is a cDNA sequence for P1001C.
- SEQ ID NO: 473 is the determined cDNA sequence for a first splice variant of P775P (referred to as 27505).
- SEQ ID NO: 474 is the determined cDNA sequence for a second splice
- 20 variant of P775P (referred to as 19947).
- SEQ ID NO: 475 is the determined cDNA sequence for a third splice variant of P775P (referred to as 19941).
- SEQ ID NO: 476 is the determined cDNA sequence for a fourth splice variant of P775P (referred to as 19937).
- 25 SEQ ID NO: 477 is a first predicted amino acid sequence encoded by the sequence of SEQ ID NO: 474.
- SEQ ID NO: 478 is a second predicted amino acid sequence encoded by the sequence of SEQ ID NO: 474.
- SEQ ID NO: 479 is the predicted amino acid sequence encoded by the
- 30 sequence of SEQ ID NO: 475.

SEQ ID NO: 480 is a first predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

SEQ ID NO: 481 is a second predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

5           SEQ ID NO: 482 is a third predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

SEQ ID NO: 483 is a fourth predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

10           SEQ ID NO: 484 is the first 30 amino acids of the *M. tuberculosis* antigen Ra12.

SEQ ID NO: 485 is the PCR primer AW025.

SEQ ID NO: 486 is the PCR primer AW003.

SEQ ID NO: 487 is the PCR primer AW027.

SEQ ID NO: 488 is the PCR primer AW026.

15           SEQ ID NO: 489-501 are peptides employed in epitope mapping studies.

SEQ ID NO: 502 is the determined cDNA sequence of the complementarity determining region for the anti-P503S monoclonal antibody 20D4.

SEQ ID NO: 503 is the determined cDNA sequence of the complementarity determining region for the anti-P503S monoclonal antibody JA1.

20           SEQ ID NO: 504 & 505 are peptides employed in epitope mapping studies.

SEQ ID NO: 506 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 8H2.

25           SEQ ID NO: 507 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 7H8.

SEQ ID NO: 508 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 2D4.

SEQ ID NO: 509-522 are peptides employed in epitope mapping studies.

30           SEQ ID NO: 523 is a mature form of P703P used to raise antibodies against P703P.

- SEQ ID NO: 524 is the putative full-length cDNA sequence of P703P.  
SEQ ID NO: 525 is the predicted amino acid sequence encoded by SEQ  
ID NO: 524.
- 5 SEQ ID NO: 526 is the full-length cDNA sequence for P790P.  
SEQ ID NO: 527 is the predicted amino acid sequence for P790P.  
SEQ ID NO: 528 & 529 are PCR primers.  
SEQ ID NO: 530 is the cDNA sequence of a splice variant of SEQ ID  
NO: 366.
- 10 SEQ ID NO: 531 is the cDNA sequence of the open reading frame of  
SEQ ID NO: 530.  
SEQ ID NO: 532 is the predicted amino acid encoded by the sequence of  
SEQ ID NO: 531.  
SEQ ID NO: 533 is the DNA sequence of a putative ORF of P775P.  
SEQ ID NO: 534 is the predicted amino acid sequence encoded by SEQ  
15 ID NO: 533.  
SEQ ID NO: 535 is a first full-length cDNA sequence for P510S.  
SEQ ID NO: 536 is a second full-length cDNA sequence for P510S.  
SEQ ID NO: 537 is the predicted amino acid sequence encoded by SEQ  
ID NO: 535.
- 20 SEQ ID NO: 538 is the predicted amino acid sequence encoded by SEQ  
ID NO: 536.  
SEQ ID NO: 539 is the peptide P501S-370.  
SEQ ID NO: 540 is the peptide P501S-376.  
SEQ ID NO: 541-551 are epitopes of P501S.
- 25 SEQ ID NO: 552 is an extended cDNA sequence for P712P.  
SEQ ID NO: 553-568 are the amino acid sequences encoded by  
predicted open reading frames within SEQ ID NO: 552.  
SEQ ID NO: 569 is an extended cDNA sequence for P776P.  
SEQ ID NO: 570 is the determined cDNA sequence for a splice variant  
30 of P776P referred to as contig 6.

SEQ ID NO: 571 is the determined cDNA sequence for a splice variant of P776P referred to as contig 7.

SEQ ID NO: 572 is the determined cDNA sequence for a splice variant of P776P referred to as contig 14.

5       SEQ ID NO: 573 is the amino acid sequence encoded by a first predicted ORF of SEQ ID NO: 570.

SEQ ID NO: 574 is the amino acid sequence encoded by a second predicted ORF of SEQ ID NO: 570.

10       SEQ ID NO: 575 is the amino acid sequence encoded by a predicted ORF of SEQ ID NO: 571.

SEQ ID NO: 576-586 are amino acid sequences encoded by predicted ORFs of SEQ ID NO: 569.

SEQ ID NO: 587 is a DNA consensus sequence of the sequences of P767P and P777P.

15       SEQ ID NO: 588-590 are amino acid sequences encoded by predicted ORFs of SEQ ID NO: 587.

SEQ ID NO: 591 is an extended cDNA sequence for P1020C.

SEQ ID NO: 592 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: P1020C.

20       SEQ ID NO: 593 is a splice variant of P775P referred to as 50748.

SEQ ID NO: 594 is a splice variant of P775P referred to as 50717.

SEQ ID NO: 595 is a splice variant of P775P referred to as 45985.

SEQ ID NO: 596 is a splice variant of P775P referred to as 38769.

SEQ ID NO: 597 is a splice variant of P775P referred to as 37922.

25       SEQ ID NO: 598 is a splice variant of P510S referred to as 49274.

SEQ ID NO: 599 is a splice variant of P510S referred to as 39487.

SEQ ID NO: 600 is a splice variant of P504S referred to as 5167.16.

SEQ ID NO: 601 is a splice variant of P504S referred to as 5167.1.

SEQ ID NO: 602 is a splice variant of P504S referred to as 5163.46.

30       SEQ ID NO: 603 is a splice variant of P504S referred to as 5163.42.

SEQ ID NO: 604 is a splice variant of P504S referred to as 5163.34.

SEQ ID NO: 605 is a splice variant of P504S referred to as 5163.17.

SEQ ID NO: 606 is a splice variant of P501S referred to as 10640.

SEQ ID NO: 607-615 are the sequences of PCR primers.

5           SEQ ID NO: 616 is the determined cDNA sequence of a fusion of P703P  
and PSA.

          SEQ ID NO: 617 is the amino acid sequence of the fusion of P703P and  
PSA.

          SEQ ID NO: 618 is the cDNA sequence of the gene DD3.

10           SEQ ID NO: 619 is an extended cDNA sequence for P714P.

          SEQ ID NO: 620-622 are the cDNA sequences for splice variants of  
P704P.

          SEQ ID NO: 623 is the cDNA sequence of a splice variant of P553S  
referred to as P553S-14.

15           SEQ ID NO: 624 is the cDNA sequence of a splice variant of P553S  
referred to as P553S-12.

          SEQ ID NO: 625 is the cDNA sequence of a splice variant of P553S  
referred to as P553S-10.

20           SEQ ID NO: 626 is the cDNA sequence of a splice variant of P553S  
referred to as P553S-6.

          SEQ ID NO: 627 is the amino acid sequence encoded by SEQ ID NO:  
626.

          SEQ ID NO: 628 is a first amino acid sequence encoded by SEQ ID NO:  
623.

25           SEQ ID NO: 629 is a second amino acid sequence encoded by SEQ ID  
NO: 623.

          SEQ ID NO: 630 is a first full-length cDNA sequence for prostate-  
specific transglutaminase gene (also referred to herein as P558S).

30           SEQ ID NO: 631 is a second full-length cDNA sequence for prostate-  
specific transglutaminase gene.

SEQ ID NO: 632 is the amino acid sequence encoded by the sequence of SEQ ID NO: 630.

SEQ ID NO: 633 is the amino acid sequence encoded by the sequence of SEQ ID NO: 631.

5 SEQ ID NO: 634 is the full-length cDNA sequence for P788P.

SEQ ID NO: 635 is the amino acid sequence encoded by SEQ ID NO: 634.

SEQ ID NO: 636 is the determined cDNA sequence for a polymorphic variant of P788P.

10 SEQ ID NO: 637 is the amino acid sequence encoded by SEQ ID NO: 636.

SEQ ID NO: 638 is the amino acid sequence of peptide 4 from P703P.

SEQ ID NO: 639 is the cDNA sequence that encodes peptide 4 from P703P.

15 SEQ ID NO: 640-655 are cDNA sequences encoding epitopes of P703P.

SEQ ID NO: 656-671 are the amino acid sequences of epitopes of P703P.

SEQ ID NO: 672 and 673 are PCR primers.

20 SEQ ID NO: 674 is the cDNA sequence encoding an N-terminal portion of P788P expressed in *E. coli*.

SEQ ID NO: 675 is the amino acid sequence of the N-terminal portion of P788P expressed in *E. coli*.

SEQ ID NO: 676 is the amino acid sequence of the *M. tuberculosis* antigen Ra12.

25 SEQ ID NO: 677 and 678 are PCR primers.

SEQ ID NO: 679 is the cDNA sequence for the Ra12-P510S-C construct.

SEQ ID NO: 680 is the cDNA sequence for the P510S-C construct.

SEQ ID NO: 681 is the cDNA sequence for the P510S-E3 construct.

SEQ ID NO: 682 is the amino acid sequence for the Ra12-P510S-C construct.

SEQ ID NO: 683 is the amino acid sequence for the P510S-C construct.

SEQ ID NO: 684 is the amino acid sequence for the P510S-E3 construct.

5 SEQ ID NO: 685-690 are PCR primers.

SEQ ID NO: 691 is the cDNA sequence of the construct Ra12-P775P-ORF3.

SEQ ID NO: 692 is the amino acid sequence of the construct Ra12-P775P-ORF3.

10 SEQ ID NO: 693 and 694 are PCR primers.

SEQ ID NO: 695 is the determined amino acid sequence for a P703P His tag fusion protein.

SEQ ID NO: 696 is the determined cDNA sequence for a P703P His tag fusion protein.

15 SEQ ID NO: 697 and 698 are PCR primers.

SEQ ID NO: 699 is the determined amino acid sequence for a P705P His tag fusion protein.

SEQ ID NO: 700 is the determined cDNA sequence for a P705P His tag fusion protein.

20 SEQ ID NO: 701 and 702 are PCR primers.

SEQ ID NO: 703 is the determined amino acid sequence for a P711P His tag fusion protein.

SEQ ID NO: 704 is the determined cDNA sequence for a P711P His tag fusion protein.

25 SEQ ID NO: 705 is the amino acid sequence of the *M. tuberculosis* antigen Ra12.

SEQ ID NO: 706 and 707 are PCR primers.

SEQ ID NO: 708 is the determined cDNA sequence for the construct Ra12-P501S-E2.



SEQ ID NO: 709 is the determined amino acid sequence for the construct Ra12-P501S-E2.

SEQ ID NO: 710 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 711 is the DNA sequence encoding SEQ ID NO: 710.

5 SEQ ID NO: 712 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 713 is the DNA sequence encoding SEQ ID NO: 712.

SEQ ID NO: 714 is a peptide employed in epitope mapping studies.

SEQ ID NO: 715 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 716 is the DNA sequence encoding SEQ ID NO: 715.

10 SEQ ID NO: 717-719 are the amino acid sequences for CD4 epitopes of P501S.

SEQ ID NO: 720-722 are the DNA sequences encoding the sequences of SEQ ID NO: 717-719.

15 SEQ ID NO: 723-734 are the amino acid sequences for putative CTL epitopes of P703P.

SEQ ID NO: 735 is the full-length cDNA sequence for P789P.

SEQ ID NO: 736 is the amino acid sequence encoded by SEQ ID NO: 735.

20 SEQ ID NO: 737 is the determined full-length cDNA sequence for the splice variant of P776P referred to as contig 6.

SEQ ID NO: 738-739 are determined full-length cDNA sequences for the splice variant of P776P referred to as contig 7.

SEQ ID NO: 740-744 are amino acid sequences encoded by SEQ ID NO: 737.

25 SEQ ID NO: 745-750 are amino acid sequences encoded by the splice variant of P776P referred to as contig 7.

SEQ ID NO: 751 is the full-length cDNA sequence for human transmembrane protease serine 2.

30 SEQ ID NO: 752 is the amino acid sequence encoded by SEQ ID NO: 751.

SEQ ID NO: 753 is the cDNA sequence encoding the first 209 amino acids of human transmembrane protease serine 2.

SEQ ID NO: 754 is the first 209 amino acids of human transmembrane protease serine 2.

5 SEQ ID NO: 755 is the amino acid sequence of peptide 296-322 of P501S.

SEQ ID NO: 756-759 are PCR primers.

SEQ ID NO: 760 is the determined cDNA sequence of the Vb chain of a T cell receptor for the P501S-specific T cell clone 4E5.

10 SEQ ID NO: 761 is the determined cDNA sequence of the Va chain of a T cell receptor for the P501S-specific T cell clone 4E5.

SEQ ID NO: 762 is the amino acid sequence encoded by SEQ ID NO 760.

15 SEQ ID NO: 763 is the amino acid sequence encoded by SEQ ID NO 761.

SEQ ID NO: 764 is the full-length open reading frame for P768P including stop codon.

SEQ ID NO: 765 is the full-length open reading frame for P768P without stop codon.

20 SEQ ID NO: 766 is the amino acid sequence encoded by SEQ ID NO: 765.

SEQ ID NO: 767-772 are the amino acid sequences for predicted domains of P768P.

SEQ ID NO: 773 is the full-length cDNA sequence of P835P.

25 SEQ ID NO: 774 is the cDNA sequence of the previously identified clone FLJ13581.

SEQ ID NO: 775 is the cDNA sequence of the open reading frame for P835P with stop codon.

30 SEQ ID NO: 776 is the cDNA sequence of the open reading frame for P835P without stop codon.

SEQ ID NO: 777 is the full-length amino acid sequence for P835P.

SEQ ID NO: 778-785 are the amino acid sequences of extracellular and intracellular domains of P835P.

SEQ ID NO: 786 is the full-length cDNA sequence for P1000C.

5. SEQ ID NO: 787 is the cDNA sequence of the open reading frame for P1000C, including stop codon.

SEQ ID NO: 788 is the cDNA sequence of the open reading frame for P1000C, without stop codon.

SEQ ID NO: 789 is the full-length amino acid sequence for P1000C.

10. SEQ ID NO: 790 is amino acids 1-100 of SEQ ID NO: 789.

SEQ ID NO: 791 is amino acids 100-492 of SEQ ID NO: 789.

SEQ ID NO: 792 is the amino acid sequence of an  $\alpha$  prepro-P501S recombinant protein.

## 15 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed generally to compositions and their use in the therapy and diagnosis of cancer, particularly prostate cancer. As described further below, illustrative compositions of the present invention include, but are not restricted to, polypeptides, particularly immunogenic polypeptides, polynucleotides encoding such polypeptides, antibodies and other binding agents, antigen presenting cells (APCs) and immune system cells (e.g., T cells).

The practice of the present invention will employ, unless indicated specifically to the contrary, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art, many of which are described below for the purpose of illustration. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al. Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Maniatis et al. Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., 1984); Nucleic Acid

Hybridization (B. Hames & S. Higgins, eds., 1985); Transcription and Translation (B. Hames & S. Higgins, eds., 1984); Animal Cell Culture (R. Freshney, ed., 1986); Perbal, A Practical Guide to Molecular Cloning (1984).

All publications, patents and patent applications cited herein, whether  
5 supra or infra, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

#### Polypeptide Compositions

10 As used herein, the term "polypeptide" is used in its conventional meaning, *i.e.*, as a sequence of amino acids. The polypeptides are not limited to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-  
15 expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof. Particular polypeptides of interest in the context of this invention are amino acid subsequences comprising epitopes, *i.e.*, antigenic  
20 determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of evoking an immune response.

Particularly illustrative polypeptides of the present invention comprise those encoded by a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382  
25 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, or a sequence that hybridizes under moderately stringent conditions, or, alternatively, under highly stringent conditions, to a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175,

177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788. In specific embodiments, the polypeptides of the invention  
5 comprise amino acid sequences as set forth in any one of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791.

10 The polypeptides of the present invention are sometimes herein referred to as prostate-specific proteins or prostate-specific polypeptides, as an indication that their identification has been based at least in part upon their increased levels of expression in prostate tissue samples. Thus, a "prostate-specific polypeptide" or "prostate-specific protein," refers generally to a polypeptide sequence of the present  
15 invention, or a polynucleotide sequence encoding such a polypeptide, that is expressed in a substantial proportion of prostate tissue samples, for example preferably greater than about 20%, more preferably greater than about 30%, and most preferably greater than about 50% or more of prostate tissue samples tested, at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in other  
20 normal tissues, as determined using a representative assay provided herein. A prostate-specific polypeptide sequence of the invention, based upon its increased level of expression in tumor cells, has particular utility both as a diagnostic marker as well as a therapeutic target, as further described below.

In certain preferred embodiments, the polypeptides of the invention are  
25 immunogenic, *i.e.*, they react detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with prostate cancer. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, *Antibodies: A Laboratory  
30 Manual*, Cold Spring Harbor Laboratory, 1988. In one illustrative example, a

polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, <sup>125</sup>I-labeled Protein A.

- 5           As would be recognized by the skilled artisan, immunogenic portions of the polypeptides disclosed herein are also encompassed by the present invention. An "immunogenic portion," as used herein, is a fragment of an immunogenic polypeptide of the invention that itself is immunologically reactive (*i.e.*, specifically binds) with the B-cells and/or T-cell surface antigen receptors that recognize the polypeptide.
- 10   Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they
- 15   specifically bind to an antigen (*i.e.*, they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques.

- In one preferred embodiment, an immunogenic portion of a polypeptide of the present invention is a portion that reacts with antisera and/or T-cells at a level that
- 20   is not substantially less than the reactivity of the full-length polypeptide (*e.g.*, in an ELISA and/or T-cell reactivity assay). Preferably, the level of immunogenic activity of the immunogenic portion is at least about 50%, preferably at least about 70% and most preferably greater than about 90% of the immunogenicity for the full-length polypeptide. In some instances, preferred immunogenic portions will be identified that
- 25   have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, *e.g.*, having greater than about 100% or 150% or more immunogenic activity.

- In certain other embodiments, illustrative immunogenic portions may include peptides in which an N-terminal leader sequence and/or transmembrane domain
- 30   has been deleted. Other illustrative immunogenic portions will contain a small N-

and/or C-terminal deletion (e.g., 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

In another embodiment, a polypeptide composition of the invention may also comprise one or more polypeptides that are immunologically reactive with T cells and/or antibodies generated against a polypeptide of the invention, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof.

In another embodiment of the invention, polypeptides are provided that comprise one or more polypeptides that are capable of eliciting T cells and/or antibodies that are immunologically reactive with one or more polypeptides described herein, or one or more polypeptides encoded by contiguous nucleic acid sequences contained in the polynucleotide sequences disclosed herein, or immunogenic fragments or variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

The present invention, in another aspect, provides polypeptide fragments comprising at least about 5, 10, 15, 20, 25, 50, or 100 contiguous amino acids, or more, including all intermediate lengths, of a polypeptide composition set forth herein, such as those set forth in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791, or those encoded by a polynucleotide sequence set forth in a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

In another aspect, the present invention provides variants of the polypeptide compositions described herein. Polypeptide variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity

(determined as described below), along its length, to a polypeptide sequence set forth herein.

In one preferred embodiment, the polypeptide fragments and variants provided by the present invention are immunologically reactive with an antibody and/or  
5 T-cell that reacts with a full-length polypeptide specifically set forth herein.

In another preferred embodiment, the polypeptide fragments and variants provided by the present invention exhibit a level of immunogenic activity of at least about 50%, preferably at least about 70%, and most preferably at least about 90% or more of that exhibited by a full-length polypeptide sequence specifically set forth  
10 herein.

A polypeptide "variant," as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of  
15 the above polypeptide sequences of the invention and evaluating their immunogenic activity as described herein using any of a number of techniques well known in the art.

For example, certain illustrative variants of the polypeptides of the invention include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other illustrative variants  
20 include variants in which a small portion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

In many instances, a variant will contain conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide  
25 chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. As described above, modifications may be made in the structure of the polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, *e.g.*, with immunogenic characteristics. When it is  
30 desired to alter the amino acid sequence of a polypeptide to create an equivalent, or



even an improved, immunogenic variant or portion of a polypeptide of the invention, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence according to Table 1.

For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

TABLE 1

Amino Acids			Codons					
Alanine	Ala	A	GCA	GCC	GCG	GCU		
Cysteine	Cys	C	UGC	UGU				
Aspartic acid	Asp	D	GAC	GAU				
Glutamic acid	Glu	E	GAA	GAG				
Phenylalanine	Phe	F	UUC	UUU				
Glycine	Gly	G	GGA	GGC	GGG	GGU		
Histidine	His	H	CAC	CAU				
Isoleucine	Ile	I	AUA	AUC	AUU			
Lysine	Lys	K	AAA	AAG				
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU
Methionine	Met	M	AUG					
Asparagine	Asn	N	AAC	AAU				
Proline	Pro	P	CCA	CCC	CCG	CCU		
Glutamine	Gln	Q	CAA	CAG				
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU		
Valine	Val	V	GUA	GUC	GUG	GUU		
Tryptophan	Trp	W	UGG					
Tyrosine	Tyr	Y	UAC	UAU				

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of its

hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5);  
5 glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, *i.e.* still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are  
10 within  $\pm 2$  is preferred, those within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101 (specifically incorporated herein by reference in its entirety), states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of  
15 its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5  $\pm$  1); alanine (-0.5); histidine (-0.5); cysteine  
20 (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$   
25 is preferred, those within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that  
30 take various of the foregoing characteristics into consideration are well known to those

of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In addition, any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of  
5 flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl-methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

10 Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values  
15 include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a  
20 preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide.

25 As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For  
30 example, a polypeptide may be conjugated to an immunoglobulin Fc region.

When comparing polypeptide sequences, two sequences are said to be "identical" if the sequence of amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics

Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for  
10 Biotechnology Information. For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is  
15 reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

In one preferred approach, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polypeptide sequence in  
20 the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of  
25 matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Within other illustrative embodiments, a polypeptide may be a fusion polypeptide that comprises multiple polypeptides as described herein, or that comprises  
30 at least one polypeptide as described herein and an unrelated sequence, such as a known

tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the polypeptide or to enable the polypeptide to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the polypeptide.

Fusion polypeptides may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion polypeptide is expressed as a recombinant polypeptide, allowing the production of increased levels, relative to a non-fused polypeptide, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion polypeptide that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al.,

*Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to  
5 separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and  
10 transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

The fusion polypeptide can comprise a polypeptide as described herein together with an unrelated immunogenic protein, such as an immunogenic protein capable of eliciting a recall response. Examples of such proteins include tetanus,  
15 tuberculosis and hepatitis proteins (*see, for example, Stoute et al. New Engl. J. Med.*, 336:86-91, 1997).

In one preferred embodiment, the immunological fusion partner is derived from a *Mycobacterium* sp., such as a *Mycobacterium tuberculosis*-derived Ra12 fragment. Ra12 compositions and methods for their use in enhancing the expression  
20 and/or immunogenicity of heterologous polynucleotide/polypeptide sequences is described in U.S. Patent Application 60/158,585, the disclosure of which is incorporated herein by reference in its entirety. Briefly, Ra12 refers to a polynucleotide region that is a subsequence of a *Mycobacterium tuberculosis* MTB32A nucleic acid. MTB32A is a serine protease of 32 KD molecular weight encoded by a gene in virulent  
25 and avirulent strains of *M. tuberculosis*. The nucleotide sequence and amino acid sequence of MTB32A have been described (for example, U.S. Patent Application 60/158,585; *see also, Skeiky et al., Infection and Immun.* (1999) 67:3998-4007, incorporated herein by reference). C-terminal fragments of the MTB32A coding  
30 sequence express at high levels and remain as a soluble polypeptides throughout the purification process. Moreover, Ra12 may enhance the immunogenicity of heterologous



immunogenic polypeptides with which it is fused. One preferred Ra12 fusion polypeptide comprises a 14 KD C-terminal fragment corresponding to amino acid residues 192 to 323 of MTB32A. Other preferred Ra12 polynucleotides generally comprise at least about 15 consecutive nucleotides, at least about 30 nucleotides, at least about 60 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, or at least about 300 nucleotides that encode a portion of a Ra12 polypeptide. Ra12 polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a Ra12 polypeptide or a portion thereof) or may comprise a variant of such a sequence. Ra12 polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded fusion polypeptide is not substantially diminished, relative to a fusion polypeptide comprising a native Ra12 polypeptide. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native Ra12 polypeptide or a portion thereof.

Within other preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza B* (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (*e.g.*, the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine

amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been  
5 exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see *Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion polypeptide. A repeat portion is found in the C-terminal region starting at  
10 residue 178. A particularly preferred repeat portion incorporates residues 188-305.

Yet another illustrative embodiment involves fusion polypeptides, and the polynucleotides encoding them, wherein the fusion partner comprises a targeting signal capable of directing a polypeptide to the endosomal/lysosomal compartment, as described in U.S. Patent No. 5,633,234. An immunogenic polypeptide of the invention,  
15 when fused with this targeting signal, will associate more efficiently with MHC class II molecules and thereby provide enhanced in vivo stimulation of CD4<sup>+</sup> T-cells specific for the polypeptide.

Polypeptides of the invention are prepared using any of a variety of well known synthetic and/or recombinant techniques, the latter of which are further  
20 described below. Polypeptides, portions and other variants generally less than about 150 amino acids can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. In one illustrative example, such polypeptides are synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a  
25 growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

In general, polypeptide compositions (including fusion polypeptides) of  
30 the invention are isolated. An "isolated" polypeptide is one that is removed from its

original environment. For example, a naturally-occurring protein or polypeptide is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are also purified, *e.g.*, are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure.

### Polynucleotide Compositions

The present invention, in other aspects, provides polynucleotide compositions. The terms "DNA" and "polynucleotide" are used essentially interchangeably herein to refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. "Isolated," as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA molecule does not contain large portions of unrelated coding DNA, such as large chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA molecule as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

As will be understood by those skilled in the art, the polynucleotide compositions of this invention can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may be naturally isolated, or modified synthetically by the hand of man.

As will be also recognized by the skilled artisan, polynucleotides of the invention may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules may include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a polypeptide/protein of the invention or a portion thereof) or may comprise a sequence that encodes a variant or derivative, preferably an immunogenic variant or derivative, of such a sequence.

5           Therefore, according to another aspect of the present invention, polynucleotide compositions are provided that comprise some or all of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655,  
10 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, complements of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722,  
15 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, and degenerate variants of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788. In certain preferred embodiments, the polynucleotide sequences set forth herein encode immunogenic polypeptides, as described above.

          In other related embodiments, the present invention provides polynucleotide variants having substantial identity to the sequences disclosed herein in SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-  
25 335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a  
30 polynucleotide sequence of this invention using the methods described herein, (*e.g.*,

BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

Typically, polynucleotide variants will contain one or more substitutions, additions, deletions and/or insertions, preferably such that the immunogenicity of the polypeptide encoded by the variant polynucleotide is not substantially diminished relative to a polypeptide encoded by a polynucleotide sequence specifically set forth herein). The term "variants" should also be understood to encompass homologous genes of xenogenic origin.

In additional embodiments, the present invention provides polynucleotide fragments comprising various lengths of contiguous stretches of sequence identical to, or complementary to, one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50, 51, 52, 53, *etc.*; 100, 101, 102, 103, *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like.

In another embodiment of the invention, polynucleotide compositions are provided that are capable of hybridizing under moderate to high stringency conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-60°C, 5 X SSC, overnight; followed by washing twice at 65°C for

20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed. For example, in another embodiment, suitable  
5 highly stringent hybridization conditions include those described above, with the exception that the temperature of hybridization is increased, *e.g.*, to 60-65°C or 65-70°C.

In certain preferred embodiments, the polynucleotides described above, *e.g.*, polynucleotide variants, fragments and hybridizing sequences, encode polypeptides  
10 that are immunologically cross-reactive with a polypeptide sequence specifically set forth herein. In other preferred embodiments, such polynucleotides encode polypeptides that have a level of immunogenic activity of at least about 50%, preferably at least about 70%, and more preferably at least about 90% of that for a polypeptide sequence specifically set forth herein.

15 The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment  
20 of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative polynucleotide segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated  
25 to be useful in many implementations of this invention.

When comparing polynucleotide sequences, two sequences are said to be "identical" if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison  
30 window to identify and compare local regions of sequence similarity. A "comparison

window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, preferably 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

- 5 Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST

2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for  
5 nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments;  
10 or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and  
15 a comparison of both strands.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5  
20 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the  
25 reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal  
30 homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides



that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

Therefore, in another embodiment of the invention, a mutagenesis approach, such as site-specific mutagenesis, is employed for the preparation of immunogenic variants and/or derivatives of the polypeptides described herein. By this approach, specific modifications in a polypeptide sequence can be made through mutagenesis of the underlying polynucleotides that encode them. These techniques provides a straightforward approach to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the polynucleotide.

Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

In certain embodiments of the present invention, the inventors contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or more properties of the encoded polypeptide, such as the immunogenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example, site-specific mutagenesis is often used to alter a specific portion of a DNA molecule. In such embodiments, a primer comprising typically about 14 to about 25

nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

As will be appreciated by those of skill in the art, site-specific mutagenesis techniques have often employed a phage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. Specific details regarding these methods and protocols are found in the teachings of Maloy *et al.*, 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis *et al.*, 1982, each incorporated herein by reference, for that purpose.

As used herein, the term "oligonucleotide directed mutagenesis procedure" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable  
5 signal, such as amplification. As used herein, the term "oligonucleotide directed mutagenesis procedure" is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known  
10 rules of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U. S. Patent No. 4,237,224, specifically incorporated herein by reference in its entirety.

15 In another approach for the production of polypeptide variants of the present invention, recursive sequence recombination, as described in U.S. Patent No. 5,837,458, may be employed. In this approach, iterative cycles of recombination and screening or selection are performed to "evolve" individual polynucleotide variants of the invention having, for example, enhanced immunogenic activity.

20 In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise a sequence region of at least about 15 contiguous nucleotides that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence  
25 disclosed herein will find particular utility. Longer contiguous identical or complementary sequences, *e.g.*, those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments.

The ability of such nucleic acid probes to specifically hybridize to a  
30 sequence of interest will enable them to be of use in detecting the presence of

complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

Polynucleotide molecules having sequence regions consisting of  
5 contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization probes for use in, *e.g.*, Southern and Northern blotting. This would allow a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in  
10 various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15 and about 100 nucleotides, but larger  
15 contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

The use of a hybridization probe of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than 15 bases in  
20 length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired.

25 Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequences set forth herein, or to any continuous portion of the sequences, from about 15-25 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various

factors. For example, one may wish to employ primers from towards the termini of the total sequence.

Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCR<sup>TM</sup> technology of U. S. Patent 4,683,202 (incorporated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.

The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, *e.g.*, one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to

destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

According to another embodiment of the present invention, polynucleotide compositions comprising antisense oligonucleotides are provided. Antisense oligonucleotides have been demonstrated to be effective and targeted inhibitors of protein synthesis, and, consequently, provide a therapeutic approach by which a disease can be treated by inhibiting the synthesis of proteins that contribute to the disease. The efficacy of antisense oligonucleotides for inhibiting protein synthesis is well established. For example, the synthesis of polygalacturonase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829). Further, examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA<sub>A</sub> receptor and human EGF (Jaskulski *et al.*, Science. 1988 Jun 10;240(4858):1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989;1(4):225-32; Peris *et al.*, Brain Res Mol Brain Res. 1998 Jun 15;57(2):310-20; U. S. Patent 5,801,154; U.S. Patent 5,789,573; U. S. Patent 5,718,709 and U.S. Patent 5,610,288). Antisense constructs have also been described that inhibit and can be used to treat a variety of abnormal cellular proliferations, *e.g.* cancer (U. S. Patent 5,747,470; U. S. Patent 5,591,317 and U. S. Patent 5,783,683).

Therefore, in certain embodiments, the present invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is capable of specifically binding to polynucleotide sequence described herein, or a complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In each case, preferred compositions comprise a sequence region that is complementary,

and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein. Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence and determination of secondary structure,  $T_m$ , binding energy, and relative stability. Antisense compositions may be selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell. Highly preferred target regions of the mRNA, are those which are at or near the AUG translation initiation codon, and those sequences which are substantially complementary to 5' regions of the mRNA. These secondary structure analyses and target site selection considerations can be performed, for example, using v.4 of the OLIGO primer analysis software and/or the BLASTN 2.0.5 algorithm software (Altschul *et al.*, Nucleic Acids Res. 1997 Sep 1;25(17):3389-402).

The use of an antisense delivery method employing a short peptide vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris *et al.*, Nucleic Acids Res. 1997 Jul 15;25(14):2730-6). It has been demonstrated that several molecules of the MPG peptide coat the antisense oligonucleotides and can be delivered into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane.

According to another embodiment of the invention, the polynucleotide compositions described herein are used in the design and preparation of ribozyme molecules for inhibiting expression of the tumor polypeptides and proteins of the present invention in tumor cells. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, Proc Natl Acad Sci U S A. 1987 Dec;84(24):8788-92; Forster and Symons, Cell. 1987 Apr 24;49(2):211-20). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a

high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, Cell. 1981 Dec;27(3 Pt 2):487-96; Michel and Westhof, J Mol Biol. 1990 Dec 5;216(3):585-610; Reinhold-Hurek and Shub, Nature. 1992 May 14;357(6374):173-6). This specificity has been attributed to the requirement  
5 that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds *in trans* (and thus can cleave other RNA molecules) under physiological conditions. In general,  
10 enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to  
15 cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

The enzymatic nature of a ribozyme is advantageous over many  
20 technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of  
25 target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action  
30 (Woolf *et al.*, Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7305-9). Thus, the



specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site.

The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis  $\delta$  virus, group I intron or RNaseP RNA (in association with an RNA  
5 guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi *et al.* Nucleic Acids Res. 1992 Sep 11;20(17):4559-65. Examples of hairpin motifs are described by Hampel *et al.* (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz, Biochemistry 1989 Jun 13;28(12):4929-33; Hampel *et al.*, Nucleic  
Acids Res. 1990 Jan 25;18(2):299-304 and U. S. Patent 5,631,359. An example of the  
10 hepatitis  $\delta$  virus motif is described by Perrotta and Been, Biochemistry. 1992 Dec 1;31(47):11843-52; an example of the RNaseP motif is described by Guerrier-Takada *et al.*, Cell. 1983 Dec;35(3 Pt 2):849-57; Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, Cell. 1990 May 18;61(4):685-96; Saville and Collins, Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8826-30; Collins and Olive,  
15 Biochemistry. 1993 Mar 23;32(11):2795-9); and an example of the Group I intron is described in (U. S. Patent 4,987,071). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an  
20 RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically incorporated herein by reference) and synthesized to be tested *in vitro* and *in vivo*, as  
25 described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that  
30 prevent their degradation by serum ribonucleases (see *e.g.*, Int. Pat. Appl. Publ. No. WO

92/07065; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U. S. Patent 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

Sullivan *et al.* (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, *etc.*) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells. Ribozymes

expressed from such promoters have been shown to function in mammalian cells. Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest virus, sindbis virus vectors).

In another embodiment of the invention, peptide nucleic acids (PNAs) compositions are provided. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, *Antisense Nucleic Acid Drug Dev.* 1997 7(4) 431-37). PNA is able to be utilized in a number methods that traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (*Trends Biotechnol* 1997 Jun;15(6):224-9). As such, in certain embodiments, one may prepare PNA sequences that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

PNAs have 2-aminoethyl-glycine linkages replacing the normal phosphodiester backbone of DNA (Nielsen *et al.*, *Science* 1991 Dec 6;254(5037):1497-500; Hanvey *et al.*, *Science*. 1992 Nov 27;258(5087):1481-5; Hyrup and Nielsen, *Bioorg Med Chem.* 1996 Jan;4(1):5-23). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral molecules; secondly, PNAs are achiral, which avoids the need to develop a stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc or Fmoc protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used.

PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, MA). PNA syntheses by either Boc or Fmoc protocols are straightforward using manual or automated protocols (Norton *et al.*,

Bioorg Med Chem. 1995 Apr;3(4):437-45). The manual protocol lends itself to the production of chemically modified PNAs or the simultaneous synthesis of families of closely related PNAs.

As with peptide synthesis, the success of a particular PNA synthesis will  
5 depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines can lead to deletions of one or more residues in the product. In expectation of this difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed  
10 by the purification of PNAs by reverse-phase high-pressure liquid chromatography, providing yields and purity of product similar to those observed during the synthesis of peptides.

Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that  
15 contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and  
20 utilized modifications of PNAs (for example, Norton *et al.*, Bioorg Med Chem. 1995 Apr;3(4):437-45; Petersen *et al.*, J Pept Sci. 1995 May-Jun;1(3):175-83; Orum *et al.*, Biotechniques. 1995 Sep;19(3):472-80; Footer *et al.*, Biochemistry. 1996 Aug 20;35(33):10673-9; Griffith *et al.*, Nucleic Acids Res. 1995 Aug 11;23(15):3003-8; Pardridge *et al.*, Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5592-6; Boffa *et al.*,  
25 Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1901-5; Gambacorti-Passerini *et al.*, Blood. 1996 Aug 15;88(4):1411-7; Armitage *et al.*, Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12320-5; Seeger *et al.*, Biotechniques. 1997 Sep;23(3):512-7). U.S. Patent No. 5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to  
30 therapeutics.

Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (Anal Chem. 1993 Dec 15;65(24):3545-9) and Jensen *et al.* (Biochemistry. 1997 Apr 22;36(16):5072-7). Rose uses capillary gel electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made by Jensen *et al.* using BIAcore™ technology.

Other applications of PNAs that have been described and will be apparent to the skilled artisan include use in DNA strand invasion, antisense inhibition, mutational analysis, enhancers of transcription, nucleic acid purification, isolation of transcriptionally active genes, blocking of transcription factor binding, genome cleavage, biosensors, *in situ* hybridization, and the like.

#### Polynucleotide Identification, Characterization and Expression

Polynucleotide compositions of the present invention may be identified, prepared and/or manipulated using any of a variety of well established techniques (see generally, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989, and other like references). For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (*i.e.*, expression that is at least two fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example, using the microarray technology of Affymetrix, Inc. (Santa Clara, CA) according to the manufacturer's instructions (and essentially as described by Schena *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as tumor cells.

Many template dependent processes are available to amplify a target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by

reference in its entirety. Briefly, in PCR<sup>TM</sup>, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (*e.g.*, *Taq* polymerase). If the target sequence is present  
5 in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse  
10 transcription and PCR<sup>TM</sup> amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

Any of a number of other template dependent processes, many of which are variations of the PCR<sup>TM</sup> amplification technique, are readily known and available in  
15 the art. Illustratively, some such methods include the ligase chain reaction (referred to as LCR), described, for example, in Eur. Pat. Appl. Publ. No. 320,308 and U.S. Patent No. 4,883,750; Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880; Strand Displacement Amplification (SDA) and Repair Chain Reaction (RCR). Still other amplification methods are described in Great Britain Pat.  
20 Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025. Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (PCT Intl. Pat. Appl. Publ. No. WO 88/10315), including nucleic acid sequence based amplification (NASBA) and 3SR. Eur. Pat. Appl. Publ. No. 329,822 describes a nucleic acid amplification process involving cyclically synthesizing single-stranded  
25 RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA). PCT Intl. Pat. Appl. Publ. No. WO 89/06700 describes a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. Other amplification methods such as "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara,  
30 1989) are also well-known to those of skill in the art.

An amplified portion of a polynucleotide of the present invention may be used to isolate a full length gene from a suitable library (e.g., a tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with  $^{32}\text{P}$ ) using well known techniques. A bacterial or bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can then be assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

Alternatively, amplification techniques, such as those described above, can be useful for obtaining a full length coding sequence from a partial cDNA sequence. One such amplification technique is inverse PCR (see Triglia et al., *Nucl. Acids Res.* 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of

amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., *PCR Methods Applic. 1*:111-19, 1991) and walking PCR (Parker et al., *Nucl. Acids. Res. 19*:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (e.g., NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.



Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

10 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be  
15 engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. 20 (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be  
25 achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.) or other comparable  
30 techniques available in the art. The composition of the synthetic peptides may be

confirmed by amino acid analysis, or sequencing (*e.g.*, the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

5           In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing  
10 sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York.  
15 N.Y.

A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid,  
20 or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids); or animal cell systems.

25           The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription  
30 and translation elements, including constitutive and inducible promoters, may be used.

For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSFORT1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

In bacterial systems, any of a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For

example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express a polypeptide of interest. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. et al. (1994) *Proc. Natl. Acad. Sci.* 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, COS, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which

successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) *Cell* 22:817-23) genes which can be employed in tk.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of

skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include, for example, membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

5 A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal  
10 antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; *Serological Methods, a Laboratory Manual*, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions  
20 thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used  
25 include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained  
30 intracellularly depending on the sequence and/or the vector used. As will be understood

by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMLAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.



Antibody Compositions, Fragments Thereof and Other Binding Agents

According to another aspect, the present invention further provides binding agents, such as antibodies and antigen-binding fragments thereof, that exhibit immunological binding to a tumor polypeptide disclosed herein, or to a portion, variant or derivative thereof. An antibody, or antigen-binding fragment thereof, is said to "specifically bind," "immunologically bind," and/or is "immunologically reactive" to a polypeptide of the invention if it reacts at a detectable level (within, for example, an ELISA assay) with the polypeptide, and does not react detectably with unrelated polypeptides under similar conditions.

10 Immunological binding, as used in this context, generally refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant ( $K_d$ ) of the interaction, wherein a smaller  $K_d$  represents a greater  
15 affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and on geometric parameters that equally influence the rate in both directions. Thus, both  
20 the "on rate constant" ( $K_{on}$ ) and the "off rate constant" ( $K_{off}$ ) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of  $K_{off}/K_{on}$  enables cancellation of all parameters not related to affinity, and is thus equal to the dissociation constant  $K_d$ . See, generally, Davies et al. (1990) Annual Rev. Biochem. 59:439-473.

25 An "antigen-binding site," or "binding portion" of an antibody refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as "hypervariable  
30 regions" which are interposed between more conserved flanking stretches known as

"framework regions," or "FRs". Thus the term "FR" refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs."

Binding agents may be further capable of differentiating between patients with and without a cancer, such as prostate cancer, using the representative assays provided herein. For example, antibodies or other binding agents that bind to a tumor protein will preferably generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, more preferably at least about 30% of patients. Alternatively, or in addition, the antibody will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (*e.g.*, blood, sera, sputum, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. Preferably, a statistically significant number of samples with and without the disease will be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation

of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

A number of therapeutically useful molecules are known in the art which comprise antigen-binding sites that are capable of exhibiting immunological binding properties of an antibody molecule. The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the "F(ab)" fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the "F(ab')<sub>2</sub>" fragment which comprises both antigen-binding sites. An "Fv" fragment can be produced by preferential proteolytic cleavage of an IgM, and on rare occasions IgG or IgA immunoglobulin molecule. Fv fragments are, however, more commonly derived using recombinant techniques known in the art. The Fv fragment includes a non-covalent V<sub>H</sub>::V<sub>L</sub> heterodimer including an antigen-binding site which retains much of the antigen recognition and binding capabilities of the native antibody molecule. Inbar et al. (1972) Proc. Nat. Acad. Sci. USA 69:2659-2662; Hochman et al. (1976) Biochem 15:2706-2710; and Ehrlich et al. (1980) Biochem 19:4091-4096.

A single chain Fv ("sFv") polypeptide is a covalently linked V<sub>H</sub>::V<sub>L</sub> heterodimer which is expressed from a gene fusion including V<sub>H</sub>- and V<sub>L</sub>-encoding genes linked by a peptide-encoding linker. Huston et al. (1988) Proc. Nat. Acad. Sci. USA 85(16):5879-5883. A number of methods have been described to discern chemical structures for converting the naturally aggregated--but chemically separated--light and heavy polypeptide chains from an antibody V region into an sFv molecule which will fold into a three dimensional structure substantially similar to the structure of an

antigen-binding site. See, e.g., U.S. Pat. Nos. 5,091,513 and 5,132,405, to Huston et al.; and U.S. Pat. No. 4,946,778, to Ladner et al.

Each of the above-described molecules includes a heavy chain and a light chain CDR set, respectively interposed between a heavy chain and a light chain FR set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other. As used herein, the term "CDR set" refers to the three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as "CDR1," "CDR2," and "CDR3" respectively. An antigen-binding site, therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region. A polypeptide comprising a single CDR, (e.g., a CDR1, CDR2 or CDR3) is referred to herein as a "molecular recognition unit." Crystallographic analysis of a number of antigen-antibody complexes has demonstrated that the amino acid residues of CDRs form extensive contact with bound antigen, wherein the most extensive antigen contact is with the heavy chain CDR3. Thus, the molecular recognition units are primarily responsible for the specificity of an antigen-binding site.

As used herein, the term "FR set" refers to the four flanking amino acid sequences which frame the CDRs of a CDR set of a heavy or light chain V region. Some FR residues may contact bound antigen; however, FRs are primarily responsible for folding the V region into the antigen-binding site, particularly the FR residues directly adjacent to the CDRs. Within FRs, certain amino residues and certain structural features are very highly conserved. In this regard, all V region sequences contain an internal disulfide loop of around 90 amino acid residues. When the V regions fold into a binding-site, the CDRs are displayed as projecting loop motifs which form an antigen-binding surface. It is generally recognized that there are conserved structural regions of FRs which influence the folded shape of the CDR loops into certain "canonical" structures--regardless of the precise CDR amino acid sequence. Further, certain FR residues are known to participate in non-covalent interdomain contacts which stabilize the interaction of the antibody heavy and light chains.

A number of "humanized" antibody molecules comprising an antigen-binding site derived from a non-human immunoglobulin have been described, including chimeric antibodies having rodent V regions and their associated CDRs fused to human constant domains (Winter et al. (1991) *Nature* 349:293-299; Lobuglio et al. (1989) *Proc. Nat. Acad. Sci. USA* 86:4220-4224; Shaw et al. (1987) *J Immunol.* 138:4534-4538; and Brown et al. (1987) *Cancer Res.* 47:3577-3583), rodent CDRs grafted into a human supporting FR prior to fusion with an appropriate human antibody constant domain (Riechmann et al. (1988) *Nature* 332:323-327; Verhoeyen et al. (1988) *Science* 239:1534-1536; and Jones et al. (1986) *Nature* 321:522-525), and rodent CDRs supported by recombinantly veneered rodent FRs (European Patent Publication No. 519,596, published Dec. 23, 1992). These "humanized" molecules are designed to minimize unwanted immunological response toward rodent antihuman antibody molecules which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients.

As used herein, the terms "veneered FRs" and "recombinantly veneered FRs" refer to the selective replacement of FR residues from, *e.g.*, a rodent heavy or light chain V region, with human FR residues in order to provide a xenogeneic molecule comprising an antigen-binding site which retains substantially all of the native FR polypeptide folding structure. Veneering techniques are based on the understanding that the ligand binding characteristics of an antigen-binding site are determined primarily by the structure and relative disposition of the heavy and light chain CDR sets within the antigen-binding surface. Davies et al. (1990) *Ann. Rev. Biochem.* 59:439-473. Thus, antigen binding specificity can be preserved in a humanized antibody only wherein the CDR structures, their interaction with each other, and their interaction with the rest of the V region domains are carefully maintained. By using veneering techniques, exterior (*e.g.*, solvent-accessible) FR residues which are readily encountered by the immune system are selectively replaced with human residues to provide a hybrid molecule that comprises either a weakly immunogenic, or substantially non-immunogenic veneered surface.

The process of veneering makes use of the available sequence data for human antibody variable domains compiled by Kabat et al., in Sequences of Proteins of Immunological Interest, 4th ed., (U.S. Dept. of Health and Human Services, U.S. Government Printing Office, 1987), updates to the Kabat database, and other accessible U.S. and foreign databases (both nucleic acid and protein). Solvent accessibilities of V region amino acids can be deduced from the known three-dimensional structure for human and murine antibody fragments. There are two general steps in veneering a murine antigen-binding site. Initially, the FRs of the variable domains of an antibody molecule of interest are compared with corresponding FR sequences of human variable domains obtained from the above-identified sources. The most homologous human V regions are then compared residue by residue to corresponding murine amino acids. The residues in the murine FR which differ from the human counterpart are replaced by the residues present in the human moiety using recombinant techniques well known in the art. Residue switching is only carried out with moieties which are at least partially exposed (solvent accessible), and care is exercised in the replacement of amino acid residues which may have a significant effect on the tertiary structure of V region domains, such as proline, glycine and charged amino acids.

In this manner, the resultant "veneered" murine antigen-binding sites are thus designed to retain the murine CDR residues, the residues substantially adjacent to the CDRs, the residues identified as buried or mostly buried (solvent inaccessible), the residues believed to participate in non-covalent (*e.g.*, electrostatic and hydrophobic) contacts between heavy and light chain domains, and the residues from conserved structural regions of the FRs which are believed to influence the "canonical" tertiary structures of the CDR loops. These design criteria are then used to prepare recombinant nucleotide sequences which combine the CDRs of both the heavy and light chain of a murine antigen-binding site into human-appearing FRs that can be used to transfect mammalian cells for the expression of recombinant human antibodies which exhibit the antigen specificity of the murine antibody molecule.

In another embodiment of the invention, monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in

this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include  $^{90}\text{Y}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{211}\text{At}$ , and  $^{212}\text{Bi}$ . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred  
5 toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a  
10 substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an  
15 antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which  
20 otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups,  
25 sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of  
30 different cleavable linker groups have been described. The mechanisms for the



intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Patent No. 4,638,045, to Kohn et al.), by  
5 serum complement-mediated hydrolysis (e.g., U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody.  
10 Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent  
15 bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for  
20 radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For  
25 example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

### T Cell Compositions

The present invention, in another aspect, provides T cells specific for a tumor polypeptide disclosed herein, or for a variant or derivative thereof. Such cells

may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.

T cells may be stimulated with a polypeptide, polynucleotide encoding a polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide of interest. Preferably, a tumor polypeptide or polynucleotide of the invention is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for a polypeptide of the present invention if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., *Cancer Res.* 54:1065-1070, 1994. Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a tumor polypeptide (100 ng/ml - 100 µg/ml, preferably 200 ng/ml - 25 µg/ml) for 3 - 7 days will typically result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (see Coligan et

al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998)). T cells that have been activated in response to a tumor polypeptide, polynucleotide or polypeptide-expressing APC may be CD4<sup>+</sup> and/or CD8<sup>+</sup>. Tumor polypeptide-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

For therapeutic purposes, CD4<sup>+</sup> or CD8<sup>+</sup> T cells that proliferate in response to a tumor polypeptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*. Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a tumor polypeptide, or a short peptide corresponding to an immunogenic portion of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a tumor polypeptide. Alternatively, one or more T cells that proliferate in the presence of the tumor polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution.

#### Pharmaceutical Compositions

In additional embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, T-cell and/or antibody compositions disclosed herein in pharmaceutically-acceptable carriers for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.

It will be understood that, if desired, a composition as disclosed herein may be administered in combination with other agents as well, such as, *e.g.*, other proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as

described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or DNA compositions.

Therefore, in another aspect of the present invention, pharmaceutical compositions are provided comprising one or more of the polynucleotide, polypeptide, antibody, and/or T-cell compositions described herein in combination with a physiologically acceptable carrier. In certain preferred embodiments, the pharmaceutical compositions of the invention comprise immunogenic polynucleotide and/or polypeptide compositions of the invention for use in prophylactic and therapeutic vaccine applications. Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995). Generally, such compositions will comprise one or more polynucleotide and/or polypeptide compositions of the present invention in combination with one or more immunostimulants.

It will be apparent that any of the pharmaceutical compositions described herein can contain pharmaceutically acceptable salts of the polynucleotides and polypeptides of the invention. Such salts can be prepared, for example, from pharmaceutically acceptable non-toxic bases, including organic bases (e.g., salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (e.g., sodium, potassium, lithium, ammonium, calcium and magnesium salts).

In another embodiment, illustrative immunogenic compositions, e.g., vaccine compositions, of the present invention comprise DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the polynucleotide may be administered within any of a variety of delivery systems known to those of ordinary skill in the art. Indeed, numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate polynucleotide expression systems will, of course, contain the necessary regulatory DNA regulatory sequences for expression in a patient (such as a suitable promoter and terminating signal). Alternatively, bacterial delivery systems may involve

the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

Therefore, in certain embodiments, polynucleotides encoding immunogenic polypeptides described herein are introduced into suitable mammalian host cells for expression using any of a number of known viral-based systems. In one illustrative embodiment, retroviruses provide a convenient and effective platform for gene delivery systems. A selected nucleotide sequence encoding a polypeptide of the present invention can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject. A number of illustrative retroviral systems have been described (*e.g.*, U.S. Pat. No. 5,219,740; Miller and Rosman (1989) *BioTechniques* 7:980-990; Miller, A. D. (1990) *Human Gene Therapy* 1:5-14; Scarpa et al. (1991) *Virology* 180:849-852; Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-8037; and Boris-Lawrie and Temin (1993) *Cur. Opin. Genet. Develop.* 3:102-109.

In addition, a number of illustrative adenovirus-based systems have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) *J. Virol.* 57:267-274; Bett et al. (1993) *J. Virol.* 67:5911-5921; Mittereder et al. (1994) *Human Gene Therapy* 5:717-729; Seth et al. (1994) *J. Virol.* 68:933-940; Barr et al. (1994) *Gene Therapy* 1:51-58; Berkner, K. L. (1988) *BioTechniques* 6:616-629; and Rich et al. (1993) *Human Gene Therapy* 4:461-476).

Various adeno-associated virus (AAV) vector systems have also been developed for polynucleotide delivery. AAV vectors can be readily constructed using techniques well known in the art. See, *e.g.*, U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 and WO 93/03769; Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines* 90 (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129;

Kotin, R. M. (1994) Human Gene Therapy 5:793-801; Shelling and Smith (1994) Gene Therapy 1:165-169; and Zhou et al. (1994) J. Exp. Med. 179:1867-1875.

Additional viral vectors useful for delivering the polynucleotides encoding polypeptides of the present invention by gene transfer include those derived from the pox family of viruses, such as vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the novel molecules can be constructed as follows. The DNA encoding a polypeptide is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the polypeptide of interest into the viral genome. The resulting TK<sup>sup</sup>(-) recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression or coexpression of one or more polypeptides described herein in host cells of an organism. In this particular system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide or polynucleotides of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into polypeptide by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al. Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.

Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the coding sequences of interest. Recombinant avipox viruses, expressing immunogens from mammalian pathogens, are known to confer

protective immunity when administered to non-avian species. The use of an Avipox vector is particularly desirable in human and other mammalian species since members of the Avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant Avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, e.g., WO 91/12882; WO 89/03429; and WO 92/03545.

Any of a number of alphavirus vectors can also be used for delivery of polynucleotide compositions of the present invention, such as those vectors described in U.S. Patent Nos. 5,843,723; 6,015,686; 6,008,035 and 6,015,694. Certain vectors based on Venezuelan Equine Encephalitis (VEE) can also be used, illustrative examples of which can be found in U.S. Patent Nos. 5,505,947 and 5,643,576.

Moreover, molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al. *J. Biol. Chem.* (1993) 268:6866-6869 and Wagner et al. *Proc. Natl. Acad. Sci. USA* (1992) 89:6099-6103, can also be used for gene delivery under the invention.

Additional illustrative information on these and other known viral-based delivery systems can be found, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al., *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993.

In certain embodiments, a polynucleotide may be integrated into the genome of a target cell. This integration may be in a specific location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the polynucleotide may be stably maintained in the cell as a separate, episomal segment of

DNA. Such polynucleotide segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. The manner in which the expression construct is delivered to a cell and where in the cell the polynucleotide remains is dependent on the type of expression  
5 construct employed.

In another embodiment of the invention, a polynucleotide is administered/delivered as "naked" DNA, for example as described in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable  
10 beads, which are efficiently transported into the cells.

In still another embodiment, a composition of the present invention can be delivered via a particle bombardment approach, many of which have been described. In one illustrative example, gas-driven particle acceleration can be achieved with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK)  
15 and Powderject Vaccines Inc. (Madison, WI), some examples of which are described in U.S. Patent Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device,  
20 propelling the particles into a target tissue of interest.

In a related embodiment, other devices and methods that may be useful for gas-driven needle-less injection of compositions of the present invention include those provided by Bioject, Inc. (Portland, OR), some examples of which are described in U.S. Patent Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851; 5,399,163; 5,520,639  
25 and 5,993,412.

According to another embodiment, the pharmaceutical compositions described herein will comprise one or more immunostimulants in addition to the immunogenic polynucleotide, polypeptide, antibody, T-cell and/or APC compositions of this invention. An immunostimulant refers to essentially any substance that enhances  
30 or potentiates an immune response (antibody and/or cell-mediated) to an exogenous



antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins.

5 Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated  
10 sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Within certain embodiments of the invention, the adjuvant composition  
15 is preferably one that induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN- $\gamma$ , TNF $\alpha$ , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as  
20 provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman,  
25 *Ann. Rev. Immunol.* 7:145-173, 1989.

Certain preferred adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL<sup>®</sup> adjuvants are available from Corixa Corporation (Seattle, WA; see, for example, US  
30 Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing

oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by  
5 Sato et al., *Science* 273:352, 1996. Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example  
10 combinations of at least two of the following group comprising QS21, QS7, Quil A,  $\beta$ -escin, or digitonin.

Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix,  
15 particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or  
20 suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol<sup>R</sup> to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

In one preferred embodiment, the adjuvant system includes the  
25 combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL<sup>®</sup> adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. Another particularly preferred adjuvant formulation employing QS21, 3D-

MPL<sup>®</sup> adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 is disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn<sup>®</sup>; Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

Other preferred adjuvants include adjuvant molecules of the general formula



wherein,  $n$  is 1-50,  $A$  is a bond or  $-\text{C}(\text{O})-$ ,  $R$  is  $\text{C}_{1-50}$  alkyl or Phenyl  $\text{C}_{1-50}$  alkyl.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein  $n$  is between 1 and 50, preferably 4-24, most preferably 9; the  $R$  component is  $\text{C}_{1-50}$ , preferably  $\text{C}_4\text{-C}_{20}$  alkyl and most preferably  $\text{C}_{12}$  alkyl, and  $A$  is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12<sup>th</sup> edition: entry 7717). These adjuvant molecules are described in WO

99/52549. The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

5           According to another embodiment of this invention, an immunogenic composition described herein is delivered to a host via antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or  
10 maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

15           Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (*see* Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In  
20 general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex*  
25 *vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (*see* Zitvogel et al., *Nature Med.* 4:594-600, 1998).

          Dendritic cells and progenitors may be obtained from peripheral blood,  
30 bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph

nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF $\alpha$  to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from  
5 peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF $\alpha$ , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature"  
10 cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc $\gamma$  receptor and mannose receptor. The mature  
15 phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide of the  
20 invention (or portion or other variant thereof) such that the encoded polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a pharmaceutical composition comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be  
25 administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or  
30 progenitor cells with the tumor polypeptide, DNA (naked or within a plasmid vector) or

RNA; or with antigen-expressing recombinant bacterium or viruses (*e.g.*, vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (*e.g.*, a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will typically vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intracranial, intraperitoneal, subcutaneous and intramuscular administration.

Carriers for use within such pharmaceutical compositions are biocompatible, and may also be biodegradable. In certain embodiments, the formulation preferably provides a relatively constant level of active component release. In other embodiments, however, a more rapid rate of release immediately upon administration may be desired. The formulation of such compositions is well within the level of ordinary skill in the art using known techniques. Illustrative carriers useful in this regard include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other illustrative delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (*e.g.*, a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (*see e.g.*, U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

In another illustrative embodiment, biodegradable microspheres (*e.g.*, polylactate polyglycolate) are employed as carriers for the compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763;

5,814,344, 5,407,609 and 5,942,252. Modified hepatitis B core protein carrier systems, such as described in WO/99 40934, and references cited therein, will also be useful for many applications. Another illustrative carrier/delivery system employs a carrier comprising particulate-protein complexes, such as those described in U.S. Patent No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

The pharmaceutical compositions of the invention will often further comprise one or more buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate.

The pharmaceutical compositions described herein may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are typically sealed in such a way to preserve the sterility and stability of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

The development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation, is well known in the art, some of which are briefly discussed below for general purposes of illustration.

In certain applications, the pharmaceutical compositions disclosed herein may be delivered *via* oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they

may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (see, for example, Mathiowitz *et al.*, Nature 1997 Mar 27;386(6623):410-4; Hwang *et al.*, Crit Rev Ther Drug Carrier Syst 1998;15(3):243-84; U. S. Patent 5,641,515; U. S. Patent 5,580,579 and U. S. Patent 5,792,451). Tablets, troches, pills, capsules and the like may also contain any of a variety of additional components, for example, a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.

Typically, these formulations will contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.



For oral administration, the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

10 In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally. Such approaches are well known to the skilled artisan, some of which are further described, for example, in U. S. Patent 5,543,158; U. S. Patent 5,641,515 and U. S. Patent 5,399,363. In certain embodiments, solutions of the active compounds  
15 as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally will contain a preservative to prevent the growth of microorganisms.

20 Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U. S. Patent 5,466,468). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and  
25 storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as  
30 lecithin, by the maintenance of the required particle size in the case of dispersion and/or

by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

- 5 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

In one embodiment, for parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered  
10 isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml  
15 of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. Moreover, for human administration, preparations will of course preferably meet sterility, pyrogenicity, and the general safety and purity  
20 standards as required by FDA Office of Biologics standards.

In another embodiment of the invention, the compositions disclosed herein may be formulated in a neutral or salt form. Illustrative pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for  
25 example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be

administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.

The carriers can further comprise any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption  
5 delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary  
active ingredients can also be incorporated into the compositions. The phrase  
10 "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the  
15 lungs *via* nasal aerosol sprays has been described, *e.g.*, in U. S. Patent 5,756,353 and U. S. Patent 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga *et al.*, J Controlled Release 1998 Mar 2;52(1-2):81-7) and lysophosphatidyl-glycerol compounds (U. S. Patent 5,725,871) are also well-known in the pharmaceutical arts. Likewise, illustrative transmucosal drug delivery in the form of  
20 a polytetrafluoroethylene support matrix is described in U. S. Patent 5,780,045.

In certain embodiments, liposomes, nanocapsules, microparticles, lipid particles, vesicles, and the like, are used for the introduction of the compositions of the present invention into suitable host cells/organisms. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid  
25 particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like. Alternatively, compositions of the present invention can be bound, either covalently or non-covalently, to the surface of such carrier vehicles.

The formation and use of liposome and liposome-like preparations as potential drug carriers is generally known to those of skill in the art (see for example,  
30 Lasic, Trends Biotechnol 1998 Jul;16(7):307-21; Takakura, Nippon Rinsho 1998

Mar;56(3):691-5; Chandran *et al.*, Indian J Exp Biol. 1997 Aug;35(8):801-9; Margalit, Crit Rev Ther Drug Carrier Syst. 1995;12(2-3):233-61; U.S. Patent 5,567,434; U.S. Patent 5,552,157; U.S. Patent 5,565,213; U.S. Patent 5,738,868 and U.S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

5               Liposomes have been used successfully with a number of cell types that are normally difficult to transfect by other procedures, including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, J Biol Chem. 1990 Sep 25;265(27):16337-42; Muller *et al.*, DNA Cell Biol. 1990 Apr;9(3):221-9). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery  
10 systems. Liposomes have been used effectively to introduce genes, various drugs, radiotherapeutic agents, enzymes, viruses, transcription factors, allosteric effectors and the like, into a variety of cultured cell lines and animals. Furthermore, the use of liposomes does not appear to be associated with autoimmune responses or unacceptable toxicity after systemic delivery.

15               In certain embodiments, liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)).

                  Alternatively, in other embodiments, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the  
20 present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (see, for example, Quintanar-Guerrero *et al.*, Drug Dev Ind Pharm. 1998 Dec;24(12):1113-28). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1  $\mu\text{m}$ ) may be designed using polymers able to be degraded *in vivo*. Such particles can be made as described, for  
25 example, by Couvreur *et al.*, Crit Rev Ther Drug Carrier Syst. 1988;5(1):1-20; zur Muhlen *et al.*, Eur J Pharm Biopharm. 1998 Mar;45(2):149-55; Zambaux *et al.* J Controlled Release. 1998 Jan 2;50(1-3):31-40; and U. S. Patent 5,145,684.

Cancer Therapeutic Methods

In further aspects of the present invention, the pharmaceutical compositions described herein may be used for the treatment of cancer, particularly for the immunotherapy of prostate cancer. Within such methods, the pharmaceutical compositions described herein are administered to a patient, typically a warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Accordingly, the above pharmaceutical compositions may be used to prevent the development of a cancer or to treat a patient afflicted with a cancer. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. As discussed above, administration of the pharmaceutical compositions may be by any suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8<sup>+</sup> cytotoxic T lymphocytes and CD4<sup>+</sup> T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The

polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever et al., *Immunological Reviews* 157:177, 1997).

Alternatively, a vector expressing a polypeptide recited herein may be introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitary, intraperitoneal or intratumor administration.

Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous,

intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells *in vitro*. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 25  $\mu$ g to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

#### Cancer Detection and Diagnostic Compositions, Methods and Kits

In general, a cancer may be detected in a patient based on the presence of one or more prostate tumor proteins and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, sputum urine and/or tumor biopsies)

obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as prostate cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a prostate tumor sequence should be present at a level that is at least three fold higher in tumor tissue than in normal tissue

There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length prostate tumor proteins and polypeptide portions thereof to which the binding agent binds, as described above.



The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10  $\mu$ g, and preferably about 100 ng to about 1  $\mu$ g, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (*see, e.g.*, Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized

on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of  
5 detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically  
10 blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact  
15 time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with prostate cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve  
20 equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second  
25 antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of  
30 binding that occurs over a period of time. Unbound detection reagent is then removed

and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

10 To determine the presence or absence of a cancer, such as prostate cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with  
15 samples from patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985,  
20 p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a  
25 signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1  $\mu$ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such tumor protein specific antibodies may correlate with the presence of a cancer.

A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient is incubated with a tumor polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with polypeptide (e.g., 5 - 25 µg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of tumor polypeptide to serve as a control. For CD4<sup>+</sup> T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8<sup>+</sup> T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a tumor protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a tumor protein of the invention that is at least 10

nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the  
5 diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence as disclosed herein. Techniques for both PCR based assays and hybridization assays are well known in the art (*see, for example, Mullis et al., Cold*  
10 *Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules.  
15 PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold  
20 or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above  
25 for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the

cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound  
5 binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

As noted above, to improve sensitivity, multiple tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific  
10 for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

15 The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a tumor protein.  
20 Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

25 Alternatively, a kit may be designed to detect the level of mRNA encoding a tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be

present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a tumor protein.

The following Examples are offered by way of illustration and not by way of limitation.

5

## EXAMPLES

### EXAMPLE 1

#### ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC POLYPEPTIDES

10

This Example describes the isolation of certain prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library was constructed from prostate tumor poly A<sup>+</sup> RNA using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning kit (BRL Life Technologies, Gaithersburg, MD 20897) following the manufacturer's protocol. Specifically, prostate tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A<sup>+</sup> RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, CA 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BAXI adaptors (Invitrogen, San Diego, CA) and digested with NotI. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, CA), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen) and transformed into ElectroMax *E. coli* DH10B cells (BRL Life Technologies) by electroporation.

Using the same procedure, a normal human pancreas cDNA expression library was prepared from a pool of six tissue specimens (Clontech). The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis.

30



The prostate tumor library contained  $1.64 \times 10^7$  independent colonies, with 70% of clones having an insert and the average insert size being 1745 base pairs. The normal pancreas cDNA library contained  $3.3 \times 10^6$  independent colonies, with 69% of clones having inserts and the average insert size being 1120 base pairs. For both libraries, sequence analysis showed that the majority of clones had a full length cDNA sequence and were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination.

cDNA library subtraction was performed using the above prostate tumor and normal pancreas cDNA libraries, as described by Hara *et al.* (*Blood*, 84:189-199, 1994) with some modifications. Specifically, a prostate tumor-specific subtracted cDNA library was generated as follows. Normal pancreas cDNA library (70  $\mu$ g) was digested with EcoRI, NotI, and SfuI, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100  $\mu$ l of H<sub>2</sub>O, heat-denatured and mixed with 100  $\mu$ l (100  $\mu$ g) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50  $\mu$ l) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23  $\mu$ l H<sub>2</sub>O to form the driver DNA.

To form the tracer DNA, 10  $\mu$ g prostate tumor cDNA library was digested with BamHI and XhoI, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5  $\mu$ l H<sub>2</sub>O. Tracer DNA was mixed with 15  $\mu$ l driver DNA and 20  $\mu$ l of 2 x hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68 °C water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12  $\mu$ l H<sub>2</sub>O, mixed with 8  $\mu$ l driver DNA and 20  $\mu$ l of 2 x hybridization buffer, and subjected to a hybridization at 68

<sup>0</sup>C for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/XhoI site of chloramphenicol resistant pBCSK<sup>+</sup> (Stratagene, La Jolla, CA 92037) and transformed into ElectroMax *E. coli* DH10B cells by electroporation to generate a prostate tumor specific subtracted cDNA library (referred to as "prostate subtraction 1").

To analyze the subtracted cDNA library, plasmid DNA was prepared from 100 independent clones, randomly picked from the subtracted prostate tumor specific library and grouped based on insert size. Representative cDNA clones were further characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A (Foster City, CA). Six cDNA clones, hereinafter referred to as F1-13, F1-12, F1-16, H1-1, H1-9 and H1-4, were shown to be abundant in the subtracted prostate-specific cDNA library. The determined 3' and 5' cDNA sequences for F1-12 are provided in SEQ ID NO: 2 and 3, respectively, with determined 3' cDNA sequences for F1-13, F1-16, H1-1, H1-9 and H1-4 being provided in SEQ ID NO: 1 and 4-7, respectively.

The cDNA sequences for the isolated clones were compared to known sequences in the gene bank using the EMBL and GenBank databases (release 96). Four of the prostate tumor cDNA clones, F1-13, F1-16, H1-1, and H1-4, were determined to encode the following previously identified proteins: prostate specific antigen (PSA), human glandular kallikrein, human tumor expression enhanced gene, and mitochondria cytochrome C oxidase subunit II. H1-9 was found to be identical to a previously identified human autonomously replicating sequence. No significant homologies to the cDNA sequence for F1-12 were found.

Subsequent studies led to the isolation of a full-length cDNA sequence for F1-12 (also referred to as P504S). This sequence is provided in SEQ ID NO: 107, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 108. cDNA splice variants of P504S are provided in SEQ ID NO: 600-605.

To clone less abundant prostate tumor specific genes, cDNA library subtraction was performed by subtracting the prostate tumor cDNA library described above with the normal pancreas cDNA library and with the three most abundant genes

in the previously subtracted prostate tumor specific cDNA library: human glandular kallikrein, prostate specific antigen (PSA), and mitochondria cytochrome C oxidase subunit II. Specifically, 1  $\mu$ g each of human glandular kallikrein, PSA and mitochondria cytochrome C oxidase subunit II cDNAs in pCDNA3.1 were added to the driver DNA and subtraction was performed as described above to provide a second subtracted cDNA library hereinafter referred to as the "subtracted prostate tumor specific cDNA library with spike".

Twenty-two cDNA clones were isolated from the subtracted prostate tumor specific cDNA library with spike. The determined 3' and 5' cDNA sequences for the clones referred to as J1-17, L1-12, N1-1862, J1-13, J1-19, J1-25, J1-24, K1-58, K1-63, L1-4 and L1-14 are provided in SEQ ID NOS: 8-9, 10-11, 12-13, 14-15, 16-17, 18-19, 20-21, 22-23, 24-25, 26-27 and 28-29, respectively. The determined 3' cDNA sequences for the clones referred to as J1-12, J1-16, J1-21, K1-48, K1-55, L1-2, L1-6, N1-1858, N1-1860, N1-1861, N1-1864 are provided in SEQ ID NOS: 30-40, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to three of the five most abundant DNA species, (J1-17, L1-12 and N1-1862; SEQ ID NOS: 8-9, 10-11 and 12-13, respectively). Of the remaining two most abundant species, one (J1-12; SEQ ID NO:30) was found to be identical to the previously identified human pulmonary surfactant-associated protein, and the other (K1-48; SEQ ID NO:33) was determined to have some homology to *R. norvegicus* mRNA for 2-arylpropionyl-CoA epimerase. Of the 17 less abundant cDNA clones isolated from the subtracted prostate tumor specific cDNA library with spike, four (J1-16, K1-55, L1-6 and N1-1864; SEQ ID NOS:31, 34, 36 and 40, respectively) were found to be identical to previously identified sequences, two (J1-21 and N1-1860; SEQ ID NOS: 32 and 38, respectively) were found to show some homology to non-human sequences, and two (L1-2 and N1-1861; SEQ ID NOS: 35 and 39, respectively) were found to show some homology to known human sequences. No significant homologies were found to the polypeptides J1-13, J1-19, J1-24, J1-25, K1-58, K1-63, L1-4, L1-14 (SEQ ID NOS: 14-15, 16-17, 20-21, 18-19, 22-23, 24-25, 26-27, 28-29, respectively).

Subsequent studies led to the isolation of full length cDNA sequences for J1-17, L1-12 and N1-1862 (SEQ ID NOS: 109-111, respectively). The corresponding predicted amino acid sequences are provided in SEQ ID NOS: 112-114. L1-12 is also referred to as P501S. A cDNA splice variant of P501S is provided in SEQ ID NO: 606.

5 In a further experiment, four additional clones were identified by subtracting a prostate tumor cDNA library with normal prostate cDNA prepared from a pool of three normal prostate poly A+ RNA (referred to as "prostate subtraction 2"). The determined cDNA sequences for these clones, hereinafter referred to as U1-3064, U1-3065, V1-3692 and 1A-3905, are provided in SEQ ID NO: 69-72, respectively.

10 Comparison of the determined sequences with those in the gene bank revealed no significant homologies to U1-3065.

A second subtraction with spike (referred to as "prostate subtraction spike 2") was performed by subtracting a prostate tumor specific cDNA library with spike with normal pancreas cDNA library and further spiked with PSA, J1-17,

15 pulmonary surfactant-associated protein, mitochondrial DNA, cytochrome c oxidase subunit II, N1-1862, autonomously replicating sequence, L1-12 and tumor expression enhanced gene. Four additional clones, hereinafter referred to as V1-3686, R1-2330, 1B-3976 and V1-3679, were isolated. The determined cDNA sequences for these clones are provided in SEQ ID NO:73-76, respectively. Comparison of these sequences

20 with those in the gene bank revealed no significant homologies to V1-3686 and R1-2330.

Further analysis of the three prostate subtractions described above (prostate subtraction 2, subtracted prostate tumor specific cDNA library with spike, and prostate subtraction spike 2) resulted in the identification of sixteen additional clones,

25 referred to as 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1G-4734, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4810, 1I-4811, 1J-4876, 1K-4884 and 1K-4896. The determined cDNA sequences for these clones are provided in SEQ ID NOS: 77-92, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to 1G-4741, 1G-4734, 1I-4807, 1J-4876 and

30 1K-4896 (SEQ ID NOS: 79, 81, 87, 90 and 92, respectively). Further analysis of the

isolated clones led to the determination of extended cDNA sequences for 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4807, 1J-4876, 1K-4884 and 1K-4896, provided in SEQ ID NOS: 179-188 and 191-193, respectively, and to the determination of additional partial cDNA sequences for 1I-4810 and 1I-4811, provided in SEQ ID NOS: 189 and 190, respectively.

Additional studies with prostate subtraction spike 2 resulted in the isolation of three more clones. Their sequences were determined as described above and compared to the most recent GenBank. All three clones were found to have homology to known genes, which are Cysteine-rich protein, KIAA0242, and KIAA0280 (SEQ ID NO: 317, 319, and 320, respectively). Further analysis of these clones by Synteni microarray (Synteni, Palo Alto, CA) demonstrated that all three clones were over-expressed in most prostate tumors and prostate BPH, as well as in the majority of normal prostate tissues tested, but low expression in all other normal tissues.

An additional subtraction was performed by subtracting a normal prostate cDNA library with normal pancreas cDNA (referred to as "prostate subtraction 3"). This led to the identification of six additional clones referred to as 1G-4761, 1G-4762, 1H-4766, 1H-4770, 1H-4771 and 1H-4772 (SEQ ID NOS: 93-98). Comparison of these sequences with those in the gene bank revealed no significant homologies to 1G-4761 and 1H-4771 (SEQ ID NOS: 93 and 97, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1G-4761, 1G-4762, 1H-4766 and 1H-4772 provided in SEQ ID NOS: 194-196 and 199, respectively, and to the determination of additional partial cDNA sequences for 1H-4770 and 1H-4771, provided in SEQ ID NOS: 197 and 198, respectively.

Subtraction of a prostate tumor cDNA library, prepared from a pool of polyA<sup>+</sup> RNA from three prostate cancer patients, with a normal pancreas cDNA library (prostate subtraction 4) led to the identification of eight clones, referred to as 1D-4297, 1D-4309, 1D-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280 (SEQ ID NOS: 99-107). These sequences were compared to those in the gene bank as described above. No significant homologies were found to 1D-4283 and 1D-4304 (SEQ ID NOS: 103 and 104, respectively). Further analysis of the isolated clones led to the

determination of extended cDNA sequences for 1D-4309, 1D-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280, provided in SEQ ID NOS: 200-206, respectively.

cDNA clones isolated in prostate subtraction 1 and prostate subtraction  
5 2, described above, were colony PCR amplified and their mRNA expression levels in prostate tumor, normal prostate and in various other normal tissues were determined using microarray technology (Synteni, Palo Alto, CA). Briefly, the PCR amplification products were dotted onto slides in an array format, with each product occupying a unique location in the array. mRNA was extracted from the tissue sample to be tested,  
10 reverse transcribed, and fluorescent-labeled cDNA probes were generated. The microarrays were probed with the labeled cDNA probes, the slides scanned and fluorescence intensity was measured. This intensity correlates with the hybridization intensity. Two clones (referred to as P509S and P510S) were found to be over-expressed in prostate tumor and normal prostate and expressed at low levels in all other  
15 normal tissues tested (liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon). The determined cDNA sequences for P509S and P510S are provided in SEQ ID NO: 223 and 224, respectively. Comparison of these sequences with those in the gene bank as described above, revealed some homology to previously  
20 identified ESTs.

Additional studies led to the isolation of the full-length cDNA sequence for P509S. This sequence is provided in SEQ ID NO: 332, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 339. Two variant full-length cDNA sequences for P510S are provided in SEQ ID NO: 535 and 536, with the  
25 corresponding predicted amino acid sequences being provided in SEQ ID NO: 537 and 538, respectively. Additional splice variants of P510S are provided in SEQ ID NO: 598 and 599.

## EXAMPLE 2

## DETERMINATION OF TISSUE SPECIFICITY OF PROSTATE-SPECIFIC POLYPEPTIDES

Using gene specific primers, mRNA expression levels for the  
5 representative prostate-specific polypeptides F1-16, H1-1, J1-17 (also referred to as P502S), L1-12 (also referred to as P501S), F1-12 (also referred to as P504S) and N1-1862 (also referred to as P503S) were examined in a variety of normal and tumor tissues using RT-PCR.

Briefly, total RNA was extracted from a variety of normal and tumor  
10 tissues using Trizol reagent as described above. First strand synthesis was carried out using 1-2 µg of total RNA with SuperScript II reverse transcriptase (BRL Life Technologies) at 42 °C for one hour. The cDNA was then amplified by PCR with gene-specific primers. To ensure the semi-quantitative nature of the RT-PCR, β-actin was used as an internal control for each of the tissues examined. First, serial dilutions of the  
15 first strand cDNAs were prepared and RT-PCR assays were performed using β-actin specific primers. A dilution was then chosen that enabled the linear range amplification of the β-actin template and which was sensitive enough to reflect the differences in the initial copy numbers. Using these conditions, the β-actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was  
20 minimized by DNase treatment and by assuring a negative PCR result when using first strand cDNA that was prepared without adding reverse transcriptase.

mRNA Expression levels were examined in four different types of tumor tissue (prostate tumor from 2 patients, breast tumor from 3 patients, colon tumor, lung tumor), and sixteen different normal tissues, including prostate, colon, kidney, liver,  
25 lung, ovary, pancreas, skeletal muscle, skin, stomach, testes, bone marrow and brain. F1-16 was found to be expressed at high levels in prostate tumor tissue, colon tumor and normal prostate, and at lower levels in normal liver, skin and testes, with expression being undetectable in the other tissues examined. H1-1 was found to be expressed at high levels in prostate tumor, lung tumor, breast tumor, normal prostate, normal colon  
30 and normal brain, at much lower levels in normal lung, pancreas, skeletal muscle, skin,

small intestine, bone marrow, and was not detected in the other tissues tested. J1-17 (P502S) and L1-12 (P501S) appear to be specifically over-expressed in prostate, with both genes being expressed at high levels in prostate tumor and normal prostate but at low to undetectable levels in all the other tissues examined. N1-1862 (P503S) was found to be over-expressed in 60% of prostate tumors and detectable in normal colon and kidney. The RT-PCR results thus indicate that F1-16, H1-1, J1-17 (P502S), N1-1862 (P503S) and L1-12 (P501S) are either prostate specific or are expressed at significantly elevated levels in prostate.

Further RT-PCR studies showed that F1-12 (P504S) is over-expressed in 60% of prostate tumors, detectable in normal kidney but not detectable in all other tissues tested. Similarly, R1-2330 was shown to be over-expressed in 40% of prostate tumors, detectable in normal kidney and liver, but not detectable in all other tissues tested. U1-3064 was found to be over-expressed in 60% of prostate tumors, and also expressed in breast and colon tumors, but was not detectable in normal tissues.

RT-PCR characterization of R1-2330, U1-3064 and 1D-4279 showed that these three antigens are over-expressed in prostate and/or prostate tumors.

Northern analysis with four prostate tumors, two normal prostate samples, two BPH prostates, and normal colon, kidney, liver, lung, pancreas, skeletal muscle, brain, stomach, testes, small intestine and bone marrow, showed that L1-12 (P501S) is over-expressed in prostate tumors and normal prostate, while being undetectable in other normal tissues tested. J1-17 (P502S) was detected in two prostate tumors and not in the other tissues tested. N1-1862 (P503S) was found to be over-expressed in three prostate tumors and to be expressed in normal prostate, colon and kidney, but not in other tissues tested. F1-12 (P504S) was found to be highly expressed in two prostate tumors and to be undetectable in all other tissues tested.

The microarray technology described above was used to determine the expression levels of representative antigens described herein in prostate tumor, breast tumor and the following normal tissues: prostate, liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon. L1-12 (P501S) was found to be



over-expressed in normal prostate and prostate tumor, with some expression being detected in normal skeletal muscle. Both J1-12 and F1-12 (P504S) were found to be over-expressed in prostate tumor, with expression being lower or undetectable in all other tissues tested. N1-1862 (P503S) was found to be expressed at high levels in prostate tumor and normal prostate, and at low levels in normal large intestine and normal colon, with expression being undetectable in all other tissues tested. R1-2330 was found to be over-expressed in prostate tumor and normal prostate, and to be expressed at lower levels in all other tissues tested. 1D-4279 was found to be over-expressed in prostate tumor and normal prostate, expressed at lower levels in normal spinal cord, and to be undetectable in all other tissues tested.

Further microarray analysis to specifically address the extent to which P501S (SEQ ID NO: 110) was expressed in breast tumor revealed moderate over-expression not only in breast tumor, but also in metastatic breast tumor (2/31), with negligible to low expression in normal tissues. This data suggests that P501S may be over-expressed in various breast tumors as well as in prostate tumors.

The expression levels of 32 ESTs (expressed sequence tags) described by Vasmatazis *et al.* (*Proc. Natl. Acad. Sci. USA* 95:300-304, 1998) in a variety of tumor and normal tissues were examined by microarray technology as described above. Two of these clones (referred to as P1000C and P1001C) were found to be over-expressed in prostate tumor and normal prostate, and expressed at low to undetectable levels in all other tissues tested (normal aorta, thymus, resting and activated PBMC, epithelial cells, spinal cord, adrenal gland, fetal tissues, skin, salivary gland, large intestine, bone marrow, liver, lung, dendritic cells, stomach, lymph nodes, brain, heart, small intestine, skeletal muscle, colon and kidney). The determined cDNA sequences for P1000C and P1001C are provided in SEQ ID NO: 384 and 472, respectively. The sequence of P1001C was found to show some homology to the previously isolated Human mRNA for JM27 protein. Subsequent comparison of the sequence of SEQ ID NO: 384 with sequences in the public databases, led to the identification of a full-length cDNA sequence of P1000C (SEQ ID NO: 786), which encodes a 492 amino acid sequence. Analysis of the amino acid sequence using the PSORT II program led to the

identification of a putative transmembrane domain from amino acids 84-100. The cDNA sequence of the open reading frame of P1000C, including the stop codon, is provided in SEQ ID NO: 787, with the open reading frame without the stop codon being provided in SEQ ID NO: 788. The full-length amino acid sequence of P1000C is  
5 provided in SEQ ID NO: 789. SEQ ID NO: 790 and 791 represent amino acids 1-100 and 100-492 of P1000C, respectively.

The expression of the polypeptide encoded by the full length cDNA sequence for F1-12 (also referred to as P504S; SEQ ID NO: 108) was investigated by immunohistochemical analysis. Rabbit-anti-P504S polyclonal antibodies were  
10 generated against the full length P504S protein by standard techniques. Subsequent isolation and characterization of the polyclonal antibodies were also performed by techniques well known in the art. Immunohistochemical analysis showed that the P504S polypeptide was expressed in 100% of prostate carcinoma samples tested (n=5).

The rabbit-anti-P504S polyclonal antibody did not appear to label benign  
15 prostate cells with the same cytoplasmic granular staining, but rather with light nuclear staining. Analysis of normal tissues revealed that the encoded polypeptide was found to be expressed in some, but not all normal human tissues. Positive cytoplasmic staining with rabbit-anti-P504S polyclonal antibody was found in normal human kidney, liver, brain, colon and lung-associated macrophages, whereas heart and bone marrow were  
20 negative.

This data indicates that the P504S polypeptide is present in prostate cancer tissues, and that there are qualitative and quantitative differences in the staining between benign prostatic hyperplasia tissues and prostate cancer tissues, suggesting that this polypeptide may be detected selectively in prostate tumors and therefore be useful  
25 in the diagnosis of prostate cancer.

## EXAMPLE 3

ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC  
POLYPEPTIDES BY PCR-BASED SUBTRACTION

5 A cDNA subtraction library, containing cDNA from normal prostate subtracted with ten other normal tissue cDNAs (brain, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, spleen and thymus) and then submitted to a first round of PCR amplification, was purchased from Clontech. This library was subjected to a second round of PCR amplification, following the manufacturer's protocol. The  
10 resulting cDNA fragments were subcloned into the vector pT7 Blue T-vector (Novagen, Madison, WI) and transformed into XL-1 Blue MRF' *E. coli* (Stratagene). DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A.

Fifty-nine positive clones were sequenced. Comparison of the DNA  
15 sequences of these clones with those in the gene bank, as described above, revealed no significant homologies to 25 of these clones, hereinafter referred to as P5, P8, P9, P18, P20, P30, P34, P36, P38, P39, P42, P49, P50, P53, P55, P60, P64, P65, P73, P75, P76, P79 and P84. The determined cDNA sequences for these clones are provided in SEQ ID NO: 41-45, 47-52 and 54-65, respectively. P29, P47, P68, P80 and P82 (SEQ ID  
20 NO: 46, 53 and 66-68, respectively) were found to show some degree of homology to previously identified DNA sequences. To the best of the inventors' knowledge, none of these sequences have been previously shown to be present in prostate.

Further studies employing the sequence of SEQ ID NO: 67 as a probe in standard full-length cloning methods, resulted in the isolation of three cDNA sequences  
25 which appear to be splice variants of P80 (also known as P704P). These sequences are provided in SEQ ID NO: 620-622.

Further studies using the PCR-based methodology described above resulted in the isolation of more than 180 additional clones, of which 23 clones were found to show no significant homologies to known sequences. The determined cDNA  
30 sequences for these clones are provided in SEQ ID NO: 115-123, 127, 131, 137, 145,

147-151, 153, 156-158 and 160. Twenty-three clones (SEQ ID NO: 124-126, 128-130, 132-136, 138-144, 146, 152, 154, 155 and 159) were found to show some homology to previously identified ESTs. An additional ten clones (SEQ ID NO: 161-170) were found to have some degree of homology to known genes. Larger cDNA clones  
5 containing the P20 sequence represent splice variants of a gene referred to as P703P. The determined DNA sequence for the variants referred to as DE1, DE13 and DE14 are provided in SEQ ID NOS: 171, 175 and 177, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 172, 176 and 178, respectively. The determined cDNA sequence for an extended spliced form of P703 is  
10 provided in SEQ ID NO: 225. The DNA sequences for the splice variants referred to as DE2 and DE6 are provided in SEQ ID NOS: 173 and 174, respectively.

mRNA Expression levels for representative clones in tumor tissues (prostate (n=5), breast (n=2), colon and lung) normal tissues (prostate (n=5), colon, kidney, liver, lung (n=2), ovary (n=2), skeletal muscle, skin, stomach, small intestine  
15 and brain), and activated and non-activated PBMC was determined by RT-PCR as described above. Expression was examined in one sample of each tissue type unless otherwise indicated.

P9 was found to be highly expressed in normal prostate and prostate tumor compared to all normal tissues tested except for normal colon which showed  
20 comparable expression. P20, a portion of the P703P gene, was found to be highly expressed in normal prostate and prostate tumor, compared to all twelve normal tissues tested. A modest increase in expression of P20 in breast tumor (n=2), colon tumor and lung tumor was seen compared to all normal tissues except lung (1 of 2). Increased expression of P18 was found in normal prostate, prostate tumor and breast tumor  
25 compared to other normal tissues except lung and stomach. A modest increase in expression of P5 was observed in normal prostate compared to most other normal tissues. However, some elevated expression was seen in normal lung and PBMC. Elevated expression of P5 was also observed in prostate tumors (2 of 5), breast tumor and one lung tumor sample. For P30, similar expression levels were seen in normal  
30 prostate and prostate tumor, compared to six of twelve other normal tissues tested.

Increased expression was seen in breast tumors, one lung tumor sample and one colon tumor sample, and also in normal PBMC. P29 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to the majority of normal tissues. However, substantial expression of P29 was observed in normal colon and normal lung (2 of 2). P80 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to all other normal tissues tested, with increased expression also being seen in colon tumor.

Further studies resulted in the isolation of twelve additional clones, hereinafter referred to as 10-d8, 10-h10, 11-c8, 7-g6, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3, 8-h11, 9-f12 and 9-f3. The determined DNA sequences for 10-d8, 10-h10, 11-c8, 8-d4, 8-d9, 8-h11, 9-f12 and 9-f3 are provided in SEQ ID NO: 207, 208, 209, 216, 217, 220, 221 and 222, respectively. The determined forward and reverse DNA sequences for 7-g6, 8-b5, 8-b6 and 8-g3 are provided in SEQ ID NO: 210 and 211; 212 and 213; 214 and 215; and 218 and 219, respectively. Comparison of these sequences with those in the gene bank revealed no significant homologies to the sequence of 9-f3. The clones 10-d8, 11-c8 and 8-h11 were found to show some homology to previously isolated ESTs, while 10-h10, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3 and 9-f12 were found to show some homology to previously identified genes. Further characterization of 7-G6 and 8-G3 showed identity to the known genes PAP and PSA, respectively.

mRNA expression levels for these clones were determined using the micro-array technology described above. The clones 7-G6, 8-G3, 8-B5, 8-B6, 8-D4, 8-D9, 9-F3, 9-F12, 9-H3, 10-A2, 10-A4, 11-C9 and 11-F2 were found to be over-expressed in prostate tumor and normal prostate, with expression in other tissues tested being low or undetectable. Increased expression of 8-F11 was seen in prostate tumor and normal prostate, bladder, skeletal muscle and colon. Increased expression of 10-H10 was seen in prostate tumor and normal prostate, bladder, lung, colon, brain and large intestine. Increased expression of 9-B1 was seen in prostate tumor, breast tumor, and normal prostate, salivary gland, large intestine and skin, with increased expression of 11-C8 being seen in prostate tumor, and normal prostate and large intestine.

An additional cDNA fragment derived from the PCR-based normal prostate subtraction, described above, was found to be prostate specific by both microarray technology and RT-PCR. The determined cDNA sequence of this clone (referred to as 9-A11) is provided in SEQ ID NO: 226. Comparison of this sequence with those  
5 in the public databases revealed 99% identity to the known gene HOXB13.

Further studies led to the isolation of the clones 8-C6 and 8-H7. The determined cDNA sequences for these clones are provided in SEQ ID NO: 227 and 228, respectively. These sequences were found to show some homology to previously isolated ESTs.

10 PCR and hybridization-based methodologies were employed to obtain longer cDNA sequences for clone P20 (also referred to as P703P), yielding three additional cDNA fragments that progressively extend the 5' end of the gene. These fragments, referred to as P703PDE5, P703P6.26, and P703PX-23 (SEQ ID NO: 326, 328 and 330, with the predicted corresponding amino acid sequences being provided in  
15 SEQ ID NO: 327, 329 and 331, respectively) contain additional 5' sequence. P703PDE5 was recovered by screening of a cDNA library (#141-26) with a portion of P703P as a probe. P703P6.26 was recovered from a mixture of three prostate tumor cDNAs and P703PX\_23 was recovered from cDNA library (#438-48). Together, the additional sequences include all of the putative mature serine protease along with part of  
20 the putative signal sequence. The full-length cDNA sequence for P703P is provided in SEQ ID NO: 524, with the corresponding amino acid sequence being provided in SEQ ID NO: 525.

Using computer algorithms, the following regions of P703P were predicted to represent potential HLA A2-binding CTL epitopes: amino acids 164-172  
25 of SEQ ID NO: 525 (SEQ ID NO: 723); amino acids 160-168 of SEQ ID NO: 525 (SEQ ID NO: 724); amino acids 239-247 of SEQ ID NO: 525 (SEQ ID NO: 725); amino acids 118-126 of SEQ ID NO: 525 (SEQ ID NO: 726); amino acids 112-120 of SEQ ID NO: 525 (SEQ ID NO: 727); amino acids 155-164 of SEQ ID NO: 525 (SEQ ID NO: 728); amino acids 117-126 of SEQ ID NO: 525 (SEQ ID NO: 729); amino acids  
30 164-173 of SEQ ID NO: 525 (SEQ ID NO: 730); amino acids 154-163 of SEQ ID NO:

525 (SEQ ID NO: 731); amino acids 163-172 of SEQ ID NO: 525 (SEQ ID NO: 732); amino acids 58-66 of SEQ ID NO: 525 (SEQ ID NO: 733); and amino acids 59-67 of SEQ ID NO: 525 (SEQ ID NO: 734).

P703P was found to show some homology to previously identified proteases, such as thrombin. The thrombin receptor has been shown to be preferentially expressed in highly metastatic breast carcinoma cells and breast carcinoma biopsy samples. Introduction of thrombin receptor antisense cDNA has been shown to inhibit the invasion of metastatic breast carcinoma cells in culture. Antibodies against thrombin receptor inhibit thrombin receptor activation and thrombin-induced platelet activation. Furthermore, peptides that resemble the receptor's tethered ligand domain inhibit platelet aggregation by thrombin. P703P may play a role in prostate cancer through a protease-activated receptor on the cancer cell or on stromal cells. The potential trypsin-like protease activity of P703P may either activate a protease-activated receptor on the cancer cell membrane to promote tumorigenesis or activate a protease-activated receptor on the adjacent cells (such as stromal cells) to secrete growth factors and/or proteases (such as matrix metalloproteinases) that could promote tumor angiogenesis, invasion and metastasis. P703P may thus promote tumor progression and/or metastasis through the activation of protease-activated receptor. Polypeptides and antibodies that block the P703P-receptor interaction may therefore be usefully employed in the treatment of prostate cancer.

To determine whether P703P expression increases with increased severity of Gleason grade, an indicator of tumor stage, quantitative PCR analysis was performed on prostate tumor samples with a range of Gleason scores from 5 to > 8. The mean level of P703P expression increased with increasing Gleason score, indicating that P703P expression may correlate with increased disease severity.

Further studies using a PCR-based subtraction library of a prostate tumor pool subtracted against a pool of normal tissues (referred to as JP: PCR subtraction) resulted in the isolation of thirteen additional clones, seven of which did not share any significant homology to known GenBank sequences. The determined cDNA sequences for these seven clones (P711P, P712P, novel 23, P774P, P775P, P710P and P768P) are

provided in SEQ ID NO: 307-311, 313 and 315, respectively. The remaining six clones (SEQ ID NO: 316 and 321-325) were shown to share some homology to known genes. By microarray analysis, all thirteen clones showed three or more fold over-expression in prostate tissues, including prostate tumors, BPH and normal prostate as compared to normal non-prostate tissues. Clones P711P, P712P, novel 23 and P768P showed over-expression in most prostate tumors and BPH tissues tested ( $n=29$ ), and in the majority of normal prostate tissues ( $n=4$ ), but background to low expression levels in all normal tissues. Clones P774P, P775P and P710P showed comparatively lower expression and expression in fewer prostate tumors and BPH samples, with negative to low expression in normal prostate.

Further studies led to the isolation of an extended cDNA sequence for P712P (SEQ ID NO: 552). The amino acid sequences encoded by 16 predicted open reading frames present within the sequence of SEQ ID NO: 552 are provided in SEQ ID NO: 553-568.

The full-length cDNA for P711P was obtained by employing the partial sequence of SEQ ID NO: 307 to screen a prostate cDNA library. Specifically, a directionally cloned prostate cDNA library was prepared using standard techniques. One million colonies of this library were plated onto LB/Amp plates. Nylon membrane filters were used to lift these colonies, and the cDNAs which were picked up by these filters were denatured and cross-linked to the filters by UV light. The P711P cDNA fragment of SEQ ID NO: 307 was radio-labeled and used to hybridize with these filters. Positive clones were selected, and cDNAs were prepared and sequenced using an automatic Perkin Elmer/Applied Biosystems sequencer. The determined full-length sequence of P711P is provided in SEQ ID NO: 382, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 383.

Using PCR and hybridization-based methodologies, additional cDNA sequence information was derived for two clones described above, 11-C9 and 9-F3, herein after referred to as P707P and P714P, respectively (SEQ ID NO: 333 and 334). After comparison with the most recent GenBank, P707P was found to be a splice variant of the known gene HoxB13. In contrast, no significant homologies to P714P



were found. Further studies employing the sequence of SEQ ID NO: 334 as a probe in standard full-length cloning methods, resulted in an extended cDNA sequence for P714P. This sequence is provided in SEQ ID NO: 619. This sequence was found to show some homology to the gene that encodes human ribosomal L23A protein.

5 Clones 8-B3, P89, P98, P130 and P201 (as disclosed in U.S. Patent Application No. 09/020,956, filed February 9, 1998) were found to be contained within one contiguous sequence, referred to as P705P (SEQ ID NO: 335, with the predicted amino acid sequence provided in SEQ ID NO: 336), which was determined to be a splice variant of the known gene NKX 3.1.

10 Further studies on P775P resulted in the isolation of four additional sequences (SEQ ID NO: 473-476) which are all splice variants of the P775P gene. The sequence of SEQ ID NO: 474 was found to contain two open reading frames (ORFs). The predicted amino acid sequences encoded by these ORFs are provided in SEQ ID NO: 477 and 478. The cDNA sequence of SEQ ID NO: 475 was found to contain an  
15 ORF which encodes the amino acid sequence of SEQ ID NO: 479. The cDNA sequence of SEQ ID NO: 473 was found to contain four ORFs. The predicted amino acid sequences encoded by these ORFs are provided in SEQ ID NO: 480-483. Additional splice variants of P775P are provided in SEQ ID NO: 593-597.

20 Subsequent studies led to the identification of a genomic region on chromosome 22q11.2, known as the Cat Eye Syndrome region, that contains the five prostate genes P704P, P712P, P774P, P775P and B305D. The relative location of each of these five genes within the genomic region is shown in Fig. 10. This region may therefore be associated with malignant tumors, and other potential tumor genes may be contained within this region. These studies also led to the identification of a potential  
25 open reading frame (ORF) for P775P (provided in SEQ ID NO: 533), which encodes the amino acid sequence of SEQ ID NO: 534.

Comparison of the clone of SEQ ID NO: 325 (referred to as P558S) with sequences in the GenBank and GeneSeq DNA databases showed that P558S is identical to the prostate-specific transglutaminase gene, which is known to have two forms. The  
30 full-length sequences for the two forms are provided in SEQ ID NO: 630 and 631, with

the corresponding amino acid sequences being provided in SEQ ID NO: 632 and 633, respectively. The cDNA sequence of SEQ ID NO: 631 has a 15 pair base insert, resulting in a 5 amino acid insert in the corresponding amino acid sequence (SEQ ID NO: 633). This insert is not present in the sequence of SEQ ID NO: 630.

5 Further studies on P768P (SEQ ID NO: 315) led to the identification of the putative full-length open reading frame (ORF). The cDNA sequence of the ORF with stop codon is provided in SEQ ID NO: 764. The cDNA sequence of the ORF without stop codon is provided in SEQ ID NO: 765, with the corresponding amino acid sequence being provided in SEQ ID NO: 766. This sequence was found to show 86%  
10 identity to a rat calcium transporter protein, indicating that P768P may represent a human calcium transporter protein. The locations of transmembrane domains within P768P were predicted using the PSORT II computer algorithm. Six transmembrane domains were predicted at amino acid positions 118-134, 172-188, 211-227, 230-246, 282-298 and 348-364. The amino acid sequences of SEQ ID NO: 767-772 represent  
15 amino acids 1-134, 135-188, 189-227, 228-246, 247-298 and 299-511 of P768P, respectively.

#### EXAMPLE 4

##### SYNTHESIS OF POLYPEPTIDES

20

Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems 430A peptide synthesizer using Fmoc chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of  
25 conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid  
30 (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of

0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

5

## EXAMPLE 5

FURTHER ISOLATION AND CHARACTERIZATION OF  
PROSTATE-SPECIFIC POLYPEPTIDES BY PCR-BASED SUBTRACTION

10

A cDNA library generated from prostate primary tumor mRNA as described above was subtracted with cDNA from normal prostate. The subtraction was performed using a PCR-based protocol (Clontech), which was modified to generate larger fragments. Within this protocol, tester and driver double stranded cDNA were separately digested with five restriction enzymes that recognize six-nucleotide  
15 restriction sites (MluI, MscI, PvuII, SalI and StuI). This digestion resulted in an average cDNA size of 600 bp, rather than the average size of 300 bp that results from digestion with RsaI according to the Clontech protocol. This modification did not affect the subtraction efficiency. Two tester populations were then created with different adapters, and the driver library remained without adapters.

20

The tester and driver libraries were then hybridized using excess driver cDNA. In the first hybridization step, driver was separately hybridized with each of the two tester cDNA populations. This resulted in populations of (a) unhybridized tester cDNAs, (b) tester cDNAs hybridized to other tester cDNAs, (c) tester cDNAs hybridized to driver cDNAs and (d) unhybridized driver cDNAs. The two separate  
25 hybridization reactions were then combined, and rehybridized in the presence of additional denatured driver cDNA. Following this second hybridization, in addition to populations (a) through (d), a fifth population (e) was generated in which tester cDNA with one adapter hybridized to tester cDNA with the second adapter. Accordingly, the second hybridization step resulted in enrichment of differentially expressed sequences  
30 which could be used as templates for PCR amplification with adaptor-specific primers.

The ends were then filled in, and PCR amplification was performed using adaptor-specific primers. Only population (e), which contained tester cDNA that did not hybridize to driver cDNA, was amplified exponentially. A second PCR amplification step was then performed, to reduce background and further enrich  
5 differentially expressed sequences.

This PCR-based subtraction technique normalizes differentially expressed cDNAs so that rare transcripts that are overexpressed in prostate tumor tissue may be recoverable. Such transcripts would be difficult to recover by traditional subtraction methods.

10 In addition to genes known to be overexpressed in prostate tumor, seventy-seven further clones were identified. Sequences of these partial cDNAs are provided in SEQ ID NO: 29 to 305. Most of these clones had no significant homology to database sequences. Exceptions were JPTPN23 (SEQ ID NO: 231; similarity to pig valosin-containing protein), JPTPN30 (SEQ ID NO: 234; similarity to rat mRNA for  
15 proteasome subunit), JPTPN45 (SEQ ID NO: 243; similarity to rat *norvegicus* cytosolic NADP-dependent isocitrate dehydrogenase), JPTPN46 (SEQ ID NO: 244; similarity to human subclone H8 4 d4 DNA sequence), JP1D6 (SEQ ID NO: 265; similarity to *G. gallus* dynein light chain-A), JP8D6 (SEQ ID NO: 288; similarity to human BAC clone RG016J04), JP8F5 (SEQ ID NO: 289; similarity to human subclone H8 3 b5 DNA  
20 sequence), and JP8E9 (SEQ ID NO: 299; similarity to human Alu sequence).

Additional studies using the PCR-based subtraction library consisting of a prostate tumor pool subtracted against a normal prostate pool (referred to as PT-PN PCR subtraction) yielded three additional clones. Comparison of the cDNA sequences of these clones with the most recent release of GenBank revealed no significant  
25 homologies to the two clones referred to as P715P and P767P (SEQ ID NO: 312 and 314). The remaining clone was found to show some homology to the known gene KIAA0056 (SEQ ID NO: 318). Using microarray analysis to measure mRNA expression levels in various tissues, all three clones were found to be over-expressed in prostate tumors and BPH tissues. Specifically, clone P715P was over-expressed in most  
30 prostate tumors and BPH tissues by a factor of three or greater, with elevated expression

seen in the majority of normal prostate samples and in fetal tissue, but negative to low expression in all other normal tissues. Clone P767P was over-expressed in several prostate tumors and BPH tissues, with moderate expression levels in half of the normal prostate samples, and background to low expression in all other normal tissues tested.

5 Further analysis, by microarray as described above, of the PT-PN PCR subtraction library and of a DNA subtraction library containing cDNA from prostate tumor subtracted with a pool of normal tissue cDNAs, led to the isolation of 27 additional clones (SEQ ID NO: 340-365 and 381) which were determined to be over-expressed in prostate tumor. The clones of SEQ ID NO: 341, 342, 345, 347, 348, 349,  
10 351, 355-359, 361, 362 and 364 were also found to be expressed in normal prostate. Expression of all 26 clones in a variety of normal tissues was found to be low or undetectable, with the exception of P544S (SEQ ID NO: 356) which was found to be expressed in small intestine. Of the 26 clones, 11 (SEQ ID NO: 340-349 and 362) were found to show some homology to previously identified sequences. No significant  
15 homologies were found to the clones of SEQ ID NO: 350, 351, 353-361, and 363-365.

Comparison of the sequence of SEQ ID NO: 362 with sequences in the GenBank and GeneSeq DNA databases showed that this clone (referred to as P788P) is identical to GeneSeq Accession No. X27262, which encodes a protein found in the GeneSeq protein Accession No. Y00931. The full length cDNA sequence of P788P is  
20 provided in SEQ ID NO: 634, with the corresponding predicted amino acid being provided in SEQ ID NO: 635. Subsequently, a full-length cDNA sequence for P788P that contains polymorphisms not found in the sequence of SEQ ID NO: 634, was cloned multiple times by PCR amplification from cDNA prepared from several RNA templates from three individuals. This determined cDNA sequence of this polymorphic variant of  
25 P788P is provided in SEQ ID NO: 636, with the corresponding amino acid sequence being provided in SEQ ID NO: 637. The sequence of SEQ ID NO: 637 differs from that of SEQ ID NO: 635 by six amino acid residues. The P788P protein has 7 potential transmembrane domains at the C-terminal portion and is predicted to be a plasma membrane protein with an extracellular N-terminal region.

Further studies on the clone of SEQ ID NO: 352 (referred to as P790P) led to the isolation of the full-length cDNA sequence of SEQ ID NO: 526. The corresponding predicted amino acid is provided in SEQ ID NO: 527. Data from two quantitative PCR experiments indicated that P790P is over-expressed in 11/15 tested prostate tumor samples and is expressed at low levels in spinal cord, with no expression being seen in all other normal samples tested. Data from further PCR experiments and microarray experiments showed over-expression in normal prostate and prostate tumor with little or no expression in other tissues tested. P790P was subsequently found to show significant homology to a previously identified G-protein coupled prostate tissue receptor.

Additional studies on the clone of SEQ ID NO: 354 (referred to as P776P) led to the isolation of an extended cDNA sequence, provided in SEQ ID NO: 569. The determined cDNA sequences of three additional splice variants of P776P are provided in SEQ ID NO: 570-572. The amino acid sequences encoded by two predicted open reading frames (ORFs) contained within SEQ ID NO: 570, one predicted ORF contained within SEQ ID NO: 571, and 11 predicted ORFs contained within SEQ ID NO: 569, are provided in SEQ ID NO: 573-586, respectively. Further studies led to the isolation of the full-length sequence for the clone of SEQ ID NO: 570 (provided in SEQ ID NO: 737). Full-length cloning efforts on the clone of SEQ ID NO: 571 led to the isolation of two sequences (provided in SEQ ID NO: 738 and 739), representing a single clone, that are identical with the exception of a polymorphic insertion/deletion at position 1293. Specifically, the clone of SEQ ID NO: 739 (referred to as clone F1) has a C at position 1293. The clone of SEQ ID NO: 738 (referred to as clone F2) has a single base pair deletion at position 1293. The predicted amino acid sequences encoded by 5 open reading frames located within SEQ ID NO: 737 are provided in SEQ ID NO: 740-744, with the predicted amino acid sequences encoded by the clone of SEQ ID NO: 738 and 739 being provided in SEQ ID NO: 745-750.

Comparison of the cDNA sequences for the clones P767P (SEQ ID NO: 314) and P777P (SEQ ID NO: 350) with sequences in the GenBank human EST database showed that the two clones matched many EST sequences in common,

suggesting that P767P and P777P may represent the same gene. A DNA consensus sequence derived from a DNA sequence alignment of P767P, P777P and multiple EST clones is provided in SEQ ID NO: 587. The amino acid sequences encoded by three putative ORFs located within SEQ ID NO: 587 are provided in SEQ ID NO: 588-590.

5 The clone of SEQ ID NO: 342 (referred to as P789P) was found to show homology to a previously identified gene. The full length cDNA sequence for P789P and the corresponding amino acid sequence are provided in SEQ ID NO: 735 and 736, respectively.

## 10 EXAMPLE 6

### PEPTIDE PRIMING OF MICE AND PROPAGATION OF CTL LINES

6.1. This Example illustrates the preparation of a CTL cell line specific for cells expressing the P502S gene.

15 Mice expressing the transgene for human HLA A2Kb (provided by Dr L. Sherman, The Scripps Research Institute, La Jolla, CA) were immunized with P2S#12 peptide (VLGWVAEL; SEQ ID NO: 306), which is derived from the P502S gene (also referred to herein as J1-17, SEQ ID NO: 8), as described by Theobald et al., *Proc. Natl. Acad. Sci. USA* 92:11993-11997, 1995 with the following modifications. Mice were  
20 immunized with 100µg of P2S#12 and 120µg of an I-A<sup>b</sup> binding peptide derived from hepatitis B Virus protein emulsified in incomplete Freund's adjuvant. Three weeks later these mice were sacrificed and using a nylon mesh single cell suspensions prepared. Cells were then resuspended at  $6 \times 10^6$  cells/ml in complete media (RPMI-1640; Gibco BRL, Gaithersburg, MD) containing 10% FCS, 2mM Glutamine (Gibco BRL), sodium  
25 pyruvate (Gibco BRL), non-essential amino acids (Gibco BRL),  $2 \times 10^{-5}$  M 2-mercaptoethanol, 50U/ml penicillin and streptomycin, and cultured in the presence of irradiated (3000 rads) P2S#12-pulsed (5mg/ml P2S#12 and 10mg/ml β2-microglobulin) LPS blasts (A2 transgenic spleens cells cultured in the presence of 7µg/ml dextran sulfate and 25µg/ml LPS for 3 days). Six days later, cells ( $5 \times 10^5$ /ml) were  
30 restimulated with  $2.5 \times 10^6$ /ml peptide pulsed irradiated (20,000 rads) EL4A2Kb cells

(Sherman et al, *Science* 258:815-818, 1992) and  $3 \times 10^6$ /ml A2 transgenic spleen feeder cells. Cells were cultured in the presence of 20U/ml IL-2. Cells continued to be restimulated on a weekly basis as described, in preparation for cloning the line.

P2S#12 line was cloned by limiting dilution analysis with peptide pulsed  
5 EL4 A2Kb tumor cells ( $1 \times 10^4$  cells/ well) as stimulators and A2 transgenic spleen cells as feeders ( $5 \times 10^5$  cells/ well) grown in the presence of 30U/ml IL-2. On day 14, cells were restimulated as before. On day 21, clones that were growing were isolated and maintained in culture. Several of these clones demonstrated significantly higher reactivity (lysis) against human fibroblasts (HLA A2Kb expressing) transduced with  
10 P502S than against control fibroblasts. An example is presented in Figure 1.

This data indicates that P2S #12 represents a naturally processed epitope of the P502S protein that is expressed in the context of the human HLA A2Kb molecule.

15 6.2. This Example illustrates the preparation of murine CTL lines and CTL clones specific for cells expressing the P501S gene.

This series of experiments were performed similarly to that described above. Mice were immunized with the P1S#10 peptide (SEQ ID NO: 337), which is  
20 derived from the P501S gene (also referred to herein as L1-12, SEQ ID NO: 110). The P1S#10 peptide was derived by analysis of the predicted polypeptide sequence for P501S for potential HLA-A2 binding sequences as defined by published HLA-A2 binding motifs (Parker, KC, et al, *J. Immunol.*, 152:163, 1994). P1S#10 peptide was synthesized as described in Example 4, and empirically tested for HLA-A2 binding  
25 using a T cell based competition assay. Predicted A2 binding peptides were tested for their ability to compete HLA-A2 specific peptide presentation to an HLA-A2 restricted CTL clone (D150M58), which is specific for the HLA-A2 binding influenza matrix peptide fluM58. D150M58 CTL secretes TNF in response to self-presentation of peptide fluM58. In the competition assay, test peptides at 100-200  $\mu$ g/ml were added to  
30 cultures of D150M58 CTL in order to bind HLA-A2 on the CTL. After thirty minutes,



CTL cultured with test peptides, or control peptides, were tested for their antigen dose response to the fluM58 peptide in a standard TNF bioassay. As shown in Figure 3, peptide P1S#10 competes HLA-A2 restricted presentation of fluM58, demonstrating that peptide P1S#10 binds HLA-A2.

5 Mice expressing the transgene for human HLA A2Kb were immunized as described by Theobald et al. (*Proc. Natl. Acad. Sci. USA* 92:11993-11997, 1995) with the following modifications. Mice were immunized with 62.5µg of P1S #10 and 120µg of an I-A<sup>b</sup> binding peptide derived from Hepatitis B Virus protein emulsified in incomplete Freund's adjuvant. Three weeks later these mice were sacrificed and single  
10 cell suspensions prepared using a nylon mesh. Cells were then resuspended at  $6 \times 10^6$  cells/ml in complete media (as described above) and cultured in the presence of irradiated (3000 rads) P1S#10-pulsed (2µg/ml P1S#10 and 10mg/ml β2-microglobulin) LPS blasts (A2 transgenic spleens cells cultured in the presence of 7µg/ml dextran sulfate and 25µg/ml LPS for 3 days). Six days later cells ( $5 \times 10^5$ /ml) were restimulated  
15 with  $2.5 \times 10^6$ /ml peptide-pulsed irradiated (20,000 rads) EL4A2Kb cells, as described above, and  $3 \times 10^6$ /ml A2 transgenic spleen feeder cells. Cells were cultured in the presence of 20 U/ml IL-2. Cells were restimulated on a weekly basis in preparation for cloning. After three rounds of *in vitro* stimulations, one line was generated that recognized P1S#10-pulsed Jurkat A2Kb targets and P501S-transduced Jurkat targets as  
20 shown in Figure 4.

A P1S#10-specific CTL line was cloned by limiting dilution analysis with peptide pulsed EL4 A2Kb tumor cells ( $1 \times 10^4$  cells/ well) as stimulators and A2 transgenic spleen cells as feeders ( $5 \times 10^5$  cells/ well) grown in the presence of 30U/ml IL-2. On day 14, cells were restimulated as before. On day 21, viable clones were  
25 isolated and maintained in culture. As shown in Figure 5, five of these clones demonstrated specific cytolytic reactivity against P501S-transduced Jurkat A2Kb targets. This data indicates that P1S#10 represents a naturally processed epitope of the P501S protein that is expressed in the context of the human HLA-A2.1 molecule.

## EXAMPLE 7

PRIMING OF CTL *IN VIVO* USING NAKED DNA IMMUNIZATION

## WITH A PROSTATE ANTIGEN

The prostate-specific antigen L1-12, as described above, is also referred  
5 to as P501S. HLA A2Kb Tg mice (provided by Dr L. Sherman, The Scripps Research  
Institute, La Jolla, CA) were immunized with 100 µg P501S in the vector VR1012  
either intramuscularly or intradermally. The mice were immunized three times, with a  
two week interval between immunizations. Two weeks after the last immunization,  
immune spleen cells were cultured with Jurkat A2Kb-P501S transduced stimulator  
10 cells. CTL lines were stimulated weekly. After two weeks of *in vitro* stimulation, CTL  
activity was assessed against P501S transduced targets. Two out of 8 mice developed  
strong anti-P501S CTL responses. These results demonstrate that P501S contains at  
least one naturally processed HLA-A2-restricted CTL epitope.

15

## EXAMPLE 8

## ABILITY OF HUMAN T CELLS TO RECOGNIZE PROSTATE-SPECIFIC POLYPEPTIDES

This Example illustrates the ability of T cells specific for a prostate  
tumor polypeptide to recognize human tumor.

20

Human CD8<sup>+</sup> T cells were primed *in vitro* to the P2S-12 peptide (SEQ  
ID NO: 306) derived from P502S (also referred to as J1-17) using dendritic cells  
according to the protocol of Van Tsai et al. (*Critical Reviews in Immunology* 18:65-75,  
1998). The resulting CD8<sup>+</sup> T cell microcultures were tested for their ability to  
recognize the P2S-12 peptide presented by autologous fibroblasts or fibroblasts which  
25 were transduced to express the P502S gene in a  $\gamma$ -interferon ELISPOT assay (see  
Lalvani et al., *J. Exp. Med.* 186:859-865, 1997). Briefly, titrating numbers of T cells  
were assayed in duplicate on 10<sup>4</sup> fibroblasts in the presence of 3 µg/ml human  $\beta_2$ -  
microglobulin and 1 µg/ml P2S-12 peptide or control E75 peptide. In addition, T cells  
were simultaneously assayed on autologous fibroblasts transduced with the P502S gene  
30 or as a control, fibroblasts transduced with HER-2/*neu*. Prior to the assay, the

fibroblasts were treated with 10 ng/ml  $\gamma$ -interferon for 48 hours to upregulate class I MHC expression. One of the microcultures (#5) demonstrated strong recognition of both peptide pulsed fibroblasts as well as transduced fibroblasts in a  $\gamma$ -interferon ELISPOT assay. Figure 2A demonstrates that there was a strong increase in the number of  $\gamma$ -interferon spots with increasing numbers of T cells on fibroblasts pulsed with the P2S-12 peptide (solid bars) but not with the control E75 peptide (open bars). This shows the ability of these T cells to specifically recognize the P2S-12 peptide. As shown in Figure 2B, this microculture also demonstrated an increase in the number of  $\gamma$ -interferon spots with increasing numbers of T cells on fibroblasts transduced to express the P502S gene but not the HER-2/*neu* gene. These results provide additional confirmatory evidence that the P2S-12 peptide is a naturally processed epitope of the P502S protein. Furthermore, this also demonstrates that there exists in the human T cell repertoire, high affinity T cells which are capable of recognizing this epitope. These T cells should also be capable of recognizing human tumors which express the P502S gene.

### EXAMPLE 9

#### ELICITATION OF PROSTATE ANTIGEN-SPECIFIC CTL RESPONSES IN HUMAN BLOOD

This Example illustrates the ability of a prostate-specific antigen to elicit a CTL response in blood of normal humans.

Autologous dendritic cells (DC) were differentiated from monocyte cultures derived from PBMC of normal donors by growth for five days in RPMI medium containing 10% human serum, 50 ng/ml GM-CSF and 30 ng/ml IL-4. Following culture, DC were infected overnight with recombinant P501S-expressing vaccinia virus at an M.O.I. of 5 and matured for 8 hours by the addition of 2 micrograms/ml CD40 ligand. Virus was inactivated by UV irradiation, CD8<sup>+</sup> cells were isolated by positive selection using magnetic beads, and priming cultures were initiated in 24-well plates. Following five stimulation cycles using autologous fibroblasts

retrovirally transduced to express P501S and CD80, CD8+ lines were identified that specifically produced interferon-gamma when stimulated with autologous P501S-transduced fibroblasts. The P501S-specific activity of cell line 3A-1 could be maintained following additional stimulation cycles on autologous B-LCL transduced with P501S. Line 3A-1 was shown to specifically recognize autologous B-LCL transduced to express P501S, but not EGFP-transduced autologous B-LCL, as measured by cytotoxicity assays ( $^{51}\text{Cr}$  release) and interferon-gamma production (Interferon-gamma Elispot; see above and Lalvani et al., *J. Exp. Med.* 186:859-865, 1997). The results of these assays are presented in Figures 6A and 6B.

10

## EXAMPLE 10

## IDENTIFICATION OF A NATURALLY PROCESSED CTL EPIOTOPE CONTAINED WITHIN THE PROSTATE-SPECIFIC ANTIGEN P703P

15

The 9-mer peptide p5 (SEQ ID NO: 338) was derived from the P703P antigen (also referred to as P20). The p5 peptide is immunogenic in human HLA-A2 donors and is a naturally processed epitope. Antigen specific human CD8+ T cells can be primed following repeated *in vitro* stimulations with monocytes pulsed with p5 peptide. These CTL specifically recognize p5-pulsed and P703P-transduced target cells in both ELISPOT (as described above) and chromium release assays. Additionally, immunization of HLA-A2Kb transgenic mice with p5 leads to the generation of CTL lines which recognize a variety of HLA-A2Kb or HLA-A2 transduced target cells expressing P703P.

Initial studies demonstrating that p5 is a naturally processed epitope were done using HLA-A2Kb transgenic mice. HLA-A2Kb transgenic mice were immunized subcutaneously in the footpad with 100  $\mu\text{g}$  of p5 peptide together with 140  $\mu\text{g}$  of hepatitis B virus core peptide (a Th peptide) in Freund's incomplete adjuvant. Three weeks post immunization, spleen cells from immunized mice were stimulated *in vitro* with peptide-pulsed LPS blasts. CTL activity was assessed by chromium release assay five days after primary *in vitro* stimulation. Retrovirally transduced cells expressing the

30

control antigen P703P and HLA-A2Kb were used as targets. CTL lines that specifically recognized both p5-pulsed targets as well as P703P-expressing targets were identified.

Human *in vitro* priming experiments demonstrated that the p5 peptide is immunogenic in humans. Dendritic cells (DC) were differentiated from monocyte  
5 cultures derived from PBMC of normal human donors by culturing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, the DC were pulsed with 1 ug/ml p5 peptide and cultured with CD8+ T cell enriched PBMC. CTL lines were restimulated on a weekly basis with p5-pulsed monocytes. Five to six weeks after initiation of the CTL cultures,  
10 CTL recognition of p5-pulsed target cells was demonstrated. CTL were additionally shown to recognize human cells transduced to express P703P, demonstrating that p5 is a naturally processed epitope.

Studies identifying a further peptide epitope (referred to as peptide 4) derived from the prostate tumor-specific antigen P703P that is capable of being  
15 recognized by CD4 T cells on the surface of cells in the context of HLA class II molecules were carried out as follows. The amino acid sequence for peptide 4 is provided in SEQ ID NO: 638, with the corresponding cDNA sequence being provided in SEQ ID NO: 639.

Twenty 15-mer peptides overlapping by 10 amino acids and derived  
20 from the carboxy-terminal fragment of P703P were generated using standard procedures. Dendritic cells (DC) were derived from PBMC of a normal female donor using GM-CSF and IL-4 by standard protocols. CD4 T cells were generated from the same donor as the DC using MACS beads and negative selection. DC were pulsed overnight with pools of the 15-mer peptides, with each peptide at a final concentration  
25 of 0.25 microgram/ml. Pulsed DC were washed and plated at  $1 \times 10^4$  cells/well of 96-well V-bottom plates and purified CD4 T cells were added at  $1 \times 10^5$ /well. Cultures were supplemented with 60 ng/ml IL-6 and 10 ng/ml IL-12 and incubated at 37 °C. Cultures were restimulated as above on a weekly basis using DC generated and pulsed as above as antigen presenting cells, supplemented with 5 ng/ml IL-7 and 10 u/ml IL-2.  
30 Following 4 *in vitro* stimulation cycles, 96 lines (each line corresponding to one well) were tested for specific proliferation and cytokine production in response to the

stimulating pools with an irrelevant pool of peptides derived from mammaglobin being used as a control.

One line (referred to as 1-F9) was identified from pool #1 that demonstrated specific proliferation (measured by 3H proliferation assays) and cytokine production (measured by interferon-gamma ELISA assays) in response to pool #1 of P703P peptides. This line was further tested for specific recognition of the peptide pool, specific recognition of individual peptides in the pool, and in HLA mismatch analyses to identify the relevant restricting allele. Line 1-F9 was found to specifically proliferate and produce interferon-gamma in response to peptide pool #1, and also to peptide 4 (SEQ ID NO: 638). Peptide 4 corresponds to amino acids 126-140 of SEQ ID NO: 327. Peptide titration experiments were conducted to assess the sensitivity of line 1-F9 for the specific peptide. The line was found to specifically respond to peptide 4 at concentrations as low as 0.25 ng/ml, indicating that the T cells are very sensitive and therefore likely to have high affinity for the epitope.

To determine the HLA restriction of the P703P response, a panel of antigen presenting cells (APC) was generated that was partially matched with the donor used to generate the T cells. The APC were pulsed with the peptide and used in proliferation and cytokine assays together with line 1-F9. APC matched with the donor at HLA-DRB0701 and HLA-DQB02 alleles were able to present the peptide to the T cells, indicating that the P703P-specific response is restricted to one of these alleles.

Antibody blocking assays were utilized to determine if the restricting allele was HLA-DR0701 or HLA-DQ02. The anti-HLA-DR blocking antibody L243 or an irrelevant isotype matched IgG2a were added to T cells and APC cultures pulsed with the peptide RMPTVLQCVNVS VVS (SEQ ID NO: 638) at 250 ng/ml. Standard interferon-gamma and proliferation assays were performed. Whereas the control antibody had no effect on the ability of the T cells to recognize peptide-pulsed APC, in both assays the anti-HLA-DR antibody completely blocked the ability of the T cells to specifically recognize peptide-pulsed APC.

To determine if the peptide epitope RMPTVLQCVNVS VVS (SEQ ID NO: 638) was naturally processed, the ability of line 1-F9 to recognize APC pulsed with recombinant P703P protein was examined. For these experiments a number of

recombinant P703P sources were utilized; *E. coli*-derived P703P, Pichia-derived P703P and baculovirus-derived P703P. Irrelevant protein controls used were *E. coli*-derived L3E (a lung-specific antigen) and baculovirus-derived mammaglobin. In interferon-gamma ELISA assays, line 1-F9 was able to efficiently recognize both *E. coli* forms of P703P as well as Pichia-derived recombinant P703P, while baculovirus-derived P703P was recognized less efficiently. Subsequent Western blot analysis revealed that the *E. coli* and Pichia P703P protein preparations were intact while the baculovirus P703P preparation was approximately 75% degraded. Thus, peptide RMPTVLQCVNVS VVS (SEQ ID NO: 638) from P703P is a naturally processed peptide epitope derived from P703P and presented to T cells in the context of HLA-DRB-0701

In further studies, twenty-four 15-mer peptides overlapping by 10 amino acids and derived from the N-terminal fragment of P703P (corresponding to amino acids 27-154 of SEQ ID NO: 525) were generated by standard procedures and their ability to be recognized by CD4 cells was determined essentially as described above. DC were pulsed overnight with pools of the peptides with each peptide at a final concentration of 10 microgram/ml. A large number of individual CD4 T cell lines (65/480) demonstrated significant proliferation and cytokine release (IFN-gamma) in response to the P703P peptide pools but not to a control peptide pool. The CD4 T cell lines which demonstrated specific activity were restimulated on the appropriate pool of P703P peptides and reassayed on the individual peptides of each pool as well as a peptide dose titration of the pool of peptides in a IFN-gamma release assay and in a proliferation assay.

Sixteen immunogenic peptides were recognized by the T cells from the entire set of peptide antigens tested. The amino acid sequences of these peptides are provided in SEQ ID NO: 656-671, with the corresponding cDNA sequences being provided in SEQ ID NO: 640-655, respectively. In some cases the peptide reactivity of the T cell line could be mapped to a single peptide, however some could be mapped to more than one peptide in each pool. Those CD4 T cell lines that displayed a representative pattern of recognition from each peptide pool with a reasonable affinity for peptide were chosen for further analysis (I-1A, -6A; II-4C, -5E; III-6E, IV-4B, -3F, -9B, -10F, V-5B, -4D, and -10F). These CD4 T cell lines were restimulated on the

appropriate individual peptide and reassayed on autologous DC pulsed with a truncated form of recombinant P703P protein made in *E. coli* (a.a. 96 - 254 of SEQ ID NO: 525), full-length P703P made in the baculovirus expression system, and a fusion between influenza virus NS1 and P703P made in *E. coli*. Of the T cell lines tested, line I-1A  
5 recognized specifically the truncated form of P703P (*E. coli*) but no other recombinant form of P703P. This line also recognized the peptide used to elicit the T cells. Line 2-4C recognized the truncated form of P703P (*E. coli*) and the full length form of P703P made in baculovirus, as well as peptide. The remaining T cell lines tested were either peptide-specific only (II-5E, II-6F, IV-4B, IV-3F, IV-9B, IV-10F, V-5B and V-4D) or  
10 were non-responsive to any antigen tested (V-10F). These results demonstrate that the peptide sequence RPLLANDLMLIKLDE (SEQ ID NO: 671; corresponding to a.a. 110-124 of SEQ ID NO: 525) recognized by the T cell line I-1A, and the peptide sequences SVSESdTIRSISIAS (SEQ ID NO: 668; corresponding to a.a. 125-139 of SEQ ID NO: 525) and ISIASQCPTAGNSCL (SEQ ID NO: 667; corresponding to a.a. 135-149 of  
15 SEQ ID NO: 525) recognized by the T cell line II-4C may be naturally processed epitopes of the P703P protein.

#### EXAMPLE 11

##### EXPRESSION OF A BREAST TUMOR-DERIVED ANTIGEN IN PROSTATE

20

Isolation of the antigen B305D from breast tumor by differential display is described in US Patent Application No. 08/700,014, filed August 20, 1996. Several different splice forms of this antigen were isolated. The determined cDNA sequences  
25 for these splice forms are provided in SEQ ID NO: 366-375, with the predicted amino acid sequences corresponding to the sequences of SEQ ID NO: 292, 298 and 301-303 being provided in SEQ ID NO: 299-306, respectively. In further studies, a splice variant of the cDNA sequence of SEQ ID NO: 366 was isolated which was found to contain an additional guanine residue at position 884 (SEQ ID NO: 530), leading to a  
30 frameshift in the open reading frame. The determined DNA sequence of this ORF is



provided in SEQ ID NO: 531. This frameshift generates a protein sequence (provided in SEQ ID NO: 532) of 293 amino acids that contains the C-terminal domain common to the other isoforms of B305D but that differs in the N-terminal region.

The expression levels of B305D in a variety of tumor and normal tissues were examined by real time PCR and by Northern analysis. The results indicated that B305D is highly expressed in breast tumor, prostate tumor, normal prostate and normal testes, with expression being low or undetectable in all other tissues examined (colon tumor, lung tumor, ovary tumor, and normal bone marrow, colon, kidney, liver, lung, ovary, skin, small intestine, stomach). Using real-time PCR on a panel of prostate tumors, expression of B305D in prostate tumors was shown to increase with increasing Gleason grade, demonstrating that expression of B305D increases as prostate cancer progresses.

#### EXAMPLE 12

##### 15 GENERATION OF HUMAN CTL *IN VITRO* USING WHOLE GENE PRIMING AND STIMULATION TECHNIQUES WITH THE PROSTATE-SPECIFIC ANTIGEN P501S

Using *in vitro* whole-gene priming with P501S-vaccinia infected DC (see, for example, Yee et al, *The Journal of Immunology*, 157(9):4079-86, 1996), human CTL lines were derived that specifically recognize autologous fibroblasts transduced with P501S (also known as L1-12), as determined by interferon- $\gamma$  ELISPOT analysis as described above. Using a panel of HLA-mismatched B-LCL lines transduced with P501S, these CTL lines were shown to be likely restricted to HLAB class I allele. Specifically, dendritic cells (DC) were differentiated from monocyte cultures derived from PBMC of normal human donors by growing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, DC were infected overnight with recombinant P501S vaccinia virus at a multiplicity of infection (M.O.I) of five, and matured overnight by the addition of 3  $\mu$ g/ml CD40 ligand. Virus was inactivated by UV irradiation. CD8+ T cells were isolated using a magnetic bead system, and priming cultures were initiated

using standard culture techniques. Cultures were restimulated every 7-10 days using autologous primary fibroblasts retrovirally transduced with P501S and CD80. Following four stimulation cycles, CD8<sup>+</sup> T cell lines were identified that specifically produced interferon- $\gamma$  when stimulated with P501S and CD80-transduced autologous  
5 fibroblasts. A panel of HLA-mismatched B-LCL lines transduced with P501S were generated to define the restriction allele of the response. By measuring interferon- $\gamma$  in an ELISPOT assay, the P501S specific response was shown to be likely restricted by HLA B alleles. These results demonstrate that a CD8<sup>+</sup> CTL response to P501S can be elicited.

10 To identify the epitope(s) recognized, cDNA encoding P501S was fragmented by various restriction digests, and sub-cloned into the retroviral expression vector pBIB-KS. Retroviral supernatants were generated by transfection of the helper packaging line Phoenix-Ampho. Supernatants were then used to transduce Jurkat/A2Kb cells for CTL screening. CTL were screened in IFN-gamma ELISPOT  
15 assays against these A2Kb targets transduced with the "library" of P501S fragments. Initial positive fragments P501S/H3 and P501S/F2 were sequenced and found to encode amino acids 106-553 and amino acids 136-547, respectively, of SEQ ID NO: 113. A truncation of H3 was made to encode amino acid residues 106-351 of SEQ ID NO: 113, which was unable to stimulate the CTL, thus localizing the epitope to amino acid  
20 residues 351-547. Additional fragments encoding amino acids 1-472 (Fragment A) and amino acids 1-351 (Fragment B) were also constructed. Fragment A but not Fragment B stimulated the CTL thus localizing the epitope to amino acid residues 351-472. Overlapping 20-mer and 18-mer peptides representing this region were tested by pulsing Jurkat/A2Kb cells versus CTL in an IFN-gamma assay. Only peptides P501S-369(20)  
25 and P501S-369(18) stimulated the CTL. Nine-mer and 10-mer peptides representing this region were synthesized and similarly tested. Peptide P501S-370 (SEQ ID NO: 539) was the minimal 9-mer giving a strong response. Peptide P501S-376 (SEQ ID NO: 540) also gave a weak response, suggesting that it might represent a cross-reactive epitope.

In subsequent studies, the ability of primary human B cells transduced with P501S to prime MHC class I-restricted, P501S-specific, autologous CD8 T cells was examined. Primary B cells were derived from PBMC of a homozygous HLA-A2 donor by culture in CD40 ligand and IL-4, transduced at high frequency with recombinant P501S in the vector pBIB, and selected with blastocidin-S. For *in vitro* priming, purified CD8<sup>+</sup> T cells were cultured with autologous CD40 ligand + IL-4 derived, P501S-transduced B cells in a 96-well microculture format. These CTL microcultures were re-stimulated with P501S-transduced B cells and then assayed for specificity. Following this initial screen, microcultures with significant signal above background were cloned on autologous EBV-transformed B cells (BLCL), also transduced with P501S. Using IFN-gamma ELISPOT for detection, several of these CD8 T cell clones were found to be specific for P501S, as demonstrated by reactivity to BLCL/P501S but not BLCL transduced with control antigen. It was further demonstrated that the anti-P501S CD8 T cell specificity is HLA-A2-restricted. First, antibody blocking experiments with anti-HLA-A,B,C monoclonal antibody (W6.32), anti-HLA-B,C monoclonal antibody (B1.23.2) and a control monoclonal antibody showed that only the anti-HLA-A,B,C antibody blocked recognition of P501S-expressing autologous BLCL. Secondly, the anti-P501S CTL also recognized an HLA-A2 matched, heterologous BLCL transduced with P501S, but not the corresponding EGFP transduced control BLCL.

A naturally processed, CD8, class I-restricted peptide epitope of P501S was identified as follows. Dendritic Cells (DC) were isolated by Percol gradient followed by differential adherence, and cultured for 5 days in the presence of RPMI medium containing 1% human serum, 50ng/ml GM-CSF and 30ng/ml IL-4. Following culture, DC were infected for 24 hours with P501S-expressing adenovirus at an MOI of 10 and matured for an additional 24 hours by the addition of 2ug/ml CD40 ligand. CD8 cells were enriched for by the subtraction of CD4<sup>+</sup>, CD14<sup>+</sup> and CD16<sup>+</sup> populations from PBMC with magnetic beads. Priming cultures containing 10,000 P501S-expressing DC and 100,000 CD8<sup>+</sup> T cells per well were set up in 96-well V-bottom plates with RPMI containing 10% human serum, 5ng/ml IL-12 and 10ng/ml IL-6. Cultures were stimulated every 7 days using autologous fibroblasts retrovirally

transduced to express P501S and CD80, and were treated with IFN-gamma for 48-72 hours to upregulate MHC Class I expression. 10u/ml IL-2 was added at the time of stimulation and on days 2 and 5 following stimulation. Following 4 stimulation cycles, one P501S-specific CD8+ T cell line (referred to as 2A2) was identified that produced  
5 IFN-gamma in response to IFN-gamma-treated P501S/CD80 expressing autologous fibroblasts, but not in response to IFN-gamma-treated P703P/CD80 expressing autologous fibroblasts in a  $\gamma$ -IFN Elispot assay. Line 2A2 was cloned in 96-well plates with 0.5 cell/well or 2 cells/well in the presence of 75,000 PBMC/well, 10,000 B-LCL/well, 30ng/ml OKT3 and 50u/ml IL-2. Twelve clones were isolated that showed  
10 strong P501S specificity in response to transduced fibroblasts.

Fluorescence activated cell sorting (FACS) analysis was performed on P501S-specific clones using CD3-, CD4- and CD8-specific antibodies conjugated to PercP, FITC and PE respectively. Consistent with the use of CD8 enriched T cells in the priming cultures, P5401S-specific clones were determined to be CD3+, CD8+ and  
15 CD4-.

To identify the relevant P501S epitope recognized by P501S specific CTL, pools of 18-20 mer or 30-mer peptides that spanned the majority of the amino acid sequence of P501S were loaded onto autologous B-LCL and tested in  $\gamma$ -IFN Elispot assays for the ability to stimulate two P501S-specific CTL clones, referred to as 4E5  
20 and 4E7. One pool, composed of five 18-20 mer peptides that spanned amino acids 411-486 of P501S (SEQ ID NO: 113), was found to be recognized by both P501S-specific clones. To identify the specific 18-20 mer peptide recognized by the clones, each of the 18-20 mer peptides that comprised the positive pool were tested individually in  $\gamma$ -IFN Elispot assays for the ability to stimulate the two P501S-specific CTL clones, 4E5 and  
25 4E7. Both 4E5 and 4E7 specifically recognized one 20-mer peptide (SEQ ID NO: 710; cDNA sequence provided in SEQ ID NO: 711) that spanned amino acids 453-472 of P501S. Since the minimal epitope recognized by CD8+ T cells is almost always either a 9 or 10-mer peptide sequence, 10-mer peptides that spanned the entire sequence of SEQ ID NO: 710 were synthesized that differed by 1 amino acid. Each of these 10-mer  
30 peptides was tested for the ability to stimulate two P501S-specific clones, (referred to as 1D5 and 1E12). One 10-mer peptide (SEQ ID NO: 712; cDNA sequence provided in

SEQ ID NO: 713) was identified that specifically stimulated the P501S-specific clones. This epitope spans amino acids 463-472 of P501S. This sequence defines a minimal 10-mer epitope from P501S that can be naturally processed and to which CTL responses can be identified in normal PBMC. Thus, this epitope is a candidate for use as a vaccine moiety, and as a therapeutic and/or diagnostic reagent for prostate cancer.

To identify the class I restriction element for the P501S-derived sequence of SEQ ID NO: 712, HLA blocking and mismatch analyses were performed. In  $\gamma$ -IFN Elispot assays, the specific response of clones 4A7 and 4E5 to P501S-transduced autologous fibroblasts was blocked by pre-incubation with 25ug/ml W6/32 (pan-Class I blocking antibody) and B1.23.2 (HLA-B/C blocking antibody). These results demonstrate that the SEQ ID NO: 712-specific response is restricted to an HLA-B or HLA-C allele.

For the HLA mismatch analysis, autologous B-LCL (HLA-A1,A2,B8,B51, Cw1, Cw7) and heterologous B-LCL (HLA-A2,A3,B18,B51,Cw5,Cw14) that share the HLAB51 allele were pulsed for one hour with 20ug/ml of peptide of SEQ ID NO: 712, washed, and tested in  $\gamma$ -IFN Elispot assays for the ability to stimulate clones 4A7 and 4E5. Antibody blocking assays with the B1.23.2 (HLA-B/C blocking antibody) were also performed. SEQ ID NO: 712-specific response was detected using both the autologous (D326) and heterologous (D107) B-LCL, and furthermore the responses were blocked by pre-incubation with 25ug/ml of B1.23.2 HLA-B/C blocking antibody. Together these results demonstrate that the P501S-specific response to the peptide of SEQ ID NO: 712 is restricted to the HLA-B51 class I allele. Molecular cloning and sequence analysis of the HLA-B51 allele from D3326 revealed that the HLA-B51 subtype of D326 is HLA-B51011.

Based on the 10-mer P501S-derived epitope of SEQ ID NO: 712, two 9-mers with the sequences of SEQ ID NO: 714 and 715 were synthesized and tested in Elispot assays for the ability to stimulate two P501S-specific CTL clones derived from line 2A2. The 10-mer peptide of SEQ ID NO: 712, as well as the 9-mer peptide of SEQ ID NO: 715, but not the 9-mer peptide of SEQ ID NO: 714, were capable of stimulating the P501S-specific CTL to produce IFN-gamma. These results demonstrate that the peptide of SEQ ID NO: 715 is a 9-mer P501S-derived epitope recognized by P501S-

specific CTL. The DNA sequence encoding the epitope of SEQ ID NO: 715 is provided in SEQ ID NO: 716.

To identify the class I restricting allele for the P501S-derived peptide of SEQ ID NO: 712 and 715 specific response, each of the HLA B and C alleles were  
5 cloned from the donor used in the *in vitro* priming experiment. Sequence analysis indicated that the relevant alleles were HLA-B8, HLA-B51, HLA-Cw01 and HLA-Cw07. Each of these alleles were subcloned into an expression vector and co-transfected together with the P501S gene into VA-13 cells. Transfected VA-13 cells were then tested for the ability to specifically stimulate the P501S-specific CTL in  
10 ELISPOT assays. VA-13 cells transfected with P501S and HLA-B51 were capable of stimulating the P501S-specific CTL to secrete gamma-IFN. VA-13 cells transfected with HLA-B51 alone or P501S + the other HLA-alleles were not capable of stimulating the P501S-specific CTL. These results demonstrate that the restricting allele for the P501S-specific response is the HLAB51 allele. Sequence analysis revealed that the  
15 subtype of the relevant restricting allele is HLA-B51011.

To determine if the P501S-specific CTL could recognize prostate tumor cells that express P501S, the P501S-positive lines LnCAP and CRL2422 (both expressing "moderate" amounts of P501S mRNA and protein), and PC-3 (expressing low amounts of P501S mRNA and protein), plus the P501S-negative cell line DU-145  
20 were retrovirally transduced with the HLA-B51011 allele that was cloned from the donor used to generate the P501S-specific CTL. HLA-B51011- or EGFP-transduced and selected tumor cells were treated with gamma-interferon and androgen (to upregulate stimulatory functions and P501S, respectively) and used in gamma-interferon Elispot assays with the P501S-specific CTL clones 4E5 and 4E7. Untreated  
25 cells were used as a control.

Both 4E5 and 4E7 efficiently and specifically recognized LnCAP and CRL2422 cells that were transduced with the HLA-B51011 allele, but not the same cell lines transduced with EGFP. Additionally, both CTL clones specifically recognized PC-3 cells transduced with HLA-B51011, but not the P501S-negative tumor cell line  
30 DU-145. Treatment with gamma-interferon or androgen did not enhance the ability of CTL to recognize tumor cells. These results demonstrate that P501S-specific CTL,

generated by *in vitro* whole gene priming, specifically and efficiently recognize prostate tumor cell lines that express P501S.

A naturally processed CD4 epitope of P501S was identified as follows.

CD4 cells specific for P501S were prepared as described above. A series of 16 overlapping peptides were synthesized that spanned approximately 50% of the amino terminal portion of the P501S gene (amino acids 1- 325 of SEQ ID NO: 113). For priming, peptides were combined into pools of 4 peptides, pulsed at 4  $\mu$ g/ml onto dendritic cells (DC) for 24 hours, with TNF-alpha. DC were then washed and mixed with negatively selected CD4+ T cells in 96 well U-bottom plates. Cultures were re-stimulated weekly on fresh DC loaded with peptide pools. Following a total of 4 stimulation cycles, cells were rested for an additional week and tested for specificity to APC pulsed with peptide pools using  $\gamma$ -IFN ELISA and proliferation assays. For these assays, adherent monocytes loaded with either the relevant peptide pool at 4 $\mu$ g/ml or an irrelevant peptide at  $\mu$ g/ml were used as APC. T cell lines that demonstrated either specific cytokine secretion or proliferation were then tested for recognition of individual peptides that were present in the pool. T cell lines could be identified from pools A and B that recognized individual peptides from these pools.

From pool A, lines AD9 and AE10 specifically recognized peptide 1 (SEQ ID NO: 719), and line AF5 recognized peptide 39 (SEQ ID NO: 718). From pool B, line BC6 could be identified that recognized peptide 58 (SEQ ID NO: 717). Each of these lines were stimulated on the specific peptide and tested for specific recognition of the peptide in a titration assay as well as cell lysates generated by infection of HEK 293 cells with adenovirus expressing either P501S or an irrelevant antigen. For these assays, APC-adherent monocytes were pulsed with either 10, 1, or 0.1  $\mu$ g/ml individual P501S peptides, and DC were pulsed overnight with a 1:5 dilution of adenovirally infected cell lysates. Lines AD9, AE10 and AF5 retained significant recognition of the relevant P501S-derived peptides even at 0.1 mg/ml. Furthermore, line AD9 demonstrated significant (8.1 fold stimulation index) specific activity for lysates from adenovirus-P501S infected cells. These results demonstrate that high affinity CD4 T cell lines can be generated toward P501S-derived epitopes, and that at least a subset of these T cells specific for the P501S derived sequence of SEQ ID NO: 719 are specific for an epitope that is naturally processed by human cells. The DNA sequences encoding the amino acid sequences of SEQ ID NO: 717-719 are provided in SEQ ID NO: 720-722, respectively.

To further characterize the P501S-specific activity of AD9, the line was cloned using anti-CD3. Three clones, referred to as 1A1, 1A9 and 1F5, were identified that were specific for the P501S-1 peptide (SEQ ID NO: 719). To determine the HLA restriction allele for the P501S-specific response, each of these clones was tested in class II antibody blocking and HLA mismatch assays using proliferation and gamma-interferon assays. In antibody blocking assays and measuring gamma-interferon production using ELISA assays, the ability of all three clones to recognize peptide pulsed APC was specifically blocked by co-incubation with either a pan-class II blocking antibody or a HLA-DR blocking antibody, but not with a HLA-DQ or an irrelevant antibody. Proliferation assays performed simultaneously with the same cells confirmed these results. These data indicate that the P501S-specific response of the clones is restricted by an HLA-DR allele. Further studies demonstrated that the restricting allele for the P501S-specific response is HLA-DRB1501.



## EXAMPLE 13

IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS  
BY MICROARRAY ANALYSIS

5 This Example describes the isolation of certain prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library as described above was screened using microarray analysis to identify clones that display at least a three fold over-expression in prostate tumor and/or normal prostate tissue, as compared to  
10 non-prostate normal tissues (not including testis). 372 clones were identified, and 319 were successfully sequenced. Table I presents a summary of these clones, which are shown in SEQ ID NOs:385-400. Of these sequences SEQ ID NOs:386, 389, 390 and 392 correspond to novel genes, and SEQ ID NOs: 393 and 396 correspond to previously identified sequences. The others (SEQ ID NOs:385, 387, 388, 391, 394, 395 and 397-  
15 400) correspond to known sequences, as shown in Table I.

**Table I**  
**Summary of Prostate Tumor Antigens**

Known Genes	Previously Identified Genes	Novel Genes
T-cell gamma chain	P504S	23379 (SEQ ID NO:389)
Kallikrein	P1000C	23399 (SEQ ID NO:392)
Vector	P501S	23320 (SEQ ID NO:386)
CGI-82 protein mRNA (23319; SEQ ID NO:385)	P503S	23381 (SEQ ID NO:390)
PSA	P510S	
Ald. 6 Dehyd.	P784P	
L-iditol-2 dehydrogenase (23376; SEQ ID NO:388)	P502S	
Ets transcription factor PDEF (22672; SEQ ID NO:398)	P706P	
hTGR (22678; SEQ ID NO:399)	19142.2, bangur.seq (22621; SEQ ID NO:396)	
KIAA0295(22685; SEQ ID NO:400)	5566.1 Wang (23404; SEQ ID NO:393)	
Prostatic Acid Phosphatase(22655; SEQ ID NO:397)	P712P	
transglutaminase (22611; SEQ ID NO:395)	P778P	
HDLBP (23508; SEQ ID NO:394)		
CGI-69 Protein(23367; SEQ ID NO:387)		
KIAA0122(23383; SEQ ID NO:391)		
TEEG		

CGI-82 showed 4.06 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 43% of prostate tumors, 25% normal prostate, not detected in other normal tissues tested. L-idoitol-2 dehydrogenase showed 4.94 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 90% of prostate tumors, 100% of normal prostate, and not detected in other normal tissues tested. Ets transcription factor PDEF showed 5.55 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 47% prostate tumors, 25% normal prostate and not detected in other normal tissues tested. hTGR1 showed 9.11 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 63% of prostate tumors and is not detected in normal tissues tested including normal prostate. KIAA0295 showed 5.59 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 47% of prostate tumors, low to undetectable in normal tissues tested including normal prostate tissues. Prostatic acid phosphatase showed 9.14 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 67% of prostate tumors, 50% of normal prostate, and not detected in other normal tissues tested. Transglutaminase showed 14.84 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 30% of prostate tumors, 50% of normal prostate, and is not detected in other normal tissues tested. High density lipoprotein binding protein (HDLBP) showed 28.06 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 97% of prostate tumors, 75% of normal prostate, and is undetectable in all other normal tissues tested. CGI-69 showed 3.56 fold over-expression in prostate tissues as compared to other normal tissues tested. It is a low abundant gene, detected in more than 90% of prostate tumors, and in 75% normal prostate tissues. The expression of this gene in normal tissues was very low. KIAA0122 showed 4.24 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 57% of prostate tumors, it was undetectable in all normal tissues tested including normal prostate tissues. 19142.2 bangur showed 23.25 fold over-expression in prostate tissues as compared to other

normal tissues tested. It was over-expressed in 97% of prostate tumors and 100% of normal prostate. It was undetectable in other normal tissues tested. 5566.1 Wang showed 3.31 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 97% of prostate tumors, 75% normal prostate and was also over-expressed in normal bone marrow, pancreas, and activated PBMC. Novel clone 23379 (also referred to as P553S) showed 4.86 fold over-expression in prostate tissues as compared to other normal tissues tested. It was detectable in 97% of prostate tumors and 75% normal prostate and is undetectable in all other normal tissues tested. Novel clone 23399 showed 4.09 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 27% of prostate tumors and was undetectable in all normal tissues tested including normal prostate tissues. Novel clone 23320 showed 3.15 fold over-expression in prostate tissues as compared to other normal tissues tested. It was detectable in all prostate tumors and 50% of normal prostate tissues. It was also expressed in normal colon and trachea. Other normal tissues do not express this gene at high level.

Subsequent full-length cloning studies on P553S, using standard techniques, revealed that this clone is an incomplete spliced form of P501S. The determined cDNA sequences for four splice variants of P553S are provided in SEQ ID NO: 623-626. An amino acid sequence encoded by SEQ ID NO: 626 is provided in SEQ ID NO: 627. The cDNA sequence of SEQ ID NO: 623 was found to contain two open reading frames (ORFs). The amino acid sequences encoded by these two ORFs are provided in SEQ ID NO: 628 and 629.

#### EXAMPLE 14

#### IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS BY ELECTRONIC SUBTRACTION

This Example describes the use of an electronic subtraction technique to identify prostate-specific antigens.

Potential prostate-specific genes present in the GenBank human EST database were identified by electronic subtraction (similar to that described by Vasmatizis et al., *Proc. Natl. Acad. Sci. USA* 95:300-304, 1998). The sequences of EST clones (43,482) derived from various prostate libraries were obtained from the GenBank public human EST database. Each prostate EST sequence was used as a query sequence in a BLASTN (National Center for Biotechnology Information) search against the human EST database. All matches considered identical (length of matching sequence >100 base pairs, density of identical matches over this region > 70%) were grouped (aligned) together in a cluster. Clusters containing more than 200 ESTs were discarded since they probably represented repetitive elements or highly expressed genes such as those for ribosomal proteins. If two or more clusters shared common ESTs, those clusters were grouped together into a "supercluster," resulting in 4,345 prostate superclusters.

Records for the 479 human cDNA libraries represented in the GenBank release were downloaded to create a database of these cDNA library records. These 479 cDNA libraries were grouped into three groups: Plus (normal prostate and prostate tumor libraries, and breast cell line libraries, in which expression was desired), Minus (libraries from other normal adult tissues, in which expression was not desirable), and Other (libraries from fetal tissue, infant tissue, tissues found only in women, non-prostate tumors and cell lines other than prostate cell lines, in which expression was considered to be irrelevant). A summary of these library groups is presented in Table II.

**Table II**  
**Prostate cDNA Libraries and ESTs**

Library	# of Libraries	# of ESTs
Plus	25	43,482
Normal	11	18,875
Tumor	11	21,769
Cell lines	3	2,838
Minus	166	
Other	287	

5            Each supercluster was analyzed in terms of the ESTs within the supercluster. The tissue source of each EST clone was noted and used to classify the superclusters into four groups: Type 1- EST clones found in the Plus group libraries only; no expression detected in Minus or Other group libraries; Type 2- EST clones derived from the Plus and Other group libraries only; no expression detected in the

10 Minus group; Type 3- EST clones derived from the Plus, Minus and Other group libraries, but the number of ESTs derived from the Plus group is higher than in either the Minus or Other groups; and Type 4- EST clones derived from Plus, Minus and Other group libraries, but the number derived from the Plus group is higher than the number derived from the Minus group. This analysis identified 4,345 breast clusters

15 (see Table III). From these clusters, 3,172 EST clones were ordered from Research Genetics, Inc., and were received as frozen glycerol stocks in 96-well plates.

Table III  
Prostate Cluster Summary

Type	# of Superclusters	# of ESTs Ordered
1	688	677
2	2899	2484
3	85	11
4	673	0
Total	4345	3172

5           The EST clone inserts were PCR-amplified using amino-linked PCR  
primers for Synteni microarray analysis. When more than one PCR product was  
obtained for a particular clone, that PCR product was not used for expression analysis.  
In total, 2,528 clones from the electronic subtraction method were analyzed by  
microarray analysis to identify electronic subtraction breast clones that had high levels  
10 of tumor vs. normal tissue mRNA. Such screens were performed using a Synteni (Palo  
Alto, CA) microarray, according to the manufacturer's instructions (and essentially as  
described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and  
Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Within these analyses,  
the clones were arrayed on the chip, which was then probed with fluorescent probes  
15 generated from normal and tumor prostate cDNA, as well as various other normal  
tissues. The slides were scanned and the fluorescence intensity was measured.

Clones with an expression ratio greater than 3 (*i.e.*, the level in prostate  
tumor and normal prostate mRNA was at least three times the level in other normal  
tissue mRNA) were identified as prostate tumor-specific sequences (Table IV). The  
20 sequences of these clones are provided in SEQ ID NO: 401-453, with certain novel  
sequences shown in SEQ ID NO: 407, 413, 416-419, 422, 426, 427 and 450.

Table IV

Prostate-tumor Specific Clones

SEQ ID NO.	Sequence Designation	Comments
401	22545	previously identified P1000C
402	22547	previously identified P704P
403	22548	known
404	22550	known
405	22551	PSA
406	22552	prostate secretory protein 94
407	22553	novel
408	22558	previously identified P509S
409	22562	glandular kallikrein
410	22565	previously identified P1000C
411	22567	PAP
412	22568	B1006C (breast tumor antigen)
413	22570	novel
414	22571	PSA
415	22572	previously identified P706P
416	22573	novel
417	22574	novel
418	22575	novel
419	22580	novel
420	22581	PAP
421	22582	prostatic secretory protein 94
422	22583	novel
423	22584	prostatic secretory protein 94
424	22585	prostatic secretory protein 94
425	22586	known
426	22587	novel
427	22588	novel
428	22589	PAP
429	22590	known
430	22591	PSA
431	22592	known
432	22593	Previously identified P777P
433	22594	T cell receptor gamma chain
434	22595	Previously identified P705P
435	22596	Previously identified P707P
436	22847	PAP
437	22848	known
438	22849	prostatic secretory protein 57



439	22851	PAP
440	22852	PAP
441	22853	PAP
442	22854	previously identified P509S
443	22855	previously identified P705P
444	22856	previously identified P774P
445	22857	PSA
446	23601	previously identified P777P
447	23602	PSA
448	23605	PSA
449	23606	PSA
450	23612	novel
451	23614	PSA
452	23618	previously identified P1000C
453	23622	previously identified P705P

Further studies on the clone of SEQ ID NO: 407 (also referred to as P1020C) led to the isolation of an extended cDNA sequence provided in SEQ ID NO: 591. This extended cDNA sequence was found to contain an open reading frame that  
5 encodes the predicted amino acid sequence of SEQ ID NO: 592. The P1020C cDNA and amino acid sequences were found to show some similarity to the human endogenous retroviral HERV-K pol gene and protein.

#### EXAMPLE 15

##### 10 FURTHER IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS BY MICROARRAY ANALYSIS

This Example describes the isolation of additional prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library as described above  
15 was screened using microarray analysis to identify clones that display at least a three fold over-expression in prostate tumor and/or normal prostate tissue, as compared to non-prostate normal tissues (not including testis). 142 clones were identified and sequenced. Certain of these clones are shown in SEQ ID NO: 454-467. Of these sequences, SEQ ID NO: 459-460 represent novel genes. The others (SEQ ID NO: 454-  
20 458 and 461-467) correspond to known sequences. Comparison of the determined

cDNA sequence of SEQ ID NO: 461 with sequences in the Genbank database using the BLAST program revealed homology to the previously identified transmembrane protease serine 2 (TMPRSS2). The full-length cDNA sequence for this clone is provided in SEQ ID NO: 751, with the corresponding amino acid sequence being  
5 provided in SEQ ID NO: 752. The cDNA sequence encoding the first 209 amino acids of TMPRSS2 is provided in SEQ ID NO: 753, with the first 209 amino acids being provided in SEQ ID NO: 754.

The sequence of SEQ ID NO: 462 (referred to as P835P) was found to correspond to the previously identified clone FLJ13518 (Accession AK023643; SEQ ID  
10 NO: 774), which had no associated open reading frame (ORF). This clone was used to search the Geneseq DNA database and matched a clone previously identified as a G protein-coupled receptor protein (DNA Geneseq Accession A09351; amino acid Geneseq Accession Y92365), that is characterized by the presence of seven transmembrane domains. The sequences of fragments between these domains are  
15 provided in SEQ ID NO: 778-785, with SEQ ID NO: 778, 780, 782 and 784 representing extracellular domains and SEQ ID NO: 779, 781, 783 and 785 representing intracellular domains. SEQ ID NO: 778-785 represent amino acids 1-28, 53-61, 83-103, 124-143, 165-201, 226-238, 263-272 and 297-381, respectively, of P835P. The full-length cDNA sequence for P835P is provided in SEQ ID NO: 773. The cDNA  
20 sequence of the open reading frame for P835P, including stop codon, is provided in SEQ ID NO: 775, with the open reading frame without stop codon being provided in SEQ ID NO: 776 and the corresponding amino acid sequence being provided in SEQ ID NO: 777.

25

## EXAMPLE 16

### FURTHER CHARACTERIZATION OF PROSTATE-SPECIFIC ANTIGEN P710P

This Example describes the full length cloning of P710P.

The prostate cDNA library described above was screened with the P710P  
30 fragment described above. One million colonies were plated on LB/Ampicillin plates.

Nylon membrane filters were used to lift these colonies, and the cDNAs picked up by these filters were then denatured and cross-linked to the filters by UV light. The P710P fragment was radiolabeled and used to hybridize with the filters. Positive cDNA clones were selected and their cDNAs recovered and sequenced by an automatic Perkin Elmer/Applied Biosystems Division Sequencer. Four sequences were obtained, and are presented in SEQ ID NO: 468-471. These sequences appear to represent different splice variants of the P710P gene. Subsequent comparison of the cDNA sequences of P710P with those in Genbank revealed homology to the DD3 gene (Genbank accession numbers AF103907 & AF103908). The cDNA sequence of DD3 is provided in SEQ ID NO: 618.

#### EXAMPLE 17

##### PROTEIN EXPRESSION OF PROSTATE-SPECIFIC ANTIGENS

This example describes the expression and purification of prostate-specific antigens in *E. coli*, baculovirus, mammalian and yeast cells.

##### a) Expression of P501S in *E. coli*

Expression of the full-length form of P501S was attempted by first cloning P501S without the leader sequence (amino acids 36-553 of SEQ ID NO: 113) downstream of the first 30 amino acids of the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 484) in pET17b. Specifically, P501S DNA was used to perform PCR using the primers AW025 (SEQ ID NO: 485) and AW003 (SEQ ID NO: 486). AW025 is a sense cloning primer that contains a HindIII site. AW003 is an antisense cloning primer that contains an EcoRI site. DNA amplification was performed using 5  $\mu$ l 10X Pfu buffer, 1  $\mu$ l 20 mM dNTPs, 1  $\mu$ l each of the PCR primers at 10  $\mu$ M concentration, 40  $\mu$ l water, 1  $\mu$ l Pfu DNA polymerase (Stratagene, La Jolla, CA) and 1  $\mu$ l DNA at 100 ng/ $\mu$ l. Denaturation at 95°C was performed for 30 sec, followed by 10 cycles of 95°C for 30 sec, 60°C for 1 min and by 72°C for 3 min. 20 cycles of 95°C for 30 sec, 65°C for 1 min and by 72°C for 3 min, and lastly by 1 cycle of 72°C for 10 min. The PCR product was

cloned to Ra12m/pET17b using HindIII and EcoRI. The sequence of the resulting fusion construct (referred to as Ra12-P501S-F) was confirmed by DNA sequencing.

The fusion construct was transformed into BL21(DE3)pLysE, pLysS and CodonPlus *E. coli* (Stratagene) and grown overnight in LB broth with kanamycin. The  
5 resulting culture was induced with IPTG. Protein was transferred to PVDF membrane and blocked with 5% non-fat milk (in PBS-Tween buffer), washed three times and incubated with mouse anti-His tag antibody (Clontech) for 1 hour. The membrane was washed 3 times and probed with HRP-Protein A (Zymed) for 30 min. Finally, the membrane was washed 3 times and developed with ECL (Amersham). No expression  
10 was detected by Western blot. Similarly, no expression was detected by Western blot when the Ra12-P501S-F fusion was used for expression in BL21CodonPlus by CE6 phage (Invitrogen).

An N-terminal fragment of P501S (amino acids 36-325 of SEQ ID NO: 113) was cloned down-stream of the first 30 amino acids of the *M. tuberculosis* antigen  
15 Ra12 in pET17b as follows. P501S DNA was used to perform PCR using the primers AW025 (SEQ ID NO: 485) and AW027 (SEQ ID NO: 487). AW027 is an antisense cloning primer that contains an EcoRI site and a stop codon. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the HindIII and EcoRI sites. The fusion construct (referred to as  
20 Ra12-P501S-N) was confirmed by DNA sequencing.

The Ra12-P501S-N fusion construct was used for expression in BL21(DE3)pLysE, pLysS and CodonPlus, essentially as described above. Using Western blot analysis, protein bands were observed at the expected molecular weight of 36 kDa. Some high molecular weight bands were also observed, probably due to  
25 aggregation of the recombinant protein. No expression was detected by Western blot when the Ra12-P501S-F fusion was used for expression in BL21CodonPlus by CE6 phage.

A fusion construct comprising a C-terminal portion of P501S (amino acids 257-553 of SEQ ID NO: 113) located down-stream of the first 30 amino acids of  
30 the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 484) was prepared as follows. P501S

DNA was used to perform PCR using the primers AW026 (SEQ ID NO: 488) and AW003 (SEQ ID NO: 486). AW026 is a sense cloning primer that contains a HindIII site. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the HindIII and EcoRI sites. The  
5 sequence for the fusion construct (referred to as Ra12-P501S-C) was confirmed.

The Ra12-P501S-C fusion construct was used for expression in BL21(DE3)pLysE, pLysS and CodonPlus, as described above. A small amount of protein was detected by Western blot, with some molecular weight aggregates also being observed. Expression was also detected by Western blot when the Ra12-P501S-C  
10 fusion was used for expression in BL21CodonPlus induced by CE6 phage.

A fusion construct comprising a fragment of P501S (amino acids 36-298 of SEQ ID NO: 113) located down-stream of the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 705) was prepared as follows. P501S DNA was used to perform PCR using the primers AW042 (SEQ ID NO: 706) and AW053 (SEQ ID NO: 707). AW042 is a sense  
15 cloning primer that contains a EcoRI site. AW053 is an antisense primer with stop and Xho I sites. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the EcoRI and Xho I sites. The resulting fusion construct (referred to as Ra12-P501S-E2) was expressed in B834 (DE3) pLys S *E. coli* host cells in TB media for 2 h at room temperature. Expressed protein  
20 was purified by washing the inclusion bodies and running on a Ni-NTA column. The purified protein stayed soluble in buffer containing 20 mM Tris-HCl (pH 8), 100 mM NaCl, 10 mM  $\beta$ -Me and 5% glycerol. The determined cDNA and amino acid sequences for the expressed fusion protein are provided in SEQ ID NO: 708 and 709, respectfully.

25 b) Expression of P501S in Baculovirus

The Bac-to-Bac baculovirus expression system (BRL Life Technologies, Inc.) was used to express P501S protein in insect cells. Full-length P501S (SEQ ID NO: 113) was amplified by PCR and cloned into the XbaI site of the donor plasmid pFastBacI. The recombinant bacmid and baculovirus were prepared according to the

manufacturer's instructions. The recombinant baculovirus was amplified in Sf9 cells and the high titer viral stocks were utilized to infect High Five cells (Invitrogen) to make the recombinant protein. The identity of the full-length protein was confirmed by N-terminal sequencing of the recombinant protein and by Western blot analysis (Figure 7). Specifically, 0.6 million High Five cells in 6-well plates were infected with either the unrelated control virus BV/ECD\_PD (lane 2), with recombinant baculovirus for P501S at different amounts or MOIs (lanes 4-8), or were uninfected (lane 3). Cell lysates were run on SDS-PAGE under reducing conditions and analyzed by Western blot with the anti-P501S monoclonal antibody P501S-10E3-G4D3 (prepared as described below). Lane 1 is the biotinylated protein molecular weight marker (BioLabs).

The localization of recombinant P501S in the insect cells was investigated as follows. The insect cells overexpressing P501S were fractionated into fractions of nucleus, mitochondria, membrane and cytosol. Equal amounts of protein from each fraction were analyzed by Western blot with a monoclonal antibody against P501S. Due to the scheme of fractionation, both nucleus and mitochondria fractions contain some plasma membrane components. However, the membrane fraction is basically free from mitochondria and nucleus. P501S was found to be present in all fractions that contain the membrane component, suggesting that P501S may be associated with plasma membrane of the insect cells expressing the recombinant protein.

#### c) Expression of P501S in Mammalian Cells

Full-length P501S (553 amino acids; SEQ ID NO: 113) was cloned into various mammalian expression vectors, including pCEP4 (Invitrogen), pVR1012 (Vical, San Diego, CA) and a modified form of the retroviral vector pBMN, referred to as pBIB. Transfection of P501S/pCEP4 and P501S/pVR1012 into HEK293 fibroblasts was carried out using the Fugene transfection reagent (Boehringer Mannheim). Briefly, 2 ul of Fugene reagent was diluted into 100 ul of serum-free media and incubated at room temperature for 5-10 min. This mixture was added to 1 ug of P501S plasmid DNA, mixed briefly and incubated for 30 minutes at room temperature. The

Fugene/DNA mixture was added to cells and incubated for 24-48 hours. Expression of recombinant P501S in transfected HEK293 fibroblasts was detected by means of Western blot employing a monoclonal antibody to P501S.

Transfection of p501S/pCEP4 into CHO-K cells (American Type Culture Collection, Rockville, MD) was carried out using GenePorter transfection reagent (Gene Therapy Systems, San Diego, CA). Briefly, 15  $\mu$ l of GenePorter was diluted in 500  $\mu$ l of serum-free media and incubated at room temperature for 10 min. The GenePorter/media mixture was added to 2  $\mu$ g of plasmid DNA that was diluted in 500  $\mu$ l of serum-free media, mixed briefly and incubated for 30 min at room temperature. CHO-K cells were rinsed in PBS to remove serum proteins, and the GenePorter/DNA mix was added and incubated for 5 hours. The transfected cells were then fed an equal volume of 2x media and incubated for 24-48 hours.

FACS analysis of P501S transiently infected CHO-K cells, demonstrated surface expression of P501S. Expression was detected using rabbit polyclonal antisera raised against a P501S peptide, as described below. Flow cytometric analysis was performed using a FaCScan (Becton Dickinson), and the data were analyzed using the Cell Quest program.

d) Expression of P501S in *S. cerevisiae*

P501S was expressed in yeast, directed in membranes, using the yeast  $\alpha$  prepro signal sequence. The natural signal sequence and first luminal domain of P501S was deleted in order to conserve the natural positioning of the expressed P501S protein.

Specifically, the  $\alpha$  prepro signal sequence of *S. cerevisiae* linked to amino acids 55-553 of SEQ ID NO: 113 with a His tag tail was cloned into the plasmid pRIT15068 with the CUP1 promoter and transfected into *S. cerevisiae* strain Y1790. The Y1790 strain is Leu<sup>+</sup> and His<sup>-</sup>. Expression of protein was induced by addition of either 500  $\mu$ M or 250  $\mu$ M of CuSO<sub>4</sub> at 30 °C in minimal medium supplemented with histidine. Cells were harvested 24 hours after induction. Extracts were prepared by growing cells to a concentration of OD<sub>600</sub> 5.0 in 50 mM citrate phosphate buffer (pH 4.0) plus 130 mM NaCl supplemented with protease inhibitors. Cells were disrupted

using glass beads and centrifuged for 20 min at 15,000 g. The recombinant protein was found to be 100% pellet associated.

Expression of the recombinant protein (molecular weight 63 kD) was demonstrated by Western blot analysis, using the anti-P501S monoclonal antibody 10E-D4-G3 described below. The amino acid sequence of the expressed protein is provided in SEQ ID NO: 792.

Fermentation processes for the production of the  $\alpha$  prepro-P501S-His tag recombinant protein in *S. cerevisiae* (strain Y1790 – CUP1 inducible promoter) were evaluated as follows. One hundred  $\mu$ l of a master seed containing  $2.5 \times 10^8$  cells/ml of transformed *S. cerevisiae* Y1790 were spread on FSC004AA solid medium. The composition of the FSC004AA medium is as follows: glucose 10 g/l;  $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$  0.0002 g/l; folic acid 0.000064 g/l;  $\text{KH}_2\text{PO}_4$  1 g/l;  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$  0.0004 g/l; Inositol 0.064 g/l;  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  0.5 g/l;  $\text{H}_3\text{BO}_3$  0.0005 g/l; Pyridoxine 0.008 g/l;  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  0.1 g/l; KI 0.0001 g/l; Thiamine 0.008 g/l; NaCl 0.1 g/l;  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$  0.00009 g/l; Niacin 0.000032 g/l;  $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$  0.0002 g/l; Riboflavin 0.000016 g/l; Panthotenate Ca 0.008 g/l;  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  0.00004 g/l; Biotin 0.000064 g/l; para-aminobenzoic acid 0.000016 g/l;  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$  0.0004 g/l;  $(\text{NH}_4)_2\text{SO}_4$  5 g/l; agar 18 g/l; Histidine 0.1 g/l.

Two plates were incubated for 26 h at 30 °C. These solid pre-cultures were harvested in 5 ml of liquid medium FSC007AA and 0.5 ml (or  $9.3 \times 10^7$  cells) of this suspension was used to inoculate 2 liquid pre-cultures.

The composition of the FSC007AA medium is as follows: Glucose 10 g/l;  $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$  0.0002 g/l; folic acid 0.000064 g/l;  $\text{KH}_2\text{PO}_4$  1 g/l;  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$  0.0004 g/l; Inositol 0.064 g/l;  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  0.5 g/l;  $\text{H}_3\text{BO}_3$  0.0005 g/l; Pyridoxine 0.008 g/l;  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  0.1 g/l; KI 0.0001 g/l; Thiamine 0.008 g/l; NaCl 0.1 g/l;  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$  0.00009 g/l; Niacine 0.000032 g/l;  $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$  0.0002 g/l; Riboflavin 0.000016 g/l; Panthotenate Ca 0.008 g/l;  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  0.00004 g/l; Biotin 0.000064 g/l; para-aminobenzoic acid 0.000016 g/l;  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$  0.0004 g/l;  $(\text{NH}_4)_2\text{SO}_4$  5 g/l; Histidine 0.1 g/l.

These pre-cultures were run for 20 hours in 2L flasks containing 400 ml of medium FSC007AA in order to obtain an OD of 1.8. The other characteristics of these pre-cultures are as follows: pH 2.8; glucose 2.3 g/L; ethanol 3.4 g/L.



The best timing for liquid pre-cultures for strain Y1790 was determined in preliminary experiments. Liquid pre-cultures containing 400 ml of medium and inoculated with various volumes of Master Seed (0.25, 0.5, 1 or 2 ml) were monitored in order to identify the best inoculum size and timing. Glucose, ethanol, pH, OD and cell number (determined by flow cytometry) were followed between 16 and 23 hours of culture. Glucose exhaustion and maximal biomass were obtained after 20 hour incubation with 0.5 inoculum. These conditions were adopted for transferring the pre-culture into fermentation.

In total, 800ml of pre-culture were used to inoculate a 20 L fermenter containing 5L of medium FSC002AA. Three ml of irradiated antifoam were added before inoculation. The composition of the FSC002AA medium is as follows: (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 6.4 g/l; Na<sub>2</sub>MoO<sub>4</sub>·2H<sub>2</sub>O 2.05 mg/l; folic acid 0.54 mg/l; KH<sub>2</sub>PO<sub>4</sub> 8.25 g/l; MnSO<sub>4</sub>·H<sub>2</sub>O 4.1 mg/l; inositol 540 mg/l; MgSO<sub>4</sub>·7H<sub>2</sub>O 4.69 g/l; H<sub>3</sub>BO<sub>3</sub> 5.17 mg/l; pyridoxine 68 mg/l; CaCl<sub>2</sub>·2H<sub>2</sub>O 0.92 g/l; KI 1.03 mg/l; thiamine 68 mg/l; NaCl 0.06g/l; CoCl<sub>2</sub>·6H<sub>2</sub>O 0.92 mg/l; Niacine 0.27 mg/l; HCl 1 ml/l; FeCl<sub>3</sub>·6H<sub>2</sub>O 9.92 mg/l; Riboflavin 0.13 mg/l; CuSO<sub>4</sub>·5H<sub>2</sub>O 0.41 mg/l; Glucose 0.14 g/l; Panthotenate Ca 68 mg/l; ZnSO<sub>4</sub>·7H<sub>2</sub>O 4.1 mg/l; Biotin 0.54 mg/l; para-aminobenzoic acid 0.13 mg/l; Histidine 0.3 g/l

The carbon source (glucose) was supplemented by a continuous feeding of FFB004AA medium. The composition of the FFB004AA medium is as follows: glucose 350 g/l; Na<sub>2</sub>MoO<sub>4</sub>·2H<sub>2</sub>O 5.15 mg/l; folic acid 1.36 mg/l; KH<sub>2</sub>PO<sub>4</sub> 20.6 g/l; MnSO<sub>4</sub>·H<sub>2</sub>O 10.3 mg/l; inositol 1350 mg/l; MgSO<sub>4</sub>·7H<sub>2</sub>O 11.7 g/l; H<sub>3</sub>BO<sub>3</sub> 12.9 mg/l; pyridoxine 170 mg/l; CaCl<sub>2</sub>·2H<sub>2</sub>O 2.35 g/l; KI 2.6 mg/l; thiamine 170 mg/l; NaCl 0.15 g/l; CoCl<sub>2</sub>·6H<sub>2</sub>O 2.3 mg/l; niacine 0.67 mg/l; HCl 2.5 ml/l; FeCl<sub>3</sub>·6H<sub>2</sub>O 24.8 mg/l; riboflavin; 0.33 mg/l; CuSO<sub>4</sub>·5H<sub>2</sub>O 1.03 mg/l; biotin 1.36 mg/l; panthotenate Ca 170 mg/l; ZnSO<sub>4</sub>·7H<sub>2</sub>O 10.3 mg/l; para-aminobenzoic acid: 0.33 mg/l; histidine 5.35 g/l.

The residual glucose concentration was maintained very low ( $\leq$ 50 mg/L) in order to minimize ethanol production by fermentation. This was achieved by limiting the development of the microorganism using a limited glucose feed rate. The Standard biomass content (OD 80-90) was reached in fermentation after 44 hour growth phase.

CUP1 promoter was then induced by adding 500 $\mu$ M CuSO<sub>4</sub> in order to

produce P501S antigen.  $\text{CuSO}_4$  addition was followed by ethanol accumulation (up to 6 g/L), and the glucose feeding rate was then reduced in order to consume the ethanol. The copper available for the microorganism was monitored by testing Cu ion concentration in the broth supernatant using a spectrophotometric copper assay (DETC method). The fermentation was then supplemented by  $\text{CuSO}_4$  throughout the induction phase in order to maintain its concentration between 150 and 250  $\mu\text{M}$  in the supernatant. The biomass reached an OD of 100 at the end of induction. Cells were harvested after 8 hours of induction.

Cell homogenate was prepared and analysed by SDS-PAGE and Western Blot using standard protocols. A major protein band with the expected molecular weight of 62KD was detected by Western blot using anti-P501S monoclonal antibodies. Western blot analysis also showed that the major 62KD band was progressively produced from 30 minutes of induction on, and reached a maximum after 3 hours. No more antigen seemed to be produced between 3 and 12 hours of induction.

The number of passages through a French Press necessary to extract all the antigen from the cells was evaluated. One, three and five passages were tested and total cell lysates, supernatants and pellets of cell lysates were analysed by Western blot. Three passages through a French Press were sufficient to completely extract the antigen. The antigen was present in the insoluble fraction.

20

#### e) Expression of P703P in Baculovirus

The cDNA for full-length P703P-DE5 (SEQ ID NO: 326), together with several flanking restriction sites, was obtained by digesting the plasmid pCDNA703 with restriction endonucleases Xba I and Hind III. The resulting restriction fragment (approx. 800 base pairs) was ligated into the transfer plasmid pFastBacI which was digested with the same restriction enzymes. The sequence of the insert was confirmed by DNA sequencing. The recombinant transfer plasmid pFBP703 was used to make recombinant bacmid DNA and baculovirus using the Bac-To-Bac Baculovirus expression system (BRL Life Technologies). High Five cells were infected with the recombinant virus BVP703, as described above, to obtain recombinant P703P protein.

30

e) Expression of P788P in *E. Coli*

A truncated, N-terminal portion, of P788P (residues 1-644 of SEQ ID NO: 777; referred to as P788P-N) fused with a C-terminal 6xHis Tag was expressed in *E. coli* as follows. P788P cDNA was amplified using the primers AW080 and AW081 (SEQ ID NO: 672 and 673). AW080 is a sense cloning primer with an NdeI site. AW081 is an antisense cloning primer with a XhoI site. The PCR-amplified P788P, as well as the vector pCRX1, were digested with NdeI and XhoI. Vector and insert were ligated and transformed into NovaBlue cells. Colonies were randomly screened for insert and then sequenced. P788P-N clone #6 was confirmed to be identical to the designed construct. The expression construct P788P-N #6/pCRX1 was transformed into *E. coli* BL21 CodonPlus-RIL competent cells. After induction, most of the cells grew well, achieving OD600 of greater than 2.0 after 3 hr. Coomassie stained SDS-PAGE showed an over-expressed band at about 75 kD. Western blot analysis using a 6xHisTag antibody confirmed the band was P788P-N. The determined cDNA sequence for P788P-N is provided in SEQ ID NO: 674, with the corresponding amino acid sequence being provided in SEQ ID NO: 675.

f) Expression of P510S in *E. Coli*

The P510S protein has 9 potential transmembrane domains and is predicted to be located at the plasma membrane. The C-terminal protein of this protein, as well as the predicted third extracellular domain of P510S were expressed in *E. coli* as follows.

The expression construct referred to as Ra12-P501S-C was designed to have a 6 HisTag at the N-terminal end, followed by the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 676) and then the C-terminal portion of P510S (amino residues 1176-1261 of SEQ ID NO: 538). Full-length P510S was used to amplify the P510S-C fragment by PCR using the primers AW056 and AW057 (SEQ ID NO: 677 and 678, respectively). AW056 is a sense cloning primer with an EcoRI site. AW057 is an antisense primer with stop and XhoI sites. The amplified P501S fragment and Ra12/pCRX1 were digested with EcoRI and XhoI and then purified. The insert and

vector were ligated together and transformed into NovaBlue. Colonies were randomly screened for insert and sequences. For protein expression, the expression construct was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. A mini-induction screen was performed to optimize the expression conditions. After induction  
5 the cells grew well, achieving OD 600 nm greater than 2.0 after 3 hours. Coomassie stain SDS-PAGE showed a highly over-expressed band at approx. 30 kD. Though this is higher than the expected molecular weight, western blot analysis was positive, showing this band to be the His tag-containing protein. The optimized culture conditions are as follows. Dilute overnight culture/daytime culture (LB + kanamycin +  
10 chloramphenicol) into 2xYT (with kanamycin and chloramphenicol) at a ratio of 25 ml culture to 1 liter 2xYT. Allow to grow at 37 °C until OD600 = 0.6. Take an aliquot out as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Take out a T3 sample, spin down cells and store at -80 °C. The determined cDNA and amino acid sequences for the Ra12-P510S-C construct are provided in SEQ ID NO: 679 and 682,  
15 respectively.

The expression construct P510S-C was designed to have a 5' added start codon and a glycine (GGA) codon and then the P510S C terminal fragment followed by the in frame 6x histidine tag and stop codon from the pET28b vector. The cloning strategy is similar to that used for Ra12-P510S-C, except that the PCR primers employed were  
20 those shown in SEQ ID NO: 685 and 686, respectively and the NcoI/XhoI cut in pET28b was used. The primer of SEQ ID NO: 685 created a 5' NcoI site and added a start codon. The antisense primer of SEQ ID NO: 686 creates a XhoI site on P510S C terminal fragment. Clones were confirmed by sequencing. For protein expression, the expression construct was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL  
25 competent cells. An OD600 of greater than 2.0 was obtained 30 hours after induction. Coomassie stained SDS-PAGE showed an over-expressed band at about 11 kD. Western blot analysis confirmed that the band was P510S-C, as did N-terminal protein sequencing. The optimized culture conditions are as follows: dilute overnight culture/daytime culture (LB + kanamycin + chloramphenicol) into 2x YT (+ kanamycin  
30 and chloramphenicol) at a ratio of 25 mL culture to 1 liter 2x YT, and allow to grow at

37 °C until an OD 600 of about 0.5 is reached. Take out an aliquot as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Spin down the cells and store at -80 °C until purification. The determined cDNA and amino acid sequences for the P510S-C construct are shown in SEQ ID NO: 680 and 683, respectively.

5           The predicted third extracellular domain of P510S (P510S-E3; residues 328-676 of SEQ ID NO: 538) was expressed in *E. coli* as follows. The P510S fragment was amplified by PCR using the primers shown in SEQ ID NO: 687 and 688. The primer of SEQ ID NO: 687 is a sense primer with an NdeI site for use in ligating into pPDM. The primer of SEQ ID NO: 688 is an antisense primer with an added XhoI site  
10 for use in ligating into pPDM. The resulting fragment was cloned to pPDM at the NdeI and XhoI sites. Clones were confirmed by sequencing. For protein expression, the clone was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. After induction, an OD600 of greater than 2.0 was achieved after 3 hours. Coomassie stained SDS-PAGE showed an over-expressed band at about 39 kD, and N-terminal sequencing  
15 confirmed the N-terminal to be that of P510S-E3. Optimized culture conditions are as follows: dilute overnight culture/daytime culture (LB + kanamycin + chloramphenicol) into 2x YT (kanamycin and chloramphenicol) at a ratio of 25 ml culture to 1 liter 2x YT. Allow to grow at 37 °C until OD 600 equals 0.6. Take out an aliquot as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Take out a T3  
20 sample, spin down the cells and store at -80 °C until purification. The determined cDNA and amino acid sequences for the P501S-E3 construct are provided in SEQ ID NO: 681 and 684, respectively.

g) Expression of P775S in *E. Coli*

25           The antigen P775P contains multiple open reading frames (ORF). The third ORF, encoding the protein of SEQ ID NO: 483, has the best emotif score. An expression fusion construct containing the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 676) and P775P-ORF3 with an N-terminal 6x HisTag was prepared as follows. P775P-ORF3 was amplified using the sense PCR primers of SEQ ID NO: 689 and the anti-sense PCR primer of SEQ ID NO: 690. The PCR amplified fragment of P775P and

Ra12/pCRX1 were digested with the restriction enzymes EcoRI and XhoI. Vector and insert were ligated and then transformed into NovaBlue cells. Colonies were randomly screened for insert and then sequenced. A clone having the desired sequence was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. Two hours after  
5 induction, the cell density peaked at OD600 of approximately 1.8. Coomassie stained SDS-PAGE showed an over-expressed band at about 31 kD. Western blot using 6x HisTag antibody confirmed that the band was Ra12-P775P-ORF3. The determined cDNA and amino acid sequences for the fusion construct are provided in SEQ ID NO: 691 and 692, respectively.

10

#### H) EXPRESSION OF A P703P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P703P was prepared by PCR using the primers of SEQ ID NO: 693 and 694. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag  
15 in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P703P are provided in SEQ ID NO: 695 and 696, respectively.

20

#### I) EXPRESSION OF A P705P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P705P was prepared by PCR using the primers of SEQ ID NO: 697 and 698. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag  
25 in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S and BL21 (DE3) CodonPlus expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P705P are provided in SEQ ID NO: 699 and 700, respectively.

30

**J) EXPRESSION OF A P711P HIS TAG FUSION PROTEIN IN E. COLI**

The cDNA for the coding region of P711P was prepared by PCR using the primers of SEQ ID NO: 701 and 702. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S and BL21 (DE3) CodonPlus expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P711P are provided in SEQ ID NO: 703 and 704, respectively.

10

**EXAMPLE 18****PREPARATION AND CHARACTERIZATION OF ANTIBODIES****AGAINST PROSTATE-SPECIFIC POLYPEPTIDES**

15

**a) Preparation and Characterization of Polyclonal Antibodies against P703P,****P504S and P509S**

Polyclonal antibodies against P703P, P504S and P509S were prepared as follows.

20

Each prostate tumor antigen expressed in an *E. coli* recombinant expression system was grown overnight in LB broth with the appropriate antibiotics at 37°C in a shaking incubator. The next morning, 10 ml of the overnight culture was added to 500 ml to 2x YT plus appropriate antibiotics in a 2L-baffled Erlenmeyer flask. When the Optical Density (at 560 nm) of the culture reached 0.4-0.6, the cells were induced with IPTG (1 mM). Four hours after induction with IPTG, the cells were harvested by centrifugation. The cells were then washed with phosphate buffered saline and centrifuged again. The supernatant was discarded and the cells were either frozen for future use or immediately processed. Twenty ml of lysis buffer was added to the cell pellets and vortexed. To break open the *E. coli* cells, this mixture was then run

25

through the French Press at a pressure of 16,000 psi. The cells were then centrifuged again and the supernatant and pellet were checked by SDS-PAGE for the partitioning of the recombinant protein. For proteins that localized to the cell pellet, the pellet was resuspended in 10 mM Tris pH 8.0, 1% CHAPS and the inclusion body pellet was washed and centrifuged again. This procedure was repeated twice more. The washed inclusion body pellet was solubilized with either 8 M urea or 6 M guanidine HCl containing 10 mM Tris pH 8.0 plus 10 mM imidazole. The solubilized protein was added to 5 ml of nickel-chelate resin (Qiagen) and incubated for 45 min to 1 hour at room temperature with continuous agitation. After incubation, the resin and protein mixture were poured through a disposable column and the flow through was collected. The column was then washed with 10-20 column volumes of the solubilization buffer. The antigen was then eluted from the column using 8M urea, 10 mM Tris pH 8.0 and 300 mM imidazole and collected in 3 ml fractions. A SDS-PAGE gel was run to determine which fractions to pool for further purification.

As a final purification step, a strong anion exchange resin such as HiPrepQ (Biorad) was equilibrated with the appropriate buffer and the pooled fractions from above were loaded onto the column. Each antigen was eluted off the column with a increasing salt gradient. Fractions were collected as the column was run and another SDS-PAGE gel was run to determine which fractions from the column to pool. The pooled fractions were dialyzed against 10 mM Tris pH 8.0. The proteins were then vialled after filtration through a 0.22 micron filter and the antigens were frozen until needed for immunization.

Four hundred micrograms of each prostate antigen was combined with 100 micrograms of muramyl dipeptide (MDP). Every four weeks rabbits were boosted with 100 micrograms mixed with an equal volume of Incomplete Freund's Adjuvant (IFA). Seven days following each boost, the animal was bled. Sera was generated by incubating the blood at 4°C for 12-4 hours followed by centrifugation.

Ninety-six well plates were coated with antigen by incubating with 50 microliters (typically 1 microgram) of recombinant protein at 4 °C for 20 hours. 250 microliters of BSA blocking buffer was added to the wells and incubated at room



temperature for 2 hours. Plates were washed 6 times with PBS/0.01% Tween. Rabbit sera was diluted in PBS. Fifty microliters of diluted sera was added to each well and incubated at room temperature for 30 min. Plates were washed as described above before 50 microliters of goat anti-rabbit horse radish peroxidase (HRP) at a 1:10000 dilution was added and incubated at room temperature for 30 min. Plates were again washed as described above and 100 microliters of TMB microwell peroxidase substrate was added to each well. Following a 15 min incubation in the dark at room temperature, the colorimetric reaction was stopped with 100 microliters of 1N H<sub>2</sub>SO<sub>4</sub> and read immediately at 450 nm. All polyclonal antibodies showed immunoreactivity to the appropriate antigen.

b) Preparation and Characterization of Antibodies against P501S

A murine monoclonal antibody directed against the carboxy-terminus of the prostate-specific antigen P501S was prepared as follows.

A truncated fragment of P501S (amino acids 355-526 of SEQ ID NO: 113) was generated and cloned into the pET28b vector (Novagen) and expressed in *E. coli* as a thioredoxin fusion protein with a histidine tag. The trx-P501S fusion protein was purified by nickel chromatography, digested with thrombin to remove the trx fragment and further purified by an acid precipitation procedure followed by reverse phase HPLC.

Mice were immunized with truncated P501S protein. Serum bleeds from mice that potentially contained anti-P501S polyclonal sera were tested for P501S-specific reactivity using ELISA assays with purified P501S and trx-P501S proteins. Serum bleeds that appeared to react specifically with P501S were then screened for P501S reactivity by Western analysis. Mice that contained a P501S-specific antibody component were sacrificed and spleen cells were used to generate anti-P501S antibody producing hybridomas using standard techniques. Hybridoma supernatants were tested for P501S-specific reactivity initially by ELISA, and subsequently by FACS analysis of reactivity with P501S transduced cells. Based on these results, a monoclonal hybridoma referred to as 10E3 was chosen for further subcloning. A number of subclones were

generated, tested for specific reactivity to P501S using ELISA and typed for IgG isotype. The results of this analysis are shown below in Table V. Of the 16 subclones tested, the monoclonal antibody 10E3-G4-D3 was selected for further study.

5

Table V

Isotype analysis of murine anti-P501S monoclonal antibodies

Hybridoma clone	Isotype	Estimated [Ig] in supernatant ( $\mu\text{g/ml}$ )
4D11	IgG1	14.6
1G1	IgG1	0.6
4F6	IgG1	72
4H5	IgG1	13.8
4H5-E12	IgG1	10.7
4H5-EH2	IgG1	9.2
4H5-H2-A10	IgG1	10
4H5-H2-A3	IgG1	12.8
4H5-H2-A10-G6	IgG1	13.6
4H5-H2-B11	IgG1	12.3
10E3	IgG2a	3.4
10E3-D4	IgG2a	3.8
10E3-D4-G3	IgG2a	9.5
10E3-D4-G6	IgG2a	10.4
10E3-E7	IgG2a	6.5
8H12	IgG2a	0.6

The specificity of 10E3-G4-D3 for P501S was examined by FACS analysis. Specifically, cells were fixed (2% formaldehyde, 10 minutes), permeabilized (0.1% saponin, 10 minutes) and stained with 10E3-G4-D3 at 0.5 – 1  $\mu\text{g/ml}$ , followed by incubation with a secondary, FITC-conjugated goat anti-mouse Ig antibody (Pharmingen, San Diego, CA). Cells were then analyzed for FITC fluorescence using an Excalibur fluorescence activated cell sorter. For FACS analysis of transduced cells, B-LCL were retrovirally transduced with P501S. For analysis of infected cells, B-LCL were infected with a vaccinia vector that expresses P501S. To demonstrate specificity in these assays, B-LCL transduced with a different antigen (P703P) and uninfected B-LCL vectors were utilized. 10E3-G4-D3 was shown to bind with P501S-transduced B-

LCL and also with P501S-infected B-LCL, but not with either uninfected cells or P703P-transduced cells.

To determine whether the epitope recognized by 10E3-G4-D3 was found on the surface or in an intracellular compartment of cells, B-LCL were transduced with P501S or HLA-B8' as a control antigen and either fixed and permeabilized as described above or directly stained with 10E3-G4-D3 and analyzed as above. Specific recognition of P501S by 10E3-G4-D3 was found to require permeabilization, suggesting that the epitope recognized by this antibody is intracellular.

The reactivity of 10E3-G4-D3 with the three prostate tumor cell lines Lncap, PC-3 and DU-145, which are known to express high, medium and very low levels of P501S, respectively, was examined by permeabilizing the cells and treating them as described above. Higher reactivity of 10E3-G4-D3 was seen with Lncap than with PC-3, which in turn showed higher reactivity than DU-145. These results are in agreement with the real time PCR and demonstrate that the antibody specifically recognizes P501S in these tumor cell lines and that the epitope recognized in prostate tumor cell lines is also intracellular.

Specificity of 10E3-G4-D3 for P501S was also demonstrated by Western blot analysis. Lysates from the prostate tumor cell lines Lncap, DU-145 and PC-3, from P501S-transiently transfected HEK293 cells, and from non-transfected HEK293 cells were generated. Western blot analysis of these lysates with 10E3-G4-D3 revealed a 46 kDa immunoreactive band in Lncap, PC-3 and P501S-transfected HEK cells, but not in DU-145 cells or non-transfected HEK293 cells. P501S mRNA expression is consistent with these results since semi-quantitative PCR analysis revealed that P501S mRNA is expressed in Lncap, to a lesser but detectable level in PC-3 and not at all in DU-145 cells. Bacterially expressed and purified recombinant P501S (referred to as P501SStr2) was recognized by 10E3-G4-D3 (24 kDa), as was full-length P501S that was transiently expressed in HEK293 cells using either the expression vector VR1012 or pCEP4. Although the predicted molecular weight of P501S is 60.5 kDa, both transfected and "native" P501S run at a slightly lower mobility due to its hydrophobic nature.

Immunohistochemical analysis was performed on prostate tumor and a panel of normal tissue sections (prostate, adrenal, breast, cervix, colon, duodenum, gall bladder, ileum, kidney, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis). Tissue samples were fixed in formalin solution for 24 hours and embedded in paraffin before being sliced into 10 micron sections. Tissue sections were permeabilized and incubated with 10E3-G4-D3 antibody for 1 hr. HRP-labeled anti-mouse followed by incubation with DAB chromogen was used to visualize P501S immunoreactivity. P501S was found to be highly expressed in both normal prostate and prostate tumor tissue but was not detected in any of the other tissues tested.

To identify the epitope recognized by 10E3-G4-D3, an epitope mapping approach was pursued. A series of 13 overlapping 20-21 mers (5 amino acid overlap; SEQ ID NO: 489-501) was synthesized that spanned the fragment of P501S used to generate 10E3-G4-D3. Flat bottom 96 well microtiter plates were coated with either the peptides or the P501S fragment used to immunize mice, at 1 microgram/ml for 2 hours at 37 °C. Wells were then aspirated and blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature, and subsequently washed in PBS containing 0.1% Tween 20 (PBST). Purified antibody 10E3-G4-D3 was added at 2 fold dilutions (1000 ng – 16 ng) in PBST and incubated for 30 minutes at room temperature. This was followed by washing 6 times with PBST and subsequently incubating with HRP-conjugated donkey anti-mouse IgG (H+L)Affinipure F(ab') fragment (Jackson ImmunoResearch, West Grove, PA) at 1:20000 for 30 minutes. Plates were then washed and incubated for 15 minutes in tetramethyl benzidine. Reactions were stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. As shown in Fig. 8, reactivity was seen with the peptide of SEQ ID NO: 496 (corresponding to amino acids 439-459 of P501S) and with the P501S fragment but not with the remaining peptides, demonstrating that the epitope recognized by 10E3-G4-D3 is localized to amino acids 439-459 of SEQ ID NO: 113.

In order to further evaluate the tissue specificity of P501S, multi-array immunohistochemical analysis was performed on approximately 4700 different human tissues encompassing all the major normal organs as well as neoplasias derived from

these tissues. Sixty-five of these human tissue samples were of prostate origin. Tissue sections 0.6 mm in diameter were formalin-fixed and paraffin embedded. Samples were pretreated with HIER using 10 mM citrate buffer pH 6.0 and boiling for 10 min. Sections were stained with 10E3-G4-D3 and P501S immunoreactivity was visualized with HRP. All the 65 prostate tissues samples (5 normal, 55 untreated prostate tumors, 5 hormone refractory prostate tumors) were positive, showing distinct perinuclear staining. All other tissues examined were negative for P501S expression.

c) Preparation and Characterization of Antibodies against P503S

10 A fragment of P503S (amino acids 113-241 of SEQ ID NO: 114) was expressed and purified from bacteria essentially as described above for P501S and used to immunize both rabbits and mice. Mouse monoclonal antibodies were isolated using standard hybridoma technology as described above. Rabbit monoclonal antibodies were isolated using Selected Lymphocyte Antibody Method (SLAM) technology at  
15 Immgenics Pharmaceuticals (Vancouver, BC, Canada). Table VI, below, lists the monoclonal antibodies that were developed against P503S.

Table VI

Antibody	Species
20D4	Rabbit
JA1	Rabbit
1A4	Mouse
1C3	Mouse
1C9	Mouse
1D12	Mouse
2A11	Mouse
2H9	Mouse
4H7	Mouse
8A8	Mouse
8D10	Mouse
9C12	Mouse
6D12	Mouse

The DNA sequences encoding the complementarity determining regions (CDRs) for the rabbit monoclonal antibodies 20D4 and JA1 were determined and are provided in SEQ ID NO: 502 and 503, respectively.

5 In order to better define the epitope binding region of each of the antibodies, a series of overlapping peptides were generated that span amino acids 109-213 of SEQ ID NO: 114. These peptides were used to epitope map the anti-P503S monoclonal antibodies by ELISA as follows. The recombinant fragment of P503S that was employed as the immunogen was used as a positive control. Ninety-six well  
10 microtiter plates were coated with either peptide or recombinant antigen at 20 ng/well overnight at 4 °C. Plates were aspirated and blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature then washed in PBS containing 0.1% Tween 20 (PBST). Purified rabbit monoclonal antibodies diluted in PBST were added to the wells and incubated for 30 min at room temperature. This was  
15 followed by washing 6 times with PBST and incubation with Protein-A HRP conjugate at a 1:2000 dilution for a further 30 min. Plates were washed six times in PBST and incubated with tetramethylbenzidine (TMB) substrate for a further 15 min. The reaction was stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using at ELISA plate reader. ELISA with the mouse monoclonal antibodies was performed with  
20 supernatants from tissue culture run neat in the assay.

All of the antibodies bound to the recombinant P503S fragment, with the exception of the negative control SP2 supernatant. 20D4, JA1 and 1D12 bound strictly to peptide #2101 (SEQ ID NO: 504), which corresponds to amino acids 151-169 of SEQ ID NO: 114. 1C3 bound to peptide #2102 (SEQ ID NO: 505), which corresponds  
25 to amino acids 165-184 of SEQ ID NO: 114. 9C12 bound to peptide #2099 (SEQ ID NO: 522), which corresponds to amino acids 120-139 of SEQ ID NO: 114. The other antibodies bind to regions that were not examined in these studies.

Subsequent to epitope mapping, the antibodies were tested by FACS analysis on a cell line that stably expressed P503S to confirm that the antibodies bind to  
30 cell surface epitopes. Cells stably transfected with a control plasmid were employed as

a negative control. Cells were stained live with no fixative. 0.5 ug of anti-P503S monoclonal antibody was added and cells were incubated on ice for 30 min before being washed twice and incubated with a FITC-labelled goat anti-rabbit or mouse secondary antibody for 20 min. After being washed twice, cells were analyzed with an Excalibur  
5 fluorescent activated cell sorter. The monoclonal antibodies 1C3, 1D12, 9C12, 20D4 and JA1, but not 8D3, were found to bind to a cell surface epitope of P503S.

In order to determine which tissues express P503S, immunohistochemical analysis was performed, essentially as described above, on a panel of normal tissues (prostate, adrenal, breast, cervix, colon, duodenum, gall bladder,  
10 ileum, kidney, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis). HRP-labeled anti-mouse or anti-rabbit antibody followed by incubation with TMB was used to visualize P503S immunoreactivity. P503S was found to be highly expressed in prostate tissue, with lower levels of expression being observed in cervix, colon, ileum and kidney, and no expression being observed in adrenal, breast, duodenum, gall  
15 bladder, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis.

Western blot analysis was used to characterize anti-P503S monoclonal antibody specificity. SDS-PAGE was performed on recombinant (rec) P503S expressed in and purified from bacteria and on lysates from HEK293 cells transfected with full length P503S. Protein was transferred to nitrocellulose and then Western blotted with  
20 each of the anti-P503S monoclonal antibodies (20D4, JA1, 1D12, 6D12 and 9C12) at an antibody concentration of 1 ug/ml. Protein was detected using horse radish peroxidase (HRP) conjugated to either a goat anti-mouse monoclonal antibody or to protein A-sepharose. The monoclonal antibody 20D4 detected the appropriate  
25 molecular weight 14 kDa recombinant P503S (amino acids 113-241) and the 23.5 kDa species in the HEK293 cell lysates transfected with full length P503S. Other anti-P503S monoclonal antibodies displayed similar specificity by Western blot.

#### d) Preparation and Characterization of Antibodies against P703P

Rabbits were immunized with either a truncated (P703Ptr1; SEQ ID NO: 172) or full-length mature form (P703Pfl; SEQ ID NO: 523) of recombinant P703P

protein was expressed in and purified from bacteria as described above. Affinity purified polyclonal antibody was generated using immunogen P703Pfl or P703Ptrl attached to a solid support. Rabbit monoclonal antibodies were isolated using SLAM technology at Immgenics Pharmaceuticals. Table VII below lists both the polyclonal and monoclonal antibodies that were generated against P703P.

Table VII

Antibody	Immunogen	Species/type
Aff. Purif. P703P (truncated); #2594	P703Ptrl	Rabbit polyclonal
Aff. Purif. P703P (full length); #9245	P703Pfl	Rabbit polyclonal
2D4	P703Ptrl	Rabbit monoclonal
8H2	P703Ptrl	Rabbit monoclonal
7H8	P703Ptrl	Rabbit monoclonal

10           The DNA sequences encoding the complementarity determining regions (CDRs) for the rabbit monoclonal antibodies 8H2, 7H8 and 2D4 were determined and are provided in SEQ ID NO: 506-508, respectively.

Epitope mapping studies were performed as described above. Monoclonal antibodies 2D4 and 7H8 were found to specifically bind to the peptides of  
15   SEQ ID NO: 509 (corresponding to amino acids 145-159 of SEQ ID NO: 172) and SEQ ID NO: 510 (corresponding to amino acids 11-25 of SEQ ID NO: 172), respectively. The polyclonal antibody 2594 was found to bind to the peptides of SEQ ID NO: 511-514, with the polyclonal antibody 9427 binding to the peptides of SEQ ID NO: 515-517.

20           The specificity of the anti-P703P antibodies was determined by Western blot analysis as follows. SDS-PAGE was performed on (1) bacterially expressed recombinant antigen; (2) lysates of HEK293 cells and Ltk<sup>-/-</sup> cells either untransfected or transfected with a plasmid expressing full length P703P; and (3) supernatant isolated from these cell cultures. Protein was transferred to nitrocellulose and then Western blotted using the anti-P703P polyclonal antibody #2594 at an antibody concentration of  
25   1 ug/ml. Protein was detected using horse radish peroxidase (HRP) conjugated to an anti-rabbit antibody. A 35 kDa immunoreactive band could be observed with



recombinant P703P. Recombinant P703P runs at a slightly higher molecular weight since it is epitope tagged. In lysates and supernatants from cells transfected with full length P703P, a 30 kDa band corresponding to P703P was observed. To assure specificity, lysates from HEK293 cells stably transfected with a control plasmid were also tested and were negative for P703P expression. Other anti-P703P antibodies showed similar results.

Immunohistochemical studies were performed as described above, using anti-P703P monoclonal antibody. P703P was found to be expressed at high levels in normal prostate and prostate tumor tissue but was not detectable in all other tissues tested (breast tumor, lung tumor and normal kidney).

e) Preparation and Characterization of Antibodies against P504S

Full-length P504S (SEQ ID NO: 108) was expressed and purified from bacteria essentially as described above for P501S and employed to raise rabbit monoclonal antibodies using Selected Lymphocyte Antibody Method (SLAM) technology at Immgenics Pharmaceuticals (Vancouver, BC, Canada). The anti-P504S monoclonal antibody 13H4 was shown by Western blot to bind to both expressed recombinant P504S and to native P504S in tumor cells.

Immunohistochemical studies using 13H4 to assess P504S expression in various prostate tissues were performed as described above. A total of 104 cases, including 65 cases of radical prostatectomies with prostate cancer (PC), 26 cases of prostate biopsies and 13 cases of benign prostate hyperplasia (BPH), were stained with the anti-P504S monoclonal antibody 13H4. P504S showed strongly cytoplasmic granular staining in 64/65 (98.5%) of PCs in prostatectomies and 26/26 (100%) of PCs in prostatic biopsies. P504S was stained strongly and diffusely in carcinomas (4+ in 91.2% of cases of PC; 3+ in 5.5%; 2+ in 2.2% and 1+ in 1.1%) and high grade prostatic intraepithelial neoplasia (4+ in all cases). The expression of P504S did not vary with Gleason score. Only 17/91 (18.7%) of cases of NP/BPH around PC and 2/13 (15.4%) of BPH cases were focally (1+, no 2+ to 4+ in all cases) and weakly positive for P504S in large glands. Expression of P504S was not found in small atrophic glands, postatrophic hyperplasia, basal cell hyperplasia and transitional cell metaplasia in either biopsies or

prostatectomies. P504S was thus found to be over-expressed in all Gleason scores of prostate cancer (98.5 to 100% of sensitivity) and exhibited only focal positivities in large normal glands in 19/104 of cases (82.3% of specificity). These findings indicate that P504S may be usefully employed for the diagnosis of prostate cancer.

5

## EXAMPLE 19

CHARACTERIZATION OF CELL SURFACE EXPRESSION AND  
CHROMOSOME LOCALIZATION OF THE PROSTATE-SPECIFIC ANTIGEN P501S

10 This example describes studies demonstrating that the prostate-specific antigen P501S is expressed on the surface of cells, together with studies to determine the probable chromosomal location of P501S.

The protein P501S (SEQ ID NO: 113) is predicted to have 11 transmembrane domains. Based on the discovery that the epitope recognized by the anti-  
15 P501S monoclonal antibody 10E3-G4-D3 (described above in Example 17) is intracellular, it was predicted that following transmembrane determinants would allow the prediction of extracellular domains of P501S. Fig. 9 is a schematic representation of the P501S protein showing the predicted location of the transmembrane domains and the intracellular epitope described in Example 17. Underlined sequence represents the  
20 predicted transmembrane domains, bold sequence represents the predicted extracellular domains, and italicized sequence represents the predicted intracellular domains. Sequence that is both bold and underlined represents sequence employed to generate polyclonal rabbit serum. The location of the transmembrane domains was predicted using HHMTOP as described by Tusnady and Simon (Principles Governing Amino  
25 Acid Composition of Integral Membrane Proteins: Applications to Topology Prediction, *J. Mol. Biol.* 283:489-506, 1998).

Based on Fig. 9, the P501S domain flanked by the transmembrane domains corresponding to amino acids 274-295 and 323-342 is predicted to be extracellular. The peptide of SEQ ID NO: 518 corresponds to amino acids 306-320 of  
30 P501S and lies in the predicted extracellular domain. The peptide of SEQ ID NO: 519,

which is identical to the peptide of SEQ ID NO: 518 with the exception of the substitution of the histidine with an asparagine, was synthesized as described above. A Cys-Gly was added to the C-terminus of the peptide to facilitate conjugation to the carrier protein. Cleavage of the peptide from the solid support was carried out using the following cleavage mixture: trifluoroacetic acid:ethanediol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for two hours, the peptide was precipitated in cold ether. The peptide pellet was then dissolved in 10% v/v acetic acid and lyophilized prior to purification by C18 reverse phase hplc. A gradient of 5-60% acetonitrile (containing 0.05% TFA) in water (containing 0.05% TFA) was used to elute the peptide. The purity of the peptide was verified by hplc and mass spectrometry, and was determined to be >95%. The purified peptide was used to generate rabbit polyclonal antisera as described above.

Surface expression of P501S was examined by FACS analysis. Cells were stained with the polyclonal anti-P501S peptide serum at 10 µg/ml, washed, incubated with a secondary FITC-conjugated goat anti-rabbit Ig antibody (ICN), washed and analyzed for FITC fluorescence using an Excalibur fluorescence activated cell sorter. For FACS analysis of transduced cells, B-LCL were retrovirally transduced with P501S. To demonstrate specificity in these assays, B-LCL transduced with an irrelevant antigen (P703P) or nontransduced were stained in parallel. For FACS analysis of prostate tumor cell lines, Lncap, PC-3 and DU-145 were utilized. Prostate tumor cell lines were dissociated from tissue culture plates using cell dissociation medium and stained as above. All samples were treated with propidium iodide (PI) prior to FACS analysis, and data was obtained from PI-excluding (*i.e.*, intact and non-permeabilized) cells. The rabbit polyclonal serum generated against the peptide of SEQ ID NO: 519 was shown to specifically recognize the surface of cells transduced to express P501S, demonstrating that the epitope recognized by the polyclonal serum is extracellular.

To determine biochemically if P501S is expressed on the cell surface, peripheral membranes from Lncap cells were isolated and subjected to Western blot analysis. Specifically, Lncap cells were lysed using a dounce homogenizer in 5 ml of homogenization buffer (250 mM sucrose, 10 mM HEPES, 1mM EDTA, pH 8.0, 1

complete protease inhibitor tablet (Boehringer Mannheim)). Lysate samples were spun at 1000 g for 5 min at 4 °C. The supernatant was then spun at 8000g for 10 min at 4 °C. Supernatant from the 8000g spin was recovered and subjected to a 100,000g spin for 30 min at 4 °C to recover peripheral membrane. Samples were then separated by SDS-PAGE and Western blotted with the mouse monoclonal antibody 10E3-G4-D3 (described above in Example 17) using conditions described above. Recombinant purified P501S, as well as HEK293 cells transfected with and over-expressing P501S were included as positive controls for P501S detection. LCL cell lysate was included as a negative control. P501S could be detected in Lncap total cell lysate, the 8000g (internal membrane) fraction and also in the 100,000g (plasma membrane) fraction. These results indicate that P501S is expressed at, and localizes to, the peripheral membrane.

To demonstrate that the rabbit polyclonal antiserum generated to the peptide of SEQ ID NO: 519 specifically recognizes this peptide as well as the corresponding native peptide of SEQ ID NO: 518, ELISA analyses were performed. For these analyses, flat-bottomed 96 well microtiter plates were coated with either the peptide of SEQ ID NO: 519, the longer peptide of SEQ ID NO: 520 that spans the entire predicted extracellular domain, the peptide of SEQ ID NO: 521 which represents the epitope recognized by the P501S-specific antibody 10E3-G4-D3, or a P501S fragment (corresponding to amino acids 355-526 of SEQ ID NO: 113) that does not include the immunizing peptide sequence, at 1 µg/ml for 2 hours at 37 °C. Wells were aspirated, blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature and subsequently washed in PBS containing 0.1% Tween 20 (PBST). Purified anti-P501S polyclonal rabbit serum was added at 2 fold dilutions (1000 ng - 125 ng) in PBST and incubated for 30 min at room temperature. This was followed by washing 6 times with PBST and incubating with HRP-conjugated goat anti-rabbit IgG (H+L) Affinipure F(ab') fragment at 1:20000 for 30 min. Plates were then washed and incubated for 15 min in tetramethyl benzidine. Reactions were stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. As shown in Fig. 11, the anti-P501S polyclonal rabbit serum specifically recognized the

peptide of SEQ ID NO: 519 used in the immunization as well as the longer peptide of SEQ ID NO: 520, but did not recognize the irrelevant P501S-derived peptides and fragments.

In further studies, rabbits were immunized with peptides derived from the P501S sequence and predicted to be either extracellular or intracellular, as shown in Fig. 9. Polyclonal rabbit sera were isolated and polyclonal antibodies in the serum were purified, as described above. To determine specific reactivity with P501S, FACS analysis was employed, utilizing either B-LCL transduced with P501S or the irrelevant antigen P703P, of B-LCL infected with vaccinia virus-expressing P501S. For surface expression, dead and non-intact cells were excluded from the analysis as described above. For intracellular staining, cells were fixed and permeabilized as described above. Rabbit polyclonal serum generated against the peptide of SEQ ID NO: 548, which corresponds to amino acids 181-198 of P501S, was found to recognize a surface epitope of P501S. Rabbit polyclonal serum generated against the peptide SEQ ID NO: 551, which corresponds to amino acids 543-553 of P501S, was found to recognize an epitope that was either potentially extracellular or intracellular since in different experiments intact or permeabilized cells were recognized by the polyclonal sera. Based on similar deductive reasoning, the sequences of SEQ ID NO: 541-547, 549 and 550, which correspond to amino acids 109-122, 539-553, 509-520, 37-54, 342-359, 295-323, 217-274, 143-160 and 75-88, respectively, of P501S, can be considered to be potential surface epitopes of P501S recognized by antibodies.

In further studies, mouse monoclonal antibodies were raised against amino acids 296 to 322 to P501S, which are predicted to be in an extracellular domain. A/J mice were immunized with P501S/adenovirus, followed by subsequent boosts with an *E. coli* recombinant protein, referred to as P501N, that contains amino acids 296 to 322 of P501S, and with peptide 296-322 (SEQ ID NO: 755) coupled with KLH. The mice were subsequently used for splenic B cell fusions to generate anti-peptide hybridomas. The resulting 3 clones, referred to as 4F4 (IgG1,kappa), 4G5 (IgG2a,kappa) and 9B9 (IgG1,kappa), were grown for antibody production. The 4G5 mAb was purified by passing the supernatant over a Protein A-sepharose column,

followed by antibody elution using 0.2M glycine, pH 2.3. Purified antibody was neutralized by the addition of 1M Tris, pH 8, and buffer exchanged into PBS.

For ELISA analysis, 96 well plates were coated with P501S peptide 296-322 (referred to as P501-long), an irrelevant P775 peptide, P501S-N, P501TR2, P501S-  
5 long-KLH, P501S peptide 306-319 (referred to as P501-short)-KLH, or the irrelevant peptide 2073-KLH, all at a concentration of 2 ug/ml and allowed to incubate for 60 minutes at 37 °C. After coating, plates were washed 5X with PBS + 0.1% Tween and then blocked with PBS, 0.5% BSA, 0.4% Tween20 for 2 hours at room temperature. Following the addition of supernatants or purified mAb, the plates were incubated for  
10 60 minutes at room temperature. Plates were washed as above and donkey anti-mouse IgHRP-linked secondary antibody was added and incubated for 30 minutes at room temperature, followed by a final washing as above. TMB peroxidase substrate was added and incubated 15 minutes at room temperature in the dark. The reaction was stopped by the addition of 1N H<sub>2</sub>SO<sub>4</sub> and the OD was read at 450 nM. All three hybrid  
15 clones secreted mAb that recognized peptide 296-322 and the recombinant protein P501N.

For FACS analysis, HEK293 cells were transiently transfected with a P501S/VR1012 expression constructs using Fugene 6 reagent. After 2 days of culture, cells were harvested and washed, then incubated with purified 4G5 mAb for 30 minutes  
20 on ice. After several washes in PBS, 0.5% BSA, 0.01% azide, goat anti-mouse Ig-FITC was added to the cells and incubated for 30 minutes on ice. Cells were washed and resuspended in wash buffer including 1% propidium iodide and subjected to FACS analysis. The FACS analysis confirmed that amino acids 296-322 of P501S are in an extracellular domain and are cell surface expressed.

25 The chromosomal location of P501S was determined using the GeneBridge 4 Radiation Hybrid panel (Research Genetics). The PCR primers of SEQ ID NO: 528 and 529 were employed in PCR with DNA pools from the hybrid panel according to the manufacturer's directions. After 38 cycles of amplification, the reaction products were separated on a 1.2% agarose gel, and the results were analyzed  
30 through the Whitehead Institute/MIT Center for Genome Research web server

(<http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl>) to determine the probable chromosomal location. Using this approach, P501S was mapped to the long arm of chromosome 1 at WI-9641 between q32 and q42. This region of chromosome 1 has been linked to prostate cancer susceptibility in hereditary prostate cancer (Smith *et al.* *Science* 274:1371-1374, 1996 and Berthon *et al.* *Am. J. Hum. Genet.* 62:1416-1424, 1998). These results suggest that P501S may play a role in prostate cancer malignancy.

## EXAMPLE 20

### REGULATION OF EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGEN P501S

10

Steroid (androgen) hormone modulation is a common treatment modality in prostate cancer. The expression of a number of prostate tissue-specific antigens have previously been demonstrated to respond to androgen. The responsiveness of the prostate-specific antigen P501S to androgen treatment was examined in a tissue culture system as follows.

15

Cells from the prostate tumor cell line LNCaP were plated at  $1.5 \times 10^6$  cells/T75 flask (for RNA isolation) or  $3 \times 10^5$  cells/well of a 6-well plate (for FACS analysis) and grown overnight in RPMI 1640 media containing 10% charcoal-stripped fetal calf serum (BRL Life Technologies, Gaithersburg, MD). Cell culture was continued for an additional 72 hours in RPMI 1640 media containing 10% charcoal-stripped fetal calf serum, with 1 nM of the synthetic androgen Methyltrienolone (R1881; New England Nuclear) added at various time points. Cells were then harvested for RNA isolation and FACS analysis at 0, 1, 2, 4, 8, 16, 24, 28 and 72-hours post androgen addition. FACS analysis was performed using the anti-P501S antibody 10E3-G4-D3 and permeabilized cells.

20

25

For Northern analysis, 5-10 micrograms of total RNA was run on a formaldehyde denaturing gel, transferred to Hybond-N nylon membrane (Amersham Pharmacia Biotech, Piscataway, NJ), cross-linked and stained with methylene blue. The filter was then prehybridized with Church's Buffer (250 mM  $\text{Na}_2\text{HPO}_4$ , 70 mM  $\text{H}_3\text{PO}_4$ , 1 mM EDTA, 1% SDS, 1% BSA in pH 7.2) at 65 °C for 1 hour. P501S DNA was

30

labeled with  $^{32}\text{P}$  using High Prime random-primed DNA labeling kit (Boehringer Mannheim). Unincorporated label was removed using MicroSpin S300-HR columns (Amersham Pharmacia Biotech). The RNA filter was then hybridized with fresh Church's Buffer containing labeled cDNA overnight, washed with 1X SCP (0.1 M NaCl, 0.03 M  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 0.001 M  $\text{Na}_2\text{EDTA}$ ), 1% sarkosyl (n-lauroylsarcosine) and exposed to X-ray film.

Using both FACS and Northern analysis, P501S message and protein levels were found to increase in response to androgen treatment.

10

## EXAMPLE 20

## PREPARATION OF FUSION PROTEINS OF PROSTATE-SPECIFIC ANTIGENS

The example describes the preparation of a fusion protein of the prostate-specific antigen P703P and a truncated form of the known prostate antigen PSA. The truncated form of PSA has a 21 amino acid deletion around the active serine site. The expression construct for the fusion protein also has a restriction site at 3' end, immediately prior to the termination codon, to aid in adding cDNA for additional antigens.

The full-length cDNA for PSA was obtained by RT-PCR from a pool of RNA from human prostate tumor tissues using the primers of SEQ ID NO: 607 and 608, and cloned in the vector pCR-Blunt II-TOPO. The resulting cDNA was employed as a template to make two different fragments of PSA by PCR with two sets of primers (SEQ ID NO: 609 and 610; and SEQ ID NO: 611 and 612). The PCR products having the expected size were used as templates to make truncated forms of PSA by PCR with the primers of SEQ ID NO: 611 and 613, which generated PSA (delta 208-218 in amino acids). The cDNA for the mature form of P703P with a 6X histidine tag at the 5' end, was prepared by PCR with P703P and the primers of SEQ ID NO: 614 and 615. The cDNA for the fusion of P703P with the truncated form of PSA (referred to as FOPP) was then obtained by PCR using the modified P703P cDNA and the truncated form of PSA cDNA as templates and the primers of SEQ ID NO: 614 and 615. The FOPP



cDNA was cloned into the NdeI site and XhoI site of the expression vector pCRX1, and confirmed by DNA sequencing. The determined cDNA sequence for the fusion construct FOPP is provided in SEQ ID NO: 616, with the amino acid sequence being provided in SEQ ID NO: 617.

5           The fusion FOPP was expressed as a single recombinant protein in *E. coli* as follows. The expression plasmid pCRX1FOPP was transformed into the *E. coli* strain BL21-CodonPlus RIL. The transformant was shown to express FOPP protein upon induction with 1 mM IPTG. The culture of the corresponding expression clone was inoculated into 25 ml LB broth containing 50 ug/ml kanamycin and 34 ug/ml  
10 chloramphenicol, grown at 37 °C to OD600 of about 1, and stored at 4 °C overnight. The culture was diluted into 1 liter of TB LB containing 50 ug/ml kanamycin and 34 ug/ml chloramphenicol, and grown at 37 °C to OD600 of 0.4. IPTG was added to a final concentration of 1 mM, and the culture was incubated at 30 °C for 3 hours. The cells were pelleted by centrifugation at 5,000 RPM for 8 min. To purify the protein, the  
15 cell pellet was suspended in 25 ml of 10 mM Tris-Cl pH 8.0, 2mM PMSF, complete protease inhibitor and 15 ug lysozyme. The cells were lysed at 4 °C for 30 minutes, sonicated several times and the lysate centrifuged for 30 minutes at 10,000 x g. The precipitate, which contained the inclusion body, was washed twice with 10 mM Tris-Cl pH 8.0 and 1% CHAPS. The inclusion body was dissolved in 40 ml of 10 mM Tris-Cl  
20 pH 8.0, 100 mM sodium phosphate and 8 M urea. The solution was bound to 8 ml Ni-NTA (Qiagen) for one hour at room temperature. The mixture was poured into a 25 ml column and washed with 50 ml of 10 mM Tris-Cl pH 6.3, 100 mM sodium phosphate, 0.5% DOC and 8M urea. The bound protein was eluted with 350 mM imidazole, 10 mM Tris-Cl pH 8.0, 100 mM sodium phosphate and 8 M urea. The fractions containing  
25 FOPP proteins were combined and dialyzed extensively against 10 mM Tris-Cl pH 4.6, aliquoted and stored at - 70 °C.

## EXAMPLE 21

REAL-TIME PCR CHARACTERIZATION OF THE PROSTATE-SPECIFIC ANTIGEN P501S IN  
PERIPHERAL BLOOD OF PROSTATE CANCER PATIENTS

5           Circulating epithelial cells were isolated from fresh blood of normal individuals and metastatic prostate cancer patients, mRNA isolated and cDNA prepared using real-time PCR procedures. Real-time PCR was performed with the Taqman<sup>TM</sup> procedure using both gene specific primers and probes to determine the levels of gene expression.

10           Epithelial cells were enriched from blood samples using an immunomagnetic bead separation method (Dynal A.S., Oslo, Norway). Isolated cells were lysed and the magnetic beads removed. The lysate was then processed for poly A+ mRNA isolation using magnetic beads coated with Oligo(dT)25. After washing the beads in buffer, bead/poly A+ RNA samples were suspended in 10 mM Tris HCl pH 8.0

15           and subjected to reversed transcription. The resulting cDNA was subjected to real-time PCR using gene specific primers. Beta-actin content was also determined and used for normalization. Samples with P501S copies greater than the mean of the normal samples + 3 standard deviations were considered positive. Real time PCR on blood samples was performed using the Taqman<sup>TM</sup> procedure but extending to 50 cycles using

20           forward and reverse primers and probes specific for P501S. Of the eight samples tested, 6 were positive for P501S and  $\beta$ -actin signal. The remaining 2 samples had no detectable  $\beta$ -actin or P501S. No P501S signal was observed in the four normal blood samples tested.

25

## EXAMPLE 22

EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGENS P703P AND P501S IN  
SCID MOUSE-PASSAGED PROSTATE TUMORS

30           When considering the effectiveness of antigens in the treatment of prostate cancer, the continued presence of the antigens in tumors during androgen

ablation therapy is important. The presence of the prostate-specific antigens P703P and P501S in prostate tumor samples grown in SCID mice in the presence of testosterone was evaluated as follows.

Two prostate tumors that had metastasized to the bone were removed from patients, implanted into SCID mice and grown in the presence of testosterone. Tumors were evaluated for mRNA expression of P703P, P501S and PSA using quantitative real time PCR with the SYBR green assay method. Expression of P703P and P501S in a prostate tumor was used as a positive control and the absence in normal intestine and normal heart as negative controls. In both cases, the specific mRNA was present in late passage tumors. Since the bone metastases were grown in the presence of testosterone, this implies that the presence of these genes would not be lost during androgen ablation therapy.

#### EXAMPLE 23

##### ANTI-P503S MONOCLONAL ANTIBODY INHIBITS TUMOR GROWTH *IN VIVO*

The ability of the anti-P503S monoclonal antibody 20D4 to suppress tumor formation in mice was examined as follows.

Ten SCID mice were injected subcutaneously with HEK293 cells that expressed P503S. Five mice received 150 micrograms of 20D4 intravenously at day 0 (time of tumor cell injection), day 5 and day 9. Tumor size was measured for 50 days. Of the five animals that received no 20D4, three formed detectable tumors after about 2 weeks which continued to enlarge throughout the study. In contrast, none of the five mice that received 20D4 formed tumors. These results demonstrate that the anti-P503S Mab 20D4 displays potent anti-tumor activity *in vivo*.

#### EXAMPLE 24

##### CHARACTERIZATION OF A T CELL RECEPTOR CLONE FROM A P501S-SPECIFIC T CELL CLONE

T cells have a limited lifespan. However, cloning of T cell receptor (TCR) chains and subsequent transfer essentially enables infinite propagation of the T

cell specificity. Cloning of tumor-antigen TCR chains allows the transfer of the specificity into T cells isolated from patients that share the TCR MHC-restricting allele. Such T cells could then be expanded and used in adoptive transfer settings to introduce the tumor antigen specificity into patients carrying tumors that express the antigen. T cell receptor alpha and beta chains from a CD8 T cell clone specific for the prostate-specific antigen P501S were isolated and sequenced as follows.

Total mRNA from  $2 \times 10^6$  cells from CTL clone 4E5 (described above in Example 12) was isolated using Trizol reagent and cDNA was synthesized. To determine Va and Vb sequences in this clone, a panel of Va and Vb subtype-specific primers was synthesized and used in RT-PCR reactions with cDNA generated from each of the clones. The RT-PCR reactions demonstrated that each of the clones expressed a common Vb sequence that corresponded to the Vb7 subfamily. Furthermore, using cDNA generated from the clone, the Va sequence expressed was determined to be Va6. To clone the full TCR alpha and beta chains from clone 4E5, primers were designed that spanned the initiator and terminator-coding TCR nucleotides. The primers were as follows: TCR Valpha-6 5'(sense): GGATCC---GCCGCCACC---ATGTCACTTTCTAGCCTGCT (SEQ ID NO: 756) BamHI site Kozak TCR alpha sequence TCR alpha 3' (antisense): GTCGAC---TCAGCTGGACCACAGCCGCAG (SEQ ID NO: 757) Sall site TCR alpha constant sequence TCR Vbeta-7. 5'(sense): GGATCC---GCCGCCACC---ATGGGCTGCAGGCTGCTCT (SEQ ID NO: 758) BamHI site Kozak TCR alpha sequence TCR beta 3' (antisense): GTCGAC---TCAGAAATCCTTTCTCTTGAC (SEQ ID NO: 759) Sall site TCR beta constant sequence. Standard 35 cycle RT-PCR reactions were established using cDNA synthesized from the CTL clone and the above primers, employing the proofreading thermostable polymerase PWO (Roche, Nutley, NJ).

The resultant specific bands (approx. 850 bp for alpha and approx. 950 for beta) were ligated into the PCR blunt vector (Invitrogen) and transformed into *E. coli*. *E. coli* transformed with plasmids containing full-length alpha and beta chains were identified, and large scale preparations of the corresponding plasmids were generated. Plasmids containing full-length TCR alpha and beta chains were submitted

for sequencing. The sequencing reactions demonstrated the cloning of full-length TCR alpha and beta chains with the determined cDNA sequences for the Vb and Va chains being shown in SEQ ID NO: 760 and 761, respectively. The corresponding amino acid sequences are shown in SEQ ID NO: 762 and 763, respectively. The Va sequence was  
5 shown by nucleotide sequence alignment to be 99% identical (347/348) to Va6.2, and the Vb to be 99% identical to Vb7 (336/338),

From the foregoing it will be appreciated that, although specific  
embodiments of the invention have been described herein for purposes of illustration,  
10 various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## CLAIMS

## What is Claimed:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(b) complements of the sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(d) sequences that hybridize to a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788 under moderately stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-

375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(f) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788; and

(g) degenerate variants of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

(b) sequences having at least 70% identity to a sequence of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

(c) sequences having at least 90% identity to a sequence of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-

629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

- (d) sequences encoded by a polynucleotide of claim 1;
- (e) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and
- (f) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. A host cell transformed or transfected with an expression vector according to claim 3.

5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. A method for detecting the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

7. A fusion protein comprising at least one polypeptide according to claim 2.



8. The fusion protein of claim 7, wherein the fusion protein comprises a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 682, 692, 695, 699, 703 and 709; and

(b) sequences encoded by SEQ ID NO: 679, 691, 696, 700, 704 and 708.

9. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 or 786-788 under moderately stringent conditions.

10. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1; and
- (c) antigen-presenting cells that express a polypeptide according to claim 1,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

11. An isolated T cell population, comprising T cells prepared according to the method of claim 10.

12. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 11; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

13. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 12.

14. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 12.

15. A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 9;
- (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and
- (d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

16. A diagnostic kit comprising at least one oligonucleotide according to claim 9.

17. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

18. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate; and

(b) administering to the patient an effective amount of the proliferated T cells,

thereby inhibiting the development of a cancer in the patient.




Fig. 1




Fig. 2A




Fig. 25




Fig. 3




Fig. 4






Fig. 5




Fig. 6B





Fig. 6A

# Expression of P501S by the Baculovirus Expression System



0.6 million high 5 cells in 6-well plate were infected with an unrelated control virus BV/ECD\_PD (lane 2), without virus (lane 3), or with recombinant baculovirus for P501 at different MOIs (lane 4-8). Cell lysates were run on SDS-PAGE under the reducing conditions and analyzed by Western blot with a monoclonal antibody against P501S (P501S-10E3-G4D3). Lane 1 is the biotinylated protein molecular weight marker (BioLabs).

Fig. 7

Figure 8. Mapping of the epitope recognized by 10E3-G4-D3




Fig. 8

# Figure 1. Schematic of P501S with predicted transmembrane, cytoplasmic, and extracellular regions

MVQRIWVSHLRHK AQLIAVNLITGLEVCIAAGIT VVPPIILLEVGVREKFM TMVLGIGPYLGILVCYPLLGSAS  
 DWVRGRYGRRRP EIWALSGLILLSEFLPRAGIWL AGELCTDPDPRPLE LALLILGVGLIDFGGOVCFTPL  
 FALISDLFRDPDHCRQ AYSVYAFMSLGGCTGVIIIPAI DWVVSALAPYLCTQRE  
 CLPGLLTLPETCYVAATILY AEEAICGPTPEAGLSAPSISPHCCPCRAKIAFRNIGALLPRI  
 HQLCCHMPRTLR LPYAEILCSWMAIMETTFYTIPT VGEGLYOGVYPRAPGTLEARRIHYDEGYR  
 MSLGLFLQCAISLYFSLYM DRIVQRECTRAVYLAS VAAFPVAAGATCLSHSVAVVTA SAA  
 LTGEITSALQILPYTLASLY HREKQVFLPKYRGDTGGASSEDSTMTSFLPGPKPGAPFPNGHIVGAGGSGL  
 LPPPPALCGASACDVSVRVVVGEPTEARVVVGRG ICILDLAIDSAFLLSQVAPSE MGSIVQLSQS  
 VTAYMVSAAGILYAIYFAT QVVFDKSDIAKYSA

Underlined sequence: Predicted transmembrane domain; **Bold sequence**: Predicted extracellular domain;  
*Italic sequence*: Predicted intracellular domain. Sequence in bold/underlined: used to generate polyclonal rabbit serum

Localization of domains predicted using IMMTOPI (G.R. Tusnady and I. Simon (1998) Principles  
 Governing Amino Acid Composition of Integral Membrane Proteins: Applications to topology Prediction. J. Mol. Biol. 283,  
 489-506.

Fig. 9

# Genomic Map of (5) Corixa Candidate Genes




Fig. 10

# FIGURE 4. Elisa assay of rabbit polyclonal antibody specificity




Fig. 11

## SEQUENCE LISTING

<110> Corixa Corporation  
 Smithkline Beechan Biologicals S.A.  
 Xu, Jiangchun  
 Dillon, Davin C.  
 Mitcham, Jennifer L.  
 Harlocker, Susan L.  
 Jiang, Yuqui  
 Reed, Steven G.  
 Kalos, Michael D.  
 Fanger, Gary R.  
 Retter, Marc W.  
 Stolk, John A.  
 Day, Craig H.  
 Skeiky, Yasir A.W.  
 Wang, Aijun  
 Meagher, Medeleine Joy  
 Vanderbrugge, Didier  
 Dewerchin, Marianne  
 Dehottay, Ph.  
 de Rop, Philippe

<120> COMPOSITIONS AND METHODS FOR THE THERAPY AND  
 DIAGNOSIS OF PROSTATE CANCER

<130> 210121.42722PC

<140> PCT

<141> 2001-01-16

<160> 792

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 814

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(814)

<223> n = A,T,C or G

<400> 1

tttttttttt	tttttcacag	tataacagct	ctttattttct	gtgagttcta	ctaggaaatc	60
atcaaactcg	agggttgtct	ggaggacttc	aatacacctc	cccccatagt	gaatcagctt	120
ccaggggggc	cagtcctctc	ccttacttca	tccccatccc	atgccaaagg	aagaccctcc	180
ctccttggct	cacagccttc	tctaggcttc	ccagtgcctc	caggacagag	tgggttatgt	240
tttcagctcc	atccttgctg	tgagtgtctg	gtgcgtttgtg	cctccagctt	ctgctcagtg	300
cttcattggac	agtgtccagc	acatgtcact	ctccactctc	tcagtgtgga	tccactagtt	360
ctagagcggc	cgccaccgcg	gtggagctcc	agcttttgtt	cccttttagtg	agggttaatt	420
gcgcgcttgg	cgtaatcatg	gtcataactg	tttcctgtgt	gaaattgta	tccgctcaca	480
attccacaca	acatacgagc	cggaagcata	aagtgtaaag	cctgggggtgc	ctaattgagtg	540
anctaactca	cattaattgc	gttgcgctca	ctgnccgctt	tccagtcngg	aaaactgtcg	600
tgccagctgc	attaatgaat	cggccaacgc	ncgggggaaa	gcggtttgcg	ttttgggggc	660



tcttccgctt	ctcgtctcact	nantcctgcg	ctcgggtcctt	cggtcgcg	gaacgggtatc	720
actcctcaaa	gngngtatta	cggttatccn	naaatcnggg	gatacccg	aaaaanttt	780
aacaaaagg	cancaaagg	cngaaacgta	aaaa			814

&lt;210&gt; 2

&lt;211&gt; 816

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(816)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 2

acagaaatgt	tggatggtgg	agcacctttc	tatacgactt	acaggacagc	agatggggaa	60
ttcatggctg	ttggagcaat	agaaccccag	ttctacgagc	tgctgatcaa	aggacttgga	120
ctaaagtctg	atgaacttcc	caatcagatg	agcatggatg	attggccaga	aatgaagaag	180
aagtttgacg	atgtatttgc	aaagaagacg	aaggcagagt	ggtgtcaaat	ctttgacggc	240
acagatgcct	gtgtgactcc	ggttctgact	tttgaggagg	ttgttcatca	tgatcacaac	300
aaggaacggg	gctcgtttat	caccagtggg	gagcaggacg	tgagcccccg	ccctgcacct	360
ctgctgttaa	acaccccagc	catcccttct	ttcaaaagg	atccactagt	tctagaagcg	420
gccgccaccg	cggtggagct	ccagcttttg	ttccctttag	tgagggttaa	ttgcgcgctt	480
ggcgtaata	tggtcatagc	tgtttcctgt	gtgaaattgt	tatccgctca	caattccccc	540
aacatacgag	ccggaacata	aagtgttaag	cctgggggtgc	ctaattgagt	agctaactcn	600
cattaattgc	gttgcgctca	ctgcccgtct	tccagtcggg	aaaactgtcg	tgccactgcn	660
ttantgaatc	ngcccacccc	cgggaaaagg	cggttgcntt	ttgggcctct	tccgctttcc	720
tcgctcattg	atcctngcnc	ccggtcttcg	gctgcggnga	acggttcact	cctcaaaggc	780
ggtntnccgg	ttatcccca	acnggggata	cccnga			816

&lt;210&gt; 3

&lt;211&gt; 773

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(773)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 3

cttttgaaag	aagggatggc	tggggtgttt	aacagcagag	gtgcaggggc	ggggctcacg	60
tcctgctcct	cactggtgat	aaacgagccc	cggttcctgt	tgtgatcatg	atgaacaacc	120
tcctcaaaag	tcagaaccgg	agtcacacag	gcatctgtgc	cgtcaaagat	ttgacaccac	180
tctgccttcg	tcttctttgc	aaatacatct	gcaaacttct	tcttcatttc	tgccaatca	240
tccatgtctc	tctgattggg	aagttcatca	gacttttagt	canntccttt	gatcagcagc	300
tcgtagaact	ggggttctat	tgctccaaca	gccatgaatt	ccccatctgc	tgctcgttaa	360
gtcgtataga	aagggtgctc	accatccaac	atgttctgtc	ctcgaggggg	ggcccgggtac	420
ccaattcgcc	ctatantgag	tcgtattacg	cgcgctcact	ggccgtcggt	ttacaacgtc	480
gtgactggga	aaaccctggg	cgttaccaac	ttaatgcgct	tgagcacat	ccccctttcg	540
ccagctgggc	gtaatanccg	aaaggccccg	accgatcgcc	cttccaacag	ttgcgcacct	600
gaatgggnaa	atgggacccc	cctgttacgc	cgcattnaac	ccccgcnggg	tttngttggt	660
acccccacnt	nnaccgctta	cactttgcca	gcgccttanc	gcccgtctcc	tttncctttt	720
cttcccttcc	tttncncncn	ctttcccccg	gggtttcccc	cntcaaacc	cna	773

&lt;210&gt; 4

&lt;211&gt; 828

&lt;212&gt; DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(828)

<223> n = A,T,C or G

<400> 4

cctcctgagt	cctactgacc	tgtgctttct	ggtgtggagt	ccagggctgc	taggaaaagg	60
aatgggcaga	cacaggtgta	tgccaatgtt	tctgaaatgg	gtataatttc	gtcctctcct	120
tcggaacact	ggctgtctct	gaagacttct	cgctcagttt	cagtgaggac	acacacaaag	180
acgtgggtga	ccatgttggt	tgtgggggtgc	agagatggga	gggggtgggc	ccaccctgga	240
agagtggaca	gtgacacaag	gtggacactc	tctacagatc	actgaggata	agctggagcc	300
acaatgcatg	aggcacacac	acagcaagga	tgacnctgta	aacatagccc	acgtgtcctt	360
gngggcactg	ggaagcctan	atnaggccgt	gagcanaaag	aaggggagga	tccactagtt	420
ctanagcggc	cgccaccgcy	gtgganctcc	ancttttggt	cccttttagtg	aggggtaatt	480
gcgcgcttgg	cntaatcatg	gtcatanctn	tttctgtgtg	gaaattgtta	tccgctcaca	540
attccacaca	acatacganc	cggaacata	aantgtaaac	ctgggggtgcc	taatgantga	600
ctaactcaca	ttaattgcgt	tgcgctcact	gcccgccttc	caatcnggaa	acctgtcttg	660
ccncttgcat	tnatgaatcn	gccaaccccc	ggggaaaagc	gtttgcgttt	tgggcgctct	720
tccgcttctt	cnctcantta	ntccctncnc	tcggtcattc	cggctgcngc	aaaccgggtc	780
accnctcca	aaggggggtat	tccggtttcc	ccnaatccgg	gganancc		828

<210> 5

<211> 834

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(834)

<223> n = A,T,C or G

<400> 5

tttttttttt	tttttactga	tagatggaat	ttattaagct	tttcacatgt	gatagcacat	60
agtttttaatt	gcatccaaaag	tactaacaaa	aactctagca	atcaagaatg	gcagcatgtt	120
atttttataac	aatcaacacc	tgtggccttt	aaaatttggt	tttcataaga	taattttatac	180
tgaagttaaat	ctagccatgc	ttttaaaaaa	tgcttttaggt	cactccaagc	ttggcagtta	240
acattttggca	ttaaacaataa	taaaacaatc	acaattttaat	aaataacaaa	tacaacattg	300
tagggcataa	tcatatacag	tataaggaaa	aggtggtagt	gttgagtaag	cagttattag	360
aatagaatac	cttggcctct	atgcaaatat	gtctagacac	tttgattcac	tcagccctga	420
cattcagttt	tcaaagtagg	agacagggtc	tacagtatca	ttttacagtt	tccaacacat	480
tgaaaacaag	tagaaaatga	tgagttgatt	tttattaatg	cattacatcc	tcaagagtta	540
tcaccaaccc	ctcagttata	aaaaattttc	aagttatatt	agtcataata	cttggtgtgc	600
ttatttttaa	ttagtgtctaa	atggattaag	tgaagacaac	aatggtcccc	taatgtgatt	660
gattttggtc	atttttacca	gcttctaaat	ctnaactttc	aggcttttga	actggaacat	720
tgnatnacag	tggttccanag	tttcaaccta	ctggaacatt	acagtgtgct	tgattcaaaa	780
tggtattttg	ttaaaaatta	aattttaacc	tggtggaaaa	ataatttgaa	atna	834

<210> 6

<211> 818

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(818)

<223> n = A,T,C or G

&lt;400&gt; 6

tttttttttt	tttttttttt	aagacctca	tcaatagatg	gagacatata	gaaatagtca	60
aaccacatct	acaaaatgcc	agtatcaggc	ggcggcttcg	aagccaaagt	gatgtttgga	120
tgtaaagtga	aatattagtt	ggcggatgaa	gcagatagtg	aggaaagttg	agccaataat	180
gacgtgaagt	ccgtggaagc	ctgtggctac	aaaaaatgtt	gagccgtaga	tgccgtcgga	240
aatggtgaag	ggagactcga	agtactctga	ggctttagtg	agggtaaaat	agagacccag	300
taaaattgta	ataagcagtg	cttgaattat	ttggtttcgg	ttgttttcta	ttagactatg	360
gtgagctcag	gtgattgata	ctcctgatgc	gagtaatacg	gatgtgttta	ggagtggggac	420
ttctagggga	tttagcgggg	tgatgcctgt	tggggggccag	tgccctccta	gttgggggggt	480
aggggctagg	ctggagtggg	aaaaggctca	gaaaaatcct	gcgaagaaaa	aaacttctga	540
ggtaataaat	aggattatcc	cgtatcgaag	gccttttttg	acaggtgggtg	tgtggtggcc	600
ttggtatgtg	ctttctcgtg	ttacatcgcg	ccatcattgg	tatatgggta	gtgtgttggg	660
ttantangg	ctantatgaa	gaacttttgg	antggaatta	aatcaatngc	ttggccggaa	720
gtcattanga	nggctnaaaa	ggcctgttta	ngggtctggg	ctnggtttta	cccnacccat	780
ggaatncnc	ccccggacna	ntgnatccct	attcttaa			818

&lt;210&gt; 7

&lt;211&gt; 817

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(817)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 7

tttttttttt	tttttttttt	tggtctctaga	gggggtagag	ggggtgctat	agggtaaata	60
cgggccctat	ttcaaagatt	tttaggggaa	ttaattctag	gacgatgggt	atgaaactgt	120
ggtttgctcc	acagatttca	gagcattgac	cgtagtatac	ccccggtcgt	gtagcgggta	180
aagtggtttg	gttttagacgt	ccgggaattg	catctgtttt	taagcctaata	gtggggacag	240
ctcatgagtg	caagacgtct	tgtgatgtaa	ttattatacn	aatgggggct	tcaatcggga	300
gtactactcg	attgtcaacg	tcaaggagtc	gcaggtcgcc	tggttctagg	aataatgggg	360
gaagtatgta	ggaattgaag	attaatccgc	cgtagtcggg	gttctcctag	gttcaatacc	420
attgggtggc	aattgatttg	atggtaaggg	gagggatcgt	tgaactcgtc	tgttatgtaa	480
aggatncctt	ngggatggga	aggcnatnaa	ggactangga	tnaatggcgg	gcangatatt	540
tcaaacngtc	tctanttcct	gaaacgtctg	aaatgttaat	aanaattaan	tttngttatt	600
gaatnttng	gaaaagggct	tacaggacta	gaaaccaaata	angaaaanta	atnntaangg	660
cnttatcntn	aaaggtnata	accnctccta	tnatccacc	caatngnatt	ccccacncnn	720
acnattggat	nccccanttc	canaaanggc	onccccccgg	tgnannccnc	cttttgttcc	780
cttnantgan	ggttattenc	ccctngcntt	atcancc			817

&lt;210&gt; 8

&lt;211&gt; 799

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(799)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 8

catttccggg	tttactttct	aaggaaagcc	gagcggaagc	tgctaacgtg	ggaatcgggtg	60
cataaggaga	actttctgct	ggcacgcgct	agggacaagc	gggagagcga	ctccgagcgt	120
ctgaagcgca	cgtcccagaa	ggtggacttg	gcaactgaaac	agctgggaca	catccgcgag	180
tacgaacagc	gocgtgaaagt	gctggagcgg	gaggtccagc	agtgtagccc	cgtcctgggg	240

tggttgcccg	angcctganc	cgtctctgect	tgctgcccc	angtgggccg	ccaccccctg	300
acctgcctgy	gtccaaacac	tgagccctgc	tggtgggactt	caagganaac	ccccacangg	360
ggattttgct	cctanantaa	ggctcatctg	ggcctcggcc	ccccacactg	gttggccttg	420
tctttgangt	gagccccatg	tccatctggg	ccactgtcng	gaccaccttt	ngggagtgtt	480
ctccttacaa	ccacannatg	ccgggtcctt	cccggaaacc	antccancc	tgngaaggat	540
caagnccctgn	atccactnnt	netanaaccg	gccnccnccg	cngtgggaacc	cnccttntgt	600
tccttttctt	tnagggttaa	tnnccgcttg	gccttnccan	ngtccctncnc	nttttccnnt	660
gttnaaattg	ttangcnccc	nccnntcccn	cnnccnnan	cccgaaccnn	annttnnann	720
ncctgggggt	nccnncgat	tgaccncc	nccctntant	tgcnttnggg	nncnntgccc	780
ctttccctct	nggganncg					799

&lt;210&gt; 9

&lt;211&gt; 801

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(801)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 9

acgccttgat	cctcccagge	tggtgactggt	tctgggagga	gccgggcatg	ctgtggtttg	60
taangatgac	actcccaaag	gtggtcctga	cagtggccca	gatggacatg	gggtcacct	120
caaggacaag	gccaccaggt	gcgggggccc	aagcccacat	gacccctact	ctatgagcaa	180
aatcccctgt	gggggcttct	ccttgaagtc	cgccancagg	gctcagtctt	tggaaccang	240
caggtcatgg	gggtgtngnc	caactggggg	ccncaacgca	aaanggcnc	gggcctcngn	300
cacccatccc	angacgcggc	tacactnctg	gacctccnc	tccaccactt	tcatgcgctg	360
ttcntaccg	cgnatntgtc	ccanctgttt	cngtgcenac	tccancttct	nggacgtgcg	420
ctacatacgc	ccggantcnc	netcccgttt	tgccctatc	cacgtncan	caacaaattt	480
cncctantg	caccnattec	cacttttnc	agntttccnc	nncgngcttc	cttntaaaag	540
ggttganccc	cggaaaatnc	cccaaagggg	gggggcccng	tacccaactn	ccccctnata	600
gctgaanccc	ccatnaccnn	gnctcnatgg	ancntccnt	tttaannacn	ttctnaactt	660
gggaanancc	ctcgnccntn	ccccnttaa	tccncccttg	cnangnncnt	ccccnntcc	720
ncccnntng	gcntntnann	cnaaaaagge	ccnnnancaa	tctcctnncn	cctcanttcg	780
ccanccctcg	aatcggccn	c				801

&lt;210&gt; 10

&lt;211&gt; 789

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(789)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 10

cagtctatnt	ggccagtggt	gcagctttcc	ctgtggctgc	cggtgccaca	tgctgtccc	60
acagtgtggc	cgtggtgaca	gcttcagccg	ccctcaccgg	gttcaccttc	tcagccctgc	120
agatccctgc	ctacacactg	gcctccctct	accaccggga	gaagcaggtg	ttcctgcccc	180
aataccgagg	ggacactgga	ggtgctagca	gtgaggacag	cctgatgacc	agcttcctgc	240
caggccctaa	gcctggagct	cccttcctta	atggacacgt	gggtgctgga	ggcagtgccc	300
tgctccacc	tccaccgcg	ctctgcgggg	cctctgcctg	tgatgtctcc	gtacgtgtgg	360
tggtgggtga	gccaccgan	gccagggtgg	ttccgggccc	gggcatctgc	ctggacctcg	420
ccatccctga	tagtgcttcc	tgctgtccca	ngtgcccca	tccctgttta	tggtgtccat	480
tgtccagctc	agccagctct	tcactgccta	tatggtgtct	gccgcaggcc	tggtgtcggg	540
cccatttact	ttgctacaca	ggtantattt	gacaagaacg	anttgcccaa	atactcagcg	600

ttaaaaaatt	ccagcaacat	tgggggtgga	aggcctgcct	cactgggtcc	aactccccgc	660
tcctgttaac	cccatggggc	tgccggcttg	gccgccaatt	tctgttgctg	ccaaantnat	720
gtggtctctc	gctgccacct	gttgctggct	gaagtgcnta	cngcncanct	nggggggtng	780
ggngttccc						789

<210> 11  
 <211> 772  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(772)  
 <223> n = A,T,C or G

<400> 11						
ccccacctac	ccaaatatta	gacaccaaca	cagaaaagct	agcaatggat	tcccttctac	60
tttgttaaat	aaataagtta	aatatTTTaaa	tgccctgtgc	tctgtgatgg	caacagaagg	120
accaacaggc	cacatcctga	taaaaggtaa	gaggggggtg	gatcagcaaa	aagacagtgc	180
tgtgggctga	ggggacctgg	ttcttgtgtg	ttgccccctca	ggactcttcc	cctacaaata	240
actttcatat	gttcaaattcc	catggaggag	tgtttcatcc	tagaaactcc	catgcaagag	300
ctacattaaa	cgaagctgca	ggttaagggg	cttanagatg	ggaaaccagg	tgactgagtt	360
tattcagctc	ccaaaaaccc	ttctctaggt	gtgtctcaac	taggaggcta	gctgttaacc	420
ctgagcctgg	gtaatccacc	tgcaagatcc	ccgcattcca	gtgcatggaa	cccttctggc	480
ctccctgtat	aagtccagac	tgaaaccccc	ttggaaggnc	tccagtcagg	cagccctana	540
aaactgggaa	aaaagaaaag	gacgccccan	ccccagctg	tgcanctacg	cacctcaaca	600
gcacaggggtg	gcagcaaaaa	aaccacttta	ctttggcaca	aacaaaaact	ngggggggca	660
accccggcac	cccnangggg	gttaacagga	ancngggnaa	cntggaaccc	aattnaggca	720
ggcccnccac	ccnaatntt	gctgggaaat	ttttcctccc	ctaaattntt	tc	772

<210> 12  
 <211> 751  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(751)  
 <223> n = A,T,C or G

<400> 12						
gccccaatc	cagctgccac	accaccacg	gtgactgcat	tagttcggat	gtcatacaaa	60
agctgattga	agcaaccctc	tacttttttg	tcgtgagcct	tttgcttggg	gcaggtttca	120
ttggctgtgt	tggtgacgtt	gtcattgcaa	cagaatgggg	gaaaggcact	gttctctttg	180
aagtanggtg	agtcctcaaa	atccgtatag	ttggtgaagc	cacagcactt	gagccctttc	240
atggtggtgt	tccacacttg	agtgaagtct	tcctgggaac	cataatcttt	cttgatggca	300
ggcactacca	gcaacgtcag	ggaagtgtc	agccattgtg	gtgtacacca	aggcgaccac	360
agcagctgcn	acctcagcaa	tgaagatgan	gaggangatg	aagaagaacg	tcnccaggggc	420
acacttgctc	tcagtcttan	caccatanca	gcccntgaaa	accaananca	aagaccacna	480
cnccggctgc	gatgaagaaa	tnaccccneg	ttgacaaaact	tgcatggcac	tggganccac	540
agtggccnca	aaaatcttca	aaaaggatgc	cccactnatt	gaccccccaa	atgccactg	600
ccaacagggg	ctgccccacn	cncnnaacga	tgancnatt	gnacaagatc	tncntggtct	660
tnatnaacnt	gaaccctgcn	tngtggctcc	tgttcaggnc	cnnggcctga	cttctnaann	720
aangaactcn	gaagncccca	cngganannc	g			751

<210> 13  
 <211> 729  
 <212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(729)

<223> n = A,T,C or G

<400> 13

gagccaggcg	tcctctgcc	tgcccactca	gtggcaacac	ccgggagctg	ttttgtcctt	60
tgtggancct	cagcagtncc	ctctttcaga	actcantgcc	aagancctg	aacaggagcc	120
accatgcagt	gcttcagctt	cattaagacc	atgatgatcc	tcttcaattt	gctcatcttt	180
ctgtgtggtg	cagccctggt	ggcagtgggc	atctgggtgt	caatcgatgg	ggcatccttt	240
ctgaagatct	tcgggccact	gtcgtccagt	gccatgcagt	ttgtcaacgt	gggctacttc	300
ctcatcgagc	ccggcggtgt	ggtcttagct	ctagggttcc	tgggctgcta	tggtgctaag	360
actgagagca	agtgtgccct	cgtgacgttc	ttcttcatcc	tcctcctcat	cttcattgct	420
gaggttgcaa	tgtgtggtc	gccttggtgt	acaccacaat	ggctgagcac	ttcctgacgt	480
tgtctgtaat	gcctgccatc	aanaaaagat	tatgggttcc	caggaanact	tcactcaagt	540
gttggaacac	caccatgaaa	gggctcaagt	gctgtggctt	cnnccaacta	tacggatttt	600
gaagantcac	ctacttcaaa	gaaaanagtg	cctttccccc	atttctgttg	caattgacaa	660
acgtccccaa	cacagccaat	tgaaaacctg	cacccaaccc	aaanggtcc	ccaaccanaa	720
attnaaggg						729

<210> 14

<211> 816

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(816)

<223> n = A,T,C or G

<400> 14

tgtctttcct	caaagttggt	cttgttgcca	taacaaccac	cataggtaaa	gcggggcgag	60
tgttcgctga	aggggttgta	gtaccagcgc	gggatgctct	ccttgagag	tcctgtgtct	120
ggcaggtcca	cgcagtgcc	tttgtcactg	gggaaatgga	tgcgtggag	ctcgtcaaag	180
ccactcgtgt	atttttcaca	ggcagcctcg	tccgacgcgt	cggggcagtt	gggggtgtct	240
tcacactcca	ggaaactgtc	natgcagcag	ccattgctgc	agcggaaactg	ggtgggctga	300
cangtgccag	agcacactgg	atggcgctt	tccatgnnan	gggccctgng	ggaaagtccc	360
tganccccan	anctgcctct	caaangcccc	accttgcaaa	ccccgacagg	ctagaatgga	420
atctttcttc	cgaaaggtag	ttntttctgt	tgcccaancc	anccccntaa	acaaactctt	480
gcanatctgc	tcgngggggg	tctantacc	ancgtgggaa	aagaacccca	ggcngcgaa	540
caancttggt	tggatncgaa	gcnataatct	nctnttctgc	ttggtggaca	gcaccantna	600
ctgtnnanct	ttagnccntg	gtcctcntgg	ggtgnncttg	aacctaatcn	ccnntcaact	660
gggacaaggt	aantngccnt	cctttnaatt	cccnancntn	ccccctggtt	tgggggtttt	720
cncnctcta	ccccagaaan	nccgtgttcc	cccccaacta	ggggccnaaa	ccnntnttcc	780
cacaacctn	ccccacccac	gggttcngnt	ggttng			816

<210> 15

<211> 783

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(783)

<223> n = A,T,C or G

&lt;400&gt; 15

ccaaggcctg	ggcaggcata	nacttgaagg	tacaacccca	ggaacccctg	gtgctgaagg	60
atgtgaaaaa	cacagattgg	cgctactgc	gggtgacac	ggatgtcagg	gtagagagga	120
aagacccaaa	ccaggtggaa	ctgtggggac	tcaaggaang	cacctacctg	ttccagctga	180
cagtgactag	ctcagaccac	ccagaggaca	cgccaacgt	cacagtcact	gtgctgtcca	240
ccaagcagac	agaagactac	tgcctcgcat	ccaacaangt	gggtcgctgc	cggggctctt	300
tcccacgctg	gtactatgac	cccacggagc	agatctgcaa	gagtttcgtt	tatggaggct	360
gcttgggcaa	caagaacaac	taccttcggg	aagaagagtg	cattctancc	tgtcnggggtg	420
tgcaagggtg	gcctttgana	ngcanctctg	gggtcangc	gactttcccc	cagggccctt	480
ccatggaaag	gcgccatcca	ntgttctctg	gcacctgtca	gcccacccag	ttccgctgca	540
ncaatggctg	ctgcacnac	antttcctng	aattgtgaca	acacccccc	ntgcccccaa	600
ccctcccaac	aaagcttccc	tgttnaaaaa	tacnccantt	ggcttttnac	aaacncccg	660
cncctcctnt	ttcccnntn	aacaaagggc	nctngccttt	gaactgccn	aaccnnggaa	720
tctnccnngg	aaaaantncc	ccccctggtt	cctnnaancc	cctccncaaa	anctncccc	780
ccc						783

&lt;210&gt; 16

&lt;211&gt; 801

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(801)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 16

gcccccaattc	cagctgccac	accacccacg	gtgactgcat	tagttcggat	gtcatacaaa	60
agctgattga	agcaaccctc	tacttttttg	tcgtgagcct	tttgcttggg	gcagggtttca	120
ttggctgtgt	tggtgacgtt	gtcattgcaa	cagaatgggg	gaaaggcact	gttctctttg	180
aagtaggggtg	agtcctcaaa	atccgtatag	ttggtgaagc	cacagcactt	gagccctttc	240
atggtgggtg	tccacacttg	agtgaagtct	tcctgggaac	cataatcttt	cttgatggca	300
ggcactacca	gcaacgtcag	gaagtgtca	gccattgttg	tgtacacca	ggcgaccaca	360
gcagctgcaa	cctcagcaat	gaagatgagg	aggaggatga	agaagaacgt	cncgagggca	420
cacttgctct	ccgtcttagc	accatagcag	cccangaaac	caagagcaaa	gaccacaacg	480
ccngctgcga	atgaaagaaa	ntacccacgt	tgacaaactg	catggccact	ggaogacagt	540
tggcccgaaan	atcttcagaa	aagggatgcc	ccatcgattg	aacacccana	tgccactgc	600
cnacagggct	gcncncncn	gaaagaatga	gccattgaag	aaggatcntc	ntggtcttaa	660
tgaactgaaa	ccntgcatgg	tggccctgt	tcagggctct	tggcagtga	ttctganaaa	720
aaggaacngc	ntnagcccc	caaangana	aaacaccccc	gggtgttgcc	ctgaattggc	780
ggccaaggan	ccctgccccn	g				801

&lt;210&gt; 17

&lt;211&gt; 740

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(740)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 17

gtgagagcca	ggcgtccctc	tgcctgccca	ctcagtggca	acacccggga	gctgttttgt	60
cctttgtgga	gcctcagcag	ttccctcttt	cagaactcac	tgccaagagc	cctgaacagg	120
agccaccatg	cagtgttca	gcttcattaa	gaccatgatg	atcctcttca	atttgctcat	180
ctttctgtgt	ggtgcagccc	tgttggcagt	gggcatctgg	gtgtcaatcg	atggggcatc	240
ctttctgaag	atcttcgggc	cactgtcgtc	cagtgccatg	cagtttgtca	acgtgggcta	300

cttcctcatc	gcagccggcg	ttgtggtctt	tgctcttggg	ttcctgggct	gctatgggtgc	360
taagacggag	agcaagtgtg	ccctcgtgac	gttcttcttc	atcctcctcc	tcattcttcat	420
tgctgaagtt	gcagctgctg	tggtcgcctt	gggtgtacacc	acaatggctg	aaccatttct	480
gacgttgctg	gtantgcctg	ccatcaanaa	agattatggg	ttcccaggaa	aaattcactc	540
aantntggaa	caccnccatg	aaaagggctc	caattttctgn	tggtctcccc	aactataccg	600
gaattttgaa	agantcnccc	tacttccaaa	aaaaaanant	tgcttttnc	ccntttctgt	660
tgcaatgaaa	acntcccaan	acngccaatn	aaaacctgcc	cnnncaaaaa	ggntcncaaa	720
caaaaaaant	nnaagggttn					740

&lt;210&gt; 18

&lt;211&gt; 802

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(802)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 18

ccgctgggtg	cgctgggtcca	gnagnagccac	gaagcacgtc	agcatacaca	gcctcaatca	60
caaggtcttc	cagctgccgc	acattacgca	gggcaagagc	ctccagcaac	actgcatatg	120
ggatacactt	tacttttagca	gccagggtga	caactgagag	gtgtcgaagc	ttattcttct	180
gagcctctgt	tagtggagga	agattccggg	cttcagctaa	gtagtcagcg	tatgtcccat	240
aagcaaacac	tgtgagcagc	cggaaggtag	aggcaaaagc	actctcagcc	agctctctaa	300
cattgggcat	gtccagcagt	tctccaaaaca	cgtagacacc	agnngcctcc	agcacctgat	360
ggatgagtgt	ggccagcgct	gcccccttgg	ccgacttggc	taggagcaga	aattgctcct	420
ggttctgccc	tgtcaccttc	acttccgcac	tcactactgc	actgagtgtg	ggggacttgg	480
gtcaggatg	tccagagacg	tggttccgcc	ccctcnctta	atgacaccgn	ccanncaacc	540
gtcggctccc	gccgantgng	ttcgctcgtnc	ctgggtcagg	gtctgctggc	cnctacttgc	600
aancttcgtc	nggcccattg	aattcacccn	accggaactn	gtangatcca	ctnnttctat	660
aaccggnccg	caccgcnnt	ggaactccac	tcttnttnc	tttacttgag	ggttaaggct	720
acccttnnccg	ttaccttggg	ccaaaccntn	ccntgtgtcg	anatngtnaa	tcnggncna	780
tnccancnc	atangaagcc	ng				802

&lt;210&gt; 19

&lt;211&gt; 731

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(731)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 19

cnaagcttcc	aggtnacggg	ccgcnaancc	tgaccenagg	tancanaang	cagnncngcgg	60
gagcccaccg	tcacngngng	gngtctttat	nggagggggc	ggagccacat	cnctggacnt	120
cntgacccca	actccccncc	ncncantgca	gtgatgagtg	cagaactgaa	ggtnacgtgg	180
caggaaccaa	gancaaannc	tgtctcnntc	caagtcggcn	nagggggcgg	ggctggccac	240
gncatccnt	cnagtgtctgn	aaagccccnn	cctgtctact	tgtttggaga	acngcnnnnga	300
catgcccagn	gttanataac	nggcngagag	tnantttgcc	tctcccttcc	ggctgcgcgn	360
cngntntgct	tagnggacat	aacctgacta	cttaactgaa	cccnngaate	tnccnccct	420
ccactaagct	cagaacaaaa	aacttcgaca	ccactcantt	gtcacctgnc	tgctcaagta	480
aagtgtaccc	catncccaat	gtntgctnga	ngctctgncc	tgcnttangt	tcggctcctgg	540
gaagacctat	caattnaagc	tatgtttctg	actgcctctt	gctccctgna	acaancnacc	600
cnncnntcca	agggggggnc	ggcccccaat	cccccaacc	ntnaattnan	tttancccn	660
cccccnngcc	cggcctttta	cnanctcnn	nnacnnggna	aaaccnnngc	tttncccaac	720



nnaatccncc t

731

<210> 20  
 <211> 754  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (1)...(754)  
 <223> n = A,T,C or G

<400> 20  
 tttttttttt tttttttttt taaaaaaccct ctcatttnaa tgnaaacttc cgaaattgtc 60  
 caacccccctc ntccaaatnn ccntttccgg gnggggggttc caaacccaan ttanntttgg 120  
 annntaaatt aaatnttntt tggnggnnna anccnaatgt nangaaagtt naaccacanta 180  
 tnancttnaa tncctggaaa ccngtngntt ccaaaaaatnt ttaaccctta antccctccg 240  
 aaatngttna nggaaaaccct aantttctent aaggttgttt gaaggntnaa tnaaaanccc 300  
 nnccaattgt ttttngccac gcctgaatta attggnntcc gntgttttcc nttaaaanaa 360  
 ggnnancccc ggttantnaa tccccccnnc cccaattata ccganttttt ttngaattgg 420  
 ganccnccgg gaattaacgg ggnnnntccc tnttgggggg cnggnncccc cccctccggg 480  
 ggttngggnc aggnccnaat tgtttaaggg tccgaaaaat ccctccnaga aaaaaanctc 540  
 ccaggntgag nntnggggtt nccccccccc cangggccct ctcgnanagt tgggggttgg 600  
 ggggcctggg attttntttc ccctnttnc tccccccccc ccnggganag aggttngngt 660  
 tttgntcnc ggccccnccn aaganctttn ccganttnan ttaaatccnt gcctnggcga 720  
 agtccnttgn agggntaaan ggccccctnn cggt 754

<210> 21  
 <211> 755  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (1)...(755)  
 <223> n = A,T,C or G

<400> 21  
 atcancccat gaccccaaac nngggaccnc tcancgggnc nnnccnaccnc cggccnatca 60  
 nngtnagnnc actncnnttn natcacnccc cncnactac gcccnananc cnaagcncta 120  
 nncanatncc actganngcg cgangtngan ngagaaanct nataccanag ncaccanacn 180  
 ccagctgtcc nanaangcct nnnatacngg nnnatccaat ntgnancctc cnaagtattn 240  
 nncnccanac gattttcctn anccgattac ccntncccc tanccctcc ccccaacna 300  
 cgaaggcnc ggnccnaagg nngcgnccc ccgctagntc cccncaagt cncncccta 360  
 aactcancn nattaacngc ttctgagta tcaactcccc aatctcacc tactcaactc 420  
 aaaaanacn gatacaaat aatncaagcc tgnttatnac actntgactg ggtctctatt 480  
 ttagnggtcc ntnaancntc ctaatacttc cagtctncc tcnccaattt ccnaanggct 540  
 ctttngaca gcatntttt gttcccnntt gggttcttan ngaattgcc ttctntgaac 600  
 gggctcctt tttccttcgg ttanccctgn ttcnccggc cagttattat ttcccntttt 660  
 aaattcctnc cntttanttt tggcnttca aacccccggc cttgaaaacg gccccctggt 720  
 aaaaggttgt tttganaaaa ttttggtttt gttcc 755

<210> 22  
 <211> 849  
 <212> DNA  
 <213> Homo sapien  
 <220>

<221> misc\_feature  
 <222> (1)...(849)  
 <223> n = A,T,C or G

<400> 22  
 tttttttttt tttttangtg tngtctgtgca ggtagaggct tactacaant gtgaanacgt 60  
 acgctnngan taangcgacc cganttctag gannncnccct aaaatcanac tgtgaagatn 120  
 atcctgnnna cggaanggtc accggnngat nntgctaggg tgneenctcc cannnenttn 180  
 cataacteng nggcectgcc caccaccttc ggcggcccng ngnceggggc cgggtcattn 240  
 gnnttaacen cactnngcna ncggtttccn nccccnnng accnnggcga tccgggggtnc 300  
 tctgtcttcc cctgnagncn anaaantggg ccnccgnccc ctttaccctt nnacaagcca 360  
 cngccnteta nccnngcccc cccctccant nngggggact gccnannigt ccgttinctng 420  
 nnaccccnnn gggtnccctcg gttgtcgant cnaccgnang ccanggattc cnaaggaagg 480  
 tgcgttnttg gcccctaccc ttcgctnccg nncacccttc ccgacnanga nccgctcccg 540  
 cncnncgnng cctcncctcg caacaccgcg nctentcngt nccggnnccc ccccacccgc 600  
 nccctcncnc ngngcnancn ctccnccncc gtctcannca ccaccccgcc ccgccaggcc 660  
 ntcanccacn ggnngacnng nagnncnntc gcnccegcgn gdcnccctt ccgcnngaa 720  
 ctncntcngg ccantnncgc tcaancnna cnaaacgcg ctgcgcggcc cgnagcgnc 780  
 ncctccncca gtccctcccg ctcccnacc angnttccn cgaggacacn nnaccccgcc 840  
 nncangcgg 849

<210> 23  
 <211> 872  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(872)  
 <223> n = A,T,C or G

<400> 23  
 gcgcaaaacta tacttcgctc gnactcgtgc gcctcgtcnc tcttttcctc cgcaaccatg 60  
 tctgacnanc ccgattnggc ngatatcnan aagntcganc agtccaaact gantaacaca 120  
 cacacnncan aganaaatcc nctgccttcc anagtancn attgaacnng agaaccangc 180  
 nggcgaatcg taatnaggcg tgcgcgcga atntgtcncc gtttattntn ccagcntcnc 240  
 ctncncccc tacntcttcn nagctgtcnn acccctngtn cgnaccccc naggtcggga 300  
 tcgggttttn nntgaccngg cnnccccctc cccntccat nacganccnc ccgcaccacc 360  
 nanngcncgc nccccgnnct cttcgccncc ctgtcctntn cccctgtngc ctggcnngn 420  
 accgcattga cctcgcgnn ctncnngaaa ncnanacgt ccgggttggn annancgctg 480  
 tgggnnngcg tctgcncgc gtctcttcn ncncttcca ccattctnt tacngggtct 540  
 ccncgcctc tcnncacnc cctgggacgc tntcctntgc ccccttnac tccccctt 600  
 cgnctgncc cgnccccacc ntcatttnca nacgntcttc acaannncc ggntnncctc 660  
 cnancnngcn gtcancnag ggaagggng ggnccnntg nttgacgttg ngngangtc 720  
 cgaanantcc tcnccntcan cctacccct cgggcgnnct ctngttncc aacttancaa 780  
 ntctcccccg ngngcncntc tcagcctcnc cncccnct ctctgcantg tntctgctc 840  
 tnaccnntac gantnttcgn cncctcttt cc 872

<210> 24  
 <211> 815  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(815)  
 <223> n = A,T,C or G

## &lt;400&gt; 24

gcatgcaagc	ttgagtattc	tatagngtca	cctaaatanc	ttggcntaat	catgggtcnta	60
nctgncttcc	tgtgtcaa	gtatacnaa	tanatatgaa	tctnatntga	caaganngta	120
tcntncatta	gtaacaantg	tnntgtccat	cctgtcngan	canattccca	tnnattncgn	180
cgcattcncn	gcncantatn	taatngggaa	ntcnntnnn	ncaccnncat	ctatcntncc	240
gcncctgac	tggnagagat	ggatnanttc	tnntntgacc	nacatgttca	tcttggattn	300
aanancccc	cgcngnccac	cgggtngnng	cnagecnntc	ccaagacctc	ctgtggaggt	360
aacctgcgtc	aganncatca	aacntgggaa	acccgcnncc	angtnnaagt	ngnnncanan	420
gatcccgtcc	aggnttnacc	atcccttcnc	agcgccecc	ttngtgcctt	anagnnagc	480
gtgtccnanc	cnctcaacat	ganacgcgcc	agnccanccg	caattnggca	caatgtcgnc	540
gaaccccc	gggggantna	tncaaanccc	caggattgtc	cncncangaa	atcccnanc	600
ccnccctac	ccncttttgg	gacngtgacc	aantcccga	gtncagtc	ggcngnctc	660
ccccaccggt	nnccntgggg	gggtgaanct	cnmntcanc	cnngcgaggn	ntcgnaagga	720
accggncctn	ggncgaanng	ancnntcnga	agnccnct	cgtataacc	cccctcncca	780
ncnncngnt	agntcccccc	cngggtnccg	aangg			815

## &lt;210&gt; 25

&lt;211&gt; 775

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(775)

&lt;223&gt; n = A,T,C or G

## &lt;400&gt; 25

ccgagatgtc	tcgctccgtg	gccttagctg	tgctcgcgt	actctctctt	tctggcctgg	60
aggctatcca	gcgtactcca	aagattcagg	tttactcacg	tcattccagca	gagaatggaa	120
agtcaaat	cctgaattgc	tatgtgtctg	ggtttcaccc	atccgacatt	gaanttgc	180
tactgaagaa	tgganagaga	attgaaaaag	tgagcattc	agacttgtct	ttcagcaagg	240
actggctctt	ctatctcntg	tactacactg	aattcacccc	cactgaaaaa	gatgagtatg	300
cctgccgtgt	gaaccatgtg	actttgtcac	agcccaagat	agttaagtgg	gatcgagaca	360
tgtaagcagn	cnncatggaa	gtttgaagat	gccgcatttg	gattggatga	attccaaatt	420
ctgcttgctt	gcntttta	antgatatgc	ntatacaccc	taccctttat	gnccccc	480
tgtaggggtt	acatnantgt	tcnctntngga	catgatcttc	ctttataant	ccnccnttcg	540
aattgcccgt	cncccngttn	ngaattgttc	cnnaaccacg	gttggctccc	ccaggctncc	600
tcttacggaa	gggcctgggc	cnctttnc	gggtggggga	accnaaaatt	tcnctnttgc	660
ccncccncca	cnntcttng	nnncanttt	ggaacccttc	cnattccctt	tggcctcnna	720
nccttnncta	anaaaacttn	aaancgtngc	naaanntttt	acttcccccc	ttacc	775

## &lt;210&gt; 26

&lt;211&gt; 820

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(820)

&lt;223&gt; n = A,T,C or G

## &lt;400&gt; 26

anattantac	agtgtaatct	tttcccagag	gtgtgtanag	ggaacggggc	ctagaggcat	60
cccanagata	ncttatanca	acagtgtctt	gaccaagagc	tgctgggcac	atttcctgca	120
gaaaagggtg	cgttccccat	cactcctcct	ctcccatagc	catcccagag	gggtgagtag	180
ccatcangcc	ttcgttggga	gggagtcang	gaaacaacan	accacagagc	anacagacca	240
ntgatgacca	tgggcgggag	cgagcctctt	ccctgnaccg	gggtggcana	nganagccta	300
nctgaggggt	cacactataa	acgttaacga	ccnagatnan	cacctgcttc	aagtgcaccc	360

ttcctacctg	acnaccagng	accnnaact	gngcctggg	gacagcctg	ggancagcta	420
acnnagcaact	cacctgcccc	cccatggccg	tnccgntccc	tggtcctgnc	aaggggaagct	480
ccctgttgga	attncgggga	naccaaggga	nccccctcct	ccanctgtga	aggaaaaann	540
gatggaattt	tncccttccg	gccnntcccc	tcttcttcta	cacgccccct	ntactctntc	600
tccctctntt	ntcctgmenc	acttttnacc	ccnnnatttc	ccttnattga	tcggannctn	660
ganattccac	tnnccgctnc	cntcnatcng	naanacnaaa	nactntctna	cccnggggat	720
gggnncctcg	ntcatectct	ctttttcnct	accnccnntt	ctttgcctct	ccttngatca	780
tccaaccntc	gntggccntn	ccccccnnn	tcctttncce			820

&lt;210&gt; 27

&lt;211&gt; 818

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(818)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 27

tctgggtgat	ggcctcttcc	tcttcagggg	cctctgactg	ctctgggcca	aagaatctct	60
tgtttcttct	ccgagcccca	ggcagcggtg	attcagccct	gcccacactg	attctgatga	120
ctgcggtatg	tgtgacggac	ccaaggggca	aataggggtc	caggggtccag	ggagggggcg	180
ctgctgagca	cttccgcgcc	tcacctgccc	cagccccctg	catgagctct	gggctgggtc	240
tccgcctcca	gggttctgct	cttccangca	ngccancaag	tggcgctggg	ccacactggc	300
ttcttctctg	cccntccctg	gctctganc	tctgtcttcc	tgctctgtgc	angcnccttg	360
gatctcagtt	tccctcnctc	anngaactct	gtttctgann	tcttcantta	actntgantt	420
tatnaccnan	tggnctgtnc	tgtcnnactt	taatgggccc	gaccggctaa	tccctccctc	480
netcccttcc	anttcnnnna	accngcttnc	cntctctctc	ccntancccg	ccnggggaanc	540
ctccttttgc	ctnaccangg	gccnnnaccg	cccnnnctn	ggggggcnnng	gtnnctnenc	600
ctgntnnccc	cnctcnctnt	tnctctgctc	cnnncnccgn	nngcannttc	ncngtccenn	660
tnnctcttcn	ngntnctgnaa	ngntcnctnt	tnnnnngnnc	ngntnntnnc	tccctctenc	720
cnnntgnang	tnnttnnnnc	ncngnncccc	nnnnccnnnn	nggnntnnnn	tctnncnngc	780
cccncccccc	ngnattaagg	cctccnntct	ccggccnc			818

&lt;210&gt; 28

&lt;211&gt; 731

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(731)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 28

aggaagggcg	gagggatatt	gtanggggatt	gagggatagg	agnataangg	gggaggtgtg	60
tcccaacatg	anggtgnngt	tctcttttga	angaggggtg	ngtttttann	ccnggtgggt	120
gattnaaccc	cattgtatgg	agnnaaaggn	tttnagggat	ttttcggctc	ttatcagtat	180
ntanattcct	gtnaatcgga	aatnatntt	tcnnccngga	aatnttgctc	ccatccgnaa	240
attnctcccg	ggtagtgcat	nttngggggg	cngccangtt	tcccaggctg	ctanaatcgt	300
actaaagntt	naagtgggan	tncaaataaa	aacctnncac	agagnatccn	taccogactg	360
tnnnttncct	tcgcccctng	actctgcnnng	agcccaatac	ccnngnngnat	gtcncccnng	420
nnngcgnenc	tgaaannnnnc	tcngggctnn	gancatcang	gggtttcgca	tcaaaagcnn	480
cgtttcncat	naaggcaactt	tngcctcatc	caaccnctng	ccctcnccca	tttngccgtc	540
nggttcncct	acgctnntng	cncctnnntn	ganattttnc	ccgcctnggg	naancctcct	600
gnaatgggta	gggncttntc	ttttnacenn	gnggtntact	aatcnctnc	acgentnctt	660
tctcnacccc	cccccttttt	caatcccanc	ggcnaatggg	gtctccccnn	cgangggggg	720

nnncccannc c

731

<210> 29  
 <211> 822  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(822)  
 <223> n = A,T,C or G

<400> 29  
 actagtccag tgtgggtggaa ttccattgtg ttgggggncc ttctatgant antnttagat 60  
 cgctcanacc tcacancctc ccnaccnangc ctataangaa nannaataga nctgtncnnt 120  
 atntntacnc tcatanncct cnnaccacac tccctcttaa cccntactgt gcctatngcn 180  
 tnnctantct ntggcgccctn cnanccaccn gtggggccnac cncnngnatt ctcnatctcc 240  
 tcnccatntn gcctananta ngtncatacc ctataacctac nccaatgcta nnnctaancn 300  
 tccatnantt annntaacta ccaactgacnt ngactttcnc atnanctcct aatttgaatc 360  
 tactctgact cccacngcct annnattage ancntcccc nacnatntct caaccaaate 420  
 ntcaacaacc tatctanctg ttcnccaacc nttncctccg atccccnnac aacccccctc 480  
 ccaaataccc nccacctgac ncctaaccn caccatcccg gcaagccnan ggncatttan 540  
 ccaactggaat cacnatngga naaaaaaaac ccnaactctc tancncnnat ctccctaana 600  
 aatnctcctn naatttactn ncantnccat caanccacn tgaaacnnaa cccctgtttt 660  
 tanatccctt ctttcgaaaa ccnaccctt annncccaac ctttngggcc ccccnctnc 720  
 ccnaatgaag gncncccaat cnangaaacg nccntgaaaa ancnaggcna anannntccg 780  
 canatcctat cccttanttn ggggnccctt nccngggcc cc 822

<210> 30  
 <211> 787  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(787)  
 <223> n = A,T,C or G

<400> 30  
 cggcgcctg ctctggcaca tgccctcctga atggcatcaa aagtgatgga ctgcccattg 60  
 ctagagaaga ccttctctcc tactgtcatt atggagccct gcagactgag ggctcccctt 120  
 gtctgcagga tttgatgtct gaagtctgtg agtgtggctt ggagctcctc atctacatna 180  
 gctggaagcc ctggagggcc tctctcgcca gcctccccct tctctccacg ctctccangg 240  
 acaccagggg ctccaggcag cccattatc ccagnangac atgggtgttc tccacgcgga 300  
 cccatggggc ctgnaaggcc aggtgtcct ttgacaccat ctctcccgtc ctgcctggca 360  
 ggccgtggga tccactantt ctanaacggn cgccaccncg gtgggagctc cagcttttgt 420  
 tccnttaat gaaggttaat tgcncgcttg gcgtaatcat nggtcanaac tnttctctgt 480  
 gtgaaattgt ttntcccctc ncnattcnc ncnacatacn aaccgggaan cataaagtgt 540  
 taaagcctgg gggtngectn nngaanaac tnaactcaat taattgcgtt ggctcatggc 600  
 ccgctttccn ttcnngaaaa ctgtcntccc ctgcnttnt gaatcgcca ccccnnggg 660  
 aaaagcggtt tgcnttttng ggggntcctt ccncttcccc cctcnctaan cctncgcct 720  
 cggtcgttnc nggtngcggg gaangggnat nnnctccnc naagggggng agnnngntat 780  
 ccccaaa 822

<210> 31  
 <211> 799  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(799)  
 <223> n = A,T,C or G

<400> 31  
 tttttttttt tttttttggc gatgctactg ttttaattgca ggaggtgggg gtgtgtgtac 60  
 catgtaccag ggctattaga agcaagaagg aaggagggag ggcagagcgc cctgctgagc 120  
 aacaaaggac tcctgcagcc ttctctgtct gtctcttggc gcaggcacat ggggaggcct 180  
 cccgcagggt gggggccacc agtccagggg tgggagcact acanggggtg ggagtgggtg 240  
 gtggtggtn cnaatggcct gncacanatc cctacgattc ttgacacctg gatttcacca 300  
 ggggaccttc tgtttcccca nggnaacttc nttnatctcn aaagaacaca actgtttctt 360  
 cngcanttct ggctgttcat ggaaagcaca ggtgtccnat ttnggctggg acttggtaca 420  
 tatggttccg gccacctct cccntcnaaa aagtaattca ccccccccn cctctnttg 480  
 cctgggccct taantaccca caccggaact canttannta ttcatcttng gntgggcttg 540  
 ntnatcnccn cctgaangcg ccaagttgaa aggccacgcc gthcccnctc cccatagnan 600  
 nttttnnct canctaatagc cccccnggc aacnatccaa tcccccccn tgggggcccc 660  
 agcccanggc ccccgntctg ggnnnccngn cncgnantcc ccaggntctc ccantcngnc 720  
 ccnnngcncc cccgcacgca gaacanaagg ntngagccnc cgcannnnnn nggtnncnac 780  
 ctcgcccccc ccnnccngng 799

<210> 32  
 <211> 789  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(789)  
 <223> n = A,T,C or G

<400> 32  
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60  
 ttttnccnag ggcaggttta ttgacaacct cncgggacac aancaggctg gggacaggac 120  
 ggcaacaggc tccggcgggc gcggcgggcg ccctacctgc ggtaccaaata ntgcagcctc 180  
 cgctcccgt tgatnttccct ctgcagctgc aggatgccnt aaaacagggc ctgggccntn 240  
 ggtgggcacc ctgggatttn aatttcacag ggcacaatgc ggtcgcancc cctcaccacc 300  
 nattaggaat agtggtnnta ccnccnccg ttggcnact cccntggaa accacttntc 360  
 gcggctccg catctggctc taaaccttgc aaacnctggg gccctctttt tggttantnt 420  
 nccngccaca atcatnactc agactggcnc gggctggccc caaaaaancn ccccaaaacc 480  
 ggnccatgtc ttncgggggt tgctgcnatn tncatcacct cccgggcncn ncaggncaac 540  
 ccaaaagtgc ttngggcccn caaaaaanct ccggggggnc ccagtttcaa caaagtcac 600  
 ccccttggcc cccaaatcct cccccgntt nctgggtttg ggaacccacg cctctnnctt 660  
 tggnnggcaa gntggntccc ccttcgggccc cccgggtggc ccnctctaa ngaaaacncc 720  
 ntcctnnnca ccatcccccc nngnnacgnc tancaangna tccctttttt tanaaacggg 780  
 cccccnccg 789

<210> 33  
 <211> 793  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(793)  
 <223> n = A,T,C or G

&lt;400&gt; 33

gacagaacat	gttggatggt	ggagcacctt	tctatacgac	ttacaggaca	gcagatgggg	60
aattcatggc	tggttgagca	atanaacccc	agttctacga	gctgctgac	aaaggacttg	120
gactaaagtc	tgatgaactt	cccaatcaga	tgagcatgga	tgattggcca	gaaatgaana	180
agaagtttgc	agatgtat	gcaaagaaga	cgaaggcaga	gtggtgtcaa	atctttgacg	240
gcacagatgc	ctgtgtgact	cgggttctga	cttttgagga	ggttgttcat	catgatcaca	300
acaangaacg	gggctcgttt	atcaccantg	aggagcagga	cgtgagcccc	cgccctgcac	360
ctctgctgtt	aaacacccca	gccatccctt	ctttcaaaag	ggatccacta	cttctagagc	420
ggncgccacc	gcggtggagc	tccagctttt	gttcccttta	gtgagggtta	attgcgcgct	480
tggcgtaatc	atggtcatan	ctgtttcctg	tgtgaaattg	ttatccgctc	acaattccac	540
acaacatacg	anccggaagc	atnaaatttt	aaagcctggg	ggtngcctaa	tgantgaact	600
nactcacatt	aattggcttt	gcgctcactg	cccgttttcc	agtcgggaaa	acctgtcctt	660
gccagctgcc	nttaatgaat	cnggccaccc	cccggggaaa	aggcngtttg	cttnttgggg	720
cgcncctccc	gctttctcgc	ttcctgaant	ccttcccccc	ggtctttcgg	cttgcggcna	780
acggtatcna	cct					793

&lt;210&gt; 34

&lt;211&gt; 756

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(756)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 34

gccgcgaccg	gcatgtacga	gcaactcaag	ggcgagtggg	accgtaaaag	ccccaatctt	60
ancaagtgcg	gggaanagct	gggtcgactc	aagctagtgc	ttctggagct	caacttcttg	120
ccaaccacag	ggaccaagct	gaccaaacag	cagctaattc	tgccccgtga	catactggag	180
atcggggcc	aatggagcat	cctacgcaan	gacatcccc	ccttcgagcg	ctacatggcc	240
cagctcaaat	gctactactt	tgattacaan	gagcagctcc	ccgagtcagc	ctatatgcac	300
cagctcttgg	gcctcaacct	cctcttctctg	ctgtcccaga	accgggtggc	tgantnccac	360
acgganttgg	ancggctgcc	tgcccaanga	catacanacc	aatgtctaca	tcnaccacca	420
gtgtcctgga	gcaatactga	tggaangcag	ctaccncaa	gtnttctctg	ccnagggtta	480
catccccgcg	cgagagctac	accttcttca	ttgacatcct	gctcgacact	atcagggatg	540
aaaatcgcn	ggttgctcca	gaaaggctnc	aanaanatcc	tttctnctga	aggccccggg	600
atnncntagt	ntagaatcg	gcccgcacac	gcggtgganc	ctccaaacctt	tcgttncctt	660
ttactgagg	ttnattgccg	cccttgccgt	tatcatggtc	acnccngttn	cctgtgttga	720
aattnttaac	cccccaaat	tccacgccna	cattng			756

&lt;210&gt; 35

&lt;211&gt; 834

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(834)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 35

ggggatctct	anactnacct	gnatgeatgg	ttgtcggtgt	ggtcgctgtc	gatgaanatg	60
aacaggatct	tgcccttgaa	gctctcggct	gctgtnttta	agttgctcag	tctgccgtca	120
tagtcagaca	cncctttggg	caaaaaacan	caggatntga	gtcttgattt	cacctccaat	180
aatcttcngg	gctgtctgct	cggtgaactc	gatgacnang	ggcagctggg	tgtgtntgat	240
aaantccanc	angttctcct	tggtgacctc	cccttcaaa	ttgttcgggc	cttcatcaaa	300
cttctnmaan	angannancc	cancctttgtc	gagctggnat	ttgganaaca	cgtcactgtt	360

ggaaactgat	cccaaattggt	atgtcatcca	tgcctctgc	tgcctgcaaa	aaacttgctt	420
ggcncaaate	cgactcccn	tccttgaaag	aagccnatca	cacccccctc	cctggactcc	480
nncaangact	ctnccgctnc	ccntccnng	cagggttggt	ggcannccgg	gccccgtgcg	540
ttcttcagcc	agttcacnat	nttcacagc	ccctctgcca	gctgtntat	tccttggggg	600
ggaanccgtc	tctcccttcc	tgaannaact	ttgaccgtng	gaatagccgc	gcntcnccnt	660
acntnctggg	ccgggttcaa	antccctccn	ttgncnntcn	cctcgggcca	ttctggattt	720
nccnaacttt	ttccttcccc	cnccccncgg	ngtttggnnt	tttcatnggg	ccccaaactc	780
gctnttgccc	antcccttgg	gggentntan	cnccccctnt	gtccccntng	ggcc	834

&lt;210&gt; 36

&lt;211&gt; 814

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(814)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 36

cgngcgcctt	ccngccgcgc	cccgtttcca	tgacnaaggc	tcccttcang	ttaaatacnn	60
cctagnaaac	attaatgggt	tgtctacta	atacatcata	cnaaccagta	agcctgcca	120
naacgccaac	tcaggccatt	cctaccaaag	gaagaaaggc	tggctctccc	acccccgta	180
ggaaaggcct	gccttghtaag	acaccacaat	ncggctgaat	ctnaagtctt	gtgttttact	240
aatggaaaaa	aaaaataaac	aanaggtttt	gttctcatgg	ctgcccaccg	cagcctggca	300
ctaaaacanc	ccagcgctca	cttctgcttg	ganaaatatt	ctttgtctct	ttggacatca	360
ggcttgatgg	tatcactgcc	acntttccac	ccagctgggc	ncccttcccc	catntttgtc	420
antganctgg	aaggccctgaa	ncttagtctc	caaaagtctc	ngcccacaag	accggccacc	480
agggggangtc	ntttncagtg	gatctgcca	anantaccn	tatcatcnnt	gaataaaaag	540
gcccctgaac	ganatgcttc	cancancctt	taagacccat	aatcctngaa	ccatgggtgcc	600
cttcgggtct	gatccnaaag	gaatgttcct	gggtcccant	ccctcctttg	ttntttacgt	660
tgtnttggac	ccntgctngn	atnaccnaan	tganatcccc	ngaagcacc	tnccctggc	720
atgttganttt	cntaaattct	ctgccctacn	netgaaagca	cnattccctn	ggcncnnaan	780
ggngaactca	agaaggtctn	ngaaaaacca	cncn			814

&lt;210&gt; 37

&lt;211&gt; 760

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(760)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 37

gcatgctgct	cttcctcaaa	gttggttcttg	ttgccataac	aaccaccata	ggtaaagcgg	60
gcgcagtgtt	cgctgaagg	gttgtagtac	cagcgcgga	tgtctcctt	gcagagtcct	120
gtgtctggca	ggctcacgca	atgccctttg	tactgggga	aatggatgcg	ctggagctcg	180
tcnaanccac	tcgtgtat	ttcacangca	gcctcctccg	aagcntccgg	gcagttgggg	240
gtgtcgtcac	actccactaa	actgtcgatn	cancagccca	ttgctgcagc	ggaactgggt	300
gggctgacag	gtgccagaac	acactggatn	ggcctttcca	tggaagggcc	tgggggaaat	360
cncctnancc	caaactgcct	ctcaaaggcc	accttgca	ccccgacagg	ctagaaatgc	420
actcttcttc	ccaaaggtag	ttgttcttgt	tgcccaagca	ncctccanca	aaccaaanc	480
ttgcaaaaate	tgctccgtgg	gggtcatnnn	taccanggtt	ggggaaanaa	acccggcngn	540
ganccncctt	gtttgaatgc	naaggnaata	atcctcctgt	cttgcttggg	tggaaanagca	600
caattgaact	gttaacnttg	ggccgngttc	cncnngggtg	gtctgaaact	aatcaccgtc	660
actggaaaaa	ggtangtgcc	ttccttgaat	tcccaaantt	cccctngntt	tgggtntttt	720



ctectctncc ctaaaaatcg tnttcccccc centanggcg

760

<210> 38  
 <211> 724  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (1)...(724)  
 <223> n = A,T,C or G

<400> 38  
 tttttttttt tttttttttt tttttttttt tttttaaaaa cccctccat tgaatgaaaa 60  
 ctocnaaat tgtccaacc cctcnccaa atnccattt ccgggggggg gttccaaacc 120  
 caaattaatt ttggantita aattaaatnt tnatnngggg aanaanccaa atgtnaagaa 180  
 aatttaaccc attatnaact taaatnccn gaaaccntg gnttccaaaa atttttaacc 240  
 cttaaatccc tccgaaattg ntaanggaaa accaaattcn cctaaggctn tttgaagggt 300  
 ngatttaaac ccccttnant tnttttnacc cnngnctnaa ntatttngnt tccggtgtt 360  
 tcctnttaan cntnggtaac tcccngtaat gaannnccct aanccaatta aaccgaattt 420  
 tttttgaatt ggaaattccn ngggaattna ccgggggttt tcccntttgg gggccatncc 480  
 ccncctttcg ggggtttgggn ntaggttgaa tttttnnang nccccaaaaa ncccccaana 540  
 aaaaaactcc caagnnttaa ttngaattnc ccccttccca ggctttttgg gaaaggnggg 600  
 tttntggggg ccngggantt cnttcccccn ttncncccc cccccnggt aaanggttat 660  
 ngnttttgtt ttttgggccc cttnanggac cttccggatn gaaattaaat ccccggnccg 720  
 gccg 724

<210> 39  
 <211> 751  
 <212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (1)...(751)  
 <223> n = A,T,C or G

<400> 39  
 tttttttttt tttttctttg ctacatttta atttttattt tgattttttt taatgctgca 60  
 caacacaata tttatttcat ttgtttcttt tatttcattt tatttgtttg ctgctgctgt 120  
 tttatttatt tttactgaaa gtgagaggga acttttgttg ctttttttcc ttttctgta 180  
 ggccgctta agctttctaa atttggaaca tctaagcaag ctgaanggaa aagggggttt 240  
 cgcaaaatca ctggggggaa nggaaagggt gctttgttaa tcatgcccta tgggtgggtga 300  
 ttaactgctt gtacaattac ntttcacttt taattaattg tgctnaangc ttttaattana 360  
 cttgggggtt cctcccccac accaaccncc ctgacaaaaa gtgccngccc tcaaattnatg 420  
 tcccggcnnt cnttgaaaca cacngcngaa ngttctcatt ntcccnccnc caggtnaaaa 480  
 tgaagggtta ccatntttta cncacctcc acntggcnnn gcctgaatcc tcnaaaancn 540  
 cctcaancn aattnctnng ccccggtcnc gcntnngtcc cnccegggt cggggaantn 600  
 caccgccnga anncnntnnc naacnaaatt ccgaaaatat tccnntcnc tcaattcccc 660  
 cnnagactnt cctcnncnnc cncaattttc ttttnntcac gaacnccgnc cnnaaatgn 720  
 nnnnccctc cncngtccn naatcnccan c 751

<210> 40  
 <211> 753  
 <212> DNA  
 <213> Homo sapien  
 <220>

<221> misc\_feature  
 <222> (1)...(753)  
 <223> n = A,T,C or G

<400> 40  
 gtggtatttt ctgtaagatc aggtgttctt cctctgtagg ttttagaggaa acaccctcat 60  
 agatgaaaac ccccccgaga cagcagcact gcaactgcca agcagccggg gtaggagggg 120  
 cgccctatgc acagctgggc ccttgagaca gcagggttc gatgtcaggc tcgatgtcaa 180  
 tgggtctggaa gcggcggttg tacctgcgta ggggcacacc gtcaggggccc accaggaact 240  
 tctcaaagtt ccaggcaacn tcgttgcgac acaccggaga ccagggtgatn agcttgggggt 300  
 cggtcataa cgcgggtggc tcgtcgctgg gagctggcag ggcctcccgc aggaaggcna 360  
 ataaaagggt cgcgcccgca ccgttcant cgcacttctc naanaccatg angttgggct 420  
 cnaaccacc accannccgg acttccttga nggaattccc aaatctcttc gntcttgggc 480  
 ttctnctgat gccctantg gttgccnngn atgccaanca nccccaancc ccggggtcct 540  
 aaanaccn cctcctcctt tcatctgggt tntntcccc ggacctgggt tcctctcaag 600  
 ggancccata tctcnaccan tactcacnt ncccccent gnnaccanc cttctanngn 660  
 tccccnccg nccctctggc cntcaaan gcttnacna cctgggtctg ccttcccccc 720  
 tnccctatct gnaccccn tttgtctcan tnt 753

<210> 41  
 <211> 341  
 <212> DNA  
 <213> Homo sapien

<400> 41  
 actatatcca tcacaacaga catgcttcat cccatagact tottgacata gcttcaaatg 60  
 agtgaacca tccttgattt atatacatat atgttctcag tattttggga gcctttccac 120  
 ttctttaaac ctgttgcatt atgaacactg aaaataggaa tttgtgaaga gtaaaaaagt 180  
 tatagcttgt ttacgtagta agtttttgaa gtctacattc aatccagaca cttagttgag 240  
 tggttaaactg tgatttttaa aaaatatcat ttgagaatat totttcagag gtattttcat 300  
 ttttactttt tgattaattg tgttttatat attagggtag t 341

<210> 42  
 <211> 101  
 <212> DNA  
 <213> Homo sapien

<400> 42  
 acttactgaa tttagttctg tgctcttctt tatttagtgt tgtatcataa atactttgat 60  
 gtttcaaaca ttctaaataa ataattttca gtggcttcat a 101

<210> 43  
 <211> 305  
 <212> DNA  
 <213> Homo sapien

<400> 43  
 acatctttgt tacagtctaa gatgtgttct taaatcacca ttcttctctg gtcctcaccc 60  
 tccagggtgg tctcacactg taattagagc tattgaggag tctttacagc aaattaagat 120  
 tcagatgcct tgctaagtct agagttctag agttatgtt cagaaagtct aagaaaccca 180  
 cctcttgaga ggtcagtaaa gaggacttaa tatttcatat ctacaaaatg accacaggat 240  
 tggatacaga acgagagtta tcctggataa ctcagagctg agtacctgcc cggggggccc 300  
 tcgaa 305

<210> 44  
 <211> 852  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(852)  
 <223> n = A,T,C or G

<400> 44  
 acataaatat cagagaaaag tagtctttga aatattttacg tccaggaggt ctttggtttct 60  
 gattatttgg tgtgtgtttt ggtttgtgtc caaagtattg gcagcttcag ttttcatttt 120  
 ctctccatcc tcgggcattc ttcccaaatt tatataaccag tcttcgtcca tccacacgct 180  
 ccagaatttc tctttttag taatatctca tagctcggct gagcttttca taggtcatgc 240  
 tgctgttgtt cttcttttta ccccatagct gagccactgc ctctgatttc aagaacctga 300  
 agacgccctc agatcgggtc tccatttta ttaatcctgg gttcttgtct gggttcaaga 360  
 ggatgtcgcg gatgaattcc cataagttag tccctctcgg gttgtgcttt ttggtgtggc 420  
 acttggcagg ggggtcttgc tcctttttca tatcagggtga ctctgcaaca ggaaggtgac 480  
 tgggtggtgt catggagatc tgagcccggc agaaagtttt gctgtccaac aaatctactg 540  
 tgctaccata gttggtgtca tataaatagt tctngtcttt ccagggtgtc atgatggaag 600  
 gctcagtttg ttcagtcctg acaatgacat tgtgtgtgga ctggaacagg tcactactgc 660  
 actggccggt ccacttcaga tgctgcaagt tgctgtagag gagntgcccc gccgtccctg 720  
 ccgcccgggt gaactcctgc aaactcatgc tgcaaagggt ctgcgcgttg atgtcgaact 780  
 cntggaaaag gatacaattg gcatccagct ggttgggtgc caggaggtga tggagccact 840  
 cccacacctg gt 852

<210> 45  
 <211> 234  
 <212> DNA  
 <213> Homo sapien

<400> 45  
 acaacagacc cttgctcgct aacgacctca tgctcatcaa gttggacgaa tccgtgtccg 60  
 agtctgacac catccggagc atcagcattg cttcgcagtg ccctaccgcg gggaaactctt 120  
 gcctcgtttc tggctgggggt ctgctggcga acggcagaat gcctaccgtg ctgcagtgcg 180  
 tgaacgtgtc ggtggtgtct gaggaggtct gcagtaagct ctatgacccg ctgt 234

<210> 46  
 <211> 590  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(590)  
 <223> n = A,T,C or G

<400> 46  
 acttttttatt taaatgttta taaggcagat ctatgagaat gatagaaaac atggtgtgta 60  
 atttgatagc aatatttttg agattacaga gttttagtaa ttaccaatta cacagttaaa 120  
 aagaagataa tatattccaa gcanatacaa aatatctaata gaaagatcaa ggcaggaaaa 180  
 tgantataac taattgacaa tggaaaatca attttaatgt gaattgcaca ttatccttta 240  
 aaagctttca aaanaaanaa ttattgcagt ctanttaatt caaacagtgt taaatggtat 300  
 caggataaan aactgaagg canaaagaat taattttcac ttcattgtaac ncacccanat 360  
 ttacaatggc ttaaatgcan ggaaaaagca gtggaagtag ggaagtantc aaggtctttc 420  
 tggctctctaa tctgccttac tctttgggtg tggctttgat cctctggaga cagctgccag 480  
 ggctcctgtt atatcccaa tcccagcagc aagatgaagg gatgaaaaag gacacatgct 540  
 gccttccttt gaggagactt catctcactg gccaacactc agtcacatgt 590

<210> 47  
 <211> 774

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(774)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 47

acaagggggc	ataatgaagg	agtggggana	gatttttaaag	aaggaaaaaa	aacgaggccc	60
tgaacagaat	tttctgnac	aacggggcctt	caaaataatt	ttcttgggga	ggttcaagac	120
gcttcaactgc	ttgaaactta	aatggatgtg	ggacanaatt	ttctgtaatg	accctgaggg	180
cattacagac	gggactctgg	gaggaaggat	aaacagaaaag	gggacaaaag	ctaataccaa	240
aacatcaaag	aaaggaagg	ggcgtcatac	ctcccagcct	acacagttct	ccagggctct	300
cctcatccct	ggaggacgac	agtggaggaa	caactgacca	tgtccccagg	ctcctgtgtg	360
ctggctcctg	gtcttcagcc	cccagctctg	gaagcccacc	ctctgctgat	cctgcgtggc	420
ccacactcct	tgaacacaca	tccccagggt	atattcctgg	acatggctga	acctcctatt	480
cctacttcog	agatgccttg	ctccctgcag	cctgtcaaaa	tcccactcac	cctccaaacc	540
acggcatggg	aagcctttct	gacttgcctg	attactccag	catcttggaa	caatccctga	600
ttccccactc	cttagaggca	agataggggtg	gttaagagta	gggctggacc	acttggagcc	660
aggctgctgg	cttcaaattn	tggctcattt	acgagctatg	ggaccttggg	caagtnatct	720
tcacttctat	gggcntcatt	ttgttctacc	tgcaaaatgg	gggataataa	tagt	774

&lt;210&gt; 48

&lt;211&gt; 124

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(124)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 48

canaaattga	aattttataa	aaaggcattt	ttctcttata	tccataaaat	gatataattt	60
ttgcaantat	anaaatgtgt	cataaattat	aatgttcctt	aattacagct	caacgcaact	120
tggt						124

&lt;210&gt; 49

&lt;211&gt; 147

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(147)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 49

gccgatgcta	ctattttatt	gcaggaggtg	gggggtgtttt	tattattctc	tcaacagctt	60
tgtggctaca	ggtggtgtct	gactgcatna	aaaanttttt	tacgggtgat	tgcaaaaatt	120
ttagggcacc	catatcccaa	gcantgt				147

&lt;210&gt; 50

&lt;211&gt; 107

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 50

acattaaatt aataaaagga ctgttggggt tctgctaaaa cacatggctt gatataattgc 60  
atggtttgag gttaggagga gttaggcata tgttttggga gaggggt 107

&lt;210&gt; 51

&lt;211&gt; 204

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 51

gtcctaggaa gtctagggga cacacgactc tgggggtcacg gggccgacac acttgcacgg 60  
cggaagaa aggagagaa gtgacaccgt cagggggaaa tgacagaaag gaaaatcaag 120  
gccttgcaag gtcagaaagg ggactcaggg ctccaccac agccctgcc cacttgcca 180  
cctccctttt gggaccagca atgt 204

&lt;210&gt; 52

&lt;211&gt; 491

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(491)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 52

acaaagataa catttatctt ataacaaaaa ttgatagtt ttaaaggtta gtattgtgta 60  
gggtattttt caaaagacta aagagataac tcaggtaaaa agttagaaat gtataaaaca 120  
ccatcagaca ggttttttaa aaacaacata ttacaaaatt agacaatcat ctttaaaaaa 180  
aaaacttctt gtatcaattt cttttgttca aaatgactga cttaantatt tttaaatatt 240  
tcanaaacac ttctcaaaa attttcaana tggtagcttt canatgtnc ctcagtocca 300  
atgttgctca gataaataaa tctcgtgaga acttaccacc caccacaagc tttctggggc 360  
atgcaacagt gtcttttctt tnotttttct tttttttttt ttacaggcac agaaactcat 420  
caattttatt tggataacaa aggtctcca aattatattg aaaaataaat ccaagttaat 480  
atcactcttg t 491

&lt;210&gt; 53

&lt;211&gt; 484

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(484)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 53

acataattta gcagggctaa ttaccataag atgctattta ttaanaggtn tatgatctga 60  
gtattaacag ttgctgaagt ttggtatttt tatgcagcat tttctttttg ctttgataac 120  
actacagaac ccttaaggac actgaaaatt agtaagtaaa gttcagaaac attagctgct 180  
caatcaaate tctacataac actatagtaa ttaaaacggt aaaaaaaagt gttgaaatct 240  
gcactagtat anaccgtcc tgtcaggata anactgcttt ggaacagaaa gggaaaaanc 300  
agctttgant ttctttgtgc tgatangagg aaaggctgaa ttaccttggt gcctctccct 360  
aatgattggc aggtcnggta aatnccaaaa catattccaa ctcaacactt cttttccnec 420  
tancttgant ctgtgtattc caggancagg cggtatggaat gggccagccc ncggatgttc 480  
cant 484

&lt;210&gt; 54

<211> 151  
 <212> DNA  
 <213> Homo sapien

<400> 54  
 actaaacctc gtgcttgtga actccatata gaaaacgggtg ccatccctga acacggctgg 60  
 ccactgggta tactgctgac aaccgcaaca acaaaaacac aaatccttgg cactggctag 120  
 tctatgtcct ctcaagtgcc tttttgtttg t 151

<210> 55  
 <211> 91  
 <212> DNA  
 <213> Homo sapien

<400> 55  
 acctggcttg tctccgggtg gttcccggcg cccccacgg tccccagaac ggacactttc 60  
 gccctccagt ggatactcga gccaaagtgg t 91

<210> 56  
 <211> 133  
 <212> DNA  
 <213> Homo sapien

<400> 56  
 ggcggtatgtg cgttgggttat atacaaatat gtcattttat gtaagggact tgagtatact 60  
 tggatttttg gtatctgttg gttgggggga cgtccagga accaatacc catggatacc 120  
 aagggacaac tgt 133

<210> 57  
 <211> 147  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(147)  
 <223> n = A,T,C or G

<400> 57  
 actctggaga acctgagccg ctgctccgcc tctgggatga ggtgatgcan gcngtggcgc 60  
 gactgggagc tgagcccttc cctttgcgcc tgcctcagag gattgttgcc gaentgcana 120  
 tctcantggg ctggatncat gcagggt 147

<210> 58  
 <211> 198  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(198)  
 <223> n = A,T,C or G

<400> 58  
 acagggatat aggtttnaag ttattgtnat tgtaaaatac attgaatttt ctgtatactc 60  
 tgattacata catttatcct ttaaaaaaga tgtaaatctt aatttttatg ccatctatta 120  
 atttaccat gagttacctt gtaaatagaga agtcatgata gcactgaatt ttaactagtt 180  
 ttgacttcta agtttgggt 198

<210> 59  
 <211> 330  
 <212> DNA  
 <213> Homo sapien

<400> 59

acaacaaatg ggttgtgagg aagtcttatac agcaaaaactg gtgatggcta ctgaaaagat	60
ccattgaaaa ttatcattaa tgattttaaa tgacaagtta tcaaaaactc actcaatttt	120
cacctgtgct agcttgctaa aatgggagtt aactctagag caaatatagt atcttctgaa	180
tacagtcaat aaatgacaaa gccagggcct acaggtggtt tccagacttt ccagaccag	240
cagaaggaaat ctattttatc acatggatct ccgctgtgct tcaaaatacc taatgatatt	300
tttctgtcttt attggacttc tttgaagagt	330

<210> 60  
 <211> 175  
 <212> DNA  
 <213> Homo sapien

<400> 60

accgtgggtg ccttctacat tcttgacggc tcttcacca acatctggtt ctacttcggc	60
gtcgtgggct ccttctcttt catctcctc cagctgggtc tgctcatcga ctttgccgac	120
tcctggaacc agcgggtggc gggcaaggcc gaggagtgcg attcccgtgc ctggt	175

<210> 61  
 <211> 154  
 <212> DNA  
 <213> Homo sapien

<400> 61

acccacttt tcctcctgtg agcagtctgg acttctcact gctacatgat gaggggtgagt	60
ggttgttgc cttcaacagt atcctcccct ttccggatct gctgagccgg acagcagtgc	120
tggactgcac agccccggg ctccacattg ctgt	154

<210> 62  
 <211> 30  
 <212> DNA  
 <213> Homo sapien

<400> 62

cgctcgagcc ctatagttag tcgtattaga	30
----------------------------------	----

<210> 63  
 <211> 89  
 <212> DNA  
 <213> Homo sapien

<400> 63

acaagtcatt tcagcacccct ttgctcttca aaactgacca tcttttatat ttaatgcttc	60
ctgtatgaat aaaaatggtt atgtcaagt	89

<210> 64  
 <211> 97  
 <212> DNA  
 <213> Homo sapien

<400> 64

accggagtaa ctgagtcggg acgctgaatc tgaatccacc aataaataaa ggttctgcag	60
---	----

aatcagtgca tccaggattg gtccttggat ctgggggt

97

&lt;210&gt; 65

&lt;211&gt; 377

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(377)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 65

acaacaanaa ntcccttctt taggccactg atggaaacct ggaacccctt tttgatggca	60
gcatggcgctc ctaggccttg acacagcggc tgggggtttg gctntcccaa accgcacacc	120
ccaaccctgg tctaccaca nttctggcta tgggctgtct ctgccactga acatcagggt	180
tcggtcataa natgaaatcc caanggggac agaggtcagt agaggaagct caatgagaaa	240
ggtgctgttt gctcagccag aaaacagctg cctggcattc gccgctgaac tatgaaccgg	300
tgggggtgaa ctaccccan gaggaatcat gcctgggcga tgcaanggtg ccaacaggag	360
gggcggggagg agcatgt	377

&lt;210&gt; 66

&lt;211&gt; 305

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 66

acgcctttcc ctcagaattc agggaagaga ctgtcgctg ccttctccg ttgttgctg	60
agaacccgtg tgccccttcc caccatatcc accctcgctc catctttgaa ctcaaacacg	120
aggaactaac tgcaccctgg tcctctcccc agtccccagt tcaccctcca tccctcacct	180
tcctccactc taagggatat caacactgcc cagcacaggg gccctgaatt tatgtggttt	240
ttatatattt tttaataaga tgcactttat gtcatttttt aataaagtct gaagaattac	300
tggtt	305

&lt;210&gt; 67

&lt;211&gt; 385

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 67

actacacaca ctccacttgc ctttgtgaga cactttgtcc cagcacttta ggaatgctga	60
ggtcggacca gccacatctc atgtgcaaga ttgccagca gacatcaggt ctgagagttc	120
cccttttaaa aaaggggact tgcttaaaaa agaagtctag ccacgattgt gtagagcagc	180
tgtgctgtgc tggagattca cttttgagag agttctcctc tgagacctga tctttagagg	240
ctgggcagtc ttgcacatga gatggggctg gtctgatctc agcactcctt agtctgcttg	300
cctctcccag ggccccagcc tggccacacc tgcttacagg gcactctcag atgccatac	360
catagtttct gtgctagtgg accgt	385

&lt;210&gt; 68

&lt;211&gt; 73

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 68

acttaaccag atatattttt accccagatg gggatattct ttgtaaaaaa tgaaaataaa	60
gtttttttaa tgg	73

&lt;210&gt; 69



<211> 536  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(536)  
 <223> n = A,T,C or G

<400> 69  
 actagtccag tgtggtggaa ttccattgtg ttggggggtc tcaccctcct ctctgcagc 60  
 tccagctttg tgetctgcct ctgaggagac catggcccag catctgagta ccctgctgct 120  
 cctgctggcc accctagctg tggccctggc ctggagcccc aaggaggagg ataggataat 180  
 cccgggtggc atctataacg cagacctcaa tgatgagtgg gtacagcgctg cccttcactt 240  
 cgccatcagc gagtataaca aggccaccaa agatgactac tacagacgct cgctgcgggt 300  
 actaagagcc aggcaacaga ccgttggggg ggtgaattac ttcttcgacg tagagggtggg 360  
 ccgaaccata tgtaccaagt cccagcccaa cttggacacc tgtgccttcc atgaacagcc 420  
 agaactgcag aagaaacagt tgtgctcttt cgagatctac gaagttccct ggggagaaca 480  
 gaangtcctt gggtgaaatc cagggtgtcaa gaaatcctan ggatctgttg ccaggc 536

<210> 70  
 <211> 477  
 <212> DNA  
 <213> Homo sapien

<400> 70  
 atgaccccta acagggggccc tctcagccct cctaattgacc tccggcctag ccatgtgatt 60  
 tcaattccac tccataacgc tcctcactact aggcctacta accaacacac taaccatata 120  
 ccaatgatgg cgcgatgtaa cagagaaaag cacataccaa ggccaccaca caccacctgt 180  
 ccaaaaaggc cttcgatacg ggataatcct atttattacc tcagaagttt ttttcttcgc 240  
 agggattttt ctgagccttt taccactcca gcctagcccc taccceccaa ctaggagggc 300  
 actggccccc aacaggcatc accccgctaa atcccctaga agtcccactc ctaaacacat 360  
 ccgtattact cgcacagga gtatcaatca cctgagctca ccatagtcta atagaaaaca 420  
 accgaaacca aattattcaa agcactgctt attacaattt tactgggtct ctattttt 477

<210> 71  
 <211> 533  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(533)  
 <223> n = A,T,C or G

<400> 71  
 agagctatag gtacagtgtg atctcagctt tgcaaacaca ttttctacat agatagtact 60  
 aggtattaat agatatgtaa agaaagaaat cacaccatta ataatggtaa gattgggttta 120  
 tgtgatttta gtggtatttt tggcaccctt atatatgttt tccaaacttt cagcagtgat 180  
 attattttcca taacttaaaa agtgagtttg aaaaagaaaa tctccagcaa gcatctcatt 240  
 taaataaagg tttgtcatct ttaaaaatac agcaatatgt gactttttta aaaagctgtc 300  
 aaataggtgt gaccctacta ataattatta gaaatcatt taaaaacatc gagtacctca 360  
 agtcagtttg ccttgaaaaa tatcaaatat aactcttaga gaaatgtaca taaaagaatg 420  
 cttcgtaatt ttggagtang aggttccctc ctcaattttg tattttttaa aagtacatgg 480  
 taaaaaaaaa aattcacaac agtatataag gctgtaaaaa gaagaattct gcc 533

<210> 72  
 <211> 511

<212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(511)  
 <223> n = A,T,C or G

<400> 72

tattacggaa	aaacacacca	cataattcaa	ctancaaaga	anactgcttc	agggcgtgta	60
aatgaaagg	cttccaggca	gttatctgat	taaagaacac	taaaagagg	acaaggctaa	120
aagccgcagg	atgtctacac	tatancaggc	gctatttggg	ttggctggag	gagctgtgga	180
aaacatgga	agattggtgc	tgganacgc	cgtggctatt	cctcattgtt	attacanagt	240
gaggttctct	gtgtgccac	tggtttgaaa	accgttctnc	aataatgata	gaatagtaca	300
cacatgagaa	ctgaaatggc	ccaaaccagg	aaagaaagcc	caactagatc	ctcagaanac	360
gcttctaggg	acaataaccg	atgaagaaaa	gatggcctcc	ttgtgcccc	gtctgttatg	420
atttctctcc	attgcagcna	naaacccgtt	cttctaagca	aacncagggt	atgatggcna	480
aaatacacc	cctcttgaag	naccnggagg	a			511

<210> 73  
 <211> 499  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(499)  
 <223> n = A,T,C or G

<400> 73

cagtgccagc	actggtgcc	gtaccagtag	caataacagt	gccagtgcc	gtgccagcac	60
cagtgggtgc	ttcagtgctg	gtgccagcct	gaccgccact	ctcacatttg	ggctcttcgc	120
tggccttgg	ggagctgggt	ccagcaccag	tggcagctct	ggtgcctgtg	gtttctccta	180
caagttagat	tttagatatt	gttaatcctg	ccagtctttc	tcttcaagcc	aggggtgcac	240
ctcagaaacc	tactcaacac	agcactctag	gcagccacta	tcaatcaatt	gaagttgaca	300
ctctgcatta	aatctatttg	ccattttctga	aaaaaaaaaa	aaaaaaagg	cggccgctcg	360
antctagagg	gcccgtttta	accgctgat	cagcctcgac	tgtgccttct	anttgccagc	420
catctgttgt	ttgcccctcc	cccngtgcct	tccttgaccc	tggaaagtgc	cactcccact	480
gtcctttcct	aantaaaat					499

<210> 74  
 <211> 537  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(537)  
 <223> n = A,T,C or G

<400> 74

tttcatagga	gaacacactg	aggagatact	tgaagaattt	ggattcagcc	gcgaagagat	60
ttatcagctt	aactcagata	aaatcattga	aagtaataag	gtaaaagcta	gtctctaact	120
tccaggccca	cggctcaagt	gaatttgaat	actgcattta	cagtgtagag	taacacataa	180
cattgtatgc	atggaaacat	ggaggaacag	tattacagt	tcctaccact	ctaatacaga	240
aaagaattac	agactctgat	tctacagtga	tgattgaatt	ctaaaaatgg	taatacattag	300
ggcttttgat	ttataanact	ttgggtactt	atactaaatt	atggtagtta	tactgccttc	360
cagtttgctt	gatataattg	ttgatattaa	gattcttgac	ttatatattg	aatgggttct	420

actgaaaaan gaatgatata ttcttgaaga catogatata catttattta cactcttgat 480  
tctacaatgt agaaaatgaa ggaaatgccc caaattgtat ggtgataaaa gtccccgt 537

<210> 75  
<211> 467  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(467)  
<223> n = A,T,C or G

<400> 75  
caaanacaat tgttcaaaag atgcaaatga tacactactg ctgcagctca caaacacctc 60  
tgcatattac acgtacctcc tcctgctcct caagtagtgt ggtctatttt gccatcatca 120  
cctgctgtct gcttagaaga acggctttct gctgcaangg agagaaatca taacagacgg 180  
tggcacaagg aggccatctt ttccatcatcg gttattgtcc ctagaagcgt cttctgagga 240  
tctagttggg ctttctttct gggtttgggc catttcantt ctcattgtgt tactattcta 300  
tcattattgt ataacggttt tcaaaccngt gggcacncag agaacctcac tctgtaataa 360  
caatgaggaa tagccacggg gatctccagc accaaatctc tccatgttnt tccagagctc 420  
ctccagccaa cccaaatagc cgctgctatn gtgtagaaca tccctgn 467

<210> 76  
<211> 400  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(400)  
<223> n = A,T,C or G

<400> 76  
aagctgacag cattcggggc gagatgtctc gctccgtggc cttagctgtg ctgcgcgtac 60  
tctctcttc tggcctggag gctatccagc gtactccaaa gattcagggt tactcacgtc 120  
atccagcaga gaattgaaa tcaaatttcc tgaattgcta tgtgtctggg ttcatccat 180  
ccgacattga agttgactta ctgaagaatg gagagagaat tgaaaaagt gagcattcag 240  
acttgtcttt cagcaaggac tggctcttct atctcttgta ctacactgaa ttcaccccca 300  
ctgaaaaaga tgagtatgcc tgccgtgtga accatgtgac tttgtcacag cccaagatng 360  
ttnagtggga tcganacatg taagcagcan catggggaggt 400

<210> 77  
<211> 248  
<212> DNA  
<213> Homo sapien

<400> 77  
ctggagtgcc ttgggtgttc aagcccctgc aggaagcaga atgcaccttc tgaggcacct 60  
ccagctgccc cggcggggga tgcgaggctc ggagcaccct tgcccggctg tgattgctgc 120  
caggcactgt tcattctcagc ttttctgtcc ctttgcctcc ggcaagcgct tctgtgaaa 180  
gttcatactt ggagcctgat gtcttaacga ataaaggctc catgctccac ccgaaaaaaa 240  
aaaaaaaa 248

<210> 78  
<211> 201  
<212> DNA  
<213> Homo sapien

<400> 78  
 actagtccag tgtggtggaa ttccattgtg ttgggcccac cacaatggct acctttaaca 60  
 tcaccagac ccgcccctgc ccgtgcccac cgctgctgct aacgacagta tgatgcttac 120  
 tctgctactc ggaaactatt tttatgtaat taatgtatgc tttcttggtt ataaatgcct 180  
 gatttaaaaa aaaaaaaaaa a 201

<210> 79  
 <211> 552  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(552)  
 <223> n = A,T,C or G

<400> 79  
 tccttttgtt aggtttttga gacaacccta gacctaaact gtgtcacaga cttctgaatg 60  
 tttaggcagt gctagtaatt tcctcgtaat gattctgtta ttactttcct attctttatt 120  
 cctctttctt ctgaagatta atgaagttga aaattgaggt ggataaatac aaaaaggtag 180  
 tgtgatagta taagtatcta agtgcagatg aaagtgtgtt atatatatcc attcaaaatt 240  
 atgcaagtta gtaattactc agggtttaact aaattacttt aatatgctgt tgaacctact 300  
 ctgttccttg gctagaaaaa attataaaca ggactttgtt agtttgggaa gccaaattga 360  
 taatattcta tgttctaataa gttgggctat acataaanta tnaagaaata tggaaattta 420  
 ttcccaggaa tatgggggtc atttatgaat antaccggg anagaagttt tgantnaaac 480  
 cngttttggt taatacgtta atatgtcctn aatnaacaag gcntgactta tttccaaaaa 540  
 aaaaaaaaaa aa 552

<210> 80  
 <211> 476  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(476)  
 <223> n = A,T,C or G

<400> 80  
 acagggattt gagatgctaa ggccccagag atcgtttgat ccaaccctct tattttcaga 60  
 ggggaaaatg gggcctagaa gttacagagc atctagctgg tgcgctggca cccctggcct 120  
 cacacagact ccgagtagc tgggactaca ggcacacagt cactgaagca ggccctgttt 180  
 gcaattcacg ttgccacctc caacttaaac attcttcata tgtgatgtcc ttagtcacta 240  
 aggttaaaact ttcccaccca gaaaaggcaa cttagataaa atcttagagt actttcatac 300  
 tcttctaagt cctcttccag cctcactttg agtcctcctt gggggttgat aggaantntc 360  
 tcttggtttt ctcaataaaa tctctatcca tctcatgttt aatttggtac gcntaaaaat 420  
 gctgaaaaaa ttaaaatggt ctggtttcnc tttaaaaaaa aaaaaaaaaa aaaaaa 476

<210> 81  
 <211> 232  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(232)  
 <223> n = A,T,C or G

<400> 81  
 tttttttttg tatgccttctn ctgtggngtt attgtttgctg ccaccttgga ggagcccagt 60  
 ttctttctgta tctttctttt ctggggggtc ttctctggctc tgccctccca ttcccagcct 120  
 ctcatcccca tcttgcactt ttgctagggt tggaggcgct ttcttggtag cccctcagag 180  
 actcagtcag cgggaataag tcttaggggt ggggggtgtg gcaagccggc ct 232

<210> 82  
 <211> 383  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(383)  
 <223> n = A,T,C or G

<400> 82  
 aggcggggagc agaagctaaa gccaaagccc aagaagagtg gcagtgccag cactgggtgcc 60  
 agtaccagta ccaataacat gccagtgccca gtgccagcac cagtgggtggc ttcagtgtctg 120  
 gtgccagcct gaccgccact ctcacatttg ggctcttcgc tggccttggt ggagctgggt 180  
 ccagcaccag tggcagctct ggtgcctgtg gtttctccta caagtgaat tttagatatt 240  
 gttaatcctg ccagtccttc tcttcaagcc aggggtgcac ctcagaaacc tactcaacac 300  
 agcactctng gcagccacta tcaatcaatt gaagttgaca ctctgcatta aatctatttg 360  
 ccatttcaaa aaaaaaaaaa aaa 383

<210> 83  
 <211> 494  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(494)  
 <223> n = A,T,C or G

<400> 83  
 accgaattgg gaccgtggc ttataagcga tcatgtcctc cagtattacc tcaacgagca 60  
 gggagatcga gtctatacgc tgaagaaatt tgaccgatg ggacaacaga cctgtctcagc 120  
 ccatcctgct cgtttctccc cagatgacaa atactctcga caccgaatca ccatcaagaa 180  
 acgcttcaag gtgtcatga cccagcaacc gcgccctgtc ctctgagggt ccttaaaactg 240  
 atgtcttttc tgccacctgt taccctcgg agactccgta accaaactct tcggactgtg 300  
 agccctgatg cctttttgcc agccatactc tttggentcc agtctctcgt ggcgattgat 360  
 tatgtttgtg tgaggcaatc atggtggcat caccatnaa ggaacacat ttganttttt 420  
 tttncatat tttaaattac naccagaata nttcagaata aatgaattga aaaactctta 480  
 aaaaaaaaaa aaaa 494

<210> 84  
 <211> 380  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(380)  
 <223> n = A,T,C or G

<400> 84

gctggtagcc	tatggcgtgg	ccacggangg	gctcctgagg	cacgggacag	tgacttccca	60
agtatcctgc	gccgcgtctt	ctaccgtccc	tacctgcaga	tcttcgggca	gattccccag	120
gaggacatgg	acgtggccct	catggagcac	agcaactgct	cgctggagcc	cggcttctgg	180
gcacaccctc	ctggggccca	ggcgggcacc	tgcgtctccc	agtatgccaa	ctggctgggtg	240
gtgctgctcc	tcgtcatctt	cctgctcgtg	gccaacatcc	tgctgggtcac	ttgctcattg	300
ccatgttcag	tiacacattc	ggcaaagtac	agggcaacag	cnatctctac	tggaaggcc	360
agcgttncgg	cctcatccgg					380

<210> 85  
 <211> 481  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(481)  
 <223> n = A,T,C or G

<400> 85	
gagttagctc	ctccacaacc
tnccatcgte	atactgtagg
ggaaactctc	aatcaagtca
tgtgaaagga	tctccagaag
gtcgattctg	catgtccagc
ctatcatgcc	nttgaacgtg
ccagattctg	cattaccaga
aaagaacacc	tcctggaagt
t	

ttgatgaggt	cgtctgcagt	ggcctctcgc	ttcataccgc	60
ctcctgcat	cttggggcgg	ctaatatcca		120
aacctgtggc	tggttctgtc	ttccgctcgg		180
tcttccccac	acttttgatg	actttattga		240
accagctctc	tgacagtgag	gtcaccagcc		300
tgtggggggg	gnagtctcac			360
aaaaganatt	gacaactcgc	ccaggngaa		420
cctcgctcent	tgggtggnngc	gentnccttt		480
				481

<210> 86  
 <211> 472  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(472)  
 <223> n = A,T,C or G

<400> 86	
aacatcttcc	tgtataatgc
acttggaana	gcaacttnaa
taaacagtgt	gtcaatctgc
ccctattcac	acctgttaaa
cacaagtccg	aaaaaagcaa
catgggacag	agccatttga
atatntgagc	ggaagantag
tgttnacnaa	agttatgtct

tggtataat	cgatccgatn	ttgtctgctg	agaattoatt	60
tggtattaaa	attcacaata	tgcaacactt		120
tgatcatcacc	agtctgggaa	taagggtatg		180
gcatttttga	ttcaacatct	ttttttttga		240
ttnttaattt	gttagccaat	tcactttctt		300
aaattgcata	atattgagct	ttgggagctg		360
tcaccagaca	caactccttt	catattggga		420
ggatgctttt	gtggcaattc	tg		472

<210> 87  
 <211> 413  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(413)  
 <223> n = A,T,C or G

&lt;400&gt; 87

agaaaccagt	atctctnaaa	acaacctctc	ataccttgtg	gacctaat	ttgtgtgcgtg	60
tgtgtgtg	cgcataattat	atagacaggc	acatcttttt	tacttttgta	aaagcttatg	120
cctcttttgg	atctatatct	gtgaaagttt	taatgatctg	ccataatgtc	ttggggacct	180
ttgtctttgt	tgtaaattgg	actagagaaa	acacctatnt	tatgagtcaa	tctagttngt	240
tttattcgac	atgaaggaaa	tttccagatn	acaacactna	caaactctcc	cttgactagg	300
ggggacaaa	aaaagcnaaa	ctgaacatna	gaaacaattn	cctgggtgaga	aattncataa	360
acagaaattg	ggtngtatat	tgaaanann	catcattnaa	acgttttttt	ttt	413

&lt;210&gt; 88

&lt;211&gt; 448

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (448)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 88

cgcagcgggt	cctctctatc	tagctccagc	ctctcgctg	ccccactccc	cgcgtcccgc	60
gtcctagccn	accatggccg	ggccccctgc	cgccccgctg	ctcctgctgg	ccatcctggc	120
cgtggccctg	gccgtgagcc	ccgcggcccg	ctccagtccc	ggcaagccgc	cgcgcctggg	180
gggaggccca	tggaccccg	gtggaagaag	aagggtgtgc	gcgtgcaactg	gactttgccg	240
tccgcnanta	caacaaaccc	gcaacnactt	ttaccnagen	cgcgctgcag	gttgtgccgc	300
cccaancaaa	ttgttactng	gggtaantaa	ttcttggaag	ttgaacctgg	gccaaacnng	360
tttaccagaa	ccnagccaat	tngaacaatt	nccccctccat	aacagcccct	tttaaaaagg	420
gaancantcc	tgntcttttc	caaatttt				448

&lt;210&gt; 89

&lt;211&gt; 463

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (463)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 89

gaattttgtg	cactggccac	tgtgatggaa	ccattgggcc	aggatgcttt	gagtttatca	60
gtagtgtatt	tgccaaagtt	ggtgttgtaa	catgagtatg	taaaatgtca	aaaaattagc	120
agaggtctag	gtctgcatat	cagcagacag	tttgtccgtg	tattttgtag	ccttgaagtt	180
ctcagtgcga	agttntttct	gatgcgaagt	tctnattcca	gtgttttagt	cctttgcac	240
tttnatgttn	agacttgcct	ctntnaaatt	gcttttgtnt	tctgcaggta	ctatctgtgg	300
tttaacaaaa	tagaannact	tctctgcttn	gaanatttga	atatcttaca	tctnaaaatn	360
aaattctctcc	ccatannaaa	acccangccc	ttggganaat	ttgaaaaang	gntccttcnn	420
aattcnnana	anttcagntn	tcatacaaca	naacngganc	ccc		463

&lt;210&gt; 90

&lt;211&gt; 400

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1) ... (400)

<223> n = A,T,C or G

<400> 90

agggattgaa	ggtctnttnt	actgtcggac	tgttcancca	ccaactctac	aagttgctgt	60
cttccactca	ctgtctgtaa	gcntnttaac	ccagactgta	tcttcataaa	tagaacaaat	120
tcttcaccag	tcacatcttc	taggaccttt	ttggattcag	ttagtataag	ctcttccact	180
tcctttgtta	agacttcatc	tggtaaaagtc	ttaagttttg	tagaaaggaa	tttaattgct	240
cgttctctaa	caatgtcctc	tccttgaagt	atttggctga	acaaccacc	tnaagtcct	300
ttgtgcatcc	attttaaata	tacttaatag	ggcattggtn	cactaggtta	aattctgcaa	360
gagtcactctg	tctgcaaaaag	ttgcgttagt	atatctgcc			400

<210> 91

<211> 480

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(480)

<223> n = A,T,C or G

<400> 91

gagctcggat	ccaataatct	ttgtctgagg	gcagcacaca	tatncagtgc	catggnaact	60
ggtctacccc	acatgggagc	agcatgccgt	agntatataa	ggtcattccc	tgagtcagac	120
atgcctcttt	gactaccgtg	tgccagtgtc	ggtgattctc	acacacctcc	nnccgtctt	180
tgtggaaaaa	ctggcacttg	nctggaacta	gcaagacatc	acttaciaat	tcacccacga	240
gacacttgaa	aggtgtaaca	aagcgactct	tgcattgctt	tttgtccctc	cggcaccagt	300
tgtcaataact	aacccgctgg	tttgcctcca	tcacatttgt	gatctgtagc	tctggatata	360
tctcctgaca	gtactgaaga	acttcttctt	ttgtttcaaa	agcaactctt	ggtgcctgtt	420
ngatcagggt	cccatttccc	agtccgaatg	ttcacatggc	atatnttact	tcccacaaaa	480

<210> 92

<211> 477

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(477)

<223> n = A,T,C or G

<400> 92

atacagccca	natccacca	cgaagatgcg	cttgttgact	gagaacctga	tgccggtcact	60
ggtcccgtg	tagccccagc	gactctccac	ctgctggaag	cggttgatgc	tgcaactcctt	120
cccacgcagg	cagcagcggg	gccggtcaat	gaactccact	cgtggcttgg	ggttgacggg	180
taantgcagg	aagaggctga	ccacctcgcg	gtccaccagg	atgcccagct	gtgcccggacc	240
tgacgcgaaa	ctcctcgatg	gtcatgagcg	ggaagcgaat	gangcccagg	gccttgccca	300
gaaccttccg	cctgttctct	ggcgtaacct	gcagctgctg	ccgctnacac	tcggcctcgg	360
accagcggac	aaacggcggt	gaacagccgc	acctcacgga	tgcccantgt	gtcgcgctcc	420
aggaacggcn	ccagcgtgtc	caggtcaatg	tcgggtgaanc	ctccgcgggt	aatggcg	477

<210> 93

<211> 377

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature



&lt;222&gt; (1)...(377)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 93

gaacggctgg	accttgccctc	gcattgtgct	gctggcagga	ataccttggc	aagcagctcc	60
agtcgagca	gccccagacc	gctgccgccc	gaagctaagc	ctgcctctgg	ccttcccctc	120
cgccctcaatg	cagaaccant	agtgggagca	ctgtgttttag	agttaagagt	gaacactgtn	180
tgattttact	tggaatttc	ctctgtttata	tagcttttcc	caatgctaata	ttccaaacaa	240
caacaacaaa	ataacatgtt	tgccgtgttna	gttggtataaa	agtangtgat	tctgtatnta	300
aagaaaatat	tactgtttaca	tatactgctt	gcaanttctg	tattttattgg	tnctctggaa	360
ataaatatat	tatttaa					377

&lt;210&gt; 94

&lt;211&gt; 495

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(495)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 94

ccctttgagg	ggttagggtc	cagttcccag	tggaagaaac	aggccaggag	aantgcgtgc	60
cgagctgang	cagatttccc	acagtgaccc	cagagccctg	ggctatagtc	tctgaccctt	120
ccaaggaaag	accaccttct	ggggacatgg	gctggagggc	aggacctaga	ggcaccaagg	180
gaaggcccca	ttccggggct	gttccccgag	gaggaaggga	aggggctctg	tgtgcccccc	240
acgaggaana	ggccctgant	cctgggatca	nacacccctt	cacgtgtatc	cccacacaaa	300
tgcaagctca	ccaaggtccc	ctctcagtec	cttccctaca	ccctgaacgg	ncactggccc	360
acacccaccc	agancancca	cccgccatgg	ggaatgttct	caaggaatcg	cngggcaacg	420
tggactctng	tcccnnaagg	gggcagaatc	tccaatagan	gganngaacc	cttgctnana	480
aaaaaaaaana	aaaaa					495

&lt;210&gt; 95

&lt;211&gt; 472

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(472)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 95

ggttacttgg	tttcattgcc	accacttagt	ggatgtcatt	tagaaccatt	ttgtctgctc	60
ccctctggaag	ccttgccgag	agcggacttt	gtaattgttg	gagaataact	gctgaatttt	120
tagctgtttt	gagttgattc	gcaccactgc	accacaactc	aatatgaaaa	ctatttnact	180
tattttattat	ccttgtaaaa	gtatacaatg	aaaattttgt	tcatactgta	tttatcaagt	240
atgatgaaaa	gcaatagata	tatattcttt	tattatgttn	aattatgatt	gccattatta	300
atcggaacaaa	tgtggagtg	atgttctttt	cacagtaata	tatgcctttt	gtaacttcac	360
ttggttattt	tattgtaaat	gaattacaaa	attcttaatt	taagaaaatg	gtangttata	420
tttanttican	taatttcttt	ccttgttttac	gttaattttg	aaaagaatgc	at	472

&lt;210&gt; 96

&lt;211&gt; 476

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(476)  
 <223> n = A,T,C or G

<400> 96  
 ctgaagcatt tcttcaaact tntctacttt tgtcattgat acctgtagta agttgacaat 60  
 gtgggtgaaat ttcaaaaatta tatgtaactt ctactagttt tactttctcc cccaagtctt 120  
 ttttaactca tgattttttac acacacaatc cagaacttat tatatagcct ctaagtcttt 180  
 attcttcaca gtagatgatg aaagagtcct ccagtgtctt gngcanaatg ttctagntat 240  
 agctggatac atacngtggg agttctataa actcatacct cagtgggact naacccaaaat 300  
 tgtgttagtc tcaattccta ccacactgag ggagcctccc aaatcactat attcttatct 360  
 gcaggtaactc ctccagaaaa acngacaggg caggcttgca tgaaaaagtn acatctgcgt 420  
 tacaaagtct atcttcctca nangtctgtn aaggaacaat ttaatcttct agcttt 476

<210> 97  
 <211> 479  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(479)  
 <223> n = A,T,C or G

<400> 97  
 actctttcta atgctgatat gatcttgagt ataagaatgc atatgtcact agaattggata 60  
 aaataatgct gcaaacttaa tgttcttatg caaaatggaa cgctaataaa acacagctta 120  
 caatcgcaaa tcaaaactca caagtgtcga tctgtttagt atttagtgtg ataagactta 180  
 gattgtgctc ctccggatat gattgtttct canatcttgg gcaatnttcc ttagtcaaat 240  
 caggctacta gaattctgtt attggatatn tgagagcatg aaatttttaa naatacactt 300  
 gtgattatna aattaatcac aaatttcact tatacctgct atcagcagct agaaaaacat 360  
 ntnnttttta natcaaagta ttttgtgttt ggaantgttn aaatgaaatc tgaatgtggg 420  
 ttcnatctta ttttttcccn gacnactant tnccttttta gggncatttc tganccatc 479

<210> 98  
 <211> 461  
 <212> DNA  
 <213> Homo sapien

<400> 98  
 agtgacttgt cctccaacaa aacccttga tcaagtttgt ggcaactgaca atcagaccta 60  
 tgctagttcc tgtcatctat tgcctactaa atgcagactg gaggggacca aaaaggggca 120  
 tcaactccag ctggattatt ttggagcctg caaatctatt cctacttgta cggactttga 180  
 agtgattcag tttcctctac ggatgagaga ctggctcaag aatatcctca tgcagcttta 240  
 tgaagccact ctgaacacgc tggttatcta gatgagaaca gagaaataaa gtcagaaaat 300  
 ttacctggag aaaagaggct ttggctgggg accatcccat tgaaccttct cttaaggact 360  
 ttaagaaaaa ctaccacatg ttgtgtatcc tgggtgccggc cgtttatgaa ctgaccaccc 420  
 tttggaataa tcttgacgct cctgaacttg ctccctctgcg a 461

<210> 99  
 <211> 171  
 <212> DNA  
 <213> Homo sapien

<400> 99  
 gtggccgcgc gcagggtgtt cctcgtaacc cagggccccc tcccttcccc aggcgtccct 60  
 cggcgccctct gcgggcccga ggaggagcgg ctggcggtgt gggggagtgt gaccacccct 120

cggtgagaaa agccttctct agcgatctga gaggcgtgcc ttgggggtac c 171

<210> 100  
<211> 269  
<212> DNA  
<213> Homo sapien

<400> 100

cggccgcaag tgcaactcca gctggggccg tgcggacgaa gattctgcc	gcagttggtc	60
cgactgcgac gacggcggcg gcgacagtcg caggtgcagc gcgggcgct	ggggtcttgc	120
aaggctgagc tgacgccgca gaggtcgtgt cacgtccbac gaccttgacg	ccgtcgggga	180
cagccggaac agagcccggt gaagcgggag gcctcgggga gcccctcggg	aagggcggcc	240
cgagagatac gcaggtgcag gtggccgccc		269

<210> 101  
<211> 405  
<212> DNA  
<213> Homo sapien

<400> 101

tttttttttt ttttggaaac tactgcgagc acagcaggtc agcaacaagt	ttattttgca	60
gctagcaagg taacagggtg gggcatgggt acatgttcag gtcaacttcc	tttgtcgtgg	120
ttgattgggt tgtctttatg ggggcggggg ggggtagggg aaacgaagca	aataacatgg	180
agtgggtgca ccctccctgt agaacctggt tacaagctt ggggcagttc	acctggtctg	240
tgaccgtcat tttcttgaca tcaatgttat tagaagtcag gatattcttt	agagagtcca	300
ctgttctgga gggagattag ggtttcttgc caaatccaac aaaatccact	gaaaaagttg	360
gatgatcagt acgaataccg aggcattatc tcatatcggg	ggcca	405

<210> 102  
<211> 470  
<212> DNA  
<213> Homo sapien

<400> 102

tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	tttttttttt	60
ggcacttaac ccatttttat ttcaaaatgt ctacaaattt aatcccata	tacgggtattt	120
tcaaaatcta aattattcaa attagccaaa tccttaccaa ataataccca	aaaatcaaaa	180
atatacttct ttcagcaaac ttgttacata aattaaaaaa atatatacgg	ctgggtgtttt	240
caaagtacaa ttatcttaac actgcaaaac ttttaaggaa ctaaaataaa	aaaaaacact	300
ccgcaaaggt taaagggaac aacaaattct tttacaacac cattataaaa	atcatatctc	360
aatcttagg ggaatatata cttcacacgg gatcttaact ttactcact	ttgtttattt	420
ttttaaaacca ttgtttgggc ccaacacaat ggaatcccc	ctggactagt	470

<210> 103  
<211> 581  
<212> DNA  
<213> Homo sapien

<400> 103

tttttttttt ttttttttga cccccctctt ataataaaca agttaccatt	ttatttttact	60
tacacatatt tattttataa ttggtattag atattcaaaa ggcagctttt	aaaatcaaac	120
taaatgaaa ctgccttaga tacataattc ttaggaatta gcttaaaatc	tgctaaagt	180
gaaaatcttc tctagctctt ttgactgtaa atttttgact cttgtaaaac	atccaaattc	240
atttttcttg tctttaaaat tatctaattt ttccattttt tccctattcc	aagtcaattt	300
gcttctctag cctcatttcc tagctcttat ctactattag taagtggctt	ttttcctaaa	360
agggaaaaca ggaagagaaa tggcacacaa aacaaacatt ttatattcat	atttctacct	420
acgttaataa aatagcattt tgtgaagcca gctcaaaaga aggcttagat	ccttttatgt	480
ccatttttagt cactaaacga tatcaaagtg ccagaatgca aaaggtttgt	gaacatttat	540

tcaaaagcta atataagata tttcacatac tcatctttct g

581

<210> 104  
<211> 578  
<212> DNA  
<213> Homo sapien

<400> 104

tttttttttt	ttttttttta	tttttctctt	cttttttttt	gaaatgagga	tcgagttttt	60
cactctctag	atagggcatg	aagaaaactc	atctttccag	ctttaaaata	acaatcaa	120
ctcttatgct	atatcatatt	ttaagttaaa	ctaagagtc	actggcttat	cttctcctga	180
aggaaatctg	ttcattcttc	tcattcatat	agttatatca	agtactacct	tgcatattga	240
gaggtttttc	ttctctattt	acacatatat	ttccatgtga	atttgtatca	aacctttatt	300
ttcatgcaaa	ctagaaaata	atgtttcttt	tgcataagag	aagagaacaa	tatagcatta	360
caaaactgct	caaattgttt	gttaagttat	ccattataat	tagttggcag	gagctaatac	420
aaatcacatt	tacgacagca	ataataaaac	tgaagtacca	gttaaatac	caaaataatt	480
aaaggaacat	ttttagcctg	ggtataatta	gctaattcac	tttacaagca	tttattagaa	540
tgaattcaca	tgttattatt	cctagcccaa	cacaatgg			578

<210> 105  
<211> 538  
<212> DNA  
<213> Homo sapien

<400> 105

tttttttttt	tttttcagta	ataatcagaa	caatatttat	ttttatattt	aaaattcata	60
gaaaagtgcc	ttacatttaa	taaaagtgtg	tttctcaaag	tgatcagagg	aattagatat	120
gtcttgaaca	ccaatattaa	tttgaggaaa	atacacaaa	atacattaag	taaattattt	180
aagatcatag	agcttgtaag	tgaaaagata	aaatttgacc	tcagaaactc	tgagcattaa	240
aatccacta	ttagcaaata	aattactatg	gacttcttgc	tttaattttg	tgatgaatat	300
ggggtgtcac	tggtaaaacca	acacattctg	aaggatacat	tacttagtga	tagattctta	360
tgtactttgc	taatacgtgg	atatgagttg	acaagtttct	ctttcttcaa	tcttttaagg	420
ggcgagaaat	gaggaagaaa	agaaaaggat	tacgcatact	gttctttcta	tggaaggatt	480
agatatgttt	cctttgccea	tattaaaaaa	ataataatgt	ttactactag	tgaaaccc	538

<210> 106  
<211> 473  
<212> DNA  
<213> Homo sapien

<400> 106

tttttttttt	tttttttagtc	aagtttctat	ttttattata	attaaagtct	tggtcatttc	60
atttatttagc	tctgcaactt	acatatttaa	attaaagaaa	cgtttttagac	aactgtacaa	120
tttataaatg	taaggtgccca	ttattgagta	atatattcct	ccaagagtgg	atgtgtccct	180
tctcccacca	actaatgaac	agcaacatta	gtttaatttt	attagtagat	atacactgct	240
gcaaacgcta	attctcttct	ccatcccat	gtgatattgt	gtatatgtgt	gagttggtag	300
aatgcatcac	aatctacaat	caacagcaag	atgaagctag	gctgggcttt	cggtgaaaat	360
agactgtgtc	tgtctgaatc	aaatgatctg	acctatcctc	ggtggcaaga	actcttcgaa	420
ccgcttctctc	aaaggcgctg	ccacatttgt	ggctctttgc	acttgtttca	aaa	473

<210> 107  
<211> 1621  
<212> DNA  
<213> Homo sapien

<400> 107

cgccatggca	ctgcagggca	tctcgggtcat	ggagctgtcc	ggcctggccc	cgggcccgtt	60
ctgtgctatg	gtcctggctg	acttcggggc	gcgtgtggta	cgcgtggacc	ggcccggctc	120

```

ccgctacgac gtgagccgct tgggccgggg caagcgctcg ctagtgctgg acctgaagca 180
gccgcgggga gccgcgctgc tgcggcgctct gtgcaagcgg tcggatgtgc tgctggagcc 240
cttccgccgc ggtgtcatgg agaaactcca gctgggcccga gagattctgc agcgggaaaa 300
tccaaggctt atttatgcca ggctgagtggt atttggccag tcaggaagct tctgccggtt 360
agctggccac gatatcaact atttggcttt gtcagggtgtt ctctcaaaaa ttggcagaag 420
tggtgagaat ccgtatgccc cgctgaatct cctggctgac tttgctggtg gtggccttat 480
gtgtgcactg ggcattataa tggctctttt tgaccgcaca cgcactgaca agggtcaggt 540
cattgatgca aatatggtgg aaggaacagc atatttaagt tcttttctgt ggaaaactca 600
gaaatcgagt ctgtgggaag cacctcgagg acagaacatg ttggatggtg gagcaccttt 660
ctatacgact tacaggacag cagatgggga attcatggct gttggagcaa tagaacccca 720
gttctacgag ctgctgatca aaggacttgg actaaagtct gatgaacttc ccaatcagat 780
gagcatggat gattggccag aaatgaagaa gaagtttgca gatgtattg caaagaagac 840
gaaggcagag tgggtgcaaa tctttgacgg cacagatgcc tgtgtgactc cggttctgac 900
ttttgaggag gttgttcac atgatcacia caaggaacgg ggctcgttta tcaccagtga 960
ggagcaggac gtgagcccc gccctgcacc tctgctgtta aacaccccag ccattcccttc 1020
tttcaaaagg gatcctttca taggagaaca cactgaggag atacttgaag aatttggatt 1080
cagccgcgaa gagatttatc agcttaactc agataaaatc attgaaagta ataaggtaaa 1140
agctagtctc taacttccag gccacggct caagtgaatt tgaatactgc atttacagtg 1200
tagagtaaca cataacattg tatgcatgga aacatggagg aacagtatta cagtgtccta 1260
ccactcta atcaagaaaaga attacagact ctgattctac agtgatgatt gaattctaaa 1320
aatggttatc attaggctt ttgatttata aaactttggg tacttatact aaattatggt 1380
agttattctg ctttccagtt tgcttgatat atttgttgat attaagattc ttgacttata 1440
ttttgaatgg gttctagtga aaaaggaatg atatatctt gaagacatcg atatacat 1500
atttacactc ttgattctac aatgtagaaa atgaggaaat gccacaaatt gtatggtgat 1560
aaaagtcacg tgaacaacaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620
a

```

&lt;210&gt; 108

&lt;211&gt; 382

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 108

```

Met Ala Leu Gln Gly Ile Ser Val Met Glu Leu Ser Gly Leu Ala Pro
1 5 10 15
Gly Pro Phe Cys Ala Met Val Leu Ala Asp Phe Gly Ala Arg Val Val
20 25 30
Arg Val Asp Arg Pro Gly Ser Arg Tyr Asp Val Ser Arg Leu Gly Arg
35 40 45
Gly Lys Arg Ser Leu Val Leu Asp Leu Lys Gln Pro Arg Gly Ala Ala
50 55 60
Val Leu Arg Arg Leu Cys Lys Arg Ser Asp Val Leu Leu Glu Pro Phe
65 70 75 80
Arg Arg Gly Val Met Glu Lys Leu Gln Leu Gly Pro Glu Ile Leu Gln
85 90 95
Arg Glu Asn Pro Arg Leu Ile Tyr Ala Arg Leu Ser Gly Phe Gly Gln
100 105 110
Ser Gly Ser Phe Cys Arg Leu Ala Gly His Asp Ile Asn Tyr Leu Ala
115 120 125
Leu Ser Gly Val Leu Ser Lys Ile Gly Arg Ser Gly Glu Asn Pro Tyr
130 135 140
Ala Pro Leu Asn Leu Leu Ala Asp Phe Ala Gly Gly Leu Met Cys
145 150 155 160
Ala Leu Gly Ile Ile Met Ala Leu Phe Asp Arg Thr Arg Thr Asp Lys
165 170 175
Gly Gln Val Ile Asp Ala Asn Met Val Glu Gly Thr Ala Tyr Leu Ser
180 185 190
Ser Phe Leu Trp Lys Thr Gln Lys Ser Ser Leu Trp Glu Ala Pro Arg

```

195	200	205
Gly Gln Asn Met Leu Asp Gly Gly Ala Pro Phe Tyr Thr Thr Tyr Arg		
210	215	220
Thr Ala Asp Gly Glu Phe Met Ala Val Gly Ala Ile Glu Pro Gln Phe		
225	230	235
Tyr Glu Leu Leu Ile Lys Gly Leu Gly Leu Lys Ser Asp Glu Leu Pro		240
	245	250
Asn Gln Met Ser Met Asp Asp Trp Pro Glu Met Lys Lys Lys Phe Ala		255
	260	265
Asp Val Phe Ala Lys Lys Thr Lys Ala Glu Trp Cys Gln Ile Phe Asp		270
	275	280
Gly Thr Asp Ala Cys Val Thr Pro Val Leu Thr Phe Glu Glu Val Val		285
	290	295
His His Asp His Asn Lys Glu Arg Gly Ser Phe Ile Thr Ser Glu Glu		300
305	310	315
Gln Asp Val Ser Pro Arg Pro Ala Pro Leu Leu Leu Asn Thr Pro Ala		320
	325	330
Ile Pro Ser Phe Lys Arg Asp Pro Phe Ile Gly Glu His Thr Glu Glu		335
	340	345
Ile Leu Glu Glu Phe Gly Phe Ser Arg Glu Glu Ile Tyr Gln Leu Asn		350
	355	360
Ser Asp Lys Ile Ile Glu Ser Asn Lys Val Lys Ala Ser Leu		365
370	375	380

<210> 109  
 <211> 1524  
 <212> DNA  
 <213> Homo sapien

<400> 109

ggcagcaggc	tgcgccaggc	cctgagcgga	ggcgggggca	gcctcgccag	cggggggccc	60
gggcctggcc	atgcctcact	gagccagcgc	ctgcgcctct	acctcgccga	cagctggaac	120
cagtgcgacc	tagtggctct	cacctgcttc	ctcctgggcg	tgggctgccc	gctgacccc	180
ggtttgtacc	acctggggccg	caactgtctc	tgcctcgact	tcattggttt	cacggtgccc	240
ctgcttcaca	tcttcacggt	caacaaacag	ctggggccca	agatcgctcat	cgtgagcaag	300
atgatgaagg	acgtgttctt	cttctctctc	ttcctcgccg	tgtggctggt	agcctatggc	360
gtggccacgg	aggggctcct	gaggccacgg	gacagtgact	tcccaagtat	cctgcgccgc	420
gtcttctacc	gtccctacct	gcagatcttc	gggcagattc	cccaggagga	catggacgtg	480
gccctcatgg	agcacagcaa	ctgctcgctc	gagcccggtc	tctgggcaca	ccctcctggg	540
gcccaggcgg	gcacctgcgt	ctcccagtat	gccaaactgg	tgggtgtgct	gctcctcgtc	600
atcttctctg	tcgtggccaa	catcctgctg	gtcaacttgc	tcattgccat	gttcagttac	660
acattcggca	aagtacaggg	caacagcgat	ctctactgga	aggcgagcgg	ttaccgcctc	720
atccgggaat	tccactctcg	gcccgcgctg	gccccgccct	ttatcgctcat	ctcccaactg	780
cgcctcctgc	tcaggcaatt	gtgcaggcga	ccccggagcc	cccagccgct	ctccccggcc	840
ctcgagcatt	tccgggttta	cctttctaag	gaagccgagc	ggaagctgct	aacgtgggaa	900
tgggtgcata	aggagaactt	tctgctggca	cgcgctaggg	acaagcgagg	gagcgactcc	960
gagcgtctga	agcgcacgtc	ccagaagggtg	gacttggcac	tgaacagact	gggacacatc	1020
cgcgagtacg	aacagcgctc	gaaagtgtcg	gagcgggagg	tccagcagtg	tagccgcgtc	1080
ctgggggtggg	tggccgaggg	cctgagccgc	tctgccttgc	tgccccagg	tgggcccaca	1140
ccccctgacc	tgcttgggtc	caaagactga	gcctgtctgg	cggacttcaa	ggagaagccc	1200
ccacagggga	ttttgctcct	agagtaaggc	tcattctggc	ctcgccccc	gcacctggtg	1260
gccttgtcct	tgaggtgagc	cccatgtcca	tctgggccac	tgtcaggacc	acctttggga	1320
gtgtcatcct	tacaaaccac	agcatgccc	gctcctcca	gaaccagtcc	cagcctggga	1380
ggatcaaggc	ctggatccc	ggccgttatc	catctggagg	ctgcagggtc	cttggggtaa	1440
cagggaccac	agacccctca	ccactcacag	attcctcaca	ctgggggaaat	aaagccattt	1500
cagaggaaaa	aaaaaaaaaa	aaaa				1524

<210> 110

<211> 3410  
 <212> DNA  
 <213> Homo sapien

<400> 110

gggaaccagc	ctgcacgcgc	tggtccggg	tgacagccgc	gcgcctcggc	caggatctga	60
gtgatgagac	gtgtcccccac	tgaggtgccc	cacagcagca	ggtgttgagc	atgggctgag	120
aagctggacc	ggcaccaaag	ggctggcaga	aatgggcgcc	tggtctgattc	ctaggcagtt	180
ggcggcagca	aggaggagag	gccgcagctt	ctggagcaga	gccgagacga	agcagttctg	240
gagtgcctga	acggcccccct	gagccctacc	cgcttgcccc	actatgggtcc	agaggctgtg	300
ggtgagccgc	ctgctgcggc	accggaaagc	ccagctcttg	ctggtcaacc	tgctaacctt	360
tgccctggag	gtgtgttttg	ccgcaggcat	cacctatgtg	ccgcctctgc	tgctggaagt	420
gggggtagag	gagaagttca	tgacctgggt	gctgggcatt	ggtccagtgc	tgggcctggt	480
ctgtgtcccc	ctcctaggct	cagccagtga	ccactggcgt	ggacgctatg	gccgcgcgcg	540
gcccttcate	tgggcactgt	ccttgggcct	cctgctgagc	ctctttctca	tcccaagggc	600
cggctggcta	gcagggtctgc	tgtgcccgga	tcccaggccc	ctggagctgg	cactgctcat	660
cctgggcgtg	gggctgctgg	acttctgtgg	ccaggtgtgc	ttcactccac	tggaggccct	720
gctctctgac	ctcttcgggg	accggacca	ctgtcgccag	gcctactctg	tctatgcctt	780
catgatcagt	cttgggggct	gcctgggcta	cctcctgcct	gccattgact	gggacaccag	840
tgccctggcc	ccctacctgg	gcacccagga	ggagtgcctc	tttggcctgc	tcaccctcat	900
cttcctcacc	tgcgttagcag	ccacactgct	ggtggctgag	gaggcagcgc	tgggcccccac	960
cgagccagca	gaagggtctg	cggcccccctc	cttgtcgccc	cactgctgtc	catgcccgggc	1020
ccgcttggtt	ttccggaacc	tgggcgccct	gcttcccccg	ctgcaccagc	tgtgctgccg	1080
catgccccgc	accctgcgcc	ggctcttcgt	ggctgagctg	tgacagctga	tgggcactcat	1140
gaccttcacg	ctgttttaca	cggatttcgt	gggcgagggg	ctgtaccagg	gcgtgccccag	1200
agctgagccg	ggcaccgagg	cccggagaca	ctatgatgaa	ggcgttcgga	tgggcagcct	1260
ggggctgttc	ctgcagtgcg	ccatctccct	ggtcttctct	ctggctcatg	accggtggt	1320
gcagcgattc	ggcactcgag	cagtctatct	ggccagtgtg	gcagctttcc	ctgtggctgc	1380
cgggtgccaca	tgctgtcccc	acagtgtggc	cgtggtgaca	gcttcagccg	ccctcaccgg	1440
gtcaccttc	tcagccctgc	agatcctgcc	ctacacactg	gcctccctct	accaccggga	1500
gaagcaggtg	ttctgcacca	aataccgagg	ggacactgga	ggtgctagca	gtgaggacag	1560
cctgatgacc	agcttctctg	caggccctaa	gcctggagct	cccttcccta	atggacacgt	1620
gggtgctgga	ggcagtggcc	tgctcccacc	tccaccgcgc	ctctgcgggg	cctctgcctg	1680
tgatgtctcc	gtacgtgtgg	tggtgggtga	gcccaccgag	gccagggtgg	ttccggggccg	1740
gggcatctgc	ctggacctcg	ccatcctgga	tagtgccctc	ctgctgtccc	aggtggcccc	1800
atccctgttt	atgggctcca	ttgtccagct	cagccagtct	gtcactgcct	atatggtgtc	1860
tgccgcaggc	ctgggtctgg	tcgccattta	ctttgtctaca	caggtagtat	ttgacaagag	1920
cgacttggcc	aaatactcag	cgtagaaaaa	ttccagcaca	ttgggggtgga	gggctgcct	1980
cactgggtcc	cagctccccg	ctcctgttag	ccccatggg	ctgccgggct	ggccgcagct	2040
ttctgttgct	gccaaagtaa	tgtggctctc	tgctgccacc	ctgtgctgct	gaggtgcgta	2100
gctgcacagc	tgggggctgg	ggcgccctc	tcctctctcc	ccagtctcta	gggctgcctg	2160
actggaggcc	ttccaagggg	gtttcagctc	ggacttatac	agggaggcca	gaagggtcc	2220
atgcactgga	atgcggggac	tctgcagggt	gattaccag	gctcagggtt	aacagctagc	2280
ctcctagttg	agacacacct	agagaagggt	ttttgggagc	tgaataaaact	cagtcacctg	2340
gtttcccatc	tctaagcccc	ttaacctgca	gcttcgttta	atgtagctct	tgcatgggag	2400
tttctaggat	gaaacactcc	tccatgggat	ttgaacatat	gacttatttg	taggggaaga	2460
gtcctgaggg	gcaacacaca	agaaccaggt	ccccctagcc	caacagcactg	tctttttgct	2520
gatccacccc	cctcttaoct	tttatcagga	tgtggcctgt	tggtccttct	gttgccatca	2580
cagagacaca	ggcattttaa	tatttaactt	atttatttaa	caaagtagaa	gggaatccat	2640
tgctagcttt	tctgtgttgg	tgtctaatat	ttgggtaggg	tgggggatcc	ccaacaatca	2700
ggtccccctga	gatagctggt	cattgggctg	atcattgcca	gaatcttctt	ctcctgggggt	2760
ctggccccc	aaaatgccta	accaggacc	ttggaaattc	tactcatccc	aatgataat	2820
tccaaatgct	gttacccaag	gttaggggtg	tgaagggaagg	tagagggtgg	ggcttcagggt	2880
ctcaacggct	tccttaacca	ccccctctct	cttggcccag	cctgggtccc	cccacttcca	2940
ctccccctcta	ctctctctag	gactgggctg	atgaaggcac	tgcccaaaat	ttccccctacc	3000
cccaactttc	ccctaccccc	aactttcccc	accagctcca	caaccctgtt	tggagctact	3060
gcaggaccag	aagcacaagg	tgcggtttcc	caagcctttg	tccatctcag	cccccagagt	3120
atatctgtgc	ttgggggaatc	tcacacagaa	actcaggagc	acccctgccc	tgagctaaag	3180

gaggtcttat	ctctcagggg	gggtttaagt	gccgtttgca	ataatgtcgt	cttattttatt	3240
tagcgggggtg	aatattttat	actgtaagt	agcaatcaga	gtataatgtt	tatgggtgaca	3300
aaatttaaagg	ctttctttata	tgttttaaaaa	aaaaaaaaaaa	aaaaaaaaaaa	aaaaaaaaaaa	3360
aaaaaaaaara	aaaaaaaaaaa	aaaaaaaaaaa	aaaaaaataa	aaaaaaaaaaa		3410

&lt;210&gt; 111

&lt;211&gt; 1289

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 111

agccaggcgt	ccctctgcct	gcccactcag	tggcaacacc	cgaggagctgt	tttgtccttt	60
gtggagcctc	agcagttccc	tctttcagaa	ctcactgccca	agagccctga	acaggagcca	120
ccatgcagtg	cttcagcttc	attaagacca	tgatgatcct	cttcaatttg	ctcatctttc	180
tgtgtggtgc	agccctgttg	gcagtgggca	tctgggtgtc	aatcgatggg	gcaccccttc	240
tgaagatctt	cgggccactg	tgcgtccagt	ccatgcagtt	tgtcaacgtg	ggctacttcc	300
tcacgcagc	cggcgttggt	gtctttgtct	ttgggttccct	gggctgctat	gggtgctaaga	360
ctgagagcaa	gtgtgcccct	gtgacgttct	tcttcacccct	cctccctcatc	ttcattgctg	420
agggttcagc	tgtgtgtgtc	gccttggtgt	acaccacaat	ggctgagcac	ttcctgacgt	480
tgtctgtagt	gcctgccatc	aagaaagatt	atgggtccca	ggaagacttc	actcaagtgt	540
ggaacaccac	catgaaaggg	ctcaagtgtc	gtggcttcac	caactatacg	gattttgagg	600
actcacccta	cttcaaagag	aacagtgcct	ttccccatt	ctgttgcaat	gacaacgtca	660
ccaacacagc	caatgaaacc	tgcaccaagc	aaaaggctca	cgaccaaaaa	gtagagggtt	720
gcttcaatca	gcttttgtat	gacatccgaa	ctaattgcagt	caccgtgggt	gggtgtggcag	780
ctggaattgg	gggcctcgag	ctggctgccca	tgattgtgtc	catgtatctg	tactgcaatc	840
tacaataagt	ccacttctgc	ctctgccact	actgctgccca	catgggaact	gtgaagaggc	900
accctggcaa	gcagcagtg	ttggggggagg	ggacaggatc	taacaatgtc	acttggggcca	960
gaatggacct	gccctttctg	ctccagactt	ggggctagat	agggaccact	ccttttagcg	1020
atgcctgact	ttccttccat	tgggtgggtg	atgggtgggg	ggcattccag	agcctctaag	1080
gtagccagtt	ctgttgccca	ttccccagt	ctattaaacc	cttgatatgc	cccctaggcc	1140
tagtggtgat	cccagtgtct	tactggggga	tgagagaaaag	gcattttata	gcctgggcat	1200
aagtgaatc	agcagagcct	ctgggtggat	gtgtagaagg	cacttcaaaa	tgcataaacc	1260
tgttacaatg	ttaaaaaaaa	aaaaaaaaaa				1289

&lt;210&gt; 112

&lt;211&gt; 315

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 112

Met	Val	Phe	Thr	Val	Arg	Leu	Leu	His	Ile	Phe	Thr	Val	Asn	Lys	Gln
1				5					10					15	
Leu	Gly	Pro	Lys	Ile	Val	Ile	Val	Ser	Lys	Met	Met	Lys	Asp	Val	Phe
			20					25					30		
Phe	Phe	Leu	Phe	Phe	Leu	Gly	Val	Trp	Leu	Val	Ala	Tyr	Gly	Val	Ala
			35				40					45			
Thr	Glu	Gly	Leu	Leu	Arg	Pro	Arg	Asp	Ser	Asp	Phe	Pro	Ser	Ile	Leu
	50					55					60				
Arg	Arg	Val	Phe	Tyr	Arg	Pro	Tyr	Leu	Gln	Ile	Phe	Gly	Gln	Ile	Pro
	65				70				75					80	
Gln	Glu	Asp	Met	Asp	Val	Ala	Leu	Met	Glu	His	Ser	Asn	Cys	Ser	Ser
				85					90					95	
Glu	Pro	Gly	Phe	Trp	Ala	His	Pro	Pro	Gly	Ala	Gln	Ala	Gly	Thr	Cys
			100					105					110		
Val	Ser	Gln	Tyr	Ala	Asn	Trp	Leu	Val	Val	Leu	Leu	Leu	Val	Ile	Phe
		115					120					125			
Leu	Leu	Val	Ala	Asn	Ile	Leu	Leu	Val	Asn	Leu	Leu	Ile	Ala	Met	Phe
	130					135					140				



Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu Tyr Trp Lys  
 145 150 155 160  
 Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg Pro Ala Leu  
 165 170 175  
 Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu Leu Arg Gln  
 180 185 190  
 Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro Ala Leu Glu  
 195 200 205  
 His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr  
 210 215 220  
 Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp  
 225 230 235 240  
 Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gln Lys Val  
 245 250 255  
 Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr Glu Gln Arg  
 260 265 270  
 Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg Val Leu Gly  
 275 280 285  
 Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly  
 290 295 300  
 Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp  
 305 310 315

<210> 113  
 <211> 553  
 <212> PRT  
 <213> Homo sapien

<400> 113  
 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala  
 1 5 10 15  
 Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu  
 20 25 30  
 Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val  
 35 40 45  
 Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly  
 50 55 60  
 Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly  
 65 70 75 80  
 Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile  
 85 90 95  
 Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu  
 100 105 110  
 Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly  
 115 120 125  
 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu  
 130 135 140  
 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala  
 145 150 155 160  
 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr  
 165 170 175  
 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu  
 180 185 190  
 Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu  
 195 200 205  
 Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly  
 210 215 220  
 Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His

[illegible]

```
<210> 114
<211> 241
<212> PRT
<213> Homo sapien
```

<400> 114															
Met	Gln	Cys	Phe	Ser	Phe	Ile	Lys	Thr	Met	Met	Ile	Leu	Phe	Asn	Leu
1				5					10					15	
Leu	Ile	Phe	Leu	Cys	Gly	Ala	Ala	Leu	Leu	Ala	Val	Gly	Ile	Trp	Val
			20					25					30		
Ser	Ile	Asp	Gly	Ala	Ser	Phe	Leu	Lys	Ile	Phe	Gly	Pro	Leu	Ser	Ser
		35					40					45			
Ser	Ala	Met	Gln	Phe	Val	Asn	Val	Gly	Tyr	Phe	Leu	Ile	Ala	Ala	Gly
	50					55					60				
Val	Val	Val	Phe	Ala	Leu	Gly	Phe	Leu	Gly	Cys	Tyr	Gly	Ala	Lys	Thr
65					70					75					80

Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile  
                   85                  90                  95  
 Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr  
                   100                  105                  110  
 Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys  
                   115                  120                  125  
 Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met  
                   130                  135                  140  
 Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp  
                   145                  150                  155                  160  
 Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn  
                   165                  170                  175  
 Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala  
                   180                  185                  190  
 His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile  
                   195                  200                  205  
 Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly  
                   210                  215                  220  
 Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu  
                   225                  230                  235                  240  
 Gln

<210> 115  
 <211> 366  
 <212> DNA  
 <213> Homo sapien

<400> 115  
 gctctttctc tccctctctc tgaatttaaat tctttcaact tgcaatttgc aaggattaca 60  
 catttcaactg tgatgtatat tgtgttgcaa aaaaaaaaaa gtgtctttgt ttaaaattac 120  
 ttggtttgtg aatccatctt gctttttccc catttgaact agtcattaac ccatctctga 180  
 actggttagaa aaacatctga agagctagtc tatcagcatc tgacaggtga attggatggt 240  
 tctcagaacc atttcaccca gacagcctgt ttctatcctg ttttaataaat tagtttgggt 300  
 tctctacatg cataacaaac cctgctccaa tctgtcacat aaaagtctgt gacttgaagt 360  
 ttagtc 366

<210> 116  
 <211> 282  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(282)  
 <223> n = A,T,C or G

<400> 116  
 acaaagatga accatttctt atattatagc aaaattaaaa tctaccogta ttctaattatt 60  
 gagaaatgag atnaaacaca atnttataaa gtctacttag agaagatcaa gtgacctcaa 120  
 agactttact attttcatat tttaagacac atgatttatt ctatttttagt aacctgggtc 180  
 atacgttaaa caaaggataa tgtgaacagc agagaggatt tgttggcaga aaatctatgt 240  
 tcaatctnga actatctana tcacagacat ttctatttctt tt 282

<210> 117  
 <211> 305  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(305)  
 <223> n = A,T,C or G

<400> 117  
 acacatgtcg cttcactgcc ttcttagatg cttctgggtca acatanagga acagggacca 60  
 tattttatcct ccctcctgaa acaattgcaa aataanacaa aatatatgaa acaattgcaa 120  
 aataaggcaa aatatatgaa acaacaggtc tcgagatatt ggaaatcagt caatgaagga 180  
 tactgatccc tgatcactgt cctaattgcag gatgtgggaa acagatgagg tcacctctgt 240  
 gactgccccca gcttactgcc tgtagagagt ttctangctg cagttcagac agggagaaat 300  
 tgggt 305

<210> 118  
 <211> 71  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(71)  
 <223> n = A,T,C or G

<400> 118  
 accaaggtgt ntgaatctct gacgtgggga tctctgattc ccgcacaatc tgagtggaaa 60  
 aantcctggg t 71

<210> 119  
 <211> 212  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(212)  
 <223> n = A,T,C or G

<400> 119  
 actccggttg gtgtcagcag cacgtggcat tgaacatngc aatgtggagc ccaaaccaca 60  
 gaaaatgggg tgaaattggc caactttcta tnaacttatg ttggcaantt tgccaccaac 120  
 agtaagctgg cccttctaataaaaagaaaat tgaaaggttt ctactaanc ggaattaant 180  
 aatggantca aganactccc aggcctcagc gt 212

<210> 120  
 <211> 90  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(90)  
 <223> n = A,T,C or G

<400> 120  
 actcgttgca natcaggggc cccccagagt caccgttgca ggagtccttc tggctcttgcc 60  
 ctccgccggc gcagaacatg ctggggtggt 90

<210> 121  
 <211> 218  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(218)  
 <223> n = A,T,C or G

<400> 121  
 tgtancgtga anacgacaga nagggttgtc aaaaatggag aanccttgaa gtcattttga 60  
 gaataagatt tgctaaaaga tttggggcta aaacatgggtt attgggagac atttctgaag 120  
 atatncangt aaattangga atgaattcat ggttcctttt ggaattcctt tacgatngcc 180  
 agcatanact tcatgtgggg atancagcta cccttgta 218

<210> 122  
 <211> 171  
 <212> DNA  
 <213> Homo sapien

<400> 122  
 taggggtgta tgcaactgta aggacaaaaa ttgagactca actggcttaa ccaataaagg 60  
 catttgtag ctcatggaac aggaagtcgg atgggtggggc atcttcagtg ctgcatgagt 120  
 caccaccccg gcggggtcat ctgtgccaca ggtccctgtt gacagtgcgg t 171

<210> 123  
 <211> 76  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(76)  
 <223> n = A,T,C or G

<400> 123  
 ttagcgtga agacnacaga atgggtgtgtg ctgtgctatc caggaacaca tttattatca 60  
 ttatcaanta ttgtgt 76

<210> 124  
 <211> 131  
 <212> DNA  
 <213> Homo sapien

<400> 124  
 acctttcccc aaggccaatg tcctgtgtgc taactggccg gctgcaggac agctgcaatt 60  
 caatgtgctg ggtcatatgg aggggaggag actctaaaat agccaatttt attctcttgg 120  
 ttaagatttg t 131

<210> 125  
 <211> 432  
 <212> DNA  
 <213> Homo sapien

<400> 125  
 actttatcta ctggctatga aatagatggg ggaaaattgc gttaccaact ataccactgg 60  
 cttgaaaaag aggtgatagc tcttcagagg acttgtgact tttgctcaga tgctgaagaa 120

ctacagtctg catttggcag aaatgaagat gaatttggat taaatgagga tgctgaagat	180
ttgcctcacc aaacaaaagt gaaacaactg agagaaaatt ttcaggaaaa aagacagtgg	240
ctcttgaagt atcagtcact tttgagaatg tttcttagtt actgcatact tcatggatcc	300
catggtgggg gtcttgcacg tgtaagaatg gaattgattt tgcttttgca agaattctcag	360
caggaaacat cagaaccact attttctagc cctctgtcag agcaaacctc agtgcctctc	420
ctctttgctt gt	432

<210> 126  
 <211> 112  
 <212> DNA  
 <213> Homo sapien

<400> 126	
acacaacttg aatagtaaaa tagaaactga gctgaaattt ctaattcact ttctaaccat	60
agtaagaatg atatttcccc ccagggatca ccaaataattt ataaaaattt gt	112

<210> 127  
 <211> 54  
 <212> DNA  
 <213> Homo sapien

<400> 127	
accacgaaac cacaacaag atggaagcat caatccactt gccaaagcaca gcag	54

<210> 128  
 <211> 323  
 <212> DNA  
 <213> Homo sapien

<400> 128	
acctcattag taattgtttt gttgtttcat ttttttctaa tgtctcccct ctaccagctc	60
acctgagata acagaatgaa aatggaagga cagccagatt tctcctttgc tctctgctca	120
ttctctctga agtctagggt acccattttg gggacccatt ataggcaata aacacagttc	180
ccaaagcatt tggacagttt cttgtttgtg tttagaatgg ttttcctttt tcttagcctt	240
ttcttgcaaa aggtcactc agtcccttgc ttgctcagtg gactgggctc cccagggcct	300
aggtgcctt cttttccatg tcc	323

<210> 129  
 <211> 192  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc feature  
 <222> (1)...(192)  
 <223> n = A,T,C or G

<400> 129	
acatacatgt gtgtatattt ttaaatatca cttttgtatc actctgactt tttagcatatc	60
tgaaaacaca ctaacataat ttntgtgaac catgatcaga tacaacccaa atcattcatc	120
tagcacattc atctgtgata naaagatagg tgagtttcat ttccttcacg ttggccaatg	180
gataaacaaa gt	192

<210> 130  
 <211> 362  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(362)  
 <223> n = A,T,C or G

<400> 130  
 ccctttttta tggaatgagt agactgtatg tttgaanatt tanccacaac ctcttttgaca 60  
 tataatgacg caacaaaaag gtgctgttta gtcctatggt tcagtttatg cccctgacaa 120  
 gtttccattg tgttttgccg atcttctggc taatcgtggt atcctccatg ttattagtaa 180  
 ttctgtattc ctttttgcta acgcctgga gatgtaacct gctangaggc taactttata 240  
 cttatttaaa agctcttatt ttgtggtcat taaaatggca atttatgtgc agcaacttat 300  
 tgcagcagga agcacgtgtg gggttggtgt aaagctcttt gctaatactta aaaagtaatg 360  
 gg 362

<210> 131  
 <211> 332  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(332)  
 <223> n = A,T,C or G

<400> 131  
 ctttttgaaa gatcgtgtcc actcctgtgg acatcttgtt ttaatggagt ttcccatgca 60  
 gtangactgg tatggttgca gctgtccaga taaaaacatt tgaagagctc caaaatgaga 120  
 gttctcccag gttcgccctg ctgctccaag tctcagcagc agcctctttt aggaggcatc 180  
 ttctgaacta gattaaggca gcttgtaaat ctgatgtgat ttgggtttatt atccaactaa 240  
 cttccatctg ttatcactgg agaaagccca gactcccan gacnggtacg gattgtgggc 300  
 atanaaggat tgggtgaagc tggcgttgtg gt 332

<210> 132  
 <211> 322  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(322)  
 <223> n = A,T,C or G

<400> 132  
 acttttgcca ttttgtatat ataaacaatc ttgggacatt ctctgaaaa ctaggtgtcc 60  
 agtggctaag agaactcgat ttcaagcaat tctgaaagga aaaccagcat gacacagaat 120  
 ctcaaattcc caaacagggg ctctgtggga aaaatgaggg aggaccttg tatctcgggt 180  
 tttagcaagt taaaatgaan atgacaggaa aggcttattt atcaacaaag agaagagttg 240  
 ggatgcttct aaaaaaaact ttggtagaga aaataggaat gctnaatcct agggaagcct 300  
 gtaacaatct acaattgggtc ca 322

<210> 133  
 <211> 278  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(278)

<223> n = A,T,C or G

<400> 133

acaagccttc	acaagtttaa	ctaaattggg	attaatcttt	ctgtanttat	ctgcataatt	60
cttggttttc	tttccatctg	gctcctgggt	tgacaatttg	tggaacaac	tctattgcta	120
ctatttaaaa	aaaatcacaa	atctttccct	ttaagctatg	ttnaattcaa	actattcctg	180
ctattcctgt	tttgtcaaag	aaattatatt	tttcaaaaata	tgtntatttg	tttgatgggt	240
cccacgaaac	actaataaaa	accacagaga	ccagcctg			278

<210> 134

<211> 121

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(121)

<223> n = A,T,C or G

<400> 134

gtttanaaaa	cttgtttagc	tccatagagg	aaagaatggt	aaactttgta	ttttaaaaca	60
tgattctctg	aggtaaact	tggttttcaa	atgttatatt	tacttgtatt	ttgcttttgg	120
t						121

<210> 135

<211> 350

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(350)

<223> n = A,T,C or G

<400> 135

acttanaacc	atgcctagca	catcagaatc	cctcaaagaa	catcagtata	atcctataacc	60
atancaagt	gtgactgggt	aagcgtgcga	caaaggtcag	ctggcacatt	acttggtgtc	120
aaacttgata	cttttgttct	aagtaggaac	tagtatacag	tncctaggan	tggtactcca	180
gggtgcccc	caactcctgc	agccgctcct	ctgtgccagn	ccctgnaagg	aaactttcgt	240
ccacctcaat	caagccctgg	gccatgctac	ctgcaattgg	ctgaacaaac	gtttgctgag	300
ttcccaagga	tgcaaagcct	ggtgctcaac	tcctggggcg	tcaactcagt		350

<210> 136

<211> 399

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(399)

<223> n = A,T,C or G

<400> 136

tgtaccgtga	agacgacaga	agttgcatgg	cagggacagg	gcagggccga	ggccagggtt	60
gctgtgattg	tatccgaata	ntcctcgtga	gaaaagataa	tgagatgacg	tgagcagcct	120
gcagacttgt	gtctgccttc	aanaagccag	acaggaaggc	cctgcctgcc	ttggotctga	180
cctggcggcc	agccagccag	ccacaggtgg	gcttcttctc	tttgtggtga	caacnccaag	240
aaaactgcag	aggcccaggg	tcaggtgtna	gtgggtangt	gaccataaaa	caccaggtgc	300



tcccaggaac cccgggcaaag gccatcccca cctacagcca gcatgcccac tggcgtgatg 360  
 ggtgcagang gatgaagcag ccagntgttc tgctgtggt 399

<210> 137

<211> 165

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(165)

<223> n = A,T,C or G

<400> 137

actggtgtgg tngggggtga tgctggtggt anaagttgan gtgacttcan gatggtgtgt 60  
 ggaggaagtg tgtgaacgta gggatgtaga ngttttggcc gtgctaaatg agcttcggga 120  
 ttggtgtgtc ccactggtgg tcaactgtcat tgggtggggtt cctgt 165

<210> 138

<211> 338

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(338)

<223> n = A,T,C or G

<400> 138

actcactgga atgccacatt cacaacagaa tcagaggtct gtgaaaacat taatggctcc 60  
 ttaacttctc cagtaagaat cagggacttg aaatggaaac gttaacagcc acatgoccaa 120  
 tgctgggcag tctcccatgc cttccacagt gaaagggctt gagaaaaatc acatccaatg 180  
 tcatgtgttt ccagccacac caaaagggtgc ttgggggtgga gggctggggg catananggt 240  
 cangcctcag gaagcctcaa gtccattca gctttgccac tgtacattcc ccatntttaa 300  
 aaaaactgat gccttttttt tttttttttg taaaattc 338

<210> 139

<211> 382

<212> DNA

<213> Homo sapien

<400> 139

gggaatcttg gtttttggca tctggtttgc ctatagccga ggccactttg acagaacaaa 60  
 gaaagggact tcgagtaaga aggtgattta cagccagcct agtgcccga gtgaaggaga 120  
 attcaaacag acctcgatcat tcctggtgtg agcctggtcg gctcaccgcc tatcatctgc 180  
 atttgctta ctcaggtgct accggactct ggccctgat gtctgtagt tcaaggatg 240  
 ccttatttgt cttctacacc ccacagggcc ccctaactct tcggatgtgt ttttaataat 300  
 gtcagctatg tgccccatcc tccttcatgc cctccctccc tttcctacca ctgctgagt 360  
 gcctggaact tgttttaaagt gt 382

<210> 140

<211> 200

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(200)

<223> n = A,T,C or G

<400> 140

acccaaanctt	ctttctgttg	tggtngattt	tactataggg	gtttngcttn	ttctaaanat	60
acttttcatt	taacancttt	tgtaagtgt	caggctgcac	tttgctccat	anaattattg	120
ttttcacatt	tcaacttgta	tggtttgtc	tcttanagca	ttggtgaaat	cacatatttt	180
atattcagca	taaaggagaa					200

<210> 141

<211> 335

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(335)

<223> n = A,T,C or G

<400> 141

actttatttt	caaaacactc	atatgttgca	aaaaacacat	agaaaaataa	agtttggtgg	60
gggtgctgac	taaacttcaa	gtcacagact	tttatgtgac	agattggagc	agggtttggt	120
atgcatgtag	agaacccaaa	ctaatttatt	aaacaggata	gaaacaggct	gtctgggtga	180
aatggttctg	agaaccatcc	aattcacctg	tcagatgctg	atanactagc	tcttcagatg	240
tttttctacc	agttcagaga	tnggttaatg	actantcca	atggggaaaa	agcaagatgg	300
attcacaac	caagtaattt	taaacaagaa	cactt			335

<210> 142

<211> 459

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(459)

<223> n = A,T,C or G

<400> 142

accaggttaa	tattgccaca	tatatccttt	ccaattgcgg	gctaaacaga	cggtgtattta	60
gggttgttta	aagacaaccc	agcttaatat	caagagaaat	tgtgaccttt	catggagtat	120
ctgatggaga	aaacactgag	ttttgacaaa	tcttatttta	ttcagatagc	agtctgatca	180
cacatgggtcc	aacaacactc	aaataataaa	tcaaatatna	tcagatgtta	aagattggtc	240
ttcaaacatc	atagccaatg	atgccccgct	tgccataat	ctctccgaca	taaaaccaca	300
tcaacacctc	agtggccacc	aaaccattca	gcacagcttc	cttaactgtg	agctgtttga	360
agctaccagt	ctgagcacta	ttgactatnt	ttttcangct	ctgaatagct	ctagggatct	420
cagcangggg	gggaggaacc	agctcaacct	tggcgtant			459

<210> 143

<211> 140

<212> DNA

<213> Homo sapien

<400> 143

acatttcctt	ccaccaagtc	aggactcctg	gcttctgtgg	gagttcttat	cacctgaggg	60
aaatccaaac	agtctctcct	agaaaggaat	agtgtcacca	acccaccca	tctccctgag	120
accatccgac	ttccctgtgt					140

<210> 144

<211> 164

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(164)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 144

acttcagtaa caacatacaa taacaacatt aagtgtatat tgccatcttt gtcattttct	60
atctatacca ctctcccttc tgaaaacaan aatcactanc caatcactta tacaaatttg	120
aggcaattaa tccatatttg ttttcaataa ggaaaaaaag atgt	164

&lt;210&gt; 145

&lt;211&gt; 303

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(303)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 145

acgtagacca tccaactttg tatttgtaat ggcaaacatc cagnagcaat tcctaaacaa	60
actggagggt atttataccc aattatccca ttcattaaca tgccctcctc ctcaggctat	120
gcaggacagc tatcataagt cggcccaggc atccagatac taccatttgt ataaacttca	180
gtaggggagt ccatccaagt gacaggtcta atcaaaggag gaaatggaac ataagcccag	240
tagtaaaatn ttgcttagct gaaacagcca caaaagactt accgccgtgg tgattaccat	300
caa	303

&lt;210&gt; 146

&lt;211&gt; 327

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(327)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 146

actgcagctc aattagaagt ggtctctgac tttcatcanc ttctccctgg gctccatgac	60
actggcctgg agtgactcat tgcctctggtt ggttgagaga gtccttttgc caacaggcct	120
ccaagtcagg gctgggattt gtttccttcc cacattctag caacaatatg ctggccactt	180
cctgaacagg gaggggtggga ggagccagca tggaacaagc tgccactttc taaagtagcc	240
agacttgccc ctgggcctgt cacacctact gatgaccttc tgtgcctgca ggatggaatg	300
taggggtgag ctgtgtgact ctatggt	327

&lt;210&gt; 147

&lt;211&gt; 173

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(173)

&lt;223&gt; n = A,T,C or G

<400> 147  
 acattgtttt ttgagataa agcattgana gagctctcct taacgtgaca caatggaagg 60  
 actggaacac ataccacat ctttgttctg agggataatt ttctgataaa gtcttgctgt 120  
 atattcaagc acatatgtta tatattatc agttccatgt ttatagccta gtt 173

<210> 148  
 <211> 477  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(477)  
 <223> n = A,T,C or G

<400> 148  
 acaaccactt tatctcatcg aatttttaac ccaaactcac tcaactgtgcc tttctatcct 60  
 atgggatata ttatttgatg ctccatttca tcacacatat atgaataata cactcatact 120  
 gccctactac ctgctgcaat aatcacattc ccttcctgtc ctgaccctga agccattggg 180  
 gtggctcctag tggccatcag tccangectg caccttgagc ccttgagctc cattgctcac 240  
 nccancccac ctccaccgacc ccatoctctt acacagctac ctcccttgctc tctaacccca 300  
 tagattatnt ccaaattcag tcaattaagt tactattaac actctaccog acatgtccag 360  
 caccactggg aagccttctc cagccaacac acacacacac acacncacac acacacatat 420  
 ccaggcacag gctacctcat cttcacaatc acccctttaa ttaccatgct atggtgg 477

<210> 149  
 <211> 207  
 <212> DNA  
 <213> Homo sapien

<400> 149  
 acagttgtat tataatatca agaaataaac ttgcaatgag agcattttaag agggaagaac 60  
 taacgtattt tagagagcca aggaaggttt ctgtggggag tgggatgtaa ggtggggcct 120  
 gatgataaat aagagtcagc caggtaagtg ggtggtgtgg tatgggcaca gtgaagaaca 180  
 ttccaggcag agggaacagc agtgaaa 207

<210> 150  
 <211> 111  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(111)  
 <223> n = A,T,C or G

<400> 150  
 acccttgattt cattgctgct ctgatggaaa cccaactatc taatttagct aaaacatggg 60  
 cacttaaagt tggtcagtgt ttggacttgt taactantgg catctttggg t 111

<210> 151  
 <211> 196  
 <212> DNA  
 <213> Homo sapien

<400> 151  
 agcgcggcag gtcatttga acattccaga tacctatcat tactcgatgc tgttgataac 60

agcaagatgg ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaaccat 120  
 ggataccaac cggaaaaccc ctatcccgca cagcccactg tggccccac tgtctacgag 180  
 gtgcatccgg ctacgt 196

<210> 152  
 <211> 132  
 <212> DNA  
 <213> Homo sapien

<400> 152  
 acagcacttt cacatgtaag aaggagagaaa ttcctaaatg taggagaaaag ataacagAAC 60  
 cttcccccttt tcatctagtgt gtggaaacct gatgctttat gttgacagga atagaaccag 120  
 gagggagttt gt 132

<210> 153  
 <211> 285  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(285)  
 <223> n = A,T,C or G

<400> 153  
 acaanaccca nganaggcca ctggccgtgg tgtcatggcc tccaaacatg aaagtgtcag 60  
 cttctgtctt tatgtcctca tctgacaact ctttaccatt tttatcctcg ctcagcagga 120  
 gcacatcaat aaagtccaaa gtcttggact tggccttggc ttggaggag tcatcaacac 180  
 cctggctagt gaggggtgcgg cgcgctcct ggatgacggc atctgtgaag tcgtgcacca 240  
 gtctgcaggc cctgtggaag cgcgctccac acggagtnag gaatt 285

<210> 154  
 <211> 333  
 <212> DNA  
 <213> Homo sapien

<400> 154  
 accacagtcc tgttgggcca gggcttcatg accctttctg tgaaaagcca tattatcacc 60  
 accccaaatt tttccttaaa tatctttaac tgaaggggtc agcctcttga ctgcaaagac 120  
 cctaagccgg ttacacagct aactcccact ggccctgatt tgtgaaattg ctgctgcctg 180  
 attggcacag gagtccaagg ttttcagtc cctcctcctg tggaaacgaga ctctgatttg 240  
 agtttcacaa attctcgggc cacctcgtca ttgctcctct gaaataaaat ccggagaatg 300  
 gtcaggcctg tctcatccat atggatcttc cgg 333

<210> 155  
 <211> 308  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(308)  
 <223> n = A,T,C or G

<400> 155  
 actggaaata ataaaaccca catcacagtg ttgtgtcaaa gatcatcagg gcatggatgg 60  
 gaaagtgtt tgggaactgt aaagtgccta acacatgatc gatgattttt gttataatat 120  
 ttgaatcacg gtgcatacaa actctcctgc ctgctcctcc tgggccccag cccagccc 180

atcacagctc actgctctgt tcatccaggc ccagcatgta gtggctgatt cttcttggt 240  
 gcttttagcc tccanaagtt tctctgaagc caaccaaac tctangtgta aggcattgtg 300  
 gccctgg 308

<210> 156  
 <211> 295  
 <212> DNA  
 <213> Homo sapien

<400> 156  
 accttgctcg gtgcttgga catattagga actcaaaata tgagatgata acagtgccta 60  
 ttattgatta ctgagagaac tgtagacat ttagttgaag attttctaca caggaactga 120  
 gaataggaga ttatgtttgg ccctcatatt ctctcctatc ctcttgctt cattctatgt 180  
 ctaatatatt ctcaatcaaa taaggtttagc ataatcagga aatcgaccaa ataccaatat 240  
 aaaaccagat gtctatcctt aagattttca aatagaaaac aaattaacag actat 295

<210> 157  
 <211> 126  
 <212> DNA  
 <213> Homo sapien

<400> 157  
 acaagtttaa atagtgtgt cactgtgcat gtgctgaaat gtgaaatcca ccacatttct 60  
 gaagagcaaa acaaattctg tcatgtaatc tctatcttgg gtcgtgggta tatctgtccc 120  
 cttagt 126

<210> 158  
 <211> 442  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(442)  
 <223> n = A,T,C or G

<400> 158  
 acccaactgg cttggaaaca cccatcctta atacgatgat ttttctgtcg tgtgaaaatg 60  
 aanccagcag gctgccccta gtcagtcctt ccttccagag aaaaagagat ttgagaaagt 120  
 gctgggtaaa ttcaccatta atttctctcc ccaaactctc tgagtcttcc cttaatattt 180  
 ctggtgggtt tgaccaaaagc aggtcatggg ttgttgagca tttgggatcc cagtgaagta 240  
 natgtttgta gccttgcata cttagccctt cccacgcaca aacggagtgg cagagtggg 300  
 ccaacctgt tttcccagtc cacgtagaca gattcacagt gcggaattct ggaagctgga 360  
 nacagacggg ctctttgcag agccgggact ctgagangga catgaggggc tctgcctctg 420  
 tgttcattct ctgatgtcct gt 442

<210> 159  
 <211> 498  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(498)  
 <223> n = A,T,C or G

<400> 159  
 acttccagggt aacgttggtt tttccgttga gcctgaactg atgggtgacg ttgtaggttc 60

tccaacaaga	actgaggttg	cagagcgggt	aggggaagagt	gctgttccag	ttgcacctgg	120
gctgctgtgg	actgttgttg	attcctcact	acggcccaag	gttgtggaac	tggcanaaaag	180
gtgtgttggt	gganttggagc	tcgggcggct	gtggtaggtt	gtgggctctt	caacaggggc	240
tgctgtggtg	ccgggangtg	aangtgttg	gtcacttgag	cttggccagc	tctggaaagt	300
antanattct	tcctgaaggc	cagcgcttg	ggagctggca	ngggtcantg	ttgtgtgtaa	360
cgaaccagtg	ctgctgtggg	tgggtgtana	tcctccacaa	agcctgaagt	tatggtgtcn	420
tcaggtaana	atgtggtttc	agtgtccctg	ggcngctgtg	gaaggttgta	nattgtcacc	480
aagggaataa	gctgtgtgt					498

&lt;210&gt; 160

&lt;211&gt; 380

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(380)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 160

acctgcatcc	agcttcctg	ccaaactcac	aaggagacat	caacctctag	acagggaaac	60
agcttcagga	tacttcagg	agacagagcc	accagcagca	aaacaaatat	tcccatgcct	120
ggagcatggc	atagaggaag	ctganaaatg	tggggtctga	ggaagccatt	tgagtctggc	180
cactagacat	ctcatcagcc	acttgtgtga	agagatgccc	catgaccca	gatgcctctc	240
cpacccttac	ctccatctca	cacacttgag	ctttccactc	tgtataattc	taacatcctg	300
gagaaaaatg	gcagtttgac	cgaacctgtt	cacaacggta	gaggctgatt	tctaacgaaa	360
cttgtagaat	gaagcctgga					380

&lt;210&gt; 161

&lt;211&gt; 114

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 161

actccacatc	ccctctgagc	aggcggttgt	cgttcaaggt	gtatttggcc	ttgcctgtca	60
cactgtccac	tggccctta	tccacttggt	gcttaatccc	tcgaaagagc	atgt	114

&lt;210&gt; 162

&lt;211&gt; 177

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 162

actttctgaa	tcgaatcaaa	tgatacttag	tgtagtittta	atatacctcat	atatatcaaa	60
gttttactac	tctgataatt	ttgtaaacca	ggtaaccaga	acatccagtc	atacagcttt	120
tggtgatata	taacttggca	ataaccagtc	ctggtgatac	ataaaactac	tcactgt	177

&lt;210&gt; 163

&lt;211&gt; 137

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(137)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 163

catttatataca gacaggcgtg aagacattca cgacaaaaac gcgaaattct atcccgtgac	60
canagaaggc agctacggct actcctacat cctggcgtgg gtggccttcg cctgcacctt	120
catcagcggc atgatgt	137

<210> 164  
 <211> 469  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(469)  
 <223> n = A,T,C or G

<400> 164	
cttatcacaa tgaatgttct cctgggcagc gttgtgatct ttgccacctt cgtgacttta	60
tgcaatgcat catgctatct catacctaat gagggagttc caggagattc aaccaggaaa	120
tgcatggatc tcaaaggaaa caaacaccca ataaactcgg agtggcagac tgacaactgt	180
gagacatgca cttgctacga aacagaaatt tcatgttgca cccttgtttc tacacctgtg	240
ggttatgaca aagacaactg ccaaagaatc ttcaagaagg aggactgcaa gtatatcgtg	300
gtggagaaga aggacccaaa aaagacctgt tctgtcagtg aatggataat ctaatgtgct	360
tctagtaggc acagggtcc caggccaggc ctcattctcc tctggcctct aatagtcaat	420
gattgtgtag ccatgcctat cagtaaaaag atntttgagc aaacacttt	469

<210> 165  
 <211> 195  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(195)  
 <223> n = A,T,C or G

<400> 165	
acagtttttt atatatatcg acattgccgg cacttggtgtt cagtttcata aagctgggtg	60
atccgctgtc atccactatt ccttggctag agtaaaaatt attcttatag cccatgtccc	120
tgcaggccgc ccgcccgtag ttctcgttcc agtcgtcttg gcacacaggg tgccaggact	180
tcctctgaga tgagt	195

<210> 166  
 <211> 383  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(383)  
 <223> n = A,T,C or G

<400> 166	
acatcttagt agtgtggcac atcagggggc catcagggtc acagtcactc atagcctcgc	60
cgaggctcga gtccacacca ccggtgtagg tgtgtcctaat cttgggcttg gcgcccacct	120
ttggagaagg gatattgctgc acacacatgt ccacaaagcc tgtgaactcg ccaaagaatt	180
tttgagacc agcctgagca aggggcggat gttcagcttc agctcctect tcgtcagggtg	240
gatgccaacc tcgtctangg tccgtgggaa gctgggtgcc acntcaccta caacctgggc	300
gangatctta taaagaggct ccnagataaa ctccacgaaa cttctctggg agctgctagt	360
nggggccttt ttggtgaact ttc	383



<210> 167  
 <211> 247  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(247)  
 <223> n = A,T,C or G

<400> 167

acagagccag	accttggcca	taaatgaanc	agagattaag	actaaacccc	aagtcganat	60
tggagcagaa	actggagcaa	gaagtgggcc	tggggctgaa	gtagagacca	aggccactgc	120
tatanccata	cacagagcca	actctcaggc	caaggcnatg	gttggggcag	anccagagac	180
tcaatctgan	tccaaagtgg	tggtctggaac	actggctcatg	acanaggcag	tgactctgac	240
tgangtc						247

<210> 168  
 <211> 273  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(273)  
 <223> n = A,T,C or G

<400> 168

acttctaagt	tttctagaag	tggaaggatt	gtantcatcc	tgaaaatggg	tttacttcaa	60
aateccctcan	ccttgttctt	cacnactgtc	tatactgana	gtgtcatgtt	tccacaaagg	120
gctgacacct	gagcctgnat	tttcaatcat	ccctgagaag	ccctttccag	taggggtgggc	180
aattcccaac	ttccttgcca	caagcttccc	aggctttctc	ccctggaaaa	ctccagcttg	240
agtcccatgat	acactcatgg	gctgccttgg	gca			273

<210> 169  
 <211> 431  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(431)  
 <223> n = A,T,C or G

<400> 169

acagccttgg	cttccccaaa	ctccacagtc	tcagtgcaga	aagatcatct	tccagcagtc	60
agctcagacc	agggtcaaag	gatgtgacat	caacagtttc	tggtttcaga	acaggttcta	120
ctactgtcaa	atgacccccc	atacttcctc	aaaggctgtg	gtaagttttg	cacagggtgag	180
ggcagcagaa	aggggggtant	tactgatgga	caccatcttc	tctgtatact	ccacactgac	240
cttgccatgg	gcaaaggccc	ctaccacaaa	aacaatagga	tactgctgg	gcaccagctc	300
acgcacatca	ctgacaaccg	ggatggaaaa	agaantgcca	actttcatac	atccaactgg	360
aaagtgatct	gatactggat	tcttaattac	cttcaaaagc	ttctgggggc	catcagctgc	420
tcgaacactg	a					431

<210> 170  
 <211> 266  
 <212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(266)

<223> n = A,T,C or G

<400> 170

acctgtgggc	tgggctgtta	tgcctgtgcc	ggctgtctgaa	agggagttca	gaggtgggagc	60
tcaaggagct	ctgcaggcat	tttgccaanc	ctctccanag	canagggagc	aacctacact	120
ccccgctaga	aagacaccag	attggagtcc	tgggaggggg	agttgggggtg	ggcatttgat	180
gtatacttgt	cacctgaatg	aangagccag	agaggaanga	gacgaanatg	anattggcct	240
tcaaagctag	gggtctggca	ggtgga				266

<210> 171

<211> 1248

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(1248)

<223> n = A,T,C or G

<400> 171

ggcagccaaa	tcataaacgg	cgaggactgc	agccccgact	cgcagccctg	gcaggcggca	60
ctggtcatgg	aaaacgaatt	gttctgtctg	ggcgtcctgg	tgcattccgca	gtgggtgctg	120
tcagccgcac	actgtttcca	gaagtgtgtg	cagagctcct	acaccatcgg	gctgggcctg	180
cacagtcttg	aggccgacca	agagccaggg	agccagatgg	tggaggccag	cctctccgta	240
cggcaccag	agtacaacag	acccttgctc	gctaacgacc	tcatgtctcat	caagttggac	300
gaatccgtgt	ccgagtctga	caccatccgg	agcatcagca	ttgcttcgca	gtgccctacc	360
gcggggaact	cttgccctcg	ttctggctgg	gggtctgtgg	cgaacggcag	aatgcctacc	420
gtgctgcagt	gcgtgaacgt	gtcggtggtg	tctgaggagg	tctgcagtaa	gctctatgac	480
ccgctgtacc	accccagcat	gttctgcgcc	ggcggagggg	aagaccagaa	ggactcctgc	540
aacgggtgact	ctggggggcc	cctgatctgc	aacgggtact	tgcagggcct	tgtgtctttc	600
ggaaaagccc	cgtgtggcca	agttggcgtg	ccagggtgtc	acaccaacct	ctgcaaattc	660
actgagtggg	tagagaaaac	cgtccaggcc	agttaactct	ggggactggg	aacccatgaa	720
attgaccccc	aaatacatcc	tgcggaagga	attcaggaat	atctgttccc	agccccctcc	780
ccctcaggcc	caggagtcca	ggccccccagc	ccctcctccc	tcaaaccaag	ggtacagatc	840
cccagcccct	cctccctcag	acccaggagt	ccagaccccc	cagccccctcc	tccctcagac	900
ccaggagtcc	agccccctcc	ccctcagacc	caggagtcca	gacccccccag	ccccctcctcc	960
ctcagaccca	gggggtccagg	cccccaaccc	ctcctccctc	agactcagag	gtccaagccc	1020
ccaaccntc	attccccaga	cccagagggtc	cagggtcccag	cccctcntcc	ctcagaccca	1080
gcggtccaat	gccacctaga	ctntccctgt	acacagtgcc	cccttggtggc	acgttgaccc	1140
aaccttacca	gttggttttt	catttttngt	ccctttcccc	tagatccaga	aataaagttt	1200
aagagaagng	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaa		1248

<210> 172

<211> 159

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(159)

<223> Xaa = Any Amino Acid

<400> 172

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
 1 5 10 15  
 Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
 20 25 30  
 Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
 35 40 45  
 Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
 50 55 60  
 Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu  
 65 70 75 80  
 Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe  
 85 90 95  
 Cys Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser  
 100 105 110  
 Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe  
 115 120 125  
 Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn  
 130 135 140  
 Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser  
 145 150 155

<210> 173  
 <211> 1265  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(1265)  
 <223> n = A,T,C or G

<400> 173

ggcagcccgc actcgcagcc ctggcaggcg gcaactgggtca tggaaaacga attgttctgc 60  
 tcgggcgtcc tgggtgcatcc gcagtgggtg ctgtcagccg cacactgttt ccagaactcc 120  
 tacaccatcg ggctgggcct gcacagtott gaggccgacc aagagccagg gagccagatg 180  
 gtggaggcca gcctctccgt acggcaccca gagtacaaca gacccttgct cgctaacgac 240  
 ctcattgctca tcaagttgga cgaatccgtg tccgagtctg acaccatccg gagcatcagc 300  
 attgcttcgc agtgccttac cgcggggaac tcttgccctg tttctggctg gggctctgctg 360  
 gcgaacgggtg agctcacggg tgtgtgtctg cctcttcaa ggaggtcctc tgcccagtcg 420  
 cgggggctga cccagagctc tgcgtccag gcagaatgcc taccgtgctg cagtgcgtga 480  
 acgtgtcggg ggtgtctgag gaggtctgca gtaagctcta tgaccgctg taccacccca 540  
 gcatgttctg cgcggcgga gggcaagacc agaaggactc ctgcaacggg gactctgggg 600  
 ggccccctgat ctgcaacggg tacttgaggg gccttgtgtc tttcggaaaa gccccgtgtg 660  
 gccaaagtgg cgtgccaggt gtctacacca acctctgcaa attcactgag tggatagaga 720  
 aaaccgtcca ggccagttaa ctctggggac tgggaaccca tgaaattgac ccccaaatac 780  
 atcctgcgga aggaattcag gaatatctgt tcccagcccc tcctccctca ggcccaggag 840  
 tccaggcccc cagccctcc tccctcaaac caagggtaga gatccccagc cctcctccc 900  
 tcagaccag gagtccagac cccccagccc ctctccctc agaccagga gtccagcccc 960  
 tcctcctca gaccaggag tccagacccc ccagccctc ctccctcaga cccagggggtt 1020  
 gagggcccca acccctcctc ctccagagtc agagggtcaa gcccacaacc cctcgttccc 1080  
 cagaccaga ggttnaggtc ccagccctc ttcctcaga cccagnggtc caatgccacc 1140  
 tagattttcc ctgnacacag tgcccccttg tggngangttg acccaacctt accagttggt 1200  
 ttttcatttt tngtcccttt ccctagatc cagaaataaa gtttaagaga nngngcaaaaa 1265  
 aaaaa

<210> 174  
 <211> 1459  
 <212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(1459)

<223> n = A,T,C or G

<400> 174

ggtcagccgc	acactgtttc	cagaagtgcg	tgcagagctc	ctacaccatc	gggctgggce	60
tgcacagtct	tgaggccgac	caagagccag	ggagccagat	ggtggaggcc	agcctctccg	120
tacggcacc	agagtacaac	agacccttgc	tcgctaacga	cctcatgtct	atcaagttgg	180
acgaatccgt	gtccgagtct	gacaccatcc	ggagcatcag	cattgtctcg	cagtgcctta	240
ccgcggggaa	ctcttgccct	gtttctggct	gggtctgct	ggcgaacggg	gagctcacgg	300
gtgtgtgtct	gccctcttca	aggaggtcct	ctgccagtc	gcgggggctg	accagagct	360
ctgcgtccca	ggcagaatgc	ctaccgtgct	gcagtgcgtg	aacgtgtcgg	tggtgtctga	420
ngaggtctgc	antaagctct	atgaccctgc	gtaccacccc	ancatgttct	gcgcggcg	480
agggcaagac	cagaaggact	cctgcaacgt	gagagagggg	aaaggggagg	gcaggcgact	540
cagggaaggg	tggagaaggg	ggagacagag	acacacaggg	ccgcatggcg	agatgcagag	600
atggagagac	acacagggag	acagtgacaa	ctagagagag	aaactgagag	aaacagagaa	660
ataaacacag	gaataaagag	aagcaaagga	agagagaaac	agaaacagac	atggggaggc	720
agaaacacac	acacatagaa	atgcagttga	ccttccaaca	gcatggggcc	tgagggcggt	780
gacctccacc	caatagaaaa	tcctottata	acttttgact	ccccaaaaac	ctgactagaa	840
atagcctact	gttgacgggg	agccttacca	ataacataaa	tagtcgattt	atgcatacgt	900
tttatgcatt	catgatatac	ctttgttgga	attttttgat	atttctaagc	tacacagttc	960
gtctgtgaat	ttttttaaat	tggtgcaact	ctcctaaaat	ttttctgatg	tggtttattga	1020
aaaaatccaa	gtataagtgg	acttgtgcat	tcaaaccagg	gttggttcaag	ggtcaactgt	1080
gtaccagag	ggaaacagtg	acacagattc	atagaggtga	aacacgaaga	gaaacaggaa	1140
aatcaagac	tctacaaaga	ggctggggcag	ggtggctcat	gcctgtaatc	ccagcacttt	1200
gggaggcgag	gcaggcagat	cacttgaggt	aaggagttca	agaccagcct	ggccaaaatg	1260
gtgaaatcct	gtctgtacta	aaaatacaaa	agttagctgg	atatggtggc	aggcgccctgt	1320
aatcccagtg	acttgggagg	ctgaggcagg	agaattgctt	gaatatggga	ggcagagggt	1380
gaagtgaagt	gagatcacac	cactatactc	cagctggggc	aacagagtaa	gactctgtct	1440
caaaaaaaaa	aaaaaaaaa					1459

<210> 175

<211> 1167

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(1167)

<223> n = A,T,C or G

<400> 175

gcgcagccct	ggcaggcggc	actggctcatg	gaaaacgaat	tggtctgctc	gggcgtcctg	60
gtgcatccgc	agtgggtgct	gtcagccgca	cactgtttcc	agaactccta	caccatcggg	120
ctgggcctgc	acagtcttga	ggccgaccaa	gagccaggga	gccagatggg	ggaggccagc	180
ctctccgtac	ggcaccaga	gtacaacaga	ctcttgctcg	ctaacgaact	catgtctatc	240
aagttggacg	aatccgtgtc	cgagtctgac	accatccgga	gcatcagcat	tgcttcgcag	300
tgccctaccg	cggggaactc	ttgcctcgtn	tctggctggg	gtctgctggc	gaacggcaga	360
atgcctaccg	tgctgcactg	cgtgaacgtg	tcgggtggtg	ctgaggangt	ctgcagtaag	420
ctctatgacc	cgctgtacca	ccccagcatg	ttctgcgccg	gcggagggca	agaccagaag	480
gactcctgca	acggtgactc	tggggggccc	ctgatctgca	acgggtactt	gcagggcctt	540
gtgtctttcg	gaaaagcccc	gtgtggccaa	cttggcgtgc	caggtgtcta	caccaacctc	600
tgcaaattca	ctgagtggat	agagaaaacc	gtccagncca	gttaactctg	gggaotggga	660
acccatgaaa	ttgaccccca	aatacatcct	gcggaangaa	ttcaggaata	tctgttccca	720
gcccctctc	cctcaggccc	aggagtccag	gccccagcc	cctcctccct	caaaccaagg	780

```

gtacagatcc ccagccctc ctccctcaga cccaggagtc cagaccccc agccctctnt 840
ccntcagacc caggagtcca gccctctctc cntcagacgc aggagtccag accccccagc 900
ccntctntccg tcagaccagc ggggtgcaggc ccccaacccc tntccntca gagtccagag 960
tccaagcccc caaccctctg ttcccagac ccagaggtnc aggtcccagc cctctctccc 1020
tcagaccagc cgggtccatg ccacctagan tntccctgta cacagtgcgc ccttggtggca 1080
ngttgaccca accttaccag ttgggttttc attttttgtc cctttcccct agatccagaa 1140
ataaagtnta agagaagcgc aaaaaaa 1167

```

<210> 176  
 <211> 205  
 <212> PRT  
 <213> Homo sapien

<220>  
 <221> VARIANT  
 <222> (1) ... (205)  
 <223> Xaa = Any Amino Acid

<400> 176

```

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
 1          5          10          15
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
          20          25          30
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
          35          40          45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Leu Leu Leu
          50          55          60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65          70          75          80
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
          85          90          95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met
          100          105          110
Pro Thr Val Leu His Cys Val Asn Val Ser Val Val Ser Glu Xaa Val
          115          120          125
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala
          130          135          140
Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly
145          150          155          160
Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys
          165          170          175
Ala Pro Cys Gly Gln Leu Gly Val Pro Gly Val Tyr Thr Asn Leu Cys
          180          185          190
Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Xaa Ser
          195          200          205

```

<210> 177  
 <211> 1119  
 <212> DNA  
 <213> Homo sapien

<400> 177

```

gcgcactcgc agccctggca ggcggcactg gtcattgaaa acgaattggt ctgctcgggc 60
gtcctgggtgc atccgcagtg ggtgctgtca gccgcacact gtttcagaa ctcctacacc 120
atcgggctgg gcctgcacag tcttgaggcc gaccaagagc cagggagcca gatgggtggag 180
gccagcctct ccgtacggca cccagagtac aacagaccct tgctcgctaa cgacctcatg 240
ctcatcaagt tggacgaatc cgtgtccgag tctgacacca tccggagcat cagcattgct 300
tcgcagtgcc ctaccgcggg gaactcttgc ctcgtttctg gctggggtct gctggcgaac 360

```

```

gatgctgtga ttgccatcca gtcccagact gtgggaggct gggagtgtga gaagctttcc 420
caaccctggc agggttgtac catttcggca acttccagtg caaggacgtc ctgctgcatc 480
ctcactgggt gctcactact gctcactgca tcacccgaa cactgtgac aactagccag 540
caccatagtt ctccgaagtc agactatcat gattactgtg ttgactgtgc tgtctattgt 600
actaaccatg ccgatgttta ggtgaaatta gcgtcacttg gcctcaacca tcttggtatc 660
cagttatcct cactgaattg agatttcctg cttcagtgtc agccattccc acataatttc 720
tgacctacag aggtgaggga tcatatagct cttcaaggat gctggtaact ccctcacaaa 780
ttcattttct ctgtttagt gaaagggtgc ccctctggag cctcccaggg tgggtgtgca 840
ggtcacaatg atgaatgtat gatcgtgttc ccattaccca aagcctttaa atccctcatg 900
ctcagtacac cagggcaggt ctagcatttc ttcatttagt gtatgctgtc cattcatgca 960
accacctcag gactcctgga ttctctgcct agttgagctc ctgcatgctg cctccttggg 1020
gaggtgaggg agagggccca tggttcaatg ggatctgtgc agttgtaaca cattaggtgc 1080
ttaataaaca gaagctgtga tgttaaaaaa aaaaaaaaa 1119

```

<210> 178  
 <211> 164  
 <212> PRT  
 <213> Homo sapien

<220>  
 <221> VARIANT  
 <222> (1)...(164)  
 <223> Xaa = Any Amino Acid

<400> 178

Met	Glu	Asn	Glu	Leu	Phe	Cys	Ser	Gly	Val	Leu	Val	His	Pro	Gln	Trp
1				5					10					15	
Val	Leu	Ser	Ala	Ala	His	Cys	Phe	Gln	Asn	Ser	Tyr	Thr	Ile	Gly	Leu
			20					25					30		
Gly	Leu	His	Ser	Leu	Glu	Ala	Asp	Gln	Glu	Pro	Gly	Ser	Gln	Met	Val
		35					40					45			
Glu	Ala	Ser	Leu	Ser	Val	Arg	His	Pro	Glu	Tyr	Asn	Arg	Pro	Leu	Leu
	50					55					60				
Ala	Asn	Asp	Leu	Met	Leu	Ile	Lys	Leu	Asp	Glu	Ser	Val	Ser	Glu	Ser
65					70				75					80	
Asp	Thr	Ile	Arg	Ser	Ile	Ser	Ile	Ala	Ser	Gln	Cys	Pro	Thr	Ala	Gly
			85					90						95	
Asn	Ser	Cys	Leu	Val	Ser	Gly	Trp	Gly	Leu	Leu	Ala	Asn	Asp	Ala	Val
			100					105					110		
Ile	Ala	Ile	Gln	Ser	Xaa	Thr	Val	Gly	Gly	Trp	Glu	Cys	Glu	Lys	Leu
		115				120						125			
Ser	Gln	Pro	Trp	Gln	Gly	Cys	Thr	Ile	Ser	Ala	Thr	Ser	Ser	Ala	Arg
	130					135					140				
Thr	Ser	Cys	Cys	Ile	Leu	Thr	Gly	Cys	Ser	Leu	Leu	Leu	Thr	Ala	Ser
145					150					155					160
Pro	Gly	Thr	Leu												

<210> 179  
 <211> 250  
 <212> DNA  
 <213> Homo sapien

<400> 179

ctggagtgcc	ttggtgtttc	aagcccctgc	aggaagcaga	atgcaccttc	tgaggcacct	60
ccagctgccc	ccggccgggg	gatgcgaggc	tcggagcacc	cttgcccggc	tgtgattgct	120
gccaggcact	gttcatctca	gcttttctgt	ccctttgctc	ccggcaagcg	cttctgctga	180
aagttcatat	ctggagcctg	atgtcttaac	gaataaaggt	cccatgctcc	acccgaaaaa	240

aaaaaaaaaa

250

&lt;210&gt; 180

&lt;211&gt; 202

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 180

actagtcag	tgtggtgaa	ttccattgtg	ttggggcccaa	cacaatggct	acctttaaca	60
tcacccagac	cccgccctg	cccggtgccc	acgtgctgc	taacgacagt	atgatgctta	120
ctctgctact	cggaaactat	ttttatgtaa	ttaatgtatg	ctttcttggt	tataaatgcc	180
tgatttaaaa	aaaaaaaaaa	aa				202

&lt;210&gt; 181

&lt;211&gt; 558

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(558)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 181

tccytttkt	naggtttkkg	agacamccck	agacctwaan	ctgtgtcaca	gacttcyngg	60
aatgtttagg	cagtgcctagt	aatttcytcg	taatgattct	gttattactt	tcctnattct	120
ttattcctct	ttcttctgaa	gattaatgaa	gttgaaaatt	gaggtggata	aatacaaaaa	180
ggtagtgtga	tagtataagt	atctaagtgc	agatgaaagt	gtgttatata	tatccattca	240
aaattatgca	agttagtaat	tactcagggt	taactaaatt	actttaatat	gctgttgaac	300
ctactctgtt	ccttggctag	aaaaaattat	aaacaggact	ttgttagttt	gggaagccaa	360
attgataata	ttctatgttc	taaaagttgg	gctatacata	aattattaag	aaatatggaw	420
ttttattccc	aggaatatgg	kgttcatttt	atgaatatta	cscrggatag	awgtwtgagt	480
aaaaycagtt	ttggtwaata	ygtwaatatg	tcmtaaataa	acaakgcttt	gacttatttc	540
caaaaaaaaa	aaaaaaaaa					558

&lt;210&gt; 182

&lt;211&gt; 479

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(479)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 182

acagggwttk	grggatgcta	agsgcccrga	rwtygtttga	tccaaccctg	gcttwttttc	60
agaggggaaa	atggggccta	gaagttacag	mscatytagy	tggtgcgmtg	gcacccctgg	120
cstcacacag	astcccgagt	agctgggact	acaggcacac	agtcactgaa	gcaggccctg	180
ttwgcaattc	acgttgccac	ctccaactta	aacattcttc	atatgtgatg	tccttagtca	240
ctaagggttaa	actttccac	ccagaaaagg	caacttagat	aaaatccttag	agtactttca	300
tactmttcta	agtcctcttc	cagcctcact	kkgagtcctm	cytggggggt	gataggaant	360
ntctcttggc	tttctcaata	aartctctat	ycatctcatg	tttaatttgg	tacgcataa	420
awtgstgara	aaattaaaat	gttctgggty	mactttaaaa	aaaaaaaaaa	aaaaaaaaa	479

&lt;210&gt; 183

&lt;211&gt; 384

&lt;212&gt; DNA

<213> Homo sapien

<400> 183

aggcgggagc	agaagctaaa	gccaaagccc	aagaagagt	gcagtgccag	cactgggtgcc	60
agtaccagta	ccaataacag	tgccagtgcc	agtgccagca	ccagtgggtg	cttcagtgt	120
ggtgccagcc	tgaccgccac	tctcacattt	gggtctctcg	ctggccttgg	tggagctgg	180
gccagcacca	gtggcagctc	tggtgcctgt	ggtttctcct	acaagtgaga	ttttagatat	240
tgttaatcct	gccagtcttt	ctcttcaagc	caggggtgcat	cctcagaaac	ctactcaaca	300
cagcactcta	ggcagccact	atcaatcaat	tgaagttgac	actctgcatt	aratctattt	360
gccatttcaa	aaaaaaaaaa	aaaa				384

<210> 184

<211> 496

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(496)

<223> n = A,T,C or G

<400> 184

accgaattgg	gaccgctggc	ttataagcga	tcatgtyynt	ccrgtatcac	ctcaacgagc	60
aggagatcgc	agtctatacg	ctgaagaaat	ttgaccgat	gggacaacag	acctgctcag	120
cccatcctgc	tcggttctcc	ccagatgaca	aatactctsg	acaccgaatc	accatcaaga	180
aacgcttcaa	ggtgctcatg	acccagcaac	cgcgcctgt	cctctgaggg	tcccttaaac	240
tgatgtcttt	tctgccacct	gttacccttc	ggagactccg	taaccaaact	cttcggactg	300
tgagccctga	tgcccttttg	ccagccatac	tctttggcat	ccagtctctc	gtggcgattg	360
attatgcttg	tgtgaggcaa	tcatggtggc	atcaccata	aagggaacac	atttgacttt	420
tttttctcat	attttaaatt	actacmagaw	tattwmagaw	waaatgawtt	gaaaaactst	480
taaaaaaaaa	aaaaaa					496

<210> 185

<211> 384

<212> DNA

<213> Homo sapien

<400> 185

gctggtagcc	tatggcgkkg	cccacggagg	ggctcctgag	gccacggrac	agtgacttcc	60
caagtatcyt	gcgscgcgtc	ttctaccgtc	cctacctgca	gatcttcggg	cagattcccc	120
aggaggacat	ggacgtggcc	ctcatggagc	acagcaactg	ytctcggag	cccggcttct	180
gggcacaccc	tcttgggggc	caggcgggca	cctgcgtctc	ccagtatgcc	aactggctgg	240
tggtgctgct	cctcgtcatc	ttcctgctcg	tggccaacat	cctgctggtc	aacttgctca	300
ttgccatgtt	cagttacaca	ttcggcaaag	tacagggcaa	cagcgatctc	tactgggaag	360
gcgcagcgtt	accgcctcat	ccgg				384

<210> 186

<211> 577

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(577)

<223> n = A,T,C or G

<400> 186

gagttagctc	ctccacaacc	ttgatgaggt	cgtctgcagt	ggcctctcgc	ttcataccgc	60
------------	------------	------------	------------	------------	------------	----



tncatcgtc	atactgtagg	tttgccacca	cytcctggca	tcttggggcy	gcntaatatt	120
ccaggaaact	ctcaatcaag	tcaccgtcga	tgaaacctgt	gggctgggtc	tgtcttccgc	180
tcgggtgtgaa	aggatctccc	agaaggagtg	ctcgatcttc	cccacacttt	tgatgacttt	240
attgagtcga	ttctgcatgt	ccagcaggag	gttgtagcag	ctctctgaca	gtgagggtcac	300
cagccctatc	atgccgttga	mcgtgccgaa	garcaccgag	ccttgtgtgg	gggkkgaaat	360
ctcaccacaga	ttctgcatta	ccagagagcc	gtggcaaaaag	acattgacaa	actcgcccag	420
gtggaaaaag	amcamctcct	ggargtgctn	gccgctcctc	gtcmgttggt	ggcagcgctw	480
tccttttgac	acacaaaaca	gttaaaggca	ttttcagccc	ccagaaantt	gtcatcatcc	540
aagatntcgc	acagcactna	tccagttggg	attaaat			577

<210> 187  
 <211> 534  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(534)  
 <223> n = A,T,C or G

<400> 187						
aacatcttcc	tgtataatgc	tgtgtaatat	cgatccgatn	ttgtctgstg	agaatycatw	60
actkggaaaa	gmaacattaa	agcctggaca	ctggtattaa	aattcacaat	atgcaacact	120
ttaaacagtg	tgtcaatctg	ctcccyynac	tttgtcatca	ccagtctggg	aakaagggtg	180
tgccctattc	acacctgtta	aaagggcgct	aagcattttt	gattcaacat	cttttttttt	240
gacacaagtc	cgaaaaaagc	aaaagtaaac	agttatyaat	ttgttagcca	attcactttc	300
ttcatgggac	agagccatyt	gatttaaaaa	gcaaattgca	taatattgag	cttygggagc	360
tgatatttga	gcggaagagt	agcctttcta	cttcaccaga	cacaactccc	tttcatattg	420
ggatgttnac	naaagtwatg	tctctwacag	atgggatgct	tttgtggcaa	ttctgttctg	480
aggatctccc	agtttattta	ccacttgcac	aagaaggcgt	tttcttcctc	aggc	534

<210> 188  
 <211> 761  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(761)  
 <223> n = A,T,C or G

<400> 188						
agaaaccagt	atctctnaaa	acaacctctc	ataccttgtg	gacctaat	tgtgtgcgtg	60
tgtgtgtgcg	cgcataattat	atagacaggc	acatcttttt	tacttttgta	aaagcttatg	120
cctctttggt	atctatatct	gtgaaagttt	taatgatctg	ccataatgtc	ttggggacct	180
ttgtcttctg	tgtaaatggg	actagagaaa	acacctatnt	tatgagtcaa	tctagttngt	240
tttattcgac	atgaaggaaa	tttccagatn	acaacactna	caaactctcc	ctkgackarg	300
ggggacaaaag	aaaagcaaaa	ctgamcataa	raaacaatwa	cctgggtgaga	arttgcataa	360
acagaaatwr	ggtagtatat	tgaarnacag	catcattaaa	rmgttwtktt	wttctccctt	420
gcaaaaaaca	tgtacngact	tcccgttgag	taatgccaa	ttgttttttt	tatnataaaa	480
cttgcccttc	attacatggt	tnaaagtggt	gtgggtgggc	aaaatattga	aatgatggaa	540
ctgactgata	aagctgtaca	aataagcagt	gtgcctaaca	agcaacacag	taatggtgac	600
atgcttaatt	cacaaatgct	aatttcatta	taaatgtttg	ctaaaataca	ctttgaacta	660
tttttctgtn	ttcccagagc	tgagatntta	gattttatgt	agtatnaagt	gaaaaantac	720
gaaaataata	acattgaaga	aaaananaaa	aaanaaaaaa	a		761

<210> 189  
 <211> 482

<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(482)  
<223> n = A,T,C or G

<400> 189  
 tttttttttt tttgccgatn ctactatntt attgcaggan gtgggggtgt atgcaccgca 60  
 caccggggct atnagaagca agaaggaagg agggagggca cagccccttg ctgagcaaca 120  
 aagccgcctg ctgccttctc tgtctgtctc ctggtgcagg cacatgggga gaccttcccc 180  
 aaggcagggg ccaccagtcc aggggtggga atacaggggg tgggangtgt gcataagaag 240  
 tgataggcac aggccaccg gtacagacc ctgggtcct gacaggtna tttcgaccag 300  
 gtcattgtgc cctgcccagg cacagcgtan atctggaaaa gacagaatgc tttccttttc 360  
 aaatttggct ngtcatngaa ngggcanttt tccaantng gctnggtctt ggtacncttg 420  
 gtteggccca gtcncngtc caaaaantat tcaccnct ccnaattgct tgcnggncce 480  
 cc 482

<210> 190  
<211> 471  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(471)  
<223> n = A,T,C or G

<400> 190  
 tttttttttt ttttaaaaca gtttttcaca acaaaattta ttagaagaat agtgggttttg 60  
 aaaactctcg catccagtga gaactaccat acaccacatt acagctngga atgtnctcca 120  
 aatgtctggt caaatgatac aatggaacca ttcaatctta cacatgcacg aaagaacaag 180  
 cgtttttgac atacaatgca caaaaaaaa aggggggggg gaccacatgg attaaaattt 240  
 taagtactca tcacatacat taagacacag ttctagtcca gtchaaaatc agaactgcnt 300  
 tgaaaaattt catgtatgca atccaaccaa agaacttnat tggatgatcat gantnctcta 360  
 ctacatcnac ctgtatcatt gccaggaacn aaaagttnaa ancacncngt acaaaaanaa 420  
 tctgtaattn anttcaacct ccgtacngaa aaatntntnt tatacactcc c 471

<210> 191  
<211> 402  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(402)  
<223> n = A,T,C or G

<400> 191  
 gagggattga aggtctgttc tastgtcggm ctgttcagcc accaactcta acaagttgct 60  
 gtcttccact cactgtctgt aagcttttta acccagacwg tatcttcata aatagaacaa 120  
 attcttcacc agtcacatct tctaggacct ttttggttgc agttagtata agctcttcca 180  
 cttcctttgt taagacttca tctggttaaag tcttaagttt tgtagaaagg aattyaattg 240  
 ctggttctct aacaatgtcc tctccttgaa gtatttggct gaacaacca cctaaagtcc 300  
 ctttgtgcat ccatttttaa tatacttaat agggcattgk tncactagg taaattctgc 360  
 aagagtcac tgtctgcaaa agttgcgtta gtatatctgc ca 402

<210> 192  
 <211> 601  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(601)  
 <223> n = A,T,C or G

<400> 192  
 gagctcggat ccaataatct ttgtctgagg gcagcacaca tatncagtgc catggnaact 60  
 ggtctacccc acatgggagc agcatgccgt agntatataa ggtcattccc tgagtcagac 120  
 atgcytyttt gaytaccgtg tgccaagtgc ttggtgattct yaacacacyt ccatcccgyt 180  
 cttttgtgga aaaactggca cttktctgga actagcarga catcacttac aaattcacccc 240  
 acgagacact tgaaagggtg aacaaagcga ytccttgcat gctttttgtc cctccggcac 300  
 cagttgtcaa tactaaccgg ctgggttgcc tccatcacat ttgtgatctg tagctctgga 360  
 tacatctcct gacagtactg aagaacttct tcttttgttt caaaagcarg tcttggtgcc 420  
 tgttgatca ggttcccat tcccagtcyg aatgttcaca tggcatattt wacttcccac 480  
 aaaacattgc gatttgaggc tcagcaacag caaatcctgt tccggcattg gctgcaagag 540  
 cctcgatgta gccggccagc gccaaaggcag ggcgcgtgag ccccaccagc agcagaagca 600  
 g 601

<210> 193  
 <211> 608  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(608)  
 <223> n = A,T,C or G

<400> 193  
 atacagccca natcccacca cgaagatgcg cttgttgact gagaacctga tgcgggtcact 60  
 ggtcccgtg tagccccagc gactctccac ctgctggaag cggttgatgc tgcactcytt 120  
 cccaacgcag gcagmagcgg gscgggtcaa tgaactccay tctgtggttg gggtkgacgg 180  
 tkaagtgcag gaagaggctg accacctcgc ggtccaccag gatgcccgac tgtgcgggac 240  
 ctgcagcgaa actcctcgat ggtcatgagc gggaagcgaa tgaggcccag ggccttgccc 300  
 agaaccttcc gctgtttctc tggcgtcacc tgcagctgct gccgctgaca ctgcgcctcg 360  
 gaccagcgga caaacggcrt tgaacagccg cacctcacgg atgcccagtg tgtcgcgctc 420  
 caggammgsc accagcgtgt ccagggtcaat gtcgggtgaag ccctccgcgg gtrattggcgt 480  
 ctgcagtggt tttgtcgatg ttctccaggc acaggctggc cagctgcggg tcatcgaaga 540  
 gtcgcgcctg cgtgagcagc atgaaggcgt tgtcggctcg cagttcttct tcaggaactc 600  
 cagcaat 608

<210> 194  
 <211> 392  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(392)  
 <223> n = A,T,C or G

<400> 194  
 gaacggctgg accttgccctc gcattgtgct tgctggcagg gaataccttg gcaagcagyt 60

ccagtcgcgag	cagccccaga	ccgctgcgcg	ccgaagctaa	gcctgcctct	ggccttcccc	120
tccgcctcaa	tgcagaacca	gtagtgggag	cactgtgttt	agagttaaga	gtgaacactg	180
tttgatttta	cttggaatt	tcctctgtta	tatagctttt	cccaatgcta	atttccaaac	240
aacaacaaca	aaataacatg	tttgccctgtt	aagttgtata	aaagtaggtg	attctgtatt	300
taaagaaaat	attactgtta	catatactgc	ttgcaatttc	tgtattttatt	gktnctstgg	360
aaataaatat	agttattaaa	ggttgtcant	cc			392

<210> 195  
 <211> 502  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(502)  
 <223> n = A,T,C or G

<400> 195						
ccsttkgagg	ggtkaggkyc	cagttyccga	gtggaagaaa	caggccagga	gaagtgcgtg	60
ccgagctgag	gcagatgttc	ccacagtgc	ccccagagcc	stgggstata	gtytctgacc	120
cctcncaagg	aaagaccacs	ttctggggac	atgggctgga	gggcaggacc	tagaggcacc	180
aaggggaaggc	cccattccgg	ggstgttccc	cgaggaggaa	gggaaggggc	tctgtgtgcc	240
ccccasgagg	aagaggccct	gagtcctggg	atcagacacc	ccttcacgtg	tatccccaca	300
caaatgcaag	ctcaccaagg	tccctctca	gtcccttcc	stacaccctg	amcggccact	360
gscscacacc	caccagagc	acgccaccgc	ccatggggar	tgtgctcaag	gartcgcnng	420
gcarcgtgga	catctngtcc	cagaaggggg	cagaatctcc	aatagangga	ctgarcmstt	480
gctnanaaaa	aaaaanaaaa	aa				502

<210> 196  
 <211> 665  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(665)  
 <223> n = A,T,C or G

<400> 196						
ggttacttgg	tttcattgcc	accacttagt	ggatgtcatt	tagaaccatt	ttgtctgctc	60
cctctggaag	ccttgccgag	agcggacttt	gtaattgttg	gagaataact	gctgaatttt	120
wagctgtttk	gagttgatts	gcaccactgc	accacaaact	tcaatatgaa	aacyawttga	180
actwatthtat	tatcttgtga	aaagtataac	aatgaaaatt	ttgttcatac	tgtattkac	240
aagtatgatg	aaaagcaawa	gatatatatt	cttttattat	gttaaattat	gattgccatt	300
attaatcggc	aaaatgtgga	gtgtatgttc	ttttcacagt	aatatatgcc	ttttgtaact	360
tcacttgggt	atthttattgt	aaatgartta	caaaaattctt	aatttaagar	aatgggtatgt	420
watatttatt	tcattaattt	ctttcctkgt	ttacgtwaat	tttgaaaaga	wtgcatgatt	480
tcttgacaga	aatcgatctt	gatgctgtgg	aagtagtttg	accacatcc	ctatgagttt	540
ttcttagaat	gtataaagg	tgtagcccat	cnaacttcaa	agaaaaaat	gaccacatac	600
tttgcaatca	ggctgaaatg	tggcatgctn	ttctaattcc	aactttataa	actagcaaan	660
aagtg						665

<210> 197  
 <211> 492  
 <212> DNA  
 <213> Homo sapien

<220>

<221> misc\_feature  
 <222> (1)...(492)  
 <223> n = A,T,C or G

<400> 197

tttntttttt	ttttttttgc	aggaaggatt	ccattttattg	tggatgcatt	ttcacaatat	60
atgtttattg	gagcgatcca	ttatcagtga	aaagtatcaa	gtgtttataa	natttttagg	120
aaggcagatt	cacagaacat	gctngtcngc	ttgcagtttt	acctcgtana	gatnacagag	180
aattatagtc	naaccagtaa	acnagggaatt	tacttttcaa	aagattaaat	ccaaactgaa	240
caaaattcta	ccctgaaact	tactccatcc	aaatattgga	ataanagtca	gcagtgatac	300
attctcttct	gaactttaga	ttttctagaa	aaatatgtaa	tagtgatcag	gaagagctct	360
tgttcaaaag	tacaacnaag	caatgttccc	ttacatagg	ccttaattca	aactttgatc	420
catttcactc	ccatcacggg	agtcaatgct	acctgggaca	cttgtatttt	gttcatnctg	480
ancntggctt	aa					492

<210> 198  
 <211> 478  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(478)  
 <223> n = A,T,C or G

<400> 198

tttnttttgn	atttcantct	gtannaanta	ttttcattat	gtttattana	aaaatatnaa	60
tgtntccacn	acaaatcatn	ttacntnagt	aagaggccan	ctacattgta	caacatacac	120
tgagtatatt	ttgaaaagga	caagttttaa	gtanacncat	attgccganc	atancacatt	180
tatacatggc	ttgattgata	tttagcacag	canaaaactga	gtgagttacc	agaaanaaat	240
nataatgttc	aatcngattt	aagatacaaa	acagatcccta	tgttacatan	catcntgtag	300
gagttgtggc	tttatgttta	ctgaaagtca	atgcagttcc	tgtacaaaga	gatggccgta	360
agcattctag	tacctctact	ccatgggttaa	gaatcgtaca	cttatgttta	catatgtnca	420
gggtaagaat	tgtgttaagt	naanttatgg	agagggtccan	gagaaaaatt	tgatncaa	478

<210> 199  
 <211> 482  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(482)  
 <223> n = A,T,C or G

<400> 199

agtgaattgt	cctccaacaa	aacccttga	tcaagtttgt	ggcactgaca	atcagacctta	60
tgctagtccc	tgtcatctat	tcgctactaa	atgcagactg	gaggggacca	aaaaggggca	120
tcaactccag	ctggattatt	ttggagcctg	caaattctatt	cctacttgta	cggaacttga	180
agtgaattcag	tttctcttac	ggatgagaga	ctggetcaag	aatatcctca	tgcagcttta	240
tgaagccnac	tctgaacacg	ctggttatct	nagatgagaa	ncagagaaat	aaagtcnaga	300
aaatttacct	ggangaaaag	aggctttingg	ctggggacca	tccatttgaa	ccttctctta	360
anggacttta	agaanaaaact	accacatgtn	tgtngtatcc	tgggtgccngg	ccgtttantg	420
aacntngacn	ncacccttnt	ggaatanant	cttgaacngcn	tcttgaactt	gctcctctgc	480
ga						482

<210> 200  
 <211> 270

```
<220>
<221> misc_feature
<222> (1)...(270)
<223> n = A,T,C or G
```

<400> 200						
cggccgcgaag	tgcaactcca	gctgggggccg	tgcggacgaa	gattctgcca	gcagttggtc	60
cgactgcgac	gacggcgggcg	gcgacagtcg	caggtgcagc	gcggggcgct	ggggtcttgc	120
aaggctgagc	tgacgcgcga	gaggtcgtgt	cacgtcccac	gaccttgacg	ccgtcgggga	180
cagccggaac	agagcccggt	gaangcggga	ggcctcgggg	agcccctcgg	gaagggcggc	240
ccgagagata	cgcaggtgca	ggtggccgcc				270

```
<210> 201
<211> 419
<212> DNA
<213> Homo sapien
```

```
<220>
<221> misc_feature
<222> (1)...(419)
<223> n = A,T,C or G
```

<400> 201						
tttttttttt	ttttggaatc	tactgcgagc	acagcaggtc	agcaacaagt	ttatttttgca	60
gctagcaagg	taacagggta	gggcatgggt	acatgttcag	gtcaacttcc	tttgtcgtgg	120
ttgattgggt	tgtctttatg	ggggcggggt	ggggtagggg	aaancgaagc	anaantaaca	180
tggagtgggt	gcaccctccc	tgtagaacct	ggttacnaaa	gctttggggc	gttcacctgg	240
tctgtgaccg	tcattttctt	gacatcaatg	ttattagaag	tcaggatatc	ttttgagag	300
tccactgtnt	ctggaggggag	attagggttt	cttgccaana	tccaancaaa	atccacntga	360
aaaagtgtga	tgtatncanq	acngaatacc	ganggcatan	ttctcatant	cgggtggcca	419

```
<210> 202
<211> 509
<212> DNA
<213> Homo sapien
```

```
<220>
<221> misc_feature
<222> (1)...(509)
<223> n = A,T,C or G
```

<400> 202						
tttntttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	60
tggcacttaa	tccattttta	tttcaaaatg	tctacaaant	ttnaatncnc	cattatacng	120
gtnattttnc	aaaatctaaa	nnttattcaa	atntnagcca	aantccttac	ncaaatnnaa	180
tacncncaaa	aatcaaaaat	atacntntct	ttcagcaaac	ttngttacat	aaattaaaaa	240
aatatatacg	gctggtgttt	tcaaagtaca	attatcttaa	cactgcaaac	atntttnnaa	300
ggaactaaaa	taaaaaaaaa	cactnccgca	aagggttaaag	ggaacaacaa	attcntttta	360
caacancnnc	nattataaaa	atcatatctc	aaatcttagg	ggaatatata	cttcacacng	420
ggatcttaac	ttttactnca	ctttgtttat	ttttttanaa	ccattgtntt	gggcccaaca	480
caatgqnaat	nccnccncnc	tggaactagt				509

<210>	203
<211>	583
<212>	DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(583)

<223> n = A,T,C or G

<400> 203

tttttttttt	ttttttttga	ccccctctt	ataaaaaaca	agttaccatt	ttattttact	60
tacacatatt	tattttataa	ttggtattag	atattcaaaa	ggcagctttt	aaaatcaaac	120
taaatggaaa	ctgccttaga	tacataattc	ttaggaatta	gcttaaaatc	tgccataaagt	180
gaaaatcttc	tctagctctt	ttgactgtaa	atttttgact	cttgtaaaac	atccaaattc	240
atttttcttg	tctttaaaat	tatctaattc	ttccattttt	tccctattcc	aagtcaattt	300
gcttctctag	cctcatttcc	tagctcttat	ctactattag	taagtggctt	ttttcctaaa	360
agggaaaaca	ggaagagana	atggcacaca	aaacaaacat	tttatattca	tatttctacc	420
tacgttaata	aaatagcatt	ttgtgaagcc	agctcaaaag	aaggcttaga	tccttttatg	480
tccattttag	tcactaaacg	atatcnaaag	tgccagaatg	caaaagggtt	gtgaacattt	540
attcaaaagc	taatataaga	tatttcacat	actcatcttt	ctg		583

<210> 204

<211> 589

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(589)

<223> n = A,T,C or G

<400> 204

ttttttttnt	tttttttttt	tttttttctc	ttcttttttt	ttganaatga	ggatcgagtt	60
tttcaactctc	tagatagggc	atgaagaaaa	ctcatctttc	cagcttttaa	ataacaatca	120
aatctcttat	gctatatcat	attttaagtt	aaactaatga	gtcactggct	tatcttctcc	180
tgaaggaaat	ctgttcattc	ttctcattca	tatagttata	tcaagtacta	ccttgcatat	240
tgagagggtt	ttcttctcta	tttacacata	tatttccatg	tgaatttgta	tcaaaccctt	300
attttcatgc	aaactagaaa	ataatgtntt	cttttgcata	agagaagaga	acaatatnag	360
cattacaaaa	ctgctcaaat	tgtttggtta	gnntatccat	tataattagt	tnggcaggag	420
ctaatacaaa	tcacattttac	ngacnagcaa	taataaaact	gaagtaccag	ttaaatatcc	480
aaaataatta	aaggaacatt	tttagcctgg	gtataattag	ctaattcact	ttacaagcat	540
ttattnagaa	tgaattcaca	tgttattatt	ccttagccca	acacaatgg		589

<210> 205

<211> 545

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(545)

<223> n = A,T,C or G

<400> 205

tttttntttt	ttttttcagt	aataatcaga	acaatattta	tttttatatt	taaaattcat	60
agaaaagtgc	cttacattta	ataaaagttt	gtttctcaaa	gtgatcagag	gaattagata	120
tngtcttgaa	caccaatatt	aatttgagga	aaatacacca	aaatacatta	agtaaattat	180
ttaagatcat	agagcttgta	agtgaaga	taaaatttga	cctcagaaac	tctgagcatt	240
aaaaatccac	tattagcaaa	taaattacta	tggacttctt	gctttaattt	tgatgatgaat	300
atgggggtgc	actggtaaac	caacacattc	tgaaggatac	attacttagt	gatagattct	360

tatgtacttt	gctanatnac	gtggatatga	gttgacaagt	ttctctttct	tcaatctttt	420
aaggggcnga	ngaaatgagg	aagaaaagaa	aaggattacg	catactgttc	tttctatngg	480
aaggattaga	tatgtttcct	ttgccaatat	taaaaaata	ataatgttta	ctactagtga	540
aaccc						545

<210> 206  
 <211> 487  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(487)  
 <223> n = A,T,C or G

<400> 206	
tttttttttt	tttttagtc aagtttctna tttttattat aattaaagtc ttggtcattt 60
catttattag	ctctgcaact tacatattta aattaaagaa acgttnttag acaactgtna 120
caatttataa	atgtaagggtg ccattattga gtanatatat tcctccaaga gtggatgtgt 180
cccttctccc	accaactaat gaancagcaa cattagttta attttattag tagatnatac 240
actgctgcaa	acgctaattc tcttctccat ccccatgtng atattgtgta tatgtgtgag 300
ttggtnagaa	tgcatcanca atctnacaat caacagcaag atgaagctag gcntgggctt 360
tcggtgaaaa	tagactgtgt ctgtctgaat caaatgatct gacctatcct cgggtggcaag 420
aactcttoga	accgcttcct caaaggcngc tgccacattt gtggcntctn ttgcacttgt 480
ttcaaaa	
	487

<210> 207  
 <211> 332  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(332)  
 <223> n = A,T,C or G

<400> 207	
tgaattggct	aaaagactgc atttttanaa ctagcaactc ttatttcttt cctttaaaaa 60
tacatagcat	taaatcccaa atcctattta aagacctgac agcttgagaa ggtcactact 120
gcatttatag	gaccttctgg tggttctgct gttacntttg aantctgaca atccttgana 180
atctttgcat	gcagaggagg taaaagggtat tggattttca cagaggaana acacagcgca 240
gaaatgaagg	ggccaggctt actgagcttg tccactggag ggctcatggg tgggacatgg 300
aaaagaaggc	agcctaggcc ctggggagcc ca 332

<210> 208  
 <211> 524  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(524)  
 <223> n = A,T,C or G

<400> 208	
agggcggtgt	gcggaggggcgt ttactgtttt gtctcagtaa caataaatat aaaaagactg 60
gttgtgttcc	ggcccatccc aaccacgaag ttgatttctc ttgtgtgcag agtgactgat 120
tttaaggac	atggagcttg tcacaatgtc acaatgtcac agtgtgaagg gcacactcac 180



tcccgcgtga	ttcacattta	gcaaccaaca	atagctcatg	agtccatact	tgtaaatact	240
tttggcagaa	tacttnttga	aacttgcaga	tgataactaa	gatccaagat	atttcccaaa	300
gtaaatagaa	gtgggtcata	atattaatta	cctgttcaca	tcagcttcca	tttacaagtc	360
atgagccag	acactgacat	caaactaagc	ccacttagac	tcctcaccac	cagtctgtcc	420
tgtcatcaga	caggaggetg	tcacottgac	caaattctca	ccagtcaatc	atctatccaa	480
aaaccattac	ctgatccact	tccggtaatg	caccaccttg	gtga		524

<210> 209  
 <211> 159  
 <212> DNA  
 <213> Homo sapien

gggtgaggaa	atccagagtt	gccatggaga	aaattccagt	gtcagcattc	ttgctccttg	60
tggccctctc	ctacactctg	gccagagata	ccacagtcaa	acctggagcc	aaaaaggaca	120
caaaggactc	tcgacccaaa	ctgccccaga	ccctctcca			159

<210> 210  
 <211> 256  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(256)  
 <223> n = A,T,C or G

actccctggc	agacaaaggc	agaggagaga	gctctgttag	ttctgtgttg	ttgaactgcc	60
actgaatttc	tttccacttg	gactattaca	tgccanttga	gggactaatg	gaaaaacgta	120
tggggagatt	ttanccaatt	tangtntgta	aatggggaga	ctggggcagg	cgggagagat	180
ttgcagggtg	naaatgggan	ggctgggttg	ttanatgaac	agggacatag	gaggtaggca	240
ccaggatgct	aatca					256

<210> 211  
 <211> 264  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(264)  
 <223> n = A,T,C or G

acattgtttt	tttgagataa	agcattgaga	gagctctcct	taacgtgaca	caatggaagg	60
actggaacac	atacccacat	ctttgttctg	agggataatt	ttctgataaa	gtcttgctgt	120
atattcaagc	acatatgtta	tatattattc	agttccatgt	ttatagccta	gttaaggaga	180
ggggagatac	attcngaaag	aggactgaaa	gaaatactca	agtnngaaaa	cagaaaaaga	240
aaaaaaggag	caaatgagaa	gcct				264

<210> 212  
 <211> 328  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature

<222> (1)...(328)

<223> n = A,T,C or G

<400> 212

acccaaaaat ccaatgctga atatttggct tcattattcc canattcttt gattgtcaaa	60
ggatttaaatg ttgtctcagc ttgggcactt cagttaggac ctaaggatgc cagccggcag	120
gtttatatat gcagcaacaa tattcaagcg cgacaacagg ttattgaact tgcccgccag	180
ttnaatttca ttcccattga cttgggatcc ttatcatcag ccagagagat tgaaaattta	240
cccctacnac tctttactct ctgganaggg ccagtgggtg tagctataag cttggccaca	300
tttttttttc ctttattcct ttgtcaga	328

<210> 213

<211> 250

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(250)

<223> n = A,T,C or G

<400> 213

acttatgagc agagcgacat atccnagtgt agactgaata aaactgaatt ctctccagtt	60
taaagcattg ctcaactgaag ggatagaagt gactgccagg agggaaagta agccaaggct	120
cattatgcc aagganatat acatttcaat tctccaaact tcttcctcat tccaagagtt	180
ttcaatattt gcatgaacct gctgataanc catgttaana aacaaatata tctctnacct	240
tctcatcggt	250

<210> 214

<211> 444

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(444)

<223> n = A,T,C or G

<400> 214

accagaatc caatgctgaa tatttggcct cattattccc agattctttg attgtcaaag	60
gatttaaatgt tgtctcagct tgggcacttc agttaggacc taaggatgcc agccggcagg	120
tttatatatg cagcaacaat attcaagcgc gacaacaggc tattgaactt gcccgccagt	180
tgaatttcat tcccattgac ttgggatcct tatcatcagc canagagatt gaaaatttac	240
ccctacgact ctttactctc tggagagggc cagtgggtgg agctataagc ttggccacat	300
ttttttttcc tttattcctt tgtcagagat gcgattcatc catatgctan aaaccaacag	360
agtgactttt acaaaaattcc tataganatt gtgaataaaa ccttacctat agttgccatt	420
actttgctct ccctaataata cctc	444

<210> 215

<211> 366

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(366)

<223> n = A,T,C or G

&lt;400&gt; 215

acttatgagc	agagcgacat	atccaagtgt	anactgaata	aaactgaatt	ctctccagtt	60
taaagcattg	ctcactgaag	ggatagaagt	gactgccagg	agggaaaagta	agccaaggct	120
cattatgccca	aagganatat	acattttcaat	tctccaaact	tcttctcat	tccaagagtt	180
ttcaatat	gcatgaacct	gctgataagc	catgttgaga	aacaaatata	tctctgacct	240
tctcatcggt	aagcagaggc	tgtaggcaac	atggaccata	gcgaanaaaa	aacttagtaa	300
tccaagctgt	tttctacact	gtaaccagg	ttccaaccaa	ggtggaaatc	tcctatactt	360
ggtgcc						366

&lt;210&gt; 216

&lt;211&gt; 260

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(260)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 216

ctgtataaac	agaactccac	tgcanagagg	agggccgggc	caggagaatc	tcogcttgtc	60
caagacaggg	gcctaaggag	ggtctccaca	ctgctnntaa	gggctnttnc	atTTTTTTT	120
taataaaaag	tnnaaaaggc	ctcttctcaa	ctTTTTTccc	ttnggctgga	aaatttaaaa	180
atcaaaaatt	tctnaagtt	ntcaagctat	catatatact	ntatcctgaa	aaagcaacat	240
aattcttcct	tccttcctt					260

&lt;210&gt; 217

&lt;211&gt; 262

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(262)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 217

acctacgtgg	gtaagtttan	aaatgttata	atttcaggaa	naggaacgca	tataattgta	60
tcttgccctat	aatttttctat	tttaataagg	aaatagcaaa	ttgggggtggg	gggaatgtag	120
ggcattctac	agtttgagca	aaatgcaatt	aaatgtggaa	ggacagcact	gaaaaatttt	180
atgaataatc	tgtatgatta	tatgtctcta	gagtagattt	ataattagcc	acttaccta	240
atatacttca	tgcttgtaaa	gt				262

&lt;210&gt; 218

&lt;211&gt; 205

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(205)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 218

accaaggtgg	tgcatcaccg	gaantggatc	aangacacca	tcgtggccaa	cccctgagca	60
cccctatcaa	ctcccctttt	tagtaaaact	ggaaccttgg	aaatgaccag	gccaaagactc	120
aggcctcccc	agtttctact	acctttgtcc	ttangtntna	ngtccagggt	tgctaggaaa	180
anaaatcagc	agacacaggt	gtaaa				205

<210> 219  
 <211> 114  
 <212> DNA  
 <213> Homo sapien

<400> 219  
 tactgttttg tctcagtaac aataaataca aaaagactgg ttgtgttccg gcccaccca 60  
 accacgaagt tgatttctct tgtgtgcaga gtgactgatt ttaaaggaca tgga 114

<210> 220  
 <211> 93  
 <212> DNA  
 <213> Homo sapien

<400> 220  
 actagccagc acaaaaggca gggtagcctg aattgctttc tgctctttac atttctttta 60  
 aaataagcat ttagtgctca gtccctactg agt 93

<210> 221  
 <211> 167  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(167)  
 <223> n = A,T,C or G

<400> 221  
 actangtgca ggtgcgcaca aatatttgtc gatattccct tcatcttgga ttccatgagg 60  
 tcttttgccc agcctgtggc tctactgtag taagtttctg ctgatgagga gccagnatgc 120  
 cccccactac cttccctgac gtcgccana aatcacccaa cctctgt 167

<210> 222  
 <211> 351  
 <212> DNA  
 <213> Homo sapien

<400> 222  
 agggcggtgt gcggagggcg gtactgacct cattagtagg aggatgcatt ctggcacccc 60  
 gttcttcacc tgtcccccaa tccttaaaag gccatactgc ataaagtcaa caacagataa 120  
 atgtttgctg aattaaagga tggatgaaaa aaattaataa tgaatttttg cataatccaa 180  
 ttttctcttt tatatttcta gaagaagttt ctttgagcct attagatccc gggaatcttt 240  
 taggtgagca tgattagaga gctttaggtg tgcttttaca tatactctggc atatttgagt 300  
 ctcgatcaaa aacaatagat tggtaaagggt ggtattattg tattgataag t 351

<210> 223  
 <211> 383  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(383)  
 <223> n = A,T,C or G

<400> 223

aaaacaaaca	aacaaaaaaa	acaattcttc	attcagaaaa	attatcttag	ggactgatat	60
tggttaattat	ggtcaattta	atwrrtrttkt	ggggcatttc	cttacattgt	cttgacaaga	120
ttaaaatgtc	tgtgccaaaa	ttttgtattt	tatttgaggaga	cttccttatca	aaagtaatgc	180
tgccaaagga	agtctaagga	attagtagtg	ttcccmtcac	ttgtttggag	tgtgctattc	240
taaaagattt	tgatttcctg	gaatgacaat	tatatatttaa	ctttgggtggg	ggaaanagtt	300
ataggaccac	agtcttctact	tctgatactt	gtaaattaat	cttttattgc	acttgttttg	360
accattaagc	tatatgttta	aaa				383

&lt;210&gt; 224

&lt;211&gt; 320

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 224

cccctgaagg	cttcttggtta	gaaaatagta	cagttacaac	caataggaac	aacaaaaaga	60
aaaagtttgt	gacattgtag	tagggagtg	gtacccctta	ctcccatca	aaaaaaaaat	120
ggatacatgg	ttaaaggata	raagggaat	atattatcat	atgttctaaa	agagaaggaa	180
gagaaaatac	tactttctcr	aaatggaagc	ccttaaagggt	gctttgatac	tgaaggacac	240
aaatgtggcc	gtccatcctc	ctttaragtt	gcatgacttg	gacacggtaa	ctgttgacgt	300
tttaractcm	gcattgtgac					320

&lt;210&gt; 225

&lt;211&gt; 1214

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 225

gaggactgca	gcccgcactc	gcagccctgg	caggcggcac	tggctcatgga	aaacgaattg	60
ttctgctcgg	gcgtcctggg	gcacccgcag	tgggtgctgt	cagccgcaca	ctgtttccag	120
aactcctaca	ccatcgggct	gggcctgcac	agtcttgagg	ccgaccaaga	gccaggggagc	180
cagatgggtg	aggccagcct	ctccgtacgg	caccagaggt	acaacagacc	cttgctcgt	240
aacgacctca	tgctcatcaa	gttggacgaa	tccgtgtccg	agtctgacac	catccggagc	300
atcagcattg	cttcgcagtg	ccctaccgcg	gggaactctt	gcctcgtttc	tggctggggg	360
ctgctggoga	acggcagaat	gcctaccgtg	ctgcagtgcg	tgaacgtgtc	gggtggtgtc	420
gaggaggtct	gcagtaagct	ctatgaccgg	ctgtaccacc	ccagcatgtt	ctgcgccggc	480
ggagggcaag	accagaagga	ctcctgcaac	ggtgactctg	ggggggccct	gatctgcaac	540
gggtacttgc	agggccttgt	gtctttcgga	aaagccccgt	gtggccaagt	tggcgtgcca	600
ggtgtctaca	ccaacctctg	caaattcact	gagtggatag	agaaaaccgt	ccaggccagt	660
taactctggg	gactgggaac	ccatgaaatt	gacccccaaa	tacatcctgc	ggaagggaatt	720
caggaatata	tgttccagc	ccctcctccc	tcaggcccgag	gagtccaggc	ccccagcccc	780
tcctccctca	aaccaagggt	acagatcccc	agccccctct	ccctcagacc	caggagtcca	840
gacccccag	ccccctctcc	ctcagaccca	ggagtccagc	ccctcctccc	tcagaccag	900
gagtccagac	ccccagccc	ctcctccctc	agaccagggg	gtccaggccc	ccaacccctc	960
ctccctcaga	ctcagaggtc	caagccccca	acccctcctt	ccccagaccc	agaggtccag	1020
gtcccagccc	ctcctccctc	agaccagcgg	gtccaatgcc	acctagactc	tccctgtaca	1080
cagtgcctcc	ttgtggcag	ttgacccaac	cttaccagtt	ggtttttcat	tttttgcctc	1140
tttcccttag	atccagaaat	aaagtctaag	agaagcgcaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaa					1214

&lt;210&gt; 226

&lt;211&gt; 119

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 226

accagtatg	tgcagggaga	cggaacccca	tgtgacagcc	cactccacca	gggttcccaa	60
agaacctggc	ccagtcataa	tcattcatcc	tgacagtggc	aataatcacg	ataaccagt	119

<210> 227  
 <211> 818  
 <212> DNA  
 <213> Homo sapien

<400> 227  
 acaattcata gggacgacca atgaggacag ggaatgaacc cggctctccc ccagccctga 60  
 tttttgctac atatggggtc ccttttcatt ctttgcaaaa acactgggtt ttctgagaac 120  
 acggacggtt cttagcaciaa tttgtgaaat ctgtgtaraa ccgggctttg caggggagat 180  
 aattttcctc ctctggagga aagggtggtga ttgacaggca gggagacagt gacaaggcta 240  
 gagaaagcca cgctcggcct tctctgaaac aggatggaac ggcagacccc tgaaaacgaa 300  
 gcttgtcccc ttccaatcag ccacttctga gaacccccat ctaacttctt actggaaaag 360  
 agggcctcct caggagcagt ccaagagttt tcaaagataa cgtgacaact accatctaga 420  
 ggaaagggtg caccctcagc agagaagccg agagcttaac tctggtcggt tccagagaca 480  
 acctgctggc tgtcttggtg tgcgcccagc ctttgagagg ccactacccc atgaacttct 540  
 gccatccact ggacatgaag ctgaggacac tgggcttcaa cactgagttg tcatgagagg 600  
 gacaggtctt gccctcaagc cggctgaggg cagcaaccac tctcctcccc tttctcacgc 660  
 aaagccattc ccacaaatcc agaccatacc atgaagcaac gagacccaaa cagtttggtc 720  
 caagaggata tgaggactgt ctcagcctgg ctttgggctg acaccatgca cacacacaag 780  
 gtccacttct aggttttcag cctagatggg agtcgtgt 818

<210> 228  
 <211> 744  
 <212> DNA  
 <213> Homo sapien

<400> 228  
 actggagaca ctgttgaact tgatcaagac ccagaccacc ccaggtctcc ttcgtgggat 60  
 gtcattgacgt ttgacatacc tttggaacga gcctcctcct tggaagatgg aagaccgtgt 120  
 tcgtggccga cctggcctct cctggcctgt ttcttaagat gcggagtcac atttcaatgg 180  
 taggaaaagt ggcttcgtaa aatagaagag cagtcactgt ggaactacca aatggcgaga 240  
 tgctcgggtg acattggggg gctttgggat aaaagattta tgagccaact attctctggc 300  
 accagattct aggccagttt gttccactga agcttttccc acagcagtc acctctgcag 360  
 gctggcagct gaattggctt cgggtggctc tgtggcaaga tcacactgag atcgatgggt 420  
 gagaaggcta ggatgcttgt ctagtgttct tagctgtcac gttggctcct tccaggttgg 480  
 ccagacgggtg ttggccactc ccttctaaaa cacaggcgcc ctctggtga cagtgacctg 540  
 ccgtgggtatg ccttggccca ttccagcagt ccagttatg catttcaagt ttggggtttg 600  
 ttcttttctg taatgttctt ctgtgttgtc agctgtcttc atttctctgg ctaagcagca 660  
 ttgggagatg tggaccagag atccactcct taagaaccag tggcgaaaga cactttcttt 720  
 cttcactctg aagtagctgg tggg 744

<210> 229  
 <211> 300  
 <212> DNA  
 <213> Homo sapien

<400> 229  
 cgagtctggg ttttgtctat aaagtttgat cctcctttt ctcatccaaa tcatgtgaac 60  
 cattacacat cgaaataaaa gaaagggtggc agacttggcc aacgccaggc tgacatgtgc 120  
 tgcagggttg ttgtttttta attattattg ttagaaacgt caccacagc ccctgttaat 180  
 ttgtatgtga cagccaactc tgagaaggtc ctatttttcc acctgcagag gatccagtct 240  
 cactaggctc ctcttggccc tcacactgga gtctccgcca gtgtgggtgc ccactgacat 300

<210> 230  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

## &lt;400&gt; 230

cagcagaaca	aatacaata	tgaagagtgc	aaagatctca	taaaatctat	gctgaggaat	60
gagcgacagt	tcaaggagga	gaagcttgca	gagcagctca	agcaagctga	ggagctcagg	120
caatataaag	tcctggttca	cactcaggaa	cgagagctga	cccagttaag	ggagaagttg	180
cggaaggga	gagatgcctc	cctctcattg	aatgagcatc	tccagccct	cctcactccg	240
gatgaaccgg	acaagtccca	ggggcaggac	ctccaagaaa	cagacctcgg	ccgcgaccac	300

g

301

&lt;210&gt; 231

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 231

gcaagcacgc	tggcaaactct	ctgtcaggtc	agctccagag	aagccattag	tcatttttagc	60
caggaactcc	aagtccacat	ccttggaac	tggggacttg	cgcaggtag	ccttgaggat	120
ggcaacacgg	gacttctcat	caggaagtgg	gatgtagatg	agctgatcaa	gacggccagg	180
tctgaggatg	gcaggatcaa	tgatgtcagg	ccggttggtg	ccgccaatga	tgaacacatt	240
tttttttgtg	gacatgccat	ccatttctgt	caggatctgg	ttgatgactc	ggtcagcagc	300

c

301

&lt;210&gt; 232

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 232

agtaggtatt	tcgtgagaag	ttcaacacca	aaactggaac	atagttctcc	ttcaagtgtt	60
ggcgacagcg	gggcttccctg	attctggaat	ataactttgt	gtaaattaac	agccacctat	120
agaagagtcc	atctgctgtg	aaggagagac	agagaactct	gggttcogtc	gtcctgtcca	180
cgtgctgtac	caagtgtctg	tgccagcctg	ttacctgttc	tcaactgaaa	tctggctaatt	240
gctcttgtgt	atcacttctg	attctgacaa	tcaatcaatc	aatggcctag	agcactgact	300

g

301

&lt;210&gt; 233

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 233

atgactgact	tcccagtaag	gctctctaag	gggtaagtag	gaggatccac	aggatttgag	60
atgctaaggc	cccagagatc	gtttgatcca	accctcttat	tttcagaggg	gaaaatgggg	120
cctagaagtt	acagagcatc	tagctggtgc	gctggcacc	ctggcctcac	acagactccc	180
gagtagctgg	gactacaggc	acacagtcac	tgaagcaggc	cctgtagca	attctatgcg	240
tacaaattaa	catgagatga	gtagagactt	tattgagaaa	gcaagagaaa	atcctatcaa	300

c

301

&lt;210&gt; 234

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 234

aggctctaca	catcgagact	catccatgat	tgatatgaat	ttaaaaatta	caagcaaaga	60
catttttattc	atcatgatgc	tttcttttgt	ttcttctttt	cgttttcttc	tttttctttt	120
tcaatttcag	caacatactt	ctcaatttct	tcaggattta	aaatcttgag	ggattgatct	180
cgcctcatga	cagcaagttc	aatgtttttg	ccacctgact	gaaccacttc	caggagtgcc	240
ttgatcacca	gcttaatggt	cagatcatct	gcttcaatgg	cttcgtcagt	atagttcttc	300

t

301

<210> 235  
 <211> 283  
 <212> DNA  
 <213> Homo sapien

<400> 235

tggggctgtg	catcaggcgg	gtttgagaaa	tattcaattc	tcagcagaag	ccagaatttg	60
aattccctca	tcttttaggg	aatcatttac	caggtttgga	gaggattcag	acagctcagg	120
tgctttcact	aatgtctctg	aacttctgtc	cctctttgtt	catggatagt	ccaataaata	180
atgttatctt	tgaactgatg	ctcataggag	agaatataag	aactctgagt	gatatcaaca	240
ttagggattc	aaagaaatat	tagatttaag	ctcacactgg	tca		283

<210> 236  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 236

aggtcctcca	ccaactgcct	gaagcacggt	taaaattggg	aagaagtata	gtgcagcata	60
aatactttta	aatcgatcag	atttccctaa	cccacatgca	atcttcttca	ccagaagagg	120
tcggagcagc	atcattaata	ccaagcagaa	tgcgtaatag	ataaatacaa	tggtatatag	180
tgggtagacg	gcttcgatgag	tacagtgtac	tgtggtatcg	taatctggac	ttgggttgta	240
aagcatcgtg	taccagtcag	aaagcatcaa	tactcgacat	gaacgaatat	aaagaacacc	300
a.						301

<210> 237  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 237

cagtggtagt	ggtggtggac	gtggcggttg	tcgtggtgcc	ttttttggtg	cccgtcacaa	60
actcaatttt	tgttcgctcc	tttttgccct	tttccaattt	gtccatctca	attttctggg	120
ccttggtctaa	tgcctcatag	taggagtcct	cagaccagcc	atggggatca	aacatatacct	180
ttgggtagtt	ggtgccaaagc	tcgtcaatgg	cacagaatgg	atcagcttct	cgtaaatcta	240
gggttccgaa	attctttctt	cctttggata	atgtagttca	tatccattcc	ctcctttatc	300
t						301

<210> 238  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 238

gggcagggttt	tttttttttt	ttttttgatg	gtgcagaccc	ttgctttatt	tgtctgactt	60
gttcacagtt	cagccccctg	ctcagaaaac	caacgggcca	gctaaggaga	ggaggaggca	120
ccttgagact	tccggagtcg	aggctctcca	gggttcccca	gcccatcaat	cattttctgc	180
acccctgcc	tgggaagcag	ctccctgggg	ggtgggaatg	ggtgactaga	agggatttca	240
gtgtgggacc	cagggctctgt	tcttcacagt	aggaggtgga	agggatgact	aatttcttta	300
t						301

<210> 239  
 <211> 239  
 <212> DNA  
 <213> Homo sapien



## &lt;400&gt; 239

ataagcagct agggaattct ttatttagta atgtcctaac ataaaagttc acataactgc	60
ttctgtcaaa ccatgatact gagctttgtg acaaccaga aataactaag agaaggcaaa	120
cataatacct tagagatcaa gaaacattta cacagttcaa ctgtttaaaa atagctcaac	180
attcagccag tgagtagagt gtgaatgcc aacatacacag tatacaggtc cttcaggga	239

&lt;210&gt; 240

&lt;211&gt; 300

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 240

ggctctaagt aagcagcagc ttccacattt taacgcaggt ttacggtgat actgtccttt	60
gggatctgcc ctccagtggg accttttaag gaagaagtgg gcccaagcta agttccacat	120
gctgggtgag ccagatgact tctgttccct ggtaactttc ttcaatgggg cgaatggggg	180
ctgccaggtt tttaaaatca tgcttcatct tgaagcacac ggtaacttca ccctcctcac	240
gctgtgggtg tactttgatg aaaataccca ctttgttggc ctttctgaag ctataatgtc	300

&lt;210&gt; 241

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 241

gaggtctggt gctgaggtct ctgggctagg aagaggaggt ctgtggagct ggaagccaga	60
cctcttttga ggaaactcca gcagctatgt tgggtgtctct gagggaatgc aacaaggctg	120
ctcctccatg tattggaaaa ctgcaaactg gactcaactg gaaggaagtg ctgctgccag	180
tgtgaagaac cagcctgagg tgacagaaac ggaagcaaac aggaacagcc agtcttttct	240
tcctcctcct gtcatacggg ctctctcaag catcctttgt tgtcaggggc ctaaaaggga	300
g	301

&lt;210&gt; 242

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 242

ccgaggtcct gggatgcaac caatcactct gtttcacgtg acttttatca ccatacaatt	60
tgtggcattt cctcattttc tacattgtag aatcaagagt gtaaataaat gtatatcgat	120
gtcttcaaga atatatcatt cttttttcac tagaaccat tcaaaatata agtcaagaat	180
cttaatatca acaaataat caagcaaact ggaaggcaga ataactacca taatttagta	240
taagtaccca aagttttata aatcaaaagc cctaatagata accattttta gaattcaatc	300
a	301

&lt;210&gt; 243

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 243

aggtaagtcc cagtttgaag ctcaaaagat ctggtatgag cataggctca tcgacgacat	60
ggtggcccaa gctatgaaat cagagggagg cttcatctgg gcctgtaaaa actatgatgg	120
tgacgtgcag tcggactctg tggcccaagg gtatggctct ctcgcatga tgaccagcgt	180
gctggtttgt ccagatggca agacagtaga agcagaggct gccacggga ctgtaaccgg	240
tcactaccgc atgttccaga aaggacagga gacgtccacc aatcccattg cttccatttt	300
t	301

&lt;210&gt; 244

<211> 300  
 <212> DNA  
 <213> Homo sapien

<400> 244  
 gctggtttgc aagaatgaaa tgaatgattc tacagctagg acttaacctt gaaatggaaa 60  
 gtcattgcaat ccattttgca ggatctgtct gtgcacatgc ctctgtagag agcagcattc 120  
 ccaggacact tggaaacagt tgacactgta aggtgcttgc tcccccaagac acatcctaaa 180  
 aggtgttgta atggtgaaaa cgtcttcctt ctttattgcc ccttcttatt tatgtgaaca 240  
 actgtttgtc ttttgtgtat cttttttaaa ctgtaaagtt caattgtgaa aatgaatata 300

<210> 245  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 245  
 gtctgagtat ttaaaatggt attgaaatta tcccccaacca atgttagaaa agaaagaggt 60  
 tatatactta gataaaaaat gaggtgaatt actatccatt gaaatcatgc tcttagaatt 120  
 aaggccagga gatattgtca ttaatgtara cttcaggaca ctagagtata gcagccctat 180  
 gttttcaaag agcagagatg caattaaata ttgttttagca tcaaaaaggc cactcaatac 240  
 agctaataaa atgaaagacc taattttctaa agcaattctt tataatttac aaagttttta 300  
 g 301

<210> 246  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 246  
 ggtctgtcct acaatgcctg cttcttgaaa gaagtcggca ctttctagaa tagctaaata 60  
 acctgggctt atttttaaaga actatttgta gctcagattg gttttcctat ggctaaaata 120  
 agtgcttctt gtgaaaatta aataaaacag ttaattcaaa gccttgatat atgttaccac 180  
 taacaatcat actaaatata ttttgaagta caaagtttga catgctctaa agtgacaacc 240  
 caaatgtgtc ttacaaaaca cgttcctaac aaggtatgct ttacactacc aatgcagaaa 300  
 c 301

<210> 247  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 247  
 aggtcctttg gcagggtcga tggatcagag ctcaaactgg agggaaaggc atttcgggta 60  
 gcctaagagg ggcactggcg gcagcacaac caaggaaggc aaggttggtt cccccacgct 120  
 gtgtcctgtg ttcagggtgcg acacacaatc ctcatgggaa caggatcacc catgctgtgc 180  
 ccttgatgat caaggttggg gcttaagtgg attaaggag gcaagttctg ggttccttgc 240  
 cttttcaaac catgaagtca ggctctgtat ccctcctttt cctaactgat attctaacta 300  
 a 301

<210> 248  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 248  
 aggtccttgg agatgccatt tcagccgaag gactcttctw ttccggaagta caccctcact 60  
 attaggaaga ttcttagggg taatttttct gaggaaggag aactagccaa ctttaagaatt 120

acaggaagaa agtggtttgg aagacagecca aagaaataaa agcagattaa attgtatcag 180  
 gtacattcca gcctgttggc aactccataa aaacatttca gattttaatc ccgaatttag 240  
 ctaatgagac tggatttttg ttttttatgt tgtgtgtcgc agagctaaaa actcagttcc 300  
 c 301

<210> 249  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 249  
 gtccagagga agcacctggg gctgaactag gcttgccctg ctgtgaactt gcacttggag 60  
 ccctgacgct gctgttctcc ccgaaaaacc cgaccgacct ccgcgatctc cgccccgcc 120  
 ccaggagac acagcagtga ctacagagctg gtgcacact gtgcctccct cctcaccgcc 180  
 catcgtaatg aattattttg aaaattaatt ccaecatcct ttcagattct ggatggaaag 240  
 actgaatctt tgactcagaa ttgtttgctg aaaagaatga tgtgactttc ttagtcattt 300  
 a 301

<210> 250  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 250  
 ggtctgtgac aaggacttgc aggctgtggg aggcaagtga cccttaacac tacacttctc 60  
 cttatcttta ttggcttgat aaacataatt atttctaaca ctagcttatt tccagttgcc 120  
 cataagcaca tcagtacttt tctctggctg gaatagtaaa cttaaagtatg gtacatctac 180  
 ctaaaagact actatgtgga ataatacata ctaatgaagt attacatgat ttaaagacta 240  
 caataaaacc aaacatgctt ataacattaa gaaaaacaat aaagatacat gattgaaacc 300  
 a 301

<210> 251  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 251  
 gccgaggtcc tacatttggc ccagtttccc cctgcatact ctccagggcc cctgcctcat 60  
 agacaacctc atagagcata ggagaactgg ttgccctggg ggcaggggga ctgtctggat 120  
 ggcaggggtc ctcaaaaatg ccactgtcac tgccaggaaa tgcttctgag cagtacacct 180  
 cattgggatc aatgaaaagc ttcaagaaat cttcaggctc actctcttga aggcccgga 240  
 cctctggagg ggggcagtgg aatcccagct ccaggacgga tctgtcgaa aagatatcct 300  
 c 301

<210> 252  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 252  
 gcaaccaatc actctgtttc acgtgacttt tatcaccata caatttgtgg catttctca 60  
 ttttctacat tgtagaatca agagtgtaaa taaatgtata tcgatgtctt caagaatata 120  
 tcattccttt ttcactagga acccattcaa aatataagtc aagaatctta atatcaacaa 180  
 atatatcaag caaactggaa ggcagaataa ctaccataat ttagtataag taccctaaagt 240  
 tttataaatc aaaagcccta atgataacca tttttagaat tcaatcatca ctgtagaatc 300  
 a 301

<210> 253

<211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 253  
 ttccctaaga agatgttatt ttgttgggtt ttgttcccc tccatctcga ttctcgtacc 60  
 caactaaaaa aaaaaaataa agaaaaaatg tgctgcgttc tgaaaaataa ctcccttagct 120  
 tggctcgatt gttttcagac cttaaaatat aaacttggtt cacaagcttt aatccatgtg 180  
 gatttttttt cttagagaac cacaaaacat aaaaggagca agtcggactg aataacctgtt 240  
 tccatagtgc ccacagggtg ttctctacat tttctccata ggaaaatgct ttttcccaag 300  
 g 301

<210> 254  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 254  
 cgctgcgcct ttcccttggg ggagggggcaa ggccagaggg ggtccaagtg cagcacgagg 60  
 aacttgacca attcccttga agcgggtggg tttaaccctg taaatgggaa caaaatcccc 120  
 ccaaattctt tcatcttacc ctggtggact cctgactgta gaattttttg gttgaaacaa 180  
 gaaaaaataa aagcttttga cttttcaagg ttgcttaaca ggtactgaaa gactggcctc 240  
 acttaaaact agccaggaaa agctgcagat ttattaatgg gtgtgttagt gtgcagtgcc 300  
 t 301

<210> 255  
 <211> 302  
 <212> DNA  
 <213> Homo sapien

<400> 255  
 agcttttttt tttttttttt tttttttttt ttcattaaaa aatagtgtct tttattataa 60  
 attactgaaa tgtttctttt ctgaatataa atataaatat gtgcaaagtt tgacttggat 120  
 tgggattttg ttgagttctt caagcatctc ctaataccct caagggcctg agtagggggg 180  
 aggaaaaagg actggagggt gaatctttat aaaaaacaag agtgattgag gcagattgta 240  
 aacattatta aaaaacaaga aacaaacaaa aaaatagaga aaaaaaccac cccaacacac 300  
 aa 302

<210> 256  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(301)  
 <223> n = A,T,C or G

<400> 256  
 gttccagaaa acattgaagg tggcttccca aagtctaact agggataccc cctctagcct 60  
 aggaccctcc tccccacacc tcaatccacc aaaccatcca taatgcaccc agataggccc 120  
 acccccaaaa gcctggacac cttgagcaca cagttatgac caggacagac tcatctctat 180  
 aggcaaatag ctgctggcaa actggcatta cctggtttgt ggggatgggg gggcaagtgt 240  
 gtggcctctc ggcctgggta gcaagaacat tcagggttagg cctaagttan tcgtgttagt 300  
 t 301

<210> 257  
 <211> 301

<212> DNA  
<213> Homo sapien

<400> 257

gttggtggagg	aactctggct	tgctcattaa	gtcctactga	ttttcactat	cccctgaatt	60
tccccactta	tttttgtctt	tcactatcgc	aggccttaga	agaggtctac	ctgcctccag	120
tcttacctag	tccagtctac	cccctggagt	tagaatggcc	atcctgaagt	gaaaagtaat	180
gtcacattac	tcccttcagt	gatttcttgt	agaagtgcc	atccctgaat	gccaccaaga	240
tcttaatctt	cacatcttta	atcttatctc	tttgactcct	ctttacaccg	gagaaggctc	300
c						301

<210> 258  
<211> 301  
<212> DNA  
<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 258

cagcagtagt	agatgccgta	tgccagcacg	cccagcactc	ccaggatcag	caccagcacc	60
agggggccag	ccaccaggcg	cagaagcaag	ataaacagta	ggctcaagac	cagagccacc	120
cccagggcaa	caagaatcca	ataccaggac	tgggcaaaat	cttcaaagat	cttaacactg	180
atgtctcggg	cattgaggct	gtcaataana	cgctgatccc	ctgctgtatg	gtgggtgcat	240
tggtgatccc	tgggagcgcc	ggtggagtaa	cgttggtcca	tggaaagcag	cgcccacaac	300
t						301

<210> 259  
<211> 301  
<212> DNA  
<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 259

tcatatatgc	aaacaaatgc	agactangcc	tcaggcagag	actaaaggac	atctcttggg	60
gtgtcctgaa	gtgatttggg	cccctgaggg	cagacaccta	agtaggaatc	ccagtgggaa	120
gcaaagccat	aaggaagccc	aggattcctt	gtgatcagga	agtgggccag	gaaggctctg	180
tccagctcac	atctcatctg	catgcagcac	ggaccggatg	cgcccactgg	gtcttggttt	240
ccctcccatc	ttctcaagca	gtgtccttgt	tgagccattt	gcatccttgg	ctccagggtg	300
c						301

<210> 260  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 260

ttttttttct	ccctaaggaa	aaagaaggaa	caagtctcat	aaaaccaa	aagcaatggt	60
aagggtgtctt	aacttgaaaa	agattaggag	tcactggttt	acaagttata	attgaatgaa	120
agaactgtaa	cagccacagt	tggccatttc	atgccaatgg	cagcaaaca	caggattaac	180
tagggcaaaa	taaataagt	tgtggaagcc	ctgataagtg	cttaataaac	agactgattc	240
actgagacat	cagtacctgc	ccgggcggcc	gctcgagccg	aattctgcag	atatccatca	300

c

301

<210> 261  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 261  
aaatattcga gcaaactctg taactaatgt gtctccataa aaggctttga actcagtga 60  
tctgcttcca tccacgattc tagcaatgac ctctcggaca tcaaagctcc tcttaagggtt 120  
agcaccaact attccataca attcatcagc aggaaataaa ggctcttcag aagggttcaat 180  
ggtgacatcc aattttcttct gataatttag attcctcaca accttcctag ttaagtgaag 240  
ggcatgatga tcatccaaag cccagtggtc acttactcca gactttctgc aatgaagatc 300  
a 301

<210> 262  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 262  
gaggagagcc tggtacagca tttgtaagca cagaatactc caggagtatt tgtaattgtc 60  
tgtgagcttc ttgccgcaag tctctcagaa atttaaaaag atgcaaatacc ctgagtcacc 120  
cctagacttc ctaaaccaga tcctctgggg ctggaacctg gcaactctgca tttgtaatga 180  
gggctttctg gtgcacacct aattttgtgc atctttgccc taaatcctgg attagtggcc 240  
catcattacc cccacattat aatgggatag attcagagca gatactctcc agcaaagaat 300  
c 301

<210> 263  
<211> 301  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(301)  
<223> n = A,T,C or G

<400> 263  
tttagcttgt ggtaaatgac tcacaaaact gattttaaaa tcaagttaat gtgaattttg 60  
aaaattacta cttaatccta attcacata acaatggcat taagggttga cttaggttgg 120  
ttcttagtat tatttatggt aaataggctc ttaccacttg caaataactg gccacatcat 180  
taatgactga cttcccagta aggtctctta aggggtaagt angaggatcc acaggatttg 240  
agatgctaag gccccagaga tcgtttgatc caaccctctt attttcagag gggaaaatgg 300  
g 301

<210> 264  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 264  
aaagacgtta aaccactcta ctaccacttg tggaactctc aaagggtaaa tgacaaascc 60  
aatgaatgac tctaaaaaca atatttacat ttaatggttt gtagacaata aaaaaacaag 120  
gtggatagat ctagaattgt aacattttta gaaaaccata scatttgaca gatgagaaag 180  
ctcaattata gatgcaaagt tataactaaa ctactatagt agtaaagaaa tacatttcac 240  
acccttcata taaattcact atcttggctt gaggcactcc ataaaatgta tcacgtgcat 300  
a 301

<210> 265  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 265

tgcccaagtt	atgtgtaagt	gtatccgcac	ccagaggtaa	aactacactg	tcattctttgt	60
cttcttgtga	cgcagtattt	cttctctggg	gagaagccgg	gaagtcttct	cctggctcta	120
catattcttg	gaagtctcta	atcaactttt	gttccatttg	tttcatttct	tcaggaggga	180
ttttcagttt	gtcaacatgt	tctctaacaa	cacttgccca	tttctgtaa	gaatccaaag	240
cagtccaagg	ctttgacatg	tcaacaacca	gcataactag	agtatccttc	agagatacgg	300
c						301

<210> 266  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 266

taccgtctgc	ccttctccc	atccaggcca	tctgcgaatc	tacatgggtc	ctcctattcg	60
acaccagatc	actctttcct	ctaccacacag	gottgctatg	agcaagagac	acaacctcct	120
ctcttctgtg	ttccagcttc	ttttcctggt	cttcccaccc	cttaagttct	attcctgggg	180
atagagacac	caatacccat	aacctctctc	ctaagcctcc	ttataacca	gggtgcacag	240
cacagactcc	tgacaactgg	taaggccaat	gaactgggag	ctcacagctg	gctgtgcctg	300
a						301

<210> 267  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 267

aaagagcaca	ggccagctca	gcctgccttg	gccatctaga	ctcagcctgg	ctccatgggg	60
gttctcagtg	ctgagtcctat	ccaggaaaag	ctcacctaga	ccttctgagg	ctgaatcttc	120
atctccacag	gcagcttctg	agagcctgat	attcctagcc	ttgatgggtc	ggagtaaagc	180
ctcattctga	ttcctctcct	tcttttcttt	caagttggct	ttcctcacat	ccctctgttc	240
aattegcttc	agcttgtctg	ctttagccct	catttcacga	agcttcttct	ctttggcatc	300
t						301

<210> 268  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 268

aatgtctcac	tcaactactt	cccagcctac	cgtggcctaa	ttctgggagt	tttcttctta	60
gatcttggga	gagctgggtc	ttctaaggag	aaggaggaag	gacagatgta	actttggatc	120
tcgaagagga	agtctaattg	aagtaattag	tcaacgggtc	ttgttttagac	tcttgggaata	180
tgctgggtgg	ctcagtgagc	ccttttggag	aaagcaagta	ttattcttaa	ggagtaacca	240
cttcccattg	ttctactttc	taccatcatc	aattgtatat	tatgtattct	ttggagaact	300
a						301

<210> 269  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

&lt;400&gt; 269

taacaatata	cactagctat	ctttttaact	gtccatcatt	agcaccaatg	aagattcaat	60
aaaattacct	ttattcacac	atctcaaaac	aattctgcaa	attcttagtg	aagtttaact	120
atagtcacag	accttaaata	ttcacattgt	tttctatgtc	tactgaaaat	aagttcacta	180
cttttctgga	tattctttac	aaaatcttat	taaaattcct	ggtattatca	cccccaatta	240
tacagtagca	caaccacctt	atgtagtttt	tacatgatag	ctctgtagaa	gtttcacatc	300
t						301

&lt;210&gt; 270

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 270

cattgaagag	cttttgcgaa	acatcagaac	acaagtgtt	ataaaattaa	ttaagcctta	60
cacaagaata	catattcctt	ttattttctaa	ggagttaaac	atagatgtag	ctgatgtgga	120
gagcttgctg	gtgcagtgc	tattggataa	cactattcat	ggccgaattg	atcaagtcaa	180
ccaactcctt	gaactggatc	atcagaagaa	gggtggtgca	cgatatactg	cactagataa	240
tggaccaacc	aactaaattc	tctcaccagg	ctgtatcagt	aaactggctt	aacagaaaac	300
a						301

&lt;210&gt; 271

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(301)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 271

aaaaggttct	cataagatta	acaattttaa	taaatatttg	atagaacatt	ctttctcatt	60
tttatagctc	atcttttagg	ttgatattca	gttcatgctt	cccttgctgt	tcttgatcca	120
gaattgcaat	cacttcatca	gcctgtatto	gtccaatto	tctataaagt	gggtccaagg	180
tgaaccacag	agccacagca	cacctcttct	ccttggtgac	tgccttcacc	ccatganggt	240
tctctcctcc	agatganaac	tgatcatgcy	cccacatttt	gggtttttata	gaagcagtca	300
c						301

&lt;210&gt; 272

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 272

taaattgcta	agccacagat	aacaccaatc	aaatggaaca	aatcactgtc	ttcaaagtgc	60
ttatcagaaa	accaaattgag	cctggaatct	tcataatacc	taaacatgcc	gtatttagga	120
tccaataatt	ccctcatgat	gagcaagaaa	aattctttgc	gcacccctcc	tgcattccaca	180
gcattcttct	caacaaatat	aaccttgagt	ggcttcttgt	aatctatgtt	ctttgttttc	240
ctaaggactt	ccattgcatc	tcctacaata	ttttctctac	gcaccactag	aattaagcag	300
g						301

&lt;210&gt; 273

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;



<221> misc\_feature  
 <222> (1)...(301)  
 <223> n = A,T,C or G

<400> 273  
 acatgtgtgt atgtgtatct ttgggaaaan aanaagacat cttgtttayt atttttttgg 60  
 agagangctg ggacatggat aatcacwtaa ttigtctayta tyactttaat ctgactygaa 120  
 gaaccgtcta aaaataaaaat ttacatgtc dtatattcct tatagtatgc ttatttcacc 180  
 ttytttctgt ccagagagag tatcagtgac ananatttma gggatgaamac atgmattggg 240  
 gggacttnty tttacngagm accctgcccg sgcgccctcg makcngantt ccgesananc 300  
 t 301

<210> 274  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(301)  
 <223> n = A,T,C or G

<400> 274  
 ottatatact ctttctcaga ggcaaaagag gagatgggta atgtagacaa ttcttttgagg 60  
 aacagtaaat gattattaga gagaangaat ggaccaagga gacagaaatt aacttgtaaa 120  
 tgattctctt tggaatctga atgagatcaa gaggccagct ttagcttggtg gaaaagtcca 180  
 tctaggtatg gttgcattct cgtcttcttt tctgcagtag ataatgaggt aaccgaaggc 240  
 aatttgctt cttttgataa gaagctttct tggatcatatc aggaaattcc aganaaagtc 300  
 c 301

<210> 275  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(301)  
 <223> n = A,T,C or G

<400> 275  
 tcggtgtcag cagcacgtgg cattgaacat tgcaatgtgg agcccaaacc acagaaaatg 60  
 gggtgaaatt ggccaacttt ctattaactt atgttggaat ttttgccacc aacagtaagc 120  
 tggcccttct aataaaaagaa aattgaaagg tttctcacta aacggaatta agtagtgag 180  
 tcaagagact cccaggcctc agcgtacctg cccgggcggc cgctcgaagc cgaattctgc 240  
 agatatccat cacactggcg gncgctcgan catgcatcta gaaggnccaa ttcgccctat 300  
 a 301

<210> 276  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 276  
 tgtacacata ctcaataaat aaatgactgc attgtggtat tattactata ctgattatat 60  
 ttatcatgtg acttctaatt agaaaatgta tccaaaagca aaacagcaga tatacaaaat 120  
 taaagagaca gaagatagac attaacagat aaggcaactt atacattgag aatccaaatc 180  
 caatacattt aaacatttgg gaaatgaggg ggacaaatgg aagccagatc aaatttgtgt 240

aaaactattc agtatgtttc ccttgcttca tgtctgagaa ggctctcctt caatggggat 300  
g 301

<210> 277  
<211> 301  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)...(301)  
<223> n = A,T,C or G

<400> 277  
tttgttgatg tcagtatttt attacttgcg ttatgagtgc tcacctggga aattctaaag 60  
atacagagga cttggaggaa gcagagcaac tgaatttaac ttaaaagaag gaaaacattg 120  
gaatcatggc actcctgata ctttcccaaa tcaacactct caatgcccc aacctgctct 180  
caccatagtg gggagactaa agtggccacg gatttgctt angtgtgcag tgcgttctga 240  
gttcnctgtc gattacatct gaccagtctc ctttttccga agtccntccg ttcaatcttg 300  
c 301

<210> 278  
<211> 301  
<212> DNA  
<213> Homo sapien  
  
<220>  
<221> misc\_feature  
<222> (1)...(301)  
<223> n = A,T,C or G

<400> 278  
taccactaca ctccagcctg ggcaacagag caagacctgt ctcaaagcat aaaatggaat 60  
aacatatcaa atgaaacagg gaaaatgaag ctgacaattt atggaagcca gggcttgtca 120  
cagtctctac tgttattatg cattacctgg gaatttatat aagcccttaa taataatgcc 180  
aatgaacatc tcatgtgtgc tcacaatggt ctggcactat tataagtgtc tcacagggtt 240  
tatgtgttct tcgtaacttt atggantagg tactcggccg cgaacacgct aagccgaatt 300  
c 301

<210> 279  
<211> 301  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(301)  
<223> n = A,T,C or G

<400> 279  
aaagcaggaa tgacaaagct tgcttttctg gtatgttcta ggtgtattgt gacttttact 60  
gttatattaa ttgccaatat aagtaaataat agattatata tgtatagtgt ttcacaaagc 120  
ttagaccttt accttccagc caccacacag tgcttgatat ttcagagtca gtcattgggt 180  
atacatgtgt agttccaaag cacataagct agaanaanaa atatttctag ggagcactac 240  
catctgtttt cacatgaaat gccacacaca tagaactcca acatcaattt cattgcacag 300  
a 301

<210> 280

<211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 280  
 ggtactggag ttttcctccc ctgtgaaaac gtaactactg ttgggagtga attgaggatg 60  
 tagaaaggtg gtggaaccaa attgtggtca atggaaatag gagaatatgg ttctcactct 120  
 tgagaaaaaa acctaagatt agcccaggta gttgcctgta acttcagttt ttctgcctgg 180  
 gtttgatata gtttaggggtt ggggttagat taagatctaa attacatcag gacaaagaga 240  
 cagactatta actccacagt taattaagga ggtatgttcc atgtttattt gttaaagcag 300  
 t 301

<210> 281  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 281  
 aggtacaaga aggggaatgg gaaagagctg ctgctgtggc attgttcaac ttggatatctc 60  
 gccgagcaat ccaaactcctg aatgaagggg catcttctga aaaaggagat ctgaatctca 120  
 atgtggtagc aatggcttta tcgggttata cggatgagaa gaactccctt tggagagaaa 180  
 tgtgtagcac actgcgatta cagctaaata acccgtattt gtgtgtcatg tttgcatttc 240  
 tgacaagtga aacaggatct tacgatggag ttttgtatga aaacaaagt gcagtacctc 300  
 g 301

<210> 282  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 282  
 caggtactac agaattaaaa tactgacaag caagtagttt cttggcgtgc acgaattgca 60  
 tccagaaccc aaaaattaag aaattcaaaa agacattttg tgggcacctg ctagcacaga 120  
 agcgcagaag caaagcccag gcagaacctat gctaacctta cagctcagcc tgcacagaag 180  
 cgcagaagca aagcccaggc agaacctatg taaccttaca gctcagcctg cacagaagcg 240  
 cagaagcaaa gcccaggcag aacatgctaa ccttacagct cagcctgcac agaagcacag 300  
 a 301

<210> 283  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 283  
 atctgtatac ggcagacaaa ctttatarag tgtagagagg tgagcgaaag gatgcaaaag 60  
 cactttgagg gctttataat aatatgctgc ttgaaaaaaa aaatgtgtag ttgatactca 120  
 gtgcatctcc agacatagta aggggttgct ctgaccaatc aggtgatcat tttttctatc 180  
 acttcccagg ttttatgcaa aaattttgtt aaattctata atggtgatag gcactcttta 240  
 ggaaacatat acatttttaa aaatctattt tatgtaagaa ctgacagacg aatttgcttt 300  
 g 301

<210> 284  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 284  
 caggtacaaa acgctattaa gtggcttaga atttgaacat ttgtggtctt tatttacttt 60

```

gcttcgtgtg tgggcaaagc aacatcttcc ctaaatatat attaccaaga aaagcaagaa      120
gcagattagg tttttgacaa aacaaacagg ccaaaagggg gctgacctgg agcagagcat      180
ggtgagaggc aaggcatgag agggcaagtt tgttgtggac agatctgtgc ctactttatt      240
actggagtaa aagaaaacaa agttcattga tgtcgaagga tatatacagt gttagaatt      300
a                                                                                   301

```

```

<210> 285
<211> 301
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

```

```

<400> 285
acatcaccat gatcggatcc cccacccatt atacgttgta tgtttacata aatactcttc      60
aatgatcatt agtgttttaa aaaaaatact gaaaactcct tctgcatccc aatctctaac      120
caggaaagca aatgctatct acagacctgc aagccctccc tcaaacnaaa ctatttctgg      180
attaaatatg tctgacttct tttagaggtca cacgactagg caaatgctat ttacgatctg      240
caaaagctgt ttgaagagtc aaagccccca tgtgaacacg atttctggac cctgtaacag      300
t                                                                                   301

```

```

<210> 286
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 286
taccactgca ttccagcctg ggtgacagag tgagactccg tctccaaaaa aaactttgct      60
tgtatattat ttttgacctta cagtggatca ttctagtagg aaaggacagt aagatttttt      120
atcaaaatgt gtcatgccag taagagatgt tatattcttt tctcatttct tccccaccca      180
aaaataagct accatatagc ttataagtct caaatttttg ctttttacta aaatgtgatt      240
gtttctgttc atttgtgtatg cttcatcacc tatattaggc aaattccatt ttttcccttg      300
t                                                                                   301

```

```

<210> 287
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 287
tacagatctg ggaactaaat attaaaaatg agtgtggctg gatatatgga gaatgttggg      60
cccagaagga acgtagagat cagatattac aacagctttg ttttgagggt tagaaatatg      120
aaatgatttg gttatgaacg cacagttagg gcagcagggc cagaatcctg accctctgcc      180
ccgtgggtat ctctcccca gcttggctgc ctcatgttat cacagtattc cattttgttt      240
gttgcatgtc ttgtgaagcc atcaagattt tctcgtctgt tttcctctca ttggtaatgc      300
t                                                                                   301

```

```

<210> 288
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 288
gtacacctaa ctgcaaggac agctgaggaa tgtaatgggc agccgctttt aaagaagtag      60
agtcaatagg aagacaaaatt ccagttccag ctcatctgga gtatctgcaa agctgcaaaa      120

```

```

gatcttttaa gacaatttca agagaatatt tccttaaagt tggcaatttg gagatcatatc 180
aaaagcatct gcttttgtga ttttaatttag ctcatctggc cactggaaga atccaaacag 240
tctgccttaa ttttggaatga atgcatgatg gaaattcaat aatttagaaa gttaaaaaaa 300
a 301

```

```

<210> 289
<211> 301
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

```

```

<400> 289
ggtacactgt ttccatgtta tgtttctaca cattgctacc tcagtgtccc tggaaactta 60
gcttttcatg tctccaagta gtccaccttc atttaactct ttgaaactgt atcatctttg 120
ccaagtaaga gtggtggcct atttcagctg ctttgacaaa atgactggct cctgacttaa 180
cgttctataa atgaatgtgc tgaagcaaaag tgcccatggt ggccggcgaan aagagaaaga 240
tgtgttttgt tttggactct ctgtgggtccc ttccaatgct gtgggtttcc aaccagnnga 300
a 301

```

```

<210> 290
<211> 301
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

```

```

<400> 290
acactgagct cttcttgata aatatacaga atgcttggca tatacaagat tctatactac 60
tgactgatct gttcatttct ctccacagtc ttacccccaa aagcttttcc accctaagtg 120
ttctgacctc cttttctaata cacagtaggg atagaggcag anccacctac aatgaacatg 180
gagttctatc aagaggcaga aacagcacag aatcccagtt ttaccattcg ctagcagtg 240
tgccttgaac aaaaacattt ctccatgtct catthttcttc atgcctcaag taacagtga 300
a 301

```

```

<210> 291
<211> 301
<212> DNA
<213> Homo sapien

```

```

<400> 291
caggtaccaa tttcttctat cctagaaaca tttcatttta tgttgttgaa acataacaac 60
tatatcagct agattttttt tctatgcttt acctgctatg gaaaatttga cacattctgc 120
tttactcttt tgtttatagg tgaatcacia aatgtatttt tatgtattct gtagtccaat 180
agccatggct gtttacttca ttttaatttat ttagcataaa gacattatga aaaggcctaa 240
acatgagctt cacttcccca ctaactaatt agcatctgtt atttcttaac ogtaatgcct 300
a 301

```

```

<210> 292
<211> 301
<212> DNA
<213> Homo sapien

```

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(301)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 292

accttttagt	agtaatgtct	aataataaat	aagaaatcaa	ttttataagg	tccatatagc	60
tgtattaaat	aatttttaag	tttaaaagat	aaaataccat	catttttaaat	gttggtattc	120
aaaaccaaag	natataaccg	aaaggaaaaa	cagatgagac	ataaaatgat	ttgcnagatg	180
ggaaatatag	tasttyatga	atgttnatta	aattccagtt	ataatagtgg	ctacacactc	240
tcactacaca	cacagacccc	acagtcctat	atgccacaaa	cacatttcca	taacttgaaa	300
a						301

&lt;210&gt; 293

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 293

ggtaccaagt	gctggtgcc	gcctgttacc	tgttctcact	gaaaagtctg	gctaattgctc	60
ttgtgtagtc	acttctgatt	ctgacaatca	atcaatcaat	ggcctagagc	actgactggt	120
aacacaaacg	tcactagcaa	agtagcaaca	gctttaagtc	taaatacaaa	gctgttctgt	180
gtgagaattt	tttaaaaggc	tacttgtata	ataacccttg	tcatttttaa	tgtacctcgg	240
ccgcgaccac	gctaagccga	attctgcaga	tatccatcac	actggcggcc	gctcgagcat	300
g						301

&lt;210&gt; 294

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(301)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 294

tgaccataa	caatatacac	tagctatctt	tttaactgtc	catcattagc	accaatgaag	60
attcaataaa	attaccttta	ttcacacatc	tcaaaaacaat	tctgcaaatt	cttagtgaag	120
tttaactata	gtcacaganc	ttaaatattc	acattgtttt	ctatgtctac	tgaaaataag	180
ttcactactt	ttctgggata	ttctttacaa	aatcttatta	aaattcctgg	tattatcacc	240
cccaattata	cagtagcaca	accaccttat	gtagttttta	catgatagct	ctgtagaggt	300
t						301

&lt;210&gt; 295

&lt;211&gt; 305

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 295

gtactctttc	tctcccctcc	tctgaattta	attctttcaa	cttgcaattt	gcaaggatta	60
cacatttcac	tgtgatgtat	attgtgttgc	aaaaaaaaaa	gtgtctttgt	ttaaaattac	120
ttggtttgtg	aatccatctt	gctttttccc	cattggaact	agtcattaac	ccatctctga	180
actggtagaa	aaacrtctga	agagctagtc	tatcagcatc	tgacaggtga	attggatggt	240
tctcagaacc	atttcaccca	gacagcctgt	ttctatcctg	tttaataaat	tagtttggtg	300
tctct						305

<210> 296  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 296  
 aggtactatg ggaagctgct aaaataatat ttgatagtaa aagtatgtaa tgtgctatct 60  
 cacctagtag taaactaaaa ataaactgaa actttatgga atctgaagtt attttccttg 120  
 attaaataga attaataaac caatatgagg aaacatgaaa ccatgcaatc tactatcaac 180  
 tttgaaaaag tgattgaacg aaccacttag ctttcagatg atgaacactg ataagtcatt 240  
 tgtcattact ataaatttta aaatctgtta ataagatggc ctatagggag gaaaaagggg 300  
 c 301

<210> 297  
 <211> 300  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(300)  
 <223> n = A,T,C or G

<400> 297  
 actgagtttt aactggacgc caagcaggca aggctggaag gttttgctct ctttgtgcta 60  
 aaggttttga aaaccttgaa ggagaatcat tttgacaaga agtacttaag agtctagaga 120  
 acaaagangt gaaccagctg aaagctctcg ggggaanctt acatgtgttg ttaggcctgt 180  
 tccatcattg ggagtgcact ggccatccct caaaatttgt ctgggctggc ctgagtggc 240  
 accgcacctc ggccgcgacc acgctaagcc gaattctgca gatatccatc acactggcgg 300

<210> 298  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(301)  
 <223> n = A,T,C or G

<400> 298  
 tatgggggttt gtcacccaaa agctgatgct gagaaaggcc tccctggggc ccctcccgcg 60  
 ggcactctgag agacctggtg ttccagtgtt tctggaaatg ggtcccagtg ccgccggctg 120  
 tgaagctctc agatcaatca cgggaagggc ctggcggttg tggccacctg gaaccaccct 180  
 gtccctgtctg tttaattttc actaycaggt tttctctggg cattacnatt tgttccccta 240  
 caacagtgac ctgtgcattc tgctgtggcc tgctgtgtct gcaggtggct ctcagcgagg 300  
 t 301

<210> 299  
 <211> 301  
 <212> DNA  
 <213> Homo sapien

<400> 299  
 gttttgagac ggagttttcac tcttgttgcc cagactggac tgcaatggca gggctctctgc 60  
 tcaactgcacc ctctgcctcc caggttcgag caattctcct gcctcagcct cccaggtagc 120  
 tgggattgca ggctcacgcc accataccca gctaattttt ttgtattttt agtagagacg 180  
 gagtttcgcc atgttggcca gctggtctca aactcctgac ctcaagcgac ctgcctgcct 240

cggcctccca aagtgctgga attataggca tgagtcaaca cgcccagcct aaagatatatt 300  
t 301

<210> 300  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 300  
attcagtttt atttgctgcc ccagtatctg taaccaggag tgccacaaaa tcttgccaga 60  
tatgtcccac acccactggg aaaggctccc acctggctac ttccctctatc agctgggtca 120  
gtgcattcc acaaggttct cagcctaatt agtttacta cctgccagtc tcaaaactta 180  
gtaaagcaag accatgacat tccccacgg aaatcagagt ttgccccacc gtcttggtac 240  
tataaagcct gcctctaaca gtcccttgctt cttcacacca atcccgagcg catcccccat 300  
g 301

<210> 301  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 301  
ttaaattttt gagaggataa aaaggacaaa taatctagaa atgtgtottc ttcagtctgc 60  
agaggacccc aggtctccaa gcaaccacat ggtcaagggc atgaataatt aaaagttggt 120  
gggaactcac aaagaccctc agagctgaga caccacaac agtgggagct cacaagacc 180  
ctcagagctg agacaccac aacagtggga gtcacaaaag accctcagag ctgagacacc 240  
cacaacagca cctcgttcag ctgccacatg tgtgaataag gatgcaatgt ccagaagtgt 300  
t 301

<210> 302  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 302  
aggtacacat ttagcttggt gtaaatgact cacaaaactg atttttaaatt caagttaatg 60  
tgaattttga aaattactac ttaatcctaa ttcacaataa caatggcatt aaggtttgac 120  
ttgagttggt tcttagtatt atttatggta aataggctct taccattgc aaataactgg 180  
ccacatcatt aatgactgac ttcccagtaa ggctctctaa ggggtaagta ggaggatcca 240  
caggatttga gatgctaagg ccccagagat cgtttgatcc aaccctctta ttttcagagg 300  
g 301

<210> 303  
<211> 301  
<212> DNA  
<213> Homo sapien

<400> 303  
aggtaccaac tgtggaaata ggtagaggat ctttttttct ttccatatca actaagttgt 60  
atattgtttt ttgacagttt aacacatctt cttctgtcag agattctttc acaatagcac 120  
tggttaattg aactaccgct tgcattgtta aaatgggtgt ttgtgaaatg atcataggcc 180  
agtaacgggt atgtttttct aactgatctt ttgctcgttc caaagggacc tcaagacttc 240  
catcgatttt atatctgggg tctagaaaag gagttaatct gttttccctc ataaattcac 300  
c 301

<210> 304  
<211> 301  
<212> DNA



&lt;213&gt; Homo sapien

&lt;400&gt; 304

acatggatgt	tattttgcag	actgtcaacc	tgaatttgta	tttgcttgac	attgccta	60
tattagtttc	agtttcagct	taccacttt	ttgtctgcaa	catgcaraas	agacagtgcc	120
cttttttagtg	tatcatatca	ggaatcatct	cacattgggt	tgtgccatta	ctgggtgcagt	180
gactttcagc	cacttgggta	aggtggagtt	ggccatatgt	ctccactgca	aaattactga	240
ttttcctttt	gtaattaata	agtgtgtgtg	tgaagattct	ttgagatgag	gtatataatct	300
c						301

&lt;210&gt; 305

&lt;211&gt; 301

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(301)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 305

gangtacagc	gtgggtcaagg	taacaagaag	aaaaaatgt	gagtggcatc	ctgggatgag	60
cagggggaca	gacctggaca	gacacgttgt	catttgctgc	tgtgggtagg	aaaatgggag	120
taaaggagga	gaaacagata	caaatctcc	aactcagtat	taaggatttc	tcatgcctag	180
aatattggta	gaaacaagaa	tacattcata	tggcaaataa	ctaaccatgg	tgaacaaaa	240
ttctgggatt	taagttggat	accaangaaa	ttgtattaaa	agagctgttc	atggaataag	300
a						301

&lt;210&gt; 306

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 306

Val	Leu	Gly	Trp	Val	Ala	Glu	Leu
1				5			

&lt;210&gt; 307

&lt;211&gt; 637

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 307

acaggggratg	aagggaaagg	gagaggatga	ggaagccccc	ctgggggattt	ggttttgtcc	60
ttgtgatcag	gtggtctatg	gggcttatcc	ctacaaagaa	gaatccagaa	atagggggcac	120
attgaggaat	gatacttgag	cccaaagagc	attcaatcat	tgttttattt	gccttmtttt	180
cacaccattg	gtgagggagg	gattaccacc	ctgggggttat	gaagatgggt	gaacacccca	240
cacatagcac	cggagatatg	agatcaacag	tttcttagcc	atagagattc	acagcccaga	300
gcaggaggac	gcttgcacac	catgcaggat	gacatggggg	atgcgctcgg	gattgggtgtg	360
aagaagcaag	gactgttaga	ggcaggcttt	atagtaacaa	gacgggtggg	caaactctga	420
tttccgtggg	ggaatgtcat	ggtcttgctt	tactaagttt	tgagactggc	aggtagtga	480
actcattagg	ctgagaacct	tgtggaatgc	acttgacca	setgatagag	gaagtagcca	540
ggtgggagcc	tttccagtg	ggtgtgggac	atatctggca	agattttgtg	gcactcctgg	600
ttacagatac	tggggcagca	aataaaactg	aatcttg			637

&lt;210&gt; 308

&lt;211&gt; 647

&lt;212&gt; DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1)...(647)

<223> n = A,T,C or G

<400> 308

acgattttca	ttatcatgta	aatcgggtca	ctcaaggggc	caaccacagc	tgggagccac	60
tgctcagggg	aaggttcata	tgggactttc	tactgcccaa	ggttctatac	aggatataaa	120
ggngcctcac	agtatagatc	tggtagcaaa	gaagaagaaa	caaacactga	tctctttctg	180
ccaccctct	gacccttttg	aactcctctg	accctttaga	acaagcctac	ctaatatctg	240
ctagagaaaa	gaccaacaac	ggcctcaaag	gatctcttac	catgaaggtc	tcagctaatt	300
cttgggctaag	atgtgggttc	cacattaggt	tctgaatatg	gggggaaggg	tcaatttgct	360
catttttgtgt	gtggataaag	tcaggatgcc	cagggggccag	agcagggggc	tgcttgcttt	420
gggaacaatg	gctgagcata	taaccatagg	ttatggggaa	caaaacaaca	tcaaagtcac	480
tgtatcaatt	gccatgaaga	cttgagggac	ctgaatctac	cgattcatct	taaggcagca	540
ggaccagttt	gagtggcaac	aatgcagcag	cagaatcaat	ggaaacaaca	gaatgattgc	600
aatgtccttt	tttttctcct	gcttctgact	tgataaaaag	ggaccgt		647

<210> 309

<211> 460

<212> DNA

<213> Homo sapien

<400> 309

actttatagt	ttaggctgga	cattggaaaa	aaaaaaaaagc	cagaacaaca	tgtgatagat	60
aatatgattg	gctgcacact	tccagactga	tgaatgatga	acgtgatgga	ctattgtatg	120
gagcacatct	tcagcaagag	ggggaaatac	tcatcatttt	tggccagcag	ttgtttgatc	180
accaaacttc	atgccagaat	actcagcaaa	ccttcttagc	tcttgagaag	tcaaagtcog	240
ggggaattta	ttcctggcaa	ttttaattgg	actccttatg	tgagagcagc	ggctaccocg	300
ctgggggtgt	ggagcgcaac	cgctactagt	ggacatgcag	tggcagagct	cctggtaacc	360
acctagagga	atacacaggc	acatgtgtga	tgccaagcgt	gacacctgta	gcactcaaat	420
ttgtcttggt	tttgtctttc	ggtgtgtaag	attctttaag			460

<210> 310

<211> 539

<212> DNA

<213> Homo sapien

<400> 310

acgggactta	tcaaataaag	ataggaaaag	aagaaaactc	aaatattata	ggcagaaatg	60
ctaaagggtt	taaaatatgt	caggattgga	agaaggcatg	gataaagaac	aaagttcagt	120
taggaaagag	aaacacagaa	ggaagagaca	caataaaaag	cattatgtat	tctgtgagaa	180
gtcagacagt	aagattttgt	ggaaatgggt	tggtttgttg	tatggatgtg	attttagcaa	240
taatctttat	ggcagagaaa	gctaaaatcc	tttagcttgc	gtgaatgatc	acttgctgaa	300
ttcctcaagg	taggcatgat	gaaggagggt	ttagaggaga	cacagacaca	atgaactgac	360
ctagatagaa	agccttagta	tactcagcta	ggaatagtga	ttctgagggc	acactgtgac	420
atgattatgt	cattacatgt	atggtagtga	tggggatgat	aggaaggaag	aacttatggc	480
atattttcac	ccccacaaaa	gtcagttaaa	tattgggaca	ctaaccatcc	aggtcaaga	539

<210> 311

<211> 526

<212> DNA

<213> Homo sapien

<220>

<221> misc\_feature

100

&lt;222&gt; (1)...(526)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 311

caaatttgag	ccaatgacat	agaattttac	aatcaagaa	gcttattctg	gggccatttc	60
ttttgacgtt	ttctctaac	tactaaagag	gcattaatga	tccataaatt	atattatcta	120
catttacagc	atttaaaatg	tggtcagcat	gaaatattag	ctacagggga	agctaaataa	180
attaaacatg	gaataaagat	ttgtccttaa	atataatcta	caagaagact	ttgatatttg	240
tttttcacaa	gtgaagcatt	cttataaagt	gtcataacct	ttttggggaa	actatgggaa	300
aaaatgggga	aactctgaag	ggttttaagt	atcttacctg	aagctacaga	ctccataacc	360
tctctttaca	gggagctcct	gcagccccta	cagaaatgag	tggctgagat	tcttgattgc	420
acagcaagag	cttctcatct	aaaccctttc	cctttttagt	atctgtgtat	caagtataaa	480
agttctataa	actgtagtnt	acttatittta	atccccaaag	cacagt		526

&lt;210&gt; 312

&lt;211&gt; 500

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; (1)...(500)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 312

cctctctctc	cccaccccct	gactctagag	aactggggtt	tctcccagta	ctccagcaat	60
tcattttctga	aagcagttga	gccactttat	tccaaagtac	actgcagatg	ttcaaactct	120
ccattttctct	ttcccttcca	cctgcccagtt	ttgctgactc	tcaacttgto	atgagtgtaa	180
gcattaagga	cattatgctt	cttcgattct	gaagacaggc	cctgctcatg	gatgactctg	240
gcttcttagg	aaaatatatt	tcttccaaaa	tcagtaggaa	atctaaactt	atccccctct	300
tgcagatgtc	tagcagcttc	agacatttgg	ttagaacccc	atgggaaaaa	aaaaaatcct	360
tgctaattgt	gtttcctttg	taaaccanga	ttcttatttg	nctggtatag	aatatcagct	420
ctgaacgtgt	ggtaaagatt	tttgtgtttg	aatataggag	aaatcagttt	gctgaaaagt	480
tagtcttaat	tatctattgg					500

&lt;210&gt; 313

&lt;211&gt; 718

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; (1)...(718)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 313

ggagatttgt	gtggtttgca	gccgaggagg	accaggaaga	tctgcatggt	gggaaggacc	60
tgatgataga	gaggtgagaa	ataagaaagg	ctgctgactt	taccatctga	ggccacacat	120
ctgctgaaat	ggagataaatt	aacatcacta	gaaacagcaa	gatgacaata	taatgtctaa	180
gtagtgacat	gtttttgcac	atttccagcc	cttttaataa	tccacacaca	caggaagcac	240
aaaaggaagc	acagagatcc	ctgggagaaa	tgcccggccg	ccatcttggg	tcatcgatga	300
gcctcgccct	gtgcctgntc	ccgcttgtga	gggaaggaca	ttagaaaatg	aattgatgtg	360
ttccttaaa	gatggcagga	aaacagatcc	tggtgtggat	atttatttga	acgggattac	420
agatttgaaa	tgaagtcaca	aagttagcat	taccaatgag	aggaaaacag	acgagaaaat	480
cttgatgggt	cacaagacat	gcaacaaaca	aaatggaata	ctgtgatgac	acgagcagcc	540
aactggggag	gagataccac	ggggcagagg	tcaggattct	ggccctgctg	cctaactgtg	600
cgttatacca	atcatttcta	tttctaccct	caaacaagct	gtngaataac	tgacttacgg	660
ttcttntggc	ccacattttc	atnatccacc	ccntctnttt	aannttantic	caaanagt	718

<210> 314  
 <211> 358  
 <212> DNA  
 <213> Homo sapien

<400> 314  
 gtttattttac attacagaaa aaacatcaag acaatgtata ctatttcaaa tatatccata 60  
 cataatcaaa tatagctgta gtacatgttt tcattgggtg agattaccac aaatgcaagg 120  
 caacatgtgt agatctcttg tcttattctt ttgtctataa tactgtattg tgtagtccaa 180  
 gctctcggtta gtccagccac tgtgaaacat gctcccttta gattaacctc gtggacgctc 240  
 ttgttgattt gctgaactgt agtgccctgt attttgcttc tgtctgtgaa ttctgttgct 300  
 tctggggcat ttccttggtga tgcagaggac caccacacag atgacagcaa tctgaatt 358

<210> 315  
 <211> 341  
 <212> DNA  
 <213> Homo sapien

<400> 315  
 taccacctcc ccgctggcac tgatgagccg catcaccatg gtcaccagca ccatgaaggc 60  
 atagggtgat atgaggacat ggaatgggcc cccaaggatg gtctgtccaa agaagcgagt 120  
 gacccccatt ctgaagatgt ctggaacctc taccagcagg atgatgatag cccaatgac 180  
 agtcaccagc tccccgacca gccggatata gtccttaggg gtcattgtagg ctctctgaag 240  
 tagcttctgc tgtaagaggg tgttgctccg ggggctcgtg cggttattgg tcttgggctt 300  
 gagggggcgg tagatgcagc acatggtgaa gcagatgatg t 341

<210> 316  
 <211> 151  
 <212> DNA  
 <213> Homo sapien

<400> 316  
 agactgggca agactcttac gcccacact gcaatttggg cttgttgccg tatccattta 60  
 tgtgggcctt tctcgagttt ctgattataa acaccactgg agcgatgtgt tgactggact 120  
 cattcagga gctctgggtg caatattagt t 151

<210> 317  
 <211> 151  
 <212> DNA  
 <213> Homo sapien

<400> 317  
 agaactagt gtcctaatg aaatacctga aacatatatt ggcatttata aatggctcaa 60  
 atcttcattt atctctggcc ttaacctgg ctctgagggc tgcggccagc agatcccagg 120  
 ccagggctct gttcttgcca cactgcttg a 151

<210> 318  
 <211> 151  
 <212> DNA  
 <213> Homo sapien

<400> 318  
 actgggtggga ggcgctgttt agttggctgt ttccagaggg gtctttcgga gggacctcct 60  
 gctgcaggct ggagtgtctt tattcctggc gggagaccgc acattccact gctgaggctg 120  
 tggggggcgg ttatcaggca gtgataaaca t 151

<210> 319

<211> 151  
 <212> DNA  
 <213> Homo sapien

<400> 319  
 aactagtggg tccagagcta taggtacagt gtgatctcag ctttgcaaac acattttcta 60  
 catagatagt actaggtatt aatagatatg taaagaaaga aatcacacca ttaataatgg 120  
 taagattggg tttatgtgat tttagtgggt a 151

<210> 320  
 <211> 150  
 <212> DNA  
 <213> Homo sapien

<400> 320  
 aactagtggg tccactagtc cagtgtgggt gaattccatt gtgttgggggt tctagatcgc 60  
 gagcggctgc cctttttttt tttttttttg ggggggaatt tttttttttt aatagttatt 120  
 gagtgttcta cagcttacag taaataccat 150

<210> 321  
 <211> 151  
 <212> DNA  
 <213> Homo sapien

<400> 321  
 agcaactttg tttttcatcc aggttatttt aggcttagga tttcctctca cactgcagtt 60  
 taggggtggc ttgtaaccag ctatggcata ggtgttaacc aaaggctgag taaacatggg 120  
 tgccctctgag aaatcaaagt cttcatacac t 151

<210> 322  
 <211> 151  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(151)  
 <223> n = A,T,C or G

<400> 322  
 atccagcatc ttctcctggt tcttgccctc cttttttcttc ttcttasatt ctgcttgagg 60  
 tttgggcttg gtcagtttgc cacagggctt ggagatgggt acagtcttct ggcattcggc 120  
 attgtgcagg gctcgttca nacttccagt t 151

<210> 323  
 <211> 151  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(151)  
 <223> n = A,T,C or G

<400> 323  
 tgaggacttg tktttttttt ctttattttt aatcctctta ckttgtaa atattgccta 60  
 nagactcant tactaccag tttgtggtt twtgggagaa atgtaactgg acagttagct 120  
 gttcaatyaa aaagacactt ancccatgtg g 151

<210> 324  
 <211> 461  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(461)  
 <223> n = A,T,C or G

<400> 324  
 acctgtgtgg aatttcagct ttcctcatgc aaaaggattt tgtatccccg gcctacttga 60  
 agaagtggtc agctaaagga atccagggtg ttggttggac tgtaataacc tttgatgaaa 120  
 agagttacta cgaatcccat cttggttcca gctatatcac tgacagcatg gtagaagact 180  
 gcgaacctca cttctagact ttcacgggtg gacgaaacgg gttcagaaac tgccaggggc 240  
 ctcatcacgg gatattcaaaa taccctttgt gctaccagg ccctggggaa tcagggtgact 300  
 cacacaaatg caatagtgtg tcaactgcatt tttacctgaa ccaaagctaa acccggtgtt 360  
 gccaccatgc accatggcat gccagagttc aacactgttg ctcttgaaaa ttgggtctga 420  
 aaaaacgcac aagagcccct gccctgccct agctgangca c 461

<210> 325  
 <211> 400  
 <212> DNA  
 <213> Homo sapien

<400> 325  
 aactgtttc catgttatgt ttctacacat tgctacctca gtgctcctgg aaacttagct 60  
 tttgatgtct ccaagtagtc caccttcatt taactctttg aaactgtatc atctttgcc 120  
 agtaagagtg gtggcctatt tcagctgctt tgacaaaatg actggctcct gacttaacgt 180  
 tctataaatg aatgtgctga agcaaagtgc ccatgggtggc ggcgaagaag agaaagatgt 240  
 gttttgtttt ggactctctg tggctcccttc caatgctgtg gggttccaac caggggaagg 300  
 gtcccttttg cattgccaaag tgccataacc atgagcacta cgctaccatg gttctgcctc 360  
 ctggccaagc aggtctggtt gcaagaatga aatgaatgat 400

<210> 326  
 <211> 1215  
 <212> DNA  
 <213> Homo sapien

<400> 326  
 ggaggactgc agcccgact cgcagccctg gcaggcggca ctggtcatgg aaaacgaatt 60  
 gttctgctcg ggcgtcctgg tgcacccgca gtgggtgctg tcagccgcac actgtttcca 120  
 gaactcctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccaggag 180  
 ccagatggtg gaggccagcc tctccgtacg gcacccagag tacaacagac ccttgctcgc 240  
 taacgacctc atgctcatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300  
 catcagcatt gcttcgcagt gccctaccgc ggggaactct tgcctcgttt ctggctgggg 360  
 totgctggcg aacggcagaa tgccctaccgt gctgcagtgc gtgaacgtgt cgggtggtgc 420  
 tgaggaggtc tgcagtaagc tctatgacct gctgtaccac cccagcatgt tctgcgccgg 480  
 cggagggcaa gaccagaagg actcctgcaa cgggtgactct ggggggcccc tgatctgcaa 540  
 cgggtacttg cagggccttg tgtctttcgg aaaagccccg tgtggccaag ttggcgtgcc 600  
 aggtgtctac accaactctt gcaaattcac tgagtggata gagaaaaccg tccaggccag 660  
 ttaactctgg ggactgggaa cccatgaaat tgacccccaa atacatcctg cggaaggaa 720  
 tcaggaatat ctgtttccag cccctcctcc ctccaggcca ggagtccagg ccccagccc 780  
 ctctccctc aaaccaaggg tacagatccc cagccccctc tccctcagac ccaggagtcc 840  
 agacccccca gccctcctc cctcagacct aggagtccag cccctcctcc ctccagccca 900  
 ggagtccaga cccccagcc cctcctccct cagacccagg ggtccaggcc cccaaccct 960  
 cctccctcag actcagaggt ccaagcccc aaccctcct tccccagacc cagaggtcca 1020

```

ggccccagcc cctcctccct cagaccagc ggtccaatgc cacctagact ctccctgtac 1080
acagtcccc cttgtggcac gttgacccaa ccttaccagt tggtttttca tttttgtcc 1140
ctttccccta gatccagaaa taaagtctaa gagaagcgca aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaaa aaaaaa 1215

```

<210> 327  
 <211> 220  
 <212> PRT  
 <213> Homo sapien

```

<400> 327
Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu Val Met
1      5      10      15
Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val
20     25     30
Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly
35     40     45
Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu
50     55     60
Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu Ala
65     70     75     80
Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp
85     90     95
Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn
100    105    110
Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met Pro
115    120    125
Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val Cys
130    135    140
Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala Gly
145    150    155    160
Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly Pro
165    170    175
Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys Ala
180    185    190
Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys Lys
195    200    205
Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
210    215    220

```

<210> 328  
 <211> 234  
 <212> DNA  
 <213> Homo sapien

```

<400> 328
cgctcgtctc tggtagctgc agccaatca taaacggcga ggactgcagc ccgcactcgc 60
agccctggca ggcggcactg gtcattgaaa acgaattgtt ctgctcgggc gtcctgggtc 120
atccgcagtg ggtgctgtca gccacacact gtttccagaa ctctacacc atcgggctgg 180
gcctgcacag tcttgaggcc gaccaagagc caggagacca gatggtggag gcca 234

```

<210> 329  
 <211> 77  
 <212> PRT  
 <213> Homo sapien

```

<400> 329
Leu Val Ser Gly Ser Cys Ser Gln Ile Ile Asn Gly Glu Asp Cys Ser

```

1	5	10	15
Pro His Ser Gln Pro Trp Gln Ala Ala Leu Val Met Glu Asn Glu Leu			
	20	25	30
Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val Leu Ser Ala Thr			
	35	40	45
His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly Leu His Ser Leu			
	50	55	60
Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu Ala			
65	70	75	

<210> 330  
 <211> 70  
 <212> DNA  
 <213> Homo sapien

<400> 330  
 cccaacacaa tggcccgatc ccatccctga ctccgccctc aggatcgctc gtctctggta 60  
 gctgcagcca 70

<210> 331  
 <211> 22  
 <212> PRT  
 <213> Homo sapien

<400> 331  
 Gln His Asn Gly Pro Ile Pro Ser Leu Thr Pro Pro Ser Gly Ser Leu  
 1 5 10 15  
 Val Ser Gly Ser Cys Ser  
 20

<210> 332  
 <211> 2507  
 <212> DNA  
 <213> Homo sapien

<400> 332  
 tgggtgccgct gcagccggca gagatgggtg agctcatggt cccgctggtg ctccctccttc 60  
 tgcccttctt tctgtatatg gctgcgcccc aaatcaggaa aatgctgtcc agtgggggtg 120  
 gtacatcaac tggttcagctt cctgggaaag tagttgtggt cacaggagct aatacaggta 180  
 tcgggaagga gacagccaaa gagctggctc agagaggagc tcgagtatat ttagcttgcc 240  
 gggatgtgga aaaggggga ttggtggcca aagagatcca gaccacgaca ggaaccagc 300  
 aggtgttggt gcggaactg gacctgtctg atactaagtc tattcgagct ttgtctaagg 360  
 gcttcttagc tgaggaaaag cacctccacg ttttgatcaa caatgcagga gtgatgatgt 420  
 gtccgtactc gaagacagca gatggctttg agatgcacat aggagtcaac cacttgggtc 480  
 acttcctcct aaccatctg ctgctagaga aactaaagga atcagcccca tcaaggatag 540  
 taaatgtgtc ttccctcgca catcacctgg gaaggatcca ctccataaac ctgcagggcg 600  
 agaaattcta caatgcaggc ctggcctact gtcacagcaa gctagccaac atcctcttca 660  
 cccaggaact ggcccggaga ctaaaaggct ctggcggttac gacgtattct gtacacctg 720  
 gcacagtcca atctgaactg gttcggcact catctttcat gagatggatg tgggtggcttt 780  
 tctccttttt catcaagact cctcagcagg gagcccagac cagcctgcac tgtgccttaa 840  
 cagaaggtct tgagattcta agtgggaatc atttcagtga ctgtcatgtg gcatgggtct 900  
 ctgcccgaagc tcgtaatgag actatagcaa ggcggctgtg ggacgtcagt tgtgacctgc 960  
 tgggcctccc aatagactaa caggcagtcg cagttggacc caagagaaga ctgcagcaga 1020  
 ctacacagta cttcttgta aaatgattct ccttcaaggt tttcaaaacc ttagcacaa 1080  
 agagagcaaa accttcagc cttgectgct tgggtgtccag ttaaaactca gtgtactgcc 1140  
 agattcgtct aaatgtctgt catgtccaga tttactttgc ttctgttact gccagagtta 1200  
 ctagagatat cataatagga taagaagacc ctcatatgac ctgcacagct cattttcctt 1260  
 ctgaaagaaa ctactaccta ggagaatcta agctatagca gggatgattt atgcaaattt 1320



gaactagctt	ctttgttcac	aattcagttc	ctcccaacca	accagtcttc	acttcaagag	1380
ggccacactg	caacctcagc	ttaacatgaa	taacaaagac	tggctcagga	gcagggcttg	1440
cccaggcatg	gtggatcacc	ggaggtcagt	agttcaagac	cagcctggcc	aacatggtga	1500
aacccacact	ctactaaaaa	ttgtgtatat	ctttgtgtgt	cttcctgttt	atgtgtgcca	1560
agggagtatt	ttcacaaagt	tcaaaacagc	cacaataatc	agagatggag	caaaccagtg	1620
ccatccagtc	tttatgcaaa	tgaatgctg	caaagggaag	cagattctgt	atatgttggg	1680
aactacccac	caagagcaca	tgggtagcag	ggaagaagta	aaaaaagaga	aggagaatac	1740
tggaagataa	tgcacaaaat	gaagggaacta	gttaaggatt	aactagccct	ttaaggatta	1800
actagttaag	gattaatagc	aaaagayatt	aaatatgcta	acatagctat	ggaggaattg	1860
agggcaagca	cccaggactg	atgaggtcct	aacaaaaacc	agtgtggcaa	aaaaaaaaaa	1920
aaaaaaaaaa	aaaaatccta	aaaacaaaca	aacaaaaaaa	acaattcttc	attcagaaaa	1980
attatcttag	ggactgatat	tggtaatatt	ggtcaattta	ataatatttt	ggggcatttc	2040
cttacattgt	cttgacaaga	ttaaaatgtc	tgtgccaaaa	ttttgtattt	tatttggaga	2100
cttcttatca	aaagtaatgc	tgccaaagga	agtctaagga	attagtagtg	ttcccatcac	2160
ttgtttggag	tgtgctattc	taaaagattt	tgatttcctg	gaatgacaat	tatatattta	2220
ctttggtggg	ggaaagagtt	ataggaccac	agtccttact	tctgatactt	gtaaattaat	2280
cttttattgc	acttgttttg	accattaagc	tatatgttta	gaaatggtca	ttttacggaa	2340
aaattagaaa	aattctgata	atagtgcaga	ataaatgaat	taatgtttta	cttaatttat	2400
attgaactgt	caatgacaaa	taaaaattct	ttttgattat	tttttgtttt	catttaccag	2460
aataaaaacg	taagaattaa	aagtttgatt	acaaaaaaaa	aaaaaaa		2507

&lt;210&gt; 333

&lt;211&gt; 3030

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 333

gcaggcgact	tgcgagctgg	gagcgattta	aaacgctttg	gattcccccg	gcctgggtgg	60
ggagagcgag	ctgggtgccc	cctagattcc	ccgccccgcg	acctcatgag	ccgaccctcg	120
gctccatgga	gcccggcaat	tatgccacct	tggatggagc	caaggatata	gaaggcttgc	180
tgggagcggg	aggggggagg	aatctggtcg	cccactcccc	tctgaccagc	caccagcgcg	240
cgcctacgct	gatgcctgct	gtcaactatg	cccccttggg	tctgccaggc	tcggcgaggc	300
cgccaaagca	atgccaccca	tgcctggggg	tgccccaggg	gacgtcccca	gctcccgtgc	360
cttatggtta	ctttggaggc	gggtactact	cctgcgcagt	gtcccggagc	tcgctgaaac	420
cctgtgcccc	ggcagccacc	ctggccgcgt	accccgcggg	gactcccacg	gccgggggag	480
agtaaccacg	ycgccccact	gagtttgcc	tctatccggg	atatccggga	acctaccagc	540
ctatggccag	ttacctggac	gtgtctgtgg	tgcagactct	gggtgctcct	ggagaaccgc	600
gacatgactc	cctgttgcc	gtggacagtt	accagtcttg	ggctctcgct	ggtggctgga	660
acagccagat	gtgttgccag	ggagaacaga	accaccagg	tcccttttgg	aaggcagcat	720
ttgcagactc	cagcgggcag	cacctcctg	acgcctgcgc	ctttcgtcgc	ggccgcaaga	780
aacgcattcc	gtacagcaag	gggcagttgc	gggagctgga	gcgggagtat	gcggctaaca	840
agttcatcac	caaggacaag	aggcgcaaga	tctcggcagc	caccagcctc	tcggagcgcc	900
agattaccat	ctggtttcag	aaccgcccgg	tcaaagagaa	gaaggttctc	gccaagggtga	960
agaacagcgc	tacccttaaa	gagatctcct	tgcctgggtg	ggaggagcga	aagtgggggt	1020
gtcctgggga	gaccaggaac	ctgccaagcc	caggctgggg	ccaaggactc	tgctgagagg	1080
cccctagaga	caacaccctt	cccaggccac	tggctgctgg	actgttccct	aggagcggcc	1140
tgggtaccca	gtatgtgcag	ggagacggaa	cccattgtga	cagcccactc	caccagggtt	1200
cccaaagaac	ctggcccagt	cataatcatt	catactgaca	gtggcaataa	tcacgataac	1260
cagtactagc	tgccatgata	gttagcctca	tattttctat	ctagagctct	gtagagcaat	1320
ttagaaaccg	ctttcatgaa	ttgagcta	tatgaataaa	tttggaaggc	gatccctttg	1380
caggggaagct	ttctctcaga	cccccttcca	ttacacctct	caccctggta	acagcaggaa	1440
gactgaggag	aggggaacgg	gcagattcgt	tgtgtggctg	tgatgtccgt	ttagcatttt	1500
tctcagctga	cagctgggta	ggtggacaat	tgtagaggct	gtctcttcc	ccctccttgt	1560
ccacccata	gggtgtaccc	actggtcttg	gaagcaccca	tccttaatac	gatgattttt	1620
ctgtcgtgtg	aaaatgaagc	cagcaggctg	cccctaagtc	gtccttccct	ccagagaaaa	1680
agagatttga	gaaagtgcct	gggtaattca	ccattaattt	cctcccccaa	actctctgag	1740
tcttccctta	atattttctg	tggttctgac	caaagcaggt	catggtttgt	tgagcatttg	1800
ggatcccagt	gaagtagatg	ttttagacct	tgcatactta	gcccttccca	ggcacaacag	1860

gagtggcaga	gtggtgccaa	ccctgttttc	ccagtcacag	tagacagatt	cacagtgcgg	1920
aattctggaa	gctggagaca	gacgggctct	ttgcagagcc	gggactctga	gagggacatg	1980
agggcctctg	cctctgtgtt	cattctctga	tgtcctgtac	ctgggctcag	tgcccgggtg	2040
gactcatctc	ctggccgcgc	agcaaagcca	gcggttcgt	gctggtcctt	cctgcacctt	2100
aggctggggg	tggggggcct	gccggcgcat	tctccacgat	tgagcgcaca	ggcctgaagt	2160
ctggacaacc	cgcagaaccg	aagctccgag	cagcgggtcg	gtggcgagta	gtggggtcgg	2220
tggcgagcag	ttggtggtgg	gccggcgccg	ccactacctc	gaggacattt	ccctcccggg	2280
gccagctctc	ctagaaaccc	cgcggcgccg	gccgcagcca	agtgtttatg	gccccgggtc	2340
gggtgggatc	ctagccctgt	ctcctctcct	gggaaggagt	gagggtgagg	cgtgacttag	2400
acacctacaa	atctattttac	caaagaggag	cccgggactg	agggaaaagg	ccaaagagtg	2460
tgagtgcattg	cggactgggg	gttcaggagg	agaggacgag	gaggaggaag	atgaggtcga	2520
tttcttgatt	taaaaaatcg	tccaagcccc	gtggtccagc	ttaaggctct	cgtttacatg	2580
cgccgctcag	agcaggtcac	tttctgcctt	ccacgtcctc	cttcaaggaa	gccccatgtg	2640
ggtagctttc	aatatcgcat	gttcttactc	ctctgcctct	ataagctcaa	accaccaaac	2700
gatcgggcaa	gtaaaccccc	tccctcgccg	acttcggaac	tggcgagagt	tcagcgcaga	2760
tgggcctgtg	gggagggggc	aagatagatg	agggggagcg	gcatggtgcg	gggtgacccc	2820
ttggagagag	gaaaaaggcc	acaagagggg	ctgccaccgc	cactaacgga	gatggccctg	2880
gtagagacct	ttgggggtct	ggaacctctg	gactccccat	gctctaactc	ccacactctg	2940
ctatcagaaa	cttaaaccttg	aggattttct	ctgtttttca	ctcgcaataa	aytcagagca	3000
aacaaaaaaa	aaaaaaaaaa	aaaactcgag				3030

&lt;210&gt; 334

&lt;211&gt; 2417

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 334

ggcgccgct	ctagagctag	tgggatcccc	cgggctgcac	gaattcggca	cgagtgaatt	60
ggagttttac	ctgtattgtt	ttaatttcaa	caagcctgag	gactagccac	aaatgtaccc	120
agtttacaaa	tgaggaaaca	ggtgcaaaaa	ggttggtacc	tgtcaaagg	cgtatgtggc	180
agagccaaga	tttagccca	gttatgtctg	atgaacttag	cctatgctct	ttaaacttct	240
gaatgctgac	cattgaggat	atctaaactt	agatcaattg	cattttccct	ccaagactat	300
ttacttatca	atacaataat	accaccttta	ccaatctatt	gttttgatac	gagactcaaa	360
tatgccagat	aatatgtaaa	gcaacctaca	agctctctaa	tcatgctcac	ctaaaagatt	420
ccgggactct	atatggctca	aagaaacttc	ttctagaaat	ataaaagaga	aaattggatt	480
atgcataaat	tcattattaa	tttttttcat	ccatccttta	attcagcaaa	catttatctg	540
ttgttgactt	tatgcagtat	ggccttttaa	ggattggggg	acagggtgaag	aacgggggtgc	600
cagaatgcat	cctcctacta	atgaggtcag	tacacatttg	catttttaaaa	tgccctgtcc	660
agctgggcat	ggtggatcat	gcctgtaatc	tcaacattgg	aaggccaagg	caggaggatt	720
gcttcagccc	aggagttcaa	gaccagcctg	ggcaacatag	aaagacccca	tctctcaatc	780
aatcaatcaa	tgccctgtct	ttgaaaataa	aactccttaa	gaaagggtta	atgggcaggg	840
tgtggtagct	catgcctata	atacagcact	ttgggaggct	gaggcaggag	gatcacttta	900
gccagaagt	tcaagaccag	cctgggcaac	aagtgcacc	tcatctcaat	tttttaataa	960
aatgaataca	tacataagga	aagataaaaa	gaaaagtta	atgaaagaat	acagtataaa	1020
acaaatctct	tggacctaaa	agtatttttg	ttcaagccaa	atattgtgaa	tcacctctct	1080
gtgttgagga	tacagaatat	ctaagccag	gaaactgagc	agaaagtcca	tgtactaact	1140
aatcaacccg	aggcaaggca	aaaatgagac	taactaatca	atccgaggca	aggggcaaat	1200
tagacggaac	ctgactctgg	tctattaagc	gacaactttc	cctctgttgt	atttttcttt	1260
tattcaatgt	aaaaggataa	aaactctcta	aaactaaaaa	caatgtttgt	caggagttac	1320
aaacctatgac	caactaatta	tggggaatca	taaaatatga	ctgtatgaga	tcttgatggt	1380
ttacaaagtg	taccactgt	taatcacttt	aaacattaat	gaacttaaaa	atgaatttac	1440
ggagattgga	atgtttcttt	cctgttgtat	tagttggctc	aggctgccat	aacaaaatac	1500
cacagactgg	gaggcttaag	taacagaaat	tcatttctca	cagttctggg	ggctggaagt	1560
ccacgatcaa	ggtgcaggaa	aggcaggctt	cattctgagg	cccctctctt	ggctcacatg	1620
tggccaccct	cccactgcgt	gotcacatga	cctctttgtg	ctcctggaaa	gaggggtgtg	1680
gggacagagg	gaaagagaag	gagagggaac	tctctggtgt	ctcgtctttc	aaggacccta	1740
acctgggcca	ctttggccca	ggcactgtgg	ggtggggggg	tgtggctgct	ctgctctgag	1800
tggccaagat	aaagcaacag	aaaaatgtcc	aaagctgtgc	agcaaagaca	agccaccgaa	1860

cagggatctg	ctcatcagt	tggggacctc	caagtcggcc	accctggagg	caagcccca	1920
cagagcccat	gcaaggtggc	agcagcagaa	gaagggaatt	gtccctgtcc	ttggcacatt	1980
cctcaccgac	ctggtgatgc	tggacactgc	gatgaatggt	aatgtggatg	agaatatgat	2040
ggactcccag	aaaaggagac	ccagctgctc	aggtggctgc	aaatcattac	agccttcac	2100
ctggggagga	actggggggc	tggttctggg	tcagagagca	gcccagtgag	ggtgagagct	2160
acagcctgtc	ctgccagctg	gatccccagt	cccgggtcaac	cagtaatcaa	ggctgagcag	2220
atcaggcttc	ccggagctgg	tcttggaag	ccagccctgg	ggtgagttgg	ctcctgctgt	2280
ggtactgaga	caatatgtgc	ataaattcaa	tgcgcccttg	tatccctttt	tcttttttat	2340
ctgtctacat	ctataatcac	tatgcatact	agtctttgtt	agtgtttcta	ttcmaacttaa	2400
tagagatatg	ttatact					2417

<210> 335  
 <211> 2984  
 <212> DNA  
 <213> Homo sapien

<400> 335						
atccctcctt	ccccactctc	ctttccagaa	ggcacttggg	gtcttatctg	ttggactctg	60
aaaacacttc	aggcgccctt	ccaaggcttc	cccaaacc	taagcagccg	cagaagcgct	120
cccagctgc	cttctccac	actcaggtga	tcgagttgga	gaggaagttc	agccatcaga	180
agtacctgtc	ggcccctgaa	cgggcccacc	tggccaagaa	cctcaagctc	acggagacc	240
aagtgaagat	atggttccag	aacagacgct	ataagactaa	gcgaaagcag	ctctcctcgg	300
agctgggaga	cttggaag	cactcctctt	tggcgccct	gaaagaggag	gccttctccc	360
gggcctccct	ggtctcgtg	tataacagct	atccttacta	cccatacctg	tactgcgtgg	420
gcagctggag	cccagctttt	tggtaatgcc	agctcaggtg	acaaccatta	tgatcaaaaa	480
ctgccttccc	cagggtgtct	ctatgaaaag	cacaaggggc	caaggtcagg	gagcaagagg	540
tgtgcacacc	aaagctattg	gagatttgcg	tggaaatctc	asattcttca	ctggtgagac	600
aatgaaacaa	cagagacagt	gaaagtttta	atacctaagt	cattccccca	gtgcatactg	660
taggtcattt	tttttgcttc	tggctacctg	tttgaagggg	agagagggaa	aatcaagtgg	720
tattttccag	cactttgtat	gattttggat	gagctgtaca	cccaaggatt	ctgttctgca	780
actccatcct	cctgtgtcac	tgaatatcaa	ctctgaaaga	gcaaaccctaa	caggagaaag	840
gacaaccagg	atgaggatgt	caccaactga	attaaactta	agtccagaag	cctcctgttg	900
gccttggaa	atggccaagg	ctctctctgt	ccctgtaaaa	gagaggggca	aatagagagt	960
ctccaagaga	acgccctcat	gctcagcaca	tatttgcatg	ggagggggag	atgggtggga	1020
ggagatgaaa	atatcagctt	ttcttattcc	tttttattcc	ttttaaaatg	gtatgccaac	1080
ttaagtattt	acaggggtggc	ccaaatagaa	caagatgcac	tcgctgtgat	tttaagacaa	1140
gctgtataaa	cagaactcca	ctgcaagagg	gggggcccgg	ccaggagaat	ctcctgttgt	1200
ccaagacagg	ggcctaagga	gggtctccac	actgctgcta	ggggctgttg	cattttttta	1260
ttagtagaaa	gtggaaaggc	ctcttctcaa	cttttttccc	ttgggctgga	gaatttagaa	1320
tcagaagttt	cctggagttt	tcaggctatc	atatatactg	tatcctgaaa	ggcaacataa	1380
ttcttccttc	cctcctttta	aaattttgtg	ttcctttttg	cagcaattac	tcactaaagg	1440
gcttcatttt	agtccagatt	tttagtctgg	ctgcacctaa	cttatgcctc	gcttatttag	1500
cccagatct	ggtctttttt	tttttttttt	tttttccgtc	tcccaaagc	tttatctgtc	1560
ttgacttttt	aaaaaagttt	gggggcagat	tctgaattgg	ctaaaagaca	tgcattttta	1620
aaactagcaa	ctcttatttc	tttcttttaa	aaatacatag	cattaaatcc	caaactcctat	1680
ttaaagacct	gacagcttga	gaaggtcact	actgcattta	taggaccttc	ttggtggtct	1740
gctgttacgt	ttgaagtctg	acaatccttg	agaattcttg	catgcagagg	aggtaagagg	1800
tattggattt	tcacagagga	agaacacagc	gcagaatgaa	gggccaggct	tactgagctg	1860
tccagtgagg	ggctcatggg	tgggacatgg	aaaagaaggc	agcctaggcc	ctggggagcc	1920
cagtccactg	agcaagcaag	ggactgagtg	agccttttgc	aggaaaaggc	taagaaaaag	1980
gaaaaccatt	ctaaaacaca	acaagaaact	gtccaaatgc	tttggaact	gtgtttattg	2040
cctataatgg	gtccccaata	tgggtaacct	agacttcaga	gagaatgagc	agagagcaaa	2100
ggagaaatct	ggctgtcctt	ccattttcat	tctgttatct	caggtgagct	ggtagagggg	2160
agacattaga	aaaaaatgaa	acaacaaaac	aattactaat	gaggtacgct	gaggcctggg	2220
agtctcttga	ctccactact	taattccgtt	tagtgagaaa	cctttcaatt	ttctttttat	2280
agaagggcca	gcttactgtt	ggtggcaaaa	ttgccaacat	aagttaatag	aaagttggcc	2340
aatttcaccc	cattttctgt	ggtttgggct	ccacattgca	atgttcaatg	ccacgtgctg	2400
ctgacaccga	ccggagtact	agccagcaca	aaaggcaggg	tagcctgaat	tgctttctgc	2460

tctttacatt	tcttttaaaa	taagcattta	gtgctcagtc	cctactgagt	actctttctc	2520
tcccctcctc	tgaattta	tctttcaact	tgcaatttgc	aaggattaca	catttcactg	2580
tgatgtatat	tgtgttgcaa	aaaaaaaaaa	aagtgtcttt	gtttaaaatt	acttggtttg	2640
tgaatccatc	ttgctttttc	cccattggaa	ctagtcatta	acccatctct	gaactggtag	2700
aaaaacatct	gaagagctag	tctatcagca	tctgacaggt	gaattggatg	gttctcagaa	2760
ccatttcacc	cagacagect	gtttctatcc	tgtttaataa	attagtttgg	gttctctaca	2820
tgcataacaa	accctgctcc	aatctgtcac	ataaaagtct	gtgacttgaa	gtttagtcag	2880
cacccccacc	aaactttatt	tttctatgtg	ttttttgcaa	catatgagtg	ttttgaaaat	2940
aaagtaccca	tgtctttatt	agaaaaaaaa	aaaaaaaaaa	aaaa		2984

<210> 336  
 <211> 147  
 <212> PRT  
 <213> Homo sapien

<400> 336

Pro	Ser	Phe	Pro	Thr	Leu	Leu	Ser	Arg	Arg	His	Leu	Gly	Ser	Tyr	Leu
1				5					10					15	
Leu	Asp	Ser	Glu	Asn	Thr	Ser	Gly	Ala	Leu	Pro	Arg	Leu	Pro	Gln	Thr
			20					25					30		
Pro	Lys	Gln	Pro	Gln	Lys	Arg	Ser	Arg	Ala	Ala	Phe	Ser	His	Thr	Gln
		35					40					45			
Val	Ile	Glu	Leu	Glu	Arg	Lys	Phe	Ser	His	Gln	Lys	Tyr	Leu	Ser	Ala
		50				55					60				
Pro	Glu	Arg	Ala	His	Leu	Ala	Lys	Asn	Leu	Lys	Leu	Thr	Glu	Thr	Gln
65				70					75					80	
Val	Lys	Ile	Trp	Phe	Gln	Asn	Arg	Arg	Tyr	Lys	Thr	Lys	Arg	Lys	Gln
				85				90						95	
Leu	Ser	Ser	Glu	Leu	Gly	Asp	Leu	Glu	Lys	His	Ser	Ser	Leu	Pro	Ala
			100					105					110		
Leu	Lys	Glu	Glu	Ala	Phe	Ser	Arg	Ala	Ser	Leu	Val	Ser	Val	Tyr	Asn
		115					120					125			
Ser	Tyr	Pro	Tyr	Tyr	Pro	Tyr	Leu	Tyr	Cys	Val	Gly	Ser	Trp	Ser	Pro
	130					135					140				
Ala	Phe	Trp													
145															

<210> 337  
 <211> 9  
 <212> PRT  
 <213> Homo sapien

<400> 337

Ala	Leu	Thr	Gly	Phe	Thr	Phe	Ser	Ala
1				5				

<210> 338  
 <211> 9  
 <212> PRT  
 <213> Homo sapien

<400> 338

Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile
1				5				

<210> 339  
 <211> 318

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 339

Met Val Glu Leu Met Phe Pro Leu Leu Leu Leu Leu Leu Pro Phe Leu  
 1 5 10 15  
 Leu Tyr Met Ala Ala Pro Gln Ile Arg Lys Met Leu Ser Ser Gly Val  
 20 25 30  
 Cys Thr Ser Thr Val Gln Leu Pro Gly Lys Val Val Val Val Thr Gly  
 35 40 45  
 Ala Asn Thr Gly Ile Gly Lys Glu Thr Ala Lys Glu Leu Ala Gln Arg  
 50 55 60  
 Gly Ala Arg Val Tyr Leu Ala Cys Arg Asp Val Glu Lys Gly Glu Leu  
 65 70 75 80  
 Val Ala Lys Glu Ile Gln Thr Thr Thr Gly Asn Gln Gln Val Leu Val  
 85 90 95  
 Arg Lys Leu Asp Leu Ser Asp Thr Lys Ser Ile Arg Ala Phe Ala Lys  
 100 105 110  
 Gly Phe Leu Ala Glu Glu Lys His Leu His Val Leu Ile Asn Asn Ala  
 115 120 125  
 Gly Val Met Met Cys Pro Tyr Ser Lys Thr Ala Asp Gly Phe Glu Met  
 130 135 140  
 His Ile Gly Val Asn His Leu Gly His Phe Leu Leu Thr His Leu Leu  
 145 150 155 160  
 Leu Glu Lys Leu Lys Glu Ser Ala Pro Ser Arg Ile Val Asn Val Ser  
 165 170 175  
 Ser Leu Ala His His Leu Gly Arg Ile His Phe His Asn Leu Gln Gly  
 180 185 190  
 Glu Lys Phe Tyr Asn Ala Gly Leu Ala Tyr Cys His Ser Lys Leu Ala  
 195 200 205  
 Asn Ile Leu Phe Thr Gln Glu Leu Ala Arg Arg Leu Lys Gly Ser Gly  
 210 215 220  
 Val Thr Thr Tyr Ser Val His Pro Gly Thr Val Gln Ser Glu Leu Val  
 225 230 235 240  
 Arg His Ser Ser Phe Met Arg Trp Met Trp Trp Leu Phe Ser Phe Phe  
 245 250 255  
 Ile Lys Thr Pro Gln Gln Gly Ala Gln Thr Ser Leu His Cys Ala Leu  
 260 265 270  
 Thr Glu Gly Leu Glu Ile Leu Ser Gly Asn His Phe Ser Asp Cys His  
 275 280 285  
 Val Ala Trp Val Ser Ala Gln Ala Arg Asn Glu Thr Ile Ala Arg Arg  
 290 295 300  
 Leu Trp Asp Val Ser Cys Asp Leu Leu Gly Leu Pro Ile Asp  
 305 310 315

&lt;210&gt; 340

&lt;211&gt; 483

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 340

gccgaggtct gccttcacac ggaggacacg agactgcttc ctcaagggt cctgcctgcc 60  
 tggacactgg tgggaggcgc tgtttagttg gctgttttca gaggggtctt tcggagggac 120  
 ctctgctgc aggtctggagt gtctttattc ctggcgggag accgcacatt ccactgctga 180  
 ggttgtggtt gcggtttatc aggcagtgat aaacataaga tgtcatttcc ttgactccgg 240  
 ccttcaattt tctctttggc tgacgacgga gtccgtggtg tcccgatgta actgaccct 300  
 gctccaaacg tgacatcact gatgctcttc tcgggggtgc tgatggcccg cttggtcacg 360  
 tgctcaatct cgccattcga ctcttgctcc aaactgtatg aagacacctg actgcacgtt 420

ttttctgggc ttccagaatt taaagtgaag ggcagcactc ctaagctccg actccgatgc 480  
ctg 483

<210> 341  
<211> 344  
<212> DNA  
<213> Homo sapien

<400> 341  
ctgctgctga gtcacagatt tcattataaa tagcctccct aaggaaaata cactgaatgc 60  
tatttttact aaccattcta tttttataga aatagctgag agtttctaaa ccaactctct 120  
gctgccttac aagtattaaa tattttactt ctttccataa agagtagctc aaaatatgca 180  
attaatttaa taatttctga tgaagggttt atctgcagta atatgtatat catctattag 240  
aatttactta atgaaaaact gaagagaaca aaatttgtaa ccactagcac ttaagtactc 300  
ctgattctta acattgtctt taatgaccac aagacaacca acag 344

<210> 342  
<211> 592  
<212> DNA  
<213> Homo sapien

<400> 342  
acagcaaaaa agaaactgag aagcccaaty tgctttcttg ttaacatcca cttatccaac 60  
caatgtggaa acttcttata cttgggtcca ttatgaagtt ggacaattgc tgctatcaca 120  
cctggcaggt aaaccaatgc caagagagtg atggaaacca ttggcaagac tttgttgatg 180  
accaggattg gaattttata aaaatattgt tgatgggaag ttgctaaagg gtgaattact 240  
tccctcagaa gagtgtaaag aaaagtcaga gatgctataa tagcagctat ttaattggc 300  
aagtgccact gtggaaagag ttcctgtgtg tgcgaagtt ctgaaggcca gtcaaatca 360  
tcagcatggg ctgtttggg caaatgcaaa agcacaggtc tttttagcat gctggctctc 420  
cccgtgtcct tatgcaata atcgtcttct tctaaatttc tcttaggctt cattttccaa 480  
agttcttctt ggtttgtgat gtcttttctg ctttccatta attctataaa atagtatggc 540  
ttcagccacc cactcttcgc cttagcttga ccgtgagttc cggctgccgc tg 592

<210> 343  
<211> 382  
<212> DNA  
<213> Homo sapien

<400> 343  
ttcttgacct cctcctcctt caagctcaaa caccacctcc cttattcagg accggcactt 60  
cttaatgttt gtggtttct ctccagcctc tcttaggagg ggtaatggtg gatttggcat 120  
cttgtaactc tcttttctcc tttcttcccc tttctctgcc cgcctttccc atcctgctgt 180  
agacttcttg attgtcagtc tgtgtcacat ccagtattg ttttggttcc tgttcccttt 240  
ctgactgcc aaggggctca gaacccagc aatcccttcc tttcactacc ttcttttttg 300  
ggggtagtgt gaagggactg aaattgtggg gggaaggtag gaggcacatc aataaaggag 360  
aaaccaccaa gctgaaaaaa aa 382

<210> 344  
<211> 536  
<212> DNA  
<213> Homo sapien

<400> 344  
ctgggcctga agctgtaggg taaatcagag gcaggcttct gagtgaatgag agtcctgaga 60  
caataggcca cataaacttg gctggatgga acctcacaat aaggtggtca cctcttggtt 120  
gtttaggggg atgccaagga taaggccagc tcagttatat gaagagaagc agaacaacaa 180  
agtctttcag agaaatggat gcaatcagag tgggatcccg gtcacatcaa ggtcacactc 240  
caccttcagt tgctgaatg gttgccaggc cagaaaaatc cacccttac gattgctggc 300

tcgaccctat atcccccgcc cgcgtccctt tctccataaa attctttotta gtagctatta	360
ccttcttatt atttgatcta gaaattgccc tccttttacc cctaccatga gccctacaaa	420
caactaacct gccactaata gttatgtcat cctctttatt aatcatcatc ctagccctaa	480
gtctggccta tgagtgacta caaaaaggat tagactgagc cgaataacaa aaaaaa	536

&lt;210&gt; 345

&lt;211&gt; 251

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 345

accttttgag gtctctctca ccacctccac agccaccgtc accgtgggat gtgctggatg	60
tgaatgaagc ccccatcttt gtgcctcctg aaaagagagt ggaagtgtcc gaggactttg	120
gcgtggggcca ggaaatcaca tcctacactg cccaggagcc agacacattt atggaacaga	180
aaataacata tcggatttgg agagacactg ccaactggct ggagattaat ccggacactg	240
gtgccatttc c	251

&lt;210&gt; 346

&lt;211&gt; 282

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(282)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 346

cgcgtctctg acactgtgat catgacaggg gttcaaacag aaagtgcctg ggccctcctt	60
ctaagtcttg ttaccaaaaa aaggaaaaag aaaagatctt ctacagttaca aattctggga	120
agggagacta tacctggctc ttgccctaag tgagaggtot tccctcccgcc accaaaaaat	180
agaaaggctt tctatttcac tggcccaggt agggggaagg agagtaactt tgagtctgtg	240
ggtctcattt cccaagggtgc cttcaatgct catnaaaacc aa	282

&lt;210&gt; 347

&lt;211&gt; 201

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(201)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 347

acacacataa tattataaaa tgccatctaa ttggaaggag ctttctatca ttgcaagtca	60
taaatataac ttttaaaana ntactancag cttttaccta ngctcctaaa tgcttgtaaa	120
tctgagactg actggaccga cccagaccga gggcaaagat acatgttacc atatcatctt	180
tataaagaat ttttttttgt c	201

&lt;210&gt; 348

&lt;211&gt; 251

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 348

ctgttaatca caacatttgt gcatcacttg tgccaagtga gaaaatgttc taaaatcaca	60
agagagaaca gtgccagaat gaaactgacc ctaagtccca ggtgcccctg ggcaggcaga	120

aggagacact	cccagcatgg	aggagggttt	atcttttcat	cctaggtcag	gtctacaatg	180
ggggaagggtt	ttattataga	actccaaca	gccacctca	ctcctgccac	ccacccgatg	240
gccctgcctc	c					251

<210> 349  
 <211> 251  
 <212> DNA  
 <213> Homo sapien

<400> 349						
taaaaatcaa	gccatttaaat	tgtatctttg	aaggtaaaca	atatatggga	gctggatcac	60
aaccctgag	gatgccagag	ctatgggtcc	agaacatgg	gtggtattat	caacagagtt	120
cagaagggtc	tgaactctac	gtgttaccag	agaacataat	gcaattcatg	cattccactt	180
agcaattttg	taaaatacca	gaaacagacc	ccaagagtct	ttcaagatga	ggaaaattca	240
actcctggtt	t					251

<210> 350  
 <211> 908  
 <212> DNA  
 <213> Homo sapien

<400> 350						
ctggacactt	tgcgagggt	tttgcctggt	gctgctgctg	cccgatcatgc	tactcatcgt	60
agcccgcccg	gtgaagctcg	ctgctttccc	tacctcctta	agtgactgcc	aaacgcccac	120
cggttggaat	tgctctggtt	atgatgacag	agaaaatgat	ctcttcctct	gtgacaccaa	180
cacctgtaaa	tttgatgggg	aatgtttaag	aattggagac	actgtgactt	gcgtctgtca	240
gttcaagtgc	aacaatgact	atgtgcctgt	gtgtggctcc	aatggggaga	gctaccagaa	300
tgagtgttac	ctgcgacagg	ctgcatgcaa	acagcagagt	gagatacttg	tggtgtcaga	360
aggatcatgt	gccacagtcc	atgaaggctc	tggagaaaact	agtcaaaagg	agacatccac	420
ctgtgatatt	tgccagtttg	gtgcagaatg	tgacgaagat	gccgaggatg	tctggtgtgt	480
gtgtaatat	gactgttctc	aaaccaactt	caatcccctc	tgcgcttctg	atgggaaatc	540
ttatgataat	gcatgccaaa	tcaaagaagc	atcgtgtcag	aaacaggaga	aaattgaagt	600
catgtctttg	ggtcgatgtc	aagataaacac	aactacaact	actaagtctg	aagatgggca	660
ttatgcaaga	acagattatg	cagagaatgc	taacaaatta	gaagaaagtg	ccagagaaca	720
ccacatacct	tgtccggaac	attacaatgg	cttctgcatg	catgggaagt	gtgagcatte	780
tatcaatatg	caggagccat	cttgacaggtg	tgatgctggt	tatactggac	aacactgtga	840
aaaaaaggac	tacagtgttc	tatacgttgt	tcccgtcctt	gtacgatttc	agtatgtctt	900
aatcgacg						908

<210> 351  
 <211> 472  
 <212> DNA  
 <213> Homo sapien

<400> 351						
ccagttattt	gcaagtggta	agagcctatt	taccataaat	aatactaaga	accaactcaa	60
gtcaaaccct	aatgccattg	ttattgtgaa	ttaggattaa	gtagtaattt	tcaaaattca	120
cattaacttg	attttaaaat	cagwtttgyg	agtcatttac	cacaagctaa	atgtgtacac	180
tatgataaaa	acaaccattg	tattcctggt	tttctaataa	gtcctaattt	ctaactgt	240
atatatcctt	cgacatcaat	gaactttggt	ttcttttact	ccagtaataa	agtaggcaca	300
gatctgtcca	caacaaactt	gccctctcat	gccttgcttc	tcaccatgct	ctgctccagg	360
tcagccccct	tttggcctgt	ttgttttgtc	aaaaacctaa	tctgcttctt	gottttcttg	420
gtaatatata	tttagggaag	atgttgcttt	gccacacac	gaagcaaagt	aa	472

<210> 352  
 <211> 251  
 <212> DNA  
 <213> Homo sapien



## &lt;400&gt; 352

ctcaaagcta atctctcggg aatcaaacca gaaaagggca aggatcttag gcatgggtgga	60
tgtggataag gccaggtcaa tggctgcaag catgcagaga aagaggtaca tcggagcgtg	120
caggctgcgt tccgtcctta cgatgaagac cacgatgcag tttccaaaca ttgccactac	180
atacatggaa aggaggggga agccaacca gaaatgggct ttctctaate ctgggatacc	240
aataagcaca a	251

&lt;210&gt; 353

&lt;211&gt; 436

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 353

tttttttttt tttttttttt ttttttacia caatgcagtc atttatttat tgagtatgtg	60
cacattatgg tattattact atactgatta tatttatcat gtgacttcta attaraaaat	120
gtatccaaaa gcaaaacagc agatatacaa aattaaagag acagaagata gacattaaca	180
gataaggcaa cttatacatt gacaatccaa atccaatata tttaaacatt tgggaaatga	240
gggggacaaa tggaagccar atcaaatttg tgtaaaacta ttcagtatgt ttcccttgct	300
tcatgtctga raaggctctc ccttcaatgg ggatgacaaa ctccaaatgc cacacaaatg	360
ttaacagaat actagattca cactggaacg ggggtaaaga agaaattatt ttctataaaa	420
gggctcctaa tgtagt	436

&lt;210&gt; 354

&lt;211&gt; 854

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 354

ccttttctag ttcaccagtt ttctgcaagg atgctgggta gggagtgtct gcaggaggag	60
caagtctgaa accaaatcta ggaacatag gaaacgagcc aggcacaggg ctgggtggcc	120
atcagggacc accctttggg ttgatatttt gcttaatctg catcttttga gtaagatcat	180
ctggcagtag aagctgttct ccagggtacat ttctctagct catgtacaaa aacatcctga	240
aggactttgt cagggtgcctt gctaaaagcc agatgcgttc ggcacttcct tgggtctgagg	300
ttaattgcac acctacaggg actgggctca tgctttcaag tattttgtcc tcaactttagg	360
gtgagtgaat gatccccatt ataggagcac ttgggagaga tcatataaaa gctgactctt	420
gagtacatgc agtaattggg tagatgtgtg ttggtgtgtct tcaattcctgc aagggtgctt	480
gttagggagt gtttccagga ggaacaagtc tgaaaccaat catgaaataa atggttaggtg	540
tgaactggaa aactaattca aaagagagat cgtgatatca gtgtggttga tacaccttgg	600
caatatggaa ggctctaatt tgcccatatt tgaaataata attcagcttt ttgtaataca	660
aaataacaaa ggattgagaa tcatggtgtc taatgtataa aagaccaggg aaacataaat	720
atatcaactg cataaatgta aaatgcatgt gacccaagaa ggccccaaggg tggcagacaa	780
cattgtaccc attttccctt ccaaaatgtg agcggcgggc ctgctgcttt caaggctgtc	840
acacgggatg tcag	854

&lt;210&gt; 355

&lt;211&gt; 676

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

## &lt;400&gt; 355

gaaattaagt atgagctaaa ttccctgtta aaacctctag gggtgacaga tctcttcaac	60
cagggtcaaag ctgatctttc tggaatgtca ccaaccaagg gcctatattt atcaaaagcc	120
atccacaagt catacctgga tgtcagcgaa gagggcacgg aggcagcagc agccactggg	180
gacagcatcg ctgtaaaaag cctaccaatg agagctcagt tcaaggcgaa ccaccccttc	240
ctgttcttta taaggcacac tcataccaac acgatcctat tctgtggcaa gcttgccctc	300
ccctaatacag atgggggttga gtaaggctca gagggtgcag agacaatcct	360
gtgactttcc cacggccaaa aagctgttca cacctcacgc acctctgtgc ctcagtttgc	420

tcactctgcaa	aataggtcta	ggatttcttc	caaccatttc	atgagttgtg	aagctaaggc	480
tttggttaatc	atggaaaaag	gtagacttat	gcagaaagcc	tttctggctt	tcttatctgt	540
ggtgtctcat	ttgagtgtg	tccagtgcac	tgatcaagtc	aatgagtaaa	attttaaggg	600
attagatttt	cttgacttgt	atgtatctgt	gagatcttga	ataagtgacc	tgacatctct	660
gcttaaagaa	aaccag					676

&lt;210&gt; 356

&lt;211&gt; 574

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 356

tttttttttt	tttttcagga	aaacattctc	ttactttatt	tgcactctcag	caaaggttct	60
catgtggcac	ctgactggca	tcaaaccaaa	gttcgtaggc	caacaaagat	gggccactca	120
caagcttccc	attttagat	ctcagtgcct	atgagtatct	gacacctgtt	cctctcttca	180
gtctcttagg	gaggcttaaa	tctgtctcag	gtgtgctaag	agtgccagcc	caaggkggtc	240
aaaagtccac	aaaactgcag	tctttgctgg	gatagtaagc	caagcagtgc	ctggacagca	300
gagttctttt	cttgggcaac	agataaccag	acaggactct	aatcgtgctc	ttattcaaca	360
ttcttctgtc	tctgcctaga	ctggaataaa	aagccaatct	ctctcgtggc	acaggggaagg	420
agatacaagc	tcgtttacat	gtgatagatc	taacaaaggc	atctaccgaa	gtctgggtctg	480
gatagacggc	acagggagct	cttaggtcag	cgtctgctgg	tggaggacat	tcctgagtcc	540
agctttgcag	cctttgtgca	acagtacttt	ccca			574

&lt;210&gt; 357

&lt;211&gt; 393

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 357

tttttttttt	tttttttttt	tttttttttt	tacagaatat	aratgcttta	tcaactgkact	60
taatattgkg	kcttggtcac	tatacttaaa	aatgcaccac	tcataaatat	ttaattcagc	120
aagccacaac	caaracttga	ttttatcaac	aaaaaccctt	aaatataaac	ggsaaaaaag	180
atagatatata	ttattccagt	ttttttaaaa	cttaaaarat	attccattgc	cgaattaara	240
araarataag	tggtatatgg	aaagaagggc	attcaagcac	actaaaraaa	cctgaggkaa	300
gcataatctg	tacaaaatta	aactgtcctt	tttggcattt	taacaaattt	gcaacgktct	360
tttttttctt	tttctgtttt	tttttttttt	tac			393

&lt;210&gt; 358

&lt;211&gt; 630

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 358

acagggtaaa	caggaggatc	cttgctctca	cggagcttac	attctagcag	gaggacaata	60
ttaatgttta	taggaaaatg	atgagtttat	gacaaaggaa	gtagatagtg	ttttacaaga	120
gcatagagta	gggaagctaa	tccagcacag	ggaggtcaca	gagacatccc	taaggaagtg	180
gagtttaaac	tgagagaagc	aagtgtctaa	actgaaggat	gtgttgaaga	agaagggaga	240
gtagaacaat	ttgggcagag	ggaaccttat	agaccctaag	gtgggaaggt	tcaaagaact	300
gaaagagagc	tagaacagct	ggagccgttc	tccggtgtaa	agaggagtca	aagagataag	360
attaaagatg	tgaagattaa	gatcttgggt	gcattcaggg	attggcactt	ctacaagaaa	420
tcaactgaagg	gagtaatgtg	acattacttt	tcaacttcagg	atggccattc	taactccagg	480
gggtagactg	gactaggtaa	gactggaggc	aggtagacct	cttctaaggc	ctgcgatagt	540
gaaagacaaa	aataagtggg	gaaattcagg	ggatagttaa	aatcagtagg	acttaatgag	600
caagccagag	gttccctccac	aacaaccagt				630

&lt;210&gt; 359

&lt;211&gt; 620

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 359

acagcattcc	aaaatataca	tctagagact	aarrgtaaat	gctctatagt	gaagaagtaa	60
taattaaaa	atgctactaa	tatagaaaat	ttataatcag	aaaaataaat	attcagggag	120
ctcaccagaa	gaataaagt	ctctgccagt	tattaaagga	ttactgctgg	tgaattaaat	180
atggcattcc	ccaagggaaa	tagagagatt	cttctggatt	atgttcaata	tttatttcac	240
aggattaact	gttttaggaa	cagatataaa	gcttcgccac	ggaagagatg	gacaaagcac	300
aaagacaaca	tgatacctta	ggaagcaaca	ctaccctttc	aggcataaaa	tttggagaaa	360
tgcaacatta	tgcttcatga	ataatatgta	gaaagaaggt	ctgatgaaaa	tgacatcctt	420
aatgtaagat	aaactttataa	gaattctggg	tcaaataaaa	ttctttgaag	aaaacatcca	480
aatgtcattg	acttatcaaa	tactatcttg	gcatataacc	tatgaaggca	aaactaaaca	540
aacaaaaagc	tcacacccaa	caaaaccatc	aacttatttt	gtattctata	acatacgaga	600
ctgtaaagat	gtgacagtgt					620

&lt;210&gt; 360

&lt;211&gt; 431

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 360

aaaaaaaaa	agccagaaca	acatgtgata	gataatatga	ttggctgcac	acttccagac	60
tgatgaatga	tgaacgtgat	ggactattgt	atggagcaca	tcttcagcaa	gagggggaaa	120
tactcatcat	ttttggccag	cagttgtttg	atcaccaaac	atcatgccag	aatactcagc	180
aaaccttctt	agctcttgag	aagtcaaagt	ccgggggaat	ttattcctgg	caattttaat	240
tggactcctt	atgtgagagc	agcggctacc	cagctggggt	ggtggagcga	acccgtcact	300
agtggacatg	cagtggcaga	gctcctggta	accacctaga	ggaatacaca	ggcacatgtg	360
tgatgccaa	cgtgacacct	gtagcactca	aatttgtctt	gtttttgtct	ttcgggtgtg	420
agattcttag	t					431

&lt;210&gt; 361

&lt;211&gt; 351

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 361

acactgattt	ccgatcaaaa	gaatcatcat	ctttaccttg	acttttcagg	gaattactga	60
actttcttct	cagaagatag	ggcacagcca	ttgccttggc	ctcacttgaa	gggtctgcat	120
ttgggtcctc	tggtctcttg	ccaagtttcc	cagccactcg	aggagaaaat	atcgggaggt	180
ttgacttcct	ccggggcttt	cccaggggct	tcaccgtgag	ccctgcggcc	ctcagggctg	240
caatcctgga	ttcaatgtct	gaaacctcgc	tctctgcctg	ctggacttct	gaggccgtca	300
ctgccactct	gtcctccagc	tctgacagct	cctcatctgt	ggtcctgttg	t	351

&lt;210&gt; 362

&lt;211&gt; 463

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 362

acttcatcag	gccataatgg	gtgcctccc	tgagaatcca	agcacctttg	gactgcgcga	60
tgtagatgag	ccggctgaag	atcttgcgca	tgccgggctt	cagggcggaag	ttcttggcgc	120
ccccggtcac	agaaatgacc	aggttgggtg	ttttcagggtg	ccagtgtctg	gtcagcagct	180
cgtaaaggat	ttccgcgtcc	gtgtcgcagg	acagacgtat	atacttccct	ttcttcccca	240
gtgtctcaaa	ctgaatatcc	ccaaaggcgt	cggtaggaaa	ttccttgggtg	tgtttcttgt	300
agttccattt	ctcacttttg	ttgatctggg	tgccttccat	gtgctggctc	tgggcatagc	360
cacacttgca	cacatttctc	ctgataagca	cgatgggtgtg	gacaggaagg	aaggatttca	420
ttgagcctgc	ttatggaaac	tggtattgtt	agcttaaata	gac		463

<210> 363  
 <211> 653  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(653)  
 <223> n = A,T,C or G

<400> 363  
 acccccagagt ncctgncctgg catactgnga acgaccaacg acacacccaa gctcggcctc 60  
 ctcttgngga ttctgggtga catcttcatg aatggcaacc gtgccagwga ggctgtcctc 120  
 tgggaggcac tacgcaagat gggactgcgt cctgggggtga gacatcctct cttggagat 180  
 ctaacgaaac ttctcaccta tgagttgtaa agcagaaata cctgnactac agacgagtgc 240  
 ccaacagcaa ccccccgaa gtatgagttc ctctrgggcc tccgttccta ccatgagasc 300  
 tagcaagatg naagtgttga gantcattgc agaggttcag aaaagagacc cntcgtgact 360  
 ggtctgcaca gttcatggag gctgcagatg aggccttgga tgctctggat gctgctgcag 420  
 ctgaggccga agcccgggct gaagcaagaa cccgcattgg aattggagat gaggctgtgt 480  
 ntgggccctg gagctgggat gacattgagt ttgagctgct gacctgggat gaggaaggag 540  
 attttgaga tcctnggtcc agaattccat ttaccttctg ggccagatac caccagaatg 600  
 cccgctccag attccctcag acctttgccg gtcccattat tggctctggt ggt 653

<210> 364  
 <211> 401  
 <212> DNA  
 <213> Homo sapien

<400> 364  
 actagaggaa agacgttaaa ccactctact accactttgtg gaactctcaa agggtaaatg 60  
 acaaagcaa tgaatgactc taaaaacaat atttacattt aatggtttgt agacaataaa 120  
 aaaacaaggt g gatagatct agaattgtaa cattttaaga aaaccatagc atttgacaga 180  
 tgagaaagct caattataga tgcaaagtta taactaaact actatagtag taaagaaata 240  
 catttcacac ccttcataata aattcactat cttggcttga ggcactccat aaaatgtatc 300  
 acgtgcatag taaatcttta tatttgctat ggcgttgac tagaggactt ggactgcaac 360  
 aagtggatgc gcggaaaatg aaatcttctt caatagccca g 401

<210> 365  
 <211> 356  
 <212> DNA  
 <213> Homo sapien

<400> 365  
 ccagtgtcat atttgggctt aaaatttcaa gaagggcact tcaaattggct ttgcatttgc 60  
 atgtttcagt gctagagcgt aggaatagac cctggcgctc actgtgagat gttcttcagc 120  
 taccagagca tcaagtctct gcagcaggctc attcttgggt aaagaaatga cttccacaaa 180  
 ctctccatcc cctggctttg gcttcggcctc tgcgttttcg gcatcatctc cgtaaatggt 240  
 gactgtcacg atgtgtatag tacagtttga caagcctggg tccatacaga ccgctggaga 300  
 acattcggca atgtcccctt tgtagccagt ttcttcttcg agctcccga gagcag 356

<210> 366  
 <211> 1851  
 <212> DNA  
 <213> Homo sapien

<400> 366  
 tcatacccat tgccagcagc ggcaccgtta gtcaggtttt ctgggaatcc cacatgagta 60  
 cttccgtgtt cttcattctt cttcaatagc cataaatctt ctagctctgg ctggctgttt 120

tcacttcctt	taagcctttg	tgactcttcc	tctgatgtca	gctttaagtc	ttgttctgga	180
ttgctgtttt	cagaagagat	ttttaacatc	tgtttttctt	tgtagtcaga	aagtaactgg	240
caaattacat	gatgatgact	agaaacagca	tactctctgg	ccgtctttcc	agatcttgag	300
aagatacatc	aacattttgc	tcaagtagag	ggctgactat	acttgctgat	ccacaacata	360
cagcaagtat	gagagcagtt	cttccatata	tatccagcgc	atttaaattc	gcttttttct	420
tgattaaaaa	tttcaccact	tgctgttttt	gctcatgtat	accaagtagc	agtggtgtga	480
ggccatgctt	gttttttgat	tcgatatcag	caccgtataa	gagcagtget	ttggccatta	540
atttatcttc	attgtagaca	gcatagtgtg	gagtgggtatt	tccatactca	tctggaatat	600
ttggatcagt	gccatgttcc	agcaacatta	acgcacattc	atcttcctgg	cattgtacgg	660
cctttgtcag	agctgtcctc	tttttgttgt	caaggacatt	aagttgacat	cgtctgtcca	720
gcacgagttt	tactacttct	gaattcccat	tggcagaggc	cagatgtaga	gcagtcctct	780
tttgcttgtc	cctcttggtc	acatccgtgt	ccctgagcat	gacgatgaga	tcctttctgg	840
ggactttacc	ccaccaggca	gctctgtgga	gcttgtccag	atcttctcca	tggacgtggt	900
acctggggtc	catgaaggcg	ctgtcatcgt	agtctcccca	agcgaccacg	ttgctcttgc	960
cgctcccctg	cagcagggga	agcagtggca	gcaccacttg	cacctcttgc	tccaagcgt	1020
cttcacagag	gagtcgttgt	ggtctccaga	agtgccacag	ttgctcttgc	cgctccccct	1080
gtccatccag	ggaggaagaa	atgcaggaaa	tgaaagatgc	atgcacgatg	gtatactcct	1140
cagccatcaa	acttctggac	agcagggtcac	ttccagcaag	gtggagaaaag	ctgtccaccc	1200
acagaggatg	agatccagaa	accacaatat	ccattcacia	acaaacactt	ttcagccaga	1260
cacaggtact	gaaatcatgt	catctgcggc	aacatgggtg	aacctaccca	atcacacatc	1320
aagagatgaa	gacactgcag	tatatctgca	caacgtaata	ctcttcatcc	ataacaaaat	1380
aatataaatt	tctctctggag	ccatatggat	gaactatgaa	ggaagaactc	cccgaagaag	1440
ccagtgcag	agaagccaca	ctgaagctct	gtcctcagcc	atcagcgcca	cggacaggat	1500
tgtgtttctt	ccccagtgat	gcagcctcaa	gttatcccca	agctgccgca	gcacacgggtg	1560
gctcctgaga	aacaccccag	ctcttccggt	ctaacacagg	caagtcaata	aatgtgataa	1620
tcacataaac	agaattaaaa	gcaaagtcac	ataagcatct	caacagacac	agaaaaggca	1680
tttgacaaaa	tccagcatcc	ttgtatttat	tgttgcagtt	ctcagaggaa	atgcttctaa	1740
cttttcccca	tttagtatta	tgttggctgt	gggcttgtca	taggtgggtt	ttattacttt	1800
aaggatatgc	ccttctatgc	ctgttttgct	gagggtttta	attctcgtgc	c	1851

<210> 367  
 <211> 668  
 <212> DNA  
 <213> Homo sapien

<400> 367

cttgagcttc	caaataygga	agactggccc	ttacacasgt	caatgttaaa	atgaatgcat	60
ttcagtattt	tgaagataaa	atttrtagat	ctataccttg	ttttttgatt	cgatatcagc	120
accrtataag	agcagtgett	tggccattaa	tttatctttc	atttrtagaca	gcrtagtgga	180
gagtgggtatt	tccatactca	tctggaatat	ttggatcagt	gccatgttcc	agcaacatta	240
acgcacattc	atcttcctgg	cattgtacgg	cctgtcagta	ttagacccaa	aaacaaatta	300
catatcttag	gaattcaaaa	taacattcca	cagctttcac	caactagtta	tatttaaagg	360
agaaaactca	tttttatgcc	atgtattgaa	atcaaaccce	cctcatgctg	atatagttgg	420
ctactgcata	cctttatcag	agctgtcctc	tttttgttgt	caaggacatt	aagttgacat	480
cgctgttcca	gcaggagttt	tactacttct	gaattcccat	tggcagaggc	cagatgtaga	540
gcagtcctat	gagagtgaga	agacttttta	ggaaattgta	gtgcactagc	tacagccata	600
gcaatgattc	atgtaactgc	aaacactgaa	tagcctgcta	ttactctgoc	ttcaaaaaaa	660
aaaaaaaa						668

<210> 368  
 <211> 1512  
 <212> DNA  
 <213> Homo sapien

<400> 368

gggtcgccca	gggggsgcgt	gggctttcct	cgggtgggtg	tgggttttcc	ctgggtgggg	60
tgggtgggc	trgaatcccc	tgctgggggt	ggcaggtttt	ggctgggatt	gacttttytc	120
ttcaaacaga	ttggaaaccc	ggagttacct	gctagttggt	gaaactgggt	ggtagacgcg	180

atctgttggc	tactactggc	ttctcctggc	tggtaaaagc	agatgggtgg	tgaggttgat	240
tccatgccgg	ctgcttcttc	tgtgaagaag	ccatttggtc	tcaggagcaa	gatgggcaag	300
tggtgctgcc	gttgcttccc	ctgctgcagg	gagagcggca	agagcaacgt	gggcacttct	360
ggagaccacg	acgactctgc	tatgaagaca	ctcaggagca	agatgggcaa	gtggtgccgc	420
cactgcttcc	cctgctgcag	ggggagtggc	aagagcaacg	tgggcgcttc	tggagaccac	480
gacgaytctg	ctatgaagac	actcaggaac	aagatgggca	agtgggtgctg	ccactgcttc	540
ccctgctgca	gggggagcrg	caagagcaag	gtgggcgctt	ggggagacta	cgatgacagt	600
gccttcatgg	agcccaggta	ccacgtccgt	ggagaagatc	tggacaagct	ccacagagct	660
gcctggtggg	gtaaagtccc	cagaaaggat	ctcatcgtca	tgctcaggga	cactgacgtg	720
aacaagaagg	acaagcaaaa	gaggactgct	ctacatctgg	cctctgccaa	tgggaattca	780
gaagtagtaa	aactcstgct	ggacagacga	tgtcaactta	atgtccttga	caacaaaaag	840
aggacagctc	tgayaaaggc	cgtacaatgc	caggaagatg	aatgtgcgtt	aatgttgctg	900
gaacatggca	ctgatccaaa	tattccagat	gagtatggaa	ataccactct	rcactaygct	960
rtctayaatg	aagataaatt	aatggccaaa	gcactgctct	tatayggtgc	tgatatcgaa	1020
tcaaaaaaca	aggtatagat	ctactaattt	tatcttcaaa	atactgaaat	gcattcattt	1080
taacattgac	gtgtgtaagg	gccagtcttc	cgtatttggg	agctcaagca	taacttgaat	1140
gaaaatattt	tgaaatgacc	taattatctm	agactttatt	ttaaatattg	ttattttcaa	1200
agaagcatta	gagggtacag	tttttttttt	ttaaatgcac	ttctggtaaa	tacttttggt	1260
gaaaacactg	aatttgtaaa	aggttaatact	tactattttt	caatttttcc	ctcctaggat	1320
ttttttcccc	taatgaatgt	aagatggcaa	aatttgcctt	gaaataggtt	ttacatgaaa	1380
actccaagaa	aagttaaaca	tgtttcagtg	aatagagatc	ctgctccttt	ggcaagttcc	1440
taaaaaacag	taatagatac	gaggtgatgc	gcctgtcagt	ggcaagggtt	aagatatttc	1500
tgatctcgtg	cc					1512

&lt;210&gt; 369

&lt;211&gt; 1853

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 369

gggtcgccca	gggggsgcgt	gggctttcct	cgggtgggtg	tgggttttcc	ctgggtgggg	60
tgggtggggc	trgaatcccc	tgctgggggt	ggcagggttt	ggctgggatt	gacttttytc	120
ttcaaacaga	ttggaaaccc	ggagttacct	gctagttggg	gaaactgggt	ggtagacgcg	180
atctgttggc	tactactggc	ttctcctggc	tggtaaaagc	agatgggtgg	tgaggttgat	240
tccatgccgg	ctgcttcttc	tgtgaagaag	ccatttggtc	tcaggagcaa	gatgggcaag	300
tggtgctgcc	gttgcttccc	ctgctgcagg	gagagcggca	agagcaacgt	gggcacttct	360
ggagaccacg	acgactctgc	tatgaagaca	ctcaggagca	agatgggcaa	gtggtgccgc	420
cactgcttcc	cctgctgcag	ggggagtggc	aagagcaacg	tgggcgcttc	tggagaccac	480
gacgaytctg	ctatgaagac	actcaggaac	aagatgggca	agtgggtgctg	ccactgcttc	540
ccctgctgca	gggggagcrg	caagagcaag	gtgggcgctt	ggggagacta	cgatgacagy	600
gccttcatgg	akcccaggta	ccacgtccrt	ggagaagatc	tggacaagct	ccacagagct	660
gcctggtggg	gtaaagtccc	cagaaaggat	ctcatcgtca	tgctcaggga	cackgaygtg	720
aacaagargg	acaagcaaaa	gaggactgct	ctacatctgg	cctctgccaa	tgggaattca	780
gaagtagtaa	aactcstgct	ggacagacga	tgtcaactta	atgtccttga	caacaaaaag	840
aggacagctc	tgayaaaggc	cgtacaatgc	caggaagatg	aatgtgcgtt	aatgttgctg	900
gaacatggca	ctgatccaaa	tattccagat	gagtatggaa	ataccactct	rcactaygct	960
rtctayaatg	aagataaatt	aatggccaaa	gcactgctct	tatayggtgc	tgatatcgaa	1020
tcaaaaaaca	agcatggcct	cacaccactg	ytacttggtr	tacatgagca	aaaacagcaa	1080
gtsgtgaaat	ttttaatyaa	gaaaaaagcg	aattttaa	gcrctggata	gatatggaag	1140
ractgctctc	atacttgctg	tatgttgtgg	atcagcaagt	atagtcagcc	ytctacttga	1200
gcaaaatrtr	gatgtatctt	ctcaagatct	ggaaagacgg	ccagagagta	tgctgtttct	1260
agtcatcatc	atgtaatattg	ccagttactt	tctgactaca	aagaaaaaca	gatgttaaaa	1320
atctcttctg	aaaacagcaa	tccagaacaa	gacttaaagc	tgacatcaga	ggaagagtca	1380
caaaggctta	aagggaagtga	aaacagccag	ccagaggcat	ggaaactttt	aaatttaa	1440
ttttggttta	atgttttttt	tttttgccct	aataatatta	gatagtccca	aatgaaatwa	1500
cctatgagac	taggcttttga	gaatcaatag	attctttttt	taagaatctt	ttggctagga	1560
gcggtgtctc	acgcctgtaa	ttccagcacc	ttgagaggct	gaggtgggca	gatcacgaga	1620
tcaggagatc	gagaccatcc	tggttaacac	ggtgaaaccc	catctctact	aaaaatacaa	1680

<210> 370  
<211> 2184  
<212> DNA  
<213> Homo sapien

ggcacgagaa	ttaaaaccct	cagcaaaaca	ggcatagaag	ggacatacct	taaagtaata	60
aaaaccacct	atgacaagcc	cacagccaac	ataatactaa	atggggaaaa	gttagaagca	120
tttctctga	gaactgcaac	aataaatata	aggatgctgg	attttgtcaa	atgccttttc	180
tgtgtctgtt	gagatgctta	tgtgactttg	cttttaattc	tgtttatgtg	attatcacat	240
ttattgactt	gcctgtgta	gaccggaaga	gctggggtgt	ttctcaggag	ccaccgtgtg	300
ctgccgcagc	ttcgggataa	cttgaggctg	catcactggg	gaagaaacac	aytcctgtcc	360
gtggcgctga	tggctgagga	catagcttca	gtgtggcttc	tctgcgactg	gcttcttcgg	420
ggagttcttc	cttcatagtt	catccatagt	gctccagagt	aaaattatat	tattttgtta	480
tggatgaaga	gtattacgtt	gtgcagatat	actgcagtg	cttcactctc	tgatgtgtga	540
ttgggtaggt	tccaccatgt	tgccgcagat	gacatgattt	cagtacctgt	gtctggctga	600
aaagtgtttg	tttgtgaatg	gatattgtgg	tttctggatc	tcactctctg	tgggtggaca	660
gctttctcca	ccttgctgga	agtgacctgc	tgtccagaag	tttgatggct	gaggagtata	720
ccatcgtgca	tgcattcttc	atttcctgca	tttcttcctc	cctggatgga	cagggggagc	780
ggcaagagca	acgtgggcac	tctctggagac	cacaacgact	cctctgtgaa	gacgcttggg	840
agcaagaggt	gcaagtgggtg	ctgccactgc	ttcccctgct	gcaggggagc	ggcaagagca	900
acgtggctgc	ttggggagac	tacgatgaca	gcgccttcac	tgatcccagg	taccacgtcc	960
atggagaaga	tctggacaag	ctccacagag	ctgcctggtg	gggtaaagtc	cccagaaagg	1020
atctcatcgt	catgctcagg	gacacggatg	tgaacaagag	ggacaagcaa	aagaggactg	1080
ctctacatct	ggcctctgcc	aatgggaatt	cagaagtagt	aaaactcgtg	ctggacagac	1140
gatgtcaact	taatgtcctt	gacaacaaaa	agaggcacgc	tctgacaaaag	gccgtacaat	1200
gccaggaaga	tgaattgtcg	ttaactgttg	tggaaacttg	cactgatcca	aatattccca	1260
atgagtatgg	aaataccact	ctacactatg	ctgtctaaa	tgaagataaa	ttaatggcca	1320
aagcactgct	cttatacggg	gctgatatac	aatcaaaaaa	caagcatggc	ctcacaccac	1380
tgctacttgg	tatacatgag	caaaaacagc	aagtggtgaa	atttttaatc	aagaaaaaag	1440
cgaattttaa	tgcgctggat	agatatggaa	gaactgctct	catacttgct	gtatgttgtg	1500
gatcagcaag	tatagtcagc	cctctacttg	agcaaaatgt	tgatgtatct	tctcaagatc	1560
tggaaagacg	gccagagagt	atgctgtttc	tagtcatcat	catgtaattt	gccagttact	1620
ttctgactac	aaagaaaaac	agatgtttaa	aatctctctt	gaaaacagca	atccagaaca	1680
agacttaaa	ctgacatcag	aggaagagtc	acaaaggctt	aaaggaagtg	aaaacagcca	1740
gccagaggca	tggaaacttt	taaattttaa	cttttggttt	aatgtttttt	ttttttgco	1800
taataatatt	agatagtc	aaatgaaatw	acctatgaga	ctaggctttg	agaatcaata	1860
gattcttttt	ttaagaatct	tttggctagg	agcgggtgtc	cacgcctgta	attccagcac	1920
cttgagaggc	tgagggtggg	agatcacgag	atcaggagat	cgagaccatc	ctggctaaca	1980
cggtgaaacc	ccatctctac	taaaaatata	aaaacttagc	tgggtgtggg	ggcgggtgcc	2040
tgtagtccca	gctactcagg	argctgagge	aggagaatgg	catgaaccgc	ggaggtggag	2100
gttgacgtga	gccgagatcc	gccactacac	tccagcctgg	gtgacagagc	aagactctgt	2160
ctcaaaaaaa	aaaaaaaaaa	aaaa				2184

<210> 371  
<211> 1855  
<212> DNA  
<213> Homo sapien

```
<220>
<221> misc_feature
<222> (1)...(1855)
<223> n = A,T,C or G
```

## &lt;400&gt; 371

tgcacgcac	ggccagtgtc	tgtgccacgt	acactgacgc	cccctgagat	gtgcacgccg	60
cacgcgcacg	ttgcacgcgc	ggcagcggct	tggctggcct	gtaacggcct	gcacgcgcac	120
gccgcccccg	cataaccgtc	agactggcct	gtaacggcct	gcaggcgac	gccgcacgcg	180
cgtaacggct	tggctgccct	gtaacggcct	gcacgtgcac	gctgcacgcg	cgtaacggc	240
ttggctggca	tgtagccgct	tggcttggct	ttgcattt	tgctkggctk	ggcggtgkty	300
tcttggattg	acgcttcctc	cttggatkg	cgtttcctcc	ttggatkgac	gtttcyyty	360
tcgcgttcct	ttgctggact	tgacctttty	tctgctgggt	ttggcattcc	tttgggggtg	420
gctgggtgtt	ttctccgggg	gggkkgccc	ttctgggggt	gggcgtgggk	cgccccagg	480
gggcgtgggc	tttccccggg	tgggtgtggg	ttttcctggg	gtgggggtgg	ctgtgctggg	540
atccccctgc	tggggttggc	agggattgac	tttttcttcc	aaacagattg	gaaacccgga	600
gtaacntgct	agttggtgaa	actggttggg	agacgcgac	tgctgggtact	actgtttctc	660
ctggctgtta	aaagcagatg	gtggctgagg	ttgattcaat	gccggctgct	tcttctgtga	720
agaagccatt	tggctctcagg	agcaagatgg	gcaagtgggt	cgccactgct	tcccctgctg	780
cagggggagc	ggcaagagca	acgtgggcac	ttctggagac	cacaacgact	cctctgtgaa	840
gacgcttggg	agcaagagg	gcaagtgggt	ctgccactg	cttccccctgc	tgcaaggagg	900
cggcaagagc	aacgtggkcg	cttggggaga	ctacgatgac	agcgccttca	tggakcccag	960
gtaccacgtc	crtggagaag	atctggacaa	gctccacaga	gctgcctggg	ggggtaaagt	1020
ccccagaaag	gatctcatcg	tcatgctcag	ggacactgay	gtgaacaaga	rggacaagca	1080
aaagaggact	gctctacatc	tggcctctgc	caatgggaat	tcagaagtag	taaaactcgt	1140
gctggacaga	cgatgtcaac	ttaatgtcct	tgacaacaaa	aagaggacag	ctctgacaaa	1200
ggccgtacaa	tgccaggaag	atgaatgtgc	gttaatgttg	ctggaacatg	gcactgatcc	1260
aaatattcca	gatgagtatg	gaaataccac	tctacactat	gctgtctaca	atgaagataa	1320
attaatggcc	aaagcactgc	tcttatacgg	tgtctgatatc	gaatcaaaaa	acaagggtata	1380
gatctactaa	ttttatcttc	aaaatactga	aatgcattca	ttttaacatt	gacgtgtgta	1440
agggccagtc	ttccgtat	ggaagctcaa	gcataacttg	aatgaaaata	ttttgaaatg	1500
acctaattat	ctaagacttt	attttaata	ttgttat	caaagaagca	ttagagggtg	1560
cagttttttt	tttttaaatg	cacttctggg	aaatactttt	gttgaaaaaca	ctgaatttgt	1620
aaaaggtaat	acttactatt	tttcaatttt	tccctcctag	gatttttttt	ccctaataaa	1680
tgtaagatgg	caaaaatttgc	cctgaaatag	gtttttacatg	aaaactccaa	gaaaagttaa	1740
acatgtttca	gtgaatagag	atcctgctcc	tttggcaagt	tcctaaaaaa	cagtaataga	1800
tacgaggtga	tgccgctgtc	agtggcaagg	tttaagatat	ttctgatctc	gtgcc	1855

## &lt;210&gt; 372

## &lt;211&gt; 1059

## &lt;212&gt; DNA

## &lt;213&gt; Homo sapien

## &lt;400&gt; 372

gcaacgtggg	cacttctgga	gaccacaacg	actcctctgt	gaagacgctt	gggagcaaga	60
ggtgcaagtg	gtgctgcca	ctgcttcccc	tgctgcaggg	gagcggcaag	agcaacgtgg	120
gcgcttgrgg	agactmcgat	gacagygcct	tcatggagcc	caggtaccac	gtccgtggag	180
aagatctgga	caagctccac	agagctgccc	tgggtgggta	aagtccccag	aaaggatctc	240
atcgtcatgc	tcaggagacac	tgaygtgaac	aagarggaca	agcaaaaagag	gactgctcta	300
catctggcct	ctgccaatgg	gaattcagaa	gtagtataaac	tcstgctgga	cagacgatgt	360
caacttaatg	tccttgacaa	caaaaagagg	acagctctga	yaaaggccgt	acaatgccag	420
gaagatgaat	gtgcgttaat	gttgctggaa	catggcactg	atccaaatat	tccagatgag	480
tatggaaata	ccactctrc	ctaygctrtc	tayaatgaag	ataaattaat	ggccaaagca	540
ctgctcttat	ayggtgctga	tatcgaatca	aaaaacaagg	tatagatcta	ctaattttat	600
cttcaaaaata	ctgaaatgca	ttcattttta	cattgacgtg	tgtaagggcc	agtcttccgt	660
atgttggaagc	tcaagcataa	cttgaatgaa	aatattttga	aatgacctaa	ttatctaaga	720
ctttattttta	aatattgtta	ttttcaaaga	agcatttagag	ggtacagttt	ttttttttta	780
aatgcacttc	tggtaaatac	ttttgttgaa	aacactgaat	ttgtaaaagg	taatacttac	840
tattttttcaa	tttttccctc	ctaggatttt	tttcccttaa	tgaatgtaag	atggcaaaat	900
ttgccctgaa	ataggtttta	catgaaaact	ccaagaaaag	ttaaacatgt	ttcagtgaat	960
agagatcctg	ctcctttggc	aagttcctaa	aaaacagtaa	tagatacgag	gtgatgcgcc	1020
tgtcagtggc	aagggtttaag	atattttctga	tctcgtgcc			1059



<210> 373  
 <211> 1155  
 <212> DNA  
 <213> Homo sapien

<400> 373

atggtggttg	aggttgattc	catgccggct	gcctcttctg	tgaagaagcc	atttgggtctc	60
aggagcaaga	tgggcaagt	gtgctgccgt	tgcttcccc	gctgcaggga	gagcggcaag	120
agcaacgtgg	gcacttctgg	agaccacgac	gactctgcta	tgaagacact	caggagcaag	180
atgggcaagt	ggtgccgcca	ctgcttcccc	tgctgcagg	ggagtggcaa	gagcaacgtg	240
ggcgcttctg	gagaccacga	cgactctgct	atgaagacac	tcaggaacaa	gatgggcaag	300
tggtgctgcc	actgcttccc	ctgctgcagg	gggagcggca	agagcaaggt	ggcgcttgg	360
ggagactacg	atgacagtgc	cttcatggag	cccagggtacc	acgtccgtgg	agaagatctg	420
gacaagctcc	acagagctgc	ctgggtgggt	aaagtcccca	gaaaggatct	catcgtcatg	480
ctcagggaca	ctgacgtgaa	caagaaggac	aagcaaaaaga	ggactgctct	acatctggcc	540
tctgccaatg	ggaattcaga	agtagtaaaa	ctcctgctgg	acagacgatg	tcaacttaat	600
gtccttgaca	acaaaaagag	gacagctctg	ataaaggccg	tacaatgcca	ggaagatgaa	660
tgtgcgttaa	tggtgctgga	acatggcact	gatccaaata	ttccagatga	gtatggaaat	720
accactctgc	actacgctat	ctataatgaa	gataaattaa	tggccaaagc	actgctctta	780
tatggtgctg	atatcgaatc	aaaaaacaag	catggcctca	caccactgtt	acttgggtgta	840
catgagcaaa	aacagcaagt	cgtgaaat	ttaatcaaga	aaaaagcgaa	tttaaatgca	900
ctggatagat	atggaaggac	tgctctcata	cttgctgtat	gttgtggatc	agcaagtata	960
gtcagccttc	tacttgagca	aaatattgat	gtatcttctc	aagatctatc	tggacagacg	1020
gccagagagt	atgctgtttc	tagtcatcat	catgtaattt	gccagttact	ttctgactac	1080
aaagaaaaac	agatgctaaa	aatctcttct	gaaaacagca	atccagaaaa	tgtctcaaga	1140
accagaaata	aataa					1155

<210> 374  
 <211> 2000  
 <212> DNA  
 <213> Homo sapien

<400> 374

atggtggttg	aggttgattc	catgccggct	gcctcttctg	tgaagaagcc	atttgggtctc	60
aggagcaaga	tgggcaagt	gtgctgccgt	tgcttcccc	gctgcaggga	gagcggcaag	120
agcaacgtgg	gcacttctgg	agaccacgac	gactctgcta	tgaagacact	caggagcaag	180
atgggcaagt	ggtgccgcca	ctgcttcccc	tgctgcagg	ggagtggcaa	gagcaacgtg	240
ggcgcttctg	gagaccacga	cgactctgct	atgaagacac	tcaggaacaa	gatgggcaag	300
tggtgctgcc	actgcttccc	ctgctgcagg	gggagcggca	agagcaaggt	ggcgcttgg	360
ggagactacg	atgacagtgc	cttcatggag	cccagggtacc	acgtccgtgg	agaagatctg	420
gacaagctcc	acagagctgc	ctgggtgggt	aaagtcccca	gaaaggatct	catcgtcatg	480
ctcagggaca	ctgacgtgaa	caagaaggac	aagcaaaaaga	ggactgctct	acatctggcc	540
tctgccaatg	ggaattcaga	agtagtaaaa	ctcctgctgg	acagacgatg	tcaacttaat	600
gtccttgaca	acaaaaagag	gacagctctg	ataaaggccg	tacaatgcca	ggaagatgaa	660
tgtgcgttaa	tggtgctgga	acatggcact	gatccaaata	ttccagatga	gtatggaaat	720
accactctgc	actacgctat	ctataatgaa	gataaattaa	tggccaaagc	actgctctta	780
tatggtgctg	atatcgaatc	aaaaaacaag	catggcctca	caccactgtt	acttgggtgta	840
catgagcaaa	aacagcaagt	cgtgaaat	ttaatcaaga	aaaaagcgaa	tttaaatgca	900
ctggatagat	atggaaggac	tgctctcata	cttgctgtat	gttgtggatc	agcaagtata	960
gtcagccttc	tacttgagca	aaatattgat	gtatcttctc	aagatctatc	tggacagacg	1020
gccagagagt	atgctgtttc	tagtcatcat	catgtaattt	gccagttact	ttctgactac	1080
aaagaaaaac	agatgctaaa	aatctcttct	gaaaacagca	atccagaaaa	agacttaag	1140
ctgacatcag	aggaagagtc	acaaagggtc	aaaggcagtg	aaaatagcca	gccagagaaa	1200
atgtctcaag	aaccagaaat	aaataaggat	ggtgatagag	aggttgaaga	agaaatgaag	1260
aagcatgaaa	gtaataatgt	gggattacta	gaaaacctga	ctaattggtg	cactgctggc	1320
aatggtgata	atggattaat	tcctcaaagg	aagagcagaa	cacctgaaaa	tcagcaat	1380
cctgacaacg	aaagtgaaga	gtatcacaga	atttgcgaa	tagtttctga	ctacaaagaa	1440
aaacagatgc	caaaatactc	ttctgaaaac	agcaaccag	aacaagactt	aaagctgaca	1500

tcagaggaag	agtcacaaag	gcttgagggc	agtgaaaatg	gccagccaga	gctagaaaat	1560
tttatggcta	tcgaagaaat	gaagaagcac	ggaagtactc	atgtcggatt	cccagaaaac	1620
ctgactaatg	gtgccactgc	tggcaatggt	gatgatggat	taattcctcc	aaggaagagc	1680
agaacacctg	aaagccagca	atttcctgac	actgagaatg	aagagtatca	cagtgcacgaa	1740
caaaatgata	ctcagaagca	attttgtgaa	gaacagaaca	ctggaatatt	acacgatgag	1800
attctgattc	atgaagaaaa	gcagatagaa	gtggttgaaa	aaatgaattc	tgagctttct	1860
cttagttgta	agaaagaaaa	agacatcttg	catgaaaata	gtacgttgcg	ggaagaaatt	1920
gccatgctaa	gactggagct	agacacaatg	aaacatcaga	gccagctaaa	aaaaaaaaaa	1980
aaaaaaaaaa	aaaaaaaaaa					2000

&lt;210&gt; 375

&lt;211&gt; 2040

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 375

atggtggttg	aggttgattc	catgcgggct	gcctcttctg	tgaagaagcc	atttggctctc	60
aggagcaaga	tgggcaagtg	gtgctgccgt	tgcttcccct	gctgcaggga	gagcggcaag	120
agcaacgtgg	gcacttctgg	agaccacgac	gactctgcta	tgaagacact	caggagcaag	180
atgggcaagt	ggtgccgcca	ctgcttcccc	tgctgcaggg	ggagtggcaa	gagcaacgtg	240
ggcgcttctg	gagaccacga	cgactctgct	atgaagacac	tcaggaacaa	gatgggcaag	300
tggtgctgcc	actgcttccc	ctgctgcagg	gggagcggca	agagcaaggt	gggcgcttgg	360
ggagactacg	atgacagtgc	cttcatggag	cccaggtacc	acgtccgtgg	agaagatctg	420
gacaagctcc	acagagctgc	ctggtggggg	aaagtcccca	gaaaggatct	catcgtcatg	480
ctcagggaca	ctgacgtgaa	caagaaggac	aagcaaaaga	ggactgctct	acatctggcc	540
tctgccaatg	ggaattcaga	agtagtaaaa	ctcctgctgg	acagacgatg	tcaacttaat	600
gtccttgaca	acaaaaagag	gacagctctg	ataaaggccg	tacaatgcca	ggaagatgaa	660
tgtgcgttaa	tgttgctgga	acatggcact	gatccaaata	ttccagatga	gtatggaaat	720
accactctgc	actacgctat	ctataatgaa	gataaattaa	tggccaaaagc	actgctctta	780
tatggtgctg	atatcgaatc	aaaaaacaag	catggcctca	caccactgtt	acttgggtga	840
catgagcaaa	aacagcaagt	cgtgaaattt	ttaatcaaga	aaaaagcgaa	tttaaatgca	900
ctggatagat	atggaaggac	tgctctcata	cttgctgtat	gttggtggatc	agcaagtata	960
gtcagccttc	tacttgagca	aaatattgat	gtatcttctc	aagatctatc	tggacagacg	1020
gccagagagt	atgctgtttc	tagtcatcat	catgtaattt	gccagttact	ttctgactac	1080
aaagaaaaac	agatgctaaa	aatctcttct	gaaaacagca	atccagaaca	agacttaaaag	1140
ctgacatcag	aggaagagtc	acaaagggtc	aaaggcagtg	aaaatagcca	gccagagaaa	1200
atgtctcaag	aaccagaaat	aaataaggat	ggtgatagag	aggttgaaga	agaaatgaag	1260
aagcatgaaa	gtaataatgt	gggattacta	gaaaacctga	ctaattggtg	cactgctggc	1320
aatggtgata	atggattaat	tcctcaaagg	aagagcagaa	cacctgaaaa	tcagcaattt	1380
cctgacaacg	aaagtgaaga	gtatcacaga	atttgcgaat	tagtttctga	ctacaaagaa	1440
aaacagatgc	caaaatactc	ttctgaaaac	agcaaccacg	aacaagactt	aaagctgaca	1500
tcagaggaag	agtcacaaag	gcttgagggc	agtgaaaatg	gccagccaga	gaaaagatct	1560
caagaaccag	aaataaataa	ggatggtgat	agagagctag	aaaattttat	ggctatcgaa	1620
gaaatgaaga	agcacggaag	tactcatgtc	ggattcccag	aaaacctgac	taatggtgcc	1680
actgctggca	atggtgatga	tggattaatt	cctccaagga	agagcagaac	acctgaaagc	1740
cagcaatttc	ctgacactga	gaatgaagag	tatcacagtg	acgaacaaaa	tgatactcag	1800
aagcaatttt	gtgaagaaca	gaacactgga	atattacacg	atgagattct	gattcatgaa	1860
gaaaagcaga	tagaagtggg	tgaaaaaatg	aattctgagc	tttctcttag	ttgtaagaaa	1920
gaaaaagaca	tcttgcatga	aaatagtacg	ttgcgggaag	aaattgccat	gctaagactg	1980
gagctagaca	caatgaaaca	tcagagccag	ctaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2040

&lt;210&gt; 376

&lt;211&gt; 329

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 376

Met Asp Ile Val Val Ser Gly Ser His Pro Leu Trp Val Asp Ser Phe

1		5		10		15									
Leu	His	Leu	Ala	Gly	Ser	Asp	Leu	Leu	Ser	Arg	Ser	Leu	Met	Ala	Glu
		20					25					30			
Glu	Tyr	Thr	Ile	Val	His	Ala	Ser	Phe	Ile	Ser	Cys	Ile	Ser	Ser	Ser
		35					40					45			
Leu	Asp	Gly	Gln	Gly	Glu	Arg	Gln	Glu	Gln	Arg	Gly	His	Phe	Trp	Arg
	50					55					60				
Pro	Gln	Arg	Leu	Leu	Cys	Glu	Asp	Ala	Trp	Glu	Gln	Glu	Val	Gln	Val
65					70					75					80
Val	Leu	Pro	Leu	Leu	Pro	Leu	Leu	Gln	Gly	Ser	Gly	Lys	Ser	Asn	Val
			85					90						95	
Val	Ala	Trp	Gly	Asp	Tyr	Asp	Asp	Ser	Ala	Phe	Met	Asp	Pro	Arg	Tyr
			100					105					110		
His	Val	His	Gly	Glu	Asp	Leu	Asp	Lys	Leu	His	Arg	Ala	Ala	Trp	Trp
		115					120					125			
Gly	Lys	Val	Pro	Arg	Lys	Asp	Leu	Ile	Val	Met	Leu	Arg	Asp	Thr	Asp
	130					135					140				
Val	Asn	Lys	Arg	Asp	Lys	Gln	Lys	Arg	Thr	Ala	Leu	His	Leu	Ala	Ser
145					150					155					160
Ala	Asn	Gly	Asn	Ser	Glu	Val	Val	Lys	Leu	Val	Leu	Asp	Arg	Arg	Cys
			165					170					175		
Gln	Leu	Asn	Val	Leu	Asp	Asn	Lys	Lys	Arg	Thr	Ala	Leu	Thr	Lys	Ala
			180					185					190		
Val	Gln	Cys	Gln	Glu	Asp	Glu	Cys	Ala	Leu	Met	Leu	Leu	Glu	His	Gly
		195					200					205			
Thr	Asp	Pro	Asn	Ile	Pro	Asp	Glu	Tyr	Gly	Asn	Thr	Thr	Leu	His	Tyr
	210					215					220				
Ala	Val	Tyr	Asn	Glu	Asp	Lys	Leu	Met	Ala	Lys	Ala	Leu	Leu	Leu	Tyr
225					230					235					240
Gly	Ala	Asp	Ile	Glu	Ser	Lys	Asn	Lys	His	Gly	Leu	Thr	Pro	Leu	Leu
			245						250				255		
Leu	Gly	Ile	His	Glu	Gln	Lys	Gln	Gln	Val	Val	Lys	Phe	Leu	Ile	Lys
		260					265					270			
Lys	Lys	Ala	Asn	Leu	Asn	Ala	Leu	Asp	Arg	Tyr	Gly	Arg	Thr	Ala	Leu
		275					280					285			
Ile	Leu	Ala	Val	Cys	Cys	Gly	Ser	Ala	Ser	Ile	Val	Ser	Pro	Leu	Leu
	290					295					300				
Glu	Gln	Asn	Val	Asp	Val	Ser	Ser	Gln	Asp	Leu	Glu	Arg	Arg	Pro	Glu
305				310						315					320
Ser	Met	Leu	Phe	Leu	Val	Ile	Ile	Met							
				325											

&lt;210&gt; 377

&lt;211&gt; 148

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(148)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 377

Met	Thr	Xaa	Pro	Ser	Trp	Ser	Pro	Gly	Thr	Thr	Ser	Val	Glu	Lys	Ile
1			5					10				15			
Trp	Thr	Ser	Ser	Thr	Glu	Leu	Pro	Trp	Trp	Gly	Lys	Val	Pro	Arg	Lys
		20					25				30				
Asp	Leu	Ile	Val	Met	Leu	Arg	Asp	Thr	Asp	Val	Asn	Lys	Xaa	Asp	Lys

125

35 40 45  
 Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu  
 50 55 60  
 Val Val Lys Leu Xaa Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp  
 65 70 75 80  
 Asn Lys Lys Arg Thr Ala Leu Xaa Lys Ala Val Gln Cys Gln Glu Asp  
 85 90 95  
 Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro  
 100 105 110  
 Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Xaa Tyr Asn Glu Asp  
 115 120 125  
 Lys Leu Met Ala Lys Ala Leu Leu Tyr Gly Ala Asp Ile Glu Ser  
 130 135 140  
 Lys Asn Lys Val  
 145

<210> 378  
 <211> 1719  
 <212> PRT  
 <213> Homo sapien

<400> 378  
 Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys  
 1 5 10 15  
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe  
 20 25 30  
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp  
 35 40 45  
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp  
 50 55 60  
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val  
 65 70 75 80  
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn  
 85 90 95  
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser  
 100 105 110  
 Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe  
 115 120 125  
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His  
 130 135 140  
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met  
 145 150 155 160  
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala  
 165 170 175  
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu  
 180 185 190  
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr  
 195 200 205  
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met  
 210 215 220  
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn  
 225 230 235 240  
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys  
 245 250 255  
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly  
 260 265 270  
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val  
 275 280 285

Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr  
 290 295 300  
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile  
 305 310 315 320  
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu  
 325 330 335  
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His Val  
 340 345 350  
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile  
 355 360 365  
 Ser Ser Glu Asn Ser Asn Pro Glu Asn Val Ser Arg Thr Arg Asn Lys  
 370 375 380  
 Pro Arg Thr His Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser  
 385 390 395 400  
 Ser Val Lys Lys Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys  
 405 410 415  
 Cys Arg Cys Phe Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly  
 420 425 430  
 Thr Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys  
 435 440 445  
 Met Gly Lys Trp Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly  
 450 455 460  
 Lys Ser Asn Val Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys  
 465 470 475 480  
 Thr Leu Arg Asn Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys  
 485 490 495  
 Cys Arg Gly Ser Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp  
 500 505 510  
 Asp Ser Ala Phe Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu  
 515 520 525  
 Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp  
 530 535 540  
 Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln  
 545 550 555 560  
 Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val  
 565 570 575  
 Val Lys Leu Leu Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn  
 580 585 590  
 Lys Lys Arg Thr Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu  
 595 600 605  
 Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp  
 610 615 620  
 Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys  
 625 630 635 640  
 Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys  
 645 650 655  
 Asn Lys His Gly Leu Thr Pro Leu Leu Gly Val His Glu Gln Lys  
 660 665 670  
 Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala  
 675 680 685  
 Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly  
 690 695 700  
 Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser  
 705 710 715 720  
 Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser  
 725 730 735  
 His His His Val Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln  
 740 745 750

—Met Leu Lys Ile Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys  
 755 760 765  
 Leu Thr Ser Glu Glu Glu Ser Gln Arg Phe Lys Gly Ser Glu Asn Ser  
 770 775 780  
 Gln Pro Glu Lys Met Ser Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp  
 785 790 795 800  
 Arg Glu Val Glu Glu Glu Met Lys Lys His Glu Ser Asn Asn Val Gly  
 805 810 815  
 Leu Leu Glu Asn Leu Thr Asn Gly Val Thr Ala Gly Asn Gly Asp Asn  
 820 825 830  
 Gly Leu Ile Pro Gln Arg Lys Ser Arg Thr Pro Glu Asn Gln Gln Phe  
 835 840 845  
 Pro Asp Asn Glu Ser Glu Glu Tyr His Arg Ile Cys Glu Leu Val Ser  
 850 855 860  
 Asp Tyr Lys Glu Lys Gln Met Pro Lys Tyr Ser Ser Glu Asn Ser Asn  
 865 870 875 880  
 Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Leu  
 885 890 895  
 Glu Gly Ser Glu Asn Gly Gln Pro Glu Leu Glu Asn Phe Met Ala Ile  
 900 905 910  
 Glu Glu Met Lys Lys His Gly Ser Thr His Val Gly Phe Pro Glu Asn  
 915 920 925  
 Leu Thr Asn Gly Ala Thr Ala Gly Asn Gly Asp Asp Gly Leu Ile Pro  
 930 935 940  
 Pro Arg Lys Ser Arg Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu  
 945 950 955 960  
 Asn Glu Glu Tyr His Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe  
 965 970 975  
 Cys Glu Glu Gln Asn Thr Gly Ile Leu His Asp Glu Ile Leu Ile His  
 980 985 990  
 Glu Glu Lys Gln Ile Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser  
 995 1000 1005  
 Leu Ser Cys Lys Lys Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu  
 1010 1015 1020  
 Arg Glu Glu Ile Ala Met Leu Arg Leu Glu Leu Asp Thr Met Lys His  
 1025 1030 1035 1040  
 Gln Ser Gln Leu Pro Arg Thr His Met Val Val Glu Val Asp Ser Met  
 1045 1050 1055  
 Pro Ala Ala Ser Ser Val Lys Lys Pro Phe Gly Leu Arg Ser Lys Met  
 1060 1065 1070  
 Gly Lys Trp Cys Cys Arg Cys Phe Pro Cys Cys Arg Glu Ser Gly Lys  
 1075 1080 1085  
 Ser Asn Val Gly Thr Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr  
 1090 1095 1100  
 Leu Arg Ser Lys Met Gly Lys Trp Cys Arg His Cys Phe Pro Cys Cys  
 1105 1110 1115 1120  
 Arg Gly Ser Gly Lys Ser Asn Val Gly Ala Ser Gly Asp His Asp Asp  
 1125 1130 1135  
 Ser Ala Met Lys Thr Leu Arg Asn Lys Met Gly Lys Trp Cys Cys His  
 1140 1145 1150  
 Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Lys Val Gly Ala Trp  
 1155 1160 1165  
 Gly Asp Tyr Asp Asp Ser Ala Phe Met Glu Pro Arg Tyr His Val Arg  
 1170 1175 1180  
 Gly Glu Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val  
 1185 1190 1195 1200  
 Pro Arg Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys  
 1205 1210 1215

Lys Asp Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly  
 1220 1225 1230  
 Asn Ser Glu Val Val Lys Leu Leu Leu Asp Arg Arg Cys Gln Leu Asn  
 1235 1240 1245  
 Val Leu Asp Asn Lys Lys Arg Thr Ala Leu Ile Lys Ala Val Gln Cys  
 1250 1255 1260  
 Gln Glu Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro  
 1265 1270 1275 1280  
 Asn Ile Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Ile Tyr  
 1285 1290 1295  
 Asn Glu Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp  
 1300 1305 1310  
 Ile Glu Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Val  
 1315 1320 1325  
 His Glu Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala  
 1330 1335 1340  
 Asn Leu Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala  
 1345 1350 1355 1360  
 Val Cys Cys Gly Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln Asn  
 1365 1370 1375  
 Ile Asp Val Ser Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu Tyr  
 1380 1385 1390  
 Ala Val Ser Ser His His His Val Ile Cys Gln Leu Leu Ser Asp Tyr  
 1395 1400 1405  
 Lys Glu Lys Gln Met Leu Lys Ile Ser Ser Glu Asn Ser Asn Pro Glu  
 1410 1415 1420  
 Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Phe Lys Gly  
 1425 1430 1435 1440  
 Ser Glu Asn Ser Gln Pro Glu Lys Met Ser Gln Glu Pro Glu Ile Asn  
 1445 1450 1455  
 Lys Asp Gly Asp Arg Glu Val Glu Glu Glu Met Lys Lys His Glu Ser  
 1460 1465 1470  
 Asn Asn Val Gly Leu Leu Glu Asn Leu Thr Asn Gly Val Thr Ala Gly  
 1475 1480 1485  
 Asn Gly Asp Asn Gly Leu Ile Pro Gln Arg Lys Ser Arg Thr Pro Glu  
 1490 1495 1500  
 Asn Gln Gln Phe Pro Asp Asn Glu Ser Glu Glu Tyr His Arg Ile Cys  
 1505 1510 1515 1520  
 Glu Leu Val Ser Asp Tyr Lys Glu Lys Gln Met Pro Lys Tyr Ser Ser  
 1525 1530 1535  
 Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu  
 1540 1545 1550  
 Ser Gln Arg Leu Glu Gly Ser Glu Asn Gly Gln Pro Glu Lys Arg Ser  
 1555 1560 1565  
 Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Leu Glu Asn Phe  
 1570 1575 1580  
 Met Ala Ile Glu Glu Met Lys Lys His Gly Ser Thr His Val Gly Phe  
 1585 1590 1595 1600  
 Pro Glu Asn Leu Thr Asn Gly Ala Thr Ala Gly Asn Gly Asp Asp Gly  
 1605 1610 1615  
 Leu Ile Pro Pro Arg Lys Ser Arg Thr Pro Glu Ser Gln Gln Phe Pro  
 1620 1625 1630  
 Asp Thr Glu Asn Glu Glu Tyr His Ser Asp Glu Gln Asn Asp Thr Gln  
 1635 1640 1645  
 Lys Gln Phe Cys Glu Glu Gln Asn Thr Gly Ile Leu His Asp Glu Ile  
 1650 1655 1660  
 Leu Ile His Glu Glu Lys Gln Ile Glu Val Val Glu Lys Met Asn Ser  
 1665 1670 1675 1680

Glu Leu Ser Leu Ser Cys Lys Lys Glu Lys Asp Ile Leu His Glu Asn  
 1685 1690 1695  
 Ser Thr Leu Arg Glu Glu Ile Ala Met Leu Arg Leu Glu Leu Asp Thr  
 1700 1705 1710  
 Met Lys His Gln Ser Gln Leu  
 1715

<210> 379  
 <211> 656  
 <212> PRT  
 <213> Homo sapien

<400> 379  
 Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys  
 1 5 10 15  
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe  
 20 25 30  
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp  
 35 40 45  
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp  
 50 55 60  
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val  
 65 70 75 80  
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn  
 85 90 95  
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser  
 100 105 110  
 Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe  
 115 120 125  
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His  
 130 135 140  
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met  
 145 150 155 160  
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala  
 165 170 175  
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu  
 180 185 190  
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr  
 195 200 205  
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met  
 210 215 220  
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn  
 225 230 235 240  
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys  
 245 250 255  
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly  
 260 265 270  
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val  
 275 280 285  
 Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr  
 290 295 300  
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile  
 305 310 315 320  
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu  
 325 330 335  
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His His Val  
 340 345 350  
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile



355                      360                      365  
 Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu  
 370                      375                      380  
 Glu Glu Ser Gln Arg Phe Lys Gly Ser Glu Asn Ser Gln Pro Glu Lys  
 385                      390                      395                      400  
 Met Ser Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Val Glu  
 405                      410                      415  
 Glu Glu Met Lys Lys His Glu Ser Asn Asn Val Gly Leu Leu Glu Asn  
 420                      425                      430  
 Leu Thr Asn Gly Val Thr Ala Gly Asn Gly Asp Asn Gly Leu Ile Pro  
 435                      440                      445  
 Gln Arg Lys Ser Arg Thr Pro Glu Asn Gln Gln Phe Pro Asp Asn Glu  
 450                      455                      460  
 Ser Glu Glu Tyr His Arg Ile Cys Glu Leu Val Ser Asp Tyr Lys Glu  
 465                      470                      475                      480  
 Lys Gln Met Pro Lys Tyr Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp  
 485                      490                      495  
 Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Leu Glu Gly Ser Glu  
 500                      505                      510  
 Asn Gly Gln Pro Glu Leu Glu Asn Phe Met Ala Ile Glu Glu Met Lys  
 515                      520                      525  
 Lys His Gly Ser Thr His Val Gly Phe Pro Glu Asn Leu Thr Asn Gly  
 530                      535                      540  
 Ala Thr Ala Gly Asn Gly Asp Asp Gly Leu Ile Pro Pro Arg Lys Ser  
 545                      550                      555                      560  
 Arg Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu Asn Glu Glu Tyr  
 565                      570                      575  
 His Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe Cys Glu Glu Gln  
 580                      585                      590  
 Asn Thr Gly Ile Leu His Asp Glu Ile Leu Ile His Glu Glu Lys Gln  
 595                      600                      605  
 Ile Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser Leu Ser Cys Lys  
 610                      615                      620  
 Lys Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu Arg Glu Glu Ile  
 625                      630                      635                      640  
 Ala Met Leu Arg Leu Glu Leu Asp Thr Met Lys His Gln Ser Gln Leu  
 645                      650                      655

&lt;210&gt; 380

&lt;211&gt; 671

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 380

Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys  
 1                      5                      10                      15  
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe  
 20                      25                      30  
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp  
 35                      40                      45  
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp  
 50                      55                      60  
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val  
 65                      70                      75                      80  
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn  
 85                      90                      95  
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser  
 100                      105                      110

Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe  
 115 120 125  
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His  
 130 135 140  
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met  
 145 150 155 160  
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala  
 165 170 175  
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu  
 180 185 190  
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr  
 195 200 205  
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met  
 210 215 220  
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn  
 225 230 235 240  
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys  
 245 250 255  
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly  
 260 265 270  
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val  
 275 280 285  
 Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr  
 290 295 300  
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile  
 305 310 315 320  
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu  
 325 330 335  
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His Val  
 340 345 350  
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile  
 355 360 365  
 Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu  
 370 375 380  
 Glu Glu Ser Gln Arg Phe Lys Gly Ser Glu Asn Ser Gln Pro Glu Lys  
 385 390 395 400  
 Met Ser Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Val Glu  
 405 410 415  
 Glu Glu Met Lys Lys His Glu Ser Asn Asn Val Gly Leu Leu Glu Asn  
 420 425 430  
 Leu Thr Asn Gly Val Thr Ala Gly Asn Gly Asp Asn Gly Leu Ile Pro  
 435 440 445  
 Gln Arg Lys Ser Arg Thr Pro Glu Asn Gln Gln Phe Pro Asp Asn Glu  
 450 455 460  
 Ser Glu Glu Tyr His Arg Ile Cys Glu Leu Val Ser Asp Tyr Lys Glu  
 465 470 475 480  
 Lys Gln Met Pro Lys Tyr Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp  
 485 490 495  
 Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Leu Glu Gly Ser Glu  
 500 505 510  
 Asn Gly Gln Pro Glu Lys Arg Ser Gln Glu Pro Glu Ile Asn Lys Asp  
 515 520 525  
 Gly Asp Arg Glu Leu Glu Asn Phe Met Ala Ile Glu Glu Met Lys Lys  
 530 535 540  
 His Gly Ser Thr His Val Gly Phe Pro Glu Asn Leu Thr Asn Gly Ala  
 545 550 555 560  
 Thr Ala Gly Asn Gly Asp Asp Gly Leu Ile Pro Pro Arg Lys Ser Arg  
 565 570 575

Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu Asn Glu Glu Tyr His  
 580 585 590  
 Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe Cys Glu Glu Gln Asn  
 595 600 605  
 Thr Gly Ile Leu His Asp Glu Ile Leu Ile His Glu Glu Lys Gln Ile  
 610 615 620  
 Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser Leu Ser Cys Lys Lys  
 625 630 635 640  
 Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu Arg Glu Glu Ile Ala  
 645 650 655  
 Met Leu Arg Leu Glu Leu Asp Thr Met Lys His Gln Ser Gln Leu  
 660 665 670

<210> 381  
 <211> 251  
 <212> DNA  
 <213> Homo sapien

<400> 381

ggagaagcgt ctgctggggc aggaaggggt ttccctgcc tctcacctgt ccctcaccaa 60  
 ggtaacatgc ttcccctaag ggtatcccaa ccagggggc tcaccatgac ctctgagggg 120  
 ccaatatccc aggagaagca ttggggaggt gggggcaggt gaaggacca ggactcacac 180  
 atcctgggccc tccaaggcag aggagaggggt cctcaagaag gtcaggagga aaatccgtaa 240  
 caagcagtca g 251

<210> 382  
 <211> 3279  
 <212> DNA  
 <213> Homo sapiens

<400> 382

ctctctgacg cccccatgct ggtgaggggc acgggcagga acagtggacc caacatggaa 60  
 atgctggagg gtgtcaggaa gtgatcgggc tctggggcag ggaggagggg tggggagtggt 120  
 cactgggagg ggacatcctg cagaaggtag gactgagcaa acaccgctg caggggaggg 180  
 gagagccctg cggcacctgg gggagcagag ggagcagcac ctgcccaggc ctgggaggag 240  
 gggcctggag ggcgtgagga ggagcgaggg ggctgcatgg ctggagttag ggatcagggg 300  
 cagggcgcca gatggcctca cacaggggaag agagggcccc tctgcaggg cctcacctgg 360  
 gccacaggag gacactgctt ttctctgag gactcaggag ctgtggatgg tgctggacag 420  
 aagaaggaca gggcctggct caggtgtcca gaggctgtcg ctggcttccc ttggggatca 480  
 gactgcaggg agggagggcg gcagggttgt ggggggagtg acgatgagga tgacctgggg 540  
 gtggctccag gccttgcccc tgcttgggcc ctacccagc ctccctcaca gtctctggc 600  
 cctcagtctc tcccctccac tccatcctcc atctggcctc agtgggtcat tctgatcact 660  
 gaactgacca taccagccc tgcccacggc cctccatggc tcccaatgc cctggagagg 720  
 ggacatctag tcagagagta gtctgaaga ggtggcctct gcgatgtgcc tgtgggggca 780  
 gcacctgca gatgggtccc gccctcatcc tgctgacctg tctgcaggga ctgtcctcct 840  
 ggaccttgcc ccttgtgtag gagctggacc ctgaagtccc ctccccatag gccaaagactg 900  
 gaggcttggt cctctgttg gactccctgc ccatattctt gtgggagtggt gttctggaga 960  
 catttctgtc tgttctgag agctgggaat tgctctcagt catctgcctg cgcggttctg 1020  
 agagatggag ttgcctagga agttattggg gccaatcttt ctactgtgt ctctcctcct 1080  
 ttacccttag ggtgattctg ggggtccact tgtctgtaat ggtgtgcttc aaggtatcac 1140  
 atcatggggc cctgagccat gtgccctgcc tgaaggcct gctgtgtaca ccaaggtggt 1200  
 gcattaccgg aagtggatca aggacaccat cgcagccaac ccctgagtgc cctgtccca 1260  
 cccctacctc tagtaaatat aagtccacct cacgttctgg catcacttgg ctttctgga 1320  
 tgctggacac ctgaagcttg gaactcacct ggccgaagct cgagcctcct gactcctact 1380  
 gacctgtgct ttctggtgtg gactccaggg ctgctaggaa aaggaatggg cagacacagg 1440  
 tgtatgcaa tgtttctgaa atgggtataa ttctgtctc tccttcggaa cactggctgt 1500  
 ctctgaagac ttctcgtcca gtttcagtga ggacacac aaagacgtgg gtgacctgt 1560  
 tgtttgtggg gtgcagagat gggaggggtg gggccaccc tggaagagtg gacagtga 1620

```

caaggtggac actctctaca gatcactgag gataagctgg agccacaatg catgaggcac 1680
acacacagca aggttgacgc tgtaaacata gcccacgctg tcctgggggc actgggaagc 1740
ctagataagg ccgtgagcag aaagaagggg aggatcctcc tatgttggtg aaggagggac 1800
tagggggaga aactgaaagc tgattaatta caggaggttt gttcagggtcc cccaaaccac 1860
cgtcagattt gatgatttcc tagcaggact tacagaaata aagagctatc atgctgtggt 1920
ttattatggt ttgttacatt gataggatac atactgaaat cagcaaacaa aacagatgta 1980
tagattagag tgtggagaaa acagaggaaa acttgcagtt acgaagactg gcaacttggc 2040
tttactaagt tttcagactg gcaggaagtc aaacctatta ggctgaggac cttgtggagt 2100
gtagctgata cagctgatag aggaactagc caggtggggg cctttccctt tggatggggg 2160
gcatatccga cagttattct ctccaagtgg agacttacgg acagcatata attctccctg 2220
caaggatgta tgataatatg tacaaagtaa ttccaactga ggaagctcac ctgatcctta 2280
gtgtccaggg tttttactgg ggtgtctgag gacgagtatg gactacttga ataattgacc 2340
tgaagtcctc agacctgagg ttccctagag ttcaaacaga tacagcatgg tccagagtc 2400
cagatgtaca aaaacaggga ttcatcacia atcccatctt tagcatgaag ggtctggcat 2460
ggcccaaggc cccaagtata tcaaggcact tgggcagaa atgccaagga atcaaagtgc 2520
atctcccagg agttattcaa ggtgagccc tttacttggg atgtacaggc tttgagcagt 2580
gcagggtctg tgagtcaacc ttttattgta caggggatga gggaaagga gaggatgagg 2640
aagccccctt ggggatttgg tttggtcttg tgatcaggtg gtctatgggg ctatccctac 2700
aaagaagaat ccagaaatag gggcacattg aggaatgata ctgagcccaa agagcattca 2760
atcattgttt tatttgccct cttttcacac cattggtgag ggagggatta ccaccctggg 2820
gttatgaaga tggttgaaca cccacacat agcaccggag atatgagatc aacagtttct 2880
tagccataga gattcacagc ccagagcagg aggacgtgc acaccatgca ggtgacatg 2940
gggatgcgc tcgggattgg tgtgaagaag caaggactgt tagaggcagg ctttatagta 3000
acaagacggt ggggcaaact ctgatttccg tgggggaatg tcatggtctt gctttactaa 3060
gttttgagac tggcaggtag tgaaactcat taggctgaga acctgtgga atgcagctga 3120
cccagctgat agaggaagta gccaggtggg agcctttccc agtgggtgtg ggacatatct 3180
ggcaagattt tgtggcactc ctggttacag atactggggc agcaaataaa actgaatctt 3240
gttttcagac cttaaaaaaa aaaaaaaaaa aaaagtttt 3279

```

&lt;210&gt; 383

&lt;211&gt; 154

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 383

```

Met Ala Gly Val Arg Asp Gln Gly Gln Gly Ala Arg Trp Pro His Thr
          5                      10                      15

```

```

Gly Lys Arg Gly Pro Leu Leu Gln Gly Leu Thr Trp Ala Thr Gly Gly
          20                      25                      30

```

```

His Cys Phe Ser Ser Glu Glu Ser Gly Ala Val Asp Gly Ala Gly Gln
          35                      40                      45

```

```

Lys Lys Asp Arg Ala Trp Leu Arg Cys Pro Glu Ala Val Ala Gly Phe
          50                      55                      60

```

```

Pro Leu Gly Ser Asp Cys Arg Glu Gly Gly Arg Gln Gly Cys Gly Gly
          65                      70                      75                      80

```

```

Ser Asp Asp Glu Asp Asp Leu Gly Val Ala Pro Gly Leu Ala Pro Ala
          85                      90                      95

```

```

Trp Ala Leu Thr Gln Pro Pro Ser Gln Ser Pro Gly Pro Gln Ser Leu
          100                      105                      110

```

```

Pro Ser Thr Pro Ser Ser Ile Trp Pro Gln Trp Val Ile Leu Ile Thr
          115                      120                      125

```

Glu Leu Thr Ile Pro Ser Pro Ala His Gly Pro Pro Trp Leu Pro Asn  
 130 135 140

Ala Leu Glu Arg Gly His Leu Val Arg Glu  
 145 150

<210> 384  
 <211> 557  
 <212> DNA  
 <213> Homo sapiens

<400> 384  
 ggatcctcta gagcgccgc ctactactac taaattcgcg gccgcgtcga cgaagaagag 60  
 aaagatgtgt tttgttttg actctctgtg gtcccttcca atgctgtggg tttccaacca 120  
 ggggaagggt cccttttgca ttgccaagtg ccataaccat gagcactact ctaccatggg 180  
 tctgcctcct ggccaagcag gctggtttgc aagaatgaaa tgaatgattc tacagctagg 240  
 acttaacctt gaaatggaaa gtottgcaat cccatttgca ggatcogtct gtgcacatgc 300  
 ctctgtagag agcagcattc ccagggacct tggaaacagt tggcactgta aggtgcttgc 360  
 tccccaaagac acatcctaaa aggtgttgta atgggtgaaa cgtcttccct ttttattgcc 420  
 ccttcttatt tatgtgaaca actgtttgtc tttttttgta tcttttttaa actgtaaaagt 480  
 tcaattgtga aaatgaatat catgcaata aattatgcga ttttttttcc aaagtaaaaa 540  
 aaaaaaaaa aaaaaaa 557

<210> 385  
 <211> 337  
 <212> DNA  
 <213> Homo sapiens

<400> 385  
 ttcccagggt atgtgcgagg gaagacacat ttactatcct tgatggggct gattccttta 60  
 gtttctctag cagcagatgg gttaggagga agtgacccaa gtggttgact cctatgtgca 120  
 tctcaaagcc atctgctgtc ttcgagtacg gacacatcat cactcctgca ttgttgatca 180  
 aaacgtggag gtgcttttcc tcagctaaga agcccttagc aaaagctcga atagacttag 240  
 tatcagacag gtccagtttc cgcaccaaca cctgctggtt ccctgtcgtg gtctggatct 300  
 ctttggccac caattcccc ttttccacat cccggca 337

<210> 386  
 <211> 300  
 <212> DNA  
 <213> Homo sapiens

<400> 386  
 gggcccgtcta ccggcccagg ccccgccctcg cgagtccctc tccccgggtg cctgcccgcga 60  
 gcccgctcgg ccagaggggt gggcgcgggg ctgcctctac cggctggcgg ctgtaactca 120  
 gcgaccttgg ccgaaggct ctagcaagga ccaccgcacc ccagccgcgg cggcgggcggc 180  
 gcggactttg cccggtgtgt ggggcggagc ggactgcgtg tccgcggacg ggcagcgaag 240  
 atgttagcct tcgctgccag gaccgtggac cgatcccagg gctgtggtgt aacctcagcc 300

<210> 387  
 <211> 537  
 <212> DNA  
 <213> Homo sapiens

<400> 387  
 gggccgagtc gggcaccaag ggactctttg caggcttccct tcctcggatc atcaaggctg 60  
 cccctcctg tgccatcatg atcagcacct atgagttcgg caaaagcttc ttccagaggc 120

```

tgaaccagga cgggttctg ggcggctgaa aggggcaagg aggcaaggac cccgtctctc 180
ccacggatgg ggagagggca ggaggagacc cagccaagtg ctttttctc agcactgagg 240
gagggggctt gtttcccttc cctcccggcg acaagctcca gggcagggt gtccctctgg 300
gcggcccagc acttctcag acacaacttc ttcttgctgc tccagtcgtg gggatcatca 360
cttaccacc cccaagttc aagaccaaat cttccagctg ccccttctgt gtttccctgt 420
gtttgctgta gctgggcatg tctccaggaa ccaagaagcc ctcagcctgg tgtagtctcc 480
ctgacccttg ttaattcctt aagtctaaag atgatgaact tcaaaaaaaa aaaaaaa 537

```

&lt;210&gt; 388

&lt;211&gt; 520

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 388

```

aggataattt ttaaaccaat caaatgaaaa aaacaaacaa acaaaaaagg aaatgtcatg 60
tgaggttaaa ccagtttgca ttcccctaata gtggaaaaag taaggaggact actcagcact 120
gtttgaagat tgcctcttct acagcttctg agaattgtgt tatttcaactt gccaaagtga 180
ggaccccttc cccaacatgc cccagcccac ccctaagcat ggtcccttgt caccaggcaa 240
ccaggaaact gctacttgtg gacctcacca gagaccagga gggtttggtt agctcacagg 300
acttccccca cccagaaga ttagcatccc atactagact cataactcaac tcaactaggc 360
tcataactcaa ttgatgggta ttagacaatt ccatttcttt ctgggtatta taaacagaaa 420
atctttcttc ttctcattac cagtaaaggc tcttggtatc tttctgttg aatgatttct 480
atgaacttgt cttattttta tgggtgggtt ttttctggt 520

```

&lt;210&gt; 389

&lt;211&gt; 365

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 389

```

cggtgcccc gtttgacaga aggaaaggcg gagcttattc aaagtctaga gggagtggag 60
gagttaaggc tggatttcag atctgcctgg ttccagccgc agtggtgccct ctgctcccc 120
aacgactttc caaataatct caccagcgcc ttccagctca ggcgtcctag aagcgtcttg 180
aagcctatgg ccagctgtct ttgtgttccc tctcaccgc ctgtcctcac agctgagact 240
cccaggaaac cttcagacta ctttctctg cttcagcaa ggggcgttg ccacattctc 300
tgagggtcag tggaagaacc tagactccca ttgctagagg tagaaagggg aagggtgctg 360
gggag 365

```

&lt;210&gt; 390

&lt;211&gt; 221

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(221)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 390

```

tgctctcca tctggcccc gacttctctg tcaggaaagt ggggatggac cccatctgca 60
tacacgntt ctcaggggtg tggaacatct ctgcttgagg ttccaggaag gcctctggct 120
gctctangag tctgancnga ntcgttgccc cantntgaca naaggaaagg cggagcttat 180
tcaaagtcta gaggagtgagg aggagttaag gctggatttc a 221

```

&lt;210&gt; 391

&lt;211&gt; 325

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(325)  
 <223> n = A,T,C or G

<400> 391  
 tggagcaggt cccgaggcct ccctagagcc tggggccgac tctgtgnega tgcangcttt 60  
 ctctcgcgcc cagcctggag ctgctcctgg catctaccaa caatcagncg aggcgagcag 120  
 tagccagggc actgctgcca acagccagtc cnaataccat catgtnaccc ggtgngctct 180  
 naanttn gat ntccanagcc ctacccatcn tagttctgct ctcccacgg ntaccagccc 240  
 cactgcccag gaatcctaca gccagtaccc tgtcccgacg tctctaccta ccagtacgat 300  
 gagacctccg gctactacta tgacc 325

<210> 392  
 <211> 277  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(277)  
 <223> n = A,T,C or G

<400> 392  
 atattgttta actccttcct ttatatcttt taacattttc atggngaaag gttcacatct 60  
 agtctcactt nggcnaagnn ctctacttg agtctcttcc ccggcctggn ccagtnagna 120  
 antaccanga accgncatgn cttanaaen ncctggtttn tgggttnntc aatgactgca 180  
 tgcagtgcac caccctgtcc actacgtgat gctgtaggat taaagtctca cagtggcgcc 240  
 ctgaggatac agcgccgcgt cctgtgttgc tggggaa 277

<210> 393  
 <211> 566  
 <212> DNA  
 <213> Homo sapiens

<400> 393  
 actagtccag tgtggtggaa ttgcgggccg cgtcgacgga caggtcagct gtctggctca 60  
 gtgatctaca ttctgaagtt gtctgaaaat gtcttcatga ttaaattcag cctaaacgtt 120  
 ttgcccggaa cactgcagag acaatgctgt gagtttccaa ccttagccca tctgcccga 180  
 gagaaggctc agtttgtcca tcagcattat catgatata ggactggta cttggttaag 240  
 gaggggtcta ggagatctgt cccttttaga gacaccttac ttataatgaa gtatttgga 300  
 ggggtggttt caaaagtaga aatgtcctgt attccgatga tcatcctgta aacattttat 360  
 catttattaa tcatccctgc ctgtgtctat tattatattc atatctctac gctggaaact 420  
 ttctgcctca atgtttactg tgcctttgtt tttgctagtt tgtgttgtg aaaaaaaaaa 480  
 cattctctgc ctgagtttta atttttgtcc aaagttattt taatctatac aattaaaagc 540  
 ttttgctat caaaaaaaaa aaaaaa 566

<210> 394  
 <211> 384  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(384)  
 <223> n = A,T,C or G

&lt;400&gt; 394

```

gaacatacat gtcccggcac ctgagctgca gtctgacatc atcgccatca cgggcctcgc 60
tgcaaattng gaccggggcca aggctggact gctggagcgt gtgaaggagc tacaggccna 120
gcaggaggac cgggcttttaa ggagttttaa gctgagtgtc actgtagacc ccaaatacca 180
tcccaagatt atcgggagaa agggggcagt aattacccaa atccggttgg agcatgacgt 240
gaacatccag tttcctgata aggacgatgg gaaccagccc caggaccaa ttaccattac 300
agggtacgaa aagaacacag aagctgccag ggatgctata ctgagaattg tgggtgaact 360
tgagcagatg gtttctgagg acgt 384

```

&lt;210&gt; 395

&lt;211&gt; 399

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 395

```

ggcaaaactg tgtgacctca ataagacctc gcagatccaa ggtcaagtat cagaagtgc 60
tctgaccttg gactccaaga cctacatcaa cagcctggct atattagatg atgagccagt 120
tatcagaggt ttcattcattg cggaaattgt ggagtctaag gaaatcatgg cctctgaagt 180
attcacgtct ttccagtacc ctgagttctc tatagagttg cctaacacag gcagaattgg 240
ccagctactt gtctgcaatt gtatcttcaa gaataccctg gccatccctt tgactgacgt 300
caagttctct ttggaaagcc tgggcatctc ctcactacag acctctgacc atgggacggt 360
gcagcctggt gagaccatcc aatcccaaat aaaatgcac 399

```

&lt;210&gt; 396

&lt;211&gt; 403

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(403)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 396

```

tggagttntc actgcaaaca agccataaag cttcagtagc aaattactgt ctcacagaaa 60
gacattttta acttctgtct cagctgctga taaaacaaat catgtgttta gcttgactcc 120
agacaaggac aacctgttcc ttcataactc tctagagaaa aaaaggagtt gttagtagat 180
actaaaaaaa gtggatgaat aatctggata tttttcctaa aaagattcct tgaaacacat 240
taggaaaatg gagggcctta tgatcagaat gctagaatta gtccattgtg ctgaagcagg 300
gttttagggga gggagtgagg gataaaagaa ggaaaaaaag aagagtgaga aaacctattt 360
atcaaagcag gtgctatcac tcaatgttag gccctgctct ttt 403

```

&lt;210&gt; 397

&lt;211&gt; 100

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(100)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 397

```

actagtncag tgtggtggaa ttcgcggccg cgtcgacctc naanccatct ctatagcaaa 60
tccatccccg ctccctgggtg gtnacagaat gactgacaaa 100

```

&lt;210&gt; 398

&lt;211&gt; 278



<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(278)  
<223> n = A,T,C or G

<400> 398  
gcgccgcgct cgacagcagt tccgccagcg ctcccccctg ggtggggatg tgctgcacgc 60  
ccacctggac atctggaagt cagcggcctg gatgaaagag cggacttcac ctggggcgat 120  
tcactactgt gcctcgacca gtgaggagag ctggaccgac agcgaggtgg actcatcatg 180  
ctccgggcag cccatccacc tgtggcagtt cctcaaggag ttgctactca agccccacag 240  
ctatggccgc ttcattangt ggctcaacaa ggagaagg 278

<210> 399  
<211> 298  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(298)  
<223> n = A,T,C or G

<400> 399  
acggaggtgg aggaagcgnc cctgggatcg anaggatggg tccatgncatt gaccncctcn 60  
ggggtgccng catggagcgc atgggcgcgg gcctgggcca cggcatggat cgcgtgggct 120  
ccgagatcga gcgcattggc ctggtcatgg accgcatggg ctccgtggag cgcattgggt 180  
ccggcattga gcgcattggc ccgctgggac tcgaccacat ggcctccanc attganccga 240  
tgggccagac catggagcgc attggctctg gcgtggagcn catgggtgcc ggcattggg 298

<210> 400  
<211> 548  
<212> DNA  
<213> Homo sapiens

<400> 400  
acatcaacta cttcctcatt ttaaggatat gcagttccct tcatcccctt ttctgcctt 60  
gtacatgtac atgtatgaaa tttccttctc ttaccgaact ctctccacac atcacaaggt 120  
caaagaacca cacgcttaga agggtaaag ggcaccctat gaaatgaaat ggtgatttct 180  
tgagtctctt ttttccacgt ttaaggggcc atggcaggac ttagagttgc gagttaagac 240  
tgagaggggc tagagaatta tttcatacag gctttgaggc caccatgtc acttatcccg 300  
tataccctct caccatcccc ttgtctactc tgatgcccc aagatgcaac tgggcagcta 360  
gttggcccca taattctggg cctttgttgt ttgttttaat tacttgggca tcccaggaag 420  
ctttccagtg atctcctacc atgggcccc ctccctggat caagcccctc ccaggccctg 480  
tccccagccc ctccctgcccc agcccacccg cttgccttgg tgctcagccc tccattggg 540  
agcaggtt 548

<210> 401  
<211> 355  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(355)  
<223> n = A,T,C or G

<400> 401  
actgtttcca tgttatgttt ctacacattg ctacctcagt gctcctggaa acttagcttt 60  
tgatgtctcc aagtagtcca ccttcattta actctttgaa actgtatcat ctttgccaag 120  
taagagtggg ggcctatttc agctgctttg acaaaatgac tggctcctga cttaacgttc 180  
tataaatgaa tgtgctgaag caaagtgcc atgggtggcg cgaagaagan aaagatgtgt 240  
tttgttttgg actctctgtg gtcccttcca atgctgnggg tttccaacca ggggaagggt 300  
cccttttgca ttgccaagtg ccataaccat gagcactact ctaccatggn tctgc 355

<210> 402

<211> 407

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(407)

<223> n = A,T,C or G

<400> 402

atggggcaag ctggataaag aaccaagacc cactggagta tgcgtgtcttc aagaaaccca 60  
tctcacatgc ggtggcatac ataggctcaa aataaaggaa tggagaaaaa tatttcaagc 120  
aaatggaaaa cagaaaaaag caggtgttgc actcctactt tctgacaaaa cagactatgc 180  
gaataaagat aaaaaagaga aggacattac aaagggtggc ctgacctttg ataatctca 240  
ttgcttgata ccaacctggg ctgttttaat tgcccaaacc aaaaggataa tttgctgagg 300  
ttgtggagct tctccctgc agagagtccc tgatctccca aaatttggtt gagatgtaag 360  
gntgattttg ctgacaactc cttttctgaa gttttactca tttccaa 407

<210> 403

<211> 303

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(303)

<223> n = A,T,C or G

<400> 403

cagtatttat agccnaactg aaaagctagt agcaggcaag tctcaaattcc aggcaccaa 60  
tcctaagcaa gagccatggc atggtgaaaa tgcaaaaggga gagtctggcc aatctacaaa 120  
tagagaacaa gacctactca gtcattgaaca aaaaggcaga caccaacatg gatctcatgg 180  
gggattggat attgtaatta tagagcagga agatgacagt gatcgtcatt tggcacaaca 240  
tcttaacaac gaccgaaacc cattatttac ataaacctcc attcggtaac catgttgaaa 300  
gga 303

<210> 404

<211> 225

<212> DNA

<213> Homo sapiens

<400> 404

aagtgttaact tttaaaaatt tagtggattt tgaaaaattct tagaggaaag taaaggaaaa 60  
attgttaatg cactcattta cctttacatg gtgaaagtgc tctcttgatc ctacaaacag 120  
acattttcca ctctgttttc catagtgtgt aagtgtatca gatgtgttgg gcatgtgaat 180  
ctccaagtgc ctgtgtaata aataaagtat ctttatttca ttcatt 225

<210> 405

<211> 334  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(334)  
<223> n = A,T,C or G

<400> 405  
gagctgttat actgtgagtt ctactaggaa atcatcaaat ctgagggttg tctggaggac 60  
ttcaatacac ctccccccat agtgaatcag cttccagggg gtccagtccc tctccttact 120  
tcatccccat cccatgccaa aggaagaccc tccctccttg gctcacagcc ttctctaggc 180  
ttcccagtgct ctccaggaca gagtgggtta tgttttcagc tccatccttg ctgtgagtg 240  
ctggtgcggt tgtgcctcct gcttctgctc agtgcttcat ggacagtgtc cagcccatgt 300  
cactctccac tctctcanig tggatcccac, ccct 334

<210> 406  
<211> 216  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(216)  
<223> n = A,T,C or G

<400> 406  
tttcataacct aatgagggag ttganatnac atnnaaccag gaaatgcatg gatctcaang 60  
gaaacaaaca cccaataaac tcggagtggc agactgacaa ctgtgagaca tgcacttgct 120  
acnaaacaca aatttnatgt tgcacccttg tttctacacc tgtgggttat gacaaagaca 180  
actgccaaag aatnttcaag aaggaggact gccant 216

<210> 407  
<211> 413  
<212> DNA  
<213> Homo sapiens

<400> 407  
gttgacttgc tagtatcatc tgcattcatt gaagcacaag aacttcatgc cttgactcat 60  
gtaaatgcaa taggattaaa aaataaattt gatatcacat ggaaacagac aaaaaatatt 120  
gtacaacatt gcaccagtg tcagattcta cacctggcca ctccaggaagc aagagttaat 180  
cccagaggtc tatgtcctaa tgtgttatgg caaatggatg tcatgcacgt accttcattt 240  
ggaaaattgt catttgtcca tgtgacagtt gatacttatt cacatttcat atgggcaacc 300  
tgccagacag gagaaagtct tcccatgtta aaagacattt attatcttgt tttcctgtca 360  
tgggagttcc agaaaaagtt aaaacagaca atgggccagg ttctgtagta aag 413

<210> 408  
<211> 183  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(183)  
<223> n = A,T,C or G

<400> 408

```

ggagctngcc ctcaattcct ccatntctat gttancatat ttaatgtctt ttggnattaa 60
tnccttaacta gttaatcctt aaagggctan ntaatcctta actagtcctt ccattgtgag 120
cattatcctt ccagtattcn ccttctnttt tatttactcc ttccctggcta cccatgtact 180
ntt 250

```

&lt;210&gt; 409

&lt;211&gt; 250

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(250)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 409

```

cccacgcatg ataagctctt tatttctgta agtcctgcta ggaaatcatc aaatctgacg 60
gtgggtttggg ggacctgaac aaacctcctg taattaatca gctttcagtt tctcccccta 120
gtccctcctt caacaacata ggaggatcct ccccttcttt ctgctcacgg ccttatctag 180
gcttcccagt gccccagga cagcgtgggc tatgtttaca gcgcntcctt gctggggggg 240
ggccntatgc 250

```

&lt;210&gt; 410

&lt;211&gt; 306

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(306)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 410

```

ggctgggtttg caagaatgaa atgaatgatt ctacagctag gacttaacct tgaaatggaa 60
agtcttgcaa tcccatTTgc aggatccgtc tgtgcacatg cctctgtaga gagcagcatt 120
cccagggacc ttggaaacag ttggcactgt aagggtgctt ctcccccaaga cacatcctaa 180
aagggtgttg aatggtgaaa accgcttcct tctttattgc cccttcttat ttatgtgaac 240
nactggttgg ctttttttgn atctttttta aactggaaag ttcaattgng aaaatgaata 300
tcntgc 306

```

&lt;210&gt; 411

&lt;211&gt; 261

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(261)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 411

```

agagatattn cttaggtnaa agttcataga gttcccatga actatatgac tggccacaca 60
ggatcttttg tatttaagga ttctgagatt ttgcttgagc aggattagat aaggctgttc 120
tttaaagtgc tgaaatggaa cagatttcaa aaaaaaaccc cacaatctag ggtgggaaca 180
aggaaggaaa gatgtgaata ggctgatggg caaaaaacca atttaccat cagttccagc 240
cttctctcaa gngagggcaa a 261

```

&lt;210&gt; 412

<211> 241  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(241)  
 <223> n = A,T,C or G

<400> 412  
 gttcaatggt acctgacatt tctacaacac ccactcacc gatgtattcg ttgccagtg 60  
 ggaacatacc agcctgaatt tggaaaaaat aattgtgttt cttgccagg aaatactacg 120  
 actgactttg atggctccac aaacataacc cagtgtaaaa acagaagatg tggaggggag 180  
 ctgggagatt tcaactgggta cattgaattc ccaactacc cangcaatta ccagccaac 240  
 a 241

<210> 413  
 <211> 231  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(231)  
 <223> n = A,T,C or G

<400> 413  
 aactcttaca atccaagtga ctcactctgtg tgcttgaatc ctttccactg tctcatctcc 60  
 ctcactcaag tttctagtag cttctctttg ttgtgaagga taatcaaact gaacaacaaa 120  
 aagtttactc tcctcatttg gaacctaaaa actctcttct tcttgggtct gagggctcca 180  
 agaatccttg aatcanttct cagatcattg gggacaccan atcaggaacc t 231

<210> 414  
 <211> 234  
 <212> DNA  
 <213> Homo sapiens

<400> 414  
 actgtccatg aagcactgag cagaagctgg aggcacaacg caccagacac tcacagcaag 60  
 gatggagctg aaaacataac ccaactctgtc ctggaggcac tgggaagcct agagaaggct 120  
 gtgagccaag gagggagggt cttccttttg catgggatgg ggatgaagta aggagaggga 180  
 ctggaccccc tggaagctga ttcactatgg ggggaggtgt attgaagtcc tcca 234

<210> 415  
 <211> 217  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(217)  
 <223> n = A,T,C or G

<400> 415  
 gcataggatt aagactgagt atcttttcta cattctttta actttctaag gggcacttct 60  
 caaaacacag accaggtagc aaatctccac tgctctaagg ntctcaccac cactttctca 120  
 cacctagcaa tagtagaatt cagtcctact tctgaggcca gaagaatggt tcagaaaaat 180  
 antggattat aaaaaataac aattaagaaa aataatc 217

<210> 416  
<211> 213  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(213)  
<223> n = A,T,C or G

<400> 416  
atgcataatnt aaagganact gcctcgcttt tagaagacat ctggncgtgt ctctgcatga 60  
ggcacagcag taaagctctt tgattcccag aatcaagaac tctccccttc agactattac 120  
cgaatgcaag gtgggtaatt gaaggccact aattgatgct caaatagaag gatattgact 180  
atattggaac agatggagtc tctactacaa aag 213

<210> 417  
<211> 303  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(303)  
<223> n = A,T,C or G

<400> 417  
nagtcttcag gcccatcagg gaagttcaca ctggagagaa gtcatacata tgtactgtat 60  
gtgggaaagg ctttactctg agttcaaata ttcaagccca tcagagagtc cacactggag 120  
agaagccata caaatgcaat gagtgtggga agagcttcag gagggattcc cattatcaag 180  
ttcatctagt ggtccacaca ggagagaaac cctataaatg tgagatatgt gggaagggct 240  
tcantcaaag ttctgtatctt caaatccatc ngaaggncca cagtatanan aaacctttta 300  
agt 303

<210> 418  
<211> 328  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(328)  
<223> n = A,T,C or G

<400> 418  
tttttggcgg tgggtgggca gggacgggac angagtctca ctctgttgcc caggctggag 60  
tgcacaggca tgatctcgcc tcaactacaac ccctgcctcc catgtccaag cgattcttgt 120  
gcctcagcct tccctgtagc tagaattaca ggcacatgcc accacaccca gctagttttt 180  
gtatttttag tagagacagg gtttcacat gttggccagg ctggtctcaa actcctnacc 240  
tcagnggtca ggctggtctc aaactcctga cctcaagtga tctgcccacc tcagcctccc 300  
aaagtgtan gattacaggc cgtgagcc 328

<210> 419  
<211> 389  
<212> DNA  
<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(389)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 419

```

cctcctcaag acggcctgtg gtccgcctcc cggcaaccaa gaagcctgca gtgccatatg 60
accctgagc catggactgg agcctgaaag gcagcgtaca ccctgctcct gatcttgctg 120
cttgtttcct ctctgtggct ccattcatag cacagttgtt gcactgaggc ttgtgcaggc 180
cgagcaaggc caagctggct caaagagcaa ccagtcaact ctgccacggg gtgccaggca 240
ccggttctcc agccaccaac ctcaactcgt cccgcaaatg gcacatcagt tcttctaccc 300
taaaggtagg accaaagggc atctgctttt ctgaagtccct ctgctctatc agccatcacg 360
tggcagccac tcnggctgtg tcgacgcgg 389

```

&lt;210&gt; 420

&lt;211&gt; 408

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 420

```

gttcctccta actcctgcc aaacagctc tctcaacat gagagctgca cccctcctcc 60
tggccagggc agcaagcctt agccttggct tcttgtttct gcttttttcc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
gtcccattga cacctttccc actgaccca taaaggaatc ctcatggcca caaggatttg 240
gccaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatataaaaa attcttgaat gagtccata aacatgaaca gggttatatt cgaagcacag 360
acgttgaccg gactttgatg aagtgcctatg acaaacctgg caagcccg 408

```

&lt;210&gt; 421

&lt;211&gt; 352

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(352)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 421

```

gctcaaaaat ctttttactg atnggcattg ctacacaatc attgaactatt acggaggcca 60
gaggagaatg aggcctggcc tgggagccct gtgcctacta naagcacatt agattatcca 120
ttcactgaca gaacaggtct tttttgggtc cttcttctcc accacnatac acttgacgtc 180
ctccttcttg aagattcttt ggcagttgtc tttgtcataa cccacaggtg tagaaacaag 240
gggtgcaacat gaaatttctg tttcgtagca agtgcattgc tcacaagttg gcangtctgc 300
cactccgagt ttattgggtg tttgtttcct ttgagatcca tgcatttctc gg 352

```

&lt;210&gt; 422

&lt;211&gt; 337

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 422

```

atgccaccat gctggcaatg cagcggggcg tcgaaggcct gcatatccag cccaagctgg 60
cgatgatcga cggcaaccgt tgcccgaagt tgccgatgcc agccgaagcg gtggtcaagg 120
gcgatagcaa ggtgccggcg atcgcggcg cgtaactcct ggccaaggtc agccgtgac 180
gtgaaatggc agctgtcgaa ttgatctacc cgggttatgg catcggcggg cataagggtc 240
atccgacacc ggtgcacctg gaagccttgc agcggctggg gccgacgccg attcacccgac 300
gcttcttccg ccggtacggc tggcctatga aaattat 337

```

<210> 423  
<211> 310  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(310)  
<223> n = A,T,C or G

<400> 423  
gctcaaaaat ctttttactg atatggcatg gctacacaat cattgactat tagaggccag 60  
aggagaatga ggcctggcct gggagccctg tgcctactan aagcncatta gattatccat 120  
tcactgacag aacaggctct ttttgggtcc ttcttctcca ccacgatata ctgagctcc 180  
tccttcttga agattctttg gcagttgtct ttgtcataac ccacaggtgt anaaacaagg 240  
gtgcaacatg aaatttctgt ttcgtagcaa gtgcatgtct cacagttgtc aagtctgccc 300  
tccgagttta 310

<210> 424  
<211> 370  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(370)  
<223> n = A,T,C or G

<400> 424  
gctcaaaaat ctttttactg atagggcatg ctacacaatc attgactatt agaggccaga 60  
ggagaatgag gcctggcctg ggagccctgt gcctactaga agcacattag attatccatt 120  
cactgacaga acaggctctt tttgggtcct tcttctccac cacgatatac ttgcagtcct 180  
ccttcttgaa gattcttttg cagttgtctt tgtcataacc cacaggtgta gaaacatcct 240  
ggttgaatct cctggaactc cctcattagg tatgaaatag catgatgcat tgcataaagt 300  
cacgaagggtg gcaaagatca caacgctgcc cagganaaca ttcattgtga taagcaggac 360  
tccgtcgacg 370

<210> 425  
<211> 216  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(216)  
<223> n = A,T,C or G

<400> 425  
aattgctatn ntttattttg ccactcaaaa taattaccaa aaaaaaaaaa tnttaaata 60  
taacaacnca acatcaaggn aaananaaca ggaatggntg actntgcata aatnggccga 120  
anattatcca ttatnttaag ggttgacttc aggntacagc acacagacaa acatgcccg 180  
gaggntntca ggaccgctcg atgtnttntg agggagg 216

<210> 426  
<211> 596  
<212> DNA  
<213> Homo sapiens



<400> 426  
 cttccagtga ggataaccct gttgccccgg gccgaggttc tccattaggc tctgattgat 60  
 tggcagtcag tgatggaagg gtgttctgat cattccgact gcccgaaggg tcgctggcca 120  
 gctctctgtt ttgctgagtt ggtagtagga cctaatttgt taattaagag tagatggtga 180  
 gctgtccttg tattttgatt aacctaatgg ccttcccagc acgactcgga ttcagctgga 240  
 gacatcacgg caacttttaa tgaaatgatt tgaaggggcca ttaagaggca cttcccgtta 300  
 ttaggcagtt catctgcact gataacttct tggcagctga gctggtcgga gctgtggccc 360  
 aaacgcacac ttggcttttg gttttgagat acaactctta atcttttagt catgcttgag 420  
 ggtggatggc cttttcagct ttaacccaat ttgcactgcc ttggaagtgt agccaggaga 480  
 atacactcat atactcgtgg gcttagaggc cacagcagat gtcattgggc tactgcctga 540  
 gtcccgtggtg tcccatccca ggaccttcca tcggcgagta cctgggagcc cgtgct 596

<210> 427

<211> 107

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(107)

<223> n = A,T,C or G

<400> 427

gaagaattca agttaggttt attcaaaggg cttacngaga atcctanacc caggncccag 60  
 cccgggagca gccttanaga gctcctgttt gactgcccgg ctcagng 107

<210> 428

<211> 38

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(38)

<223> n = A,T,C or G

<400> 428

gaacttcna anaangactt tattcactat ttacatt 38

<210> 429

<211> 544

<212> DNA

<213> Homo sapiens

<400> 429

ctttgctgga cgggaataaaa gtggacgcaa gcatgacctc ctgatgaggg cgctgcattt 60  
 attgaagagc ggctgcagcc ctgcggttca gattaaaatc cgagaattgt atagacgccg 120  
 atatccacga actcttgaag gactttctga tttatccaca atcaaatcat cggttttcag 180  
 tttggatggt ggctcatcac ctgtagaacc tgacttggcc gtggctggaa tccactcgtt 240  
 gccttccact tcagttacac ctcactcacc atcctctcct gttggttctg tgctgcttca 300  
 agatactaag ccacatttg agatgcagca gccactctcc ccaattcctc ctgtccatcc 360  
 tgatgtgcag ttaaaaaatc tgccctttta tgatgtcctt gatgttctca tcaagcccac 420  
 gagtttagtt caaagcagta ttcagcgatt tcaagagaag ttttttattt ttgctttgac 480  
 acctcaacaa gttagagaga tatgcatatc cagggatttt ttgccaggtg gtaggagaga 540  
 ttat 544

<210> 430

<211> 507  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(507)  
<223> n = A,T,C or G

<400> 430  
cttatacncaa tggggctccc aaacttggct gtgcagtggg aactccgggg gaattttgaa 60  
gaacactgac acccatcttc caccocgaca ctctgattta attgggctgc agtgagaaca 120  
gagcatcaat ttaaaaagct gcccagaatg ttntcctggg cagcgttgtg atctttgcon 180  
ccttcgtgac tttatgcaat gcatcatgct atttcatacc taatgaggga gttccaggag 240  
attcaaccag gatgtttcta cncctgtggg ttatgacaaa gacaactgcc aaagaatntt 300  
caagaaggag gactgcaagt atatcgtggt ggagaagaag gacccaaaaa agacctgttc 360  
tgtcagttaa tggataatct aatgtgcttc tagtaggcac agggctccca ggccaggcct 420  
cattctcctc tggcctctaa tagtcaatga ttgtgtagcc atgcctatca gtaaaaagat 480  
ttttgagcaa aaaaaaaaaa aaaaaaaa 507

<210> 431  
<211> 392  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(392)  
<223> n = A,T,C or G

<400> 431  
gaaaattcag aatggataaa aacaaatgaa gtacaaaata tttcagattt acatagcgat 60  
aaacaagaaa gcacttatca ggaggactta caaatggaag tacactctan aaccatcatc 120  
tatcatggct aaatgtgaga ttagcacagc tgtattattt gtacattgca aacacctaga 180  
aagagatggg aaacaaaatc ccaggagttt tgtgtgtgga gtccctgggt ttccaacaga 240  
catcattcca gcattctgag attaggngga ttggggatca ttctggagtt ggaatgttca 300  
acaaaagtga tgttgttagg taaaatgtac aacttctgga tctatgcaga cattgaaggt 360  
gcaatgagtc tggcttttac tctgctgttt ct 392

<210> 432  
<211> 387  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(387)  
<223> n = A,T,C or G

<400> 432  
ggtatccnta cataatcaaa tatagctgta gtacatgttt tcattggngt agattaccac 60  
aaatgcaagg caacatgtgt agatctcttg tcttattctt ttgtctataa tactgtattg 120  
ngtagtccaa gctctcggn a gtccagccac tngaaacat gctcccttta gattaacctc 180  
gtggacnctn ttgttgnatt gtctgaactg tagngccctg tattttgctt ctgtctgnga 240  
attctgttgc ttctggggca ttctcttng atgcagagga ccaccacaca gatgacagca 300  
atctgaattg ntccaatcac agctgcgatt aagacatact gaaatcgta aggaccggga 360  
acaacgtata gaacactgga gtccttt 387

<210> 433  
 <211> 281  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(281)  
 <223> n = A,T,C or G

<400> 433  
 ttcaactagc anagaanact gcttcagggg gtgtaaaatg aaaggcttcc acgcagttat 60  
 ctgattaaag aacactaaga gagggacaag gctagaagcc gcaggatgtc tacactatag 120  
 caggcnctat ttgggttggc tggaggagct gtggaaaaca tggagagatt ggcgctggag 180  
 atcgccgtgg ctattcctcn ttgntattac accagngagg ntctctgtnt gccactgggt 240  
 tnnaaaaccg ntatacaata atgatagaat aggacacaca t 281

<210> 434  
 <211> 484  
 <212> DNA  
 <213> Homo sapiens

<400> 434  
 ttttaaaata agcatttagt gctcagtcct tactgagtag tctttctctc ccctcctctg 60  
 aatttaattc tttcaacttg caatttgcaa ggattacaca tttcactgtg atgtatatg 120  
 tgttgcaaaa aaaaaaaagt gtctttgttt aaaattactt ggtttgtgaa tccatcttgc 180  
 tttttcccca ttggaactag tcattaaccc atctctgaac tggtagaaaa acatctgaag 240  
 agctagtcta tcagcatctg acaggtgaat tggatggttc tcagaaccat ttcaccaga 300  
 cagcctgttt ctatcctgtt taataaatta gtttgggttc tctacatgca taacaaaccc 360  
 tgctccaatc tgtcacataa aagtctgtga cttgaagttt agtcagcacc cccaccaaac 420  
 tttatttttc tatgtgtttt ttgcaacata tgagtgtttt gaaaataaag taccatgtc 480  
 ttta 484

<210> 435  
 <211> 424  
 <212> DNA  
 <213> Homo sapiens

<400> 435  
 gcgcccgtca gagcaggtca ctttctgcct tccacgtcct ccttcaagga agccccatgt 60  
 gggtagcttt caatatcgca ggttcttact cctctgcctc tataagctca aaccaccaa 120  
 cgatcgggca agtaaaccac ctccctcgcc gacttcggaa ctggcgagag ttcagcgcag 180  
 atgggcctgt ggggaggggg caagatagat gagggggagc ggcatggtgc ggggtgacc 240  
 cttggagaga ggaaaaaggc cacaagaggg gctgccaccg cactaacgg agatggccct 300  
 ggtagagacc tttgggggtc tggaaacctt ggactcccca tgctctaact cccacactct 360  
 gctatcagaa acttaaacctt gaggattttc tctgtttttc actcgcaata aattcagagc 420  
 aaac 424

<210> 436  
 <211> 667  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(667)  
 <223> n = A,T,C or G

&lt;400&gt; 436

```

accttgggaa nactctcaca atataaaggg tcgtagactt tactccaaat tccaaaaagg 60
tcctggccat gtaatcctga aagttttccc aaggtagcta taaaatcctt ataagggtgc 120
agcctcttct ggaattcctc tgatttcaaa gtctcactct caagttcttg aaaacgaggg 180
cagttcctga aaggcaggta tagcaactga tcttcagaaa gaggaactgt gtgcaccggg 240
atgggctgcc agagtaggat aggattccag atgctgacac cttctggggg aaacaggggc 300
gccaggtttg tcatagcact catcaaagtc cgggtcaacgt ctgtgcttcg aatataaacc 360
tgttcatgtt tataggactc attcaagaat tttctatata tctttcttat atactctcca 420
agttcataat gctgctccat gccagctgg gtgagttggc caaatccttg tggccatgag 480
gattccttta tggggctcagt gggaaagggt tcaatgggac ttcggctctc atgccgaaac 540
accaaagtca caaacttcaa ctccctgggt agtacacttc ggtctagcca gaaaaaaggc 600
agaaacaaga agccaagggt aaggcttgct gccctgccag gaggaggggt gcagctctca 660
tgttgag 667

```

&lt;210&gt; 437

&lt;211&gt; 693

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 437

```

ctacgtctca accctcatth ttaggtaagg aatcttaagt ccaaagatat taagtgactc 60
acacagccag gtaaggaaag ctggattggc acactaggac tctaccatac cgggttttgt 120
taaagctcag gttaggaggc tgataagctt ggaaggaaact tcagacagct ttttcagatc 180
ataaaagata attcttagcc catgttcttc tccagagcag acctgaaatg acagcacagc 240
aggtaactct ctattttcac ccctcttgct tctactctct ggcagtcaga cctgtgggag 300
gccatgggag aaagcagctc tctggatgtt tgtacagatc atggactatt ctctgtggac 360
catttctcca ggttacccta ggtgtcacta ttggggggac agccagcatc tttagctttc 420
atgtgagttt ctgtctgtct tcagtagagg aaacttttgc tcttcacact tcacatctga 480
acacctaaact gctgttgctc ctgaggtggg gaaagacaga tatagagctt acagtattta 540
tcctattttct aggcactgag ggctgtgggg taccttgtgg tgccaaaaca gatcctgttt 600
taaggacatg ttgcttcaga gatgtctgta actatctggg ggctctgttg gctctttacc 660
ctgcatcatg tgctctcttg gctgaaaatg acc 693

```

&lt;210&gt; 438

&lt;211&gt; 360

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 438

```

ctgcttatca caatgaatgt tctcctgggc agcgttgtga tctttgccac ctctgtgact 60
ttatgcaatg catcatgcta tttcatacct aatgagggag ttccaggaga ttcaaccagg 120
atgtttctac acctgtgggt tatgacaaag acaactgcc aagaatcttc aagaaggagg 180
actgcaagta tatctgggtg agaagaagga cccaaaaaag acctgttctg tcagtgaatg 240
gataatctaa tgtgcttcta gtaggcacag ggctcccagg ccaggcctca ttctcctctg 300
gcctctaata gtcaataatt gtgtagccat gcctatcagt aaaaagattt ttgagcaaac 360

```

&lt;210&gt; 439

&lt;211&gt; 431

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(431)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 439

```

gttcctnnta actcctgcc aaaaacagctc tcctcaacat gagagctgca cccctcctcc 60

```

```

tggccagggc agcaagcctt agccttggct tcttgtttct gctttttttc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgacttttgg gtttcggcat ggagaccgaa 180
gtcccattga cacctttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
gccaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatatagaaa attcttgaat gagtccata aacatgaaca ggtttatatt cgaagcacag 360
acgttgaccg gactttgatg agtgctatga caaacctggc agcccgtcga cgcgcccgcg 420
aatttagtag t
431

```

&lt;210&gt; 440

&lt;211&gt; 523

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 440

```

agagataaag cttagggtcaa agttcataga gttcccatga actatatgac tggccacaca 60
ggatcttttg tatttaagga ttctgagatt ttgcttgagc aggattagat aaggctgttc 120
tttaaatgtc tgaaatggaa cagatttcaa aaaaaaacc cacaatctag ggtgggaaca 180
aggaaggaaa gatgtgaata ggctgatggg caaaaaacca atttaccat cagttccagc 240
cttctctcaa ggagaggcaa agaaaggaga tacagtggag acatctggaa agttttctcc 300
actggaaaac tgctactatc tgtttttata tttctgttaa aatatatgag gctacagaac 360
taaaaattaa aacctctttg tgtccottgg tcttggaaca tttatgttcc ttttaaagaa 420
acaaaaatca aactttacag aaagatttga tgtatgtaat acatatagca gctcttgaag 480
tatatatatc atagcaaata agtcatctga tgagaacaag cta
523

```

&lt;210&gt; 441

&lt;211&gt; 430

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 441

```

gttcctccta actcctgcc aagacagctc tctcaacat gagagctgca cccctcctcc 60
tggccagggc agcaagcctt agccttggct tcttgtttct gctttttttc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgacttttgg gtttcggcat ggagaccgaa 180
gtcccattga cacctttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
gccaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatatagaaa attcttgaat gagtccata aacatgaaca ggtttatatt cgaagcacag 360
acgttgaccg gactttgatg agtgctatga caaacctggc agcccgtcga cgcgcccgcg 420
aatttagtag
430

```

&lt;210&gt; 442

&lt;211&gt; 362

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 442

```

ctaaggaatt agtagtggtc ccatcacttg tttggagtgt gctatttctaa aagattttga 60
tttcctggaa tgacaattat attttaactt tgggtgggga aagagttata ggaccacagt 120
cttcacttct gatacttgta aattaactt ttattgcact tgttttgacc attaagctat 180
atgtttagaa atggtcattt tacggaaaaa ttagaaaaat tctgataata gtgcagaata 240
aatgaattaa tgttttactt aatttatatt gaactgtcaa tgacaaataa aaattctttt 300
tgattatttt ttgttttcat ttaccagaat aaaaactaag aattaaaagt ttgattacag 360
tc
362

```

&lt;210&gt; 443

&lt;211&gt; 624

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(624)  
 <223> n = A,T,C or G

<400> 443  
 tttttttttt gcaacacaaat atacatcaca gtgaaatgtg taatccttgc aaattgcaag 60  
 ttgaaagaat taaattcaga ggaggggaga gaaagagtag tcagtaggga ctgagcacta 120  
 aatgcttatt ttaaaagaaa tgtaaagagc agaaagcaat tcaggctacc ctgccttttg 180  
 tgctggctag tactccggtc ggtgtcagca gcacgtggca ttgaacattg caatgtggag 240  
 cccaaaccac agaaaatggg gtgaaattgg ccaactttct attaacttgg cttcctgttt 300  
 tataaaatat tgtgaataat atcacctact tcaaagggca gttatgaggc ttaaataaac 360  
 taacgcctac aaaacactta aacatagata acataggtgc aagtactatg tatctggtac 420  
 atggtaaaca tccttattat taaagtcaac gctaaaatga atgtgtgtgc atatgctaata 480  
 agtacagaga gagggcactt aaaccaacta agggcctgga ggggaagggtt cctggaaaga 540  
 ngatgcttgt gctgggtcca aatcttgggc tactatgacc ttggccaaat tattttaaact 600  
 ttgtccctat ctgctaaaca gatc 624

<210> 444  
 <211> 425  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(425)  
 <223> n = A,T,C or G

<400> 444  
 gcacatcatt nntcttgcatt tctttgagaa taagaagatc agtaaatagt tcagaagtgg 60  
 gaagctttgt ccaggcctgt gtgtgaaccc aatgttttgc ttagaaatag aacaagtaag 120  
 ttcatgtcta tagcataaca caaaatttgc ataagtgggtg gtcagcaaat ccttgaatgc 180  
 tgcttaattg gagagggttg taaaatcctt tgtgcaacac tctaactccc tgaatgtttt 240  
 gctgtgctgg gacctgtgca tgccagacaa ggccaagctg gctgaaagag caaccagcca 300  
 cctctgcaat ctgccacctc ctgctggcag gatttgtttt tgcattcctgt gaagagccaa 360  
 ggaggcacca gggcataagt gagtagactt atgggtcgacg cggccgcgaa tttagtagta 420  
 gtaga 425

<210> 445  
 <211> 414  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(414)  
 <223> n = A,T,C or G

<400> 445  
 catgtttatg nttttggatt actttgggca cctagtgttt ctaaatcgtc tatcattctt 60  
 ttctgttttt caaaagcaga gatggccaga gtctcaacaa actgtatctt caagtctttg 120  
 tgaaattctt tgcattgtggc agattatttg atgtagtctt ctttaactag catataaatc 180  
 tgggtgtgtt cagataaatg aacagcaaaa tgtggtggaa ttaccatttg gaacattgtg 240  
 aatgaaaaat tgtgtctcta gattatgtaa caaataacta tttcctaacc attgatcttt 300  
 ggatttttat aatcctactc acaaatgact aggtcttctc tcttgtattt tgaagcagtg 360  
 tgggtgtctg attgataaaa aaaaaaaaaa tcgacgcggc cgcaattta gtag 414

<210> 446

<211> 631  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(631)  
 <223> n = A,T,C or G

<400> 446  
 acaaattaga anaaagtgcc agagaacacc acataccttg tccggaacat tacaatggct 60  
 tctgcatgca tgggaagtgt gagcattcta tcaatatgca ggagccatct tgcagggtgtg 120  
 atgctggtta tactggacaa cactgtgaaa aaaaggacta cagtgttcta tacgttggtc 180  
 ccggtcctgt acgatttcag tatgtcttaa tcgcagctgt gatttgaaca attcagattg 240  
 ctgtcatctg tgtggtggtc ctctgcatca caagggccaa actttaggta atagcattgg 300  
 actgagattt gtaaaacttc caaccttcca ggaaatgccc cagaagcaac agaattcaca 360  
 gacagaagca aaatacaggg cactacagtt cagacaatac aacaagagcg tccacgaggt 420  
 taatctaaag ggagcatggt tcacagtggc tggactaccg agagcttggg ctacacaata 480  
 cagtattata gacaaaagaa taagacaaga gatctacaca tgttgcttgg catttgtggt 540  
 aatctacacc aatgaaaaca tgtactacag ctatatattga ttatgtatgg atatatttga 600  
 aatagtatac attgtcttga tgttttttct g 631

<210> 447  
 <211> 585  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(585)  
 <223> n = A,T,C or G

<400> 447  
 ccttgggaaa antntcacaa tataaagggt cgtagacttt actccaaatt ccaaaaagggt 60  
 cctggccatg taatcctgaa agttttccca aggtagctat aaaatcctta taagggtgca 120  
 gcctcttctg gaattcctct gatttcaaag tctcactctc aagttcttga aaacgagggc 180  
 agttcctgaa aggcagggtat agcaactgat cttcagaaag aggaactgtg tgcaccggga 240  
 tgggctgcca gagtaggata ggattccaga tgctgacacc ttctggggga aacagggctg 300  
 ccagggtttgt catagcactc atcaaagtcc ggtcaacgtc tgtgcttcga atataaacct 360  
 gttcatgttt ataggactca ttcaagaatt ttctatatct ctttcttata tactctccaa 420  
 gttcataatg ctgctccatg cccagctggg tgagttggcc aaatccttgt ggccatgagg 480  
 attcctttat ggggtcagtg ggaaagggtg caatgggact tcggtctcca tgccgaaaca 540  
 ccaaagtcac aaacttcaac tccttggcta gtacacttcg gtcta 585

<210> 448  
 <211> 93  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(93)  
 <223> n = A,T,C or G

<400> 448  
 tgctcgtggg tcattctgan nccgaaactg accntgccag ccctgccgan ggccnccat 60  
 ggctccctag tgccctggag agganggggc tag 93

<210> 449  
 <211> 706  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(706)  
 <223> n = A,T,C or G

<400> 449  
 ccaagttcat gctntgtgct ggacgctgga cagggggcga aagcnnttgc tcgtgggtca 60  
 ttctganeac cgaactgacc atgccagccc tgccgatggc cctccatggc tccctagtgc 120  
 cctggagagg aggtgtctag tcagagagta gtcctggaag gtggcctctg ngaggagcca 180  
 cggggacagc atcctgcaga tggtcgggag cgtcccatc gccattcagg ctgcgcaact 240  
 gttgggaagg gcgatcgggt cgggcctctt cgctattac ccagctggcg aaagggggat 300  
 gtgctgcaag gcgattaagt tgggtaacgc cagggttttc ccagtncga cgttgtaaaa 360  
 cgacggccag tgaattgaat ttaggtgacn ctatagaaga gctatgacgt cgcattgcacg 420  
 cgtacgtaag cttggatcct ctagagcggc cgcctactac tactaaattc gcggccgagt 480  
 cgacgtggga tccncaactga gagagtggag agtgacatgt gctggacnct gtccatgaag 540  
 cactgagcag aagctggagg cacaacgcnc cagacactca cagctactca ggaggctgag 600  
 aacaggttga acctgggagg tggaggttgc aatgagctga gatcaggccn ctgcncccca 660  
 gcatggatga cagagtgaag ctatcatctt aaaaaaaaaa aaaaaa 706

<210> 450  
 <211> 493  
 <212> DNA  
 <213> Homo sapiens

<400> 450  
 gagacggagt gtcactctgt tgcccaggct ggagtgcagc aagacactgt ctaagaaaaa 60  
 acagttttta aaggtaaaaa aacataaaaa gaaatatcct atagtggaaa taagagagtc 120  
 aaatgaggct gagaacttta caaagggatc ttacagacat gtcgccaaata tcaactgcatg 180  
 agcctaagta taagaacaac ctttggggag aaaccatcat ttgacagtga ggtacaattc 240  
 caagtccagt agtgaaatgg gtggaattaa actcaaatta atcctgccag ctgaaacgca 300  
 agagacactg tcagagaggt aaaaagttag ttctatccat gaggtgattc cacagtcttc 360  
 tcaagtcacac acatctgtga actcacagac caagttctta aaccactgtt caaactctgc 420  
 tacacatcag aatcacctgg agagctttac aaactcccat tgccgagggt cgacgcgggc 480  
 gcgaatttag tag 493

<210> 451  
 <211> 501  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(501)  
 <223> n = A,T,C or G

<400> 451  
 gggcgcgctc cattcgccat tcaggctgag caactgttgg gaagggcgat cgggtcgggc 60  
 ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct gcaaggcgat taagtgggt 120  
 aacgccaggg ttttcccagt cncgacgttg taaaacgacg gccagtgaat tgaatttagg 180  
 tgacnctata gaagagctat gacgtcgcat gcacgcgtac gtaagcttgg atcctctaga 240  
 gcggccgcct actactacta aattcgcggc cgcgtcgacg tgggatccnc actgagagag 300  
 tggagagtga catgtgctgg acnctgtcca tgaagcactg agcagaagct ggaggcacia 360  
 cgcncacagc actcacagct actcaggagg ctgagaacag gttgaacctg ggagggtggg 420



gttgcaatga gctgagatca ggccnctgcn cccagcatg gatgacagag tgaaactcca 480  
tcttaaaaaa aaaaaaaaaa a 501

<210> 452  
<211> 51  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(51)  
<223> n = A,T,C or G

<400> 452  
agacggttcc accnttacaa cnccttttag gatgggnntt ggggagcaag c 51

<210> 453  
<211> 317  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(317)  
<223> n = A,T,C or G

<400> 453  
tacatcttgc tttttcccca ttggaactag tcattaaccc atctctgaac tggtagaaaa 60  
acatctgaag agctagtcta tcagcatctg gcaagtgaat tggatgggtc tcagaacctat 120  
ttcacccana cagcctgttt ctatcctgtt taataaatta gtttgggttc tctacatgca 180  
taacaaaccc tgctccaatc tgtcacataa aagtctgtga cttgaagttt antcagcacc 240  
cccacaaac tttatttttc tatgtgtttt ttgcaacata tgagtgtttt gaaaataag 300  
taccatgtc tttatta 317

<210> 454  
<211> 231  
<212> DNA  
<213> Homo sapiens

<400> 454  
ttcgaggtag aatcaactct cagagtgtag tttccttcta tagatgagtc agcattaata 60  
taagccacgc cacgctcttg aaggagtctt gaattctcct ctgctcactc agtagaacca 120  
agaagaccaa attcttctgc atcccagctt gcaaacaaaa ttgttcttct aggtctccac 180  
ccttcctttt tcagtgttcc aaagctcctc acaatttcat gaacaacagc t 231

<210> 455  
<211> 231  
<212> DNA  
<213> Homo sapiens

<400> 455  
taccaaagag ggcataataa tcagtctcac agtaggggtc accatcctcc aagtgaaaaa 60  
cattgttccg aatggggttt ccacaggcta cacacacaaa acaggaaaca tgccaagttt 120  
gtttcaacgc attgatgact tctccaagga tcttcctttg gcatcgacca cattcagggg 180  
caaagaattt ctcatagcac agtcacaaat acagggtcctc tttctcctct a 231

<210> 456  
<211> 231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 456

```
ttggcaggta cccttacaac gaagacacca taccttatgc gttattaggt ggaataatca 60
ttccattcag tattatcggt attattcttg gagaaacct gtctgtttac tgtaaccttt 120
tgcactcaaa ttccctttatc aggaataact acatagccac tatttacaac gccattggaa 180
cctttttatt tgggtgcagct gctagtcagt ccctgactga cattgccaaag t 231
```

&lt;210&gt; 457

&lt;211&gt; 231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(231)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 457

```
cgagggtaccc aggggtctga aaatctctnn ttantagtc gatagcaaaa ttgttcatca 60
gcattcctta atatgatctt gctataatta gattttttctc cattagagtt catacagttt 120
tatttgattt tattagcaat ctctttcaga agacccttga gatcattaag ctttgtatcc 180
agttgtctaa atcgatgcct catttcctct gaggtgtcgc tggcttttgt g 231
```

&lt;210&gt; 458

&lt;211&gt; 231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 458

```
aggtctgggt cccccactt ccactccct ctactctctc taggactggg ctgggccaaag 60
agaagagggg tggtaggga agccgttgag acctgaagcc ccaccctcta ccttccttca 120
acaccctaac cttgggtaac agcatttgga attatcattt gggatgagta gaatttccaa 180
ggctctgggt taggcatttt gggggggccag accccaggag aagaagattc t 231
```

&lt;210&gt; 459

&lt;211&gt; 231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 459

```
ggtaccgagg ctgctgaca cagagaaacc ccaacgcgag gaaaggaatg gccagccaca 60
ccttcgcaa acctgtggtg gccaccagt cctaaccgga caggacagag agacagagca 120
gccctgcaat gttttccctc caccacagcc atcctgtccc tcattggctc tgtgctttcc 180
actatacaca gtcaccgtcc caatgagaaa caagaaggag caccctccac a 231
```

&lt;210&gt; 460

&lt;211&gt; 231

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 460

```
gcaggataaa catgctgcaa caacagatgt gactaggaac ggccggtgac atggggaggg 60
cctatcacc tattcttggg ggtgtcttct tcacagtgtat catgaagcct agcagcaaatt 120
cccacctccc cacacgcaca cggccagcct ggagcccaca gaagggtcct cctgcagcca 180
gtggagcttg gtccagcctc cagtccaccc ctaccaggct taaggataga a 231
```

<210> 461  
 <211> 231  
 <212> DNA  
 <213> Homo sapiens

<400> 461

```
cgagggtttga gaagctctaa tgtgcagggg agccgagaag caggcggcct agggaggggtc 60
gCGTgtgctc cagaagagtG tgtgcatgcc agaggggaaa caggcgCctg tgtgtCctgg 120
gtgggggttca gtgaggagtG ggaaattggT tcagcagaac caagccgttg ggtgaataag 180
agggggattc catggcactg atagagccct atagtTtcag agctgggaat t 231
```

<210> 462  
 <211> 231  
 <212> DNA  
 <213> Homo sapiens

<400> 462

```
aggtaccctc attgtagcca tgggaaaatt gatgttcagt ggggatcagt gaattaaatg 60
gggtcatgca agtataaaaa ttataaaaaa aagacttcat gcccaatctc atatgatgtg 120
gaagaactgt tagagagacc aacagggtag tgggttagag atttccagag tcttacattt 180
tctagaggag gtattttaatt tcttctcact catccagtgt tgtatttagg a 231
```

<210> 463  
 <211> 231  
 <212> DNA  
 <213> Homo sapiens

<400> 463

```
tactccagcc tggTgacaga gcgagaccct atcaccgccc cccacccccc caaaaaaaaa 60
actgagtaga caggTgtcct ctTggcatgg taagtcttaa gtccccctcc agatctgtga 120
catttgacag gtgtcttttc ctctggacct cggTgtcccc atctgagtga gaaaaggcag 180
tggggagggtg gatcttccag tcgaagcggt atagaagccc gtgtgaaaag c 231
```

<210> 464  
 <211> 231  
 <212> DNA  
 <213> Homo sapiens

<400> 464

```
gtactcctaag attttatcta agttgccttt tctgggtggg aaagtTtaac cttagtgact 60
aaggacatca catatgaaga atgtttaagt tggaggTggc aacgtgaatt gcaaacaggg 120
cctgcttcag tgactgtgtg cctgtagtcc cagctactcg ggagtctgtg tgaggccagg 180
ggtgccagcg caccagctag atgctctgta acttctaggc cccattttcc c 231
```

<210> 465  
 <211> 231  
 <212> DNA  
 <213> Homo sapiens

<400> 465

```
catgttgttg tagctgtggt aatgctggct gcattctcaga cagggtTtaac ttcagctcct 60
gtggcaaatT agcaacaaat tctgacatca tatttatggT ttctgtatct ttgttgatga 120
aggatggcac aatttttTgct tgtgttcata atatactcag attagtTcag ctccatcaga 180
taaactggag acatgcagga cattagggtg gtgttgtagc tctggtaatg a 231
```

<210> 466  
 <211> 231  
 <212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 466

```

caggtacctc tttccattgg atactgtgct agcaagcatg ctctccgggg tttttttaat 60
ggccttcgaa cagaacttgc cacataccca ggtataatag tttctaacat ttgcccagga 120
cctgtgcaat caaatattgt ggagaattcc ctagctggag aagtcacaaa gactataggc 180
aataatggag accagtccca caagatgaca accagtcgtt gtgtgcggct g          231

```

&lt;210&gt; 467

&lt;211&gt; 311

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 467

```

gtacaccctg gcacagtcca atctgaactg gttcggcact catctttcat gagatggatg 60
tgggtggcttt tctccttttt catcaagact cctcagcagg gagcccagac cagcctgcac 120
tgtgccttaa cagaaggctc tgagattcta agtgggaatc atttcagtga ctgtcatgtg 180
gcatgggtct ctgccccagc tcgtaatgag actatagcaa ggcggctgtg ggacgtcagt 240
tgtgacctgc tgggcctccc aatagactaa caggcagtgc cagttggacc caagagaaga 300
ctgcagcaga c          311

```

&lt;210&gt; 468

&lt;211&gt; 3112

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 468

```

cattgtgttg ggagaaaaac agagggggaga tttgtgtggc tgcagccgag ggagaccagg 60
aagatctgca tgggtgggaag gacctgatga tacagagttt gataggagac aattaaaggc 120
tggaaggcac cggagacctg atgatgaagt ggactttcaa actggggcac tactgaaacg 180
atggggatggc tggatgacaga ggagatgagt tggagcaagc tcaataacaa agtggttcaa 240
cgaggacttg gaattgcatg gagctggagc tgaagttag cccaattgtt tactagttag 300
gtgaatgtgg atgattggat gatcatttct catctctgag cctcaggttc cccatccata 360
aaatgggata cacagtatga tctataaagt gggatatagt atgatctact tcaactgggtt 420
atttgaagga tgaattgaga taatttattt caggtgccta gaacaatgcc cagattagta 480
catttggttg aactgagaaa tggcataaca ccaaatttaa tatatgtcag atgttactat 540
gattatcatt caatctcata gttttgtcat ggcccaattt atcctcactt gtgcctcaac 600
aaattgaact gttaacaaag gaatctctgg tccctgggtaa tggctgagca ccactgagca 660
tttccattcc agttggcttc ttgggtttgc tagctgcac actagtcac ttaaataaat 720
gaagttttta catttctcca gtgatttttt tatctcacct ttgaagatac tatgttatgt 780
gattaaataa agaacttgag aagaacaggt ttcattaaac ataaaatcaa tgtagacgca 840
aattttctgg atgggcaata cttatgttca caggaaatgc tttaaaatat gcagaagata 900
attaaatggc aatggacaaa gtgaaaaact tagacttttt tttttttttt ggaagtatct 960
ggatgttcct tagtcaacta aaggagaact gaaaaatagc agtgagttcc acataatcca 1020
acctgtgaga ttaaggctct ttgtggggaa ggacaaagat ctgtaaattt acagtttctt 1080
tccaaagcca acgtcgaatt ttgaaacata tcaaagctct tcttcaagac aaataatcta 1140
tagtacctct tcttattggg atgcacttat gaaaaatggg ggctgtcaac atctagtac 1200
tttagctctc aaaatggttc attttaagag aaagttttag aatctcatat ttattcctgt 1260
ggaaggacag cattgtggct tggactttat aaggtcttta ttcaactaaa taggtgagaa 1320
ataagaaagg ctgctgactt taccatctga ggccacacat ctgctgaaat ggagataatt 1380
aacatcacta gaaacagcaa gatgacaata taatgtctaa gtagtgacat gtttttgcac 1440
atttccagcc cctttaaata tccacacaca caggaagcac aaaaggaagc acagagatcc 1500
ctggggagaaa tgcccgcccg ccactctggg tcatcgatga gcctcgccct gtgcctgggtc 1560
ccgcttgtga gggaaggaca ttagaaaatg aattgatgtg ttccttaaag gatgggcagg 1620
aaaacagatc ctgtttgtga tatttatttg aacgggatta cagatttgaa atgaagtcac 1680
aaagtgcaga ttaaccaatga gaggaaaaaa cagcagaaaa tcttgatggc ttcacaagac 1740
atgcaacaaa caaaatggaa tactgtgatg acatgaggca gccaaagctgg ggaggagata 1800
accacggggc agaggggtcag gattctggcc ctgctgccta aactgtgcgt tcataaccâa 1860

```

atcatttcat	atttctaacc	ctcaaaacaa	agctgttgta	atatctgac	tctacggttc	1920
cttctgggcc	caacattctc	catatatcca	gccacactca	tttttaatat	ttagttccca	1980
gatctgtact	gtgaccttcc	tacactgtag	aataacatta	ctcattttgt	tcaaagaccc	2040
ttcgtgttgc	tgcctaatat	gtagctgact	gttttttcta	aggagtgttc	tggcccaggg	2100
gatctgtgaa	caggctggga	agcatctcaa	gatctttcca	gggttatact	tactagcaca	2160
cagcatgac	attacggagt	gaattatcta	atcaacatca	tcctcagtgt	ctttgcccac	2220
actgaaattc	atttcacact	tttgtgccc	ttctcaagac	ctcaaatgt	cattccatta	2280
atatcacagg	attaactttt	ttttttaacc	tggaagaatt	caatgttaca	tgcagctatg	2340
ggaatttaat	tacatatatt	gttttccagt	gcaaagatga	ctaagtcctt	tatccctccc	2400
ctttgtttga	ttttttttcc	agtataaagt	taaaatgctt	agccttgtag	tgaggctgta	2460
tacagccaca	gcctctcccc	atccctccag	ccttatctgt	catcaccatc	aaccctccc	2520
atgcacctaa	acaaaatcta	acttgtaatt	ccttgaacat	gtcaggcata	cattattcct	2580
tctgcctgag	aagctcttcc	ttgtctctta	aatctagaat	gatgtaaagt	tttgaataag	2640
ttgactatct	tacttcatgc	aaagaaggga	cacatatgag	attcatcatc	acatgagaca	2700
gcaataacta	aaagtgtaat	ttgattataa	gagtttagat	aaatatatga	aatgcaagag	2760
ccacagaggg	aatgtttatg	gggcacgttt	gtaagcctgg	gatgtgaagc	aaaggcaggg	2820
aacctcatag	tatcttatat	aataactttc	atttctctat	ctctatcaca	atatccaaca	2880
agcttttcc	agaattcatg	cagtgcacaa	ccccaaaggt	aacctttatc	catttcatgg	2940
tgagtgcgct	ttagaatttt	ggcaaatcat	actggtcact	tatctcaact	ttgagctgtg	3000
tttgtccttg	tagttaattg	aaagaaatag	ggcactcttg	tgagccactt	tagggttcac	3060
tcctggcaat	aaagaattta	caaagagcaa	aaaaaaaaaa	aaaaaaaaaa	aa	3112

&lt;210&gt; 469

&lt;211&gt; 2229

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 469

agctctttgt	aaattcttta	ttgccaggag	tgaaccctaa	agtggctcac	aagagtgcc	60
tatttctttc	aattaactac	aaggacaaac	acatctcaaa	gttgagataa	gtgaccagta	120
tgatttgcca	aaattctaaa	gcgcactcac	catgaaatgg	ataaagggtta	cctttgggga	180
tttgactgc	atgaattctg	tgaagagctt	gttgatatt	gtgatagaga	tagagaaatg	240
aagtatatta	tataagatac	tatgaggttc	cctgcctttg	cttcacatcc	caggcttaca	300
aacgtgcccc	ataaacattc	cctctgtggc	tcttgcat	catatattta	tctaaactct	360
tataatcaaa	tacactttta	gtatttgctg	tctcatgtga	tgatgaatct	catatgtgtc	420
ccttctttgc	atgaagtaag	atagtcaact	tattcaaaac	tttacatcat	tctagattta	480
agagacaagg	aagagcttct	caggcagaag	gaataatgta	tgcctgacat	gttcaaggaa	540
ttacaagtta	gattttgttt	aggtgcatgg	gaggggttga	tggtgatgac	agataaggct	600
ggagggatgg	ggagaggctg	tggtgtata	cagcctcagt	acaaggctaa	gcattttaac	660
tttatactgg	aaaaaaaaatc	aaacaaaggg	gagggataaa	ggacttagtc	atctttgcac	720
tgaaaaacaa	aatatgtaat	taaattccca	tagctgcatg	taacattgaa	ttcttccagg	780
ttaaaaaaaa	agttaatcct	gtgatattaa	tggaatgaca	ttttgaggtc	ttgagaatgg	840
gcacaaaagt	gggaaatgaa	tttcagtatg	ggcaaagaca	ctgaggatga	tgttgattag	900
ataattcact	ccgtaatgat	catgctgtgt	gctagtgaat	ataaccctgg	aaagatcttg	960
agatgcttcc	cagcctgttc	acagatcccc	tgggccagaa	cactccttag	gaaaaacagt	1020
cagctacata	ttaggcagca	acacgaaggg	tctttgaaca	aatgagtaa	tgttattcta	1080
cagtgtagaa	aggtcacagt	acagatctgg	gaactaaata	ttaaaaatga	gtgtggctgg	1140
atatatggag	aatgttgggc	ccagaaggaa	ccgtagagat	cagatattac	aacagctttg	1200
ttttgagggg	tagaaatatg	aaatgatttg	gttatgaacg	cacagtttag	gcagcagggc	1260
cagaatcctg	accctctgcc	ccgtggttat	ctcctcccca	gcttggctgc	ctcatgtcat	1320
cacagtattc	cattttgttt	gttgcatgtc	ttgtgaagcc	atcaagattt	tctcgtctgt	1380
tttctctca	ttggtaatgc	tcacttttg	acttcatttc	aaatctgtaa	tcccggtcaa	1440
ataaatatcc	acaacaggat	ctgttttctt	gccccactct	taagggaacac	atcaattcat	1500
tttctaattg	ccttccctca	caagcgggac	caggcacagg	gcgaggctca	tcgatgacct	1560
aagatggcgg	ccgggcattt	ctcccaggga	tctctgtgct	tcctttttgtg	cttctgtgt	1620
gtgtggatat	ttaaaggggc	tggaatgtg	caaaaacatg	tcactactta	gacattatat	1680
tgatcatctg	ctgtttctag	tgatgttaat	tatctccatt	tcagcagatg	tgtggcctca	1740
gatggtaaag	tcagcagcct	ttcttatttc	tcacctggaa	atacatacga	ccatttgagg	1800

```

agacaaatgg caaggtgtca gcataccctg aacttgagtt gagagctaca cacaatatta 1860
ttgggtttccg agcatcacaa acaccctctc tgtttcttca ctgggcacag aattttaata 1920
cttatttcag tgggctgttg gcaggaacaa atgaagcaat ctacataaag tcaactagtgc 1980
agtgcctgac acacaccatt ctcttgaggt cccctctaga gatccacag gtcatatgac 2040
ttcttgggga gcagtggctc acacctgtaa tcccagcact ttgggagggt gaggcagggtg 2100
ggtcacctga ggtcaggagt tcaagaccag cctggccaat atggtgaaac cccatctcta 2160
ctaaaaatac aaaaattagc tgggcgtgct ggtgcatgcc tgtaatccca gcccacacac 2220
aatggaatt

```

&lt;210&gt; 470

&lt;211&gt; 2426

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 470

```

gtaaatctctt tattgccagg agtgaaccct aaagtggctc acaagagtgc cctattttctt 60
tcaattaact acaaggacaa acacatctca aagttgagat aagtgaccag tatgatttgc 120
caaaattcta aagcgcactc accatgaaat ggataaaggt tacctttggg gatttgcact 180
gcatgaattc tgtgaaaagc ttgttgata ttgtgataga gatagagaaa tgaagtatat 240
tatataagat actatgaggt tccctgcctt tgcttcacat cccaggctta caaacgtgcc 300
ccataaacat tccctctgtg gctcttgcac ttcatatatt tatctaaact cttataatca 360
aattacactt ttagtatttg ctgtctcatg tgatgatgaa tctcatatgt gtcccttctt 420
tgcatgaagt aagatagtca acttattcaa aactttacat cattctagat ttaagagaca 480
aggaagagct tctcaggcag aaggaataat gtatgcctga catgttcaag gaattacaag 540
ttagattttg tttaggtgca tgggaggggt tgatgggtgat gacagataag gctggaggga 600
tggggagagg ctgtggctgt atacagcctc agtacaaggc taagcatttt aactttatac 660
tggaaaaaaa atcaaacaaa ggggagggat aaaggactta gtcactcttg cactggaaaa 720
caaaatatgt aattaaattc ccatagctgc atgtaacatt gaattcttcc aggttaaaaa 780
aaaaagttaa tcctgtgata ttaatggaat gacattttga ggtcttgaga atgggcacaa 840
aagtgggaaa tgaatttcag tatgggcaaa gacactgagg atgatgttga ttagataatt 900
cactccgtaa tgatcatgct gtgtgctagt aagtataacc ctggaaagat cttgagatgc 960
ttcccagcct gttcacagat cccctgggce agaacactcc ttaggaaaaa cagtcagcta 1020
catattaggc agcaacacga agggctcttg aacaaaatga gtaatgttat tctacagtgt 1080
agaaaggtca cagtacagat ctgggaacta aatattaaaa atgagtgtgg ctggatata 1140
ggagaatgtt gggcccagaa ggaaccgtag agatcagata ttacaacagc ttgttttga 1200
gggttagaaa tatgaaatga ttgggttatg aacgcacagt ttaggcagca gggccagaat 1260
cctgaccctc tgcccctggg ttatctcctc cccagcttgg ctgcctcatg tcatcacagt 1320
attccatttt gtttgttgca tgtcttgtga agccatcaag attttctcgt ctgttttctt 1380
ctcattggta atgtctactt tgtgacttca ttcaaatct gtaatcccgt tcaaataaat 1440
atccacaaca ggatctgttt tctgcccct cctttaagga acacatcaat tcattttcta 1500
atgtccttcc ctcacaagcg ggaccaggca cagggcgagg ctcatcgatg acccaagatg 1560
gcggccgggc atttctccca gggatctctg tgcctccttt tgtgcttctt gtgtgtgtgg 1620
atatttaaag gggctggaaa tgtgcaaaaa catgtcacta cttagacatt atattgtcat 1680
cttgcgtgtt ctagtgtgtt taattatctc catttcagca gatgtgtggc ctcagatggg 1740
aaagtcagca gcctttctta ttctcacct ggaaatacat acgaccattt gaggagacaa 1800
atggcaaggt gtcagcatac cctgaacttg agttgagagc tacacacaat attattgtgt 1860
tccgagcatc acaaacaccc tctctgtttc ttactgggc acagaatttt aatacttatt 1920
tcagtgggct gttggcagga acaaatgaag caatctacat aaagtcacta gtgcagtgcc 1980
tgacacacac cattctcttg aggtcccctc tagagatccc acaggtcata tgacttcttg 2040
gggagcagtg gctcacacct gtaatcccag cactttggga ggctgaggca ggtgggtcac 2100
ctgaggtcag gagttcaaga ccagcctggc caatatgggt aaaccccatc tctactaaaa 2160
atacaaaaaa tagctgggog tgcctgtgca tgcctgtaat cccagctact tgggaggctg 2220
aggcaggaga attgctggaa catgggggca ggaggttgca gtgagctgta attgtgccat 2280
tgcactcgaa cctggcgac agagtgggac tctgtttcca aaaaacaaac aaacaaaaaa 2340
ggcatagtca gatacaacgt ggggtgggat tgtaaataga agcaggatat aaagggcagt 2400
gggtgacggg tttgcccac acaatg

```

&lt;210&gt; 471

<211> 812  
<212> DNA  
<213> Homo sapiens

<400> 471

```
gaacaaaatg agtaatgtta ttctacagt tagaaaggtc acagtacaga tctgggaact 60
aaatattaaa aatgagtgtg gctggatata tggagaatgt tgggccaga aggaaccgta 120
gagatcagat attacaacag ctttgtttg agggtagaa atatgaaatg atttggttat 180
gaacgcacag tttaggcagc agggccagaa tcctgaccct ctgcccctg gttatctcct 240
ccccagcttg gctgcctcat gtcacacag tattccattt tgtttgttgc atgtcttgtg 300
aagccatcaa gattttctcg tctgttttcc tctcattggt aatgctcact ttgtgacttc 360
atttcaaate tgtaatcccg ttcaaataaa tatccacaac aggatctggt ttccctgcca 420
tcctttaagg aacacatcaa ttcatTTTTt aatgtccttc cctcacaagc gggaccaggc 480
acagggcgag gctcatcgat gacccaagat ggcggccggg catttctccc agggatctct 540
gtgcttcctt ttgtgcttcc tgtgtgtgtg gatattttaa ggggctggaa atgtgcaaaa 600
acatgtcact acttagacat tatattgtca tcttgctgtt tctagtgtg ttaattatct 660
ccatttcagc agatgtgtgg cctcagatgg taaagtcagc agcctttctt atttctcacc 720
tctgtatcat caggtccttc ccaccatgca gatcttcctg gtctccctcg gctgcagcca 780
cacaaatctc ccctctgttt ttctgatgcc ag 812
```

<210> 472  
<211> 515  
<212> DNA  
<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)...(515)

<223> n = A,T,C or G

<400> 472

```
acggagactt attttctgat attgtctgca tatgtatggt ttttaagagtc tggaaatagt 60
cttatgactt tcctatcatg cttattaata aataatacag cccagagaag atgaaaatgg 120
gttccagaat tattggtcct tgcagcccg tgaatctcag caagaggaa caccaactga 180
caatcaggat attgaacctg gacaagagag agaaggaa cctccgatcg aagaacgtaa 240
agtagaagg gattgccagg aatggatctt ggaaaagact cggagtgagc gtggagatgg 300
ctctgatgta aaagagaaga ctccacctaa tcctaagcat gctaagacta aagaagcagg 360
agatgggcag ccataagtta aaaagaagac aagctgaagc tacacacatg gctgatgtca 420
cattgaaaat gtgactgaaa atttgaaaat tctctcaata aagtttgagt tttctctgaa 480
gaaaaaaaaa naaaaaaaaa aaanaaaan aaaaa 515
```

<210> 473  
<211> 5829  
<212> DNA  
<213> Homo sapiens

<400> 473

```
cgcatgccgg ggaagcccaa gctggctcga agagccacca gccacctgtg caagggtggg 60
cctggaccag ttggaccagc caccaagctc acctactcaa ggaagcaggg atggccagg 120
tgcaacagcc tgagtggctg ccacctgata gctgatggag cagaggcctg aggaaaatca 180
gatggcacat ttagctcttt aatggatctt aagttaattt ttctataaag cacatggcac 240
cagtcctatgc ctgagagctc gtatggcact gcggaccaca gcaggccgag ttcccaggat 300
tgccatccag gggggccttc tgtagccctg gccagacctt gcagagggtg ctgggtgctc 360
tttgagcgag ctgcgcctcc ctggcatgca caggccccag gtactgacac gctgctctga 420
gtgagcttgt cctgccttgg ctgccacctt actgctgatg gagcagcggc cttaggaaaa 480
gcaaattggc ctgtagccca actttagggg agaagaagat gtaccatgtc cggccgctag 540
ttggtgactg gtgcacctgc tcctggcgta cccttgca ggtgggtggg tgctctttgg 600
ccagcttggc ctgtgcctggc atgcacaagc ctcagtgcaa caactgtcct acaaatggag 660
```

acacagagag gaaacaagca gcgggctcag gagcaggggtg tgtgctgcct ttgggggtcc 720  
 agtccatgcc tcgggtcgta tggtagtgca ggcttcttg ttgccaagag ggggaccaca 780  
 ggccttcttg aggaggactt tacgttcaag tgcagaaagc agccaaaatt accatccatg 840  
 agactaagcc ttctgtggcc ctggcgagac ttaaaatttg tgccaaggca ggacaagctc 900  
 actcggagca gcgtgtcagt agctggggcc tatgcatgcc gggcagggcc gggctggctg 960  
 aaggagcaac cagccacctc tgcaagggtg cgcctagtgc aggcggagca tccaccacct 1020  
 caccgcctcg aggaagtggg gatggccagg ttccacagc ctgagtgtct gccaccttat 1080  
 tgcgtatgga gcagaggcct taagaaaagc agatggcact gtggccctac ctttaggggtg 1140  
 gaagaagtga tgtacatgtc cggacgctaa ttggtgactg gtacaccggc tcctgctaca 1200  
 cctttgcaga ggtggctggt tgccttttga gccagcttgt ccttgcccgg catgcacaag 1260  
 tttcagtgca acaactttgc cacaatgga gccatataga ggaaacaaga agcaggttca 1320  
 ggagaaggggt gtaccctgcc tttggggctc cagtccatgc ctcaggtgtc acatggcact 1380  
 gcgggcttct tggttgccag gaggcggacc acaggccatc ttggggagga ctttgtgttc 1440  
 aagtgcagaa agcagccagg attgccatcc agggggacct tctatagccc tggccaaacc 1500  
 ttgcaggggt gtctggttgc tctttgagcc ggcttggcct ccttggcatg cacgggcccc 1560  
 aggtgctggc acgctgctcc gagtgtgctt gtccctgctt ggctgccacc tctgcggggg 1620  
 tgcgtctgga ggggggtggac cggccaccaa ccttaccag tcaaggaggt ggatggccat 1680  
 gttccacag cctgagtggc tgccacctga ttgctgatgg agcaaaggcc ttaggaaaag 1740  
 cagatggccc ttggccctac ctttttgtta gaagaactga tgttccatgt cctgcagcga 1800  
 gtgaggttgg tggctgtgcc ccagctcct ggcgcgccct cgcagaggtg actggttgot 1860  
 ctttgggccc tcttggcctt gccagcatg cacaagctc agtgctacta ctgtgctaca 1920  
 aatggagcca tataggggaa acgagcagcc atctcaggag caagggtgat gctgcctttg 1980  
 ggggctccag tccttgcctc aagggtctta tgtcactgtg ggcttcttg ttgtcaagag 2040  
 gcagaccata ggccgtcttg agaggactt tatgttcaag tgcagaaagc agccaggatt 2100  
 gccaccctcg ggactctgcc ttctgtggcc ctggccaaac ttagaatttg gccgtagaca 2160  
 ggacaggctc acttgagta gcgtgtccgt agctgggggtc tgtgcatgcc gggcaaggcc 2220  
 gggctggctc ggggagcaac cagccacctc tgcggggggtg cgcctggagc aggtggagca 2280  
 gccaccagct caccactcc aggaagccgg ggtagccagg ttcccaaggc ctgagtgggt 2340  
 gccacctaat ggctgaagaa acagaggcct tgggaaaacc agatggcact gtggccctac 2400  
 ctttatggta gaagagctga tttagcctga ctggcagct gtgggggttg tggctggtct 2460  
 gctgctgct ggcgcatcc agcaagcctc agtgcaacaa ctgtgctgca aatggggcca tatagaggaa 2580  
 aggagcagct ggctctggag catggtgtgc actccctttg ggccttcagt ccatgtctca 2640  
 tgggtcgtat gacactgcgg gcttgttgggt tgccaagagg cagaccacag gtcatcttga 2700  
 ggaggacttt atgttccagt ccagaaagca gccagtggta ccaccaggg gacttgtgct 2760  
 tctgtgcca ggccagacgt agaatttgac aaagttagga cggctcctagt cagagcggcg 2820  
 tgtcgggtccc cggggcctgt gcatgccggg cagggccggg ctggcttggg gagcaagcag 2880  
 ccacctctgt taagggtgtg cctggagcag gtggagcagc caccaacctc acgcaactga 2940  
 agaagcagg atggccagg tccaacatcc tgagtggctg ccacctgatg gctgatggag 3000  
 cagaggcctg aggaaaagca gatggcactg ctttgtagtgt ctgttctttg tctctcttga 3060  
 tctttttcag ttaatgtctg ttttatcaga gactaggatt gcaaaccctg ctcttttttg 3120  
 ctttccattt gcttggtaaa tattcctcca tccctttatt ttaagcctat gtgtgtcttt 3180  
 gcacatgaga tgggtctcct gaatacagga caacaatggg tctttactct ttatccaact 3240  
 tgccagtctg tgtcttttaa ctggggcatt tagccattt acatttaagt ttagtattgt 3300  
 tacatgtgaa atttatcctg tcatgatgtt gctagctttt tatttttccc attagtgtgc 3360  
 agtttcttta tagtgtcaat ggtctttaca attogatag tttttgtagt ggctggtaact 3420  
 ggtttttcct ttctacgttt agtgtctcct tcaggagctc ttgtaacaca agaattgtga 3480  
 tttatttctt gtaaggtaaa tatgtggatt tatttcttgg gactgtattc tatggccttt 3540  
 accccaagaa tcattacttt ttaaaatgca attcaaatta gcataaaaca ttacagcct 3600  
 atggaaaggc ttgtggcatt agaatcctta tttataggat tattttgtgt ttttttgaga 3660  
 tatggtcttt gtcacgagg cagaagtgcc gtgggttgat cataattcac cacagccctg 3720  
 aactcttgag tccaagccat ccttttgcct taatctccca accagttgga tctgcaggca 3780  
 taaggcatca tgcgtggcta atttttcac gttttttttt ttttttgtc gagattatgg 3840  
 tgtcactgtg ttgctctggc tgatctcaaa tggttgacct caagggatct ttctgccacg 3900  
 gcctcctaaa gtgctaggat tatatgcatg atacaccatg cctattgtag agtattacat 3960  
 tattttcaaa gtcttattgt aagagccatt tattgccttt ggcctaaata actcaatata 4020  
 atatctctga aacttttttt tgacaaattt tggggcgtga tgatgagaga aggggggtttg 4080  
 aaactttcta ataagagtta acttagagcc atttaagaaa ggaaaaaaca caaattatca 4140



```

gaaaaacaac agtaagatca agtgcaaaaag ttctgtggca aagatgatga gagtaaagaa 4200
tatatgtttg tgactcatgg tggcttttac tttgttcttg aatttctgag tacgggttaa 4260
catttaaaga atctacatta tagataacat tttattgcaa gtaaagtgtat ttcaaaattt 4320
gttattgggt ttgtatgaga ttattctcag cctacttcat tatcaagcta tattatttta 4380
ttaatgtagt tcgatgatct tacagcaaag ctgaaagctg tatcttcaaa atatgtctat 4440
ttgactaaaa agttattcaa caggagttat tatctataaa aaaaatacaa caggaatata 4500
aaaaacttga ggataaaaag atgttggaag aagtaatat aaatcttaaa aaacatattg 4560
aaactacaca atggtgaaga cacattgggt aagtacaaaa atataaattg gatctagaag 4620
aaagggcaat gcaggcaata gaaaaattag tagaaatccc tttaaagggt agtttgtaaa 4680
atcaggtaag tttatttata atttgctttc atttatttca ctgcaaatta tattttggat 4740
atgtatatat attgtgcttc ctctgcctgt cttacagcaa ttgacctgc agagtcttag 4800
gaaaaagggt gcatgtgttt ttactttcaa aatattttaa ttccatcat tataacaaaa 4860
tcaatttttc agagtaatga ttctcactgt ggagtcattt gattattaag acccggtggc 4920
ataagattac atcctctgac tataaaaatc ctggaagaaa acctaggaaa tattcgtctg 4980
gacattgcac ttggcaatga atttatgggt aacctatgat ccacttccag tcaactatcca 5040
tgagttttta ttccagata catgaaatca tatgagttga aactttcttt tgattgagca 5100
gtttggaac cgtctttttg tagaatctgc aagtggatat ttggaaccct ttgaggccta 5160
tgctgaaaaa agaaatatct tcactacatg atgaccacca gcagcagctg gggaaaccag 5220
cacctgtgg aattccatac ggtgcataga atacatcctc ccttcagtcg gcttgggtca 5280
acttaggtca tgggccacct ggctgatagc agtttccaca gaaatgcttc aagatgaaag 5340
tggatgaccg ggccaccctc caccactgcc ctgtaagacc atgggacaca caggccacca 5400
gttcttttca tgtggtcatc ccctgttaga tgggagaaaa tacacctgcc tcatttttgt 5460
accttctgtg tgaacattcc acggcagact gtcgctaaat gtggatgaag aattgaatga 5520
atgaatgaat atgagagaaa atgaataaat ggttcagatc ctgggctgga aggtgtgta 5580
tgaggatggt gggtagagga gggctctgtt ttcttgctt taagtacta attgtcactt 5640
tggggcagga gcacaggctt tgaatgcaga ccgactggac ttaattctg gctttactag 5700
ttgtgattgt gtgacctgtt gaaagtact taaacctct gtgctgttt ctttatctgt 5760
aaaatggaga taataagatg tcaaaggact gtggaagaa ttaaatgctt taaaaaaaaa 5820
aaaaaaaaa
5829

```

&lt;210&gt; 474

&lt;211&gt; 1594

&lt;212&gt; DNA

&lt;213&gt; Homo. sapiens

&lt;400&gt; 474

```

atztatggat cattaatgcc tcttttagtag tttagagaaa acgtcaaaaag aaatggcccc 60
agaataagct tcttgatttg taaaattcta tgtcattggc tcaaatttgt atagtatctc 120
aaaatataaa tatatagaca tctcagataa tatatttgaa atagcaaatt cctgttagaa 180
aataatagta cttaactaga tgagaataac aggtcgccat tatttgaatt gtctcctatt 240
cgtttttcat ttgttggtt actcatgttt tacttatgag ggatatatat aacttccact 300
gttttcagaa ttattgtatg cagtcagtat gagaatgcaa ttttaagttt cttgatgctt 360
tttcacactt ctattactag aaataagaat acagtaatat tggcaaagaa aattgaccag 420
ttcaataaaa ttttttagta aatctgattg aaaataaaca ttgcttatgg ctttcttaca 480
tcaatattgt tatgtcctag acaccttatc tgaaattacg gcttcaaaat tctaattatg 540
tgcaaattgt taaaatatca atactttatg ttcaagctgg ggctcttca ggctcctgg 600
gctgagagag aaagatgcta gctccgcaag ccggagaggg aacaccgcca cattgttaca 660
cggacacacc gccacgtgga cacatgacca gactcacatg tacagacaca cggagacatt 720
accacatgga gacaccgtca cacagtcaca cggacacact ggcatagtca catggacgga 780
cacacagaca tatggagaaa tcacatggac acaccaccac actatcacag ggacacagac 840
acacggagac atcaccacat ggacacactg tcacactacc acaggggacac gagacatcac 900
actgtcacat ggacacacca tcacacacat gaacacaccg acacactgcc atatggacac 960
tggcacacac actgccacac tgtcacatgg acacacctcc acaccatcac accaccacac 1020
acactgcctg tggacacaag gacacacaga cactgtcaca cagatacaca aaacactgtc 1080
acacggagac atcaccatgc agatacaca ccacttgggt gccgtctgaa ttaccctgtc 1140
ggggggacag cagtggcata ctcatgccta agtgactggc ttacaccca gtagtgattg 1200
ccctccatca acactgccc cccagggtt ggggtacccc agcccatctt tacaacacag 1260
ggcaagggtga actaatggag tgggtggagg agttggaaga aatcccagcg tcagtcaccg 1320

```

ggatagaatt cccaaggaac cctctttttg gaggatgggt tccattttctg gaggcgatct 1380  
gccgacaggg tgaatgcctt cttgcttgct ttctggggaa tcagagagag tccgttttgt 1440  
ggtgggaaga gtgtggctgt gtactttgaa ctctgtaaa ttctctgact catgtccaca 1500  
aaaccaacag ttttgtgaat gtgtctggag gcaagggaag ggccactcag gatctatgtt 1560  
gaagggaaga ggcttggggc tggagtattc gctt 1594

<210> 475

<211> 2414

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (33)

<223> n=A, T, C or G

<400> 475

cccaacacaa tggctttata agaatgcttc acntgtgaaa aacaaatata aaagtcttct 60  
tgtagattat ttttaaggac aaatctttat tccatgttta atttatttag ctttccctgt 120  
agctaataat tcatgctgaa cacattttta atgctgtaaa ttagagataat gtaatttatg 180  
tatcattaat gcctcttttag tagtttagag aaaacgtcaa aagaaatggc cccagaataa 240  
gcttcttgat ttgtaaaatt ctatgtcatt ggctcaaatt tgtatagtat ctcaaaatat 300  
aaatatatag acatctcaga taatatattt gaaatagcaa attcctgtta gaaaataata 360  
gtacttaact agatgagaat aacaggctgc cattatttga attgtctcct attcgttttt 420  
catttgttgt gttactcatg ttttacttat ggggggatat atataacttc cgctgttttc 480  
agaagtattg tatgcagtca gtatgagaat gcaatttaag tttccttgat gctttttcac 540  
acttctatta ctgaaataa gaatacagta atattggcaa agaaaattga ccagttcaat 600  
aaaatttttt agtaaatctg attgaaaata aacattgctt atggctttct tacatcaata 660  
ttgttatgtc ctgacacct tatctgaaat tacggcttca aaattctaata tatgtgcaaa 720  
tgtgtaaaat atcaatactt tatgttcaag ctggggcctc ttcaggcgctc ctgggctgag 780  
agagaaagat gctagctccg caagccgggg agggaaacacc gccacattgt tacatggaca 840  
caccgccacg tggacacatg accagactca catgtacaga cacacggaga cattaccaca 900  
tggagacacc gtcacacagt cacacgagca cactggcata gtcacatgga cggacacaca 960  
gacatatgga gaaatcacac tgacacacca ccacactatc acagggacac agacacacgg 1020  
agacatcacc acatggacac actgtcacac taccacaggg acacgagaca tcacactgtc 1080  
acatggacac accatcacac acatgaacac accgacacac tgccatatgg acaactgccac 1140  
acacactgcc acactgtcac atggacacac ctccatacca tcacaccacc acacacactg 1200  
ccatgtggag acaaggacac acagacactg tcacacagat acacaaaaca ctgtcacacg 1260  
gagacatcac catgcagata caccaccaca tggacatagc accagacact ctgccacaca 1320  
gatacaccac cacacagaaa tgcggacaca ctgccacaca gacaccacca catcgttgcc 1380  
acactttcat gtgtcagctg gcggtgtggg cccacagact ctgggctcta atcgagaaat 1440  
tacttggaca tatagtgaag gcaaaatttt tttttatttt ctgggtaacc aagcgcgact 1500  
ctgtctcaaa aaaagaaaaa aaaagcaata tactgtgtaa tcgttgacag cataattcac 1560  
tattatgtag atcggagagc agaggattct gaatgcatga acatatcatt aacatttcaa 1620  
tacattactc ataattactg atgaactaaa gagaaaccaa gaaattatgg tgatagtatt 1680  
attgacctgg agaaatgtag acacaaaaga accgtaagat gagaaatgtg ttaacacagt 1740  
ctataagggc atgcaagaat aaaaataggg gagaaaacag gagagttttt caagagcttt 1800  
ctggatcatg aagtcaactt gtatcggtta atttttaaaa ggtttattta catgcaataa 1860  
actgcacata cttcaattgt acattttggg aattcttggc atttgtagct ctataaaacc 1920  
agcaacatat taaaatagca aacatatcca ttacctttac caccaaagtt ttcttgtgtt 1980  
ttttctactc actttttcct gcctatcccc ccatctcttc cacaggtaac cactgatcca 2040  
cttccagtca ctatccatga gtttttattt ccaaatcatat gaaatcatat gaatttctgg 2100  
tttttctctg tggagcccaa ggagcaaggg cagaatgagg aacatgatgt ttcttwccga 2160  
cagttactca tgacgtctcc atccaggact gaggggggca tccttctcca tctaggactg 2220  
ggggcatcct tctccatcca gtattggggg tcactcttct ccatccagta ttgggggtca 2280  
tcctctcca tccaggacct gaggggtgtc cttttctgcg cttccttgga tggcagctt 2340  
tccttcatg tttatagtra cttaccatta aatcactgtg ccgttttttc ctaaaataaa 2400  
aaaaaaaaa aaaa 2414

<210> 476  
<211> 3434  
<212> DNA  
<213> Homo sapiens

<400> 476

```
ctgtgctgca aatggggcca tatagaggaa aggagcagct ggctctggag catggtgtgc 60
actccctttg ggccttcagt ccatgtctca tgggtcgtat gacactgcgg gcttgttggg 120
tgccaagagg cagaccacag gtcatcttga ggaggacttt atgttccagt ccagaaagca 180
gccagtggta ccaccagggg gacttgtgct tctgtggccc aggcagacg tagaatttga 240
caaagtcagg acggtctcag tcagagcagc atgtcgggtcc ccggggcctg tgcatgccgg 300
gcagggccag gctggcttaa ggagcaagca gccacctctg ttaggggtgt gcctggagca 360
ggtggagcag ccaccaacct cagcactga aagaagcagg gatggccagg ttccaacatc 420
ctgagtggct gccacctgat ggctgatgga gcagagccct gaggaaaagc agatggcact 480
gctttgtagt gctgttcttt gtctctcttg atctttttca gttaatgtct gttttatcag 540
agactaggat tgcaaacctt gctctttttt gctttccatt tgcttggtaa atattcctcc 600
atccctttat ttttaagccta tgtgtgtctt tgcacatgag atgggtctcc tgaatacagg 660
acaacaatgg gtctttactc tttatccaac ttgccagtct gtgtctttta actggggcat 720
ttagccatt tacatttaag ttttagtattt gttacatgtg aaatttatcc tgtcatgatg 780
ttgctagctt tttatttttc ccattagttt gcagtttctt tatagtgtca atgggtctta 840
caattcgata tgtttttgta gtggctggta ctggtttttc ctttctacgt ttagtgtctc 900
cttcaggagc tcttgtaaca caagaatgtg gatttatttc ttgtaaggta aatatgtgga 960
tttattctgg gactgtattc tatggccttt accccaagaa tcattacttt ttaaaatgca 1020
attcaaatta gcataaaaca tttacagcct atggaaaggc ttgtggcatt agaatcotta 1080
tttataggat tattttgtgt ttttttgaga tatggtcttt gtcacagagg cagaagtgcc 1140
gtggtttgat cataattcac cacagccctg aactcttgag tccaagccat cttttgcct 1200
taatctcca accagttgga tctacaagca taaggcatca tgcgtggcta attttttcac 1260
gttttttttt tttttgtcga gattatggta tcaactgtgtt gctctggctg atctcaaag 1320
tttgacctca agggatcttt ctgccacagc ctctaaagt gctaggatta tatgcatgat 1380
acaccatgcc tattgtagag tattacatta ttttcaaagt cttattgtaa gagccattta 1440
ttgcctttgg cctaataaac tcaatataat atctctgaaa cttttttttg acaaattttg 1500
ggcgctgtag atgagagaag ggggtttgaa acttttcta atagagttaac ttagagccat 1560
ttaagaaagg aaaaaacaca aattatcaga aaaacaacag taagatcaag tgcaaaagtt 1620
ctgtggcaaa gatgatgaga gtaaagaata tatgtttgtg actcatgggtg gcttttactt 1680
tgttcttgaa tttctgagta cgggttaaca tttaaagaat ctacattata gataacattt 1740
tattgcaagt aaatgtattt caaaatttgt tattggtttt gtatgagatt attctcagcc 1800
tacttcatta tcaagctata ttattttatt aatgtagttc gatgatctta cagcaaagct 1860
gaaagctgta tcttcaaaat atgtctattt gactaaaaag ttattcaaca ggagttatta 1920
tctataaaaa aatacaacag gaatataaaa aacttgagga taaaaagatg ttggaaaaag 1980
taatattaaa tcttaaaaaa catatggaaa ctacacaatg gtgaagacac attggtgaag 2040
tacaanaata taaattggat ctagaagaaa gggcaatgca ggcaatagaa aaattagtag 2100
aaatcccttt aaaggttagt ttgtaaaatc aggttaagttt atttataatt tgctttcatt 2160
tatttcaactg caaattatat tttggatatg tatatatatt gtgcttcctc tgcctgtctt 2220
acagcaattt gccttgcaag gttctaggaa aaagggtggca tgtgttttta ctttcaaaat 2280
atttaaatth ccattcattat aacaaaatca atttttcaga gtaatgattc tcaactgtgga 2340
gtcatttgat tattaagacc cgttggcata agattacatc ctctgactat aaaaatcctg 2400
gaagaaaacc taggaaatat tcgtctggac attgcaactg gcaatgaatt tatgggcgct 2460
ttggaatcct gcagataata taatgataat taacaaaaac actcagagaa actgccaacc 2520
ctaggatgaa gtatattgtt actgtgcttt gggattaaaa taagtaacta cagttttatg 2580
aacttttata ctgatacaca gacactaaaa agggaaaggg tttagatgag aagctctgct 2640
atgcaatcaa gaatctcagc cactcatttc tgtaggggct gcaggagctc cctgtaaaaga 2700
gaggttatgg agtctgtagc ttcaggtaag atacttaaaa cccttcagag tttctccatt 2760
ttttcccata gtttcccaa aaaggttatg acactttata agaagcttc acttgtgaaa 2820
aacaatatc aaagtcttct tgtagattat ttttaaggac aaatctttat tccatgttta 2880
atttatttag ctttccctgt agctaataat tcatgtgaa cacattttta atgctgtaaa 2940
tgtagataat gtaatttatg tatcattaat gcctctttag tagtttagag aaaacgtcaa 3000
aagaaatggc ccagaataa gcttcttgat ttgtaaaatt ctatgtcatt ggctcaaatt 3060
```

```
<210> 477
<211> 140
<212> PRT
<213> Homo sapiens
```

<400> 477  
Met Asp Gly His Thr Asp Ile Trp Arg Asn His Met Asp Thr Pro Pro  
5' 10 15

His Tyr His Arg Asp Thr Asp Thr Arg Arg His His His Met Asp Thr  
20 25 30

Leu Ser His Tyr His Arg Asp Thr Arg His His Thr Val Thr Trp Thr  
35 40 45

His His His Thr His Glu His Thr Asp Thr Leu Pro Tyr Gly His Trp  
50 55 60

His Thr His Cys His Thr Val Thr Trp Thr His Leu His Thr Ile Thr  
65 70 75 80

Pro Pro His Thr Leu Pro Val Asp Thr Arg Thr His Arg His Cys His  
85 90 95

Thr	Asp	Thr	Gln	Asn	Thr	Val	Thr	Arg	Arg	His	His	His	Ala	Asp	Thr
			100					105					110		

Pro Pro Leu Trp Cys Arg Leu Asn Tyr Pro Ala Gly Gly Thr Ala Val  
115 120 125

Ala Tyr Ser Cys Leu Ser Asp Trp Leu Ser Pro Gln  
130 135 140

```
<210> 478
<211> 143
<212> PRT
<213> Homo sapiens
```

```
<400> 478
Met Tyr Arg His Thr Glu Thr Leu Pro His Gly Asp Thr Val Thr Gln
          5              10              15
```

Ser His Gly His Thr Gly Ile Val Thr Trp Thr Asp Thr Gln Thr Tyr  
20 25 30

Gly Glu Ile Thr Trp Thr His His His Thr Ile Thr Gly Thr Gln Thr  
35 40 45

His Gly Asp Ile Thr Thr Trp Thr His Cys His Thr Thr Thr Gly Thr

50                      55                      60  
 Arg Asp Ile Thr Leu Ser His Gly His Thr Ile Thr His Met Asn Thr  
 65                      70                      75                      80  
 Pro Thr His Cys His Met Asp Thr Gly Thr His Thr Ala Thr Leu Ser  
                     85                      90                      95  
 His Gly His Thr Ser Thr Pro Ser His His His Thr His Cys Leu Trp  
                     100                      105                      110  
 Thr Gln Gly His Thr Asp Thr Val Thr Gln Ile His Lys Thr Leu Ser  
                     115                      120                      125  
 His Gly Asp Ile Thr Met Gln Ile His His His Ser Gly Ala Val  
                     130                      135                      140

<210> 479  
 <211> 222  
 <212> PRT  
 <213> Homo sapiens

<400> 479  
 Met Tyr Arg His Thr Glu Thr Leu Pro His Gly Asp Thr Val Thr Gln  
                     5                      10                      15  
 Ser His Glu His Thr Gly Ile Val Thr Trp Thr Asp Thr Gln Thr Tyr  
                     20                      25                      30  
 Gly Glu Ile Thr Leu Thr His His His Thr Ile Thr Gly Thr Gln Thr  
                     35                      40                      45  
 His Gly Asp Ile Thr Thr Trp Thr His Cys His Thr Thr Thr Gly Thr  
                     50                      55                      60  
 Arg Asp Ile Thr Leu Ser His Gly His Thr Ile Thr His Met Asn Thr  
                     65                      70                      75                      80  
 Pro Thr His Cys His Met Asp Thr Ala Thr His Thr Ala Thr Leu Ser  
                     85                      90                      95  
 His Gly His Thr Ser Ile Pro Ser His His His Thr His Cys His Val  
                     100                      105                      110  
 Asp Thr Arg Thr His Arg His Cys His Thr Asp Thr Gln Asn Thr Val  
                     115                      120                      125  
 Thr Arg Arg His His His Ala Asp Thr Pro Pro His Gly His Ser Thr  
                     130                      135                      140  
 Arg His Ser Ala Thr Gln Ile His His His Thr Glu Met Arg Thr His  
                     145                      150                      155                      160  
 Cys His Thr Asp Thr Thr Thr Ser Leu Pro His Phe His Val Ser Ala  
                     165                      170                      175  
 Gly Gly Val Gly Pro Thr Thr Leu Gly Ser Asn Arg Glu Ile Thr Trp

180 185 190

Thr Tyr Ser Glu Gly Lys Ile Phe Phe Tyr Phe Leu Gly Asn Gln Ala  
195 200 205

Arg Leu Cys Leu Lys Lys Arg Lys Lys Lys Gln Tyr Thr Val  
210 215 220

<210> 480  
<211> 144  
<212> PRT  
<213> Homo sapiens

<400> 480  
Met Glu Pro Tyr Arg Gly Asn Glu Gln Pro Ser Gln Glu Gln Gly Val  
5 10 15

Cys Cys Leu Trp Gly Leu Gln Ser Leu Pro Gln Gly Ser Tyr Val Thr  
20 25 30

Val Gly Phe Leu Val Val Lys Arg Gln Thr Ile Gly Arg Leu Glu Arg  
35 40 45

Asp Phe Met Phe Lys Cys Arg Lys Gln Pro Gly Leu Pro Pro Ser Gly  
50 55 60

Leu Cys Leu Leu Trp Pro Trp Pro Asn Leu Glu Phe Gly Arg Arg Gln  
65 70 75 80

Asp Arg Leu Thr Trp Ser Ser Val Ser Val Ala Gly Val Cys Ala Cys  
85 90 95

Arg Ala Arg Pro Gly Trp Leu Gly Glu Gln Pro Ala Thr Ser Ala Gly  
100 105 110

Val Arg Leu Glu Gln Val Glu Gln Pro Pro Ala His Pro Leu Gln Glu  
115 120 125

Ala Gly Val Ala Arg Phe Pro Arg Pro Glu Trp Val Pro Pro Asn Gly  
130 135 140

<210> 481  
<211> 167  
<212> PRT  
<213> Homo sapiens

<400> 481  
Met His Gly Pro Gln Val Leu Ala Arg Cys Ser Glu Cys Ala Cys Pro  
5 10 15

Ala Leu Ala Ala Thr Ser Ala Gly Val Arg Leu Glu Gly Val Asp Arg  
20 25 30

Pro Pro Thr Leu Pro Ser Gln Gly Ser Gly Trp Pro Cys Ser His Ser  
           35                          40                          45  
 Leu Ser Gly Cys His Leu Met Ala Asp Gly Ala Lys Ala Leu Gly Lys  
           50                          55                          60  
 Ala Asp Gly Pro Trp Pro Tyr Leu Phe Val Arg Arg Thr Asp Val Pro  
           65                          70                          75                          80  
 Cys Pro Ala Ala Ser Glu Val Gly Gly Cys Ala Pro Ser Ser Trp Arg  
                           85                          90                          95  
 Ala Leu Ala Glu Val Thr Gly Cys Ser Leu Gly Pro Leu Gly Leu Ala  
                           100                          105                          110  
 Gln His Ala Gln Ala Ser Val Leu Leu Leu Cys Tyr Lys Trp Ser His  
           115                          120                          125  
 Ile Gly Glu Thr Ser Ser His Leu Arg Ser Lys Val Tyr Ala Ala Phe  
           130                          135                          140  
 Gly Gly Ser Ser Pro Cys Leu Lys Gly Leu Met Ser Leu Trp Ala Ser  
           145                          150                          155                          160  
 Trp Leu Ser Arg Gly Arg Pro  
                           165

&lt;210&gt; 482

&lt;211&gt; 143

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 482

Met Glu Pro Tyr Arg Gly Asn Lys Lys Gln Val Gln Glu Lys Gly Val  
                           5                          10                          15  
 Pro Cys Leu Trp Gly Ser Ser Pro Cys Leu Arg Cys His Met Ala Leu  
                           20                          25                          30  
 Arg Ala Ser Trp Leu Pro Gly Gly Gly Pro Gln Ala Ile Leu Gly Arg  
                           35                          40                          45  
 Thr Leu Cys Ser Ser Ala Glu Ser Ser Gln Asp Cys His Pro Gly Gly  
           50                          55                          60  
 Pro Ser Ile Ala Leu Ala Lys Pro Cys Arg Gly Val Trp Leu Leu Phe  
           65                          70                          75                          80  
 Glu Pro Ala Trp Pro Pro Trp His Ala Arg Ala Pro Gly Ala Gly Thr  
                           85                          90                          95  
 Leu Leu Arg Val Cys Leu Ser Cys Leu Gly Cys His Leu Cys Gly Gly  
           100                          105                          110  
 Ala Ser Gly Gly Gly Gly Pro Ala Thr Asn Leu Thr Gln Ser Arg Lys  
           115                          120                          125

169

Trp Met Ala Met Phe Pro Gln Pro Glu Trp Leu Pro Pro Asp Gly  
 130 135 140

<210> 483  
 <211> 143  
 <212> PRT  
 <213> Homo sapiens

<400> 483  
 Met Glu Thr Gln Arg Gly Asn Lys Gln Arg Ala Gln Glu Gln Gly Val  
 5 10 15  
 Cys Cys Leu Trp Gly Ser Ser Pro Cys Leu Gly Ser Tyr Gly Thr Ala  
 20 25 30  
 Gly Phe Leu Val Ala Lys Arg Arg Thr Thr Gly Leu Leu Glu Glu Asp  
 35 40 45  
 Phe Thr Phe Lys Cys Arg Lys Gln Pro Lys Leu Pro Ser Met Arg Leu  
 50 55 60  
 Ser Leu Leu Trp Pro Trp Arg Asp Leu Lys Phe Val Pro Arg Gln Asp  
 65 70 75 80  
 Lys Leu Thr Arg Ser Ser Val Ser Val Ala Gly Ala Tyr Ala Cys Arg  
 85 90 95  
 Ala Gly Pro Gly Trp Leu Lys Glu Gln Pro Ala Thr Ser Ala Arg Val  
 100 105 110  
 Arg Leu Val Gln Ala Glu His Pro Pro Pro His Pro Leu Glu Glu Val  
 115 120 125  
 Gly Met Ala Arg Phe Pro Gln Pro Glu Cys Leu Pro Pro Tyr Cys  
 130 135 140

<210> 484  
 <211> 30  
 <212> PRT  
 <213> Homo Sapien

<400> 484  
 Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe  
 1 5 10 15  
 Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile  
 20 25 30

<210> 485  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 485  
 gggaagctta tcacctatgt gccgcctctg c



<210> 486  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 486  
 gcgaattctc acgctgagta tttggcc

27

<210> 487  
 <211> 36  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 487  
 cccgaattct tagctgcca tccgaacgcc ttcata

36

<210> 488  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 488  
 gggaagcttc ttcccggct gcaccagctg tgc

33

<210> 489  
 <211> 19  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 489  
 Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala  
 1 5 10 15  
 Ser Val Ala

<210> 490  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 490  
 Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys

```
<210> 491
<211> 20
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Made in a lab

```
<210> 492
<211> 20
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Made in a lab

```
<210> 493
<211> 20
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Made in a lab

```
<210> 494
<211> 20
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Made in a lab

<400> 494  
Leu Pro Lys Tyr Arg Gly Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser  
1 5 10 15  
Leu Met Ile Ser

20

<210> 495  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

&lt;400&gt; 495

Asp	Ser	Leu	Met	Thr	Ser	Phe	Leu	Pro	Gly	Pro	Lys	Pro	Gly	Ala	Pro
1				5					10					15	
Phe	Pro	Asn	Gly												
			20												

<210> 496  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

&lt;400&gt; 496

Ala	Pro	Phe	Pro	Asn	Gly	His	Val	Gly	Ala	Gly	Gly	Ser	Gly	Leu	Leu
1				5				10						15	
Pro	Pro	Pro	Pro	Ala											
				20											

<210> 497  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

&lt;400&gt; 497

Leu	Leu	Pro	Pro	Pro	Pro	Ala	Leu	Cys	Gly	Ala	Ser	Ala	Cys	Asp	Val
1				5				10						15	
Ser	Val	Arg	Val												
			20												

<210> 498  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

&lt;400&gt; 498

Asp	Val	Ser	Val	Arg	Val	Val	Val	Gly	Glu	Pro	Thr	Glu	Ala	Arg	Val
1				5				10						15	
Val	Pro	Gly	Arg												
			20												

<210> 499  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 499  
 Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp  
 1 5 10 15  
 Ser Ala Phe Leu  
 20

<210> 500  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 500  
 Leu Asp Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met  
 1 5 10 15  
 Gly Ser Ile Val  
 20

<210> 501  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 501  
 Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met  
 1 5 10 15  
 Val Ser Ala Ala  
 20

<210> 502  
 <211> 414  
 <212> DNA  
 <213> Homo Sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(414)  
 <223> n=A,T,C or G

<400> 502  
 caccatggag acaggcctgc gctggctttt cctgggtcgt gtgctcaaag gtgtccaatg 60  
 tcagtcggtg gaggagtccg ggggtcgctt ggtcacgcct gggacacctt tgacantcac 120  
 ctgtagagtt ttgtgaatng acctcagtag caatgcaatg agctgggtcc gccaggctcc 180  
 agggaagggg ctggaatgga tcggagccat tgataattgt ccacantacg cgacctgggc 240

gaaaggccga ttnatnat ttt ccaaaacctn gaccacgggtg gatttgaaaa tgaccagtcc 300  
 gacaaccgag gacacggcca cctatttttg tggcagaatg aatactggta atagtgggtg 360  
 gaagaatatt tggggcccag gcacctgtgt caccgtntcc tcagggcaac ctaa 414

<210> 503  
 <211> 379  
 <212> DNA  
 <213> Homo Sapien

<220>  
 <221> misc\_feature  
 <222> (1)...(379)  
 <223> n=A,T,C or G

<400> 503  
 atncgatggt gcttgggtcaa aggtgtccag tgtcagtcgg tggaggagtc cggggggtcgc 60  
 ctgggtcacgc ctgggacacc cctgacactc acctgcaccg tntctggatt ngacatcagt 120  
 agctatggag tgagctgggt ccgccaggct ccagggaagg ggctgggnata catcggatca 180  
 ttagtagtag tgggtacattt tacgcgagct gggcgaaaagg ccgattcacc atttccaaaa 240  
 cctngaccac ggtggatttg aaaatcacca gtttgacaac cgaggacacg gccacctatt 300  
 tntgtgccag aggggggttt aattataaag acatttgggg cccaggcacc ctggtcaccg 360  
 tntccttagg gcaacctaa 379

<210> 504  
 <211> 19  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 504  
 Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp Ser Pro Tyr Phe Lys Glu  
 1 5 10 15  
 Asn Ser Ala

<210> 505  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 505  
 Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn Asp Asn Val Thr  
 1 5 10 15  
 Asn Thr Ala Asn  
 20

<210> 506  
 <211> 407  
 <212> DNA  
 <213> Homo Sapien

<400> 506

atggagacag	gcctgcgctg	gcttctcctg	gtcgtgtgcg	tcaaagggtgt	ccagtgtcag	60
tcgctggagg	agtccggggg	tcgcctgggc	acgcctggga	cacccctgac	actcacctgc	120
accgtctctg	gattctccct	cagtagcaat	gcaatgatct	gggtccgcca	ggctccaggg	180
aaggggctgg	aatacatcgg	atacattagt	tatggtggta	gcgcatacta	cgcgagctgg	240
gtgaaaggcc	gattcaccat	ctccaaaacc	tcgaccacgg	tggatctgag	aatgaccagt	300
ctgacaaccg	aggacacggc	cacctatttc	tgtgccagaa	atagtgattt	tagtggtatg	360
ttgtggggcc	caggcaccct	ggtcaccgtc	tcctcagggc	aacctaa		407

&lt;210&gt; 507

&lt;211&gt; 422

&lt;212&gt; DNA

&lt;213&gt; Homo Sapien

&lt;400&gt; 507

atggagacag	gcctgcgctg	gcttctcctg	gtcgtgtgc	tcaaagggtgt	ccagtgtcag	60
tcggtggagg	agtccggggg	tcgcctgggc	acgcctggga	cacccctgac	actcacctgt	120
acagtctctg	gattctccct	cagcaactac	gacctgaact	gggtccgcca	ggctccaggg	180
aaggggctgg	aatggatcgg	gatcattaat	tatggtggta	ggacggacta	cgcgaactgg	240
gcaaaaggcc	gggtcaccat	ctccaaaacc	tcgaccacgg	tggatctcaa	gatcgccagt	300
ccgacaaccg	aggacacggc	cacctatttc	tgtgccagag	gggtggaagt	cgatgagtct	360
ggtccgtgct	tgcgcatctg	gggccaggc	accctgggtc	ccgtctcctt	agggcaacct	420
aa						422

&lt;210&gt; 508

&lt;211&gt; 411

&lt;212&gt; DNA

&lt;213&gt; Homo Sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(411)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 508

atggagacag	gcctgcgctg	cttctcctg	tcgctgtgct	caaagggtgt	cagtgtcagt	60
cgggtggagg	gtccgggggt	cgccctggta	cgccctggga	acccctgaca	ctcacctgca	120
cagtctcttg	aatcgacctc	agtagctact	gcatgagctg	ggtcggccag	gctccagggg	180
aggggctgga	atggatcgga	atcattggta	ctcctgggtg	cacatactac	gcgaggtggg	240
cgaaaggccg	attcaccatc	tccaaaacct	cgaccacggg	gcatntgaaa	atcnccagtc	300
cgacaaccga	ggacacggcc	acctatttct	gtgccagaga	tcttcgggat	ggtagtagta	360
ctggttatta	taaaatctgg	ggcccaggca	ccctgggtcac	cgtctccttg	g	411

&lt;210&gt; 509

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Made in a lab

&lt;400&gt; 509

Leu	Cys	Lys	Phe	Thr	Glu	Trp	Ile	Glu	Lys	Thr	Val	Gln	Ala	Ser
1				5					10					15

&lt;210&gt; 510

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Made in a lab

&lt;400&gt; 510

Pro Glu Tyr Asn Arg Pro Leu Leu Ala Asn Asp Leu Met Leu Ile  
 1 5 10 15

&lt;210&gt; 511

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Made in a lab

&lt;400&gt; 511

Tyr His Pro Ser Met Phe Cys Ala Gly Gly Gly Gln Asp Gln Lys  
 1 5 10 15

&lt;210&gt; 512

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Made in a lab

&lt;400&gt; 512

Asp Ser Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu  
 1 5 10 15

&lt;210&gt; 513

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Made in a lab

&lt;400&gt; 513

Ala Pro Cys Gly Gln Val Gly Val Pro Asx Val Tyr Thr Asn Leu  
 1 5 10 15

&lt;210&gt; 514

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Made in a lab

&lt;400&gt; 514

Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser  
 1 5 10 15

&lt;210&gt; 515

<211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 515  
 Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg  
 1 5 10 15

<210> 516  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 516  
 Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln  
 1 5 10 15

<210> 517  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 517  
 Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met  
 1 5 10 15

<210> 518  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 518  
 Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly  
 1 5 10 15

<210> 519  
 <211> 17  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 519  
 Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg Asn Tyr Asp Glu Gly Cys  
 1 5 10 15



Gly

<210> 520  
 <211> 25  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 520  
 Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr  
 1 5 10 15  
 Glu Ala Arg Arg His Tyr Asp Glu Gly  
 20 25

<210> 521  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 521  
 Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly Ser Gly Leu Leu  
 1 5 10 15  
 Pro Pro Pro Pro Ala  
 20

<210> 522  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 522  
 Leu Leu Val Val Pro Ala Ile Lys Lys Asp Tyr Gly Ser Gln Glu Asp  
 1 5 10 15  
 Phe Thr Gln Val  
 20

<210> 523  
 <211> 254  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<220>  
 <221> VARIANT  
 <222> (1)...(254)  
 <223> Xaa = any amino acid

<400> 523

Met	Ala	Thr	Ala	Gly	Asn	Pro	Trp	Gly	Trp	Phe	Leu	Gly	Tyr	Leu	Ile
1				5				10						15	
Leu	Gly	Val	Ala	Gly	Ser	Leu	Val	Ser	Gly	Ser	Cys	Ser	Gln	Ile	Ile
			20					25					30		
Asn	Gly	Glu	Asp	Cys	Ser	Pro	His	Ser	Gln	Pro	Trp	Gln	Ala	Ala	Leu
		35					40					45			
Val	Met	Glu	Asn	Glu	Leu	Phe	Cys	Ser	Gly	Val	Leu	Val	His	Pro	Gln
	50					55					60				
Trp	Val	Leu	Ser	Ala	Thr	His	Cys	Phe	Gln	Asn	Ser	Tyr	Thr	Ile	Gly
65					70				75					80	
Leu	Gly	Leu	His	Ser	Leu	Glu	Ala	Asp	Gln	Glu	Pro	Gly	Ser	Gln	Met
				85					90					95	
Val	Glu	Ala	Ser	Leu	Ser	Val	Arg	His	Pro	Glu	Tyr	Asn	Arg	Pro	Leu
			100					105					110		
Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile	Lys	Leu	Asp	Glu	Ser	Val	Ser	Glu
		115					120					125			
Ser	Asp	Thr	Ile	Arg	Ser	Ile	Ser	Ile	Ala	Ser	Gln	Cys	Pro	Thr	Ala
	130					135					140				
Gly	Asn	Ser	Cys	Leu	Val	Ser	Gly	Trp	Gly	Leu	Leu	Ala	Asn	Gly	Arg
145					150				155					160	
Met	Pro	Thr	Val	Leu	Gln	Cys	Val	Asn	Val	Ser	Val	Val	Ser	Glu	Glu
				165					170					175	
Val	Cys	Ser	Lys	Leu	Tyr	Asp	Pro	Leu	Tyr	His	Pro	Ser	Met	Phe	Cys
			180					185					190		
Ala	Gly	Gly	Gly	Gln	Xaa	Gln	Xaa	Asp	Ser	Cys	Asn	Gly	Asp	Ser	Gly
		195					200					205			
Gly	Pro	Leu	Ile	Cys	Asn	Gly	Tyr	Leu	Gln	Gly	Leu	Val	Ser	Phe	Gly
	210					215					220				
Lys	Ala	Pro	Cys	Gly	Gln	Val	Gly	Val	Pro	Gly	Val	Tyr	Thr	Asn	Leu
225					230					235					240
Cys	Lys	Phe	Thr	Glu	Trp	Ile	Glu	Lys	Thr	Val	Gln	Ala	Ser		
				245					250						

&lt;210&gt; 524

&lt;211&gt; 765

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 524

atggccacag	caggaaatcc	ctggggctgg	ttcctgggggt	acctcatcct	tggtgtcgca	60
ggatcgctcg	tctctggtag	ctgcagccaa	atcataaacg	gcgaggactg	cagcccgcac	120
tcgcagccct	ggcaggcggc	actgggtcatg	gaaaacgaat	tggtctgctc	gggctgctctg	180
gtgcatccgc	agtgggtgct	gtcagccgca	cactgtttcc	agaactccta	caccatcggtg	240
ctgggcctgc	acagtcttga	ggccgaccaa	gagccaggga	gccagatggt	ggaggccagc	300
ctctccgtac	ggcaccacaga	gtacaacaga	cccttgctcg	ctaacgacct	catgtctatc	360
aagttggacg	aatccgtgtc	cgagtctgac	accatccgga	gcatcagcat	tgcttcgcag	420
tgccctaccg	cggggaactc	ttgcctcggt	tctggctggg	gtctgctggc	gaacggcaga	480
atgcctaccg	tgctgcagtg	cgtgaacgtg	tcggtggtgt	ctgaggaggt	ctgcagtaag	540
ctctatgacc	cgctgtacca	ccccagcatg	ttctgcgccg	gcggagggca	agaccagaag	600
gactcctgca	acggtgactc	tggggggccc	ctgatctgca	acgggtactt	gcagggcctt	660
gtgtctttcg	gaaaagcccc	gtgtggccaa	gttggcgctg	caggtgtcta	caccaacctc	720
tgcaaattca	ctgagtggat	agagaaaacc	gtccaggcca	gttaa		765

&lt;210&gt; 525

&lt;211&gt; 254

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 525

```

Met Ala Thr Ala Gly Asn Pro Trp Gly Trp Phe Leu Gly Tyr Leu Ile
 1           5           10           15
Leu Gly Val Ala Gly Ser Leu Val Ser Gly Ser Cys Ser Gln Ile Ile
          20           25           30
Asn Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu
          35           40           45
Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln
          50           55           60
Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly
65           70           75           80
Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
          85           90           95
Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu
          100          105          110
Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu
          115          120          125
Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala
          130          135          140
Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg
          145          150          155          160
Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu
          165          170          175          180
Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys
          180          185          190
Ala Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly
          195          200          205
Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly
          210          215          220
Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu
          225          230          235          240
Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
          245          250

```

&lt;210&gt; 526

&lt;211&gt; 963

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 526

```

atgagttcct gcaacttcac acatgccacc tttgtgctta ttggtatccc aggattagag 60
aaagcccat tctgggttgg cttccccctc ctttccatgt atgtagtggc aatgtttggg 120
aactgcatcg tggcttcat cgtaaggacg gaacgcagcc tgcacgctcc gatgtacctc 180
tttctctgca tgcttgacg cattgacctg gccttatcca catccaccat gcctaagatc 240
cttgcccttt tctgggttga ttcccagagag attagctttg aggcctgtct taccagatg 300
ttctttattc atgccctctc agccattgaa tccaccatcc tgctggccat ggcctttgac 360
cgttatgtgg ccatctgccca cccactgcgc catgctgcag tgctcaacaa tacagtaaca 420
gcccagattg gcatcgtggc tgtggtccgc ggatccctct tttttttccc actgcctctg 480
ctgatcaagc ggctggcctt ctgccactcc aatgtcctct cgcactccta ttgtgtccac 540
caggatgtaa tgaagtggc ctatgcagac actttgccca atgtggtata tggcttact 600
gccattctgc tggatcatgg cgtggacgta atgttcatct ccttgccta ttttctgata 660
atacgaacgg ttctgcaact gccttccaag tcagagcggg ccaaggcctt tggaacctgt 720
gtgtcacaca ttggtgtggt actgccttc tatgtgccac ttattggcct ctcaagtgtg 780
caccgctttg gaaacagcct tcatccatt gtgcgtgttg tcatgggtga catctacctg 840
ctgctgcctc ctgtcatcaa tcccatcatc tatggtgcca aaaccaaaca gatcagaaca 900
cgggtgctgg ctatgttcaa gatcagctgt gacaaggact tgcaggctgt gggaggcaag 960
tga
          963

```

Met Ser Ser Cys Asn Phe Thr His Ala Thr Phe Val Leu Ile Gly Ile  
5 10 15

Pro Gly Leu Glu Lys Ala His Phe Trp Val Gly Phe Pro Leu Leu Ser  
20 25 30

Met Tyr Val Val Ala Met Phe Gly Asn Cys Ile Val Val Phe Ile Val  
35 40 45

Arg Thr Glu Arg Ser Leu His Ala Pro Met Tyr Leu Phe Leu Cys Met  
50 55 60

Leu Ala Ala Ile Asp Leu Ala Leu Ser Thr Ser Thr Met Pro Lys Ile  
65 70 75 80

Leu Ala Leu Phe Trp Phe Asp Ser Arg Glu Ile Ser Phe Glu Ala Cys  
85 90 95

Leu Thr Gln Met Phe Phe Ile His Ala Leu Ser Ala Ile Glu Ser Thr  
100 105 110

Ile Leu Leu Ala Met Ala Phe Asp Arg Tyr Val Ala Ile Cys His Pro  
115 120 125

Leu Arg His Ala Ala Val Leu Asn Asn Thr Val Thr Ala Gln Ile Gly  
130 135 140

```
Ile Val Ala Val Val Arg Gly Ser Leu Phe Phe Phe Pro Leu Pro Leu
145                               150       155           160
```

Leu Ile Lys Arg Leu Ala Phe Cys His Ser Asn Val Leu Ser His Ser  
165 170 175

Tyr Cys Val His Gln Asp Val Met Lys Leu Ala Tyr Ala Asp Thr Leu  
180 185 190

Pro Asn Val Val Tyr Gly Leu Thr Ala Ile Leu Leu Val Met Gly Val  
195 200 205

Asp Val Met Phe Ile Ser Leu Ser Tyr Phe Leu Ile Ile Arg Thr Val  
210 215 220

Leu Gln Leu Pro Ser Lys Ser Glu Arg Ala Lys Ala Phe Gly Thr Cys  
225 230 235 240

Val Ser His Ile Gly Val Val Leu Ala Phe Tyr Val Pro Leu Ile Gly  
245 250 255

Leu Ser Val Val His Arg Phe Gly Asn Ser Leu His Pro Ile Val Arg  
260 265 270

Val Val Met Gly Asp Ile Tyr Leu Leu Leu Pro Pro Val Ile Asn Pro  
 275 280 285

Ile Ile Tyr Gly Ala Lys Thr Lys Gln Ile Arg Thr Arg Val Leu Ala  
 290 295 300

Met Phe Lys Ile Ser Cys Asp Lys Asp Leu Gln Ala Val Gly Gly Lys  
 305 310 315 320

<210> 528  
 <211> 20  
 <212> DNA  
 <213> Homo Sapien

<400> 528  
 actatgggtcc agaggctgtg

20

<210> 529  
 <211> 20  
 <212> DNA  
 <213> Homo Sapien

<400> 529  
 atcacctatg tgccgcctct

20

<210> 530  
 <211> 1852  
 <212> DNA  
 <213> Homo sapiens

<400> 530

ggcacgagaa	ttaaaaccct	cagcaaaaaca	ggcatagaag	ggacatacct	taaagtaata	60
aaaaccacct	atgacaagcc	cacagccaac	ataatactaa	atgggggaaa	gtagaagca	120
tttcctctga	gaactgcaac	aataaatata	aggatgctgg	atgttgtaa	atgccttttc	180
tgtgtctgtt	gagatgctta	tgtgactttg	cttttaattc	tgtttatgtg	attatcacat	240
ttattgactt	gcctgtgtta	gaccggaaga	gctgggggtg	ttctcaggag	ccaccgtgtg	300
ctgcggcagc	ttcgggataa	cttgaggctg	catcactggg	gaagaaacac	aytcctgtcc	360
gtggcgctga	tggctgagga	cagagcttca	gtgtggcttc	tctgogactg	gcttcttcgg	420
ggagttcttc	cttcatagtt	catccatatg	gctccagagg	aaaattatat	tattttgtta	480
tggatgaaga	gtattacgtt	gtgcagatat	actgcagtgt	cttcatctct	tgatgtgtga	540
ttgggtaggt	tccaccatgt	tgccgcagat	gacatgattt	cagtacctgt	gtctggctga	600
aaagtgtttg	tttgtgaatg	gatattgtgg	tttctggatc	tcatcctctg	tgggtggaca	660
gctttctcca	ccttgctgga	agtgcactgc	tgtccagaag	tttgatggct	gaggagtata	720
ccatcgtgca	tgcatctttc	atttcctgca	tttcttcctc	cctggatgga	cagggggagc	780
ggcaagagca	acgtgggcac	ttctggagac	cacaacgact	cctctgtgaa	gacgcttggg	840
agcaagaggt	gcaagtgggtg	ctgccactgc	ttcccctgct	gcagggggag	cggcaagagc	900
aacgtggtcg	cttggggaga	ctacgatgac	agcgccttca	tggatcccag	gtaccacgtc	960
catggagaag	atctggacaa	gctccacaga	gctgcctggt	ggggtaaagt	ccccagaaag	1020
gatctcatcg	tcatgctcag	ggacacggat	gtgaacaaga	gggacaagca	aaagaggact	1080
gctctacatc	tggcctctgc	caatgggaat	tcagaagtag	taaaactcgt	gctggacaga	1140
cgatgtcaac	ttaatgtcct	tgacaacaaa	aagaggacag	ctctgacaaa	ggccgtacaa	1200
tgccaggaag	atgaatgtgc	gttaatgttg	ctggaacatg	gcactgatcc	aaatattcca	1260
gatgagtatg	gaaataccac	tctacactat	gctgtctaca	atgaagataa	attaatggcc	1320
aaagcactgc	tcttatacgg	tgctgatata	gaatcaaaaa	acaagcatgg	cctcacacca	1380
ctgctacttg	gtatacatga	gcaaaaaacag	caagtgggtga	aatttttaat	caagaaaaaa	1440
gcgaatttaa	atgcgctgga	tagatatgga	agaactgctc	tcatacttgc	tgtatgttgt	1500
ggatcagcaa	gtatagtcag	ccctctactt	gagcaaaatg	ttgatgtatc	ttctcaagat	1560
ctggaaagac	ggccagagag	tatgctgttt	ctagtcatca	tcatgtaatt	tgccagttac	1620

```
<210> 531
<211> 879
<212> DNA
<213> Homo sapiens
```

<400> 531						
atgcatcttt	catttcctgc	atttcttcct	ccctggatgg	acagggggag	cggcaagagc	60
aacgtgggca	cttctggaga	ccacaacgac	tcctctgtga	agacgcttgg	gagcaagagg	120
tgcaagtgg	gctgccactg	cttcccctgc	tgcaagggga	gcggaagag	caacgtggtc	180
gcttggggag	actacgatga	cagcgccttc	atggatccca	ggtaccacgt	ccatggagaa	240
gatctggaca	agctccacag	agctgcctgg	tggggtaaag	tccccagaaa	ggatctcatc	300
gtcatgtctca	gggacacgga	tgtgaacaag	agggcaaacg	aaaagaggac	tgtctcatat	360
ctggcctctg	ccaatgggaa	ttcagaagta	gtaaaactcg	tgctggacag	acgatgtcaa	420
cttaaatgtcc	ttgacaacaa	aaagaggaca	gctctgacaa	aggccgtaca	atgccaggaa	480
gatgaatgtg	cgттаатgtt	gctggaacat	ggcactgata	caaataattcc	agatgagtat	540
ggaaataacca	ctctacacta	tgtgtgtctac	aatgaagata	aattaatggc	caaagcactg	600
ctcttatacg	gtgctgatat	cgaatcaaaa	aacaagcatg	gcctcacacc	actgctactt	660
ggtatacatg	agcaaaaaca	gcaagtgggtg	aaattttttaa	tcaagaaaaa	agcgaattta	720
aatgcgctgg	atagatatatg	aagaactgct	ctcatacttg	ctgtatgttg	tggatcagca	780
agtatagtca	gcctctact	tgagcaaaa	gttgatgtat	cttctcaaga	tctggaaaga	840
cqgccagaga	gtatctcttt	tctagtcatc	atcatgtaa			879

```
<210> 532
<211> 292
<212> PRT
<213> Homo sapiens
```

<400> 532  
Met His Leu Ser Phe Pro Ala Phe Leu Pro Pro Trp Met Asp Arg Gly  
5 10 15

Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp His Asn Asp Ser Ser  
20 25 30

Val Lys Thr Leu Gly Ser Lys Arg Cys Lys Trp Cys Cys His Cys Phe  
35 40 45

Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val Val Ala Trp Gly Asp  
50 55 60

Tyr Asp Asp Ser Ala Phe Met Asp Pro Arg Tyr His Val His Gly Glu  
65 70 75 80

Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg  
85 90 95

Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Arg Asp  
100 105 110

Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser  
115 120 125

Glu Val Val Lys Leu Val Leu Asp Arg Arg Cys Gln Leu Asn Val Leu

130 135 140

Asp Asn Lys Lys Arg Thr Ala Leu Thr Lys Ala Val Gln Cys Gln Glu  
145 150 155 160

Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile  
165 170 175

Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Val Tyr Asn Glu  
180 185 190

Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu  
195 200 205

Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Ile His Glu  
210 215 220

Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu  
225 230 235 240

Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala Val Cys  
245 250 255

Cys Gly Ser Ala Ser Ile Val Ser Pro Leu Leu Glu Gln Asn Val Asp  
260 265 270

Val Ser Ser Gln Asp Leu Glu Arg Arg Pro Glu Ser Met Leu Phe Leu  
275 280 285

Val Ile Ile Met  
290

<210> 533  
<211> 801  
<212> DNA  
<213> Homo sapiens

<400> 533

atgtacaagc ttcagtgc aaactgtgct acaaattggag ccacagagag gaaacaagca 60  
gcaggctcag gagcagggtg tgcgctgcct tcggctctcc aatccatgcc tcagggtccc 120  
tatgccactg cacgattctt gggtgccaa aggccaaacca caggccatct tgagaaggag 180  
tttatgttcc actgcagaaa gcagccagga tcaccatcca ggggacttgg tcttctgtgg 240  
ccctggccag acatagaatt tgtgccaaagg caggacaagc tcaactcagag cagcgtgtta 300  
gtacctcaaa tctgtgcgtg ccagacaagg ccaaactggc tcaatgagca accagccacc 360  
tctgcagggg tgcgtctgga ggaggtggac cagccaccaa ccttaccag tcaagggaagt 420  
ggatggccat gttcccacag cctgagtggc tgccacctga tggctgatag agcaaaggcc 480  
ttaggaaaag cagatggccc ttggccctac ctttttgtta gaagaactga tgttccatgt 540  
cctgcagcga gtgaggttgg tggctgtgcc cccagctcct ggcacaccct cgcagagggtg 600  
actggttgct ctttgagccc tottagcctt gccagcatg cacaagcctc agtgctacta 660  
ctgtgctaca aatggagcca tataggggaa acgagcagcc atctcaggag caaggtgtat 720  
gctgcctttg ggggctccag tccttgccctc aagggtctta tgtcactgtg ggcttcttgg 780  
ttgccaagag gcagaccata g 801

<210> 534  
<211> 266  
<212> PRT  
<213> Homo sapiens

185

&lt;400&gt; 534

Met Tyr Lys Leu Gln Cys Asn Asn Cys Ala Thr Asn Gly Ala Thr Glu  
                   5                  10                  15

Arg Lys Gln Ala Ala Gly Ser Gly Ala Gly Tyr Ala Leu Pro Ser Ala  
           20                  25                  30

Leu Gln Ser Met Pro Gln Gly Ser Tyr Ala Thr Ala Arg Phe Leu Val  
           35                  40                  45

Ala Lys Arg Pro Thr Thr Gly His Leu Glu Lys Glu Phe Met Phe His  
           50                  55                  60

Cys Arg Lys Gln Pro Gly Ser Pro Ser Arg Gly Leu Gly Leu Leu Trp  
           65                  70                  75                  80

Pro Trp Pro Asp Ile Glu Phe Val Pro Arg Gln Asp Lys Leu Thr Gln  
                   85                  90                  95

Ser Ser Val Leu Val Pro Gln Ile Cys Ala Cys Gln Thr Arg Pro Asn  
           100                  105                  110

Trp Leu Asn Glu Gln Pro Ala Thr Ser Ala Gly Val Arg Leu Glu Glu  
           115                  120                  125

Val Asp Gln Pro Pro Thr Leu Pro Ser Gln Gly Ser Gly Trp Pro Cys  
           130                  135                  140

Ser His Ser Leu Ser Gly Cys His Leu Met Ala Asp Ile Ala Lys Ala  
           145                  150                  155                  160

Leu Gly Lys Ala Asp Gly Pro Trp Pro Tyr Leu Phe Val Arg Arg Thr  
                   165                  170                  175

Asp Val Pro Cys Pro Ala Ala Ser Glu Val Gly Gly Cys Ala Pro Ser  
           180                  185                  190

Ser Trp His Thr Leu Ala Glu Val Thr Gly Cys Ser Leu Ser Pro Leu  
           195                  200                  205

Ser Leu Ala Gln His Ala Gln Ala Ser Val Leu Leu Leu Cys Tyr Lys  
           210                  215                  220

Trp Ser His Ile Gly Glu Thr Ser Ser His Leu Arg Ser Lys Val Tyr  
           225                  230                  235                  240

Ala Ala Phe Gly Gly Ser Ser Pro Cys Leu Lys Gly Leu Met Ser Leu  
           245                  250                  255

Trp Ala Ser Trp Leu Pro Arg Gly Arg Pro  
           260                  265

&lt;210&gt; 535

&lt;211&gt; 6082

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



&lt;400&gt; 535

cctccactat	tacagcttat	aggaaattac	aatccacttt	acaggcctca	aaggttcatt	60
ctggccgagc	ggacaggcgt	ggcgcccgga	gccccagcat	ccctgcttga	ggtccaggag	120
cggagcccg	ggccactgcc	gcctgatcag	cgcgaccccg	gcccgcgccc	gccccgccc	180
gcaagatgct	gcccgtgtac	caggaggtga	agcccaaccc	gctgcaggac	gcgaacctct	240
gctcacgcgt	gttcttctgg	tggctcaatc	ccttgtttaa	aattggccat	aaacggagat	300
tagaggaaga	tgatatgtat	tcagtgcctg	cagaagaccg	ctcacagcac	cttggagagg	360
agttgcaagg	gttctgggat	aaagaagttt	taagagctga	gaatgacgca	cagaagcctt	420
ctttaacaag	agcaatcata	aagtgttact	ggaaatctta	tttagttttg	ggaattttta	480
cgttaattga	ggaaagtgcc	aaagtaatcc	agcccatatt	tttgggaaaa	attattaatt	540
attttgaaaa	ttatgatccc	atggattctg	tggccttgaa	cacagcgtac	gcctatgcc	600
cgggtgctgac	tttttgacag	ctcatttttg	ctatactgca	tcacttatat	ttttatcacg	660
ttcagtgtgc	tgggatgagg	ttacgagtag	ccatgtgcc	tatgatttat	cggaggcac	720
ttcgtcttag	taacatggcc	atggggaaga	caaccacagg	ccagatagtc	aatctgctgt	780
ccaatgatgt	gaacaagttt	gatcaggtga	cagtgttctt	acacttcctg	tgggcaggac	840
cactgcaggc	gatcgagtg	actgccctac	tctggatgga	gataggaata	tcgtgccttg	900
ctgggatggc	agttctaata	attctcctgc	ccttgcaaa	ctgttttggg	aagttgttct	960
catcactgag	gagtaaaact	gcaactttct	cggatgccag	gatcaggacc	atgaatgaag	1020
ttataactgg	tataaggata	ataaaaatgt	acgcctggga	aaagtcattt	tcaaatctta	1080
ttaccaattt	gagaaagaag	gagatttcca	agattctgag	aagttcctgc	ctcaggggga	1140
tgaatttggc	ttcgtttttc	agtgcagca	aaatcatcgt	gtttgtgacc	ttcaccacct	1200
acgtgctcct	cggcagtggt	atcacagcca	gccgcgtgtt	cgtggcagtg	acgtgtatg	1260
gggctgtgcg	gctgacggtt	accctcttct	tcccctcagc	cattgagagg	gtgtcagagg	1320
caatcgtcag	catccgaaga	atccagacct	ttttgctact	tgatgagata	tcacagcgca	1380
accgtcagct	gccgtcagat	ggtaaaaaga	tggtgcatgt	gcaggatttt	actgcttttt	1440
gggataaggc	atcagagacc	ccaactctac	aaggcctttc	ctttactgtc	agacctggcg	1500
aattgttagc	tgtgttcggc	cccgtgggag	cagggaagtc	atcactgtta	agtgccgtgc	1560
tcgggggaatt	ggccccaagt	cacgggctgg	tcagcgtgca	tggaagaatt	gcctatgtgt	1620
ctcagcagcc	ctgggtgttc	tcgggaactc	tgaggagtaa	tattttattt	gggaagaaat	1680
acgaaaagga	acgatatgaa	aaagtcataa	aggcttgtgc	tctgaaaaag	gatttacagc	1740
tgttgaggga	tggatgatcg	actgtgatag	gagatcgggg	aaccacgctg	agtggagggc	1800
agaaagcacg	ggtaaacctt	gcaagagcag	tgtatcaaga	tgctgacatc	tatctcctgg	1860
acgatcctct	cagtgcagta	gatgcggaag	ttagcagaca	cttggttcgaa	ctgtgtattt	1920
gtcaaatttt	gcatgagaag	atcacaattt	tagtgactca	tcagttgcag	tacctcaaag	1980
ctgcaagtca	gattctgata	ttgaaagatg	gtaaaatggt	gcagaagggg	acttacactg	2040
agttcctaaa	atctgttata	gattttggct	cccttttaaa	gaaggataat	gaggaaagtg	2100
aacaacctcc	agttccagga	actcccacac	taaggaaatcg	taccttctca	gagttctcgg	2160
tttggctca	acaatcttct	agacctcct	tgaagatgg	tgctctggag	agccaagata	2220
cagagaatgt	cccagttaca	ctatcagagg	agaaccgttc	tgaaggaaaa	gttggttttc	2280
aggcctataa	gaattacttc	agagctggtg	ctcactggat	tgtcttcatt	ttccttattc	2340
tcctaaacac	tgcagctcag	gttgccctatg	tgcttcaaga	ttggtggcct	tcatactggg	2400
caaacaaaca	aagtatgcta	aatgtcactg	taaatggagg	aggaaatgta	accgagaagc	2460
tagatcttaa	ctggtactta	ggaattttatt	caggtttaac	tgtagctacc	gttctttttg	2520
gcatagcaag	atctctattg	gtattctacg	tccttggtta	ctcttcacaa	actttgcaca	2580
acaaaatggt	tgagtcaatt	ctgaaagctc	cgttattatt	ctttgataga	aatccaatag	2640
gaagaatttt	aaatcgtttc	tccaaagaca	ttggacactt	ggatgatttg	ctgccgctga	2700
cgtttttaga	tttcatccag	acattgctac	aagtggtttg	tgtggtctct	gtggctgtgg	2760
ccgtgattcc	ttggatcgca	atacccttgg	ttccccttgg	aatcattttc	atttttcttc	2820
ggcgatattt	tttggaacg	tcaagagatg	tgaagcgcct	ggaatctaca	actcggagtc	2880
cagtgttttc	ccacttgtea	tcttctctcc	aggggctctg	gaccatccgg	gcatacaaag	2940
cagaagagag	gtgtcaggaa	ctgtttgatg	cacaccagga	tttacattca	gaggttgggt	3000
tcttgttttt	gacaacgtcc	cgtggttcg	ccgtccgtct	ggatgccatc	tgtgccatgt	3060
ttgtcatcat	ggttgccttt	gggtccctga	ttctggcaaa	aactctggat	gccgggcagg	3120
ttggtttggc	actgtcctat	gccctcacgc	tcactgggat	gtttcagtg	tgtgttcgag	3180
aaagtgtga	agttgagaat	atgatgatct	cagtagaaag	ggtcattgaa	tacacagacc	3240
ttgaaaaaga	agcaccttgg	gaatatcaga	aacgccacc	accagcctgg	ccccatgaag	3300
gagtgataat	ctttgacaat	gtgaacttca	tgtacagtcc	aggtgggcct	ctggtactga	3360

```

agcatctgac agcactcatt aaatcacaaag aaaagggttg cattgtggga agaaccggag 3420
ctggaaaaag ttccctcatc tcagcccttt ttagattgtc agaaccggaa ggtaaaaattt 3480
ggattgataa gatcttgaca actgaaattg gacttcacga ttaaaggaag aaaatgtcaa 3540
tcataacctca ggaacctgtt ttgttcaactg gaacaatgag gaaaaacctg gatcccttta 3600
atgagcacac ggatgaggaa ctgtggaatg ccttacaaga ggtacaactt aaagaaacca 3660
ttgaagatct tcctggtaaa atggatactg aattagcaga atcaggatcc aatttttagtg 3720
ttggacaaag acaactgggtg tgccttgcca gggcaattct caggaaaaat cagatattga 3780
ttattgatga agcgacggca aatgtggatc caagaactga tgagttaata caaaaaaaat 3840
ccgggagaaa tttgccact gcaccgtgct aaccattgca cacagattga acaccattat 3900
tgacagcgac aagataatgg ttttagattc aggaagactg aaagaatatg atgagccgta 3960
tgttttgctg caaaataaag agagcctatt ttacaagatg gtgcaacaac tgggcaaggc 4020
agaagccgct gccctcactg aaacagcaaa acaggtatc ttcaaaagaa attatccaca 4080
tatttggtcac actgaccaca tggttacaaa cacttccaat ggacagccct cgaccttaac 4140
tattttcgag acagcactgt gaatccaacc aaaatgtcaa gtccgttccg aaggcatttg 4200
ccactagttt ttggactatg taaaccacat tgtacttttt tttacttttg caacaaatat 4260
ttatacataa aagatgctag ttcatttgaa tatttctccc aacttatcca aggatctcca 4320
gtctatacaa aatggtttat ttttatttaa atgtcaatag ttgtttttta aaatccaaat 4380
cagaggtgca ggcaccagt taaatgccgt ctatcaggtt ttgtgcctta agagactaca 4440
gagtcaaagc tcatttttaa aggagtagga cagagttgtc acaggttttt gttgttgttt 4500
ttattgcccc caaaattaca tgtaattttc catttatatc agggattcta tttacttgaa 4560
gactgtgaag ttgccatttt gtctcattgt tttctttgac ataactagga tccattattt 4620
cccctgaagg cttcttggtta gaaaatagta cagttacaac caataggaac aacaaaaaga 4680
aaaagtttgt gacattgtag tagggagtggt gtacccctta ctcccatca aaaaaaaaaa 4740
tggtatacat gttaaaggat agaagggcaa tttttatca tatgttctaa aagagaagga 4800
cagaaaaata ctactttctc aaaatggaag cccttaaagg tgctttgata ctgaaggaca 4860
caaatgtgac cgtccatcct ccttttagat tgcatgactt ggacacggtg actggtgcag 4920
ttttagactc agcattgtga cacttcccaa gaaggccaaa cctctaaccg acattcctga 4980
aatacgtggc attattcttt tttggatttc tcatttatgg aaggctaacc ctctgttgac 5040
tgtaagcctt ttggtttggg ctgtattgaa atcctttcta aattgcatga ataggctctg 5100
ctaacgtgat gagacaaact gaaaattatt gcaagcattg actataatta tgcagtacgt 5160
tctcaggatg catccagggg ttcatthttca tgagcctgtc cagggttagtt tactcctgac 5220
cactaatagc attgtcattt gggctttctg ttgaatgaat caacaaacca caatacttcc 5280
tggaaccttt tgtactttat ttgaactatg agtctttaat ttttctgat gatggtggct 5340
gtaatatgtt gtagtctggt tactaaaggt tttactatta tggtttgaag tggagtctca 5400
tgacctctca gaataagggtg tcacctccct gaaattgcat atatgtatat agacatgcac 5460
acgtgtgcat ttgtttgtat acatatattt gtccttcgta tagcaagttt tttgctcatc 5520
agcagagagc aacagatggt ttattgagtg aagccttaaa aagcacacac cacacacagc 5580
taactgcaa aatacattga ccgtagtagc tgttcaactc ctagtactta gaaatacacg 5640
tatggttaat gttcagtcca acaaaccaca cacagtaa at gtttattaat agtcatgggt 5700
cgtatttttag gtgactgaaa ttgcaacagt gatcataatg aggtttgtta aaatgatagc 5760
tatattcaaa atgtctatat gtttatttgg acttttgagg ttaaagacag tcatataaac 5820
gtcctgtttc tgttttaatg ttatcataga attttttaat gaaactaaat tcaattgaaa 5880
taa atgatag ttttcatctc caaaaaaaaaa aaaaaaaagg gcggccgctc gagtctagag 5940
ggcccggtta aacccgctga tcagcctcga ctgtgccttc tagttgccag ccatctgttg 6000
tttgccctc ccccggtgct tccttgacct tggaagggtg cactccact gtcctttcct 6060
aataaaatga ggaaattgca tc 6082

```

&lt;210&gt; 536

&lt;211&gt; 6140

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(6140)

&lt;223&gt; n=A,T,C or G

&lt;400&gt; 536

cagtggcgca	gtctcagctc	actgcagcct	ccacctcctg	tgttcaagca	gtcctcctgc	60
ctcagccacc	agactagcag	gtctcccccg	cctctttctt	ggaaggacac	ttgccattgg	120
atctaggacc	cacttggata	atccaggatg	atgtcttcac	tccaacatcc	tcagtttaac	180
tccattgtga	aatacccttt	tcccaaataa	cattcaattc	tttaccagga	aaggtggctc	240
aatcccttgt	ttaaaattgg	ccataaacgg	agattagagg	aagatgatat	gtattcagtg	300
ctgccagaag	accgctcaça	gcaccttgga	gaggagtgtc	aagggttctg	ggataaagaa	360
gttttaagag	ctgagaatga	cgcacagaag	ccttctttta	caagagcaat	cataaagtgt	420
tactggaaat	cttattttagt	tttggaatt	tttacgttaa	ttgaggaaag	tgccaaagta	480
atccagccca	tatttttggg	aaaaattatt	aattattttg	aaaattatga	tcccatggat	540
tctgtggctt	tgaacacagc	gtacgcctat	gccacggtgc	tgactttttg	cacgctcatt	600
ttggctatac	tgcatacact	atatttttat	cacgttcagt	gtgctgggat	gaggttacga	660
gtagccatgt	gccatatgat	ttatcggaag	gcacttcgtc	ttagtaacat	ggccatgggg	720
aagacaacca	caggccagat	agtcaatctg	ctgtccaatg	atgtgaacaa	gtttgatcag	780
gtgacagtgt	tcttacactt	cctgtgggca	ggaccactgc	aggcgatcgc	agtgactgcc	840
ctactctgga	tggagatagg	aatatcgtgc	cttgctggga	tggcagttct	aatcattctc	900
ctgcccttgc	aaagctgttt	tgggaagttg	ttctcatcac	tgaggagtaa	aactgcaact	960
ttcacggatg	ccaggatcag	gaccatgaat	gaagttataa	ctggtataag	gataataaaa	1020
atgtacgcct	gggaaaagtc	attttcaaat	cttattacca	atttgagaaa	gaaggagatt	1080
tccaagattc	tgagaagttc	ctgcctcagg	gggatgaatt	tggcttcgtt	tttcagtgc	1140
agcaaaatca	togtgtttgt	gaccttcacc	acctacgtgc	tcctcggcag	tgtgatcaca	1200
gccagccgog	tgttcgtggc	agtgcagctg	tatggggctg	tgccgctgac	ggttaccctc	1260
ttcttccctc	cagccattga	gagggtgtca	gaggcaatcg	tcagcatccg	aagaatccag	1320
acctttttgc	tacttgatga	gatatcacag	cgcaaccgtc	agctgccgtc	agatggtaaa	1380
aagatggtgc	atgtgcagga	ttttactgct	ttttgggata	aggcatcaga	gaccccaact	1440
ctacaaggcc	tttcttttac	tgtcagacct	ggcgaattgt	tagctgtggt	cggccccgtg	1500
ggagcagggg	agtcatacact	gttaagtgcc	gtgctcgggg	aattggcccc	aagtacaggg	1560
ctggtcagcg	tgcattggaag	aattgcctat	gtgtctcagc	agccctgggt	gttctcggga	1620
actctgagga	gtaataattt	attttgggaag	aaatacgaaa	aggaacgata	tgaaaaagtc	1680
ataaaggctt	gtgctctgaa	aaaggattta	cagctgtttg	aggatggtga	tctgactgtg	1740
ataggagatc	ggggaaccac	gctgagtggg	gggcagaaag	cacgggtaaa	ccttgcaaga	1800
gcagtgtatc	aagatgctga	catctatctc	ctggacgatc	ctctcagtg	agtagatgog	1860
gaagttagca	gacacttggt	cgaactgtgt	atttgtcaaa	ttttgcatga	gaagatcaca	1920
attttagtga	ctcatcagtt	gcagtacctc	aaagctgcaa	gtcagattct	gatattgaaa	1980
gatggtaaaa	tgggtgcagaa	ggggacttac	actgagttcc	taaaatctgg	tatagatttt	2040
ggctcccttt	taaagaagga	taatgaggaa	agtgaacaac	ctccagttcc	aggaactccc	2100
acactaagga	atcgtacctt	ctcagagtct	tcggtttggt	ctcaacaatc	ttctagaccc	2160
tccttgaaag	atggtgctct	ggagagccaa	gatacagaga	atgtcccagt	tacactatca	2220
gaggagaacc	gttctgaagg	aaaagtgtgt	tttcaggcct	ataagaatta	cttcagagct	2280
ggtgctcact	ggattgtctt	cattttcctt	attctcctaa	acactgcagc	tcaggttgcc	2340
tatgtgcttc	aagattggtg	gctttcatac	tgggcaaaac	aacaaagtat	gctaaatgtc	2400
actgtaaatg	gaggaggaaa	tgtaacccag	aaagctagatc	ttactggta	cttaggaatt	2460
tattcaggtt	taactgtagc	taccgttctt	tttggcatag	caagatctct	attgggtattc	2520
tacgtccttg	ttactctctc	acaaactttg	cacaacaaaa	tgtttgagtc	aattctgaaa	2580
gctccggtat	tattctttga	tagaaatcca	ataggaagaa	ttttaaatcg	tttctccaaa	2640
gacattggac	acttggatga	tttgctgccg	ctgacgtttt	tagatttcat	ccagacattg	2700
ctacaagtg	ttggtgtggt	ctctgtggct	gtggccgtga	ttccttggtg	cgcaataccc	2760
ttggttcccc	ttggaatcat	tttcattttt	cttcggcgat	atttttttga	aacgtcaaga	2820
gatgtgaagc	gcctggaatc	tacaactcgg	agtccagtg	tttcccactt	gtcatcttct	2880
ctccaggggc	tctggaccat	ccgggcatac	aaagcagaag	agaggtgtca	ggaactgttt	2940
gatgcacacc	aggatttaca	ttcagaggct	tggttcttgt	ttttgacaac	gtcccgtgg	3000
ttcgccgtcc	gtctggatgc	catctgtgcc	atgtttgtca	tcacgttg	ctttgggtcc	3060
ctgattctgg	caaaaactct	ggatgccggg	caggttggtt	tggcactgtc	ctatgccctc	3120
acgctcatgg	ggatgtttca	gtggtgtgtt	cgacaaagt	ctgaagttga	gaatatgatg	3180
atctcagtag	aaagggcat	tgaatacaca	gaccttgaaa	aagaagcacc	ttgggaatat	3240
cagaaacgcc	caccaccagc	ctggcccat	gaaggagtga	taatctttga	caatgtgaac	3300
ttcatgtaca	gtccaggtgg	gcctctggtg	ctgaagcatc	tgacagcact	cattaaatca	3360
caagaaaagg	ttggcattgt	gggaagaacc	ggagctggaa	aaagttccct	catctcagcc	3420
cttttttagat	tgtcagaacc	cgaaggtaaa	atttggtatt	ataagatctt	gacaactgaa	3480

```

attggacttc acgattttaag gaagaaaatg tcaatcatat ctcaggaacc tgttttgttc 3540
actggaacaa tgaggaaaaa cctggatccc tttaatgagc acacggatga ggaactgtgg 3600
aatgccttac aagaggtaca acttaaagaa accattgaag atcttcctgg taaaatggat 3660
actgaattag cagaatcagg atccaatttt agtggttgac aaagacaact ggtgtgcott 3720
gccagggcaa ttctcaggaa aaatcagata ttgattattg atgaagcgac ggcaaattgtg 3780
gatccaagaa ctgatgagtt aatacaaaaa aaaatccggg agaaatttgc cactgcacc 3840
gtgctaacca ttgcacacag attgaacacc attattgaca gcgacaagat aatggtttta 3900
gattcaggaa gactgaaaga atatgatgag ccgatgtttt tgctgcaaaa taaagagagc 3960
ctattttaca agatggtgca acaactgggc aaggcagaag ccgctgccct cactgaaaca 4020
gcaaaacaga gatggggttt caccatgttg gccaggctgg tctcaaactc ctgacctcaa 4080
gtgatccacc tgcttggcc tcccaaactg ctgagattac aggtgtgagc caccacgccc 4140
agcctgagta tacttcaaaa gaaattatcc acatattggt cacactgacc acatggttac 4200
aaacacttcc aatggacagc cctcgacctt aactattttc gagacagcac tgtgaatcca 4260
acaaaaatgt caagtccgtt ccgaaggcat ttgccactag tttttggact atgtaaacca 4320
cattgtactt ttttttactt tggcaacaaa tatttataca tacaagatgc tagttcattt 4380
gaatattttt cccaacttat ccaaggatct ccagctctaa caaatgggtt tattttttatt 4440
taaatgtcaa tagtkgkttt ttaaaatcca aatcagaggt gcaggccacc agttaaatgc 4500
cgtctatcag gttttgtgcc ttaagagact acagnagtca gaagctcatt tttaaaggag 4560
taggacagag ttgtcacagg tttttgttgg tgtttktatt gccccaaaa ttacatgtta 4620
atttccattt atatcagggg attctattta ctgaagact gtgaagtgc cattttgtct 4680
cattgttttc ttgacatam ctaggatcca ttatttcccc tgaaggcttc ttgkagaaaa 4740
tagtacagtt acaaccaata ggaactamca aaaagaaaaa gtttgtgaca ttgtagtagg 4800
gagtgtgtac cccttactcc ccatcaaaaa aaaaaatgga tacatggtta aaggatagaa 4860
gggcaatatt ttatcatatg ttctaaaaga gaaggaagag aaaatactac tttctcaaaa 4920
tggaagccct taaaggtgct ttgatactga aggacacaaa tgtgaccgtc catcctcctt 4980
tagagttgca tgacttggac acggttaactg ttgcagtttt agactcagca ttgtgacact 5040
tcccaagaag gccaaacctc taaccgacat tcctgaaata cgtggcatta ttcttttttg 5100
gattttctcat ttaggaaggc taaccctctg ttgamtgtam kccttttggg ttgggctgta 5160
ttgaaatcct ttctaaattg catgaatagg ctctgctaac cgtgatgaga caaactgaaa 5220
attattgcaa gcattgacta taattatgca gtacgttctc aggatgcac caggggttca 5280
ttttcatgag cctgtccagg ttagtttact cctgaccact aatagcattg tcatttgggc 5340
tttctgttga atgaatcaac aaaccacaat acttctctggg accttttgta ctttatttga 5400
actatgagtc ttaattttt cctgatgatg gtggctgtaa tatgttgagt tcagtttact 5460
aaaggtttta ctattatggg ttgaaggag tctcatgacc tctcagaaaa ggtgcacctc 5520
cctgaaattg catatatgta tatagacatg cacacgtgtg catttgtttg tatacatata 5580
tttgccttc gtatagcaag ttttttgctc atcagcagag agcaacagat gttttattga 5640
gtgaagcctt aaaaagcaca caccacacac agctaactgc caaaatacat tgaccgtagt 5700
agctgttcaa ctctagtagc ttagaaatac acgtatgggt aatgttcagt ccaacaaacc 5760
acacacagta aatgtttatt aatagtcag gttcgtattt taggtgactg aaattgcaac 5820
agtgatcata atgaggtttg ttaaaatgat agctatattc aaaatgtcta tatgtttatt 5880
tggacttttg aggttaaaga cagtcataata aacgtcctgt ttctgtttta atgttatcat 5940
agaatttttt aatgaaacta aattcaattg aaataaatga tagttttcat ctccaaaaaa 6000
aaaaaaaaag ggcggcccg cagagtcag agggcccggt ttaaaccgc tgatcagcct 6060
cgactgtgcc ttctagttgc cagccatctg ttgtttggcc ctccccctg ccttcttga 6120
ccctggaagg ggccactccc

```

&lt;210&gt; 537

&lt;211&gt; 1228

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 537

Met Leu Pro Val Tyr Gln Glu Val Lys Pro Asn Pro Leu Gln Asp Ala  
5 10 15

Asn Leu Cys Ser Arg Val Phe Phe Trp Trp Leu Asn Pro Leu Phe Lys  
20 25 30

Ile Gly His Lys Arg Arg Leu Glu Glu Asp Asp Met Tyr Ser Val Leu  
 35 40 45  
 Pro Glu Asp Arg Ser Gln His Leu Gly Glu Glu Leu Gln Gly Phe Trp  
 50 55 60  
 Asp Lys Glu Val Leu Arg Ala Glu Asn Asp Ala Gln Lys Pro Ser Leu  
 65 70 75 80  
 Thr Arg Ala Ile Ile Lys Cys Tyr Trp Lys Ser Tyr Leu Val Leu Gly  
 85 90 95  
 Ile Phe Thr Leu Ile Glu Glu Ser Ala Lys Val Ile Gln Pro Ile Phe  
 100 105 110  
 Leu Gly Lys Ile Ile Asn Tyr Phe Glu Asn Tyr Asp Pro Met Asp Ser  
 115 120 125  
 Val Ala Leu Asn Thr Ala Tyr Ala Tyr Ala Thr Val Leu Thr Phe Cys  
 130 135 140  
 Thr Leu Ile Leu Ala Ile Leu His His Leu Tyr Phe Tyr His Val Gln  
 145 150 155 160  
 Cys Ala Gly Met Arg Leu Arg Val Ala Met Cys His Met Ile Tyr Arg  
 165 170 175  
 Lys Ala Leu Arg Leu Ser Asn Met Ala Met Gly Lys Thr Thr Thr Gly  
 180 185 190  
 Gln Ile Val Asn Leu Leu Ser Asn Asp Val Asn Lys Phe Asp Gln Val  
 195 200 205  
 Thr Val Phe Leu His Phe Leu Trp Ala Gly Pro Leu Gln Ala Ile Ala  
 210 215 220  
 Val Thr Ala Leu Leu Trp Met Glu Ile Gly Ile Ser Cys Leu Ala Gly  
 225 230 235 240  
 Met Ala Val Leu Ile Ile Leu Leu Pro Leu Gln Ser Cys Phe Gly Lys  
 245 250 255  
 Leu Phe Ser Ser Leu Arg Ser Lys Thr Ala Thr Phe Thr Asp Ala Arg  
 260 265 270  
 Ile Arg Thr Met Asn Glu Val Ile Thr Gly Ile Arg Ile Ile Lys Met  
 275 280 285  
 Tyr Ala Trp Glu Lys Ser Phe Ser Asn Leu Ile Thr Asn Leu Arg Lys  
 290 295 300  
 Lys Glu Ile Ser Lys Ile Leu Arg Ser Ser Cys Leu Arg Gly Met Asn  
 305 310 315 320  
 Leu Ala Ser Phe Phe Ser Ala Ser Lys Ile Ile Val Phe Val Thr Phe  
 325 330 335  
 Thr Thr Tyr Val Leu Leu Gly Ser Val Ile Thr Ala Ser Arg Val Phe

340	345	350
Val Ala Val Thr Leu Tyr Gly Ala Val Arg Leu Thr Val Thr Leu Phe		
355	360	365
Phe Pro Ser Ala Ile Glu Arg Val Ser Glu Ala Ile Val Ser Ile Arg		
370	375	380
Arg Ile Gln Thr Phe Leu Leu Leu Asp Glu Ile Ser Gln Arg Asn Arg		
385	390	395
Gln Leu Pro Ser Asp Gly Lys Lys Met Val His Val Gln Asp Phe Thr		
	405	410
Ala Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr Leu Gln Gly Leu Ser		
	420	425
Phe Thr Val Arg Pro Gly Glu Leu Leu Ala Val Val Gly Pro Val Gly		
	435	440
Ala Gly Lys Ser Ser Leu Leu Ser Ala Val Leu Gly Glu Leu Ala Pro		
	450	455
Ser His Gly Leu Val Ser Val His Gly Arg Ile Ala Tyr Val Ser Gln		
465	470	475
Gln Pro Trp Val Phe Ser Gly Thr Leu Arg Ser Asn Ile Leu Phe Gly		
	485	490
Lys Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val Ile Lys Ala Cys Ala		
	500	505
Leu Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly Asp Leu Thr Val Ile		
	515	520
Gly Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln Lys Ala Arg Val Asn		
	530	535
Leu Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile Tyr Leu Leu Asp Asp		
	545	550
Pro Leu Ser Ala Val Asp Ala Glu Val Ser Arg His Leu Phe Glu Leu		
	565	570
Cys Ile Cys Gln Ile Leu His Glu Lys Ile Thr Ile Leu Val Thr His		
	580	585
Gln Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile Leu Ile Leu Lys Asp		
	595	600
Gly Lys Met Val Gln Lys Gly Thr Tyr Thr Glu Phe Leu Lys Ser Gly		
	610	615
Ile Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn Glu Glu Ser Glu Gln		
	625	630
Pro Pro Val Pro Gly Thr Pro Thr Leu Arg Asn Arg Thr Phe Ser Glu		
	645	650
		655

Ser Ser Val Trp Ser Gln Gln Ser Ser Arg Pro Ser Leu Lys Asp Gly  
 660 665 670  
 Ala Leu Glu Ser Gln Asp Thr Glu Asn Val Pro Val Thr Leu Ser Glu  
 675 680 685  
 Glu Asn Arg Ser Glu Gly Lys Val Gly Phe Gln Ala Tyr Lys Asn Tyr  
 690 695 700  
 Phe Arg Ala Gly Ala His Trp Ile Val Phe Ile Phe Leu Ile Leu Leu  
 705 710 715 720  
 Asn Thr Ala Ala Gln Val Ala Tyr Val Leu Gln Asp Trp Trp Leu Ser  
 725 730 735  
 Tyr Trp Ala Asn Lys Gln Ser Met Leu Asn Val Thr Val Asn Gly Gly  
 740 745 750  
 Gly Asn Val Thr Glu Lys Leu Asp Leu Asn Trp Tyr Leu Gly Ile Tyr  
 755 760 765  
 Ser Gly Leu Thr Val Ala Thr Val Leu Phe Gly Ile Ala Arg Ser Leu  
 770 775 780  
 Leu Val Phe Tyr Val Leu Val Asn Ser Ser Gln Thr Leu His Asn Lys  
 785 790 795 800  
 Met Phe Glu Ser Ile Leu Lys Ala Pro Val Leu Phe Phe Asp Arg Asn  
 805 810 815  
 Pro Ile Gly Arg Ile Leu Asn Arg Phe Ser Lys Asp Ile Gly His Leu  
 820 825 830  
 Asp Asp Leu Leu Pro Leu Thr Phe Leu Asp Phe Ile Gln Thr Leu Leu  
 835 840 845  
 Gln Val Val Gly Val Val Ser Val Ala Val Ala Val Ile Pro Trp Ile  
 850 855 860  
 Ala Ile Pro Leu Val Pro Leu Gly Ile Ile Phe Ile Phe Leu Arg Arg  
 865 870 875 880  
 Tyr Phe Leu Glu Thr Ser Arg Asp Val Lys Arg Leu Glu Ser Thr Thr  
 885 890 895  
 Arg Ser Pro Val Phe Ser His Leu Ser Ser Ser Leu Gln Gly Leu Trp  
 900 905 910  
 Thr Ile Arg Ala Tyr Lys Ala Glu Glu Arg Cys Gln Glu Leu Phe Asp  
 915 920 925  
 Ala His Gln Asp Leu His Ser Glu Ala Trp Phe Leu Phe Leu Thr Thr  
 930 935 940  
 Ser Arg Trp Phe Ala Val Arg Leu Asp Ala Ile Cys Ala Met Phe Val  
 945 950 955 960

Ile Ile Val Ala Phe Gly Ser Leu Ile Leu Ala Lys Thr Leu Asp Ala  
 965 970 975  
 Gly Gln Val Gly Leu Ala Leu Ser Tyr Ala Leu Thr Leu Met Gly Met  
 980 985 990  
 Phe Gln Trp Cys Val Arg Gln Ser Ala Glu Val Glu Asn Met Met Ile  
 995 1000 1005  
 Ser Val Glu Arg Val Ile Glu Tyr Thr Asp Leu Glu Lys Glu Ala Pro  
 1010 1015 1020  
 Trp Glu Tyr Gln Lys Arg Pro Pro Pro Ala Trp Pro His Glu Gly Val  
 1025 1030 1035 1040  
 Ile Ile Phe Asp Asn Val Asn Phe Met Tyr Ser Pro Gly Gly Pro Leu  
 1045 1050 1055  
 Val Leu Lys His Leu Thr Ala Leu Ile Lys Ser Gln Glu Lys Val Gly  
 1060 1065 1070  
 Ile Val Gly Arg Thr Gly Ala Gly Lys Ser Ser Leu Ile Ser Ala Leu  
 1075 1080 1085  
 Phe Arg Leu Ser Glu Pro Glu Gly Lys Ile Trp Ile Asp Lys Ile Leu  
 1090 1095 1100  
 Thr Thr Glu Ile Gly Leu His Asp Leu Arg Lys Lys Met Ser Ile Ile  
 1105 1110 1115 1120  
 Pro Gln Glu Pro Val Leu Phe Thr Gly Thr Met Arg Lys Asn Leu Asp  
 1125 1130 1135  
 Pro Phe Asn Glu His Thr Asp Glu Glu Leu Trp Asn Ala Leu Gln Glu  
 1140 1145 1150  
 Val Gln Leu Lys Glu Thr Ile Glu Asp Leu Pro Gly Lys Met Asp Thr  
 1155 1160 1165  
 Glu Leu Ala Glu Ser Gly Ser Asn Phe Ser Val Gly Gln Arg Gln Leu  
 1170 1175 1180  
 Val Cys Leu Ala Arg Ala Ile Leu Arg Lys Asn Gln Ile Leu Ile Ile  
 1185 1190 1195 1200  
 Asp Glu Ala Thr Ala Asn Val Asp Pro Arg Thr Asp Glu Leu Ile Gln  
 1205 1210 1215  
 Lys Lys Ser Gly Arg Asn Leu Pro Thr Ala Pro Cys  
 1220 1225  
 <210> 538  
 <211> 1261  
 <212> PRT  
 <213> Homo sapiens  
 <400> 538  
 Met Tyr Ser Val Leu Pro Glu Asp Arg Ser Gln His Leu Gly Glu Glu



194

5 10 15  
 Leu Gln Gly Phe Trp Asp Lys Glu Val Leu Arg Ala Glu Asn Asp Ala  
 20 25 30  
 Gln Lys Pro Ser Leu Thr Arg Ala Ile Ile Lys Cys Tyr Trp Lys Ser  
 35 40 45  
 Tyr Leu Val Leu Gly Ile Phe Thr Leu Ile Glu Glu Ser Ala Lys Val  
 50 55 60  
 Ile Gln Pro Ile Phe Leu Gly Lys Ile Ile Asn Tyr Phe Glu Asn Tyr  
 65 70 75 80  
 Asp Pro Met Asp Ser Val Ala Leu Asn Thr Ala Tyr Ala Tyr Ala Thr  
 85 90 95  
 Val Leu Thr Phe Cys Thr Leu Ile Leu Ala Ile Leu His His Leu Tyr  
 100 105 110  
 Phe Tyr His Val Gln Cys Ala Gly Met Arg Leu Arg Val Ala Met Cys  
 115 120 125  
 His Met Ile Tyr Arg Lys Ala Leu Arg Leu Ser Asn Met Ala Met Gly  
 130 135 140  
 Lys Thr Thr Thr Gly Gln Ile Val Asn Leu Leu Ser Asn Asp Val Asn  
 145 150 155 160  
 Lys Phe Asp Gln Val Thr Val Phe Leu His Phe Leu Trp Ala Gly Pro  
 165 170 175  
 Leu Gln Ala Ile Ala Val Thr Ala Leu Leu Trp Met Glu Ile Gly Ile  
 180 185 190  
 Ser Cys Leu Ala Gly Met Ala Val Leu Ile Ile Leu Leu Pro Leu Gln  
 195 200 205  
 Ser Cys Phe Gly Lys Leu Phe Ser Ser Leu Arg Ser Lys Thr Ala Thr  
 210 215 220  
 Phe Thr Asp Ala Arg Ile Arg Thr Met Asn Glu Val Ile Thr Gly Ile  
 225 230 235 240  
 Arg Ile Ile Lys Met Tyr Ala Trp Glu Lys Ser Phe Ser Asn Leu Ile  
 245 250 255  
 Thr Asn Leu Arg Lys Lys Glu Ile Ser Lys Ile Leu Arg Ser Ser Cys  
 260 265 270  
 Leu Arg Gly Met Asn Leu Ala Ser Phe Phe Ser Ala Ser Lys Ile Ile  
 275 280 285  
 Val Phe Val Thr Phe Thr Thr Tyr Val Leu Leu Gly Ser Val Ile Thr  
 290 295 300  
 Ala Ser Arg Val Phe Val Ala Val Thr Leu Tyr Gly Ala Val Arg Leu  
 305 310 315 320

Thr Val Thr Leu Phe Phe Pro Ser Ala Ile Glu Arg Val Ser Glu Ala  
 325 330 335  
 Ile Val Ser Ile Arg Arg Ile Gln Thr Phe Leu Leu Leu Asp Glu Ile  
 340 345 350  
 Ser Gln Arg Asn Arg Gln Leu Pro Ser Asp Gly Lys Lys Met Val His  
 355 360 365  
 Val Gln Asp Phe Thr Ala Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr  
 370 375 380  
 Leu Gln Gly Leu Ser Phe Thr Val Arg Pro Gly Glu Leu Leu Ala Val  
 385 390 395 400  
 Val Gly Pro Val Gly Ala Gly Lys Ser Ser Leu Leu Ser Ala Val Leu  
 405 410 415  
 Gly Glu Leu Ala Pro Ser His Gly Leu Val Ser Val His Gly Arg Ile  
 420 425 430  
 Ala Tyr Val Ser Gln Gln Pro Trp Val Phe Ser Gly Thr Leu Arg Ser  
 435 440 445  
 Asn Ile Leu Phe Gly Lys Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val  
 450 455 460  
 Ile Lys Ala Cys Ala Leu Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly  
 465 470 475 480  
 Asp Leu Thr Val Ile Gly Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln  
 485 490 495  
 Lys Ala Arg Val Asn Leu Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile  
 500 505 510  
 Tyr Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala Glu Val Ser Arg  
 515 520 525  
 His Leu Phe Glu Leu Cys Ile Cys Gln Ile Leu His Glu Lys Ile Thr  
 530 535 540  
 Ile Leu Val Thr His Gln Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile  
 545 550 555 560  
 Leu Ile Leu Lys Asp Gly Lys Met Val Gln Lys Gly Thr Tyr Thr Glu  
 565 570 575  
 Phe Leu Lys Ser Gly Ile Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn  
 580 585 590  
 Glu Glu Ser Glu Gln Pro Pro Val Pro Gly Thr Pro Thr Leu Arg Asn  
 595 600 605  
 Arg Thr Phe Ser Glu Ser Ser Val Trp Ser Gln Gln Ser Ser Arg Pro  
 610 615 620

Ser Leu Lys Asp Gly Ala Leu Glu Ser Gln Asp Thr Glu Asn Val Pro  
 625 630 635 640  
 Val Thr Leu Ser Glu Glu Asn Arg Ser Glu Gly Lys Val Gly Phe Gln  
 645 650 655  
 Ala Tyr Lys Asn Tyr Phe Arg Ala Gly Ala His Trp Ile Val Phe Ile  
 660 665 670  
 Phe Leu Ile Leu Leu Asn Thr Ala Ala Gln Val Ala Tyr Val Leu Gln  
 675 680 685  
 Asp Trp Trp Leu Ser Tyr Trp Ala Asn Lys Gln Ser Met Leu Asn Val  
 690 695 700  
 Thr Val Asn Gly Gly Gly Asn Val Thr Glu Lys Leu Asp Leu Asn Trp  
 705 710 715 720  
 Tyr Leu Gly Ile Tyr Ser Gly Leu Thr Val Ala Thr Val Leu Phe Gly  
 725 730 735  
 Ile Ala Arg Ser Leu Leu Val Phe Tyr Val Leu Val Asn Ser Ser Gln  
 740 745 750  
 Thr Leu His Asn Lys Met Phe Glu Ser Ile Leu Lys Ala Pro Val Leu  
 755 760 765  
 Phe Phe Asp Arg Asn Pro Ile Gly Arg Ile Leu Asn Arg Phe Ser Lys  
 770 775 780  
 Asp Ile Gly His Leu Asp Asp Leu Leu Pro Leu Thr Phe Leu Asp Phe  
 785 790 795 800  
 Ile Gln Thr Leu Leu Gln Val Val Gly Val Val Ser Val Ala Val Ala  
 805 810 815  
 Val Ile Pro Trp Ile Ala Ile Pro Leu Val Pro Leu Gly Ile Ile Phe  
 820 825 830  
 Ile Phe Leu Arg Arg Tyr Phe Leu Glu Thr Ser Arg Asp Val Lys Arg  
 835 840 845  
 Leu Glu Ser Thr Thr Arg Ser Pro Val Phe Ser His Leu Ser Ser Ser  
 850 855 860  
 Leu Gln Gly Leu Trp Thr Ile Arg Ala Tyr Lys Ala Glu Glu Arg Cys  
 865 870 875 880  
 Gln Glu Leu Phe Asp Ala His Gln Asp Leu His Ser Glu Ala Trp Phe  
 885 890 895  
 Leu Phe Leu Thr Thr Ser Arg Trp Phe Ala Val Arg Leu Asp Ala Ile  
 900 905 910  
 Cys Ala Met Phe Val Ile Ile Val Ala Phe Gly Ser Leu Ile Leu Ala  
 915 920 925  
 Lys Thr Leu Asp Ala Gly Gln Val Gly Leu Ala Leu Ser Tyr Ala Leu

930	935	940
Thr Leu Met Gly Met Phe Gln Trp Cys Val Arg Gln Ser Ala Glu Val		
945	950	955 960
Glu Asn Met Met Ile Ser Val Glu Arg Val Ile Glu Tyr Thr Asp Leu		
	965	970 975
Glu Lys Glu Ala Pro Trp Glu Tyr Gln Lys Arg Pro Pro Pro Ala Trp		
	980	985 990
Pro His Glu Gly Val Ile Ile Phe Asp Asn Val Asn Phe Met Tyr Ser		
	995	1000 1005
Pro Gly Gly Pro Leu Val Leu Lys His Leu Thr Ala Leu Ile Lys Ser		
	1010	1015 1020
Gln Glu Lys Val Gly Ile Val Gly Arg Thr Gly Ala Gly Lys Ser Ser		
	1025	1030 1035 1040
Leu Ile Ser Ala Leu Phe Arg Leu Ser Glu Pro Glu Gly Lys Ile Trp		
	1045	1050 1055
Ile Asp Lys Ile Leu Thr Thr Glu Ile Gly Leu His Asp Leu Arg Lys		
	1060	1065 1070
Lys Met Ser Ile Ile Pro Gln Glu Pro Val Leu Phe Thr Gly Thr Met		
	1075	1080 1085
Arg Lys Asn Leu Asp Pro Phe Asn Glu His Thr Asp Glu Glu Leu Trp		
	1090	1095 1100
Asn Ala Leu Gln Glu Val Gln Leu Lys Glu Thr Ile Glu Asp Leu Pro		
	1105	1110 1115 1120
Gly Lys Met Asp Thr Glu Leu Ala Glu Ser Gly Ser Asn Phe Ser Val		
	1125	1130 1135
Gly Gln Arg Gln Leu Val Cys Leu Ala Arg Ala Ile Leu Arg Lys Asn		
	1140	1145 1150
Gln Ile Leu Ile Ile Asp Glu Ala Thr Ala Asn Val Asp Pro Arg Thr		
	1155	1160 1165
Asp Glu Leu Ile Gln Lys Lys Ile Arg Glu Lys Phe Ala His Cys Thr		
	1170	1175 1180
Val Leu Thr Ile Ala His Arg Leu Asn Thr Ile Ile Asp Ser Asp Lys		
	1185	1190 1195 1200
Ile Met Val Leu Asp Ser Gly Arg Leu Lys Glu Tyr Asp Glu Pro Tyr		
	1205	1210 1215
Val Leu Leu Gln Asn Lys Glu Ser Leu Phe Tyr Lys Met Val Gln Gln		
	1220	1225 1230
Leu Gly Lys Ala Glu Ala Ala Ala Leu Thr Glu Thr Ala Lys Gln Arg		
	1235	1240 1245

Trp Gly Phe Thr Met Leu Ala Arg Leu Val Ser Asn Ser  
 1250 1255 1260

<210> 539  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 539  
 Cys Leu Ser His Ser Val Ala Val Val Thr  
 1 5 10

<210> 540  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 540  
 Ala Val Val Thr Ala Ser Ala Ala Leu  
 1 5

<210> 541  
 <211> 14  
 <212> PRT  
 <213> Homo sapiens

<400> 541  
 Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu  
 5 10

<210> 542  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 542  
 Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala  
 5 10 15

<210> 543  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 543  
 Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val  
 5 10

Met Thr

```
<210> 545
<211> 18
<212> PRT
<213> Homo sapiens
```

Ser Val

```
<210> 546
<211> 29
<212> PRT
<213> Homo sapiens
```

```
<210> 547
<211> 58
<212> PRT
<213> Homo sapiens
```

Cys Arg Met Pro Arg Thr Leu Arg Arg Leu  
50 55

200

<210> 548  
 <211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 548  
 Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu  
                                   5                                  10                                  15

Glu Cys

<210> 549  
 <211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 549  
 Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg  
                                   5                                  10                                  15

Gln Ala

<210> 550  
 <211> 14  
 <212> PRT  
 <213> Homo sapiens

<400> 550  
 Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe  
                                   5                                  10

<210> 551  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Made in a lab

<400> 551  
 Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala  
                                   5                                  10

<210> 552  
 <211> 2577  
 <212> DNA  
 <213> Homo sapiens

<400> 552  
 agcatatgta acatgacctg tgccttcagtg ttctttttgtg atcaaaaatt ccttactttt 60  
 agtttttttat ctatggtaga accaccacaga gcaggggtcc tcaactccca ggccacagac 120  
 tcataccagt ccacggacta ttatgaacca caccacacag gaggaggtga gactaggca 180  
 agccaaggaa gcttcacctg tacttacagc cacacgccat ggctcatatt acagcctgaa 240

```

ctctgcctcc actcagatca gtgataacat tagaaactca ttggagcacg aacctgttg 300
tgaactgcct atccgaagga tctaggttgt gtgcttcgta tgagaatcta atgccagatg 360
atctatcatt gtctcacttt gcccccagat aagaccatct agttgcagaa aaataagctc 420
agagcttcca ctgattctac attatggata tgtgccgccg aagcaagcac aaagccctac 480
ttttacacat gcctagtgat gcttcatgga caaggcttgg ctctgttgag tccaactaac 540
ctacctgaga ttctgagatt tctcttcaat ggcttcctgt gagctagagt ttgaaaatat 600
cttaaaatct tgagctagag atggaagtag cttggacgat tttcattatc atgtaaatcg 660
ggctactcaa ggggccaaac acagctggga gccactgtc aggggaaggt tcatatggga 720
ctttctactg cccaagggtt tatacaggat ataaagggtc ctcacagtat agatctggta 780
gcaaagaaga agaaacaaac actgatctct ttctgccacc cctctgaccc tttggaactc 840
ctctgaccct ttagaacaag cctaccta atctgctaga gaaaagacca acaacggcct 900
caaaggatct cttaccatga aggtctcagc taattcttgg ctaagatgtg ggttccacat 960
taggttctga atatgggggg aagggtcaat ttgctcattt tgtgtgtgga taaagtcagg 1020
atgccagggg gccagagcag ggggctgctg ctttgggaac aatggctgag catataacca 1080
taggtatggg aacaaaaaac atcaaaagtca ctgtatcaat tgccatgaag actcgaggga 1140
cctgaatcta ccgattcatc ttaaggcagc aggaccagtt tgagtggcaa caatgcagca 1200
gcagaatcaa tggaaacaac agaattgatt caatgtcctt ttttttctcc tcttctgac 1260
ttgataaaag ggaccgtctt ctttggattt agtgaacccc tttggttctt gaaaaattca 1320
aggagtatct aggacatagt ccccagaaga cagtacaaga ctttctgata aactggacat 1380
ttcaagrccc aaataactaa tcagaaaaat caaagatgtg atactatctt ttatcccatg 1440
cataggtgct acacttggat caaatgaaca atgttgggat ctytatggat aaaggtctta 1500
aaagtctctg gataaagaat cctgcaccca ctggtacttc taacttgtct tgttttttgt 1560
ctgwtttctg gctgatgcag gggactaact cactgccacg cgaaaactac ctgaactgaa 1620
ctatgacatc tcacctgata tgtaagatgt aactgttata attattttaa acctcaattt 1680
agcattaact agccttttta tgtaaacact tacacattat gaygactaga aacagcatat 1740
tctctggccg tctgtccaga tagatcttga gaagatacat caatgttttg ctcaagtaga 1800
aggctgacta tacttgccga tccacaacat acagcaagta tgagagcagt tctaaaatga 1860
cagagatagg aacagtaata aagttattkt aaaagcta attgatatact ttaccaattt 1920
aacatcttgc ctgtccgtgc agaatcaaac atttacatgc actaaaagac ataagcatct 1980
tcagtgtctc agtgttcac tttgtaaaa accaccaagg ttaaaaggaa gggacaaaaa 2040
aaaaaaaccc tcttatctca gtgggtatt gcatagcaga agctactaat ttgaagtcct 2100
ttgatggaca agaaacaata ttagggccac ttatctgaaa tgaacaaaga ttaagtga 2160
gatttcatca cagcttccct agactgatat gctgtaatat aaaatcagct agggggtaaa 2220
ataaataaga gctctctgca tgctgaaagc aagtaagatt aataataatg gtaagaatag 2280
tagtcacagg agtttcagtt aatgatgcca ataagcatgt gctaggcact gaattaaatg 2340
ccacatatat ctttcttatg cgcagcaaac tttgaaggat atattctcct acttttcata 2400
tatgacaaca tatttggtgg taaataacgt tcccaaggct acacacctag caagtaagaa 2460
agtttagaat taaacccagt attgtgtgaa tctaaagcct aacttttttc tctttatcac 2520
ccacctacgg cttgtcttca ttaaaggaaa agtgtatcca cttaaaaaaa aaaaaaa 2577

```

&lt;210&gt; 553

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 553

Ser Ile Cys Asn Met Thr Cys Ala Ser Val Phe Phe Cys Asp Gln Lys  
5 10 15

Phe Leu Thr Phe Ser Phe Leu Ser Met Val Glu Pro Pro Arg Ala Gly  
20 25 30

Val Leu Asn Ser Gln Ala Thr Asp Ser Tyr Gln Ser Thr Asp Tyr Tyr  
35 40 45

Glu Pro His His Thr Gly Gly Gly Glu His  
50 55



&lt;210&gt; 554

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 554

Leu Gln Lys Asn Lys Leu Arg Ala Ser Thr Asp Ser Thr Leu Trp Ile  
                                   5                                  10                                  15

Cys Ala Ala Glu Ala Ser Thr Lys Pro Tyr Phe Tyr Thr Cys Leu Val  
                                   20                                  25                                  30

Met Leu His Gly Gln Gly Leu Ala Leu Leu Ser Pro Thr Asn Leu Pro  
                                   35                                  40                                  45

Glu Ile Leu Arg Phe Leu Phe Asn Gly Phe Leu  
                                   50                                  55

&lt;210&gt; 555

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 555

Leu Gly Arg Phe Ser Leu Ser Cys Lys Ser Gly His Ser Arg Gly Gln  
                                   5                                  10                                  15

Pro Gln Leu Gly Ala Thr Ala Gln Gly Lys Val His Met Gly Leu Ser  
                                   20                                  25                                  30

Thr Ala Gln Gly Ser Ile Gln Asp Ile Lys Val Pro His Ser Ile Asp  
                                   35                                  40                                  45

Leu Val Ala Lys Lys Lys Lys Gln Thr Leu Ile Ser Phe Cys His Pro  
                                   50                                  55                                  60

Ser Asp Pro Leu Glu Leu Leu  
                                   65                                  70

&lt;210&gt; 556

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 556

Asn His Pro Glu Gln Gly Ser Ser Thr Pro Arg Pro Gln Thr His Thr  
                                   5                                  10                                  15

Ser Pro Arg Thr Ile Met Asn His Thr Thr Gln Glu Glu Val Ser Thr  
                                   20                                  25                                  30

Arg Gln Ala Lys Glu Ala Ser Pro Val Leu Thr Ala Thr Arg His Gly  
                                   35                                  40                                  45

Ser Tyr Tyr Ser Leu Asn Ser Ala Ser Thr Gln Ile Ser Asp Asn Ile

203

50                      55                      60

Arg Asn Ser Leu Glu His Glu Pro Cys Cys Glu Leu Pro Ile Arg Arg  
 65                      70                      75                      80

Ile

<210> 557  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<400> 557  
 Ser Leu Ser Ala Thr Pro Leu Thr Leu Trp Asn Ser Ser Asp Pro Leu  
                                  5                      10                      15

Glu Gln Ala Tyr Leu Ile Ser Ala Arg Glu Lys Thr Asn Asn Gly Leu  
                                  20                      25                      30

Lys Gly Ser Leu Thr Met Lys Val Ser Ala Asn Ser Trp Leu Arg Cys  
                                  35                      40                      45

Gly Phe His Ile Arg Phe  
                                  50

<210> 558  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> (1)...(77)  
 <223> Xaa = Any amino acid

<400> 558  
 Asn Asp Arg Asp Arg Asn Ser Asn Lys Val Ile Xaa Lys Ala Asn Leu  
                                  5                      10                      15

Ile Tyr Phe Thr Asn Leu Thr Ser Cys Leu Ser Val Gln Asn Gln Thr  
                                  20                      25                      30

Phe Thr Cys Thr Lys Arg His Lys His Leu Gln Cys Ser Ser Val His  
                                  35                      40                      45

Leu Cys Lys Ile Pro Pro Arg Leu Lys Gly Arg Asp Lys Lys Lys Lys  
                                  50                      55                      60

Pro Ser Tyr Leu Ser Gly Val Leu His Ser Arg Ser Tyr  
                                  65                      70                      75

<210> 559  
 <211> 50  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 559

Thr Leu Pro Pro Leu Arg Ser Val Ile Thr Leu Glu Thr His Trp Ser  
                           5                          10                          15

Thr Asn Pro Val Val Asn Cys Leu Ser Glu Gly Ser Arg Leu Cys Ala  
                   20                          25                          30

Ser Tyr Glu Asn Leu Met Pro Asp Asp Leu Ser Leu Ser His Phe Ala  
           35                          40                          45

Pro Arg  
       50

&lt;210&gt; 560

&lt;211&gt; 56

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 560

Ile Gly Ser Leu Lys Gly Pro Thr Thr Ala Gly Ser His Cys Ser Gly  
                           5                          10                          15

Glu Gly Ser Tyr Gly Thr Phe Tyr Cys Pro Arg Phe Tyr Thr Gly Tyr  
           20                          25                          30

Lys Gly Ala Ser Gln Tyr Arg Ser Gly Ser Lys Glu Glu Glu Thr Asn  
           35                          40                          45

Thr Asp Leu Phe Leu Pro Pro Leu  
       50                          55

&lt;210&gt; 561

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(57)

&lt;223&gt; Xaa = Any amino acid

&lt;400&gt; 561

Val Leu His Leu Asp Gln Met Asn Asn Val Gly Ile Xaa Met Asp Lys  
                           5                          10                          15

Gly Leu Lys Ser Pro Glu Ile Lys Asn Pro Ala Pro Thr Gly Thr Ser  
           20                          25                          30

Asn Leu Ser Cys Phe Leu Ser Xaa Phe Trp Leu Met Gln Gly Thr Asn  
           35                          40                          45

Ser Leu Pro Arg Glu Asn Tyr Leu Asn  
       50                          55

```
<210> 562
<211> 59
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> VARIANT
<222> (1)...(59)
<223> Xaa = Any amino acid
```

```

<400> 562
Asp Leu Tyr Pro Xaa Arg Ser Gln His Cys Ser Phe Asp Pro Ser Val
          5              10              15
Ala Pro Met His Gly Ile Lys Asn Ser Ile Thr Ser Leu Ile Phe Leu
          20              25              30
Ile Ser Tyr Leu Xaa Leu Glu Met Ser Ser Leu Ser Glu Ser Leu Val
          35              40              45
Leu Ser Ser Gly Asp Tyr Val Leu Asp Thr Pro
          50              55

```

```
<210> 563
<211> 79
<212> PRT
<213> Homo sapiens
```

<400> 563																
Cys	Phe	Leu	Phe	Pro	Tyr	Leu	Trp	Leu	Tyr	Ala	Gln	Pro	Leu	Phe	Pro	
				5					10					15		
Lys	Gln	Gln	Pro	Pro	Ala	Leu	Ala	Pro	Gly	His	Pro	Asp	Phe	Ile	His	
			20					25					30			
Thr	Gln	Asn	Glu	Gln	Ile	Asp	Pro	Ser	Pro	His	Ile	Gln	Asn	Leu	Met	
		35					40					45				
Trp	Asn	Pro	His	Leu	Ser	Gln	Glu	Leu	Ala	Glu	Thr	Phe	Met	Val	Arg	
	50					55					60					
Asp	Pro	Leu	Arg	Pro	Leu	Leu	Val	Phe	Ser	Leu	Ala	Asp	Ile	Arg		
65					70					75						

```
<210> 564
<211> 64
<212> PRT
<213> Homo sapiens
```

<400> 564  
Ala Cys Ser Lys Gly Ser Glu Glu Phe Gln Arg Val Arg Gly Val Ala  
5 10 15  
Glu Arg Asp Gln Cys Leu Phe Leu Leu Leu Cys Tyr Gln Ile Tyr Thr  
20 25 30

His Met Asn Leu Pro Leu Ser Ser Gly Ser Gln Leu Trp Leu Ala Pro  
50 55 60

```
<210> 565
<211> 57
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> VARIANT  
<222> (1)...(57)  
<223> Xaa = Any amino acid
```

<400> 565  
Leu Tyr Tyr Cys Ser Tyr Leu Cys His Phe Arg Thr Ala Leu Ile Leu  
5 10 15

Ala Val Cys Cys Gly Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln  
20 25 30

Asn Ile Asp Val Ser Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu  
35 40 45

Tyr Ala Val Ser Ser Xaa His Asn Val  
50 55

```
<210> 566
<211> 55
<212> PRT
<213> Homo sapiens
```

<400> 566  
Ile Leu Leu Glu Phe Phe Arg Asn Gln Arg Gly Ser Leu Asn Pro Arg  
5 10 15

Lys Thr Val Pro Phe Ile Lys Ser Glu Gly Gly Glu Lys Lys Gly His  
20 25 30

Cys Asn His Ser Val Val Ser Ile Asp Ser Ala Ala Ala Leu Leu Pro  
35 40 45

Leu Lys Leu Val Leu Leu Pro  
50 55

```
<210> 567
<211> 51
<212> PRT
<213> Homo sapiens
```

<400> 567  
Tyr Ser Asp Phe Asp Val Phe Cys Ser His Thr Tyr Gly Tyr Met Leu

5 10 15  
 Ser His Cys Ser Gln Ser Ser Ser Pro Leu Leu Trp Pro Leu Gly Ile  
 20 25 30  
 Leu Thr Leu Ser Thr His Lys Met Ser Lys Leu Thr Leu Pro Pro Ile  
 35 40 45  
 Phe Arg Thr  
 50

<210> 568  
 <211> 75  
 <212> PRT  
 <213> Homo sapiens

<400> 568  
 Lys Val Gly Glu Tyr Ile Leu Gln Ser Leu Leu Arg Ile Arg Lys Ile  
 5 10 15  
 Tyr Val Ala Phe Asn Ser Val Pro Ser Thr Cys Leu Leu Ala Ser Leu  
 20 25 30  
 Thr Glu Thr Pro Val Thr Thr Ile Leu Thr Ile Ile Ile Asn Leu Thr  
 35 40 45  
 Cys Phe Gln His Ala Glu Ser Ser Tyr Leu Phe Tyr Pro Leu Ala Asp  
 50 55 60  
 Phe Leu Leu Gln His Ile Ser Leu Gly Lys Leu  
 65 70 75

<210> 569  
 <211> 4809  
 <212> DNA  
 <213> Homo sapiens

<400> 569  
 gcatccagag tgggtggactg gttacaggct atgaacctac actgatgcgg caccaccacc 60  
 cagagtccac rggttatgtt gggtcacatt tactcttgct gtggtatggt ctatagggtt 120  
 ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtcttgtagg 180  
 aatggacttg cttcaaagtg gaggcaggca gatccttcag acgggtatat ggagccctgt 240  
 tttcagttgc ttttctaatt ctctcttacc gtttacctca aaatcttcct gaggtctcgc 300  
 ttctttttaa aatccttgct tactttgcag catcactctg acactcccat tgattcctca 360  
 gcacctactg actacacggg taggagtga agggtagaat tcatgtttta ttcattcttg 420  
 ggtctgtagc acccagcaaa gtgctcagta aatgcgcagt aattgatttg acctctgaac 480  
 aaatacacac tgtactaaga atctacacac cgaaagacaa aaacaagaca aatttgagtg 540  
 ctacaggtgt cacgcttgcc atcacacatg tgctgtgta ttctctagg tggttaccag 600  
 gagctctgcc actgcatgct cactagtgc gggttcgctc caccaccca gctgggtagc 660  
 cgctgctctc acataagggg tccaattaaa attgccagga ataaattccc ccggactttg 720  
 acttctcaag agctaagaag gtttgctgag tattctggca tgatgtttgg tgatcaaaca 780  
 actgctggcc aaaaatgatg agtatttccc cctcttgctg aagatgtgct ccatacaata 840  
 gtccatcaca ttcattcatt atcagtctgg aagtgtgcag aacaacatgt aatagataat 900  
 atgattggct gcacacttcc agactgatga atgatgaatg tgatggacta ttgtatggag 960  
 cacatcttca gcaagagggg gaaataactca tcattttatc tattacatgt tgttctggtt 1020

tttttttttt	tccaatgtcc	agcctaaact	ataaagtact	ttgagaacgc	acagtgagcc	1080
ataagcttgc	caataaagag	tcctctgtgg	tatggaactg	gcttattttca	tacacaatct	1140
gcaaacaatg	agggcactat	tggaaacata	ctgtgctgca	cagagcattt	acaccgctta	1200
tctttaatct	tccccagcaa	tccttgcttt	gtgcgcattt	atgatccttg	ctctcagaag	1260
tccacatact	tttccccaac	cgtaacaaat	tattttaactc	atctaagtga	tgtatgtccg	1320
cgcagtctga	aaacagtaat	tgtccttggg	aagaagttag	tttaagagag	ctctaggggca	1380
ctcatcacaa	ctccagccct	gccctccatg	tggtagcagc	tctttggact	ggggctaagt	1440
gcttattctt	gtgcttcatt	cctggtaagc	tcaattttctt	taccttagga	taactttgct	1500
ggaaaagggc	tcagattcag	ccgaccattg	tggcctctgt	ggctgtcaca	gcttgtccct	1560
gacatgctat	gatgttgggt	ccccttctca	tccccttggg	atttcttctg	ctggcccaca	1620
gccagaacaa	ctaggccctt	tactccacca	tccccttgtt	ttcttttgtt	tcgttggtaa	1680
aatcaatcc	ttctaccatc	catgcatagc	aattttctaaa	aactgaattt	caagagcagt	1740
atctgaagaa	acaaacatga	tttggctcctt	ttagtaaaaca	gaataaattt	taataaaatca	1800
actttgaaat	agttgtaaga	gttaagaaaa	agcacaaaaac	tgagatcatc	agagcagctt	1860
ggcctcaaag	gacaggcagc	aggattctac	agggtttgag	ccttcctaag	tgaagctgtt	1920
tcttgaggc	tccctgctcc	aagctcctag	ctaacagccc	cttctcccac	gattggcaac	1980
aaagagcaaa	aataactttg	tacttgatgc	tgagtcagtg	taaaaagcca	taaaaaatcc	2040
cctctaaatg	tcaaaatgtt	tgcctccttt	gaggcttctc	tcctcctact	gggtctggat	2100
aaattagcac	tgggcttata	ttgagtcaca	gatctggggc	ctgccacaga	gagcttcctc	2160
ctagtgtgtg	atgctttttc	tccaaactat	tgatacaaaa	tgcactggaa	tagaaatcaa	2220
cagaaactgg	tcaaaggtgt	ggcatacaca	ttctcatgta	gatgtaaagc	tgtgcttaga	2280
attcctttgt	ggagtctggg	ttggctcttg	ttttcttggg	gtttgattca	tttttttacg	2340
taaattacaa	aaaccctcca	catttcttca	tggattgtat	tagtccatgt	tctccagaga	2400
agcagaacga	gttggatgta	tgttttggaa	gagattatga	ggaaccggct	catgtgatga	2460
aggaggttga	gaggtcctgt	gctctgccat	ctgcaagctg	aagacctgga	aagctgaggg	2520
tgtggctcca	gtctgagctc	gaaggcccaa	gaaccagggg	aaccaacggg	gtagattcca	2580
ggttgaaggc	aggagaagat	ggatgtccca	gctcagcagg	caggcaggaa	gcaaatgggg	2640
taaattcctc	cttcctccac	cttttgttcc	attcaggcct	tcaacagatt	ggatgagcgc	2700
ccccccaccc	ccacactagg	gagggccatc	tgctttactg	agtccgctga	gtcaagtgcc	2760
agcctcatcc	caaaaacactc	tccagacaca	cgcagaaatg	tttcatctgg	gcacocctgtg	2820
gccagtcag	ctgacacaca	gaactaacca	tgacatggat	tcttcttaaa	gcagtgatag	2880
gagcgaacag	aaacattttc	ataattttca	attattttta	atgaaaacta	tatctgatgg	2940
aattgtttaa	acctagtctg	gccacacatt	atttcttggg	accgcccctc	cttcaatccc	3000
ttggacactg	atgactttat	gccagatta	cactggaggc	ctgtgctgat	tttctaacac	3060
atacctgcaa	ctgagctggc	aaaaagaaaa	ctaggcaagt	atgacagata	catgatgcac	3120
aggctaagt	caaaggaaag	aaaaacacca	actgcaggga	tgagggactc	acccttttag	3180
aagtttctac	ttgagcagct	agaagactac	aatgccactc	atcaaaacag	tgactcaggg	3240
ggagtatttg	ggataaaagg	ggaatctgat	gttggagggtc	aaatttgaag	tgtctttaag	3300
acctacaggt	aacgagacag	ctggacaaac	acatggaact	caggacaaag	gctctaagga	3360
cagcacagca	gctgacatcc	tgtgtgacag	ccttgaaagc	agcaggcccg	ccgctcacat	3420
tttggaaagg	aaaatgggta	caatgttgtc	tgccactttg	gggccttctt	gggtcacatg	3480
cattttacat	ttatgcagtt	gatatattta	tgtttcctgg	gtcttttata	cattagacac	3540
catgattctc	aatcctttgt	tattttgtat	tacaaaaagc	tgaattatta	tttcaaatat	3600
gggcaaatta	gagccttcca	tattgccaag	gtgtatcaac	cacactgata	ycaygatctc	3660
tcttttgaat	tagttttcca	gttcacacct	accatttatt	tcatgattgg	tttcagactt	3720
gttctcctcg	gaaacactcc	ctaacaagca	cccttgccag	aatgaagaca	caccacacac	3780
atctacecca	ttactgcatg	tactcaagag	tcagctttta	tatgatctct	cccaagtgct	3840
cctataatgg	ggatctttca	ctcaccctaa	agtgaggaca	aaataactga	aagcatgagc	3900
ccagtgccctg	taggtgtgca	attaacctca	gaccaaggaa	gtgccgaacg	catctggctt	3960
ttagcaaggc	acctgacaaa	gtccttcagg	atgtttttgt	acatgagcta	gagaaatgta	4020
cctggagaaac	agcttctact	gccagatgat	cttactcaaa	agatgcagat	taagcaaaat	4080
atcaacccaa	agggtggtcc	ctgatggccc	accagcccct	gtgcctggct	cgtttctctat	4140
gtttcctaga	tttggtttca	gacttgctcc	tcctgcagac	actccctaac	cagcatcctt	4200
cgagaaaact	ggtgaactag	aaaaggcctg	tgtgggtcac	gtggccaccc	aacaccacag	4260
cagtgtctaa	ggatatgcgtg	ggagcctgca	cagcaggagc	ggggctctct	ggagaccgcg	4320
atgagatgca	aagggcagtg	gacaaggagc	caaggagggt	ggctctagtc	acgctggtat	4380
ggtgccagct	tgaggatgct	gggcaagtcc	cgagccgtct	gccttctctag	taccacagtt	4440
accactgtct	gttacctcgc	gagttcaagt	gcttcacgtg	agacagctac	gagacaggcc	4500

```

cctggaaact ggaaaatgcy aagtaaagt catgcacaat tgttggtcac attttatctc 4560
aatcactttt accaaatcag gctaaaccct gggatttcat aacgtcttgg gctgtacaaa 4620
ttgttccttg aaatgactca gagacatttt ctgaattggc ttccatcagc caagcatttc 4680
ttcagaactg gaaaaatgct ttaaatttgg ctttgtcatg attattaaaa cactctgtac 4740
attttttatt attgaaatta acacattgcc tactttttta aaattggaaa aagaaaaaaa 4800
aaaaaaaaa 4809

```

&lt;210&gt; 570

&lt;211&gt; 951

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 570

```

aaaattgaat attgagatac cattcttttag tgttaccttt tttaccaca tgtgtttctg 60
aaaatattgg aatttttatt atcttaaaaa ttggaccggg ccttatttac catctttaat 120
ccatttttagt actatgggtg agtacatgga attgaagtct ggcttaaatc ttcagaaagt 180
tatatatcta ttttatttta tttttttgag acagagtctc gctgtgtcac ccaggctgga 240
gtgcgggtgcc acaatcttgg ctcaactgcaa cctctgagtc ccaggttcaa gcgatactca 300
tgccctcgccc tcctgagtag ctgggactac aggcgtgcac caccacatct ggctaattct 360
tttttgtatt ttttagtagag acgggggttt actgtggtct ccatctcctg acctcgtgat 420
ccgcctgcct cccaaagtgc tgggattaca ggcattgagcc accgcacaca gctgggactg 480
ggtaatttat aaagaaaaga ggtttaatga ctcacagttc cgcattggctg gagaggcctc 540
aggaaaactta caatcatggg ggaaggcgaa ggggaagcaa ggcacgtctt acatgggtggc 600
aggagagaac gagtgggggg ggagactgcc acaaactttt tttttttgag acaagagtct 660
ggccctgttg cccaggctgg agtgcagtgg catgatctca gctcactgca acctctgcct 720
cacaggttca agcaattctc atgcctcagc ctcccgcata gctgggacca caggatgca 780
ccaccacacc tagctaattt ttgtagtttt agtagagatg ggggtctcact atgttgctca 840
ggctggtcta aaactcctgg gctccagcaa tccgcctgcc ttggcctccc aaagtgtgtg 900
ggttacaggc ataagccacc acatccagcc tgccacatac ttttaaacta t 951

```

&lt;210&gt; 571

&lt;211&gt; 819

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 571

```

cagcttaaaa atggtttctt gaaatcagt attagcattc actcaccagt acccctacta 60
aggggtaggc actggtttgt actcctggga atacaggagt acaccagaat ttattttctgc 120
ttattgcttt tgttgcaaatt gccgtggctt catctgagga attctagaat tcagagggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttta cctgcattct 240
gaaagatggt tctcagggtt ttccctgacg attttcttct tttctgattc tgacaatgtt 300
ttaaatcatt gtactgttgt tatcatttct ctgcatttat tttaccatc ttcccttgta 360
acttgtccta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcacgggtg gctcacatct 480
gtaatcccag cactttgggg aggctgagac ggggtggatca cttgaggtca ggagtttgag 540
accagcctgg ccaacatggg gaaatcccgt ttcactaaaa atacaaaaat taccagggca 600
tggtggcggg cgctgtaat cccaggtaact cgggaggctg agggaggaga atcgcttgaa 660
cctgggaggc tgagggagga gaatcgcttg aaccggggag gcagagggtg cagtgaaccg 720
agatcatggt gctgcactcc agcctggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacia acaaacaaaac aaaacagaga gattttgct 819

```

&lt;210&gt; 572

&lt;211&gt; 203

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 572

```

tatagaatac tcaagctatg catcaagctt ggtaccgagc tcggatccac tatttacggc 60

```



<210> 573  
<211> 132  
<212> PRT  
<213> Homo sapiens

```

<400> 573
Met Val Glu Gly Glu Gly Glu Ala Arg His Val Leu His Gly Gly Arg
                    5                               10                    15

Arg Glu Arg Val Arg Gly Glu Thr Ala Thr Asn Phe Phe Phe Leu Arg
                20                               25                    30

Gln Glu Ser Gly Pro Val Ala Gln Ala Gly Val Gln Trp His Asp Leu
                35                               40                    45

Ser Ser Leu Gln Pro Leu Pro His Arg Phe Lys Gln Phe Ser Cys Leu
    50                               55                               60

Ser Leu Pro His Ser Trp Asp His Arg Tyr Ala Pro Pro His Leu Ala
    65                               70                               75                               80

Asn Phe Cys Ser Phe Ser Arg Asp Gly Val Ser Leu Cys Cys Ser Gly
                85                               90                               95

Trp Ser Lys Thr Pro Gly Leu Gln Gln Ser Ala Cys Leu Gly Leu Pro
    100                               105                               110

Lys Cys Trp Gly Tyr Arg His Lys Pro Pro His Pro Ala Cys His Ile
    115                               120                               125

Leu Leu Asn Tyr
    130

```

<210> 574  
<211> 62  
<212> PRT  
<213> Homo sapiens

```

<400> 574
Met Thr His Ser Ser Ala Trp Leu Glu Arg Pro Gln Glu Thr Tyr Asn
                    5                      10                      15

His Gly Gly Arg Arg Arg Gly Ser Lys Ala Arg Leu Thr Trp Trp Gln
                    20                      25                      30

Glu Arg Thr Ser Glu Gly Gly Asp Cys His Lys Leu Phe Phe Phe Glu
                    35                      40                      45

Thr Arg Val Trp Pro Cys Cys Pro Gly Trp Ser Ala Val Ala
    50                      55                      60

```

**<210> 575**

211

<211> 76  
 <212> PRT  
 <213> Homo sapiens

<400> 575  
 Met Val Lys Ser Arg Phe Thr Lys Asn Thr Lys Ile Thr Gln Ala Trp  
                                   5                                  10                                  15  
 Trp Arg Ala Pro Val Ile Pro Gly Thr Arg Glu Ala Glu Gly Gly Glu  
                                   20                                  25                                  30  
 Ser Leu Glu Pro Gly Arg Leu Arg Glu Glu Asn Arg Leu Asn Pro Gly  
                                   35                                  40                                  45  
 Gly Arg Gly Cys Ser Glu Pro Arg Ser Cys Cys Cys Thr Pro Ala Trp  
                                   50                                  55                                  60  
 Ser Thr Glu Gln Asp Ser Ala Ser Lys Thr Asn Lys  
                                   65                                  70                                  75

<210> 576  
 <211> 68  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> (1)...(68)  
 <223> Xaa = Any Amino Acid

<400> 576  
 Met Leu Gly Lys Ser Arg Ala Val Cys Leu Pro Ser Thr Thr Val Thr  
                                   5                                  10                                  15  
 Thr Val Cys Tyr Leu Ala Ser Ser Ser Ala Ser Arg Glu Thr Ala Thr  
                                   20                                  25                                  30  
 Arg Gln Ala Pro Gly Asn Trp Lys Met Xaa Ser Lys Cys His Ala Gln  
                                   35                                  40                                  45  
 Leu Leu Phe Thr Phe Tyr Leu Asn His Phe Tyr Gln Ile Arg Leu Asn  
                                   50                                  55                                  60  
 Pro Gly Tyr Ser  
 65

<210> 577  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<400> 577  
 Met Tyr Leu Glu Asn Ser Phe Tyr Cys Gln Met Ile Leu Leu Lys Arg  
                                   5                                  10                                  15  
 Cys Arg Leu Ser Lys Ile Ser Thr Gln Arg Val Val Pro Asp Gly Pro

20 25 30

Pro Ala Pro Val Pro Gly Ser Phe Pro Met Phe Pro Arg Phe Gly Phe  
 35 40 45

Arg Leu Ala Pro Pro Ala Asp Thr Pro  
 50 55

<210> 578  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 578

Met Gln Leu Ile Tyr Leu Cys Phe Leu Gly Leu Leu Tyr Ile Arg His  
 5 10 15

His Asp Ser Gln Ser Phe Val Ile Leu Tyr Tyr Lys Lys Leu Asn Tyr  
 20 25 30

Tyr Phe Lys Tyr Gly Gln Ile Arg Ala Phe His Ile Ala Lys Val Tyr  
 35 40 45

Gln Pro His  
 50

<210> 579  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 579

Met His Phe Thr Phe Met Gln Leu Ile Tyr Leu Cys Phe Leu Gly Leu  
 5 10 15

Leu Tyr Ile Arg His His Asp Ser Gln Ser Phe Val Ile Leu Tyr Tyr  
 20 25 30

Lys Lys Leu Asn Tyr Tyr Phe Lys Tyr Gly Gln Ile Arg Ala Phe His  
 35 40 45

Ile Ala Lys Val Tyr Gln Pro His  
 50 55

<210> 580  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

<400> 580

Met Glu Leu Arg Thr Lys Ala Leu Arg Thr Ala Gln Gln Leu Thr Ser  
 5 10 15

Cys Val Thr Ala Leu Lys Ala Ala Gly Pro Pro Leu Thr Phe Trp Lys  
 20 25 30

Gly Lys Trp Val Gln Cys Cys Leu Pro Leu Trp Gly Leu Leu Gly Ser  
                   35                                  40                                  45

His Ala Phe Tyr Ile Tyr Ala Val Asp Ile Phe Met Phe Pro Gly Ser  
           50                                  55                                  60

Phe Ile His  
       65

<210> 581

<211> 77

<212> PRT

<213> Homo sapiens

<400> 581

Met Leu Glu Val Lys Phe Glu Val Ser Leu Arg Pro Thr Gly Asn Glu  
                           5                                  10                                  15

Thr Ala Gly Gln Thr His Gly Thr Gln Asp Lys Gly Ser Lys Asp Ser  
                   20                                  25                                  30

Thr Ala Ala Asp Ile Leu Cys Asp Ser Leu Glu Ser Ser Arg Pro Ala  
                   35                                  40                                  45

Ala His Ile Leu Glu Gly Lys Met Gly Thr Met Leu Ser Ala Thr Leu  
           50                                  55                                  60

Gly Pro Ser Trp Val Thr Cys Ile Leu His Leu Cys Ser  
       65                                  70                                  75

<210> 582

<211> 51

<212> PRT

<213> Homo sapiens

<400> 582

Met Leu Phe Leu Gln Thr Ile Asp Thr Lys Cys Thr Gly Ile Glu Ile  
                           5                                  10                                  15

Asn Arg Asn Trp Ser Lys Val Trp His Thr His Ser His Val Asp Val  
                   20                                  25                                  30

Lys Leu Cys Leu Glu Phe Leu Cys Gly Val Trp Phe Gly Leu Gly Phe  
                   35                                  40                                  45

Leu Gly Val  
       50

<210> 583

<211> 60

<212> PRT

<213> Homo sapiens

<400> 583

214

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg  
                   5                  10                  15

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro  
                   20                  25                  30

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly  
           35                  40                  45

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys  
       50                  55                  60

&lt;210&gt; 584

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 584

Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys  
                   5                  10                  15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg  
                   20                  25                  30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro  
                   35                  40                  45

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly  
       50                  55                  60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys  
       65                  70                  75

&lt;210&gt; 585

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 585

Met Val Tyr Arg Phe Gly Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu  
                   5                  10                  15

Ala Ser Leu Gly Ser Ser Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp  
                   20                  25                  30

Arg Gln Ala Asp Pro Ser Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu  
           35                  40                  45

Leu Phe  
       50

&lt;210&gt; 586

&lt;211&gt; 60

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe  
50 55 60

**<210> 587**

<211> 1408

**<212> DNA**

<213> Homo sapiens

**<400>: 587**

ctggacactt	tgcgagggct	tttgetggct	gctgctgctg	cccgctcatgc	tactcatcgt	60
agcccccccg	gtgaagctcg	ctgctttccc	tacctcctta	agtgactgcc	aaacgcccac	120
cggctggaat	tgctctgggt	atgatgacag	agaaaatgat	ctcttcctct	gtgacaccaa	180
cacctgtaaa	tttgatgggg	aatgtttaag	aattggagac	actgtgactt	gcgtctgtca	240
gttcaagtgc	aacaatgact	atgtgcctgt	gtgtggctcc	aatggggaga	gctaccagaa	300
tgagtgttaç	ctgcgacag	ctgcatgcaa	acagcagagt	gagatacttg	tggtgtcaga	360
aggatcatgt	gccacagatg	caggatcagg	atctggagat	ggagtcctatg	aaggctctgg	420
agaaactagt	caaaaggaga	catccacctg	tgatatattgc	cagtttggtg	cagaatgtga	480
cgaagatgcc	gaggatgtct	ggtgtgtgtg	taatattgac	tgttctcaaa	ccaacttcaa	540
tccccctctgc	gcttctgatg	ggaaatctta	tgataatgca	tgccaaatca	aagaagcatc	600
gtgtcagaaa	caggagaaaa	ttgaagtcat	gtctttgggt	cgatgtcaag	ataacacaac	660
tacaactact	aagtctgaag	atgggcat	tgcaagaaca	gattatgcag	agaatgctaa	720
caaattagaa	gaaagtgcc	gagaacacca	cataccttgt	ccggaacatt	acaatggcct	780
ctgcatgcat	gggaagtgtg	agcattctat	caatatgcag	gagccattct	gcaggtgtga	840
tgctggttat	actggacaac	actgtgaaaa	aaaggactac	agtgttctat	acgttgttcc	900
cggctcgtga	cgatttcagt	atgtcttaat	cgcagctgtg	attggaacaa	ttcagattgc	960
tgatcatctgt	gtggtgggtcc	tctgcatcac	aaggaaatgc	cccagaagca	acagaattca	1020
cagacagaag	caaaatacag	ggcactacag	ttcagacaat	acaacaagag	cgtccacgag	1080
gttaatctaa	agggagcatg	tttcacagtg	gctggactac	cgagagcttg	gactacacaa	1140
tacagtatta	tagacaaaag	aataagacaa	gagatctaca	catgttgctt	tgcatattgtg	1200
gtaatctaca	ccaatgaaa	catgtactac	agctatattt	gattatgtat	ggatatattt	1260
gaaatagtat	acattgtctt	gatgtttttt	ctgtaatgta	aataaactat	ttatatcaca	1320
caatawagtt	ttttctttcc	catgtatttg	ttatatataa	taaatactca	gtgatgagaa	1380
aaaaaaaaaa	aaaaaaaaaa	rwmqacc				1408

<210> 588

<211> 81

<212> PRT

<213> Homo sapiens

**<400> 588**

Met Pro Gln Lys Gln Gln Asn Ser Gln Thr Glu Ala Lys Tyr Arg Ala  
5 10 15

Leu Gln Phe Arg Gln Tyr Asn Lys Ser Val His Glu Val Asn Leu Lys  
20 25 30

216

Gly Ala Cys Phe Thr Val Ala Gly Leu Pro Arg Ala Trp Thr Thr Gln  
           35                    40                    45  
 Tyr Ser Ile Ile Asp Lys Arg Ile Arg Gln Glu Ile Tyr Thr Cys Cys  
           50                    55                    60  
 Leu Ala Phe Val Val Ile Tyr Thr Asn Glu Asn Met Tyr Tyr Ser Tyr  
       65                    70                    75                    80  
 Ile

<210> 589  
 <211> 157  
 <212> PRT  
 <213> Homo sapiens

<400> 589  
 Met Thr Met Cys Leu Cys Val Ala Pro Met Gly Arg Ala Thr Arg Met  
                     5                    10                    15  
 Ser Val Thr Cys Asp Arg Leu His Ala Asn Ser Arg Val Arg Tyr Leu  
                     20                    25                    30  
 Trp Cys Gln Lys Asp His Val Pro Gln Met Gln Asp Gln Asp Leu Glu  
           35                    40                    45  
 Met Glu Ser Met Lys Ala Leu Glu Lys Leu Val Lys Arg Arg His Pro  
       50                    55                    60  
 Pro Val Ile Phe Ala Ser Leu Val Gln Asn Val Thr Lys Met Pro Arg  
       65                    70                    75                    80  
 Met Ser Gly Val Cys Val Ile Leu Thr Val Leu Lys Pro Thr Ser Ile  
                     85                    90                    95  
 Pro Ser Ala Leu Leu Met Gly Asn Leu Met Ile Met His Ala Lys Ser  
                     100                    105                    110  
 Lys Lys His Arg Val Arg Asn Arg Arg Lys Leu Lys Ser Cys Leu Trp  
           115                    120                    125  
 Val Asp Val Lys Ile Thr Gln Leu Gln Leu Leu Ser Leu Lys Met Gly  
       130                    135                    140  
 Ile Met Gln Glu Gln Ile Met Gln Arg Met Leu Thr Asn  
       145                    150                    155

<210> 590  
 <211> 347  
 <212> PRT  
 <213> Homo sapiens

<400> 590  
 Met Leu Leu Ile Val Ala Arg Pro Val Lys Leu Ala Ala Phe Pro Thr  
                     5                    10                    15

Ser Leu Ser Asp Cys Gln Thr Pro Thr Gly Trp Asn Cys Ser Gly Tyr  
 20 25 30  
 Asp Asp Arg Glu Asn Asp Leu Phe Leu Cys Asp Thr Asn Thr Cys Lys  
 35 40 45  
 Phe Asp Gly Glu Cys Leu Arg Ile Gly Asp Thr Val Thr Cys Val Cys  
 50 55 60  
 Gln Phe Lys Cys Asn Asn Asp Tyr Val Pro Val Cys Gly Ser Asn Gly  
 65 70 75 80  
 Glu Ser Tyr Gln Asn Glu Cys Tyr Leu Arg Gln Ala Ala Cys Lys Gln  
 85 90 95  
 Gln Ser Glu Ile Leu Val Val Ser Glu Gly Ser Cys Ala Thr Asp Ala  
 100 105 110  
 Gly Ser Gly Ser Gly Asp Gly Val His Glu Gly Ser Gly Glu Thr Ser  
 115 120 125  
 Gln Lys Glu Thr Ser Thr Cys Asp Ile Cys Gln Phe Gly Ala Glu Cys  
 130 135 140  
 Asp Glu Asp Ala Glu Asp Val Trp Cys Val Cys Asn Ile Asp Cys Ser  
 145 150 155 160  
 Gln Thr Asn Phe Asn Pro Leu Cys Ala Ser Asp Gly Lys Ser Tyr Asp  
 165 170 175  
 Asn Ala Cys Gln Ile Lys Glu Ala Ser Cys Gln Lys Gln Glu Lys Ile  
 180 185 190  
 Glu Val Met Ser Leu Gly Arg Cys Gln Asp Asn Thr Thr Thr Thr  
 195 200 205  
 Lys Ser Glu Asp Gly His Tyr Ala Arg Thr Asp Tyr Ala Glu Asn Ala  
 210 215 220  
 Asn Lys Leu Glu Glu Ser Ala Arg Glu His His Ile Pro Cys Pro Glu  
 225 230 235 240  
 His Tyr Asn Gly Phe Cys Met His Gly Lys Cys Glu His Ser Ile Asn  
 245 250 255  
 Met Gln Glu Pro Ser Cys Arg Cys Asp Ala Gly Tyr Thr Gly Gln His  
 260 265 270  
 Cys Glu Lys Lys Asp Tyr Ser Val Leu Tyr Val Val Pro Gly Pro Val  
 275 280 285  
 Arg Phe Gln Tyr Val Leu Ile Ala Ala Val Ile Gly Thr Ile Gln Ile  
 290 295 300  
 Ala Val Ile Cys Val Val Val Leu Cys Ile Thr Arg Lys Cys Pro Arg  
 305 310 315 320



Ser Asn Arg Ile His Arg Gln Lys Gln Asn Thr Gly His Tyr Ser Ser  
 325 330 335

Asp Asn Thr Thr Arg Ala Ser Thr Arg Leu Ile  
 340 345

<210> 591  
 <211> 565  
 <212> DNA  
 <213> Homo sapien

<400> 591  
 actaaagcaa atgaacaagc tgacttgcta gtatcatctg cattcattga agcacaagaa 60  
 cttcatgcct tgactcatgt aaatgcaata ggattaaaaa ataaatttga tatcacatgg 120  
 aaacagacaa aaaatattgt acaacattgc acccagtgtc agattctaca cctggccact 180  
 caggaagcaa gagttaatcc cagaggtcta tgtcctaata tgttatggca aatggatgtc 240  
 atgcacgtac cttcatttgg aaaattgtca tttgtccatg tgacagttga tacttattca 300  
 catttcatat gggcaacctg ccagacagga gaaagtactt cccatgttaa aagacattta 360  
 ttatcttggt ttcctgtcat gggagttcca gaaaaagtta aaacagacaa tgggccaggt 420  
 tactgtagta aagcatttca aaaattctta aatcagtgga aaattacaca tacaatagga 480  
 attctctata attccaagc acaggccata attgaaggaa ctaatagaac actcaaagct 540  
 caattggtta aacaaaaaaa aaaaa 565

<210> 592  
 <211> 188  
 <212> PRT  
 <213> Homo sapien

<400> 592  
 Thr Lys Ala Asn Glu Gln Ala Asp Leu Leu Val Ser Ser Ala Phe Ile  
 1 5 10 15  
 Glu Ala Gln Glu Leu His Ala Leu Thr His Val Asn Ala Ile Gly Leu  
 20 25 30  
 Lys Asn Lys Phe Asp Ile Thr Trp Lys Gln Thr Lys Asn Ile Val Gln  
 35 40 45  
 His Cys Thr Gln Cys Gln Ile Leu His Leu Ala Thr Gln Glu Ala Arg  
 50 55 60  
 Val Asn Pro Arg Gly Leu Cys Pro Asn Val Leu Trp Gln Met Asp Val  
 65 70 75 80  
 Met His Val Pro Ser Phe Gly Lys Leu Ser Phe Val His Val Thr Val  
 85 90 95  
 Asp Thr Tyr Ser His Phe Ile Trp Ala Thr Cys Gln Thr Gly Glu Ser  
 100 105 110  
 Thr Ser His Val Lys Arg His Leu Ser Cys Phe Pro Val Met Gly  
 115 120 125  
 Val Pro Glu Lys Val Lys Thr Asp Asn Gly Pro Gly Tyr Cys Ser Lys  
 130 135 140  
 Ala Phe Gln Lys Phe Leu Asn Gln Trp Lys Ile Thr His Thr Ile Gly  
 145 150 155 160  
 Ile Leu Tyr Asn Ser Gln Gly Gln Ala Ile Ile Glu Gly Thr Asn Arg  
 165 170 175  
 Thr Leu Lys Ala Gln Leu Val Lys Gln Lys Lys Lys  
 180 185

<210> 593  
 <211> 271

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(271)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 593

actttatggt	cnagtgcana	aanccncctg	gattgccacc	ntactctcag	ggctgtgant	60
tgtgcnccca	nagcaacctg	ggcacgcggg	gacagggggg	ccnacaattg	agggagcggg	120
gtccctagct	ggggtctata	catgncnggg	naagggcngc	tgagtnccat	nagcaaagga	180
nctagnatnt	gcgggggtgc	ggcctgggpc	taccctttta	agcatccntn	gatccactcc	240
angaanccng	gggtagncag	gtttnccaac	a			271

&lt;210&gt; 594

&lt;211&gt; 376

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(376)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 594

cctttggggg	nggggggaac	ctttaccatt	gtncccccttt	atttcatttg	gttnggggtc	60
gcgccctcnn	gggccaacaa	agttatcgtn	nttgaagaga	anattttttt	ggnttngncc	120
cgattaagcg	ncaaatgtgt	agcaaaangc	cgtgccactt	gtggcgtagc	tncgctcgggt	180
cgattcgacg	acaaggcgtn	gcgcgntanc	gttagtctcn	aatngaccn	gtggcatgag	240
cccacgangg	nttcgtgtcg	tcacatggnc	tctagacata	acgcncncn	ttttttncag	300
agggggntgc	cgcccttagg	gagggnagggg	tggggacact	agccaancca	nantctnacc	360
ccattgaaga	aaagggn					376

&lt;210&gt; 595

&lt;211&gt; 242

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(242)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 595

agnctgctgn	tcgtncctn	tatgtggctt	catnntgagg	acaanagtng	cactgaggct	60
tgnngnatgcc	aggcaaggnc	aagctggctc	aaaaagcatc	caccacctc	tгнаangggg	120
atgccangag	cangtgcacc	agtcccaact	angagnccn	ggcatgntac	atcttcttcc	180
acccctnaaa	ntttgngcta	caangnccat	ttttcttttt	ctcttaaggg	ncnctgggt	240
tc						242

&lt;210&gt; 596

&lt;211&gt; 535

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(535)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 596

accagttgga tactgctaaa nagatattta tgcagcctca tatgttaagt cgtatatattt	60
gaaagctttt taaatttttt ctttaagaag atttttagatg cttatcactg agtaccagag	120
ggatgtaggc tgatgccctt atcaacaaag tcaggggactg tggcacacaa ggattgacta	180
ctgcagacac ggccacaatg ctacctctag agggcctgaa tccccctgcc ctctctggtg	240
gggagaaggg ctggcagagc cattagcatg ggctccggcc aatcctggcc actttgacac	300
tcctggtgct gaaccagggg cctggaggaa gggatgaggt gggcagtaga gatgctcagg	360
gcagtggccc ctttccatcc aacttggaac tatttcagta ttttaccacc aattcagcca	420
ttcccttggt cgctggctga acatcagccc tgctccaggt ctcagtttcc cctttgtaaa	480
gggaaagctc tggattcagg gagtgatgaa gaggtcatca tgggtcttgag aattc	535

&lt;210&gt; 597

&lt;211&gt; 257

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(257)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 597

tttcnatacc caaaantacc ccatattang accanacatt tgtctnggaa aaattaccat	60
tntntaactn ttgggccacc tgagannaaa tgggtgtaat ncatgataag atggancagn	120
attnctctta agatnngatn agaccccggt tttcacggaa catatccaag naccacaatag	180
gnaacaagcc acgggnggag tcacaaacat atattcttta ctctcataat ccgtnnacaca	240
naactnttgn acttgac	257

&lt;210&gt; 598

&lt;211&gt; 222

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(222)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 598

nntggntacc gtcnaaactt nncttgggtac ccgagctcgg atccactagt ccagtgtggt	60
ggaattccat tgtgttgggc tataagctgt aatagtggag nctgtctngg ttcattgcan	120
nagncctcc gcanncaac ttggnacaac ctgtgagnag gcnataaatt attcacataa	180
tcatactgc atgaanctga ctcaaacgca tccacntaca cc	222

&lt;210&gt; 599

&lt;211&gt; 238

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(238)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 599

gcatgacatc	ancgatgtnt	ttggnnacct	ganattngct	aaaactngng	natgccgggn	60
atgnagggtt	ggtantgatc	tatgcactca	catctcatgg	ggacgtttca	tgtggagtgn	120
tcgacaangt	tgctgnancn	gagaagtgat	gatctcagtt	gaaaggggtca	tgtgaataca	180
cnttacactt	gaaaaagaag	cacattggga	atatcacgaa	acgnccacca	acatcctg	238

&lt;210&gt; 600

&lt;211&gt; 232

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(232)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 600

cgaactat	agactaccta	ggaaaattat	tttagtatca	gaagaatata	aggggtgtag	60
tactcatcag	agctaaatga	gagcgcttta	aaaatgttag	tttgtcttcc	gccatttcta	120
cagaaagctg	caatttcagg	ttttcaacct	aataggtgat	atttaanaaa	aaaaaaaagc	180
aatcgcaaat	agccccactg	cttttacaaa	tcattttttc	cccaacacaa	tg	232

&lt;210&gt; 601

&lt;211&gt; 547

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(547)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 601

cattgtgttg	gggaaaaaat	gatttgtata	agcagtgggg	ctatttgcga	ttgctttttt	60
tttttcttaa	atatcaccta	ttaggttgaa	aacctgaaat	tgcagctttc	tgtagaaatg	120
gcggaagaca	aactaacatt	tttaaagcgc	tctcathtag	ctctgatgag	tactacaccc	180
ctnatattct	tctgatacta	aaataatttt	cctagtgtag	tctaaacttt	tttaaaaaga	240
catgtaatcc	gcgaggttag	taactcaaaa	cgagtgcata	tnggaagtat	cgcagccgtt	300
nctggatnaa	attcccagct	tgctngcttg	ctnagccggg	ggcggttnaa	aaaaacatct	360
gcagcccngg	ggnaaaaacc	ttcgcatgtg	tcttacgtgt	ttacgttatt	ttatttccct	420
nnagcaaggc	nggganttgg	ggactcgaaa	tggtacagtt	gggctgggga	tcgcccttgt	480
tacataaaag	ncgtccagaa	gagggacggt	tacaggcngg	ganctccaaa	ggtcagtcct	540
tgccatt						547

&lt;210&gt; 602

&lt;211&gt; 826

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(826)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 602

cgggggggnt	tacgtctctc	tggacgcttt	tattgtacca	gggcatccc	agcccaactg	60
taccattcga	gtccctactc	ctgccttgct	ctagggaaat	aaaataacgt	aaacacgtaa	120
gaacaatgcg	aaagcgtttt	cttccctagg	ctgcagattg	tcttcttcac	cgccccctgt	180
tagctagcta	gctagctggg	aatttaatcc	agaaacggct	tgcgatacct	cctagatgca	240

ctcgttttga	gttacaaact	ccgcggatta	catgtctttt	taaaaaagtt	tagactacac	300
tagggaaaat	tatttttagta	tcagaagaat	atcagggggt	gtagtactca	tcagagctna	360
atgagagcgc	tttaaaaatg	ttagtttgtc	ttccgccatt	tctacagaaa	gctgcaattt	420
cagggttttca	ncctaatagg	tgatatntaa	gaaaaaaaaa	acaatcgcan	atagcccact	480
gctttttacaa	atcatttttc	tottctaggt	atagcctgtc	aggtggccta	atgtattttt	540
gacatctcta	ggaattttta	tagaccagaa	atgggtgcca	gagatatgcc	tgactaatac	600
ttaagtgggg	atztatgtat	ttctcaanca	agtgattaaa	gcaaaactag	gcacgaatga	660
aatcaagatc	tttaggccag	aatcatgaa	nanttttana	attattttan	gaatctgtgg	720
cttctcttct	taaaatngaa	aaaaaaattg	tttaaaccac	naaggtctga	ataccaagc	780
ncctgaacn	anagaacaan	gccggagcac	ccctcccaa	atcccc		826

&lt;210&gt; 603

&lt;211&gt; 817

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(817)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 603

nnangacttt	tgtggtntta	tacaattntt	ttttctat	ctatgaagag	aaagccacag	60
agtcctaaaa	taattctaaa	actcatcatg	actttcttgc	ctaaaagatc	ttgatttcaa	120
tcgtgcctag	ttttgcttta	atcacttgct	tgagaaatac	ataaatcccc	acttaagatt	180
agtgcaggca	tatctctggc	acccatttct	ggttctatta	aaattcctag	agatgtcaaa	240
aattacatta	ggccacctga	caggctatac	ctagaagaga	aaaaatgatt	tgtaaaagca	300
gtggggctat	ttgcgattgc	tttttttttt	tcttaaatat	cacctattag	gttgaaaacc	360
tgaaattgca	gctttctgta	gaaatggcgg	aagacaaaact	aacattttta	aagcgctctc	420
atttagctct	gatgagtact	acacccctga	tattcttctg	atactaaaat	aattttccta	480
gtgtagtcta	aactttttta	aaaagacatg	taatccgcgg	agtttgtaac	tcaaaacgag	540
tgcatctagg	aggtatcgca	agccgtttct	ggattaaatt	cccagctagc	ttgcttgctt	600
agcagggggc	ggnaaanaag	acatctgcag	cctagggaag	aaaacctttc	gcattgttct	660
tacgtgttta	cgttatttta	tttcctanaa	caaggcngaa	ttgggactcg	aatggttcag	720
ttgggggtgg	ggatcccctg	gtncataaaa	ngtcanaaag	anggtacagg	cggaaacncca	780
agggtcgccc	tgcaatttana	ctcggaattt	tggtgccc			817

&lt;210&gt; 604

&lt;211&gt; 694

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(694)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 604

cttttcaa	at	catttttnt	cttctaggt	tancctgtca	ggtggcctaa	tgtaattttt	60
gacatctcta		ngaattttta	tagaaccaga	aatgggtgcc	agagatatgc	ctgcactaat	120
cttaagtggg		gatttatgta	tttctcaagc	aagtgattaa	agcaaaacta	ggcagcattg	180
aaatcaagat		cttttaggca	anaaagtc	gatgagtttt	agaattattt	taggactctg	240
tggttttctc		ttcatagaaa	tagaaaaaaa	aattgtataa	aaccacaaaa	ggtcctgaat	300
agccaaagca		acactganca	aaaagaacan	agcagggaag	caacacacta	ccngaattca	360
aattatacta		ccagggtgta	gtaacccaaa	cagcatttcta	ttggcataaa	atagacacca	420
agaccaatgg		ancagaataa	agaacccccc	aaataaatcc	atatatntac	cgccanctga	480
ttatcaataa		cnaacaccaa	gaacatatnt	taagggaant	nctattcaat	aantagtget	540
ggnaaaaaact		gggaaatcca	tatgcagaaa	naatgaaact	agacccttat	ccctcaccat	600

acgcaaannt caacttcgga atgggattac aaaacttaag acattccaac ccaagaaact 660  
atnaaancta ctattaagaa aacagatcnc nccc 694

<210> 605  
<211> 678  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(678)  
<223> n = A,T,C or G

<400> 605  
taaaaaatcta gactacacta ggaaattatt ttantatcag aagaatatca ggggtgtagt 60  
actcatcana gctaaatgag agcgctttaa aaatgtagt ttgtcttccg ccatttctac 120  
agaaagctgc aatttcagggt tttcaacctt atagggtgata tttaagaaaa aaaaaaagca 180  
atcgcaaata gcccactgc ttttacaat cttttttct cttctaggta tagcctgtca 240  
ggtggcctaa tgtaattttt gacatctcta ggaattttaa tagaaccaga aatgggtgcc 300  
agagatatgc ctgactaat cttaagtggg gatttatgta tttctcaagc aagtgattaa 360  
agcaaaaacta ggcacgattg aaatcaanat cttttaggca agaaagtcac gatgagtttt 420  
anaattatatt taggactctg tggctttctc ttcatagaaa tagaaaaaaa aaattgtata 480  
aaaaccacaa aaggtcctga atagcccaaa gcaacactga acaaaaangaa caaagcagga 540  
agcaacacac taccggaatt caattatact accaaggtgt antaaccaaa acagcattct 600  
attgggcata aaatagacca aagaccagtg ggaaacagaa taaagaancc caaataaat 660  
cctatatatta cngccnc 678

<210> 606  
<211> 263  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (1)...(263)  
<223> n = A,T,C or G

<400> 606  
gtgggggtcng cancagccaa ctacagcttcc tttcgggctt tgtagcaga cggatcatcc 60  
tctagtccac tgtgntcaaa ttccattgtg tgggggccnc tcgctcggc canagatctg 120  
agtgancana cntgtccca ctgaggtgcc ccacagcngn ttgtnttcag cangggctna 180  
caactcgacc ggcagcngn ggctggcaga antgngcgcc tnnctattc ctacgngtn 240  
ngccgcagga aggangacag gcc 263

<210> 607  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 607  
ccatgtgggt cccggttgc tt

<210> 608  
<211> 22  
<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 608

gataggggtg ctcaggggtt gg

22

<210> 609

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 609

gctggacagg gggcaaaagc tggggcagtg aaccatgtgc

40

<210> 610

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 610

ccttgtccag atagcccagt agctgac

27

<210> 611

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 611

gatagagaaa accgtccagg ccagtattgt gggaggctgg gagtgc

46

<210> 612

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 612

gcacatggtt cactgccccca gcttttgccc cctgtccagc

40

<210> 613

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

&lt;223&gt; Primer

&lt;400&gt; 613

gccgctcgag ttagaattcg gggttggcca cgatgggtg

38

&lt;210&gt; 614

&lt;211&gt; 53

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 614

cggcgggcat atgcatcacc atcaccatca catcataaac ggcgaggact gca

53

&lt;210&gt; 615

&lt;211&gt; 46

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 615

gcactcccag cctcccacaa tactggcctg gacgggttttc tctatc

46

&lt;210&gt; 616

&lt;211&gt; 1350

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 616

atgcatcacc	atcaccatca	catcataaac	ggcgaggact	gcagcccgca	ctcgcagccc	60
tggcaggcgg	cactgggtcat	ggaaaacgaa	ttgttctgct	cgggcgtcct	ggtgcatccg	120
cagtgggtgc	tgtagccgc	acactgtttc	cagaactcct	acaccatcgg	gctgggcctg	180
cacagtcttg	agggcgacca	agagccaggg	agccagatgg	tggaggccag	cctctccgta	240
cggcaccag	agtacaacag	acccttgctc	gctaacgacc	tcatgctcat	caagttggac	300
gaatccgtgt	ccgagtctga	caccatccgg	agcatcagca	ttgcttcgca	gtgccctacc	360
gcgggggaact	cttgccctgt	ttctggctgg	ggtctgctgg	cgaacggcag	aatgcctacc	420
gtgctgcagt	gcgtgaacgt	gtcgggtggt	tctgaggagg	tctgcagtaa	gctctatgac	480
ccgctgtacc	accccgagcat	gttctgcgcc	ggcggagggc	aagaccagaa	ggactcctgc	540
aacggtgact	ctggggggcc	cctgatctgc	aacgggtact	tgcagggcct	tgtgtctttc	600
ggaaaagccc	cgtgtggcca	agttggcgtg	ccagggtgtct	acaccaacct	ctgcaaattc	660
actgagtgga	tagagaaaac	cgtccaggcc	agtattgtgg	gaggctggga	gtgcgagaag	720
cattcccaac	cctggcaggt	gcttgtggcc	tctcgtggca	gggcagtctg	cggcgggtgt	780
ctgggtgcacc	cccagtgggt	cctcacagct	gccactgca	tcaggaacaa	aagcgtgatc	840
ttgctgggtc	ggcacagcct	gtttcatcct	gaagacacag	gccagggtatt	tcaggtcagc	900
cacagcttcc	cacaccgct	ctacgatatg	agcctcctga	agaatcgatt	cctcaggcca	960
ggtgatgact	ccagccacga	cctcatgctg	ctccgcctgt	cagagcctgc	cgagctcacg	1020
gatgctgtga	aggtcatgga	cctgcccacc	caggagccag	cactggggac	cacctgctac	1080
gcctcaggct	ggggcagcat	tgaaccagag	gagttcttga	ccccaagaa	acttcagtgt	1140
gtggacctcc	atgttatttc	caatgacgtg	tgtgcgcaag	ttaccctca	gaaggtgacc	1200
aagttcatgc	tgtgtgctgg	acgctggaca	gggggcaaaa	gctggggcag	tgaacctatg	1260
gccctgcccg	aaaggccttc	cctgtacacc	aaggtggtgc	attaccggaa	gtggatcaag	1320
gacaccatcg	tggccaaccc	cgaattctaa				1350

&lt;210&gt; 617




&lt;211&gt; 449

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 617

Met His His His His His His Ile Ile Asn Gly Glu Asp Cys Ser Pro  
 1 5 10 15  
 His Ser Gln Pro Trp Gln Ala Ala Leu Val Met Glu Asn Glu Leu Phe  
 20 25 30  
 Cys Ser Gly Val Leu Val His Pro Gln Trp Val Leu Ser Ala Ala His  
 35 40 45  
 Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly Leu His Ser Leu Glu  
 50 55 60  
 Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu Ala Ser Leu Ser Val  
 65 70 75 80  
 Arg His Pro Glu Tyr Asn Arg Pro Leu Leu Ala Asn Asp Leu Met Leu  
 85 90 95  
 Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp Thr Ile Arg Ser Ile  
 100 105 110  
 Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn Ser Cys Leu Val Ser  
 115 120 125  
 Gly Trp Gly Leu Leu Ala Asn Gly Arg Met Pro Thr Val Leu Gln Cys  
 130 135 140  
 Val Asn Val Ser Val Val Ser Glu Glu Val Cys Ser Lys Leu Tyr Asp  
 145 150 155 160  
 Pro Leu Tyr His Pro Ser Met Phe Cys Ala Gly Gly Gly Gln Asp Gln  
 165 170 175  
 Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly Pro Leu Ile Cys Asn Gly  
 180 185 190  
 Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys Ala Pro Cys Gly Gln Val  
 195 200 205  
 Gly Val Pro Gly Val Tyr Thr Asn Leu Cys Lys Phe Thr Glu Trp Ile  
 210 215 220  
 Glu Lys Thr Val Gln Ala Ser Ile Val Gly Gly Trp Glu Cys Glu Lys  
 225 230 235 240  
 His Ser Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly Arg Ala Val  
 245 250 255  
 Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala Ala His  
 260 265 270  
 Cys Ile Arg Asn Lys Ser Val Ile Leu Leu Gly Arg His Ser Leu Phe  
 275 280 285  
 His Pro Glu Asp Thr Gly Gln Val Phe Gln Val Ser His Ser Phe Pro  
 290 295 300  
 His Pro Leu Tyr Asp Met Ser Leu Leu Lys Asn Arg Phe Leu Arg Pro  
 305 310 315 320  
 Gly Asp Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu Pro  
 325 330 335  
 Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr Gln Glu  
 340 345 350  
 Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile Glu  
 355 360 365  
 Pro Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu His  
 370 375 380  
 Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr  
 385 390 395 400  
 Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys Ser Trp Gly  
 405 410 415  
 Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro Ser Leu Tyr Thr Lys Val



ctggtcaaaa	ggaaccaaga	tacaaagaac	tctgagctgt	catcgtcccc	atctctgtga	2760
gccacaacca	acagcaggac	ccaacgcatg	tctgagatcc	ttaaatacaag	gaaaccagt	2820
tcatgagttg	aattctccta	ttatggatgc	tagcttctgg	ccatctctgg	ctctcctctt	2880
gacacatatt	agcttctagc	ctttgcttcc	acgactttta	tcttttctcc	aacacatcgc	2940
ttaccaatcc	tctctctgct	ctgttgcttt	ggacttcccc	acaagaattt	caacgactct	3000
caagtctttt	cttccatccc	caccactaac	ctgaatgcct	agacccttat	ttttattaat	3060
ttccaataga	tgctgcctat	gggctatatt	gcttttagatg	aacattagat	atttaaagct	3120
caagagggtc	aaaatccaac	tcattatctt	ctctttcttt	cacctccctg	ctcctctccc	3180
tatattactg	attgcactga	acagcatggt	ccccaatgta	gccatgcaaa	tgagaaaccc	3240
agtggctcct	tgtggtacat	gcatgcaaga	ctgctgaagc	cagaaggatg	actgattacg	3300
cctcatgggt	ggaggggacc	actcctgggc	cttcgtgatt	gtcaggagca	agacctgaga	3360
tgctccctgc	cttcagtgtc	ctctgcatct	cccctttcta	atgaagatcc	atagaatttg	3420
ctacatttga	gaattccaat	taggaactca	catgttttat	ctgccctatc	aattttttaa	3480
acttgctgaa	aattaagttt	tttcaaaatc	tgctccttgta	aattactttt	tcttacagt	3540
tcttggcata	ctatatcaac	tttgattctt	tgttacaact	tttcttactc	ttttatcacc	3600
aaagtggctt	ttattctctt	tattattatt	attttctttt	actactatat	tacgttggtta	3660
ttattttggt	ctctatagta	tcaattttatt	tgatttagtt	tcaattttatt	tttattgctg	3720
acttttaaaa	taagtgtatt	gggggggtggg	agaacagggg	agggagagca	ttaggacaaa	3780
tacctaattg	atgtgggact	taaaacctag	atgatgggtt	gataggtgca	gcaaaccact	3840
atggcacacg	tatacctgtg	taacaaaacct	acacattctg	cacatgtatc	ccagaacgta	3900
aagtaaaatt	taaaaaaaag	tga				3923

&lt;210&gt; 619


&lt;211&gt; 3674

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 619

agaaagtttc	cttttttttt	tttaatggtg	aaaagatata	cacatattta	gaattagcca	60
gctgggctca	gttttagatta	ttccaatttt	gttggcaaca	tccagagcat	cgtaatcagg	120
agccagtga	acatatccct	tcttctctcc	atcaggccaa	atcacggtgt	tgaccttggc	180
cacatcaatg	tcttagaact	tcttcacagc	ctgtttgatc	tggtgcttgt	tggtcttaac	240
atccacaatg	aacacaagt	tggtgtgtgc	ttctatcttc	ttcgtggtga	ctcagtgggc	300
agcggaaact	tgatgatagc	gtagtgggtca	agcttgtatc	tcctgggagc	gctcttccaa	360
agatatttgg	gctgcctcgg	gagttgcagc	gtcttgggcc	gccggaagg	gggtgacgta	420
cggatcttct	ttttttgtgt	ggctgtggac	acctttcaac	actgtcttct	tggtctttaa	480
atccttcgct	ttgggttcgg	ctataggagg	ggcaggagct	tccttcttca	cttctcggcg	540
catcttgtga	aaaggggaa	tttcctttct	aataccattt	tcacttctcc	cgaattttgt	600
ggatcgtttc	ttggtatcta	ccccagattt	caggagtgtt	ggctggatct	tagggattgt	660
gaagtcttca	tttccctgtg	gtgagatctg	aggcatgatt	ttaaacagt	tgagggaagg	720
agatctccag	gcactttaat	agaatggaga	agcaggatgg	gatttgagag	gaaatctgat	780
tttgaaaaaa	ggagaactag	agttgagttc	gtaattaact	agcaccttaa	aggtcattca	840
gcatgcccat	ctgcacagt	ggtgtaata	ccctacagaa	caaaaacaaa	aaggcaatgg	900
agaggaagct	gtaaagcact	gtacatgttt	aactcattgt	tatgtaagct	agccgaaggc	960
ttcacagact	tgaattcatc	tccaagtctc	tcttctgtga	ctggaaactc	tgcccttaggt	1020
tgcttaaaa	ttgagaaaac	gaatattgct	tccctgtcct	gccttcttga	gtacacttgc	1080
ctacacaaag	atgcacatcc	ttgtttgtgt	gtgtgtgtcc	atttgctgtg	acattcttgt	1140
gaaagtcaaa	gtttcccagc	tggtgacata	cagaagttag	tttggtgcaa	cctgtcagat	1200
gcatccctta	gacaggccct	ttgatactct	gggaagagca	ttggacttac	agtcggaacg	1260
aaaagaaaga	aatgtgatata	gtatagcgtg	cagtgaagtg	gagttttacc	tgtattgttt	1320
taatttcaac	aagcctgagg	actagccaca	aatgtaccca	gtttacaaat	gaggaaacag	1380
gtgcaaaaag	gttggtacct	gtcaaaggct	gtatgtggca	gagccaagat	ttgagccag	1440
ttatgtctga	tgaacttagc	ctatgtctct	taaacttctg	aatgtctgacc	attgaggata	1500
tctaaactta	gatcaattgc	attttccctc	caagactatt	tacttatcaa	tacaataata	1560
ccacctttac	caatctattg	ttttgatacg	agactcaa	atgccagata	tatgtaaaag	1620
caacctacaa	gctctcta	catgtctacc	taaaagattc	ccgggatcta	ataggctcaa	1680
agaaacttct	tctagaaata	taaaagagaa	aattggatta	tgcaaaaatt	cattattaat	1740



cgatgcttct	gcagggcctg	tgacttggtg	cacaacttca	gacaccatca	tcttgcagca	840
gcaccgcacc	ctcactagcc	aggggtgttg	tgacttcctc	aaggccaagg	ccacattcaa	900
ggcttcggac	ttcattgatg	cgcttgtgct	gagcaagggtg	gcttctccgg	gatcttaatt	960
caggaggtag	aatggagctt	gagatcaagt	gtctgatcaa	gcctcagtgt	atgggcgctg	1020
ttcatcctct	ggtgctgaag	cagccaagag	acccaagtct	gcctggctgc	ctcttaggat	1080
atgacagcag	agccagtggc	ctctactaga	tctgtacaa	cctcacaaaa	cacccagaca	1140
tcgggagtgc	tgccagcctg	tgatgcaaga	gtcctaattcc	tgaagacatt	gaatgacctg	1200
tcgttgtgct	gtttttacca	aaaaggatca	tgaggatcag	agaggaaaag	tcacttgccc	1260
aaagtcacac	agctgaacag	tggtggagtt	caactttgac	cgtgggctgt	ctggccccc	1320
aggtgtatgc	ttgcttctct	cccaagagac	tcctttctta	tcaggctcaa	atgaatgaaa	1380
ggaggatggt	aaagacaacg	ccattattga	cgagatcact	cccaagcgga	ttggagattg	1440
tcccaatatt	tagacctata	gcaaggcctt	gggagaaatg	gtggtgcagc	aggagagcag	1500
gaacctaacc	attgccatcc	taaggccctc	cattgtgtgg	agcaacgtgg	caccagcttt	1560
tcctgggttg	ggttgataat	ctaaatggat	gtagccgact	cattattgcg	gtatgtatag	1620
ggatgaagaa	gtaactgtaa	tgtagtggag	gaatagtaag	aaaattctta	gtgctggctt	1680
agcttaattg	atccaaaaac	ataaatgcta	ctttactatc	aattgaagca	tattatttca	1740
attattctgg	ttataatatg	gaggcaggat	gaaattgttt	ttattctttt	agaatttttt	1800
tttatcagga	aaacagaggt	aaagtgtctat	caattactat	ttaagagttc	tattttgaaa	1860
agtgagaatt	aaggattttt	cttttctttt	taaaaaaaac	ttttttaaaa	attaaaaata	1920
aaagaagcaa	aagtcttagg	aaaatgaagc	aagtagccct	gccactctat	gtacagtaat	1980
aacaatatct	gtcccagtta	ttatgtacaa	tattataaaa	aatgtcgagc	acagtaaaaa	2040
aaaaaaaaaa	a					2051

&lt;210&gt; 621

&lt;211&gt; 2841

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;


&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(2841)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 621

gcagagcaca	gcatagctgc	tttaccaaat	catggccaga	ctgcttctgt	aagcaggccc	60
ctgatcctgt	tccacctcac	tggacaggac	ctcccaactg	gggcctccag	ctacccccac	120
cagcatccct	tggccaatgg	aaatttgaaa	tgttcctggg	acagagctcc	tggagagagg	180
ggcaggccac	cacctttgct	gtttgggtga	ctagccgttc	tggcctgcag	gctttggaga	240
gcccaagctg	acaaggggta	gaagagggtc	ctcagcacag	cacagccacg	ctacgaaaac	300
atggccagac	tcttgtttaa	gtcagtcctc	gaacacattt	ctagtcaagt	ggtgaagtct	360
ttcaaccagg	gtctctggct	accttgactg	ctgttctctg	gccgacagag	gtctcaggcc	420
tccttgagtc	agagctcccg	gggggaggac	cagattgtca	tctttgctgt	ttgggtgacc	480
cagccatttc	agccttaggg	cttcagagtg	tctgaggtag	ccaggggctg	aagtgaacct	540
ccagcacagc	acagctgctg	tataaaaaac	tggccagact	ttttctttta	gcaagtccct	600
gttcttattc	ctcctgacta	ggtaagactt	ctcaacttgc	ctccagccac	atcttatttg	660
tgtgttcaga	ttggcaacag	gtttgtacct	cagtggtaga	gagctcccag	aggaaggggt	720
aggctatcat	cttccctgga	aaatacgagt	caattaggga	cttgagggga	cccccagcat	780
tccacagcag	cccttcagaa	aagtggccag	actctgtact	tgatgggcag	atcctcctgg	840
cctgtgtctc	tagccagccc	accactggag	ctatcaagcc	agtagcaact	cagcagttcc	900
ttggacagag	cttccaggag	caaatagaat	cctttctgcc	actgcctttg	cagtgaactg	960
cccttgctat	cctcagaaga	tatatcacgg	gagcaaagac	cctaagtgcc	atatcaaac	1020
ctccaataag	ctgcagttga	cccaaagaac	aagccaatcc	atctcccaca	ggttccacac	1080
acactccact	actcatcacc	agacagggaa	ccctggcttg	ggcccacagc	acagaccctc	1140
catcctgggc	cgattacact	gagtgattgc	taactcacat	gtctctggga	tggagcacc	1200
aggagacaag	caaagtgggt	gagcagcaag	tcagggtgat	tggagcccag	agggcagggg	1260
gagctatctc	tctgggctcc	acttgccctt	gtgagacact	ttgtcccagc	actccttagt	1320
ctgcttgcc	ctcccagggc	cccagcctgg	ccacacctgc	ttacagggca	ctctcagatg	1380
cccataccat	agttttctgtg	ctagtgagac	gtaccatata	agtgagagag	tgacagcaag	1440



tttcaagcaa	atggaaaaca	gaaaaaaggt	gttgcaactcc	cagtttctga	caaaacagac	1380
tctaccaata	aagataaaaa	aagagaagga	cattacaaag	gtggctctga	cctttgataa	1440
atctcattat	tgcttgatac	caacctgggc	tatttgtatt	gcccaaacga	ataggataat	1500
ttgctgaggt	tgtggagctt	ctccccttca	cagagtcctt	gatctccgaa	aatttggttg	1560
agatgtaagg	ttgattttgc	tgtacaactc	cttttttgaa	gttttactca	tttccaacaa	1620
ggaaggcaag	ttttcctgct	tccattgaca	aaggagagca	ggcacctcct	ttcctgagtt	1680
tcagcttgct	tctgacaggg	aaggagcttt	gagatttgaa	tactggcctg	ctggggtttg	1740
gacgtgcatt	gggcctgtgg	tcccatttgt	gttatttttc	tgggaaattt	cttccctttg	1800
gagtggagaa	gcttacccaa	tgctgtacc	atcatcgtac	cttaaaagaa	ctccatttta	1860
agttcagga	ctccttgga	gaagagaccg	tagccttgta	tcagatcata	aaggagaaga	1920
gcaagaggtc	cccggcaaac	atccacagat	ggccttgga	ataagtcacc	ttgctcacc	1980
tgcaaggaatg	ccagtgaact	tattgctgac	atcttgagac	tcagtaccct	catagtgtaa	2040
cggcgtcagc	agatctgcct	gtgctgggac	ttcctgtact	acccattcct	gaggggcgat	2100
gcttctgcag	ggcctgtgac	ttggtgcaca	acttcagaca	ccatcatctt	gcagcagcac	2160
cgcacctca	ctagccaggg	tgttgatgac	ttcctcaagg	ccaaggccac	attcaaggct	2220
tcggacttca	ttgatgcgt	tgtgctgagc	aagggtggctt	ctccgggatc	ttaattcagg	2280
aggtagaatg	gagcttgaga	tcaagtgtct	gatcaagcct	cagtgtatgg	gcgctgttca	2340
tcntctggtg	ctgaagcagc	caagagaccc	aagtctgcct	ggctgcntct	taggatatga	2400
cagcagagcc	agtggcctct	actagatcct	gtacaacctc	acaaaacacc	cagacatcgg	2460
gagtgtgcc	agcctgtgat	gcaagagtcc	taatcctgaa	gacattgaat	gacctgtcat	2520
tctgctgttt	ttaccaaaaa	ggatcatgag	gatcagagag	gaaaagtcac	ttgcccagg	2580
tcacacagct	gaacagtgg	ggagtccaac	tttgaccgtg	ggctgtctga	ccccagggtg	2640
tatgcttgct	tctctcccaa	gagacaactt	tcttatcagg	ctcaaataaa	tgaaggagg	2700
atgttaaagg	taggatctct	gaagcctgtg	ccagtggaac	cgcagctcat	ggctggcacc	2760
tgtgttctca	ttcttacctc	attaagagta	aagtttattg	agtttattga	atttaagtat	2820
ctttagttag	atcatatatt	attagtaaga	actgggacca	aacagatttt	ctgactctaa	2880
aagagagatt	ttcacagaaa	cagatatata	cctgtaagta	tacagacacg	catacacaca	2940
tttctttaact	gtcctataaaa	attagtcctt	attagaatgt	gggatgtata	aatgtaagag	3000
aattttcatg	ttaaaattga	cagatacatt	tttaaatgt	cctaaaataa	atttaattat	3060
ttttntttta	gaattttcca	ttattaatgt	tatttttatg	agaaactata	taactttatt	3120
gataatacat	acaataaccc	tttgtttttc	aaattgaaaa	tacagtgtat	tttgcaata	3180
actaagtcc	aattttgtat	taaaatttta	aattttcaaa	aaaaaaa		3228

&lt;210&gt; 623


&lt;211&gt; 4894

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 623

ctgcacgcgc	tggctccggg	tgacagccgc	gcgcctcggc	caggatctga	gtgatgagac	60
gtgtccccac	tgaggtgccc	cacagcagca	ggtgttgagc	atgggctgag	aagetggacc	120
ggcaccaaaag	ggctggcaga	aatgggcgcc	tggctgattc	ctaggcagtt	ggcggcagca	180
aggaggagag	gccgcagctt	ctggagcaga	gccgagacga	agcagttctg	gagtgcctga	240
acggccccct	gagccctacc	cgcctggccc	actatgggtc	agaggctgtg	ggtgagccgc	300
ctgctgcggc	accggaaagc	ccagctcttg	ctggtcaacc	tgctaaccct	tggcctggag	360
gtgtgtttgg	ccgcaggcat	cacctatgtg	ccgcctctgc	tgctggaagt	gggggtagag	420
gagaagttca	tgaccatggt	gctgggtgag	tcactacatc	ctccttcctt	cctgttccag	480
atacatgcca	cctggcatgt	gggacaggag	tacctctgcc	ctgggagctg	cttgaggga	540
gaggtgtct	gctgggaagg	cattgctggg	caggagggtg	accctgggct	gagggggcac	600
accaagagaa	agaagagaat	accaaggaca	tacccagtc	acctctggat	ccctggctct	660
gcacagagcc	tggctcatag	gagacactgg	agaaatgctc	ctaacccttg	gtagccctt	720
ttataattta	tagcgattat	ctcatttaat	gcttacaacc	accatttgag	gtgatccatt	780
ttacagagaa	ggaagcagag	gcttttaaga	ggttaggtaa	gtcttagcca	aagccaaata	840
gcagctgaac	agtagagctg	ggactccatc	aaggctctcc	agccggagct	tgctcctacc	900
cctaggacaa	ggggtggact	cctgactctg	cagataaatt	ctacaaaagc	cacagaaggc	960
aagtagtaac	cattgtgtga	caaccctca	ccccaggaa	gaggggcccc	tgtgaggatt	1020
gcaggctctg	gagtcacact	gcttgttgaa	acgctgcctc	ttaccctccc	taggtctgcg	1080





tacccccaac	tttcccctac	ccccaaacttt	ccccaccagc	tccacaaccc	tgtttggagc	4620
tactgcagga	ccagaagcac	aaagtgcggt	ttcccaagcc	tttgtccatc	tcagccccc	4680
gagtatatct	gtgcttgggg	aatctcacac	agaaactcag	gagcaccccc	tgccctgagct	4740
aaggagggtc	ttatctctca	ggggggggtt	aagtgccgtt	tgcaataatg	tcgtcttatt	4800
tatttagcgg	ggtgaatatt	ttatactgta	agtgaagcaat	cagagtataa	tgtttatggt	4860
gacaaaatta	aaggctttct	tatatgttta	aaaa			4894

&lt;210&gt; 624


&lt;211&gt; 2904

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 624

gtctatgcct	tcattgatcag	tcttgggggc	tgccctgggt	acctcctgcc	tgccattgac	60
tgggacacca	gtgccctggc	cccctacctg	ggcaccagag	aggagtgcct	ctttggcctg	120
ctcaccctca	tcttctcac	ctgcgtagca	gccacactgc	tggtggctga	ggaggcagcg	180
ctgggcccga	ccgagccagc	agaagggtcg	tcggccccc	ccttgtcgcc	ccactgctgt	240
ccatgccggg	cccgttggc	ttccgggaac	ctgggcggcc	tgcttccccg	gctgcaccag	300
ctgtgctgcc	gcatgccccg	caccctgcgc	cggtcttcg	tggtgagct	gtgcagctgg	360
atggcactca	tgaccttcac	gctgttttac	acggatttcg	tgggcgaggg	gctgtaccag	420
ggcgtgccc	gagctgagcc	gggcaccgag	gcccggagac	actatgatga	aggaaggcct	480
ctggctgtc	taggagtctg	atcagagtcg	ttgcccagct	ttgacagaag	gaaaggcgga	540
gcttattcaa	agtctagagg	gagtggagga	gttaaggctg	gatttcagat	ctgcctggtt	600
ccagccgcag	tgtgccctct	gctcccccaa	cgactttcca	aataatctca	ccagcgcctt	660
ccagctcagg	cgtcctagaa	gcgtcttgaa	gcctatggcc	agctgtcttt	gtgttccctc	720
tcaccgcgct	gtcctcacag	ctgagactcc	caggaaacct	tcagactacc	ttcctctgcc	780
ttcagcaagg	ggcgttgccc	acattctctg	agggcggttcg	gatgggcagc	ctggggctgt	840
tcttgacgtg	cgccatctcc	ctggctcttct	ctctggtcct	ggaccggctg	gtgcagcgat	900
tggcactcg	agcagtctat	ttggccagtg	tggcagcttt	ccctgtggct	gccgggtgcca	960
catgctgtc	ccacagtgtg	gccgtggtga	cagcttcagc	cgcctcacc	gggttcacct	1020
tctcagccct	gcagatcctg	ccctacacac	tggcctccct	ctaccaccgg	gagaagcagg	1080
tgttcctgcc	caaataccga	ggggacactg	gaggtgctag	cagtgaggac	agcctgatga	1140
ccagcttcc	gccaggccct	aagcctggag	ctcccttccc	taatggacac	gtgggtgctg	1200
gaggcagtgg	cctgctccca	cctccacccg	cgtctcgccg	ggcctctgcc	tgtgatgtct	1260
ccgtacgtgt	ggtggtgggt	gagccaccg	aggccagggt	ggttccgggc	cggggcatct	1320
gcctggacct	cgccatcctg	gatagtgcct	tctgctgtc	ccaggtggcc	ccatccctgt	1380
ttatgggtc	cattgtccag	ctcagccagt	ctgtcactgc	ctatatggtg	tctgccgcag	1440
gcctgggtct	ggtcgccatt	tactttgcta	cacaggtagt	atttgacaag	agcgacttgg	1500
ccaaatactc	agcgtagaaa	acttcagca	cattggggtg	gagggcctgc	ctcactgggt	1560
cccagctccc	cgctcctgtt	agccccatgg	ggctgcccgg	ctggccgcca	gtttctgttg	1620
ctgcccagg	aatgtggctc	tctgctgcca	ccctgtgctg	ctgaggtgcg	tagctgcaca	1680
gctgggggct	ggggcgctcc	tctcctctct	ccccagctct	tagggctgcc	tgactggagg	1740
ccttccaagg	gggtttcagt	ctggacttat	acaggagggc	cagaagggct	ccatgcactg	1800
gaatgcgggg	actctgcagg	tggattaccc	aggctcaggg	ttaacagcta	gcctcctagt	1860
tgagacacac	ctagagaagg	gtttttggga	gctgaataaa	ctcagtcacc	tggtttccca	1920
tctctaagcc	ccctaacctg	cagcttcggt	taattgagct	cttgcatggg	agtttctagg	1980
atgaaacact	cctccatggg	atttgaacct	atgaaagtta	tttgtagggg	aagagtcctg	2040
aggggcaaca	cacaagaacc	aggctccctc	agcccacagc	actgtctttt	tgctgatcca	2100
ccccctctt	accttttctc	aggatgtggc	ctgttgggtc	ttctgttgcc	atcacagaga	2160
cacaggcatt	taaatattta	acttatttat	ttacaaagt	agaagggaat	ccattgctag	2220
cttttctgtg	ttggtgtcta	atatttgggt	agggtggggg	atcccccaaca	atcaggtccc	2280
ctgagatagc	tggtcattgg	gctgatcatt	gccagaatct	tcttctcctg	gggtctggcc	2340
ccccaaaatg	cctaaccag	gaccttgaa	attctactca	toccaaataga	taattccaaa	2400
tgctgttacc	caagggttagg	gtgttgaagg	aaggtagagg	gtggggcttc	aggtctcaac	2460
ggcttcctta	accacccctc	ttctcttggc	ccagcctggg	tccccccact	tccactcccc	2520
tctactctct	ctaggactgg	gctgatgaag	gcactgocca	aaatttcccc	tacccccaac	2580
tttccctac	ccccaaactt	ccccaccagc	tccacaaccc	tgtttggagc	tactgcagga	2640



ccgctcctgt	tagcccatg	gggctgcegg	gctggccgce	agtttctgtt	gctgccaaag	2760
taatgtggct	ctctgctgcc	accctgtgct	gctgagggtc	gtagctgcac	agctgggggc	2820
tggggcgctc	ctctcctctc	tccccagtct	ctagggctgc	ctgactggag	gccttccaag	2880
ggggtttcag	tctggactta	tacagggagg	ccagaagggc	tccatgcact	ggaatgcggg	2940
gactctgcag	gtggattacc	caggctcagg	gttaacagct	agcctcctag	ttgagacaca	3000
cctagagaag	ggtttttggg	agctgaataa	actcagtcac	ctggtttccc	atctctaagc	3060
cccttaacct	gcagcttcgt	ttaatgtagc	tcttgcatgg	gagtttctag	gatgaaacac	3120
tcctccatgg	gatttgaaca	tatgaaagtt	atttgtaggg	gaagagtcct	gaggggcaac	3180
acacaagaac	cagggtcccct	cagcccacag	cactgtcttt	ttgctgatcc	acccccctct	3240
taccttttat	caggatgtgc	ctggttggtc	ttctgttgcc	atcacagaga	cacaggcatt	3300
taaatatatta	acttatttat	ttaacaaagt	agaagggaat	ccattgctag	cttttctgtg	3360
ttggtgtcta	atatttgggt	aggggtgggg	atcccccaaca	atcagggtccc	ctgagatagc	3420
tggtcattgg	gctgatcatt	gccagaatct	tcttctcctg	gggtctggcc	ccccaaaatg	3480
cctaaccacag	gaccttgga	attctactca	tcccaaataga	taattccaaa	tgctgttacc	3540
caaggttagg	gtgttgaagg	aaggtagagg	gtggggcttc	aggtctcaac	ggcttcccta	3600
accacccctc	ttctcttgcc	ccagcctggt	tccccccact	tccactcccc	tctactctct	3660
ctaggactgg	gctgatgaag	gcactgccca	aaatttcccc	tacccccaac	tttcccctac	3720
ccccaaacttt	ccccaccagc	tcacacaacc	tgtttgagc	tactgcagga	ccagaagcac	3780
aaagtgcggg	ttcccaagcc	tttgtccatc	tcagccccca	gagtatatct	gtgcttgggg	3840
aatctcacac	agaaactcag	gagcaccccc	tgctgagct	aaaggagggtc	ttatctctca	3900
ggggggggtt	aagtgccgtt	tgcaataatg	tcgtcttatt	tatttagcgg	ggtgaatatt	3960
ttatactgta	agtgaagcaat	cagagtataa	tgtttatggt	gacaaaatta	aaggctttct	4020
tatatgttta	aaaa					4034

&lt;210&gt; 626


&lt;211&gt; 6976

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 626

gaagctggac	cggcaccaaa	gggctggcag	aaatgggcgc	ctggctgatt	cctaggcagt	60
tggcggcagc	aaggaggaga	ggccgcagct	tctggagcag	agccgagacg	aagcagttct	120
ggagtgcctg	aacggccccc	tgagccctac	ccgcctggcc	cactatgggtc	cagaggctgt	180
gggtgagccg	cctgctgcgg	caccggaaaag	cccagctctt	gctgggtcaac	ctgctaacct	240
ttggcctgga	ggtgtgtttg	gccgcaggca	tcacctatgt	gccgcctctg	ctgctggaag	300
tgggggtaga	ggagaagtc	atgaccatgg	tgctgggtga	gtcactacat	cctccttctc	360
tcctgttcca	gatacatgcc	acctggcatg	tgggacagga	gtacctctgc	cctgggagct	420
gcttgagggg	agaggtggtc	tgctgggaag	gcattgctgg	gcaggagggt	gaccctgggc	480
tgagggggca	caccaagaga	aagaagagaa	taccaaggac	ataccccagt	cacctctgga	540
tccctggtcc	tgacagagc	ctggctcata	ggagacactg	gagaaatgct	cctaaccttt	600
ggctagccct	tttataattt	atagcgatta	tctcatttaa	tgottacaac	caccatttga	660
ggtgatccat	tttacagaga	aggaagcaga	ggcttttaag	aggttaggta	agtcttagcc	720
aaagccaaat	agcagctgaa	cagtagagct	gggactccat	caaggctctc	cagccggagc	780
ttgctcctac	ccctaggaca	aggggtggac	tctgactct	gcagataaat	tctacaaaag	840
ccacagaagg	caagtagtaa	ccattgtgtg	acaacccctc	acccccagga	agagggggcc	900
ctgtgaggat	tgacaggctc	ggagtcacac	tgcttggtga	aacgctgcct	cttaccctcc	960
ctaggctctgc	gcctttgaat	aagtatcact	tmttagttgc	tccatgcctc	agtttgtcca	1020
tctgaaaatg	ggggcatctg	taatgcctgt	gttatgagga	gtaaattaca	gcatccctgt	1080
gaagacgtag	cacagtgtcg	agtacggaat	gttatttcca	tccttctcac	ggagcttggt	1140
tccccttccc	cttgcccttt	acttgtccca	gccattgact	catactactt	cccttcttgc	1200
aggcatgggt	ccagtgtctg	gcctgggtctg	tgtcccgcctc	ctaggctcag	ccagtgacca	1260
ctggcggtgga	cgctatggcc	gccgcgggcc	cttcatctgg	gcactgtcct	tgggcatcct	1320
gctgagcctc	tttctcatcc	caagggcggg	ctggctagca	gggctgctgt	gcccggatcc	1380
caggccctctg	gagctggcac	tgctcatcct	gggcgtgggg	ctgctggact	tctgtggcca	1440
ggtgtgcttc	actccactgg	aggccctgct	ctctgacctc	ttccgggacc	cggaccactg	1500
tcgccaggcc	tactctgtct	atgccttcat	gatcagctct	gggggctgcc	tgggctacct	1560
cctgcctgcc	attgactggg	acaccagtgc	cctggccccc	tacctgggca	cccaggagga	1620



```
<210> 627
<211> 123
<212> PRT
<213> Homo sapiens
```

Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe  
5 10 15


Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val  
20 25 30

Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys  
35 40 45


Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly  
50 55 60

Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu  
65 70 75 80

Tyr His Arg Glu Lys Gln Val Leu Ile Gly Gln Trp Val Glu Ser Gly  
85 90 95



Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp  
 50 55 60  
 Ala Leu Ser Leu Gly Ile Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala  
 65 70 75 80  
 Gly Trp Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu  
 85 90 95  
 Ala Leu Leu Ile Leu Gly Val Gly Leu Leu Asp Phe Cys Gly Gln Val  
 100 105 110  
 Cys Phe Thr Pro Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro  
 115 120 125  
 Asp His Cys Arg Gln Ala Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu  
 130 135 140  
 Gly Gly Cys Leu Gly Tyr Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser  
 145 150 155 160  
 Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu  
 165 170 175  
 Leu Thr Leu Ile Phe Leu Thr Cys Val Ala Ala Thr Leu Leu Val Ala  
 180 185 190  
 Glu Glu Ala Ala Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala  
 195 200 205  
 Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe  
 210 215 220  
 Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His Gln Leu Cys Cys Arg  
 225 230 235 240  
 Met Pro Arg Thr Leu Arg Arg Leu Phe Val Ala Glu Leu Cys Ser Trp  
 245 250 255  
 Met Ala Leu Met Thr Phe Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu  
 260 265 270  
 Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg  
 275 280 285  
 Arg His Tyr Asp Glu Gly Lys Ala Leu Ala Ala Ser Arg Gly Trp Cys  
 290 295 300  
 Gly Ser Arg Pro Pro Glu Thr Thr Leu Gly Ala Val Ser Gly Leu Val  
 305 310 315 320  
 Pro Leu His Pro Gly Pro Asp Phe Ser Val Arg Lys Val Gly Met Asp  
 325 330 335  
 Pro Ile Cys Ile His Gly Phe Ser Trp Val Trp Asn Ile Ser Ala Cys  
 340 345 350





tattgcctcc	atttctctct	ctctatccct	gaaatccagg	aagtcctct	cctgggtgctc	2640
caagcagttt	gaagcccaat	ctgcaaggac	atttctcaag	ggccatgtgg	ttttgcagac	2700
aacctgtcc	tcaggcctga	actcaccata	gagacccatg	tcagcaaacg	gtgaccagca	2760
aatcctcttc	ccttattcta	aagctgcccc	ttgggagact	ccaggagaa	ggcattgctt	2820
cctccctggt	gtgaactctt	tctttggtat	tccatccact	atcctggcaa	ctcaaggctg	2880
cttctgttaa	ctgaagcctg	ctccttcttg	ttctgcccctc	cagagatttg	ctcaaattgat	2940
caataagctt	taaattaaac	tctacttcaa	gaaaaaaaa	ccg		2983

&lt;210&gt; 631


&lt;211&gt; 3064

&lt;212&gt; DNA


&lt;213&gt; Homo sapiens

&lt;400&gt; 631

aattctaaaa	atgcttttgc	aagcttgcatt	gcctgcagg	gcagcgccg	ccagtgtgat	60
ggatatctgc	agaattcggc	ttgcgtcag	ctggaattcc	gcagagatag	agtcttccct	120
ggcattgcag	gagagaatct	gaagggatga	tggatgcato	aaaagagctg	caagttctcc	180
acattgactt	cttgaatcag	gacaacgccg	tttctcacca	cacatgggag	ttccaaacga	240
gcagtccctg	gttccggcga	ggacaggtgt	ttcacctgcg	gctgggtgctg	aaccagcccc	300
tacaatccta	ccaccaactg	aaactggaat	tcagcacagg	gccgaatcct	agcatcgcca	360
aacacaccct	ggtggtgctc	gacccgagga	cgccctcaga	ccactacaac	tggcaggcaa	420
cccttcaaaa	tgagtctggc	aaagaggtca	cagtggctgt	caccagttcc	cccaatgcca	480
tcctgggcaa	gtaccaacta	aacgtgaaaa	ctggaaacca	catccttaag	tctgaagaaa	540
acatcctata	ccttctcttc	aacctatggt	gtaagagga	catggttttc	atgcctgatg	600
aggacgagcg	caaagagtac	atcctcaatg	acacgggctg	ccattacgtg	ggggctgcca	660
gaagtatcaa	atgcaaacc	tggaaactttg	gtcagtttga	gaaaaatgtc	ctggactgct	720
gcatttccct	gctgactgag	agctccctca	agcccacaga	taggagggac	cccgtgctgg	780
tgtgcagggc	catgtgtgct	atgatgagct	ttgagaaagg	ccagggcgctg	ctcattggga	840
attggactgg	ggactacgaa	ggtggcacag	ccccatacaa	gtggacaggc	agtgccccga	900
tcctgcagca	gtactacaac	acgaagcagg	ctgtgtgctt	tggccagtgc	tgggtgtttg	960
ctgggaccc	gactacagt	ctgagagcgt	tgggcatccc	agcacgcagt	gtgacaggct	1020
tcgattcagc	tcacgacaca	gaaaggaacc	tcacggtgga	cacctatgtg	aatgagaatg	1080
gcgagaaaat	caccagtatg	accacagact	ctgtctggaa	tttccatgtg	tggacggatg	1140
cctggatgaa	gcgacctac	gacggctggc	aggctgtgga	cgcaacgccg	caggagcgaa	1200
gccaggggtg	cttctgctgt	gggccatcac	cactgaccgc	catccgcaaa	ggtgacatct	1260
ttattgtcta	tgacaccaga	ttcgtcttct	cagaagtga	tggtagacagg	ctcatctggt	1320
tgggtgaagat	ggtgaatggg	caggaggagt	tacacgtaat	ttcaatggag	accacaagga	1380
tcgggaaaaa	catcagcacc	aaggcagtg	gccaaagacag	gcggagagat	atcacctatg	1440
agtacaagta	tcagaaggc	tcctctgagg	agaggcaggt	catggatcat	gccttccctc	1500
ttctcagttc	tgagagggag	cacagacagc	ctgtaaaaga	gaactttctt	cacatgtcgg	1560
tacaatcaga	tgatgtgctg	ctgggaaact	ctgttaattt	caccgtgatt	cttaaaagga	1620
agaccgctgc	cctacagaat	gtcaacatct	tgggctcctt	tgaactacag	ttgtacactg	1680
gcaagaagat	ggcaaaactg	tgtgacctca	ataagacctc	gcagatccaa	ggtcaagtat	1740
cagaagtga	tctgacctg	gactccaaga	cctacatcaa	cagcctggct	atattagatg	1800
atgagccagt	tatcagaggt	ttcatcattg	cggaaattgt	ggagtctaag	gaaatcatgg	1860
cctctgaagt	attcacgtca	aaccagtacc	ctgagttctc	tatagagttg	cctaacacag	1920
gcagaattgg	ccagctactt	gtctgcaatt	gtatcttcaa	gaataccctg	gccatccctt	1980
tgactgacgt	caagttctct	ttggaaagcc	tgggcatctc	ctcactacag	acctctgacc	2040
atgggacggt	gcagcctggt	gagaccatcc	aatcccaaat	aaaatgcacc	ccaataaaaa	2100
ctggacccaa	gaaatttatc	gtcaagttaa	gttccaaaca	agtgaagag	attaatgctc	2160
agaagattgt	tctcatcacc	aagtagcctt	gtctgatgct	gtggagcctt	agttgagatt	2220
tcagcatttc	ctaccttggt	cttagctttc	agattatgga	tgattaaatt	tgatgactta	2280
tatgagggca	gattcaagag	ccagcaggtc	aaaaaggcca	acacaaccat	aagcagccag	2340
accacaagg	ccaggtcctg	tgtatcacca	gggtcacctc	ttttacagtt	agaaacacca	2400
gccgaggcca	cagaatccca	tccctttcct	gagtcattgg	ctcaaaaatc	agggccacca	2460
ttgtctcaat	tcaaatccat	agatttcgaa	gccacagagc	tcttccctgg	agcagcagac	2520
tatgggcagc	ccagtgtgct	cacctgtgta	cgacccttga	gaagctgcca	tatcttcagg	2580
ccatgggttc	accagccctg	aaggcacctg	tcaactggag	tgtctctca	gcactgggat	2640



225                      230                      235                      240  
 Thr Ala Pro Tyr Lys Trp Thr Gly Ser Ala Pro Ile Leu Gln Gln Tyr  
~~245~~ ~~250~~ ~~255~~  
 Tyr Asn Thr Lys Gln Ala Val Cys Phe Gly Gln Cys Trp Val Phe Ala  
                     260                      265                      270  
 Gly Ile Leu Thr Thr Val Leu Arg Ala Leu Gly Ile Pro Ala Arg Ser  
                     275                      280                      285  
 Val Thr Gly Phe Asp Ser Ala His Asp Thr Glu Arg Asn Leu Thr Val  
                     290                      295                      300  
 Asp Thr Tyr Val Asn Glu Asn Gly Lys Lys Ile Thr Ser Met Thr His  
 305                      310                      315                      320  
 Asp Ser Val Trp Asn Phe His Val Trp Thr Asp Ala Trp Met Lys Arg  
                     325                      330                      335  
 Pro Asp Leu Pro Lys Gly Tyr Asp Gly Trp Gln Ala Val Asp Ala Thr  
                     340                      345                      350  
 Pro Gln Glu Arg Ser Gln Gly Val Phe Cys Cys Gly Pro Ser Pro Leu  
                     355                      360                      365  
 Thr Ala Ile Arg Lys Gly Asp Ile Phe Ile Val Tyr Asp Thr Arg Phe  
                     370                      375                      380  
 Val Phe Ser Glu Val Asn Gly Asp Arg Leu Ile Trp Leu Val Lys Met  
 385                      390                      395                      400  
 Val Asn Gly Gln Glu Glu Leu His Val Ile Ser Met Glu Thr Thr Ser  
                     405                      410                      415  
 Ile Gly Lys Asn Ile Ser Thr Lys Ala Val Gly Gln Asp Arg Arg Arg  
                     420                      425                      430  
 Asp Ile Thr Tyr Glu Tyr Lys Tyr Pro Glu Gly Ser Ser Glu Glu Arg  
                     435                      440                      445  
 Gln Val Met Asp His Ala Phe Leu Leu Leu Ser Ser Glu Arg Glu His  
                     450                      455                      460  
 Arg Arg Pro Val Lys Glu Asn Phe Leu His Met Ser Val Gln Ser Asp  
 465                      470                      475                      480  
 Asp Val Leu Leu Gly Asn Ser Val Asn Phe Thr Val Ile Leu Lys Arg  
                     485                      490                      495  
 Lys Thr Ala Ala Leu Gln Asn Val Asn Ile Leu Gly Ser Phe Glu Leu  
                     500                      505                      510  
 Gln Leu Tyr Thr Gly Lys Lys Met Ala Lys Leu Cys Asp Leu Asn Lys  
                     515                      520                      525  
 Thr Ser Gln Ile Gln Gly Gln Val Ser Glu Val Thr Leu Thr Leu Asp  
                     530                      535                      540



Ser Glu Glu Asn Ile Leu Tyr Leu Leu Phe Asn Pro Trp Cys Lys Glu  
 130 135 140

~~Asp Met Val Phe Met Pro Asn Glu Asn Glu Arg Lys Glu Thr Ile Leu~~  
~~145 150 155 160~~

Asn Asp Thr Gly Cys His Tyr Val Gly Ala Ala Arg Ser Ile Lys Cys  
 165 170 175

Lys Pro Trp Asn Phe Gly Gln Phe Glu Lys Asn Val Leu Asp Cys Cys  
 180 185 190

Ile Ser Leu Leu Thr Glu Ser Ser Leu Lys Pro Thr Asp Arg Arg Asp  
 195 200 205

Pro Val Leu Val Cys Arg Ala Met Cys Ala Met Met Ser Phe Glu Lys  
 210 215 220

Gly Gln Gly Val Leu Ile Gly Asn Trp Thr Gly Asp Tyr Glu Gly Gly  
 225 230 235 240

Thr Ala Pro Tyr Lys Trp Thr Gly Ser Ala Pro Ile Leu Gln Gln Tyr  
 245 250 255

Tyr Asn Thr Lys Gln Ala Val Cys Phe Gly Gln Cys Trp Val Phe Ala  
 260 265 270

Gly Ile Leu Thr Thr Val Leu Arg Ala Leu Gly Ile Pro Ala Arg Ser  
 275 280 285

Val Thr Gly Phe Asp Ser Ala His Asp Thr Glu Arg Asn Leu Thr Val  
 290 295 300

Asp Thr Tyr Val Asn Glu Asn Gly Glu Lys Ile Thr Ser Met Thr His  
 305 310 315 320

Asp Ser Val Trp Asn Phe His Val Trp Thr Asp Ala Trp Met Lys Arg  
 325 330 335

Pro Tyr Asp Gly Trp Gln Ala Val Asp Ala Thr Pro Gln Glu Arg Ser  
 340 345 350

Gln Gly Val Phe Cys Cys Gly Pro Ser Pro Leu Thr Ala Ile Arg Lys  
 355 360 365


Gly Asp Ile Phe Ile Val Tyr Asp Thr Arg Phe Val Phe Ser Glu Val  
 370 375 380

Asn Gly Asp Arg Leu Ile Trp Leu Val Lys Met Val Asn Gly Gln Glu  
 385 390 395 400


Glu Leu His Val Ile Ser Met Glu Thr Thr Ser Ile Gly Lys Asn Ile  
 405 410 415

Ser Thr Lys Ala Val Gly Gln Asp Arg Arg Arg Asp Ile Thr Tyr Glu  
 420 425 430

Tyr Lys Tyr Pro Glu Gly Ser Ser Glu Glu Arg Gln Val Met Asp His




ttctttacca	aagattccaa	ggccacggag	aatgtgtgca	agtgtggcta	tgcccagagc	240
cagcacatgg	aaggcaccca	gatcaaccaa	agtgagaaat	ggaactacaa	gaaacacacc	300
aaggaatttc	ctaccgacgc	ctttggggat	attcagtttg	agacactggg	gaagaaaggg	360
actgtgaccc	tgaaaacacc	caacctgggc	atttctgtga	ccggggggcg	caagaacttc	420
gccctgaagc	cgcgcattgc	caagatcttc	agccgggtca	tctacatcgc	gcagtcctaaa	480
ggtgcttgga	ttctcacggg	aggcaccatc	tatggcctga	cgaagtacat	cggggagggtg	540
gtgagagata	acaccatcag	caggagttca	gaggagaata	ttgtggccat	tggcatagca	600
gcttggggca	tgggtctcaa	ccgggacacc	ctcatcagga	attgcgatgc	taggggctat	660
tttttagccc	agtaccttat	ggatgacttc	acaagggatc	cactgtatat	cctggacaac	720
aaccacacac	atttgctgct	cgtggacaat	ggctgtcatg	gacatcccac	tgtcgaagca	780
aagctccgga	atcagctaga	gaagcatatc	tctgagcgca	ctattcaaga	ttccaactat	840
ggtggcaaga	tccccattgt	gtgttttgcc	caaggagggtg	gaaaagagac	tttgaaagcc	900
atcaatacct	ccatcaaaaa	taaaattcct	tgtgtgggtg	tgggaaggctc	gggccggatc	960
gctgatgtga	tcgctagcct	ggtggagggtg	gaggatgccc	cgacatcttc	tgccgtcaag	1020
gagaagctgg	tgcgcttttt	accccgacag	gtgtcccggc	tgtctgagga	ggagactgag	1080
agttggatca	aatgggtcaa	agaaattctc	gaatgttctc	acctattaac	agttattaaa	1140
atggaagaag	ctggggatga	aattgtgagc	aatgccatct	cctacgctct	atacaaagcc	1200
ttcagcacca	gtgagcaaga	caaggataac	tggaatgggc	agctgaagct	tctgctggag	1260
tggaaaccagc	tggacttagc	caatgatgag	attttcacca	atgaccgccg	atgggagctc	1320
gctgaccttc	aagaagtcac	gtttacggct	ctcataaagg	acagacccaa	gtttgtccgc	1380
ctctttcttg	agaattggctt	gaacctacgg	aagtttctca	cccattgatgt	cctcactgaa	1440
ctctttctca	accacttcag	cacgcttggtg	taccggaatc	tgcagatcgc	caagaattcc	1500
tataatgatg	ccctcctcac	gtttgtctgg	aaactggttg	cgaacttccg	aagaggcttc	1560
cgggaaggaag	acagaaatgg	ccgggacgag	atggacatag	aactccacga	cgtgtctcct	1620
attactcggc	accccttgca	agctctcttc	atctgggcca	ttcttcagaa	taagaaggaa	1680
ctctccaaag	tcatttgga	gcagaccagg	ggctgcactc	tggcagccct	gggagccaagc	1740
aagcttctga	agactctggc	caaagtgaag	aacgacatca	atgctgctgg	ggagtccgag	1800
gagctggcta	atgagtacga	gacccgggct	gttgagctgt	tactgagtg	ttacagcagc	1860
gatgaagact	tggcagaaca	gctgctggtc	tattcctgtg	aagcttgggg	tggaaagcaac	1920
tgtctggagc	tggcgggtga	ggccacagac	cagcatttca	ccgcccagcc	tgggggtccag	1980
aattttcttt	ctaagcaatg	gtatggagag	atttcccag	acaccaagaa	ctggaagatt	2040
atcctgtgtc	tgtttattat	acccttggtg	ggctgtggct	ttgtatcatt	taggaagaaa	2100
cctgtcgaca	agcacaagaa	gctgctttgg	tactatgtgg	cgttcttcac	ctcccccttc	2160
gtggtcttct	cctggaatgt	ggtcttctac	atcgcttcc	tctgtctgtt	tgcctacgtg	2220
ctgtctcttg	atttccattc	ggtgccacac	cccccgagc	tggctctgta	ctcgctggtc	2280
tttgtcctct	tctgtgatga	agtgaagac	tggtagttaa	atggggtgaa	ttattttact	2340
gacctgtgga	atgtgatgga	cacgctgggg	ctttttact	tcatagcagg	aattgtattt	2400
cggctccact	cttctaataa	aagctctttg	tattctggac	gagtcatttt	ctgtctggac	2460
tacattattt	tactctaaag	attgateccac	atttttactg	taagcagaaa	cttaggaccc	2520
aagattataa	tgctgcagag	gatgctgac	gatgtgttct	tcttctgtgt	cctctttgag	2580
gtgtggatgg	tggcctttgg	cgtggccagg	caagggatcc	ttaggcagaa	tgagcagcgc	2640
tggagggtga	tattccgttc	ggtcatctac	gagccctacc	tggccatgtt	cggccagggtg	2700
cccagtgacg	tggatggtac	cacgtatgac	tttgccact	gcaccttcac	tgggaatgag	2760
tccaagccac	tgtgtgtgga	gctggatgag	cacaacctgc	cccggttccc	cgagtggatc	2820
accatcccc	tgggtgtgcat	ctacatgtta	tccaccaaca	tctgtctggt	caacctgctg	2880
gtcgccatgt	ttggctacac	ggtgggcacc	gtccaggaga	acaatgacca	ggtctggaag	2940
ttccagaggt	acttctggt	gcaggagtac	tgagccgcc	tcaatatccc	cttccccctc	3000
atcgctctcg	cttacttcta	catggtgggtg	aagaagtgtc	tcaagtgttg	ctgcaaggag	3060
aaaaacatgg	agcttctgt	ctgctgtttc	aaaaatgaag	acaatgagac	tctggcatgg	3120
gaggggtgtca	tgaaggaaaa	ctacctgtgc	aagatcaaca	caaaagccaa	cgacacctca	3180
gaggaaatga	ggcatcgatt	tagacaactg	gatacaagc	ttaatgatct	caagggtctt	3240
ctgaaagaga	ttgtctaataa	aactgatga	aactctaag	gagaaaaaat	gagaaaaaat	3300
taattatagc	aagatcatat	taaggaaatgc	tgatgaacaa	ttttgctatc	gactactaaa	3360
tgagagattt	tcagaccct	gggtacatgg	tggatgattt	taaatcacc	tagtgtgtctg	3420
agaccttgag	aataaagtgt	gtgattgggt	tcatacttga	agacggatat	aaaggaagaa	3480
tatttccttt	atgtgtttct	ccagaatggt	gcctgtttct	ctctgtgtct	caatgcctgg	3540
gactggaggt	tgatagttaa	agtgtgttct	taccgctcc	tttttcttt	aatcttattt	3600






Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser  
 100 105 110  
 Cys Asp Thr Asp Ala Glu Ile Leu Tyr Glu Leu Leu Thr Gln His Trp  
 115 120 125  
 His Leu Lys Thr Pro Asn Leu Val Ile Ser Val Thr Gly Gly Ala Lys  
 130 135 140  
 Asn Phe Ala Leu Lys Pro Arg Met Arg Lys Ile Phe Ser Arg Leu Ile  
 145 150 155 160  
 Tyr Ile Ala Gln Ser Lys Gly Ala Trp Ile Leu Thr Gly Gly Thr His  
 165 170 175  
 Tyr Gly Leu Thr Lys Tyr Ile Gly Glu Val Val Arg Asp Asn Thr Ile  
 180 185 190  
 Ser Arg Ser Ser Glu Glu Asn Ile Val Ala Ile Gly Ile Ala Ala Trp  
 195 200 205  
 Gly Met Val Ser Asn Arg Asp Thr Leu Ile Arg Asn Cys Asp Ala Glu  
 210 215 220  
 Gly Tyr Phe Leu Ala Gln Tyr Leu Met Asp Asp Phe Thr Arg Asp Pro  
 225 230 235 240  
 Leu Tyr Ile Leu Asp Asn Asn His Thr His Leu Leu Leu Val Asp Asn  
 245 250 255  
 Gly Cys His Gly His Pro Thr Val Glu Ala Lys Leu Arg Asn Gln Leu  
 260 265 270  
 Glu Lys His Ile Ser Glu Arg Thr Ile Gln Asp Ser Asn Tyr Gly Gly  
 275 280 285  
 Lys Ile Pro Ile Val Cys Phe Ala Gln Gly Gly Gly Lys Glu Thr Leu  
 290 295 300  
 Lys Ala Ile Asn Thr Ser Ile Lys Asn Lys Ile Pro Cys Val Val Val  
 305 310 315 320  
 Glu Gly Ser Gly Arg Ile Ala Asp Val Ile Ala Ser Leu Val Glu Val  
 325 330 335  
 Glu Asp Ala Pro Thr Ser Ser Ala Val Lys Glu Lys Leu Val Arg Phe  
 340 345 350  
 Leu Pro Arg Thr Val Ser Arg Leu Ser Glu Glu Glu Thr Glu Ser Trp  
 355 360 365  
 Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser His Leu Leu Thr Val  
 370 375 380  
 Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val Ser Asn Ala Ile Ser  
 385 390 395 400



705		710		715		720
Phe Phe Thr Ser	Pro Phe Val Val	Phe Ser Trp Asn Val Val	Phe Tyr			
	725		730			735
Ile Ala Phe Leu	Leu Leu Phe Ala Tyr Val	Leu Leu Met Asp	Phe His			
	740		745			750
Ser Val Pro His	Pro Pro Glu Leu Val	Leu Tyr Ser Leu Val	Phe Val			
	755		760			765
Leu Phe Cys Asp	Glu Val Arg Gln Trp Tyr Val	Asn Gly Val Asn Tyr				
	770		775			780
Phe Thr Asp Leu	Trp Asn Val Met Asp Thr	Leu Gly Leu Phe Tyr	Phe			
	785		790			800
Ile Ala Gly Ile	Val Phe Arg Leu His	Ser Ser Asn Lys Ser	Ser Leu			
	805		810			815
Tyr Ser Gly Arg	Val Ile Phe Cys Leu Asp	Tyr Ile Ile Phe Thr	Leu			
	820		825			830
Arg Leu Ile His	Ile Phe Thr Val Ser Arg	Asn Leu Gly Pro Lys	Ile			
	835		840			845
Ile Met Leu Gln	Arg Met Leu Ile Asp Val	Phe Phe Phe Leu Phe	Leu			
	850		855			860
Phe Ala Val Trp	Met Val Ala Phe Gly Val	Ala Arg Gln Gly Ile	Leu			
	865		870			880
Arg Gln Asn Glu	Gln Arg Trp Arg Trp	Ile Phe Arg Ser Val	Ile Tyr			
	885		890			895
Glu Pro Tyr Leu	Ala Met Phe Gly Gln Val	Pro Ser Asp Val Asp	Gly			
	900		905			910
Thr Thr Tyr Asp	Phe Ala His Cys Thr Phe	Thr Gly Asn Glu Ser	Lys			
	915		920			925
Pro Leu Cys Val	Glu Leu Asp Glu His Asn	Leu Pro Arg Phe Pro	Glu			
	930		935			940
Trp Ile Thr Ile	Pro Leu Val Cys Ile Tyr	Met Leu Ser Thr Asn	Ile			
	945		950			955
Leu Leu Val Asn	Leu Leu Val Ala Met Phe	Gly Tyr Thr Val Gly	Thr			
	965		970			975
Val Gln Glu Asn	Asn Asp Gln Val Trp Lys	Phe Gln Arg Tyr Phe	Leu			
	980		985			990
Val Gln Glu Tyr	Cys Ser Arg Leu Asn Ile	Pro Phe Pro Phe Ile	Val			
	995		1000			1005
Phe Ala Tyr Phe	Tyr Met Val Val Lys Lys	Cys Phe Lys Cys Cys	Cys			
	1010		1015			1020



```

gaagcttggg gtggaagcaa ctgtctggag ctggcggtgg aggccacaga ccagcatttc 2100
atcgcccagc ctgggggtcca gaattttctt tctaagcaat ggtatggaga gatttcccga 2160
gacaccaaga actggaagat tatcctgtgt ctgtttatta tacccttggg gggctgtggc 2220
tttgtatcat ttaggaagaa acctgtcgac aagcacaaaga agctgctttg gtactatgtg 2280
gcggttcttca cctccccctt cgtggtcttc tcttggaaat tggctcttca catcgccctc 2340
ctcctgtgtt ttgcctacgt gctgctcatg gatttccatt cgggtgccaca cccccccgag 2400
ctggctcctgt actcgtgtgt ctttgtcttc ttctgtgatg aagttagaca gtggtacgta 2460
aatgggggtga attattttac tgacctgtgg aatgtgatgg acacgctggg gcttttttac 2520
ttcatagcag gaattgtatt tgggtccac tcttctaata aaagctcttt gtattctgga 2580
cgagtcattt tctgtctgga ctacattatt ttactctaa gattgatcca catttttact 2640
gtaagcagaa acttaggacc caagattata atgctgcaga ggatgctgat cgatgtgttc 2700
ttcttcctgt tctcttttgc ggwtggatg gtggcctttg gcgtggccag gcaagggatc 2760
cttaggcaga atgagcagcg ctggaggtgg atattccgtt cggctcatcta cgagccctac 2820
ctggccatgt tgggccaggt gccagtgac gtggatggtg ccacgtatga ctttgcccac 2880
tgcaccttca ctgggaatga gtccaagcca ctgtgtgtgg agctggatga gcacaacctg 2940
ccccggttcc ccgagtggat caccatcccc ctgggtgtgca tctacatgtt atccaccaac 3000
atcctgtctg tcaacctgct ggtcgccatg tttggctaca cgggtgggcac cgtccaggag 3060
aacaatgacc aggtctggaa gttccagagg tacttctctg tgcaggagta ctgcagccgc 3120
ctcaatatcc ccttccccct catcgtcttc gcttacttct acatggtggt gaagaagtgc 3180
ttcaagtgtt gctgcaagga gaaaaacatg gactcttctg tctgctgttt caaaaatgaa 3240
gacaatgaga ctctggcatg ggaggggtgc atgaaggaaa actaccttgt caagatcaac 3300
acaaaagcca acgacacctc agaggaaatg aggcacgatg ttagacaact ggatacaaa 3360
cttaatgatc tcaaggggtc tctgaaagag attgctaata aaatcaaata aaactgtatg 3420
aactctaata gagaaaaatc taattatagc aagatcatat taaggaatgc tgatgaacaa 3480
ttttgctatc gactactaaa tgagagattt tcagaccctt ggggtacatg tggatgattt 3540
taaatacccc tagtgtgtg agaccttgag aataaagtgt gaagggcgaa ttctgcagat 3600
atccatcaca ctggcgggcg ctcgagcatg catctagag 3639

```

&lt;210&gt; 637

&lt;211&gt; 1095

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(1095)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 637

```

Met Arg Asn Arg Arg Asn Asp Thr Leu Asp Ser Thr Arg Thr Leu Tyr
          5                      10                      15

```

```

Ser Ser Ala Ser Arg Ser Thr Asp Leu Ser Tyr Ser Glu Ser Asp Leu
          20                      25                      30

```

```

Val Asn Phe Ile Gln Ala Asn Phe Lys Lys Arg Glu Cys Val Phe Phe
          35                      40                      45

```

```

Thr Lys Asp Ser Lys Ala Thr Glu Asn Val Cys Lys Cys Gly Tyr Ala
          50                      55                      60

```

```

Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn Gln Ser Glu Lys Trp
          65                      70                      75                      80

```

```

Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr Asp Ala Phe Gly Asp
          85                      90                      95

```

```

Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser

```

100					105					110					
Cys	Asp	Thr	Asp	Ala	Glu	Ile	Leu	Tyr	Glu	Leu	Leu	Thr	Gln	His	Trp
	115						120					125			
His	Leu	Lys	Thr	Pro	Asn	Leu	Val	Ile	Ser	Val	Thr	Gly	Gly	Ala	Lys
	130					135					140				
Asn	Phe	Ala	Leu	Lys	Pro	Arg	Met	Arg	Lys	Ile	Phe	Ser	Arg	Leu	Ile
145					150					155					160
Tyr	Ile	Ala	Gln	Ser	Lys	Gly	Ala	Trp	Ile	Leu	Thr	Gly	Gly	Thr	His
				165					170					175	
Tyr	Gly	Leu	Met	Lys	Tyr	Ile	Gly	Glu	Val	Val	Arg	Asp	Asn	Thr	Ile
		180						185					190		
Ser	Arg	Ser	Ser	Glu	Glu	Asn	Ile	Val	Ala	Ile	Gly	Ile	Ala	Ala	Trp
		195					200					205			
Gly	Met	Val	Ser	Asn	Arg	Asp	Thr	Leu	Ile	Arg	Asn	Cys	Asp	Ala	Glu
	210					215					220				
Gly	Tyr	Phe	Leu	Ala	Gln	Tyr	Leu	Met	Asp	Asp	Phe	Thr	Arg	Asp	Pro
225					230					235					240
Leu	Tyr	Ile	Leu	Asp	Asn	Asn	His	Thr	His	Leu	Leu	Leu	Val	Asp	Asn
				245					250					255	
Gly	Cys	His	Gly	His	Pro	Thr	Val	Glu	Ala	Lys	Leu	Arg	Asn	Gln	Leu
			260					265					270		
Glu	Lys	Tyr	Ile	Ser	Glu	Arg	Thr	Ile	Gln	Asp	Ser	Asn	Tyr	Gly	Gly
		275					280					285			
Lys	Ile	Pro	Ile	Val	Cys	Phe	Ala	Gln	Gly	Gly	Gly	Lys	Glu	Thr	Leu
	290					295					300				
Lys	Ala	Ile	Asn	Thr	Ser	Ile	Lys	Asn	Lys	Ile	Pro	Cys	Val	Val	Val
305					310					315					320
Glu	Gly	Ser	Gly	Gln	Ile	Ala	Asp	Val	Ile	Ala	Ser	Leu	Val	Glu	Val
				325					330					335	
Glu	Asp	Ala	Leu	Thr	Ser	Ser	Ala	Val	Lys	Glu	Lys	Leu	Val	Arg	Phe
			340					345					350		
Leu	Pro	Arg	Thr	Val	Ser	Arg	Leu	Pro	Glu	Glu	Glu	Thr	Glu	Ser	Trp
		355					360					365			
Ile	Lys	Trp	Leu	Lys	Glu	Ile	Leu	Glu	Cys	Ser	His	Leu	Leu	Thr	Val
	370					375					380				
Ile	Lys	Met	Glu	Glu	Ala	Gly	Asp	Glu	Ile	Val	Ser	Asn	Ala	Ile	Ser
385					390					395					400
Tyr	Ala	Leu	Tyr	Lys	Ala	Phe	Ser	Thr	Ser	Glu	Gln	Asp	Lys	Asp	Asn
				405					410					415	

Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp Asn Gln Leu Asp Leu  
 420 425 430  
 Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg Trp Glu Ser Ala Asp  
 435 440 445  
 Leu Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe  
 450 455 460  
 Val Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr  
 465 470 475 480  
 His Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val  
 485 490 495  
 Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu  
 500 505 510  
 Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys  
 515 520 525  
 Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val  
 530 535 540  
 Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile  
 545 550 555 560  
 Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg  
 565 570 575  
 Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu  
 580 585 590  
 Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu  
 595 600 605  
 Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr  
 610 615 620  
 Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu  
 625 630 635 640  
 Ala Trp Gly Gly Ser Asn Cys Leu Glu Leu Ala Val Glu Ala Thr Asp  
 645 650 655  
 Gln His Phe Ile Ala Gln Pro Gly Val Gln Asn Phe Leu Ser Lys Gln  
 660 665 670  
 Trp Tyr Gly Glu Ile Ser Arg Asp Thr Lys Asn Trp Lys Ile Ile Leu  
 675 680 685  
 Cys Leu Phe Ile Ile Pro Leu Val Gly Cys Gly Phe Val Ser Phe Arg  
 690 695 700  
 Lys Lys Pro Val Asp Lys His Lys Lys Leu Leu Trp Tyr Tyr Val Ala  
 705 710 715 720

Phe Phe Thr Ser Pro Phe Val Val Phe Ser Trp Asn Val Val Phe Tyr  
 725 730 735  
 Ile Ala Phe Leu Leu Leu Phe Ala Tyr Val Leu Leu Met Asp Phe His  
 740 745 750  
 Ser Val Pro His Pro Pro Glu Leu Val Leu Tyr Ser Leu Val Phe Val  
 755 760 765  
 Leu Phe Cys Asp Glu Val Arg Gln Trp Tyr Val Asn Gly Val Asn Tyr  
 770 775 780  
 Phe Thr Asp Leu Trp Asn Val Met Asp Thr Leu Gly Leu Phe Tyr Phe  
 785 790 795 800  
 Ile Ala Gly Ile Val Phe Arg Leu His Ser Ser Asn Lys Ser Ser Leu  
 805 810 815  
 Tyr Ser Gly Arg Val Ile Phe Cys Leu Asp Tyr Ile Ile Phe Thr Leu  
 820 825 830  
 Arg Leu Ile His Ile Phe Thr Val Ser Arg Asn Leu Gly Pro Lys Ile  
 835 840 845  
 Ile Met Leu Gln Arg Met Leu Ile Asp Val Phe Phe Phe Leu Phe Leu  
 850 855 860  
 Phe Ala Xaa Trp Met Val Ala Phe Gly Val Ala Arg Gln Gly Ile Leu  
 865 870 875 880  
 Arg Gln Asn Glu Gln Arg Trp Arg Trp Ile Phe Arg Ser Val Ile Tyr  
 885 890 895  
 Glu Pro Tyr Leu Ala Met Phe Gly Gln Val Pro Ser Asp Val Asp Gly  
 900 905 910  
 Thr Thr Tyr Asp Phe Ala His Cys Thr Phe Thr Gly Asn Glu Ser Lys  
 915 920 925  
 Pro Leu Cys Val Glu Leu Asp Glu His Asn Leu Pro Arg Phe Pro Glu  
 930 935 940  
 Trp Ile Thr Ile Pro Leu Val Cys Ile Tyr Met Leu Ser Thr Asn Ile  
 945 950 955 960  
 Leu Leu Val Asn Leu Leu Val Ala Met Phe Gly Tyr Thr Val Gly Thr  
 965 970 975  
 Val Gln Glu Asn Asn Asp Gln Val Trp Lys Phe Gln Arg Tyr Phe Leu  
 980 985 990  
 Val Gln Glu Tyr Cys Ser Arg Leu Asn Ile Pro Phe Pro Phe Ile Val  
 995 1000 1005  
 Phe Ala Tyr Phe Tyr Met Val Val Lys Lys Cys Phe Lys Cys Cys Cys  
 1010 1015 1020  
 Lys Glu Lys Asn Met Glu Ser Ser Val Cys Cys Phe Lys Asn Glu Asp



1025	1030	1035	1040
Asn Glu Thr Leu Ala Trp Glu Gly Val Met Lys Glu Asn Tyr Leu Val			
1045		1050	1055
Lys Ile Asn Thr Lys Ala Asn Asp Thr Ser Glu Glu Met Arg His Arg			
1060	1065		1070
Phe Arg Gln Leu Asp Thr Lys Leu Asn Asp Leu Lys Gly Leu Leu Lys			
1075	1080		1085
Glu Ile Ala Asn Lys Ile Lys			
1090	1095		

<210> 638  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 638  
 Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser  
                   5                  10                  15

<210> 639  
 <211> 45  
 <212> DNA  
 <213> Homo sapiens

<400> 639  
 agaatgccta ccgtgctgca gtgcgtgaac gtgtcgggtgg tgtct 45

<210> 640  
 <211> 45  
 <212> DNA  
 <213> Homo sapiens

<400> 640  
 gagccagggga gccagatggt ggaggccagc ctctccgtac ggcac 45

<210> 641  
 <211> 45  
 <212> DNA  
 <213> Homo sapiens

<400> 641  
 gaggccgacc aagagccagg gagccagatg gtggaggcca gcctc 45

<210> 642  
 <211> 45  
 <212> DNA  
 <213> Homo sapiens

<400> 642  
 ggctgcaca gtcttgaggc cgaccaagag ccaggaggacc agatg 45

<210> 643  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 643  
tacaccatcg ggctgggcct gcacagtctt gaggccgacc aagag 45

<210> 644  
<211> 42  
<212> DNA  
<213> Homo sapiens

<400> 644  
ttccagaact cctacaccat cgggctgggc ctgcacagtc tt 42

<210> 645  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 645  
ctgtcagccg cacactgttt ccagaactcc tacaccatcg ggctg 45

<210> 646  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 646  
catccgcagt ggggtgctgtc agccgcacac tgtttccaga actcc 45

<210> 647  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 647  
tcgggcgtcc tgggtgcatcc gcagtgggtg ctgtcagccg cacac 45

<210> 648  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 648  
aacgaattgt tctgctcggg cgtcctgggtg catccgcagt ggggtg 45

<210> 649  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 649  
gcactggtca tggaaaacga attgttctgc tcgggcgtcc tgggtg 45

<210> 650  
<211> 51

<212> DNA  
<213> Homo sapiens

<400> 650  
tcgcagccct ggcaggcggc actggtcacg gaaaacgaat tgttctgctc g 51

<210> 651  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 651  
atcagcattg cttcgacgtg ccctaccgag gggaactctt gcctc 45

<210> 652  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 652  
tccgtgtccg agtctgacac catccggagc atcagcattg cttcg 45

<210> 653  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 653  
atcaagttgg acgaatccgt gtccgagtct gacaccatcc ggagc 45

<210> 654  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 654  
aacgacctca tgctcatcaa gttggacgaa tccgtgtccg agtct 45

<210> 655  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 655  
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaa 45

<210> 656  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 656  
Glu Pro Gly Ser Gln Met Val Glu Ala Ser Leu Ser Val Arg His  
5 10 15

<210> 657  
<211> 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 657

Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu Ala Ser Leu  
5 10 15

&lt;210&gt; 658

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 658

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met  
5 10 15

&lt;210&gt; 659

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 659

Tyr Thr Ile Gly Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu  
5 10 15

&lt;210&gt; 660

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 660

Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly Leu His Ser Leu  
5 10

&lt;210&gt; 661

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 661

Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu  
5 10 15

&lt;210&gt; 662

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 662

His Pro Gln Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser  
5 10 15

<210> 663  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 663  
Ser Gly Val Leu Val His Pro Gln Trp Val Leu Ser Ala Ala His  
5 10 15

<210> 664  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 664  
Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val  
5 10 15

<210> 665  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 665  
Ala Leu Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val  
5 10 15

<210> 666  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 666  
Ser Gln Pro Trp Gln Ala Ala Leu Val Met Glu Asn Glu Leu Phe Cys  
5 10 15

Ser

<210> 667  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 667  
Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn Ser Cys Leu  
5 10 15

<210> 668  
<211> 15  
<212> PRT  
<213> Homo sapiens

263

&lt;400&gt; 668

Ser Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser  
5 10 15

&lt;210&gt; 669

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 669

Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp Thr Ile Arg Ser  
5 10 15

&lt;210&gt; 670

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 670

Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser  
5 10 15

&lt;210&gt; 671

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 671

Arg Pro Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu  
5 10 15

&lt;210&gt; 672

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 672

ggaccagcat atgaggaaca gaaggaatga cactc

35

&lt;210&gt; 673

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 673

ccgctcgagt ccacccaag cttcacagg

29

```
<210> 675
<211> 652
<212> PRT
<213> Homo sapiens
```

<400> 675  
Met Arg Asn Arg Arg Asn Asp Thr Leu Asp Ser Thr Arg Thr Leu Tyr  
5 10 15  
Ser Ser Ala Ser Arg Ser Thr Asp Leu Ser Tyr Ser Glu Ser Asp Leu  
20 25 30  
Val Asn Phe Ile Gln Ala Asn Phe Lys Lys Arg Glu Cys Val Phe Phe  
35 40 45  
Thr Lys Asp Ser Lys Ala Thr Glu Asn Val Cys Lys Cys Gly Tyr Ala  
50 55 60

Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn Gln Ser Glu Lys Trp  
 65 70 75 80  
 Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr Asp Ala Phe Gly Asp  
 85 90 95  
 Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser  
 100 105 110  
 Cys Asp Thr Asp Ala Glu Ile Leu Tyr Glu Leu Leu Thr Gln His Trp  
 115 120 125  
 His Leu Lys Thr Pro Asn Leu Val Ile Ser Val Thr Gly Gly Ala Lys  
 130 135 140  
 Asn Phe Ala Leu Lys Pro Arg Met Arg Lys Ile Phe Ser Arg Leu Ile  
 145 150 155 160  
 Tyr Ile Ala Gln Ser Lys Gly Ala Trp Ile Leu Thr Gly Gly Thr His  
 165 170 175  
 Tyr Gly Leu Met Lys Tyr Ile Gly Glu Val Val Arg Asp Asn Thr Ile  
 180 185 190  
 Ser Arg Ser Ser Glu Glu Asn Ile Val Ala Ile Gly Ile Ala Ala Trp  
 195 200 205  
 Gly Met Val Ser Asn Arg Asp Thr Leu Ile Arg Asn Cys Asp Ala Glu  
 210 215 220  
 Gly Tyr Phe Leu Ala Gln Tyr Leu Met Asp Asp Phe Thr Arg Asp Pro  
 225 230 235 240  
 Leu Tyr Ile Leu Asp Asn Asn His Thr His Leu Leu Leu Val Asp Asn  
 245 250 255  
 Gly Cys His Gly His Pro Thr Val Glu Ala Lys Leu Arg Asn Gln Leu  
 260 265 270  
 Glu Lys Tyr Ile Ser Glu Arg Thr Ile Gln Asp Ser Asn Tyr Gly Gly  
 275 280 285  
 Lys Ile Pro Ile Val Cys Phe Ala Gln Gly Gly Gly Lys Glu Thr Leu  
 290 295 300  
 Lys Ala Ile Asn Thr Ser Ile Lys Asn Lys Ile Pro Cys Val Val Val  
 305 310 315 320  
 Glu Gly Ser Gly Gln Ile Ala Asp Val Ile Ala Ser Leu Val Glu Val  
 325 330 335  
 Glu Asp Ala Leu Thr Ser Ser Ala Val Lys Glu Lys Leu Val Arg Phe  
 340 345 350  
 Leu Pro Arg Thr Val Ser Arg Leu Pro Glu Glu Glu Thr Glu Ser Trp  
 355 360 365  
 Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser His Leu Leu Thr Val



370	375	380
Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val Ser Asn Ala Ile Ser		
385	390	395 400
Tyr Ala Leu Tyr Lys Ala Phe Ser Thr Ser Glu Gln Asp Lys Asp Asn		
	405	410 415
Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp Asn Gln Leu Asp Leu		
	420	425 430
Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg Trp Glu Ser Ala Asp		
	435	440 445
Leu Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe		
	450	455 460
Val Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr		
	465	470 475 480
His Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val		
	485	490 495
Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu		
	500	505 510
Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys		
	515	520 525
Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val		
	530	535 540
Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile		
	545	550 555 560
Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg		
	565	570 575
Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu		
	580	585 590
Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu		
	595	600 605
Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr		
	610	615 620
Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu		
	625	630 635 640
Ala Trp Gly Gly Leu Glu His His His His His His		
	645	650

&lt;210&gt; 676

&lt;211&gt; 132

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 676

```

Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe
1      5      10      15
Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser
20      25      30
Gly Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly
35      40      45
Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val
50      55      60
Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val
65      70      75      80
Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala
85      90      95
Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser Val Asn Trp
100     105     110
Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu
115     120     125
Gly Pro Pro Ala
130

```

&lt;210&gt; 677

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 677

ggggaattca tgatccggga gaaatttgcc cactgc

36

&lt;210&gt; 678

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 678

gggctcgagt caggagtttg agaccagcct ggc

33

&lt;210&gt; 679

&lt;211&gt; 675

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 679

```

atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60
cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120

```

```

accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180
ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcacatccc cgggtgacgtc atctcggtga cctggcaaac caagtcgggc 360
ggcacgcgta cagggaaacgt gacattggcc gagggacccc cggccgaatt catgatccgg 420
gagaaatttg cccactgcac cgtgctaacc attgcacaca gattgaacac cattattgac 480
agcgacaaga taatggtttt agattcagga agactgaaag aatatgatga gccgtatggt 540
ttgctgcaaa ataaagagag cctatttttac aagatggtgc aacaactggg caaggcagaa 600
gccgctgccc tcaactgaaac agcaaaacag agatggggtt tcaccatggt ggccaggctg 660
gtctcaaact cctga                                     675

```

&lt;210&gt; 680

&lt;211&gt; 291

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 680

```

atggggatcc gggagaaatt tgcccaactgc accgtgctaa ccattgcaca cagattgaac 60
accattattg acagcgacaa gataatggtt ttagattcag gaagactgaa agaatatgat 120
gagccgtatg ttttgctgca aaataaagag agcctatttt acaagatggt gcaacaactg 180
ggcaaggcag aagcgcgtgc cctcactgaa acagcaaaac agagatgggg tttcaccatg 240
ttggccaggc tgggtctcaa ctcctctcag caccaccacc accaccactg a 291

```

&lt;210&gt; 681

&lt;211&gt; 1074

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 681

```

atgtcagcca ttgagagggt gtcagaggca atcgtcagca tccgaagaat ccagaccttt 60
ttgtactttg atgagatata acagcgcaac cgtcagctgc cgtcagatgg taaaaagatg 120
gtgcatgtgc aggattttac tgcttttttg gataaggcat cagagacccc aactctacaa 180
ggcctttcct ttactgtcag acctggcgaa ttgttagctg tggtcggccc cgtgggagca 240
gggaagtcac cactgttaag tgccgtgctc ggggaattgg cccaagtca cgggctggtc 300
agcgtgcatg gaagaattgc ctatgtgtct cagcagccct ggggtgtctc gggaaactctg 360
aggagtaata ttttattttg gaagaaatac gaaaaggaaac gatatgaaaa agtcataaag 420
gcttgtgctc tgaaaaagga tttacagctg ttggaggatg gtgatctgac tgtgatagga 480
gatcggggaa ccacgctgag tggagggcag aaagcacggg taaaccttgc aagagcagtg 540
tatcaagatg ctgacatcta tctcctggac gatcctctca gtgcagtaga tgcggaagtt 600
agcagacact tgttcgaact gtgtatttgt caaattttgc atgagaagat cacaatttta 660
gtgactcatc agttgcagta cctcaaagct gcaagtcaga ttctgatatt gaaagatggt 720
aaaatggtgc agaaggggac ttacactgag ttcctaaaat ctggtataga ttttggctcc 780
cttttaaaaga aggataatga ggaaagtga caacctccag ttccagggaac tcccacacta 840
aggaatcgta ccttctcaga gtcttcggtt tgggtctcaac aatcttctag accctccttg 900
aaagatggtg ctctggagag ccaagataca gagaatgtcc cagttacact atcagaggag 960
aaccgttctg aaggaaaagt tggtttttcag gcctataaga attacttcag agctggtgct 1020
cactggattg tcttcatttt ccttattctc gagcaccacc accaccacca ctga 1074

```

&lt;210&gt; 682

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 682

```

Met His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
      5                                10                                15

```

```

Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala

```

20					25					30					
Ile	Ala	Gly	Gln	Ile	Lys	Leu	Pro	Thr	Val	His	Ile	Gly	Pro	Thr	Ala
		35					40					45			
Phe	Leu	Gly	Leu	Gly	Val	Val	Asp	Asn	Asn	Gly	Asn	Gly	Ala	Arg	Val
	50					55					60				
Gln	Arg	Val	Val	Gly	Ser	Ala	Pro	Ala	Ala	Ser	Leu	Gly	Ile	Ser	Thr
65					70					75					80
Gly	Asp	Val	Ile	Thr	Ala	Val	Asp	Gly	Ala	Pro	Ile	Asn	Ser	Ala	Thr
				85					90					95	
Ala	Met	Ala	Asp	Ala	Leu	Asn	Gly	His	His	Pro	Gly	Asp	Val	Ile	Ser
			100					105					110		
Val	Thr	Trp	Gln	Thr	Lys	Ser	Gly	Gly	Thr	Arg	Thr	Gly	Asn	Val	Thr
		115					120					125			
Leu	Ala	Glu	Gly	Pro	Pro	Ala	Glu	Phe	Met	Ile	Arg	Glu	Lys	Phe	Ala
	130					135					140				
His	Cys	Thr	Val	Leu	Thr	Ile	Ala	His	Arg	Leu	Asn	Thr	Ile	Ile	Asp
145					150					155					160
Ser	Asp	Lys	Ile	Met	Val	Leu	Asp	Ser	Gly	Arg	Leu	Lys	Glu	Tyr	Asp
				165					170					175	
Glu	Pro	Tyr	Val	Leu	Leu	Gln	Asn	Lys	Glu	Ser	Leu	Phe	Tyr	Lys	Met
			180					185					190		
Val	Gln	Gln	Leu	Gly	Lys	Ala	Glu	Ala	Ala	Ala	Leu	Thr	Glu	Thr	Ala
		195					200					205			
Lys	Gln	Arg	Trp	Gly	Phe	Thr	Met	Leu	Ala	Arg	Leu	Val	Ser	Asn	Ser
	210					215					220				

<210> 683

**<211> 357**

<212> PRT

<213> Homo sapiens

<400> 683

Met	Ser	Ala	Ile	Glu	Arg	Val	Ser	Glu	Ala	Ile	Val	Ser	Ile	Arg	Arg
				5					10					15	
Ile	Gln	Thr	Phe	Leu	Leu	Leu	Asp	Glu	Ile	Ser	Gln	Arg	Asn	Arg	Gln
			20					25					30		
Leu	Pro	Ser	Asp	Gly	Lys	Lys	Met	Val	His	Val	Gln	Asp	Phe	Thr	Ala
		35					40					45			
Phe	Trp	Asp	Lys	Ala	Ser	Glu	Thr	Pro	Thr	Leu	Gln	Gly	Leu	Ser	Phe

270

50		55		60
Thr Val Arg Pro Gly Glu Leu Leu Ala Val Val Gly Pro Val Gly Ala				
65		70		75
Gly Lys Ser Ser Leu Leu Ser Ala Val Leu Gly Glu Leu Ala Pro Ser				
	85		90	95
His Gly Leu Val Ser Val His Gly Arg Ile Ala Tyr Val Ser Gln Gln				
	100		105	110
Pro Trp Val Phe Ser Gly Thr Leu Arg Ser Asn Ile Leu Phe Gly Lys				
	115		120	125
Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val Ile Lys Ala Cys Ala Leu				
	130		135	140
Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly Asp Leu Thr Val Ile Gly				
	145		150	155
Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln Lys Ala Arg Val Asn Leu				
	165		170	175
Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile Tyr Leu Leu Asp Asp Pro				
	180		185	190
Leu Ser Ala Val Asp Ala Glu Val Ser Arg His Leu Phe Glu Leu Cys				
	195		200	205
Ile Cys Gln Ile Leu His Glu Lys Ile Thr Ile Leu Val Thr His Gln				
	210		215	220
Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile Leu Ile Leu Lys Asp Gly				
	225		230	235
Lys Met Val Gln Lys Gly Thr Tyr Thr Glu Phe Leu Lys Ser Gly Ile				
	245		250	255
Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn Glu Glu Ser Glu Gln Pro				
	260		265	270
Pro Val Pro Gly Thr Pro Thr Leu Arg Asn Arg Thr Phe Ser Glu Ser				
	275		280	285
Ser Val Trp Ser Gln Gln Ser Ser Arg Pro Ser Leu Lys Asp Gly Ala				
	290		295	300
Leu Glu Ser Gln Asp Thr Glu Asn Val Pro Val Thr Leu Ser Glu Glu				
	305		310	315
Asn Arg Ser Glu Gly Lys Val Gly Phe Gln Ala Tyr Lys Asn Tyr Phe				
	325		330	335
Arg Ala Gly Ala His Trp Ile Val Phe Ile Phe Leu Ile Leu Glu His				
	340		345	350
His His His His His				
	355			

<210> 684  
 <211> 96  
 <212> PRT  
 <213> Homo sapiens

<400> 684  
 Met Gly Ile Arg Glu Lys Phe Ala His Cys Thr Val Leu Thr Ile Ala  
                           5                          10                          15  
 His Arg Leu Asn Thr Ile Ile Asp Ser Asp Lys Ile Met Val Leu Asp  
                           20                          25                          30  
 Ser Gly Arg Leu Lys Glu Tyr Asp Glu Pro Tyr Val Leu Leu Gln Asn  
                           35                          40                          45  
 Lys Glu Ser Leu Phe Tyr Lys Met Val Gln Gln Leu Gly Lys Ala Glu  
                           50                          55                          60  
 Ala Ala Ala Leu Thr Glu Thr Ala Lys Gln Arg Trp Gly Phe Thr Met  
                           65                          70                          75                          80  
 Leu Ala Arg Leu Val Ser Asn Ser Leu Glu His His His His His His  
                           85                          90                          95

<210> 685  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 685  
 cgcccatggg gatccgggag aaatttgccc actgc 35

<210> 686  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 686  
 cgcctcgagg gagtttgaga ccagcctggc caaca 35

<210> 687  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 687  
gcatggacca tatgtcagcc attgagaggg tgtcagag

38

<210> 688  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR primer

<400> 688  
ccgctcgaga ataaggaâaa tgaagacaat ccag

34

<210> 689  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR primer

<400> 689  
gttgaattca tgcacggggcc ccaggtg

27

<210> 690  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR primer

<400> 690  
cccctcgagt cactatggtc tgcctcttga

30

<210> 691  
<211> 915  
<212> DNA  
<213> Homo sapiens

<400> 691  
atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60  
cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120  
accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180  
ggcgacagag tccaacgcgt ggtcgggagc gtcctggcgg caagtctcgg catctccacc 240  
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300  
gcgcttaacg ggcatcatcc cggtgacgtc atctcgggtga cctggcaaac caagtcgggc 360  
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt catgcacggg 420  
ccccagggtg tggcacgctg ctccgagtggt gcttgtcctg ccttggctgc cacctctgcg 480  
gggtgctgc tggagggggt ggaccggcca ccaaccttac ccagtcaagg aagtggatgg 540  
ccatgttccc acagcctgag tggctgccac ctgatggctg atggagcaaa ggccttagga 600  
aaagcagatg gcccttggcc ctaccttttt gttagaagaa ctgatgttcc atgtcctgca 660  
gcgagtgagg ttggtggctg tgcccccagc tcctggcgcg ccctcgcaga ggtgactggt 720

273

tgctcttttg gccctcttgg ccttgcccag catgcacaag cctcagtgct actactgtgc 780  
 tacaaatgga gccatatagg ggaaacgagc agccatctca ggagcaagggt gtatgctgcc 840  
 tttgggggct ccagtccttg cctcaagggt cttatgtcac tgtgggcttc ttggttgca 900  
 agaggcagac catag 915

&lt;210&gt; 692

&lt;211&gt; 304

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 692

Met His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu  
 5 10 15

Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala  
 20 25 30

Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala  
 35 40 45

Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val  
 50 55 60

Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr  
 65 70 75 80

Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr  
 85 90 95

Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser  
 100 105 110

Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr  
 115 120 125

Leu Ala Glu Gly Pro Pro Ala Glu Phe Met His Gly Pro Gln Val Leu  
 130 135 140

Ala Arg Cys Ser Glu Cys Ala Cys Pro Ala Leu Ala Ala Thr Ser Ala  
 145 150 155 160

Gly Val Arg Leu Glu Gly Val Asp Arg Pro Pro Thr Leu Pro Ser Gln  
 165 170 175

Gly Ser Gly Trp Pro Cys Ser His Ser Leu Ser Gly Cys His Leu Met  
 180 185 190

Ala Asp Gly Ala Lys Ala Leu Gly Lys Ala Asp Gly Pro Trp Pro Tyr  
 195 200 205

Leu Phe Val Arg Arg Thr Asp Val Pro Cys Pro Ala Ala Ser Glu Val  
 210 215 220

Gly Gly Cys Ala Pro Ser Ser Trp Arg Ala Leu Ala Glu Val Thr Gly  
 225 230 235 240

Cys Ser Leu Gly Pro Leu Gly Leu Ala Gln His Ala Gln Ala Ser Val  
 245 250 255



274

Leu Leu Leu Cys Tyr Lys Trp Ser His Ile Gly Glu Thr Ser Ser His  
 260 265 270

Leu Arg Ser Lys Val Tyr Ala Ala Phe Gly Gly Ser Ser Pro Cys Leu  
 275 280 285

Lys Gly Leu Met Ser Leu Trp Ala Ser Trp Leu Ser Arg Gly Arg Pro  
 290 295 300

&lt;210&gt; 693

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 693

cgaagtcacg tggaggccag cctc

24

&lt;210&gt; 694

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 694

cctgaccgaa ttcattaact ggcctggac

29

&lt;210&gt; 695

&lt;211&gt; 166

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(166)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 695

Met Gly His His His His His Val Glu Ala Ser Leu Ser Val Arg  
 1 5 10 15  
 His Pro Glu Tyr Asn Arg Pro Leu Leu Ala Asn Asp Leu Met Leu Ile  
 20 25 30  
 Lys Leu Asp Glu Ser Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser  
 35 40 45  
 Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn Ser Cys Leu Val Ser Gly  
 50 55 60  
 Trp Gly Leu Leu Ala Asn Gly Arg Met Pro Thr Val Leu Gln Cys Val  
 65 70 75 80  
 Asn Val Ser Val Val Ser Glu Glu Val Cys Ser Lys Leu Tyr Asp Pro

275

	85		90		95
Leu Tyr His Pro Ser Met Phe Cys Ala Gly Gly Gly Gln Xaa Gln Xaa					
	100		105		110
Asp Ser Cys Asn Gly Asp Ser Gly Gly Pro Leu Ile Cys Asn Gly Tyr					
	115		120		125
Leu Gln Gly Leu Val Ser Phe Gly Lys Ala Pro Cys Gly Gln Val Gly					
	130		135		140
Val Pro Gly Val Tyr Thr Asn Leu Cys Lys Phe Thr Glu Trp Ile Glu					
	145		150		155
Lys Thr Val Gln Ala Ser					160
	165				

<210> 696  
 <211> 504  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1)...(504)  
 <223> n = A,T,C or G

<400> 696	
atggggccatc atcatcatca tcacgtggag gccagcctct ccgtacggca cccagagtac	60
aacagaccct tgctcgctaa cgacctcatg ctcatcaagt tggacgaatc cgtgtccgag	120
tctgacacca tccggagcat cagcattgct tcgcagtgcc ctaccgcggg gaactcttgc	180
ctcgtttctg gctgggggtct gctggcgaac ggcagaatgc ctaccgtgct gcagtgcgtg	240
aacgtgtcgg tgggtgtctga ggaggtctgc agtaagctct atgaccgct gtaccacccc	300
agcatgttct gcgccggcgg agggcaanac cagaangact cctgcaacgg tgactctggg	360
gggcccctga tctgcaacgg gtacttgacg ggccttgtgt ctttcggaaa agccccgtgt	420
ggccaagtgt gcgtgccagg tgtctacacc aacctctgca aattcactga gtggatagag	480
aaaaccgtcc aggccagtta atga	504

<210> 697  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 697	
ctcagggttc cggagccgcg g	21

<210> 698  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 698	
ctatagaatt cattaccaa aagctgggct ccagc	35

<210> 699

<211> 241  
 <212> PRT  
 <213> Homo sapiens

<400> 699

Met	Gln	His	His	His	His	His	His	Leu	Arg	Val	Pro	Glu	Pro	Arg	Pro
1			5					10						15	
Gly	Glu	Ala	Lys	Ala	Glu	Gly	Ala	Ala	Pro	Pro	Thr	Pro	Ser	Lys	Pro
		20					25						30		
Leu	Thr	Ser	Phe	Leu	Ile	Gln	Asp	Ile	Leu	Arg	Asp	Gly	Ala	Gln	Arg
	35					40						45			
Gln	Gly	Gly	Arg	Thr	Ser	Ser	Gln	Arg	Gln	Arg	Asp	Pro	Glu	Pro	Glu
	50					55					60				
Pro	Glu	Pro	Glu	Pro	Glu	Gly	Gly	Arg	Ser	Arg	Ala	Gly	Ala	Gln	Asn
65					70					75				80	
Asp	Gln	Leu	Ser	Thr	Gly	Pro	Arg	Ala	Ala	Pro	Glu	Glu	Ala	Glu	Thr
			85					90						95	
Leu	Ala	Glu	Thr	Glu	Pro	Glu	Arg	His	Leu	Gly	Ser	Tyr	Leu	Leu	Asp
		100						105					110		
Ser	Glu	Asn	Thr	Ser	Gly	Ala	Leu	Pro	Arg	Leu	Pro	Gln	Thr	Pro	Lys
	115						120					125			
Gln	Pro	Gln	Lys	Arg	Ser	Arg	Ala	Ala	Phe	Ser	His	Thr	Gln	Val	Ile
	130					135					140				
Glu	Leu	Glu	Arg	Lys	Phe	Ser	His	Gln	Lys	Tyr	Leu	Ser	Ala	Pro	Glu
145					150					155					160
Arg	Ala	His	Leu	Ala	Lys	Asn	Leu	Lys	Leu	Thr	Glu	Thr	Gln	Val	Lys
			165						170					175	
Ile	Trp	Phe	Gln	Asn	Arg	Arg	Tyr	Lys	Thr	Lys	Arg	Lys	Gln	Leu	Ser
		180						185					190		
Ser	Glu	Leu	Gly	Asp	Leu	Glu	Lys	His	Ser	Ser	Leu	Pro	Ala	Leu	Lys
	195						200					205			
Glu	Glu	Ala	Phe	Ser	Arg	Ala	Ser	Leu	Val	Ser	Val	Tyr	Asn	Ser	Tyr
	210					215					220				
Pro	Tyr	Tyr	Pro	Tyr	Leu	Tyr	Cys	Val	Gly	Ser	Trp	Ser	Pro	Ala	Phe
225					230					235					240
Trp															

<210> 700  
 <211> 729  
 <212> DNA  
 <213> Homo sapiens

<400> 700

atgcagcatc	accaccatca	ccacctcagg	gttcgggagc	cgcggcccg	ggaggcgaaa	60
gcggaggggg	ccgcgcgcgc	gaccccgctc	aagccgctca	cgctccttct	catccaggac	120
atcctgcggg	acggcgcgca	gcggcaaggc	ggccgcacga	gcagccagag	acagcgcgac	180
ccggagccgg	agccagagcc	agagccagag	ggaggacgca	gccgcgccgg	ggcgcgagaac	240
gaccagctga	gcaccggggc	ccgcgcgcgc	ccggatgagg	ccgagacgct	ggcagagacc	300
gagccagaaa	ggcacttggg	gtcttatctg	ttggactctg	aaaacacttc	aggcgccctt	360
ccaaggcttc	cccaaacc	taagcagccg	cagaagcgct	cccagagctg	cttctccac	420
actcaggtga	tgcagttgga	gaggaagttc	agccatcaga	agtacctgtc	ggcccctgaa	480
cgggcccacc	tggccaagaa	cctcaagctc	acggagaccc	aagtgaagat	atgggtccag	540
aacagacgct	ataagactaa	gcgaaagcag	ctctcctcgg	agctgggaga	cttggagaa	600
cactcctttt	tgcgggcctt	gaaagaggag	gccttctccc	gggcctccct	ggtctccgtg	660
tataacagct	atccttacta	cccatacctg	cactgcgtgg	gcagctggag	cccagctttt	720
tggtaatga						729

<210> 701  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 701  
 ctactaagcg ctggagtgag ggatcag

27

<210> 702  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 702  
 catcgagaat tcactactct ctgactagat gtc

33

<210> 703  
 <211> 161  
 <212> PRT  
 <213> Homo sapiens

<400> 703  
 Met Gln His His His His His Ala Gly Val Arg Asp Gln Gly Gln  
 1 5 10 15  
 Gly Ala Arg Trp Pro His Thr Gly Lys Arg Gly Pro Leu Leu Gln Gly  
 20 25 30  
 Leu Thr Trp Ala Thr Gly Gly His Cys Phe Ser Ser Glu Glu Ser Gly  
 35 40 45  
 Ala Val Asp Gly Ala Gly Gln Lys Lys Asp Arg Ala Trp Leu Arg Cys  
 50 55 60  
 Pro Glu Ala Val Ala Gly Phe Pro Leu Gly Ser Asp Cys Arg Glu Gly  
 65 70 75 80  
 Gly Arg Gln Gly Cys Gly Gly Ser Asp Asp Glu Asp Asp Leu Gly Val  
 85 90 95  
 Ala Pro Gly Leu Ala Pro Ala Trp Ala Leu Thr Gln Pro Pro Ser Gln  
 100 105 110  
 Ser Pro Gly Pro Gln Ser Leu Pro Ser Thr Pro Ser Ser Ile Trp Pro  
 115 120 125  
 Gln Trp Val Ile Leu Ile Thr Glu Leu Thr Ile Pro Ser Pro Ala His  
 130 135 140  
 Gly Pro Pro Trp Leu Pro Asn Ala Leu Glu Arg Gly His Leu Val Arg  
 145 150 155 160  
 Glu

<210> 704  
 <211> 489  
 <212> DNA  
 <213> Homo sapiens

<400> 704  
 atgcagcatc accaccatca ccacgctgga gtgagggatc aggggcaggg cgcgagatgg 60  
 cctcacacag ggaagagagg gccctcctg cagggcctca cctgggccac aggaggacac 120  
 tgcttttcct ctgaggagtc aggagctgtg gatggtgctg gacagaagaa ggacagggcc 180  
 tggctcaggt gtccagaggc tgtcgctggc ttccctttgg gatcagactg cagggaggga 240  
 gggcggcagg gttgtggggg gagtgcgat gaggatgacc tgggggtggc tccaggcctt 300  
 gccctgcct gggccctcac ccagcctccc tcacagtctc ctggccctca gtctctcccc 360  
 tccactccat cctccatctg gcctcagtgg gtcattctga tcaactgaact gaccataccc 420  
 agccctgccc acggccctcc atggctcccc aatgccctgg agaggggaca tctagtcaga 480  
 gagtagtga 489

<210> 705  
 <211> 132  
 <212> PRT  
 <213> Homo sapiens

<400> 705  
 Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe  
 1 5 10 15  
 Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser  
 20 25 30  
 Gly Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly  
 35 40 45  
 Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val  
 50 55 60  
 Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val  
 65 70 75 80  
 Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala  
 85 90 95  
 Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser Val Asn Trp  
 100 105 110  
 Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu  
 115 120 125  
 Gly Pro Pro Ala  
 130

<210> 706  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 706  
 ggggaattca tcacctatgt gccgcctctg c

31

<210> 707  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 707  
gggctcagagt cactcgccca cgaaatccgt gtaaaacagc.

40

<210> 708  
<211> 1203  
<212> DNA  
<213> Homo sapiens

<400> 708  
atgcatacacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60  
cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120  
accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180  
ggcgacagag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240  
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300  
gcgcttaacg ggcatacatcc cggtgacgtc atctcgggtga cctggcaaac caagtcgggc 360  
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt catcacctat 420  
gtgccgcctc tgctgctgga agtgggggta gaggagaagt tcatgacat ggtgctgggc 480  
attggtccag tgctgggcct ggtctgtgtc ccgtcctag gctcagccag tgaccactgg 540  
cgtggacgct atggccgccc ccggcccttc atctgggcac tgccttggg catcctgctg 600  
agcctctttc tcatcccaag ggccggctgg ctagcagggc tgctgtgccc ggatcccagg 660  
cccctggagc tggcactgct catcctgggc gtggggctgc tggacttctg tggccagggtg 720  
tgcttcactc cactggaggc cctgctctct gacctcttcc gggaccogga cactgtcgc 780  
caggcctact ctgtctatgc cttcatgatc agtcttgggg gctgcctggg ctacctcctg 840  
cctgccattg actgggacac cagtgcctg gcccctacc tgggcaacca ggaggagtgc 900  
ctctttggcc tgctcaccct catcttcctc acctgcgtag cagccacact gctggtggct 960  
gaggaggcag cgctgggccc caccgagcca gcagaagggc tgtcggcccc ctcttgtcg 1020  
ccccactgct gtccatgccg ggcccgttg gctttccgga acctgggcgc cctgcttccc 1080  
cggctgcacc agctgtgctg ccgcatgcc cgcacctgc gccggctctt cgtggctgag 1140  
ctgtgcagct ggatggcact catgaccttc acgtgtttt acacggattt cgtgggcgag 1200  
tga 1203

<210> 709  
<211> 400  
<212> PRT  
<213> Homo sapiens

<400> 709  
Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu  
5 10 15  
Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala  
20 25 30  
Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala  
35 40 45  
Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val  
50 55 60  
Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr  
65 70 75 80  
Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr  
85 90 95  
Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser

280

100					105					110					
Val	Thr	Trp	Gln	Thr	Lys	Ser	Gly	Gly	Thr	Arg	Thr	Gly	Asn	Val	Thr
		115					120					125			
Leu	Ala	Glu	Gly	Pro	Pro	Ala	Glu	Phe	Ile	Thr	Tyr	Val	Pro	Pro	Leu
	130					135					140				
Leu	Leu	Glu	Val	Gly	Val	Glu	Glu	Lys	Phe	Met	Thr	Met	Val	Leu	Gly
145					150					155					160
Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val	Pro	Leu	Leu	Gly	Ser	Ala
				165					170					175	
Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg	Arg	Arg	Pro	Phe	Ile	Trp
			180					185					190		
Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu	Phe	Leu	Ile	Pro	Arg	Ala
		195					200					205			
Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp	Pro	Arg	Pro	Leu	Glu	Leu
	210						215				220				
Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp	Phe	Cys	Gly	Gln	Val
225					230					235					240
Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp	Leu	Phe	Arg	Asp	Pro
				245					250					255	
Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala	Phe	Met	Ile	Ser	Leu
			260					265					270		
Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile	Asp	Trp	Asp	Thr	Ser
		275					280					285			
Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu	Cys	Leu	Phe	Gly	Leu
		290				295					300				
Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala	Thr	Leu	Leu	Val	Ala
305					310					315					320
Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala	Glu	Gly	Leu	Ser	Ala
				325					330					335	
Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg	Ala	Arg	Leu	Ala	Phe
			340					345					350		
Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His	Gln	Leu	Cys	Cys	Arg
		355					360					365			
Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala	Glu	Leu	Cys	Ser	Trp
		370				375					380				
Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr	Asp	Phe	Val	Gly	Glu
385					390					395					400

281

<210> 710  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 710  
Leu Leu Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys Asp Val  
                          5                          10                          15

Ser Val Arg Val  
                  20

<210> 711  
<211> 60  
<212> DNA  
<213> Homo sapiens

<400> 711  
ctgctccac ctccaccgc gctctgcggg gcctctgcct gtgatgtctc cgtacgtgtg 60

<210> 712  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 712  
Ala Ser Ala Cys Asp Val Ser Val Arg Val  
                  5                          10

<210> 713  
<211> 30  
<212> DNA  
<213> Homo sapiens

<400> 713  
gcctctgcct gtgatgtctc cgtacgtgtg

30

<210> 714  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 714  
Ala Ser Ala Cys Asp Val Ser Val Arg  
  1                          5

<210> 715  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 715  
Ser Ala Cys Asp Val Ser Val Arg Val  
                          5

<210> 716  
<211> 27



<212> DNA  
<213> Homo sapiens

<400> 716  
tctgcctgtg atgtctccgt acgtgtg

27

<210> 717  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 717  
Gly Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser  
5 10 15

Ala Ser Asp

<210> 718  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 718  
Val Pro Pro Leu Leu Leu Glu Val Gly Val Glu Glu Lys Phe Met Thr  
5 10 15

Met Val Leu

<210> 719  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 719  
Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala  
5 10 15

Gln Leu Leu

<210> 720  
<211> 57  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(57)  
<223> n = A,T,C or G

<400> 720  
ggcnathggnc cngtnytngg nytngtntgy gtnccnytny tnggnwsngc nwsngay 57

<210> 721  
<211> 57  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(57)  
<223> n = A,T,C or G

<400> 721  
gtncncncny tnytnytnga rgtnggngtn gargaraart tyatgacnat ggtnytn 57

<210> 722  
<211> 57  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...(57)  
<223> n = A,T,C or G

<400> 722  
atgggtncarm gnytnrtgggt nwsnmgnytn ytnmgncaym gnaargenca rytnytn 57

<210> 723  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 723  
Val Leu Gln Cys Val Asn Val Ser Val  
1 5

<210> 724  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 724  
Arg Met Pro Thr Val Leu Gln Cys Val  
1 5

<210> 725  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 725  
Asn Leu Cys Lys Phe Thr Glu Trp Ile  
1 5

<210> 726  
<211> 9  
<212> PRT

<213> Homo sapiens

<400> 726

Met Leu Ile Lys Leu Asp Glu Ser Val  
1 5

<210> 727

<211> 9

<212> PRT

<213> Homo sapiens

<400> 727

Leu Leu Ala Asn Asp Leu Met Leu Ile  
1 5

<210> 728

<211> 10

<212> PRT

<213> Homo sapiens

<400> 728

Leu Leu Ala Asn Gly Arg Met Pro Thr Val  
1 5 10

<210> 729

<211> 10

<212> PRT

<213> Homo sapiens

<400> 729

Leu Met Leu Ile Lys Leu Asp Glu Ser Val  
1 5 10

<210> 730

<211> 10

<212> PRT

<213> Homo sapiens

<400> 730

Val Leu Gln Cys Val Asn Val Ser Val Val  
1 5 10

<210> 731

<211> 10

<212> PRT

<213> Homo sapiens

<400> 731

Gly Leu Leu Ala Asn Gly Arg Met Pro Thr  
1 5 10

<210> 732

<211> 10

<212> PRT

<213> Homo sapiens

<400> 732

Thr Val Leu Gln Cys Val Asn Val Ser Val

285

1

5

10

&lt;210&gt; 733

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 733

Gly Val Leu Val His Pro Gln Trp Val

1

5

&lt;210&gt; 734

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 734

Val Leu Val His Pro Gln Trp Val Leu

1

5

&lt;210&gt; 735

&lt;211&gt; 1195

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 735

```

ccgagactca cgggtcaagct aaggcgaaga gtgggtggct gaagccatac tattttatag 60
aattaatgga aagcagaaaa gacatcacaa accaagaaga actttggaaa atgaagccta 120
ggagaaatgtt agaagaagac gattatttgc ataaggacac gggagagacc agcatgctaa 180
aaagacctgt gcttttgcac ttgcacaaa cagcccatgc tgatgaattt gactgccctt 240
cagaacttca gcacacacag gaactctttc cacagtggca cttgccaatt aaaatagctg 300
ctatttatagc atctctgact tttctttaca ctcttctgag ggaagtaatt caccctttag 360
caacttccca tcaacaatat ttttataaaa ttccaatcct ggtcatcaac aaagtcttgc 420
caatggtttc catcactctc ttggcattgg tttacctgcc aggtgtgata gcagcaattg 480
tccaacttca taatggaacc aagtataaga agtttccaca ttggttggat aagtggatgt 540
taacaagaaa gcagtttggg cttctcagtt tcttttttgc tgtactgcat gcaatttata 600
gtctgtctta cccaatgagg cgatcctaca gtgagcatga gctaaactgg gcatatcaac 660
aggtccaaca aaataaagaa gatgcctgga tactggctct gttggctgtg acatctattc 720
atgtgtctct gggaattgtg ggattggcaa tactggctct gttggctgtg acatctattc 780
catctgtgag tgactctttg acatggagag aatttcacta tattcagagc aagctaggaa 840
ttgtttccct tctactgggc acaatacacg cattgatttt tgcctggaat aagtggatag 900
atataaaaca atttgtatgg tatacacctc caacttttat gatagctgtt ttccttccaa 960
ttgttgtcct gatattttaa agcatactat tcctgccatg cttgaggaag aagatactga 1020
agattagaca tggttgggaa gacgtcacca aaattaacaa aactgagata tgttcccagt 1080
tgtagaatta ctgttttacac acatttttgt tcaatattga tatattttat caccaacatt 1140
tcaagtttgt atttgttaat aaaatgatta ttcaaggaaa aaaaaa aaaaa 1195

```

&lt;210&gt; 736

&lt;211&gt; 339

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 736

Met Glu Ser Arg Lys Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys Met

5

10

15

Lys Pro Arg Arg Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp Thr  
 20 25 30  
 Gly Glu Thr Ser Met Leu Lys Arg Pro Val Leu Leu His Leu His Gln  
 35 40 45  
 Thr Ala His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu Gln His Thr  
 50 55 60  
 Gln Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys Ile Ala Ala Ile  
 65 70 75 80  
 Ile Ala Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu Val Ile His  
 85 90 95  
 Pro Leu Ala Thr Ser His Gln Gln Tyr Phe Tyr Lys Ile Pro Ile Leu  
 100 105 110  
 Val Ile Asn Lys Val Leu Pro Met Val Ser Ile Thr Leu Leu Ala Leu  
 115 120 125  
 Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Val Gln Leu His Asn Gly  
 130 135 140  
 Thr Lys Tyr Lys Lys Phe Pro His Trp Leu Asp Lys Trp Met Leu Thr  
 145 150 155 160  
 Arg Lys Gln Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala  
 165 170 175  
 Ile Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys Leu  
 180 185 190  
 Leu Asn Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala Trp  
 195 200 205  
 Ile Glu His Asp Val Trp Arg Met Glu Ile Tyr Val Ser Leu Gly Ile  
 210 215 220  
 Val Gly Leu Ala Ile Leu Ala Leu Leu Ala Val Thr Ser Ile Pro Ser  
 225 230 235 240  
 Val Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr Ile Gln Ser Lys  
 245 250 255  
 Leu Gly Ile Val Ser Leu Leu Leu Gly Thr Ile His Ala Leu Ile Phe  
 260 265 270  
 Ala Trp Asn Lys Trp Ile Asp Ile Lys Gln Phe Val Trp Tyr Thr Pro  
 275 280 285  
 Pro Thr Phe Met Ile Ala Val Phe Leu Pro Ile Val Val Leu Ile Phe  
 290 295 300  
 Lys Ser Ile Leu Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu Lys Ile  
 305 310 315 320  
 Arg His Gly Trp Glu Asp Val Thr Lys Ile Asn Lys Thr Glu Ile Cys

325

330

335

Ser Gln Leu

&lt;210&gt; 737

&lt;211&gt; 2172

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 737

aaaattgaat	attgagatac	cattcttttag	tgttaccttt	tttaccacaca	tgtgtttctg	60
aaaatattgg	aatttttattc	atcttaaaaa	ttggaccctgg	ccttattttac	catctttaat	120
ccatttttagt	actatgggtg	agtacatgga	attgaagtct	ggcttaaatac	ttcagaaagt	180
tatatatcta	ttttattttta	tttttttgag	acagagtctc	gctgtgtcac	ccaggctgga	240
gtgcggtgcc	acaatcttgg	ctcactgcaa	cctctgagtc	ccaggttcaa	gcgatactca	300
tgcctcggcc	tcctgagtag	ctgggactac	aggcgtgcac	caccacatct	ggctaattctt	360
tttttgtatt	tttagtagag	acggggtttc	actgtggtct	ccatctcctg	acctcgtgat	420
ccgcctgcct	cccaaagtgc	tgggattaca	ggcatgagcc	accgcacaca	gctgggactg	480
ggtaatttat	aaagaaaaga	ggtttaata	ctcacagttc	cgcatggctg	gagaggcctc	540
aggaaactta	caatcatggt	ggaaggcgaa	ggggaagcaa	ggcacgtctt	acatgggtggc	600
aggagagaac	gagtgagggg	ggagactgcc	acaaactttt	tttttttgag	acaagagtct	660
ggccctggtg	cccaggctgg	agtgcagtgg	catgatctca	gctcactgca	acctctgcct	720
cacaggttca	agcaattctc	atgcctcagc	ctcccgcata	gctgggacca	caggtatgca	780
ccaccacacc	tagctaattt	ttgtagtttt	agtagagatg	gggtctcact	atgttgctca	840
ggctgggtcta	aaactcctgg	gctccagcaa	tcgcctgcc	ttggcctccc	aaagtgtctg	900
ggttacaggc	ataagccacc	acatccagcc	tgccacatac	ttttaaacta	tcaggtctca	960
tgagaactca	tgcactatca	caagaatagc	atggggaaaa	tcccccccat	aatccaatca	1020
cctcccacca	ggtctcctcc	gacacgtggg	attgggtggg	gacacagagc	caaaccgtat	1080
cagatgctgc	aggggctggg	gacactgaga	ccactcagac	ctggtgtctc	tgtcactctt	1140
ctgggctctg	tctgtctcca	ggacctccct	ccccttccat	ggtatagaag	gaaagtgtctg	1200
taaggtgcaa	attgcacagg	aactccttaa	gacatacatc	atccactcag	cagtttttagg	1260
ttcgacagca	aatggagtgg	aaggaaacaga	aatttcctgt	gcaccctcc	ccgctgtctc	1320
cgccatatcg	gcctcctgca	tccagagtgg	tggactgggt	acaggctatg	aacctacact	1380
gatgcggcac	caccacccag	agtcacagg	ttatgttgg	tcacatttac	tcttgtctgtg	1440
gtatgggtcta	taggtttgga	cagatgtccg	ataatccttt	ttacattttg	gcctccttgg	1500
gtagctcgtc	ttgtaggaat	ggacttgctt	caaagtggag	gcaggcagat	ccttcagacg	1560
ggtatatgga	gccctgtttt	cagttgcttt	tctaattctc	tcttatcggt	tacctcaaaa	1620
tcttcctgag	gtctcgcttc	cttttaaaa	ccttgtctac	tttgacgcat	cactctgaca	1680
ctccattgat	tcctcagcac	ctactgacta	cacggttagg	agtgcagggt	tagaattcat	1740
gtttttattca	tccttggggtc	tgtagcacc	agcaaagtgc	tcagtaaatg	cgagtaatt	1800
gatttgacct	ctgaacaaat	acacactgta	ctaagaatct	acacaccgaa	agacaaaaac	1860
aagacaaatt	tgagtgtctac	aggtgtcacg	cttggcatca	cacatgtgcc	tgtgtattcc	1920
tctaggtgg	taccaggagc	tctgccactg	catgtccact	agtgcagggt	tcgctccacc	1980
accccagctg	ggtagccgct	gctctcacat	aaggggtcca	attaaaattg	ccaggaataa	2040
attccccgg	actttgactt	ctcaagagct	aagaagggtt	gctgagtatt	ctggcatgat	2100
gtttggtgat	caaacaactg	ctggccaaaa	atgatgagta	tttccccctc	ttgctgaaga	2160
tgtgtccat	ac					2172

&lt;210&gt; 738

&lt;211&gt; 2455

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 738

cagcttaaaa	atgggtttctt	gaaatcagtg	attagcattc	actcaccagt	acccctacta	60
aggggtaggc	actgggtttgt	actcctggga	atacaggagt	acaccagaat	ttatttctgc	120

ttattgcttt	tggtgcaaat	gccgtggctt	catctgagga	attctagaat	tcagaggggtg	180
tagccctcca	ctctgctgtc	ttgctatctg	ctctcattgc	atccgtttaa	cctgcattct	240
gaaagatgtt	tctcagggtt	ttccttgacg	atcttcttct	tttctgattc	tgacaatgtt	300
ttaaatcatt	gtactgtggt	tatcatttct	ctgcatttat	tttaccatc	ttcctttgta	360
acttgtccta	ttgtctttta	atctctgcct	gttctttatg	gctttcaact	tcataaataa	420
catgttttct	caaactctct	tgtgaattcc	agagagggcc	aggcacgggtg	gctcacatct	480
gtaatcccag	cactttgggg	aggctgagac	gggtggatca	cttgagggtca	ggagtttgag	540
accagcctgg	ccaacatggt	gaaatcccgt	ttcactaaaa	atacaaaaat	taccaggga	600
tggtggcggg	cgctgtaat	cccagggtact	cgggagggtg	aggaggaga	atcgcttgaa	660
cctgggaggg	tgagggagga	gaatcgcttg	aaccggggag	gcagagggtg	cagtgaaccg	720
agatcatggt	gctgcactcc	agcctgggtca	acagagcaag	actctgcctc	aaaaacaaac	780
aaataaacia	acaaacaaac	aaaacagaga	gattttgctg	caatgtacaa	ggagcaattt	840
gctcctttta	aaaaataatt	tttgccagg	cacagtgggt	cacacctgta	atccaggcac	900
tttggaagc	caaggtgggt	ggatcatttg	aggtcaggag	tttgagatca	gcctggccaa	960
catggtgaaa	cactatctct	attaaaaata	caaaaatgtg	ctcagtgtgg	tggtgcacat	1020
ctgtaatctc	agcctcccgc	atagctggga	ccacagggtat	gcaccaccac	acctagctaa	1080
ttttttagt	tttagtagag	atgggtctc	actatgttgc	tcaggctggt	ctaaaactcc	1140
tggtctccag	caatccgct	gccttggcct	cccaaagtgc	tggtgttaca	ggcataagcc	1200
accacatcca	gcctgccaca	tacttttaaa	ctcatggtc	tcatgagaac	tcattgacta	1260
tcacaagaat	agcatgggga	aaatcccccc	cataatccaa	tcacctccca	ccaggtctcc	1320
tcagacacgt	gggattgggt	ggggacacag	agccaaaccg	tatcagatgc	tcagggggt	1380
ggggacactg	agaccactca	gacctgggtg	ctctgtcact	cttctgggt	ctgtctgtct	1440
ccaggacctc	cctccccttc	catggtatag	aaggaaaagt	ctgtaagggt	caaattgcac	1500
aggaactcct	taagacatac	atcatccact	cagcagttt	aggttcgcag	caaatggag	1560
tggaaggaac	agaaatttcc	tgtgcacccc	tccccgctgt	ctccgccata	tcggcatcct	1620
gcacccagag	tggtggactg	gttacaggct	atgaacctac	actgatgcgg	caccaccacc	1680
cagagtccac	aggttatggt	ggttcacatt	tactcttgct	gtggtatggt	ctatagggtt	1740
ggacagatgt	ccgataatcc	tttttacatt	ttggcatcct	tggttagctc	gtctttaggt	1800
aatggacttg	cttcaaagt	gaggcaggca	gatccttcag	acgggtatat	ggagccctgt	1860
tttcagttgc	ttttctaatt	ctctcttate	gtttacctca	aaatcttcct	gaggtctcgc	1920
ttccttttaa	aatccttgct	tactttgcag	catcactctg	acactccatt	gattcctcag	1980
cacctactga	ctacacgggt	aggagtgcac	gggtagaatt	catgttttat	tcactcttgg	2040
gtctgtagca	cccagcaaag	tgtcagtaa	atgcgcagta	attgatttga	cctctgaaca	2100
aatacacact	gtataagaa	tctacacacc	gaaagacaaa	aacaagacaa	atttgagtcg	2160
tacaggtgtc	acgcttggca	tcacacatgt	gcctgtgtat	tcctctaggt	ggttaccagg	2220
agctctgcca	ctgcatgtcc	actagtgcag	ggttcgctcc	accacccag	ctgggtagcc	2280
gctgctctca	cataaggggt	ccaattaaaa	ttgccaggaa	taaattcccc	cggactttga	2340
cttctcaaga	gctaagaagg	tttgctgagt	attctggcat	gatgtttggt	gatcaacaaa	2400
ctgctggcca	aaaatgatga	gtatttcccc	ctcttgctga	agatgtgctc	catac	2455

&lt;210&gt; 739

&lt;211&gt; 2455

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 739

cagcttaaaa	atgggtttctt	gaaatcagtg	attagcattc	actcaccagt	acccctacta	60
aggggtaggg	actgggtttgt	actcctggga	atacaggagt	acaccagaat	ttattttctgc	120
ttattgcttt	tggtgcaaat	gccgtggctt	catctgagga	attctagaat	tcagaggggtg	180
tagccctcca	ctctgctgtc	ttgctatctg	ctctcattgc	atccgtttaa	cctgcattct	240
gaaagatgtt	tctcagggtt	ttccttgacg	atcttcttct	tttctgattc	tgacaatgtt	300
ttaaatcatt	gtactgtggt	tatcatttct	ctgcatttat	tttaccatc	ttcctttgta	360
acttgtccta	ttgtctttta	atctctgcct	gttctttatg	gctttcaact	tcataaataa	420
catgttttct	caaactctct	tgtgaattcc	agagagggcc	aggcacgggtg	gctcacatct	480
gtaatcccag	cactttgggg	aggctgagac	gggtggatca	cttgagggtca	ggagtttgag	540
accagcctgg	ccaacatggt	gaaatcccgt	ttcactaaaa	atacaaaaat	taccaggga	600
tggtggcggg	cgctgtaat	cccagggtact	cgggagggtg	aggaggaga	atcgcttgaa	660
cctgggaggg	tgagggagga	gaatcgcttg	aaccggggag	gcagagggtg	cagtgaaccg	720

```

agatcatgtt gctgcactcc agcctgggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacaa acaaacaaaac aaaacagaga gattttgctg caatgtacaa ggagcaattt 840
gctcctttta aaaaataatt tttggccagg cacagtggct cacacctgta atcccagcac 900
tttgggaagc caaggtgggt ggatcatttg aggtcaggag tttgagatca gcctggccaa 960
catggtgaaa cactatctct attaaaaata caaaaatgtg ctgagtgtgg tgggtgcacat 1020
ctgtaatctc agcctcccgc atagctggga ccacaggtat gcaccaccac acctagctaa 1080
ttttttagt ttttagtagag atgggggtctc actatgttgc tcaggctggg ctaaaaactcc 1140
tgggctccag caatccgcct gccttggcct cccaaagtgc tggggttaca ggcataagcc 1200
accacatcca gcctgccaca tactttttaa ctatcaggtc tcatgagaac tcatgcacta 1260
tcacaagaat agcatgggga aaatccccc cataatccaa tcacctccca ccaggctctcc 1320
tccgacacgt gggattgggt ggggacacag agccaaaccg tatcagatgc tgcaggggct 1380
ggggacactg agaccactca gacctgggtg ctctgtcact cttctgggct ctgtctgtct 1440
ccaggacctc cctccccttc catggtatag aaggaaagtg ctgtaagggtg caaattgcac 1500
aggaactcct taagacatac atcatccact cagcagtttt aggttcgcag caaaatggag 1560
tggaaggaac agaaatttcc tgtgcacccc tcccgcgtgt ctccgccata tcggcatcct 1620
gcattccagag tgggtggact gttacaggct atgaacctac actgatgcgg caccaccacc 1680
cagagtccac aggttatgtt gggtcacatt tactcttget gtgggtatgg ctataggttt 1740
ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtctttagg 1800
aatggacttg cttcaaagtg gaggcaggca gatccttcag acgggtatat ggagccctgt 1860
tttcagttgc ttttctaatt ctctcttacc gtttacctca aaatcttcct gaggtctcgc 1920
ttccttttaa aatccttgtc tactttgcag catcactctg acactccatt gattcctcag 1980
cacctactga ctacacggtt aggagtgc aa gggtagaatt catgttttat tcatcttttg 2040
gtctgtagca cccagcaaag tgctcagtaa atgcgcagta attgatttga cctctgaaca 2100
aatacacact gtactaagaa tctacacacc gaaagacaaa aacaagacaa atttgagtgc 2160
tacagggtgtc acgcttggca tcacacatgt gcctgtgtat tctcttaggt gggtaccagg 2220
agctctgcca ctgcatgtcc actagtgcag gggtcgtcc accaccccag ctgggtagcc 2280
gctgctctca cataaggggt ccaattaaaa ttgccaggaa taaattcccc cggactttga 2340
cttctcaaga gctaagaagg tttgctgagt attctggcat gatgtttgg gatcaacaa 2400
ctgctggcca aaaatgatga gtatttcccc ctcttgctga agatgtgctc catac 2455

```

&lt;210&gt; 740

&lt;211&gt; 62

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 740

```

Met Thr His Ser Ser Ala Trp Leu Glu Arg Pro Gln Glu Thr Tyr Asn
              5                      10                      15

```

```

His Gly Gly Arg Arg Arg Gly Ser Lys Ala Arg Leu Thr Trp Trp Gln
              20                      25                      30

```

```

Glu Arg Thr Ser Glu Gly Gly Asp Cys His Lys Leu Phe Phe Phe Glu
              35                      40                      45

```

```

Thr Arg Val Trp Pro Cys Cys Pro Gly Trp Ser Ala Val Ala
              50                      55                      60

```

&lt;210&gt; 741

&lt;211&gt; 135

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 741

```

Met Val Glu Gly Glu Gly Glu Ala Arg His Val Leu His Gly Gly Arg
              5                      10                      15

```



Arg Glu Arg Val Arg Gly Glu Thr Ala Thr Asn Phe Phe Phe Leu Arg  
 20 25 30

Gln Glu Ser Gly Pro Val Ala Gln Ala Gly Val Gln Trp His Asp Leu  
 35 40 45

Ser Ser Leu Gln Pro Leu Pro His Arg Phe Lys Gln Phe Ser Cys Leu  
 50 55 60

Ser Leu Pro His Ser Trp Asp His Arg Tyr Ala Pro Pro His Leu Ala  
 65 70 75 80

Asn Phe Cys Ser Phe Ser Arg Asp Gly Val Ser Leu Cys Cys Ser Gly  
 85 90 95

Trp Ser Lys Thr Pro Gly Leu Gln Gln Ser Ala Cys Leu Gly Leu Pro  
 100 105 110

Lys Cys Trp Gly Tyr Arg His Lys Pro Pro His Pro Ala Cys His Ile  
 115 120 125

Leu Leu Asn Tyr Gln Val Ser  
 130 135

<210> 742  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 742  
 Met His Tyr His Lys Asn Ser Met Gly Lys Ile Pro Pro Ile Ile Gln  
 5 10 15

Ser Pro Pro Thr Arg Ser Pro Pro Thr Arg Gly Ile Gly Trp Gly His  
 20 25 30

Arg Ala Lys Pro Tyr Gln Met Leu Gln Gly Leu Gly Thr Leu Arg Pro  
 35 40 45

Leu Arg Pro Gly Val Ser Val Thr Leu Leu Gly Ser Val Cys Leu Gln  
 50 55 60

Asp Leu Pro Pro Leu Pro Trp Tyr Arg Arg Lys Val Leu  
 65 70 75

<210> 743  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<400> 743  
 Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly  
 5 10 15

Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser  
 20 25 30

Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser  
           35                          40                          45

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe  
       50                          55                          60

<210> 744

<211> 76

<212> PRT

<213> Homo sapiens

<400> 744

Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys  
                           5                          10                          15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg  
                           20                          25                          30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro  
                           35                          40                          45

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly  
       50                          55                          60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys  
       65                          70                          75

<210> 745

<211> 76

<212> PRT

<213> Homo sapiens

<400> 745

Met Val Lys Ser Arg Phe Thr Lys Asn Thr Lys Ile Thr Gln Ala Trp  
                           5                          10                          15

Trp Arg Ala Pro Val Ile Pro Gly Thr Arg Glu Ala Glu Gly Gly Glu  
                           20                          25                          30

Ser Leu Glu Pro Gly Arg Leu Arg Glu Glu Asn Arg Leu Asn Pro Gly  
                           35                          40                          45

Gly Arg Gly Cys Ser Glu Pro Arg Ser Cys Cys Cys Thr Pro Ala Trp  
       50                          55                          60

Ser Thr Glu Gln Asp Ser Ala Ser Lys Thr Asn Lys  
       65                          70                          75

<210> 746

<211> 80

<212> PRT

<213> Homo sapiens

<400> 746

Met Leu Leu His Ser Ser Leu Val Asn Arg Ala Arg Leu Cys Leu Lys

5 10 15  
 Asn Lys Gln Ile Asn Lys Gln Thr Asn Lys Thr Glu Arg Phe Cys Cys  
 20 25 30  
 Asn Val Gln Gly Ala Ile Cys Ser Phe Lys Lys Ile Ile Phe Gly Gln  
 35 40 45  
 Ala Gln Trp Leu Thr Pro Val Ile Pro Ala Leu Trp Glu Ala Lys Val  
 50 55 60  
 Gly Gly Ser Phe Glu Val Arg Ser Leu Arg Ser Ala Trp Pro Thr Trp  
 65 70 75 80

<210> 747  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

<400> 747  
 Met His Tyr His Lys Asn Ser Met Gly Lys Ile Pro Pro His Asn Pro  
 5 10 15  
 Ile Thr Ser His Gln Val Ser Ser Asp Thr Trp Asp Trp Val Gly Thr  
 20 25 30  
 Gln Ser Gln Thr Val Ser Asp Ala Ala Gly Ala Gly Asp Thr Glu Thr  
 35 40 45  
 Thr Gln Thr Trp Cys Leu Cys His Ser Ser Gly Leu Cys Leu Ser Pro  
 50 55 60  
 Gly Pro Pro Ser Pro Ser Met Val  
 65 70

<210> 748  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 748  
 Met His Tyr His Lys Asn Ser Met Gly Lys Ile Pro Pro Ile Ile Gln  
 5 10 15  
 Ser Pro Pro Thr Arg Ser Pro Pro Thr Arg Gly Ile Gly Trp Gly His  
 20 25 30  
 Arg Ala Lys Pro Tyr Gln Met Leu Gln Gly Leu Gly Thr Leu Arg Pro  
 35 40 45  
 Leu Arg Pro Gly Val Ser Val Thr Leu Leu Gly Ser Val Cys Leu Gln  
 50 55 60  
 Asp Leu Pro Pro Leu Pro Trp Tyr Arg Arg Lys Val Leu  
 65 70 75

<210> 749  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<400> 749

Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly  
                           5                          10                          15

Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser  
                           20                          25                          30

Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser  
                           35                          40                          45

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe  
                           50                          55                          60

<210> 750  
 <211> 76  
 <212> PRT  
 <213> Homo sapiens

<400> 750

Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys  
                           5                          10                          15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg  
                           20                          25                          30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro  
                           35                          40                          45

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly  
                           50                          55                          60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys  
                           65                          70                          75

<210> 751  
 <211> 2479  
 <212> DNA  
 <213> Homo sapiens

<400> 751

gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60  
 ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaacccat ggataccaac 120  
 cggaaaaccc ctatcccgca cagcccactg tggccccac tgtctacgag gtgcatccgg 180  
 ctacgtacta cccgtcccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240  
 accccgtcgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300  
 agaaagcact gtgcatcacc ttgaccctgg ggaccttcct cgtgggagct gcgctggccg 360  
 ctggcctact ctggaagttc atgggcagca agtgctccaa ctctgggata gagtgcgact 420  
 cctcaggtac ctgcatcaac ccctctaact ggtgtgatgg cgtgtcacac tgccccggcg 480  
 gggaggacga gaatcgggtg gttcgcctct acggaccaa cttcatcctt cagatgtact 540  
 catctcagag gaagtcctgg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600

```
<210> 752
<211> 492
<212> PRT
<213> Homo sapiens
```

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu  
5 10 15

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val  
20 25 30

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro  
35 40 45

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val  
50 55 60

Val	Cys	Thr	Gln	Pro	Lys	Ser	Pro	Ser	Gly	Thr	Val	Cys	Thr	Ser	Lys
65					70					75					80

Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val  
85 90 95

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys-

295

100							105					110				
Cys	Ser	Asn	Ser	Gly	Ile	Glu	Cys	Asp	Ser	Ser	Gly	Thr	Cys	Ile	Asn	
		115						120				125				
Pro	Ser	Asn	Trp	Cys	Asp	Gly	Val	Ser	His	Cys	Pro	Gly	Gly	Glu	Asp	
	130					135					140					
Glu	Asn	Arg	Cys	Val	Arg	Leu	Tyr	Gly	Pro	Asn	Phe	Ile	Leu	Gln	Met	
145					150					155					160	
Tyr	Ser	Ser	Gln	Arg	Lys	Ser	Trp	His	Pro	Val	Cys	Gln	Asp	Asp	Trp	
				165					170					175		
Asn	Glu	Asn	Tyr	Gly	Arg	Ala	Ala	Cys	Arg	Asp	Met	Gly	Tyr	Lys	Asn	
			180					185					190			
Asn	Phe	Tyr	Ser	Ser	Gln	Gly	Ile	Val	Asp	Asp	Ser	Gly	Ser	Thr	Ser	
		195						200				205				
Phe	Met	Lys	Leu	Asn	Thr	Ser	Ala	Gly	Asn	Val	Asp	Ile	Tyr	Lys	Lys	
	210					215					220					
Leu	Tyr	His	Ser	Asp	Ala	Cys	Ser	Ser	Lys	Ala	Val	Val	Ser	Leu	Arg	
225					230					235					240	
Cys	Leu	Ala	Cys	Gly	Val	Asn	Leu	Asn	Ser	Ser	Arg	Gln	Ser	Arg	Ile	
				245					250					255		
Val	Gly	Gly	Glu	Ser	Ala	Leu	Pro	Gly	Ala	Trp	Pro	Trp	Gln	Val	Ser	
			260					265					270			
Leu	His	Val	Gln	Asn	Val	His	Val	Cys	Gly	Gly	Ser	Ile	Ile	Thr	Pro	
		275						280				285				
Glu	Trp	Ile	Val	Thr	Ala	Ala	His	Cys	Val	Glu	Lys	Pro	Leu	Asn	Asn	
	290					295					300					
Pro	Trp	His	Trp	Thr	Ala	Phe	Ala	Gly	Ile	Leu	Arg	Gln	Ser	Phe	Met	
305					310					315					320	
Phe	Tyr	Gly	Ala	Gly	Tyr	Gln	Val	Gln	Lys	Val	Ile	Ser	His	Pro	Asn	
				325					330					335		
Tyr	Asp	Ser	Lys	Thr	Lys	Asn	Asn	Asp	Ile	Ala	Leu	Met	Lys	Leu	Gln	
			340					345					350			
Lys	Pro	Leu	Thr	Phe	Asn	Asp	Leu	Val	Lys	Pro	Val	Cys	Leu	Pro	Asn	
		355						360				365				
Pro	Gly	Met	Met	Leu	Gln	Pro	Glu	Gln	Leu	Cys	Trp	Ile	Ser	Gly	Trp	
	370					375					380					
Gly	Ala	Thr	Glu	Glu	Lys	Gly	Lys	Thr	Ser	Glu	Val	Leu	Asn	Ala	Ala	
385					390					395					400	
Lys	Val	Leu	Leu	Ile	Glu	Thr	Gln	Arg	Cys	Asn	Ser	Arg	Tyr	Val	Tyr	
				405					410					415		

Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly  
 420 425 430

Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser  
 435 440 445

Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly  
 450 455 460

Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe  
 465 470 475 480

Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly  
 485 490

<210> 753  
 <211> 683  
 <212> DNA  
 <213> Homo sapiens

<400> 753  
 gtcataattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60  
 ctttgaactc aggggtcacca ccagctattg gaccttacta tgaaaacccat ggataccaac 120  
 cggaaaaccc ctatcccgca cagcccactg tggccccac tgtctacgag gtgcatccgg 180  
 ctcagtacta cccgtcccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240  
 accccgtcgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300  
 agaaagcact gtgcatcacc ttgaccctgg ggaccttcct cgtggggagct gcgctggccg 360  
 ctggcctact ctggaagttc atgggcagca agtgctccaa ctctgggata gaggcgact 420  
 cctcaggtac ctgcatcaac cctcttaact ggtgtgatgg cgtgtcacac tgccccggcg 480  
 gggaggacga gaatcgggtg gttgcctct acggaccaaa cttcatcctt cagatgtact 540  
 catctcagag gaagtcctgg caccctgtgt gccaaagcga ctggaacgag aactacgggc 600  
 gggcggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660  
 atgacagcgg atccaccaggc ttt 683

<210> 754  
 <211> 209  
 <212> PRT  
 <213> Homo sapiens

<400> 754  
 Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu  
 1 5 10 15  
 Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val  
 20 25 30  
 Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro  
 35 40 45  
 Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val  
 50 55 60  
 Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys  
 65 70 75 80  
 Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val  
 85 90 95

297

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys  
                   100                  105                  110  
 Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn  
                   115                  120                  125  
 Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp  
                   130                  135                  140  
 Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met  
                   145                  150                  155                  160  
 Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp  
                   165                  170                  175  
 Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn  
                   180                  185                  190  
 Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser  
                   195                  200                  205  
 Phe

<210> 755  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens

<400> 755  
 Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr  
   1                  5                  10                  15  
 Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg  
                   20                  25

<210> 756  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 756  
 ggatccgccg ccaccatgtc actttctagc ctgct

35

<210> 757  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer

<400> 757  
 gtcgactcag ctggaccaca gccgcag

27

<210> 758  
 <211> 34  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR primer



<400> 758  
ggatccgccg ccaccatggg ctgcaggctg ctct

34

<210> 759  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PCR primer

<400> 759  
gtcgactcag aaatcctttc tcttgac

27

<210> 760  
<211> 936  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...()  
<223> n = A,T,C or G

<400> 760  
atgggctgca ggctgntctg ctgtgcggtt ctctgtctcc tgggagcggg ccccatggaa 60  
acgggagtta cgcagacacc aagacacctg gtcattggaa tgacaaataa gaagtctttg 120  
aaatgtgaac aacatctggg tcataacgct atgtattggg acaagcaaag tgctaagaag 180  
ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240  
agtgcgttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacaccctg 300  
cagccagaag actcggccct gtatctctgc gccagcagcc aagaccggac aagcagctcc 360  
tacgagcagt acttcgggcc gggcaccagg ctacagggtc cagaggacct gaaaaacgtg 420  
ttcccacccg aggtcgctgt gtttgagcca tcagaagcag agatctccca caccctaaaag 480  
gccacactgg tgtgcctggc cacaggcttc taccccgacc acgtggagct gagctggtgg 540  
gtgaatggga aggaggtgca cagtggggtc agcacagacc cgcagcccct caaggagcag 600  
cccgccctca atgactccag atactgcctg agcagccgcc tgagggtctc ggccaccttc 660  
tggcagaacc cccgcaacca cttccgctgt caagtccagt tctacgggct ctcggagaat 720  
gacgagtgga cccaggatag ggccaaacct gtcaccaga tcgtcagcgc cgaggcctgg 780  
ggtagagcag actgtggctt cacctccgag tcttaccagc aaggggtcct gtctgccacc 840  
atcctctatg agatcttgct agggaaggcc acctgtatg ccgtgctggt cagtgccctc 900  
gtgctgatgg ccatggtcaa gagaaaggat ttctga 936

<210> 761  
<211> 834  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (1)...()  
<223> n = A,T,C or G

<400> 761  
atgtcacttt ctgacctgct naagggtggtc acagcttcac tgtggctagg acctggcatt 60  
gccagaaga taactcaaac ccaaccagga atgttcgtgc aggaaaagga ggctgtgact 120  
ctggactgca catatgacac cagtgatcaa agttatggte tcttctggta caagcagccc 180

```

agcagtgggg aaatgatttt tcttatttat caggggtctt atgacgagca aaatgcaaca 240
gaaggtcgct actcattgaa tttccagaag gcaagaaaat cgcgcaacct tgtcatctcc 300
gcttcacaac tgggggactc agcaatgtat ttctgtgcaa tgagagaggg cgcgggagga 360
ggaaacaaac tcacctttgg gacaggcact cagctaaaag tggaactcaa tatccagaac 420
cctgaccctg ccgtgtacca gctgagagac tctaaatcca gtgacaagtc tgtctgccta 480
ttcaccgatt ttgattctca aacaaatgtg tcacaaagta aggattctga tgtgtatatc 540
acagacaaaa ctgtgctaga catgaggtct atggacttca agagcaacag tgctgtggcc 600
tggagcaaca aatctgactt tgcattgtgca aacgccttca acaacagcat tattccagaa 660
gacaccttct tccccagccc agaaagttcc tgtgatgtca agctggtcga gaaaagcttt 720
gaaacagata cgaacctaaa ctttcaaaac ctgtcagtga ttgggttccg aatcctcctc 780
ctgaaagtgg ccgggtttaa tctgtcatg acgtgcggc tgtggtccag ctga 834

```

&lt;210&gt; 762

&lt;211&gt; 311

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; variant

&lt;222&gt; (1)...(311)

&lt;223&gt; Xaa = Any amino acid

&lt;400&gt; 762

```

Met Gly Cys Arg Leu Xaa Cys Cys Ala Val Leu Cys Leu Leu Gly Ala
      5                                10                                15

```

```

Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met
      20                                25                                30

```

```

Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His
      35                                40                                45

```

```

Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu
      50                                55                                60

```

```

Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro
      65                                70                                75                                80

```

```

Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His
      85                                90                                95

```

```

Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser
      100                                105                                110

```

```

Ser Gln Asp Arg Thr Ser Ser Ser Tyr Glu Gln Tyr Phe Gly Pro Gly
      115                                120                                125

```

```

Thr Arg Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu
      130                                135                                140

```

```

Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys
      145                                150                                155                                160

```

```

Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu
      165                                170                                175

```

```

Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr
      180                                185                                190

```

300

Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr  
195 200 205

Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro  
210 215 220

Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn  
225 230 235 240

Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser  
245 250 255

Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr  
260 265 270

Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly  
275 280 285

Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala  
290 295 300

Met Val Lys Arg Lys Asp Phe  
305 310

<210> 763

<211> 277

<212> PRT

<213> Homo sapiens

<400> 763

Met Ser Leu Ser Ser Leu Leu Lys Val Val Thr Ala Ser Leu Trp Leu  
5 10 15

Gly Pro Gly Ile Ala Gln Lys Ile Thr Gln Thr Gln Pro Gly Met Phe  
20 25 30

Val Gln Glu Lys Glu Ala Val Thr Leu Asp Cys Thr Tyr Asp Thr Ser  
35 40 45

Asp Gln Ser Tyr Gly Leu Phe Trp Tyr Lys Gln Pro Ser Ser Gly Glu  
50 55 60

Met Ile Phe Leu Ile Tyr Gln Gly Ser Tyr Asp Glu Gln Asn Ala Thr  
65 70 75 80

Glu Gly Arg Tyr Ser Leu Asn Phe Gln Lys Ala Arg Lys Ser Ala Asn  
85 90 95

Leu Val Ile Ser Ala Ser Gln Leu Gly Asp Ser Ala Met Tyr Phe Cys  
100 105 110

Ala Met Arg Glu Gly Ala Gly Gly Gly Asn Lys Leu Thr Phe Gly Thr  
115 120 125

Gly Thr Gln Leu Lys Val Glu Leu Asn Ile Gln Asn Pro Asp Pro Ala  
130 135 140

Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu  
 145 150 155 160  
 Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser  
 165 170 175  
 Asp Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp  
 180 185 190  
 Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala  
 195 200 205  
 Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe  
 210 215 220  
 Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe  
 225 230 235 240  
 Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe  
 245 250 255  
 Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu  
 260 265 270  
 Arg Leu Trp Ser Ser  
 275

&lt;210&gt; 764

&lt;211&gt; 1536

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 764

atgtacaacc tgttgctgtc ctacgacaga catggggacc acctgcagcc cctggacctc 60  
 gtgcccacac accaggtct caccctttc aagctggctg gaggaggagg taacactgtg 120  
 atgtttcagc acctgatgca gaagcgggaag cacacccagt ggacgtatgg accactgacc 180  
 tcgactctct atgacctcac agagatcgac tcctcagggg atgagcagtc cctgctggaa 240  
 cttatcatca ccaccaagaa gcgggaggct cgcagatcc tggaccagac gccggtgaag 300  
 gagctgggtga gcctcaagt gaagcgggtac gggcgccgt acttctgcat gctgggtgcc 360  
 atatatctgc tgtacatcat ctgcttcacc atgtgctgca tctaccgccc cctcaagccc 420  
 aggaccaata accgcacgag ccccggggac aacacctct tacagcagaa gctacttcag 480  
 gaagcctaca tgacccttaa ggacgatata cggctggtcg gggagctggg gactgtcatt 540  
 ggggctatca tcatcctgct ggtagaggtt ccagacatct tcagaatggg ggtcactcgc 600  
 ttctttggac agaccatcct tgggggcccc ttccatgtcc tcatcatcac ctatgccttc 660  
 atggtgctgg tgaccatggt gatgcggctc atcagtgcc ggggggaggt ggtacccatg 720  
 tcctttgac tcgtgctggg ctggtgcaac gtcagtact tcgccgagg attccagatg 780  
 ctaggccct tcaccatcat gattcagaag atgattttg gcgacctgat gcgattctgc 840  
 tggctgatgg ctgtggtcat cctgggcttt gcttcagcct tctatatcat cttccagaca 900  
 gaggaccccg aggagctagg ccacttctac gactacccca tggccctggt cagcaccttc 960  
 gagctgttcc ttaccatcat cgatggccca gccactaca acgtggacct gcccttcatt 1020  
 tacagcatca cctatgctgc ctttgccatc atcgccacac tgctcatgct caacctcctc 1080  
 attgccatga tggcgacac tcaactggcg gtggcccatg agcgggatga gctgtggagg 1140  
 gccagattg tggccaccac ggtgatgctg gagcgggaag tgccctcgtg cctgtggcct 1200  
 cgctccggga tctgcgagc ggagtatggc ctgggagacc gctggttcct gcgggtggaa 1260  
 gacaggcaag atctcaacc gcagcggatc caacgctacg cacaggcctt ccacaccggg 1320  
 ggctctgagg atttgacaa agactcagtg gaaaaactag agctgggctg tcccttcagg 1380

```
<210> 765
<211> 1533
<212> DNA
<213> Homo sapiens
```

```
<210> 766
<211> 511
<212> PRT
<213> Homo sapiens
```

BNSDOCID: &lt;WO 0151633A2 I &gt;

Leu Ile Ile Thr Thr Lys Lys Arg Glu Ala Arg Gln Ile Leu Asp Gln  
 85 90 95  
 Thr Pro Val Lys Glu Leu Val Ser Leu Lys Trp Lys Arg Tyr Gly Arg  
 100 105 110  
 Pro Tyr Phe Cys Met Leu Gly Ala Ile Tyr Leu Leu Tyr Ile Ile Cys  
 115 120 125  
 Phe Thr Met Cys Cys Ile Tyr Arg Pro Leu Lys Pro Arg Thr Asn Asn  
 130 135 140  
 Arg Thr Ser Pro Arg Asp Asn Thr Leu Leu Gln Gln Lys Leu Leu Gln  
 145 150 155 160  
 Glu Ala Tyr Met Thr Pro Lys Asp Asp Ile Arg Leu Val Gly Glu Leu  
 165 170 175  
 Val Thr Val Ile Gly Ala Ile Ile Ile Leu Leu Val Glu Val Pro Asp  
 180 185 190  
 Ile Phe Arg Met Gly Val Thr Arg Phe Phe Gly Gln Thr Ile Leu Gly  
 195 200 205  
 Gly Pro Phe His Val Leu Ile Ile Thr Tyr Ala Phe Met Val Leu Val  
 210 215 220  
 Thr Met Val Met Arg Leu Ile Ser Ala Ser Gly Glu Val Val Pro Met  
 225 230 235 240  
 Ser Phe Ala Leu Val Leu Gly Trp Cys Asn Val Met Tyr Phe Ala Arg  
 245 250 255  
 Gly Phe Gln Met Leu Gly Pro Phe Thr Ile Met Ile Gln Lys Met Ile  
 260 265 270  
 Phe Gly Asp Leu Met Arg Phe Cys Trp Leu Met Ala Val Val Ile Leu  
 275 280 285  
 Gly Phe Ala Ser Ala Phe Tyr Ile Ile Phe Gln Thr Glu Asp Pro Glu  
 290 295 300  
 Glu Leu Gly His Phe Tyr Asp Tyr Pro Met Ala Leu Phe Ser Thr Phe  
 305 310 315 320  
 Glu Leu Phe Leu Thr Ile Ile Asp Gly Pro Ala Asn Tyr Asn Val Asp  
 325 330 335  
 Leu Pro Phe Met Tyr Ser Ile Thr Tyr Ala Ala Phe Ala Ile Ile Ala  
 340 345 350  
 Thr Leu Leu Met Leu Asn Leu Leu Ile Ala Met Met Gly Asp Thr His  
 355 360 365  
 Trp Arg Val Ala His Glu Arg Asp Glu Leu Trp Arg Ala Gln Ile Val  
 370 375 380  
 Ala Thr Thr Val Met Leu Glu Arg Lys Leu Pro Arg Cys Leu Trp Pro

385                      390                      395                      400  
 Arg Ser Gly Ile Cys Gly Arg Glu Tyr Gly Leu Gly Asp Arg Trp Phe  
                                  405                      410                      415  
 Leu Arg Val Glu Asp Arg Gln Asp Leu Asn Arg Gln Arg Ile Gln Arg  
                                  420                      425                      430  
 Tyr Ala Gln Ala Phe His Thr Arg Gly Ser Glu Asp Leu Asp Lys Asp  
                                  435                      440                      445  
 Ser Val Glu Lys Leu Glu Leu Gly Cys Pro Phe Ser Pro His Leu Ser  
                                  450                      455                      460  
 Leu Pro Met Pro Ser Val Ser Arg Ser Thr Ser Arg Ser Ser Ala Asn  
                                  465                      470                      475                      480  
 Trp Glu Arg Leu Arg Gln Gly Thr Leu Arg Arg Asp Leu Arg Gly Ile  
                                  485                      490                      495  
 Ile Asn Arg Gly Leu Glu Asp Gly Glu Ser Trp Glu Tyr Gln Ile  
                                  500                      505                      510

&lt;210&gt; 767

&lt;211&gt; 134

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 767

Met Tyr Asn Leu Leu Leu Ser Tyr Asp Arg His Gly Asp His Leu Gln  
                                  5                      10                      15  
 Pro Leu Asp Leu Val Pro Asn His Gln Gly Leu Thr Pro Phe Lys Leu  
                                  20                      25                      30  
 Ala Gly Val Glu Gly Asn Thr Val Met Phe Gln His Leu Met Gln Lys  
                                  35                      40                      45  
 Arg Lys His Thr Gln Trp Thr Tyr Gly Pro Leu Thr Ser Thr Leu Tyr  
                                  50                      55                      60  
 Asp Leu Thr Glu Ile Asp Ser Ser Gly Asp Glu Gln Ser Leu Leu Glu  
                                  65                      70                      75                      80  
 Leu Ile Ile Thr Thr Lys Lys Arg Glu Ala Arg Gln Ile Leu Asp Gln  
                                  85                      90                      95  
 Thr Pro Val Lys Glu Leu Val Ser Leu Lys Trp Lys Arg Tyr Gly Arg  
                                  100                      105                      110  
 Pro Tyr Phe Cys Met Leu Gly Ala Ile Tyr Leu Leu Tyr Ile Ile Cys  
                                  115                      120                      125  
 Phe Thr Met Cys Cys Ile  
                                  130

305

<210> 768  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<400> 768  
 Ala Tyr Arg Pro Leu Lys Pro Arg Thr Asn Asn Arg Thr Ser Pro Arg  
                   5                  10                  15  
 Asp Asn Thr Leu Leu Gln Gln Lys Leu Leu Gln Glu Ala Tyr Met Thr  
                   20                  25                  30  
 Pro Lys Asp Asp Ile Arg Leu Val Gly Glu Leu Val Thr Val Ile Gly  
                   35                  40                  45  
 Ala Ile Ile Ile Leu Leu Val  
                   50                  55

<210> 769  
 <211> 39  
 <212> PRT  
 <213> Homo sapiens

<400> 769  
 Glu Val Pro Asp Ile Phe Arg Met Gly Val Thr Arg Phe Phe Gly Gln  
                   5                  10                  15  
 Thr Ile Leu Gly Gly Pro Phe His Val Leu Ile Ile Thr Tyr Ala Phe  
                   20                  25                  30  
 Met Val Leu Val Thr Met Val  
                   35

<210> 770  
 <211> 19  
 <212> PRT  
 <213> Homo sapiens

<400> 770  
 Met Arg Leu Ile Ser Ala Ser Gly Glu Val Val Pro Met Ser Phe Ala  
                   5                  10                  15  
 Leu Val Leu

<210> 771  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<400> 771  
 Gly Trp Cys Asn Val Met Tyr Phe Ala Arg Gly Phe Gln Met Leu Gly  
                   5                  10                  15  
 Pro Phe Thr Ile Met Ile Gln Lys Met Ile Phe Gly Asp Leu Met Arg



306

20 25 30  
 Phe Cys Trp Leu Met Ala Val Val Ile Leu Gly Phe Ala Ser Ala Phe  
 35 40 45  
 Tyr Ile Ile Phe  
 50  
 <210> 772  
 <211> 213  
 <212> PRT  
 <213> Homo sapiens  
 <400> 772  
 Gln Thr Glu Asp Pro Glu Glu Leu Gly His Phe Tyr Asp Tyr Pro Met  
 5 10 15  
 Ala Leu Phe Ser Thr Phe Glu Leu Phe Leu Thr Ile Ile Asp Gly Pro  
 20 25 30  
 Ala Asn Tyr Asn Val Asp Leu Pro Phe Met Tyr Ser Ile Thr Tyr Ala  
 35 40 45  
 Ala Phe Ala Ile Ile Ala Thr Leu Leu Met Leu Asn Leu Leu Ile Ala  
 50 55 60  
 Met Met Gly Asp Thr His Trp Arg Val Ala His Glu Arg Asp Glu Leu  
 65 70 75 80  
 Trp Arg Ala Gln Ile Val Ala Thr Thr Val Met Leu Glu Arg Lys Leu  
 85 90 95  
 Pro Arg Cys Leu Trp Pro Arg Ser Gly Ile Cys Gly Arg Glu Tyr Gly  
 100 105 110  
 Leu Gly Asp Arg Trp Phe Leu Arg Val Glu Asp Arg Gln Asp Leu Asn  
 115 120 125  
 Arg Gln Arg Ile Gln Arg Tyr Ala Gln Ala Phe His Thr Arg Gly Ser  
 130 135 140  
 Glu Asp Leu Asp Lys Asp Ser Val Glu Lys Leu Glu Leu Gly Cys Pro  
 145 150 155 160  
 Phe Ser Pro His Leu Ser Leu Pro Met Pro Ser Val Ser Arg Ser Thr  
 165 170 175  
 Ser Arg Ser Ser Ala Asn Trp Glu Arg Leu Arg Gln Gly Thr Leu Arg  
 180 185 190  
 Arg Asp Leu Arg Gly Ile Ile Asn Arg Gly Leu Glu Asp Gly Glu Ser  
 195 200 205  
 Trp Glu Tyr Gln Ile  
 210

<210> 773  
 <211> 1302  
 <212> DNA  
 <213> Homo sapiens

<400> 773

tgacacaaagg	gggtcacaca	ttccttccat	acgggtgagc	ctctacctgc	ctgggtgctgg	60
tcacagttca	gcttcttcat	gatggtggat	cccaatggca	atgaatccag	tgctacatac	120
ttcatcctaa	taggcctccc	tggtttagaa	gaggctcagt	tctggttggc	cttcccattg	180
tgctccctct	accttattgc	tgtgctaggt	aacttgacaa	tcactctacat	tgtgcggact	240
gagcacagcc	tgcatgagcc	catgtatata	tttctttgca	tgctttcagg	cattgacatc	300
ctcatctcca	cctcatccat	gccccaaatg	ctggccatct	tctggttcaa	ttccactacc	360
atccagtttg	atgcttgtct	gctacagatg	tttgccatcc	actccttatc	tgccatggaa	420
tccacagtgc	tgctggccat	ggcttttgac	cgctatgtgg	ccatctgtca	cccactgcgc	480
catgccacag	tacttacgtt	gcctcgtgtc	acaaaaattg	gtgtggctgc	tgtggtgctg	540
ggggctgcac	tgatggcacc	ccttcctgtc	ttcatcaagc	agctgccctt	ctgccgctcc	600
aatatccttt	cccattccta	ctgcctacac	caagatgtca	tgaagctggc	ctgtgatgat	660
atccgggtca	atgtcgtcta	tggccttata	gtcatcatct	ccgccattgg	cctggactca	720
cttctcatct	ccttctcata	tctgottatt	cttaagactg	tgttgggctt	gacacgtgaa	780
gcccaggcca	aggcatttgg	cacttgcgtc	tctcatgtgt	gtgctgtgtt	catattctat	840
gtacctttca	ttggattgtc	catggtgcat	cgcttttagca	agcggcgtga	ctctccgctg	900
cccgctcatct	tggccaatat	ctatctgctg	gttctcctctg	tgctcaaccc	aattgtctat	960
ggagtgaaga	caaaggagat	tgcacagcgc	atccttcgac	ttttccatgt	ggccacacac	1020
gcttcagagc	cctaggtgtc	agtgatcaaa	cttcttttcc	attcagagtc	ctctgattca	1080
gatttttaatg	ttaacatttt	ggaagacagt	attcagaaaa	aaaatttcct	taataaaaaat	1140
acaactcaga	tccttcaaat	atgaaactgg	ttggggaatc	tccatttttt	caatattatt	1200
ttcttctttg	ttttcttgct	acatataatt	attaataccc	tgactagggt	gtgggtttgag	1260
ggttattact	tttcatttta	ccatgcagtc	caaactctaaa	ct		1302

<210> 774  
 <211> 2061  
 <212> DNA  
 <213> Homo sapiens

<400> 774

acgattcgac	agcgcaccc	tgcacttttc	catgtggcca	cacacgcttc	agagccctag	60
gtgtcagtga	tcaaacttct	tttccattca	gagtcctctg	attcagattt	taatgttaac	120
atatttgaag	acagtattca	gaaaaaaaac	ttccttaata	aaaatacaac	tcagatccct	180
caaatatgaa	actggttggg	gaatctccat	tttttcaata	ttattttctt	ctttgttttc	240
ttgctacata	taattattaa	taccctgact	agggtgtggt	tggagggtta	ttacttttca	300
ttttaccatg	cagtccaaat	ctaaaactgt	tctactgatg	gtttacagca	ttctgagata	360
agaatggtac	atctagagaa	catttgccaa	aggcctaagc	acggcaaagg	aaaataaaca	420
cagaatataa	taaaatgaga	taatctagct	taaaactata	acttcctctt	cagaactccc	480
aaccacattg	gatctcagaa	aaatgctgtc	ttcaaaatga	cttctacaga	gaagaaataa	540
tttttccctc	ggacactagc	acttaagggg	aagattggaa	gtaaagcctt	gaaaagagta	600
cattttacct	cgttaatgaa	agttgacaca	ctgttctgag	agttttcaca	gcatatggac	660
cctgtttttc	ctatttaatt	ttcttatcaa	ccctttaatt	aggcaaagat	attattagta	720
ccctcattgt	agccatggga	aaattgatgt	tcatgtggga	tcagtgaatt	aaatggggtc	780
atacaagtat	aaaaattaaa	aaaaaaggac	ttcatgcccc	atctcatatg	atgtggaaga	840
actgttagag	agaccaacag	ggtagtgggt	tagagatttc	cagagtctta	cattttctag	900
aggaggtatt	taattttctc	tcaactcatc	agtgttgtat	ttaggaattt	cctggcaaca	960
gaactcatgg	ctttaatccc	actagctatt	gcttattgtc	ctggtccaat	tgccaattac	1020
ctgtgtcctg	gaagaagtga	tttctaggtt	caccattatg	gaagattcct	attcagaaag	1080
tctgcatagg	gcttatagca	agttatttat	ttttaaaagt	tccatagggt	attctgatag	1140
gcagtgaggt	tagggagcca	ccagttatga	tgggaagtat	ggaatggcag	gtcttgaaga	1200
taacattggc	cttttgagtg	tgactcgtag	ctggaaagtg	agggaatctt	caggaccatg	1260
ctttattttg	ggctttgtgc	agtatggaac	agggactttg	agaccaggaa	agcaatctga	1320

cttaggcatg	ggaatcaggc	atTTTTgtt	ctgaggggct	attaccaagg	gttaataggt	1380
ttcatcttca	acaggatatg	acaacagtgt	taaccaagaa	actcaaatta	caaatactaa	1440
aacatgtgat	catatatgtg	gtaagtttca	ttttcttttt	caatcctcag	gttccctgat	1500
atggattcct	ataacatgct	ttcatccoct	tttgtaatgg	atatcatatt	tggaaatgcc	1560
tattttaatac	ttgtattttg	tgctggactg	taagcccatg	agggcactgt	ttattattga	1620
atgtcatctc	tgttcatcat	tgactgctct	ttgctcatca	ttgaatcccc	cagcaaagtg	1680
cctagaacat	aatagtgtt	atgcttgaca	ccggttattt	ttcatcaaac	ctgattccct	1740
ctgtcctgaa	cacatagcca	ggcaattttc	cagccttctt	tgagttgggt	attattaaat	1800
tctggccatt	acttccaatg	tgagtggaag	tgacatgtgc	aatttctata	cctggctcat	1860
aaaaccctcc	catgtgcagc	ctttcatgtt	gacattaaat	gtgacttggg	aagcctatgt	1920
ttacacagag	taaataacca	gaagcctgga	tttctgaaaa	aactgtgcag	agccaaacct	1980
ctgtcatttg	caactccac	ttgtatttgt	acgaggcagt	tggataagtg	aaaaataaag	2040
tactattgtg	tcaagtctct	g				2061

&lt;210&gt; 775

&lt;211&gt; 957

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 775

atgatggtgg	atcccaatgg	caatgaatcc	agtgtacat	acttcatcct	aataggcctc	60
cctggttttag	aagaggctca	gttctggttg	gccttcccat	tgtgctccct	ctaccttatt	120
gctgtgctag	gtaacttgac	aatcatctac	attgtgcgga	ctgagcacag	cctgcatgag	180
cccattgata	tatttctttg	catgctttca	ggcattgaca	tcctcatctc	cacctcatcc	240
atgcccaaaa	tgctggccat	cttctgggtc	aattccacta	ccatccagtt	tgatgcttgt	300
ctgctacaga	tgtttgccat	ccactcctta	tctggcatgg	aatccacagt	gctgctggcc	360
atggcctttg	accgctatgt	ggccatctgt	caccactgc	gccatgccac	agtacttacg	420
ttgcctcgtg	tcaccaaaat	tggtgtggct	gctgtggtgc	ggggggtgc	actgatggca	480
ccccttctctg	tcttcatcaa	gcagctgcc	ttctgcogct	ccaatatcct	ttcccattcc	540
tactgcctac	accaagatgt	catgaagctg	gcctgtgatg	atatccgggt	caatgtcgtc	600
tatggcctta	tcgtcatcat	ctccgccatt	ggcctggact	cacttctcat	ctccttctca	660
tatctgctta	ttcttaagac	tgtgttgggc	ttgacacgtg	aagcccaggc	caaggcattt	720
ggcacttgcg	tctctcatgt	gtgtgctgtg	ttcatattct	atgtaccttt	cattggattg	780
tccatggtgc	atcgctttag	caagcggcgt	gactctccgc	tgcccgtcat	cttggccaat	840
atctatctgc	tggttctctc	tgtgtcaaac	ccaattgtct	atggagtga	gacaaaggag	900
attcgacagc	gcactcttgc	acttttccat	gtggccacac	acgttcaga	gccctag	957

&lt;210&gt; 776

&lt;211&gt; 954

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 776

atgatggtgg	atcccaatgg	caatgaatcc	agtgtacat	acttcatcct	aataggcctc	60
cctggttttag	aagaggctca	gttctggttg	gccttcccat	tgtgctccct	ctaccttatt	120
gctgtgctag	gtaacttgac	aatcatctac	attgtgcgga	ctgagcacag	cctgcatgag	180
cccattgata	tatttctttg	catgctttca	ggcattgaca	tcctcatctc	cacctcatcc	240
atgcccaaaa	tgctggccat	cttctgggtc	aattccacta	ccatccagtt	tgatgcttgt	300
ctgctacaga	tgtttgccat	ccactcctta	tctggcatgg	aatccacagt	gctgctggcc	360
atggcctttg	accgctatgt	ggccatctgt	caccactgc	gccatgccac	agtacttacg	420
ttgcctcgtg	tcaccaaaat	tggtgtggct	gctgtggtgc	ggggggtgc	actgatggca	480
ccccttctctg	tcttcatcaa	gcagctgcc	ttctgcogct	ccaatatcct	ttcccattcc	540
tactgcctac	accaagatgt	catgaagctg	gcctgtgatg	atatccgggt	caatgtcgtc	600
tatggcctta	tcgtcatcat	ctccgccatt	ggcctggact	cacttctcat	ctccttctca	660
tatctgctta	ttcttaagac	tgtgttgggc	ttgacacgtg	aagcccaggc	caaggcattt	720
ggcacttgcg	tctctcatgt	gtgtgctgtg	ttcatattct	atgtaccttt	cattggattg	780
tccatggtgc	atcgctttag	caagcggcgt	gactctccgc	tgcccgtcat	cttggccaat	840

<400> 777																
Met	Met	Val	Asp	Pro	Asn	Gly	Asn	Glu	Ser	Ser	Ala	Thr	Tyr	Phe	Ile	
				5					10					15		
Leu	Ile	Gly	Leu	Pro	Gly	Leu	Glu	Glu	Ala	Gln	Phe	Trp	Leu	Ala	Phe	
			20					25					30			
Pro	Leu	Cys	Ser	Leu	Tyr	Leu	Ile	Ala	Val	Leu	Gly	Asn	Leu	Thr	Ile	
		35					40					45				
Ile	Tyr	Ile	Val	Arg	Thr	Glu	His	Ser	Leu	His	Glu	Pro	Met	Tyr	Ile	
	50					55					60					
Phe	Leu	Cys	Met	Leu	Ser	Gly	Ile	Asp	Ile	Leu	Ile	Ser	Thr	Ser	Ser	
65					70					75					80	
Met	Pro	Lys	Met	Leu	Ala	Ile	Phe	Trp	Phe	Asn	Ser	Thr	Thr	Ile	Gln	
				85					90					95		
Phe	Asp	Ala	Cys	Leu	Leu	Gln	Met	Phe	Ala	Ile	His	Ser	Leu	Ser	Gly	
			100					105					110			
Met	Glu	Ser	Thr	Val	Leu	Leu	Ala	Met	Ala	Phe	Asp	Arg	Tyr	Val	Ala	
		115					120					125				
Ile	Cys	His	Pro	Leu	Arg	His	Ala	Thr	Val	Leu	Thr	Leu	Pro	Arg	Val	
	130					135					140					
Thr	Lys	Ile	Gly	Val	Ala	Ala	Val	Val	Arg	Gly	Ala	Ala	Leu	Met	Ala	
145					150					155					160	
Pro	Leu	Pro	Val	Phe	Ile	Lys	Gln	Leu	Pro	Phe	Cys	Arg	Ser	Asn	Ile	
				165					170					175		
Leu	Ser	His	Ser	Tyr	Cys	Leu	His	Gln	Asp	Val	Met	Lys	Leu	Ala	Cys	
			180					185					190			
Asp	Asp	Ile	Arg	Val	Asn	Val	Val	Tyr	Gly	Leu	Ile	Val	Ile	Ile	Ser	
		195					200					205				
Ala	Ile	Gly	Leu	Asp	Ser	Leu	Leu	Ile	Ser	Phe	Ser	Tyr	Leu	Leu	Ile	
	210					215					220					
Leu	Lys	Thr	Val	Leu	Gly	Leu	Thr	Arg	Glu	Ala	Gln	Ala	Lys	Ala	Phe	
225					230					235					240	
Gly	Thr	Cys	Val	Ser	His	Val	Cys	Ala	Val	Phe	Ile	Phe	Tyr	Val	Pro	
				245					250					255		

310

Phe Ile Gly Leu Ser Met Val His Arg Phe Ser Lys Arg Arg Asp Ser  
                   260                                  265                                  270

Pro Leu Pro Val Ile Leu Ala Asn Ile Tyr Leu Leu Val Pro Pro Val  
                   275                                  280                                  285

Leu Asn Pro Ile Val Tyr Gly Val Lys Thr Lys Glu Ile Arg Gln Arg  
                   290                                  295                                  300

Ile Leu Arg Leu Phe His Val Ala Thr His Ala Ser Glu Pro  
                   305                                  310                                  315

&lt;210&gt; 778

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 778

Met Met Val Asp Pro Asn Gly Asn Glu Ser Ser Ala Thr Tyr Phe Ile  
                                   5                                  10                                  15

Leu Ile Gly Leu Pro Gly Leu Glu Glu Ala Gln Phe  
                   20                                  25

&lt;210&gt; 779

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 779

Arg Thr Glu His Ser Leu His Glu Pro  
                                   5

&lt;210&gt; 780

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 780

Lys Met Leu Ala Ile Phe Trp Phe Asn Ser Thr Thr Ile Gln Phe Asp  
                                   5                                  10                                  15

Ala Cys Leu Leu Gln  
                   20

&lt;210&gt; 781

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 781

Asp Arg Tyr Val Ala Ile Cys His Pro Leu Arg His Ala Thr Val Leu  
                                   5                                  10                                  15

Thr Leu Pro Arg  
20

<210> 782  
<211> 37  
<212> PRT  
<213> Homo sapiens

<400> 782  
Phe Ile Lys Gln Leu Pro Phe Cys Arg Ser Asn Ile Leu Ser His Ser  
5 10 15

Tyr Cys Leu His Gln Asp Val Met Lys Leu Ala Cys Asp Asp Ile Arg  
20 25 30

Val Asn Val Val Tyr  
35

<210> 783  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 783  
Lys Thr Val Leu Gly Leu Thr Arg Glu Ala Gln Ala Lys  
5 10

<210> 784  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 784  
Val His Arg Phe Ser Lys Arg Arg Asp Ser  
5 10

<210> 785  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 785  
Lys Thr Lys Glu Ile Arg Gln Arg Ile Leu Arg Leu Phe His Val Ala  
5 10 15

Thr His Ala Ser Glu Pro  
20

<210> 786  
<211> 3245  
<212> DNA  
<213> Homo sapiens

&lt;400&gt; 786

gtcgacccac	gcgtccgcgc	gagctaagca	ggaggcggag	gcggaggcgg	agggcgaggg	60
gcgggggagcg	ccgcctggag	cgcggcaggt	catattgaac	attccagata	cctatcatta	120
ctcgatgctg	ttgataacag	caagatggct	ttgaactcag	ggtcaccacc	agctattgga	180
ccttactatg	aaaaccatgg	ataccaaccg	gaaaaccctt	atcccgca	gccactgtg	240
gtccccactg	tctacgaggt	gcatccggct	cagtactacc	cgtccccgt	gccccagtac	300
gccccgaggg	tcttgacgca	ggcttccaac	cccgctcgtt	gcacgcagcc	caaatcccca	360
tccgggacag	tgtgcacetc	aaagactaag	aaagcactgt	gcatcacctt	gaccctgggg	420
accttcctcg	tgggagctgc	gctggccgct	ggcctactct	ggaagttcat	gggcagcaag	480
tgctccaact	ctgggataga	gtgcgactcc	tcaggtaacct	gcatcaacce	ctctaactgg	540
tgtgatggcg	tgtcacactg	ccccggcggg	gaggacgaga	atcggtgtgt	tcgcctctac	600
ggatcaaaact	tcatccttca	ggtgtactca	tctcagagga	agtccctggca	ccctgtgtgc	660
caagacgact	ggaacgagaa	ctacgggcgg	gcggcctgca	gggacatggg	ctataagaat	720
aatttttact	ctagccaagg	aatagtggat	gacagcggat	ccaccagctt	tatgaaactg	780
aacacaagtg	ccggcaatgt	cgatatctat	aaaaaactgt	accacagtga	tgccctgttct	840
tcaaaagcag	tggtttcttt	acgctgtata	gcctgcgggg	tcaacttgaa	ctcaagccgc	900
cagagcagga	ttgtgggcgg	cgagagcgcg	ctccccgggg	cctggccctg	gcaggtcagc	960
ctgcacgtcc	agaacgtcca	cgtgtgcgga	ggctccatca	tcacccccga	gtggatcgtg	1020
acagccgccc	actgcgttga	aaaacctctt	aacaatccat	ggcattggac	ggcatttgcg	1080
gggattttga	gacaatcttt	catgttctat	ggagccggat	accaagtaga	aaaagtgatt	1140
tctcatccaa	attatgactc	caagaccaag	aacaatgaca	ttgcgctgat	gaagctgcag	1200
aagcctctga	ctttcaacga	cctagtgaag	ccagtgtgtc	tgcccaaccc	aggcatgatg	1260
ctgcagccag	aacagctctg	ctggatttcc	gggtgggggg	ccaccgagga	gaaagggag	1320
acctcagaag	tgctgaacgc	tgccaagggtg	cttctcattg	agacacagag	atgcaacagc	1380
agatatgtct	atgacaacct	gatcacacca	gccatgatct	gtgccggctt	cctgcagggg	1440
aacgtcgatt	cttgccaggg	tgacagtgga	gggcctctgg	tcacttcgaa	gaacaatatc	1500
tggtggctga	taggggatag	aagctggggg	tctggctgtg	ccaaagctta	cagaccagga	1560
gtgtacggga	atgtgatggg	attcacggac	tggatttatc	gacaaatgag	ggcagacggc	1620
taatccacat	ggtcttcgtc	cttgacgtcg	ttttacaaga	aaacaatggg	gctgggtttg	1680
cttccccgtg	catgatttac	tcttagagat	gattcagagg	tcacttcatt	tttattaaac	1740
agtgaacttg	tctggctttg	gcactctctg	ccattctgtg	caggctgcag	tggtctccct	1800
gcccagcctg	ctctccctaa	ccccttgtcc	gcaaggggtg	atggccggct	ggttgtgggc	1860
actggcggtc	aagtgtggag	gagaggggtg	gaggctgccc	cattgagatc	ttcctgctga	1920
gtcctttcca	ggggccaatt	ttggatgagc	atggagctgt	cacctctcag	ctgctggatg	1980
acttgagatg	aaaaaggaga	gacatggaaa	gggacagcgc	caggtggcac	ctgcagcggc	2040
tgccctcttg	ggccacttgg	tagtgtcccc	agcctacctc	tcacaagggg	gattttgctg	2100
atgggttctt	agagccttag	cagccctgga	tggtggccag	aaataaaggg	accagccctt	2160
catgggtggt	gacgtggtag	tcacttgtaa	ggggaacaga	aacatttttg	ttcttatggg	2220
gtgagaatat	agacagtgcc	cttggtgcga	gggaagcaat	tgaaaaggaa	cttgccctga	2280
gcactccttg	tgcaggtctc	cacctgcaca	ttgggtgggg	ctcctgggag	ggagactcag	2340
ccttcctcct	catcctccct	gacctgctc	ctagcaccct	ggagagtga	catgcccctt	2400
ggtcctggca	gggcgccaag	tctggcacca	tggtggcctc	ttcaggcctg	ctagtcaactg	2460
gaaattgagg	tccatggggg	aaatcaagga	tgctcagttt	aaggtacact	gtttccatgt	2520
tatgtttcta	cacattgcta	cctcagtgct	cctggaaact	tagcttttga	tgtctccaag	2580
tagtccacct	tcattttaact	ctttgaaact	gtatcatctt	tgccaagtaa	gagtgggtggc	2640
ctattttcagc	tgttttgaca	aaatgactgg	ctcctgactt	aacgttctat	aaatgaatgt	2700
gctgaagcaa	agtgcccatg	gtggcggcga	agaagagaaa	gatgtgtttt	gttttgact	2760
ctctgtggtc	ccttccaatg	ctgtgggttt	ccaaccaggg	gaagggtccc	ttttgcattg	2820
ccaagtggca	taacctagag	cactactcta	ccatggttct	gcctcctggc	caagcaggct	2880
ggtttgcaag	aatgaaatga	atgattctac	agctaggact	taaccttgaa	atggaaagtc	2940
ttgcaatccc	atttgacagga	tccgtctgtg	cacatgcctc	tgtagagagc	agcattccca	3000
gggaccttgg	aaacagttgg	cactgtaagg	tgcttgcctc	ccaagacaca	tcctaaaagg	3060
tgttgtaatg	gtgaaaacgt	cttccttctt	tattgccctt	tcttatttat	gtgaaaact	3120
gtttgtcttt	ttttgtatct	tttttaaaact	gtaaagttca	attgtgaaaa	tgaatatcat	3180
gcaataaat	tatgcgattt	ttttttcaaa	gtaaaaaaa	aaaaaaaaa	aaaaagggcg	3240
gccgc						3245

<210> 787  
<211> 1479  
<212> DNA  
<213> Homo sapiens

<400> 787

atggccttga	actcagggtc	accaccagct	attggacott	actatgaaaa	ccatggatac	60
caaccgaaa	accctatcc	cgcacagccc	actgtggtcc	ccactgtcta	cgagggtgat	120
ccggtcagt	actaccgctc	ccccgtgcc	cagtacgccc	cgagggctct	gacgcaggct	180
tccaaccccg	tcgtctgcac	gcagcccaaa	tccccatccg	ggacagtgtg	cacctcaaag	240
actaagaaa	caactgtgcat	caccttgacc	ctggggacct	tcctcgtggg	agctgcgctg	300
gccgctggcc	tactctggaa	gttcatgggc	agcaagtgtc	ccaactctgg	gatagagtgc	360
gactcctcag	gtacctgcat	caacccctct	aactggtgtg	atggcgtgtc	acactgcccc	420
ggcggggagg	acgagaatcg	gtgtgttcgc	ctctacggat	caaacttcat	ccttcagggtg	480
tactcatctc	agaggaagtc	ctggcaccct	gtgtgccaag	acgactggaa	cgagaactac	540
gggcggggcgg	cctgcaggga	catgggctat	aagaataatt	tttactctag	ccaaggaata	600
gtggatgaca	gcggatccac	cagctttatg	aaactgaaca	caagtgccgg	caatgtcgat	660
atctataaaa	aactgtacca	cagtgatgcc	tgtttctcaa	aagcagtggg	ttctttacgc	720
tgtatagcct	gcgggggtcaa	cttgaactca	agccgccaga	gcaggattgt	gggcggcgag	780
agcgcgctcc	cgggggcctg	gccctggcag	gtcagcctgc	acgtccagaa	cgtccacgtg	840
tgcggaggct	ccatcatcac	ccccgagtgg	atcgtgacag	ccgcccactg	cgtggaaaaa	900
cctcttaaca	atccatggca	ttggacggca	tttgccggga	ttttgagaca	atctttcatg	960
ttctatggag	ccggatacca	agtagaaaaa	gtgatttctc	atccaaatta	tgactccaag	1020
accaagaaca	atgacattgc	gctgatgaag	ctgcagaagc	ctctgacttt	caacgacctc	1080
gtgaaaccag	tgtgtctgcc	caaccaggcc	atgatgctgc	agccagaaca	gctctgctgg	1140
atttccgggt	ggggggccac	cgaggagaaa	gggaagacct	cagaagtgtc	gaacgctgcc	1200
aagggtgcttc	tcattgagac	acagagatgc	aacagcagat	atgtctatga	caacctgatc	1260
acaccagcca	tgatctgtgc	cggcttcctg	caggggaacg	togattcttg	ccagggtgac	1320
agtggagggc	ctctggtcac	ttcgaagaac	aatatctggt	ggctgatagg	ggatacaagc	1380
tggggttctg	gctgtgcaa	agcttacaga	ccaggagtgt	acgggaatgt	gatgggtattc	1440
acggactgga	tttatcgaca	aatgagggca	gacggctaa			1479

<210> 788  
<211> 1476  
<212> DNA  
<213> Homo sapiens

<400> 788

atggccttga	actcagggtc	accaccagct	attggacott	actatgaaaa	ccatggatac	60
caaccgaaa	accctatcc	cgcacagccc	actgtggtcc	ccactgtcta	cgagggtgat	120
ccggtcagt	actaccgctc	ccccgtgcc	cagtacgccc	cgagggctct	gacgcaggct	180
tccaaccccg	tcgtctgcac	gcagcccaaa	tccccatccg	ggacagtgtg	cacctcaaag	240
actaagaaa	caactgtgcat	caccttgacc	ctggggacct	tcctcgtggg	agctgcgctg	300
gccgctggcc	tactctggaa	gttcatgggc	agcaagtgtc	ccaactctgg	gatagagtgc	360
gactcctcag	gtacctgcat	caacccctct	aactggtgtg	atggcgtgtc	acactgcccc	420
ggcggggagg	acgagaatcg	gtgtgttcgc	ctctacggat	caaacttcat	ccttcagggtg	480
tactcatctc	agaggaagtc	ctggcaccct	gtgtgccaag	acgactggaa	cgagaactac	540
gggcggggcgg	cctgcaggga	catgggctat	aagaataatt	tttactctag	ccaaggaata	600
gtggatgaca	gcggatccac	cagctttatg	aaactgaaca	caagtgccgg	caatgtcgat	660
atctataaaa	aactgtacca	cagtgatgcc	tgtttctcaa	aagcagtggg	ttctttacgc	720
tgtatagcct	gcgggggtcaa	cttgaactca	agccgccaga	gcaggattgt	gggcggcgag	780
agcgcgctcc	cgggggcctg	gccctggcag	gtcagcctgc	acgtccagaa	cgtccacgtg	840
tgcggaggct	ccatcatcac	ccccgagtgg	atcgtgacag	ccgcccactg	cgtggaaaaa	900
cctcttaaca	atccatggca	ttggacggca	tttgccggga	ttttgagaca	atctttcatg	960
ttctatggag	ccggatacca	agtagaaaaa	gtgatttctc	atccaaatta	tgactccaag	1020
accaagaaca	atgacattgc	gctgatgaag	ctgcagaagc	ctctgacttt	caacgacctc	1080
gtgaaaccag	tgtgtctgcc	caaccaggcc	atgatgctgc	agccagaaca	gctctgctgg	1140



```

atttcggggt gggggggccac cgaggagaaa ggggaagacct cagaagtgtt gaacgctgcc 1200
aaggtgcttc tcattgagac acagagatgc aacagcagat atgtctatga caacctgac 1260
acaccagcca tgatctgtgc cggcttctctg caggggaacg tcgattcttg ccagggtgac 1320
agtggagggc ctctggtcac ttcgaagaac aatatctggt ggctgatagg ggatacaagc 1380
tggggttctg gctgtgccaa agcttacaga ccaggagtgt acgggaatgt gatggtattc 1440
acggactgga tttatcgaca aatgagggca gacggc 1476

```

&lt;210&gt; 789

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 789

```

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
      5      10      15
Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
      20      25      30
Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
      35      40      45
Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
      50      55      60
Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
      65      70      75      80
Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
      85      90      95
Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
      100     105     110
Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
      115     120     125
Pro Ser Asp Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
      130     135     140
Glu Asn Arg Cys Val Arg Leu Tyr Gly Ser Asn Phe Ile Leu Gln Val
      145     150     155     160
Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
      165     170     175
Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
      180     185     190
Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
      195     200     205
Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys
      210     215     220
Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg
      225     230     235     240
Cys Ile Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile
      245     250     255
Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser
      260     265     270
Leu His Val Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro
      275     280     285
Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn
      290     295     300
Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met
      305     310     315     320
Phe Tyr Gly Ala Gly Tyr Gln Val Glu Lys Val Ile Ser His Pro Asn
      325     330     335
Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln
      340     345     350

```

Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn  
 355 360 365  
 Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp  
 370 375 380  
 Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala  
 385 390 395 400  
 Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr  
 405 410 415  
 Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly  
 420 425 430  
 Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser  
 435 440 445  
 Lys Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly  
 450 455 460  
 Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe  
 465 470 475 480  
 Thr Asp Trp Ile Tyr Arg Gln Met Arg Ala Asp Gly  
 485 490

<210> 790  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<400> 790  
 Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu  
 5 10 15  
 Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val  
 20 25 30  
 Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro  
 35 40 45  
 Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val  
 50 55 60  
 Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys  
 65 70 75 80  
 Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val  
 85 90 95  
 Gly Ala Ala Leu  
 100

<210> 791  
 <211> 393  
 <212> PRT  
 <213> Homo sapiens

<400> 791  
 Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys Cys Ser Asn  
 5 10 15  
 Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn Pro Ser Asn  
 20 25 30  
 Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp Glu Asn Arg  
 35 40 45  
 Cys Val Arg Leu Tyr Gly Ser Asn Phe Ile Leu Gln Val Tyr Ser Ser  
 50 55 60  
 Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp Asn Glu Asn  
 65 70 75 80

Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn Asn Phe Tyr  
                     85                    90                    95  
 Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser Phe Met Lys  
                     100                    105                    110  
 Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys Leu Tyr His  
                     115                    120                    125  
 Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg Cys Ile Ala  
                     130                    135                    140  
 Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile Val Gly Gly  
 145                    150                    155                    160  
 Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser Leu His Val  
                     165                    170                    175  
 Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro Glu Trp Ile  
                     180                    185                    190  
 Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn Pro Trp His  
                     195                    200                    205  
 Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met Phe Tyr Gly  
                     210                    215                    220  
 Ala Gly Tyr Gln Val Glu Lys Val Ile Ser His Pro Asn Tyr Asp Ser  
 225                    230                    235                    240  
 Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln Lys Pro Leu  
                     245                    250                    255  
 Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn Pro Gly Met  
                     260                    265                    270  
 Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp Gly Ala Thr  
                     275                    280                    285  
 Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala Lys Val Leu  
                     290                    295                    300  
 Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr Asp Asn Leu  
 305                    310                    315                    320  
 Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly Asn Val Asp  
                     325                    330                    335  
 Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser Lys Asn Asn  
                     340                    345                    350  
 Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly Cys Ala Lys  
                     355                    360                    365  
 Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe Thr Asp Trp  
                     370                    375                    380  
 Ile Tyr Arg Gln Met Arg Ala Asp Gly  
 385                    390

&lt;210&gt; 792

&lt;211&gt; 595

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 792

Met Ser Phe Leu Asn Phe Thr Ala Val Leu Phe Ala Ala Ser Ser Ala  
 1                    5                    10                    15  
 Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln Ile  
                     20                    25                    30  
 Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe Asp  
                     35                    40                    45  
 Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe  
                     50                    55                    60  
 Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser  
 65                    70                    75                    80

Leu Glu Lys Arg Glu Ala Glu Ala Met Val Leu Gly Ile Gly Pro Val  
 85 90 95  
 Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp  
 100 105 110  
 Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu  
 115 120 125  
 Gly Ile Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala  
 130 135 140  
 Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile  
 145 150 155 160  
 Leu Gly Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro  
 165 170 175  
 Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg  
 180 185 190  
 Gln Ala Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu  
 195 200 205  
 Gly Tyr Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro  
 210 215 220  
 Tyr Leu Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile  
 225 230 235 240  
 Phe Leu Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala  
 245 250 255  
 Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser  
 260 265 270  
 Pro His Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly  
 275 280 285  
 Ala Leu Leu Pro Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr  
 290 295 300  
 Leu Arg Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met  
 305 310 315 320  
 Thr Phe Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln  
 325 330 335  
 Gly Val Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp  
 340 345 350  
 Glu Gly Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile  
 355 360 365  
 Ser Leu Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly  
 370 375 380  
 Thr Arg Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala  
 385 390 395 400  
 Gly Ala Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala  
 405 410 415  
 Ala Leu Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr  
 420 425 430  
 Leu Ala Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr  
 435 440 445  
 Arg Gly Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser  
 450 455 460  
 Phe Leu Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val  
 465 470 475 480  
 Gly Ala Gly Gly Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly  
 485 490 495  
 Ala Ser Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr  
 500 505 510  
 Glu Ala Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile  
 515 520 525  
 Leu Asp Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met  
 530 535 540

Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser  
545 550 555 560  
Ala Ala Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val  
565 570 575  
Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala Gly Gly His His His  
580 585 590  
His His His  
595

